American Society of Clinical Oncology 47th Annual Meeting Meeting ...

American Society of Clinical Oncology 

47th Annual Meeting 

Meeting Program 

Note: Sessions in which Special Awards are presented 

are shaded in gray

FRIDAY 

Friday, June 3, 2011 

1:00 PM - 2:15 PM 

EDUCATION SESSIONS 

Customized Cancer Treatment: A Systems Biology Approach to Drug 

Selection 

Location: E354b 

CME credit: 1.25 

Track(s): Developmental Therapeutics, Cancer Genetics, Clinical Trials 

John Mendelsohn, MD—Chair 

University of Texas M. D. Anderson Cancer Center 

Customized Cancer Medicine: Are We Ready for What It Will Take? 

Jeffrey M. Trent, PhD 

TGen 

Large-scale, Multidimensional Genomics Data: Making Sense for Patients 

Andrea Califano, PhD 

Columbia University 

Cancer’s Complexity: Are We Looking at the Wrong Levels to Develop Effective Interventions? 

Endometrial Cancer: Present State and Future Promise 

Location: E354a 


Track(s): Gynecologic Cancer 

Don S. Dizon, MD—Chair 

Warren Alpert Medical School of Brown University 

Options in the Treatment of Relapsed Endometrial Cancer: Beyond First-line Therapy 

Karen H. Lu, MD 


Molecular Characterization of Endometrial Cancer: Going beyond Histology 

David Scott Miller, MD 

University of Texas Southwestern Medical Center 

Incorporation of Adjuvant Chemotherapy into Endometrial Cancer Treatment 

Neoadjuvant Therapy in Operable Breast Cancer: Who, What, When, Why, and 

How? 

Location: Hall D1 


Track(s): Breast Cancer 

Luca Gianni, MD—Chair 

Fondazione IRCCS Istituto Nazionale dei Tumori 

Neoadjuvant Assumptions and Application to Chemotherapy, Endocrine Therapy, and Biologic 

Therapy-based Regimens 

David W. Ollila, MD 

University of North Carolina at Chapel Hill 

Surgical Implications of the Neoadjuvant Approach: Facilitating Research Biopsies, Breast 

Conservation in Previously T3–4 Tumors, and Axillary Staging—Before or After? 

Thomas A. Buchholz, MD 


Radiation in the Setting of Marked Cytoreduction: Do We Radiate a Cleared Nodal Basin or 

Breast? 

58

Pediatric Bone Sarcomas: Converging Progress on the Biologic and Clinical 

Fronts? 

Location: S504 


Track(s): Pediatric Oncology, Sarcoma 

Stephen L. Lessnick, MD, PhD—Chair 

Huntsman Cancer Institute 

Recent Progress in Understanding the Biology of Bone Tumors 

Holcombe E. Grier, MD 

Dana-Farber Cancer Institute 

Advances in the Treatment of Ewing’s Sarcoma 

Neyssa Marina, MD 

Stanford University School of Medicine 

Update on the Management of Children, Adolescents, and Young Adults with Osteosarcoma 

Radiation Therapy Updates for Primary Brain Tumors: Clinical Role for Proton 

Therapy, Stereotactic Radiosurgery, and Hypofractionated Schedules 

Location: S100bc 


Track(s): Central Nervous System Tumors 

John H. Suh, MD—Chair 

Cleveland Clinic 

Radiosurgery Applications for Primary Brain Tumors 

Eugen Hug, MD 

Paul Scherrer Institut 

Proton Therapy for Primary Brain Tumors: When to Refer 

Eric L. Chang, MD 


Abbreviated Course of Radiation Therapy in Older Patients with Glioblastoma 

Survivorship Care: Whose Job Is It? 



Track(s): Patient and Survivor Care, Health Services Research 

Julia Howe Rowland, PhD—Chair 

National Cancer Institute/National Institutes of Health 

Overview of This Emerging Challenge in Survivors’ Care 

Paul Han, MD, MA, MPH 

Maine Medical Center Research Institute 

Presentation of Data from the National Cancer Institute– and American Cancer Society–funded 

Study: Survey of Physician Attitudes Regarding Care of Cancer Survivors 

James Ross Waisman, MD 

Breastlink Medical Group Inc. 

How to Implement Survivorship Care in Practice 


59 

FRIDAY

FRIDAY 


The Identification and Treatment of the “High Risk” Patient with Non-Hodgkin 

Lymphoma and Myeloma 

Location: Arie Crown Theater 


Track(s): Lymphoma and Plasma Cell Disorders 

Francine M. Foss, MD—Chair 

Yale Cancer Center 

High-risk Peripheral T-cell Lymphoma 

Michael Pfreundschuh, MD 

Saarland University Hospital 

High-risk B-cell Non-Hodgkin Lymphoma 

Rafael Fonseca, MD 

Mayo Clinic 

High-risk Myeloma 

60

1:00 PM - 2:15 PM 

MEET THE PROFESSOR SESSION 

Implementing a Quality Research Program in a Community Setting 

(M05)—Ticketed Session 



Track(s): Clinical Trials, Practice Management and Information Technology, Professional 

Development 

Patrick J. Flynn, MD 

Metro Minnesota Community Clinical Oncology Project 

Practical Aspects of Clinical Trial Implementation in the Community Setting 

Lidia Schapira, MD 

Massachusetts General Hospital 

Talking to Patients about Clinical Trials 


61 

FRIDAY

FRIDAY 


1:00 PM - 3:15 PM 

EXTENDED EDUCATION SESSIONS 

How to Participate in Clinical Research across Borders 

Location: S100a 


Track(s): Clinical Trials, International 

Eduardo L. Cazap, MD—Chair 

Latin American-Caribbean Society of Medical Oncology 

Martine J. Piccart-Gebhart, MD, PhD 

Jules Bordet Institute 

The BIG Experience: Challenges and Opportunities 

Edward Lloyd Trimble, MD 

National Cancer Institute 

Promoting Independent Research at the U.S. National Cancer Institute 

Jean-Yves Blay, MD, PhD 

Centre Léon Bérard 

How to Participate in European Organisation for Research and Treatment of Cancer Trials 

Henry Leonidas Gomez, MD 

Instituto Nacional de Enfermedades Neoplasicas 

Leading Clinical Research in Low-resource Scenarios 

Role of Nutrition, Supplements, and Integrative Medicine in Cancer Prevention, 

Treatment, and Survivorship 

Location: E353 


Track(s): Cancer Prevention/Epidemiology, General Oncology, Patient and Survivor Care 

Charles L. Loprinzi, MD—Chair 

Mayo Clinic 

Nutrition Recommendations for Patients with Far-advanced Disease 

Heather Greenlee, ND, PhD 


Lifestyle Modification and Dietary Supplements in Cancer Prevention: What Is the Role? 

Kimberly Robien, PhD, RD 

University of Minnesota 

Approaches to Nutrition Interventions during Cancer Treatment 

Wendy Demark-Wahnefried, PhD, RD 

University of Alabama at Birmingham 

Nutrition and Physical Activity Recommendations for Cancer Survivorship: What Do We Tell 

Our Patients and Their Families after Treatment? 

Lorenzo Cohen, PhD 


Improving Patient Outcomes: The Role of Integrative Medicine in Cancer Care 

62

1:00 PM - 3:30 PM 


Grant Writing Workshop I: Basic Grant Writing 



Track(s): Professional Development, Clinical Trials 

Charles M. Rudin, MD, PhD—Chair 

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University 

Developing Hypothesis and Stating Aims 

Lei Ming, PhD 


National Cancer Institute Training and Career Development Grants 

Kathleen A. Cooney, MD 

University of Michigan Medical School, University of Michigan Comprehensive Cancer Center 

Conquer Cancer Foundation of ASCO (formerly The ASCO Cancer Foundation) Grants 

Program 

Susan Blaney, MD 

Texas Children’s Cancer Center 

Choosing a Mentor and Obtaining Letters of Support 

Heidi Nelson, MD 

Mayo Clinic 

Tips for Grant Writing in the New National Institutes of Health Format 

Donna S. Neuberg, ScD 


Statistical Considerations 

Mary L. Disis, MD 

University of Washington 

Grant Writing Pearls 

On the Shoulders of Giants: Historical Perspectives on Biomarkers and 

Colorectal Carcinoma 



Track(s): Professional Development, Gastrointestinal (Colorectal) Cancer 

Jill Gilbert, MD—Chair 

Vanderbilt University 

Robert J. Mayer, MD 


History of Systemic Treatment for Colorectal Cancer 

S. Gail Eckhardt, MD 

University of Colorado School of Medicine, Anschutz Medical Campus 

History of the Development of Novel Agents and Integration of Biomarkers in Colorectal Cancer 

Katherine Elizabeth Reeder-Hayes, MD 

University of North Carolina Hospital 

Case Study: Colorectal Carcinoma 

Jae Hong Park, MD 

Memorial Sloan-Kettering Cancer Center 

Case Study: Colorectal Carcinoma 


63 

FRIDAY

FRIDAY 


1:00 PM - 4:00 PM 

EXTENDED EDUCATION SESSION 

Maintenance of Certification and Lifelong Learning Workshop 

(MOC)—Ticketed Session 


Track(s): Professional Development 

Alexandria T. Phan, MD—Chair 


ABIM 2010 Update in Medical Oncology 

Gregory A. Masters, MD 

Thomas Jefferson University Medical School and Medical Oncology Hematology Consultants 


Anne Moore, MD 

Weill Cornell Medical College 


64

2:00 PM - 6:00 PM 

POSTER DISCUSSION SESSION 

Central Nervous System Tumors 

Display Time: 2:00 PM - 6:00 PM 

Display Location: S102 

Discussion Time: 5:00 PM - 6:00 PM 

Discussion Location: S100a 

CME credit: 1 



Mark R. Gilbert, MD—Co-Chair 


John L. Villano, MD—Co-Chair 

University of Illinois 

Discussion 

5:00 PM Martin Kelly Nicholas, MD, PhD (Abstracts #2012–2017) 

The University of Chicago 

Discussion 

5:30 PM Jeffrey J. Raizer, MD (Abstracts #2025–2030) 

Northwestern University Feinberg School of Medicine 

Discussion 

5:45 PM David M. Peereboom, MD (Abstracts #2031–2036) 


Brd. 1 A population-based study of glioblastoma multiforme (GBM) in the new 

Stupp paradigm: Have we improved outcome? (Abstract #2012) 

Z. Lwin, D. MacFadden, A. AL-Zahrani, E. Atenafu, B. Miller, C. Menard, 

N. Laperriere, W. P. Mason 

Brd. 2 Improved survival time trends for glioblastoma using the SEER 17 

population-based registries. (Abstract #2013) 

M. Koshy, J. L. Villano, T. A. Dolecek, A. Howard, S. Chmura, 

R. R. Weichselbaum, B. J. McCarthy 

Brd. 3 Real-life survival in unselected adult glioblastoma patients: A populationbased 

study. (Abstract #2014) 

M. Preusser, A. Woehrer, N. Zielonke, H. Heinzl, C. Auer, T. Waldhoer, 

K. Roessler, C. Marosi, J. A. Hainfellner 

Brd. 4 Effects of surgery with BCNU wafer placement on neurocognitive function in 

patients with one to three brain metastases. (Abstract #2015) 

M. G. Ewend, C. A. Meyers, E. Silva, M. Booth-Jones, S. Jain, S. Brem 

Brd. 5 Clinical utility of neurocognitive function (NCF), quality of life (QOL), and 

symptom assessment as prognostic factors for survival and measures of 

treatment effects on RTOG 0525. (Abstract #2016) 

T. S. Armstrong, J. S. Wefel, M. Wang, M. Won, A. Bottomley, T. R. Mendoza, 

C. Coens, M. Werner-Wasik, D. Brachman, A. K. Choucair, M. R. Gilbert 

Brd. 6 Variation over time and interdependence between disease progression and 

death among patients with glioblastoma (GBM) on RTOG 0525. (Abstract 

#2017) 

M. Wang, J. Dignam, M. Won, W. J. Curran Jr., M. P. Mehta, M. R. Gilbert 

Brd. 7 Outcome of grade 3 and 4 cytopenia in newly diagnosed glioblastoma 

multiforme (GBM) patients treated with temozolomide (TMZ). (Abstract 

#2018) 

B. E. Sanchez, J. Munoz, H. Y. Ali, J. M. Anderson, P. Kuriakose 

65 

FRIDAY

FRIDAY 


Brd. 8 Single nucleotide polymorphisms (SNPs) and circulating endothelial cells 

(CECs) as outcome predictors in patients (pts) with recurrent glioblastoma 

(rGBM) treated with bevacizumab (BEV) and sorafenib (SOR). (Abstract 

#2019) 

S. Anderson, J. M. Lafky, X. W. Carrero, T. K. Kimlinger, T. M. Halling, S. Kumar, 

P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner, E. Galanis 

Brd. 9 Detection of IDH1 mutations in a series of 91 oligodendrogliomas: 

Comparison of immunohistochemistry, DNA sequencing, and allele-specific 

PCR. (Abstract #2020) 

D. Loussouarn, A. Le Loupp, J. Frenel, F. Leclair, A. Von Deimling, M. Aumont, 

S. Martin, M. Campone, M. G. Denis 

Brd. 10 The role of the development of hypertension or proteinuria in predicting 

outcome with the use of bevacizumab for patients with glioblastoma 

multiforme (GBM). (Abstract #2021) 

C. S. Nangia, D. Wang, L. Scarpace, L. Schultz, A. Khanshour, T. Mikkelsen 

Brd. 11 Clinical use of personalized molecular biomarkers in patients with 

glioblastoma. (Abstract #2022) 

M. Holdhoff, J. O. Blakeley, C. Carson, C. H. Ferrigno, L. Blair, 

A. S. Balmanoukian, P. Burger, S. A. Grossman, L. A. Diaz Jr. 

Brd. 12 Triple-negative, low-grade gliomas: A highly aggressive tumor with dismal 

prognosis. (Abstract #2023) 

P. Metellus, B. Coulibaly, C. Colin, A. Maues de Paula, A. Barlier, A. Loundou, 

S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, L. Ouafik, D. Figarella-Branger 

Brd. 13 The role of amide proton transfer imaging in detecting active malignant 

glioma. (Abstract #2024) 

J. O. Blakeley, X. Ye, M. Lim, H. Zhu, L. Blair, A. Quinones-Hinojosa, C. Eberhart, 

P. Barker, J. Laterra, P. C. van Zijl, J. Zhou 

Brd. 14 Methotrexate (MTX) rechallenge for recurrent primary CNS lymphoma 

(PCNSL). (Abstract #2025) 

E. Pentsova, L. M. DeAngelis, A. M. Omuro 

Brd. 15 Impact of meningeal dissemination (MD) on outcome in primary CNS 

lymphoma in the G-PCNSL-SG1 trial. (Abstract #2026) 

A. Korfel, L. Fischer, P. Martus, R. Moehle, H. A. Klasen, M. Rauch, A. Roeth, 

B. Hertenstein, T. Fischer, H. Mergenthaler, T. Hundsberger, M. Leithäuser, 

T. Birnbaum, A. Florschütz, K. Jahnke, U. Herrlinger, M. Weller, E. Thiel 

Brd. 16 Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: 

Final results of a multicenter study of AINO (Italian Association of Neurooncology). 

(Abstract #2027) 

R. Soffietti, E. Trevisan, R. Ruda, L. Bertero, C. Bosa, M. Fabrini, I. Lolli 

Brd. 17 Phase II study of bevacizumab (BEV), temozolomide (TMZ), and 

hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed 

glioblastoma (GBM). (Abstract #2028) 

A. M. Omuro, K. Beal, S. Karimi, D. Correa, T. A. Chan, L. M. DeAngelis, 

I. T. Gavrilovic, C. Nolan, A. Hormigo, A. B. Lassman, T. J. Kaley, I. K. Mellinghoff, 

C. Grommes, K. Panageas, A. S. Reiner, R. Barradas, L. E. Abrey, P. H. Gutin 

Brd. 18 Randomized multicenter phase II trial of irinotecan and bevacizumab as 

neoadjuvant and adjuvant to temozolomide-based chemoradiation versus 

chemoradiation for unresectable glioblastoma: Interim results of the 

TEMAVIR study from the ANOCEF group. (Abstract #2029^) 

B. Chauffert, L. Feuvret, F. Bonnetain, L. Taillandier, H. Taillia, D. Frappaz, 

R. Schott, J. Honnorat, M. Fabbro, I. Tennevet, F. Ghiringhelli, J. S. Guillamo, 

X. Durando, D. Castera, M. Frenay, C. Campello, R. Guillevin, J. Skrzypski, 

T. S. Dabakuyo, O. L. Chinot, Association des Neuro-Oncologues d’Expression 

Francaise 

66


Brd. 19 Bevacizumab (BV) continuation following BV progression: Meta-analysis of 

five consecutive recurrent glioblastoma (GBM) trials. (Abstract #2030) 

D. A. Reardon, J. J. Vredenburgh, A. Desjardins, K. Peters, A. D. Coan, 

J. E. Herndon, H. S. Friedman 

Brd. 20 Phase II study of erlotinib with concurrent whole-brain radiation therapy for 

patients with brain metastases from non-small cell lung cancer. (Abstract 

#2031) 

J. Welsh, A. Amini, E. S. Kim, P. Allen, J. Y. Chang, L. L. Garland, J. Holt, 

D. Erdman, R. Komaki, B. Stea 

Brd. 21 Phase I study of vorinostat in combination with temozolomide in patients 

with malignant gliomas. (Abstract #2032) 

P. Y. Wen, V. K. Puduvalli, J. G. Kuhn, J. M. Reid, K. Lamborn, T. F. Cloughesy, 

S. M. Chang, J. Drappatz, W. A. Yung, M. R. Gilbert, H. Robins, F. S. Lieberman, 

A. B. Lassman, R. M. McGovern, S. Desideri, X. Ye, M. M. Ames, 

I. J. Espinoza-Delgado, S. A. Grossman, M. Prados 

Brd. 22 NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with 

recurrent glioblastoma: A North Central Cancer Treatment Group study. 


K. A. Jaeckle, D. Schiff, S. K. Anderson, E. Galanis, P. J. Stella, P. J. Flynn, 

J. N. Sarkaria, B. W. Scheithauer, B. J. Erickson, J. C. Buckner, NCCTG 

Brd. 23 TEMOBIC: An ANOCEF phase II study of BCNU and temozolomide (TMZ) 

combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas 

(AOG). (Abstract #2034) 

O. L. Chinot, K. Hoang-Xuan, M. Fabbro, L. Taillandier, J. Honnorat, M. Barrie, 

M. Sanson, C. Kerr, P. Beauchesne, S. Cartalat-Carel, D. Autran, A. Loundou, 

R. Guillevin, K. Mokhtari, D. Figarella-Branger, J. Delattre, Association des 

Neuro-Oncologues d’Expression Francaise 

Brd. 24 Open-label, dose-confirmation study of interstitial 131 I-chTNT-1/b mab for the 

treatment of glioblastoma multiforme (GBM) at first relapse: Interim results. 


W. R. Shapiro, D. Gupta, A. K. Mahapatra, S. Gopal, K. Judy, S. J. Patel, J. Shan 

Brd. 25 A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and 

radiation (RT) for newly diagnosed high-grade gliomas. (Abstract #2036) 

S. A. Jeyapalan, M. Goldmann, J. Donahue, H. Elinzano, D. L. Evans, 

B. M. O’Connor, M. A. Puthawala, A. Oyelese, D. Cielo, M. Blitstein, M. Dargush, 

A. Santaniello, M. Constantinou, T. Dipetrillo, H. Safran, Brown University 

Oncology Group 

67 

FRIDAY

FRIDAY 


2:00 PM - 6:00 PM 


Gynecologic Cancer 


Display Location: E450a 


Discussion Location: E354b 

CME credit: 1 


Daniela Matei, MD—Co-Chair 

Indiana University Simon Cancer Center 

Seiko Diane Yamada, MD—Co-Chair 


Discussion 

5:00 PM Paul J. Goodfellow, PhD (Abstracts #5012–5016) 

Washington University School of Medicine 

Discussion 

5:15 PM David R. Spriggs, MD (Abstracts #5017–5024) 


Discussion 

5:30 PM Beth Karlan, MD (Abstracts #5025–5031) 

Cedars-Sinai Medical Center 

Discussion 

5:45 PM Patricia J. Eifel, MD (Abstracts #5032–5036) 


Brd. 1 A phase II study of everolimus and letrozole in patients with recurrent 

endometrial carcinoma. (Abstract #5012) 

B. M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf, 

K. R. Adler, K. H. Lu, R. L. Coleman 

Brd. 2 Phase II study of oral ridaforolimus in patients with metastatic and/or locally 

advanced recurrent endometrial cancer: NCIC CTG IND 192. (Abstract #5013) 

H. Mackay, S. Welch, M. S. Tsao, J. J. Biagi, L. Elit, P. Ghatage, L. Martin, 

K. S. Tonkin, S. Ellard, S. K. Lau, L. McIntosh, E. A. Eisenhauer, A. M. Oza 

Brd. 3 Hormone therapy plus temsirolimus for endometrial carcinoma (EC): 

Gynecologic Oncology Group trial #248. (Abstract #5014) 

G. F. Fleming, V. L. Filiaci, P. Hanjani, J. J. Burke II, S. A. Davidson, 

K. K. Leslie, R. J. Zaino, Gynecologic Oncology Group 

Brd. 4 A phase II trial of temsirolimus and bevacizumab in patients with 

endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell 

cancer: Ovarian cancer (OC) subset—A study of the Princess Margaret, 

Mayo, Southeast phase II and California Cancer (CCCP) N01 Consortia 

NCI#8233. (Abstract #5015) 

R. Morgan, A. M. Oza, R. Qin, K. M. Laumann, H. Mackay, E. L. Strevel, S. Welch, 

D. Sullivan, R. M. Wenham, H. X. Chen, L. A. Doyle, D. R. Gandara, C. Erlichman 

Brd. 5 The search continues: Looking for predictive biomarkers for response mTOR 

inhibition in endometrial cancer. (Abstract #5016) 

L. A. Meyer, B. M. Slomovitz, B. Djordjevic, J. M. Galbincea, T. A. Johnston, 

M. Munsell, J. K. Burzawa, M. Huang, R. Broaddus, D. A. Iglesias, R. L. Coleman, 

D. M. Gershenson, T. W. Burke, J. Wolf, K. H. Lu 

Brd. 6 Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, 

NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and 

fallopian tube cancer. (Abstract #5017) 

R. L. Coleman, L. R. Duska, P. T. Ramirez, S. C. Modesitt, K. M. Schmeler, R. Iyer, 

M. Garcia, A. Sood 

68


Brd. 7 The role of bevacizumab incombination with pegylated liposomal 

doxorubicin in patients with platinum-resistant recurrent or refractory 

ovarian cancers. (Abstract #5018) 

H. Kouta, K. Kudoh, M. Takano, R. Kikuchi, T. Kita, T. Goto, K. Furuya, Y. Kikuchi 

Brd. 8 A phase II study of intermittent sorafenib with bevacizumab in patients with 

bevacizumab-naive epithelial ovarian cancer (EOC). (Abstract #5019) 

E. C. Kohn, J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville, 

H. L. Kotz, J. Squires, N. D. Houston, H. X. Chen, J. J. Wright 

Brd. 9 A phase II trial of weekly nab-paclitaxel with GM-CSF as 

chemoimmunotherapy for platinum-resistant epithelial ovarian cancer. 


R. E. Swensen, J. Childs, D. Higgins, T. Gooley, B. A. Goff, P. A. Fintak, 

B. Buening, M. L. Disis 

Brd. 10 A phase II study of ENMD-2076 in platinum-resistant ovarian cancer. 


U. Matulonis, W. P. Tew, D. Matei, K. Behbakht, G. F. Fleming, A. M. Oza 

Brd. 11 Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer 

(OC). (Abstract #5022) 

G. Scambia, D. Lorusso, G. Amadio, N. Trivellizzi, A. Pietragalla, R. De Vincenzo, 

V. Salutari, M. Di Stefano, G. Mangili, S. Montoli, G. Citterio, A. Lambiase, 

C. Bordignon 

Brd. 12 Independent radiologic review of GOG218, a phase III trial of bevacizumab 

(BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary 

peritoneal (PPC), or fallopian tube cancer (FTC). (Abstract #5023) 

R. A. Burger, M. F. Brady, J. Rhee, M. A. Sovak, H. Nguyen, M. A. Bookman 

Brd. 13 A single-center experience of EMA/CO chemotherapy for high-risk 

gestational trophoblastic neoplasia: Induction low-dose cisplatin and 

etoposide chemotherapy. (Abstract #5024) 

C. Alifrangis, R. Agarwal, D. Short, P. Savage, M. Seckl 

Brd. 14 Sequence-specific effects on DNA and cell damage with the PARP inhibitor 

olaparib (AZD2281) and carboplatin. (Abstract #5025) 

J. L. Hays, G. Kim, J. Mariani, R. F. Murphy, M. Angelos, A. McCollum, J. Lu, 

B. C. Widemann, J. Lee, E. C. Kohn 

Brd. 15 Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine 

BRCA mutation screening after a diagnosis of invasive ovarian cancer. 


K. Alsop, S. Fereday, C. Meldrum, A. deFazio, P. Webb, M. J. Birrer, 

M. Friedlander, S. B. Fox, D. Bowtell, G. Mitchell, The Australian Ovarian Cancer 

Study (AOCS) Group 

Brd. 16 Loss of heterozygosity (LOH) as a measure of whole-genome instability in 

ovarian cancer correlates with clinical outcomes. (Abstract #5027) 

G. Korpanty, K. Timms, V. Abkevich, M. Carey, A. Gutin, Y. Li, J. Li, M. Markman, 

R. Broaddus, J. S. Lanchbury, K. H. Lu, G. B. Mills, B. Hennessy 

Brd. 17 A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with 

the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triplenegative 

breast cancer. (Abstract #5028) 

J. Liu, G. F. Fleming, S. M. Tolaney, M. J. Birrer, R. T. Penson, S. T. Berlin, 

C. Whalen, K. Tyburski, K. Matijevich, E. Kasparian, M. Roche, H. Lee, 

E. P. Winer, S. P. Ivy, U. Matulonis 

Brd. 18 Effect of WBC BRCA1 promoter methylation on ovarian cancer risk. (Abstract 

#5029) 

P. Lonning, M. Bjornslett, S. Knappskog, L. Vatten, P. Romundstad, U. Axcrona, 

D. G. Evans, A. Howell, A. Dørum , R. Chrisanthar 

Brd. 19 Associations between MDM2 SNP309 and SNP285C haplotypes and ovarian 

cancer risk in BRCA1 mutation carriers. (Abstract #5030) 

M. Bjørnslett, S. Knappskog, P. Lonning, A. Dørum 

69 

FRIDAY

FRIDAY 


Brd. 20 A multivariate longitudinal algorithm for early detection of ovarian cancer 

using multiple biomarkers. (Abstract #5031) 

Z. Zhang, S. J. Skates, L. J. Sokoll, Z. Lu, C. H. Clarke, M. A. Hernandez, K. H. Lu, 

R. C. Bast 

Brd. 21 A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation 

therapy (RT) for women with locally advanced cervical cancer (CXCA): A 

GOG study. (Abstract #5032) 

K. N. Moore, M. Sill, D. S. Miller, P. Disilvestro, K. De Geest, P. G. Rose, 

H. R. Cardenes, R. S. Mannel, J. H. Farley, R. J. Schilder, P. M. Fracasso 

Brd. 22 INCA-GYN001: Erlotinib added to cisplatin and definitive radiotherapy in 

untreated patients with locally advanced squamous cell cervical 

carcinoma—Final report of a phase II trial. (Abstract #5033) 

A. N. Rodrigues, I. A. Small, C. C. Carmo, G. M. Moralez, F. Erlich, R. Grazziotin, 

M. H. Lewer, C. C. Camisao, F. V. Alves, C. G. Ferreira 

Brd. 23 Phase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2carboxaldehyde 

thiosemicarbazone (3-AP, NSC #663249) for locally 

advanced cervical and vaginal cancer. (Abstract #5034) 

C. Kunos, S. E. Waggoner, K. M. Zanotti, R. DeBernardo, N. Fusco, A. Heugel, 

J. Knazek, R. Adams, T. Radivoyevitch, A. Dowlati 

Brd. 24 Utility of preoperative ferumoxtran-10 enhanced MRI to evaluate 

retroperitoneal lymph node metastasis in advanced cervical cancer: Results 

of ACRIN 6671/GOG 0233. (Abstract #5035) 

M. Atri, Z. Zhang, H. Marques, J. Gorelick, M. Harisinghani, A. Sohaib, D. Koh, 

S. Raman, M. S. Gee, H. Choi, L. M. Landrum, R. S. Mannel, L. T. Chuang, 

J. Q. Yu, C. K. McCourt, M. Gold, ACRIN/GOG 

Brd. 25 Estimation of expectedness: How reliable are the predictions for the outcome 

of standard therapy in randomized phase III studies (RP3) in epithelial 

ovarian cancer (EOC)? (Abstract #5036) 

V. Castonguay, I. Diaz-Padilla, L. Wang, A. M. Oza 

70

2:00 PM - 6:00 PM 


Head and Neck Cancer 




Discussion Location: S406 

CME credit: 1 

Track(s): Head and Neck Cancer 


Quynh-Thu Le, MD—Co-Chair 

Stanford University Medical Center 

Barbara A. Murphy, MD—Co-Chair 

Vanderbilt Medical Center 

Discussion 

5:00 PM Quynh-Thu Le, MD (Abstracts #5507–5515^) 

Stanford University Medical Center 

Discussion 

5:15 PM Bonnie S. Glisson, MD (Abstracts #5516–5520) 


Discussion 

5:30 PM Barbara A. Murphy, MD (Abstracts #5521–5526) 

Vanderbilt Medical Center 

Discussion 

5:45 PM Lisa F. Licitra, MD (Abstracts #5527–5529) 

Fondazione IRCCS Istituto Nazionale dei Tumori 

Brd. 1 Genetic sequence variants (GSV) in relation to acute and late toxicities in 

head and neck cancer (HNC) patients treated with radiation therapy (RT). 


F. Meyer, I. Bairati, W. Xu, A. Azad, G. Liu 

Brd. 2 Interference of amphiregulin and EGFRvIII expression with outcome of 

patients with squamous cell carcinoma of the head and neck (SCCHN) 

receiving cetuximab-docetaxel treatment. (Abstract #5508) 

I. Tinhofer, K. F. Klinghammer, W. Weichert, M. Knoedler, A. Stenzinger, 

T. C. Gauler, V. Budach, U. Keilholz 

Brd. 3 MDM2 309 single nucleotide polymorphisms (SNP) and clinical outcome in 

patients with advanced squamous cell carcinoma of head and neck (SCCHN). 


M. Gasco, D. Vivenza, M. Monteverde, L. Lattanzio, I. Colantonio, G. Natoli, 

E. Miraglio, A. Comino, N. Syed, T. Crook, M. C. Merlano, C. Lo Nigro 

Brd. 4 Updated clinical and biomarker results from a phase I study of vandetanib 

with radiation therapy (RT) with or without cisplatin in locally advanced head 

and neck squamous cell carcinoma (HNSCC). (Abstract #5510) 

V. Papadimitrakopoulou, J. Heymach, S. J. Frank, J. Myers, H. Lin, H. T. Tran, 

C. Chen, F. R. Hirsch, P. B. Langmuir, J. R. Vasselli, S. M. Lippman, D. Raben 

Brd. 5 Correlation of circulating tumor cells in SCCNH patients to cancer 

reoccurrence using a negative enrichment technology. (Abstract #5511) 

K. Jatana, P. Balasubramanian, J. C. Lang, T. N. Teknos, D. E. Schuller, 

J. J. Chalmers 

Brd. 6 Predictive value of human papillomavirus (HPV) 16 in situ hybridization (ISH) 

and p16 immunohistochemistry (IHC) for HPV oncogene expression in 

paraffin-embedded oropharynx squamous cell carcinoma (OPSCC). 


M. L. Gillison, R. Jordan, M. Lingen, B. Perez-Ordonez, X. He, R. Pickard, 

A. Inman, M. Koluder, B. Jiang, P. Wakely, W. Xiao 

71 

FRIDAY

FRIDAY 


Brd. 7 H-RAS and PIK3CA mutations and response to cetuximab in head and neck 

squamous cell carcinoma (HNSCC). (Abstract #5513) 

T. Rampias, A. Giagini, K. Florou, P. Gouveris, E. Vaja, N. Haralambakis, 

P. Katsaounis, D. G. Pectasides, T. Economopoulos, A. Psyrri 

Brd. 8 Molecular prognostic prediction by support vector machine integrated 

approach for local advanced nasopharyngeal carcinoma. (Abstract #5514) 

X. Wan, X. Wu, X. Fan, H. Cai, M. Chen, J. Xu, M. Hong, Q. Liu 

Brd. 9 Exosomal-miRNA profiles as diagnostic and prognostic biomarkers in head 

and neck squamous cell carcinoma (HNSCC). (Abstract #5515^) 

G. Rabinowits, C. G. Taylor, G. H. Kloecker, A. Patel, M. B. Hall, D. D. Taylor 

Brd. 10 Phase II study of chemoradiation plus bevacizumab (BV) for 

locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary 

clinical results of RTOG 0615. (Abstract #5516) 

N. Y. Lee, Q. Zhang, A. S. Garden, J. J. Kim, D. G. Pfister, J. Mechalakos, K. Hu, 

Q. Le, B. S. Glisson, A. T. Chan, K. Ang 

Brd. 11 Phase II study of gefitinib adaptive dose escalation to skin toxicity in 

recurrent and/or metastatic squamous cell carcinoma of the head and neck. 


C. A. Perez, H. Song, L. E. Raez, M. Agulnik, T. A. Grushko, A. Dekker, 

K. Stenson, E. A. Blair, O. I. Olopade, T. Y. Seiwert, E. E. Vokes, E. E. Cohen 

Brd. 12 Phase I trial of bevacizumab combined with concurrent chemoradiation for 

squamous cell carcinoma of the head and neck: Preliminary outcome results. 


P. M. Harari, D. Khuntia, A. M. Traynor, T. Hoang, D. T. Yang, G. K. Hartig, 

T. M. McCulloch, R. Jeraj, M. J. Nyflot, P. A. Wiederholt, L. R. Gentry 

Brd. 13 A randomized phase II trial of cetuximab-based induction chemotherapy 

followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated 

radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with 

concomitant boost (CetuxPX) in patients with locoregionally advanced head 

and neck cancer (HNC). (Abstract #5519) 

T. Y. Seiwert, D. J. Haraf, E. E. Cohen, E. A. Blair, K. Stenson, J. K. Salama, 

M. Kocherginsky, V. M. Villaflor, M. Witt, R. Williams, A. Dekker, E. E. Vokes 

Brd. 14 Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to 

surgery for squamous cell carcinomas of the head and neck (SCCHN) in 

current, former, and never smokers: Objective responses and clinical 

outcomes. (Abstract #5520) 

W. N. William Jr., R. S. Weber, J. Lee, J. Myers, L. E. Ginsberg, A. K. El-Naggar, 

E. M. Sturgis, A. L. Sabichi, M. S. Kies, E. Y. Hanna, A. C. Hessel, C. Lu, S. Y. Lai, 

R. Ayuste, S. M. Lippman, E. S. Kim 

Brd. 15 A randomized phase III trial of magic mouthwash and sucralfate versus 

benzydamine hydrochloride for prophylaxis of radiation-induced oral 

mucositis in head and neck cancer. (Abstract #5521) 

J. S. Kuk, S. Parpia, S. M. Sagar, T. Tsakiridis, D. Kim, D. I. Hodson, C. Zywine, 

J. R. Wright 

Brd. 16 Neurocognitive function (NCF) in patients (pts) treated with 

chemo/bioradiotherapy (C/B-RT) for head and neck cancers (HNC). (Abstract 

#5522) 

A. R. Abdul Razak, L. L. Siu, A. Chan, G. R. Pond, K. M. Tirona, E. X. Chen, 

A. J. Hope, J. Ringash, B. O’Sullivan, J. N. Waldron, K. Chan, H. K. Gan, 

L. J. Bernstein 

Brd. 17 Patient-reported fatigue in head and neck cancer survivors. (Abstract #5523) 

G. B. Gunn, T. R. Mendoza, A. S. Garden, X. S. Wang, W. H. Morrison, S. J. Frank, 

E. Y. Hanna, C. Lu, B. M. Beadle, K. Ang, C. S. Cleeland, D. I. Rosenthal 

72


Brd. 18 Phase III trial of low-level laser therapy to prevent induced oral mucositis in 

head and neck cancer patients submitted to concurrent chemoradiation. 

(Abstract #LBA5524) 

H. S. Antunes, D. Herchenhorn, C. M. Araujo, E. Cabral, E. M. D. S. Ferreira, 

I. A. Small, M. P. Rampini, N. Teich, P. C. Rodrigues, T. G. P. D. Silva, L. F. Dias, 

C. G. M. Ferreira 

Brd. 19 The utility of using area under the curve to analyze symptom burden during 

radiation/chemoradiation for head and neck cancer. (Abstract #5525) 

T. R. Mendoza, G. B. Gunn, C. D. Fuller, X. S. Wang, D. I. Rosenthal, 

C. S. Cleeland 

Brd. 20 Toxicity in combined modality treatment of HNSCC: Cisplatin versus 

cetuximab. (Abstract #5526) 

A. Chew, J. Hay, J. J. Laskin, J. Wu, C. Ho 

Brd. 21 Correlation of HPV status and hypoxic imaging using [18F]-misonidazole 

(FMISO) PET in head and neck squamous cell carcinoma (HNSCC). (Abstract 

#5527) 

M. E. Trinkaus, R. J. Hicks, R. J. Young, L. J. Peters, B. J. Solomon, M. Bressel, 

J. Corry, R. Fisher, D. Binns, G. A. McArthur, D. Rischin 

Brd. 22 Human papillomavirus (HPV)–related head and neck squamous cell 

carcinoma (HNSCC) and outcome after treatment with epidermal growth 

factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus 

conventional chemotherapy (CT) plus RT. (Abstract #5528) 

B. Pajares, J. Trigo Perez, M. D. Toledo, M. Alvarez, L. Perez-Villa, 

C. Gonzalez-Hermoso, A. Rueda, J. A. Medina, B. Jimenez, J. Jerez, L. Perez, 

E. Alba 

Brd. 23 Human papillomavirus (HPV) and rising oropharyngeal cancer incidence and 

survival in the United States. (Abstract #5529) 

A. Chaturvedi, E. Engels, R. Pfeiffer, B. Y. Hernandez, W. Xiao, E. Kim, B. Jiang, 

M. Goodman, M. Sibug-Saber, W. Cozen, L. Liu, C. Lynch, N. Wentzensen, 

R. Jordan, S. Altekruse, W. F. Anderson, P. Rosenberg, M. L. Gillison 

73 

FRIDAY

FRIDAY 


2:00 PM - 6:00 PM 


Leukemia, Myelodysplasia, and Transplantation 


Display Location: E450b 


Discussion Location: Arie Crown Theater 

CME credit: 1 

Track(s): Leukemia, Myelodysplasia, and Transplantation 

Jane Liesveld, MD—Co-Chair 

University of Rochester Medical Center 

Harry Paul Erba, MD, PhD—Co-Chair 

University of Michigan Medical Center 

Discussion 

5:00 PM Olatoyosi Odenike, MD (Abstracts #6509–6515) 


Discussion 

5:15 PM Farhad Ravandi, MD (Abstracts #6516–6522) 


Discussion 

5:30 PM Joseph P. Uberti, MD (Abstracts #6523–6528) 

Karmanos Cancer Institute, Wayne State University 

Discussion 

5:45 PM Guido Marcucci, MD (Abstracts #6529–6533) 

The Ohio State University Comprehensive Cancer Center 

Brd. 1 Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase 

chronic myeloid leukemia (CP CML) in the BELA trial: Eighteen-month 

follow-up. (Abstract #6509) 

C. Gambacorti-Passerini, J. E. Cortes, D. Kim, H. Kantarjian, N. Khattry, 

J. H. Lipton, C. Powell, P. Harris, A. M. Countouriotis, T. H. Brummendorf 

Brd. 2 Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in 

chronic phase (CML-CP): Two-year follow-up from DASISION. (Abstract 

#6510) 

H. Kantarjian, N. P. Shah, J. E. Cortes, M. Baccarani, M. Bradley-Garelik, C. Zhu, 

A. Hochhaus 

Brd. 3 Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed 

chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month 


R. A. Larson, D. Kim, G. Rosti, L. Stenke, R. Pasquini, A. Hoenekopp, 

R. E. Blakesley, N. J. Gallagher, A. Hochhaus, T. P. Hughes, G. Saglio, 

H. Kantarjian 

Brd. 4 Five-year follow-up of patients with imatinib-resistant or -intolerant chronicphase 

chronic myeloid leukemia (CML-CP) receiving dasatinib. (Abstract 

#6512) 

N. P. Shah, J. E. Cortes, C. A. Schiffer, F. Guilhot, T. H. Brummendorf, A. C. Chen, 

D. Healey, A. Lambert, G. Saglio 

Brd. 5 A survey of current practices in the management of chronic myeloid 

leukemia (CML). (Abstract #6513) 

M. J. Mauro, J. E. Cortes, R. A. Larson, P. M. Herout, V. K. Bollu, A. Niyazov, 

H. Kantarjian 

Brd. 6 Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of 

myelofibrosis. (Abstract #6514) 

A. D. Pardanani, D. Caramazza, G. George, T. L. Lasho, W. J. Hogan, 

M. R. Litzow, K. Begna, C. A. Hanson, R. F. McClure, L. M. Bavisotto, 

G. Smith, M. Kowalski, S. Sirhan, A. W. Roberts, V. Gupta, J. Gotlib, A. Tefferi 

74


Brd. 7 Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients 

with myelofibrosis. (Abstract #6515) 

H. J. Deeg, O. Odenike, B. L. Scott, Z. Estrov, J. E. Cortes, D. A. Thomas, 

H. J. Zhu, H. Kantarjian, S. Verstovsek 

Brd. 8 Phase I trial of the targeted alpha-particle nano-generator actinium-225 

( 225 Ac-lintuzumab; anti-CD33; HuM195) in acute myeloid leukemia (AML). 


J. G. Jurcic, T. L. Rosenblat, M. R. McDevitt, N. Pandit-Taskar, J. A. Carrasquillo, 

S. M. Chanel, C. Ryan, M. G. Frattini, D. Cicic, S. M. Larson, D. A. Scheinberg 

Brd. 9 Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory 

AML. (Abstract #6517) 

E. J. Feldman, K. W. Yee, D. Rizzieri, A. S. Advani, A. Charman, A. Richardson, 

M. J. Toal, J. E. Cortes 

Brd. 10 Ponatinib in patients with acute myeloid leukemia (AML): Preliminary 

findings from a phase I study in hematologic malignancies. (Abstract #6518) 

M. Talpaz, N. P. Shah, M. W. Deininger, M. J. Mauro, I. W. Flinn, S. Lustgarten, 

W. Lindmark, J. M. Gozgit, T. Clackson, C. D. Turner, F. G. Haluska, H. Kantarjian, 

J. E. Cortes 

Brd. 11 CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly 

diagnosed AML patients age 60–75: Safety and efficacy in secondary AML 

(sAML). (Abstract #6519) 

J. E. Lancet, J. E. Cortes, T. Kovacsovics, D. Hogge, J. E. Kolitz, M. S. Tallman, 

M. Chiarella, A. C. Louie, E. J. Feldman 

Brd. 12 A phase III, open-label, randomized comparison of AS1413 (amonafide 

L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary 

acute myeloid leukemia (ACCEDE). (Abstract #6520) 

R. M. Stone, S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri, 

H. P. Erba, L. E. Damon, J. Jang, M. S. Tallman, K. Warzocha, T. Masszi, 

M. A. Sekeres, E. Miklos, H. Horst, D. L. Selleslag, S. R. Solomon, P. Venugopal, 

A. S. Lundberg, B. L. Powell 

Brd. 13 A phase I and pharmacodynamic (PD) study of the histone deacetylase 

(HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid 

malignancies. (Abstract #6521) 

O. Odenike, L. A. Godley, J. Madzo, T. Karrison, M. Green, A. S. Artz, 

R. J. Mattison, K. W. Yee, M. Bennett, N. Fulton, G. Koval, G. Malnassy, 

R. A. Larson, M. J. Ratain, W. Stock 

Brd. 14 Early lenalidomide (LEN) dose intensity and durable RBC-transfusion 

independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic 

syndromes (MDS) and del5q. (Abstract #6522) 

A. F. List, A. Giagounidis, J. T. Backstrom, T. Fu, P. Fenaux 

Brd. 15 Relapse incidence and leukemia-free survival (LFS) in patients (pts) older 

than age 60 with AM undergoing stem cell transplantation: A report of the 

East German Study Group Hematology and Oncology (OSHO). (Abstract 

#6523) 

D. Niederwieser, G. Maschmeyer, T. Fischer, L. Uharek, R. Kortmann, 

U. Hegenbart, P. Dreger, M. Herold, H. G. Sayer, H. Wolf, U. Kreibich, D. Hähling, 

C. Junghanss, N. Grobe, R. Krahl, T. Lange, H. Al-Ali, W. Pönisch, C. Nehring, 

G. Doelken 

Brd. 16 A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative 

conditioning regimen. (Abstract #6524) 

S. Kim, J. Lee, Y. Joo, H. Kim, H. Ryoo, M. Kim, G. Lee, W. Lee, J. Park, S. Bae, 

M. Hyun, D. Kim, Y. Min, Cooperative Study Group A for Hematology (COSAH) 

Brd. 17 Reduced intensity conditioning with combined haploidentical and cord blood 

transplantation results in rapid engrafment and durable remissions. 


K. Van Besien, H. Liu, E. S. Rich, L. A. Godley, O. Odenike, L. Joseph, J. P. Kline, 

V. H. Nguyen, J. M. Cunningham, R. A. Larson, W. Stock, A. Wickrema, A. S. Artz 

75 

FRIDAY

FRIDAY 


Brd. 18 Mechanism of thymic renewal after infusion of suicide gene-modified donor 

T cells after hematopoietic stem cell transplantation (HSCT) in adult patients. 


C. Bordignon, L. Vago, G. Oliveira, M. Noviello, C. Soldati, D. Ghio, I. Brigida, 

A. Aiuti, M. Lupo-Stanghellini, J. Peccatori, A. Lambiase, A. Bondanza, 

A. Del Maschio, F. Ciceri, C. Bonini 

Brd. 19 Vincristine sulfate liposomes injection (VSLI) “bridging” to potentially 

curative hematopoietic stem cell transplantation (HSCT) in adults with 

Philadelphia chromosome–negative (Ph-) acute lymphoblastic leukemia 

(ALL). (Abstract #6527) 

G. J. Schiller, S. E. Coutre, M. L. Larson, D. Ben Yehuda, P. Venugopal, 

S. Goldberg, G. L. Messerschmidt, J. Silverman, S. R. Deitcher, H. Kantarjian 

Brd. 20 A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in 

combination with fludarabine, cyclophosphamide, rituximab (FCR) for 

patients with fludarabine-refractory and/or del(17p)/p53-defective chronic 

lymphocytic leukemia (CLL). (Abstract #6528) 

J. E. Castro, L. S. Schwartzberg, J. Pinilla-Ibarz, T. J. Kipps, M. J. Cantwell 

Brd. 21 High-throughput mutation analysis in acute myeloid leukemia (AML). 


J. Dunlap, C. L. Corless, W. H. Fleming, R. Braziel, N. Leeborg, K. Gatter, 

M. Loriaux, K. Kelemen, T. Kovacsovics, G. Fan 

Brd. 22 Association of IDH1 mutations in normal karyotype acute myeloid leukemia 

samples with higher HIF-1� and VEGF-A expression. (Abstract #6530) 

M. Smonskey, P. Starostik, G. Deeb, K. Demock, R. Vargas, D. Lal, S. N. Sait, 

M. Wetzler, E. S. Wang 

Brd. 23 PRDM16 (1p36) translocations define a distinct entity of myeloid 

malignancies with poor prognosis but may also occur in lymphoid 


F. P. Duhoux, G. Ameye, K. Bahloula, M. Mozziconacci, S. Laibe, I. Wlodarska, 

L. Michaux, P. Talmant, S. Richebourg, E. Lippert, F. Speleman, C. Herens, 

S. Struski, S. Raynaud, N. Nadal, M. Lafage, N. Auger, J. Libouton, J. Demoulin, 

H. A. Poirel, Groupe Francophone de Cytogenetique Hematologique (GFCH) and 

Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO) 

Brd. 24 The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1positive 

acute lymphoblastic leukemia (ALL). (Abstract #6532) 

I. Iacobucci, A. Ferrari, A. Lonetti, C. Papayannidis, F. Paoloni, M. Abbenante, 

V. Guadagnuolo, E. Ottaviani, F. Cattina, A. Vitale, S. Paolini, S. Soverini, S. Parisi, 

M. Vignetti, M. Baccarani, G. Martinelli 

Brd. 25 Novel jumping translocations (JT) associated with genetic instability and 

aggressive disease in chronic lymphocytic leukemia (CLL). (Abstract #6533) 

C. Miller, F. Racke, G. Lozanski, A. McFaddin, J. C. Byrd, N. A. Heerema 

76

2:45 PM - 4:00 PM 


Acute Myeloid Leukemia: Update on Therapy and Molecular Basis 



Track(s): Leukemia, Myelodysplasia, and Transplantation, Geriatric Oncology 

Martin S. Tallman, MD—Chair 


Therapy of the Elderly Patient with Acute Myeloid Leukemia 

Sami N. Malek, MD 

University of Michigan Comprehensive Cancer Center 

Update on the Molecular Biology of Acute Myeloid Leukemia: Clinical Implications 

Alan Burnett, MD 

University of Wales College of Medicine 

Therapy of Acute Myeloid Leukemia in Patients Younger Than Age 55 

Challenges in HER2-positive Breast Cancer 




Mark D. Pegram, MD—Chair 

University of Miami Sylvester Comprehensive Cancer Center 

Overview and Discussion of HER2 Biology: De Novo and Acquired Resistance to Targeting 

Giuseppe Viale, MD 

European Institute of Oncology 

Controversies in Testing for HER2 

Eric P. Winer, MD 


Therapeutic Implications of HER2 Targeting in Very Small Clinical Low-risk Tumors and HER2 

Targeting after Progression 

Targeting ALK in Pediatric Malignancies 



Track(s): Pediatric Oncology, Lymphoma and Plasma Cell Disorders 

Stephan Morris, MD—Chair 

St. Jude Children’s Research Hospital 

The Role of ALK Signaling in Anaplastic Large Cell Lymphoma 

Yael P. Mosse, MD 

The Children’s Hospital of Philadelphia 

“Driver” ALK Mutations in Neuroblastoma 

Pasi A. Janne, MD, PhD 


Developing Drugs That Taget ALK and Other Genomic Aberrations 


77 

FRIDAY

FRIDAY 


When Adults Are Diagnosed with Children’s Sarcomas 



Track(s): Sarcoma, Pediatric Oncology 

Karen H. Albritton, MD—Chair 

Cooks Children’s Medical Center 

The Unique Issues of the Adolescent and Young Adult (AYA) with Sarcoma 

David Parham, MD 

University of Oklahoma Health Sciences Center 

Pathologic Differences between Adult and Pediatric Sarcomas 

Robert G. Maki, MD, PhD 

Mount Sinai School of Medicine 

The Management of the Adult with Children’s Sarcoma 

78

2:45 PM - 4:00 PM 


Setting Up a Cancer Genetics Program (M02)—Ticketed Session 



Track(s): Cancer Genetics, Cancer Prevention/Epidemiology 

Jeffrey N. Weitzel, MD 

City of Hope 

The Academic Perspective 

Therese M. Mulvey, MD 

Southcoast Hospitals Group 

Community Practice Perspective 


79 

FRIDAY

FRIDAY 


3:00 PM - 4:30 PM 

CLINICAL SCIENCE SYMPOSIUM 

Personalized Medicine 



Track(s): Developmental Therapeutics 

James L. Gulley, MD, PhD—Chair 


3:00 PM Personalized medicine in a phase I clinical trials program: The University of 

Texas M. D. Anderson Cancer Center Initiative. (Abstract #CRA2500) 

A. M. Tsimberidou, N. G. Iskander, D. S. Hong, J. J. Wheler, S. Fu, S. A. Piha-Paul, 

A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen, R. Kurzrock 

Discussion 

3:15 PM Paula M. Fracasso, MD, PhD (Abstract #CRA2500) 

University of Virginia 

3:30 PM Progression-free survival (PFS) from a phase I study of crizotinib (PF- 

02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). 


D. R. Camidge, Y. Bang, E. L. Kwak, A. T. Shaw, A. J. Iafrate, R. G. Maki, 

B. J. Solomon, S. I. Ou, R. Salgia, K. D. Wilner, D. B. Costa, G. Shapiro, 

P. LoRusso, P. Stephenson, Y. Tang, K. Ruffner, J. W. Clark 

Discussion 

3:45 PM Nasser H. Hanna, MD (Abstract #2501) 

Indiana University 

4:00 PM The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR 

and RAS/MEK/ERK pathways in first-in-human phase I study: The START 

Center experience. (Abstract #2502) 

T. Shimizu, A. W. Tolcher, K. P. Papadopoulos, M. Beeram, D. W. Rasco, 

L. S. Smith, S. Gunn, L. Smetzer, T. A. Mays, B. Kaiser, C. Alvarez, 

G. L. Mangold, A. Patnaik 

Discussion 

4:15 PM James L. Gulley, MD, PhD (Abstract #2502) 


80

3:30 PM - 4:45 PM 

SPECIAL SESSION 

ASCO/Society of Nuclear Medicine (SNM) Joint Session: Molecular Imaging in 

Cancer Clinical Trials 



Track(s): Clinical Trials, Special Session 

George W. Sledge Jr., MD—Co-Chair 


Introduction and Overview 

David A. Mankoff, MD, PhD—Co-Chair 


The Imaging Perspective 

Anthony Frank Shields, MD, PhD 

Karmanos Cancer Institute/Wayne State University 

The Medical Oncology Perspective 


81 

FRIDAY

FRIDAY 


3:30 PM - 6:00 PM 


Career Choices: Options in Academia, Private Practice, Industry, and 

Government 



John E. Pippen, MD—Chair 

Baylor Sammons Cancer Center and Texas Oncology/US Oncology 

Hybrid: Academia and Private Practice 

Martine J. Piccart-Gebhart, MD, PhD 


Academia 

Johanna C. Bendell, MD 

Sarah Cannon Research Institute 

Private Practice 

Barbara L. McAneny, MD 

New Mexico Oncology Hematology Consultants 

Hybrid: Public Policy and Private Practice 

Sandra J. Horning, MD 

Genentech Inc. 

Industry 

Richard Pazdur, MD 

U.S. Food and Drug Administration 

Government 

82

3:45 PM - 6:00 PM 


An Update on Biomarkers for the Early Detection of Cancer, Prediction of 

Prognosis, and as Surrogate Endpoints for Cancer Prevention Trials 



Track(s): Cancer Prevention/Epidemiology, Cancer Genetics 

Dean E. Brenner, MD—Chair 


Overview and Fundamental Concepts of Biomarker Development and Validation 

Carol J. Fabian, MD 

University of Kansas Medical Center 

Biomarkers as Surrogate Endpoints for Cancer Prevention Trials: Where Are We? 

Sanford D. Markowitz, MD, PhD 

Case Western Reserve University 

Biomarkers for the Early Detection of Colon Cancer 

Harvey I. Pass, MD 

New York University School of Medicine 

Early Detection and Prognostic Biomarkers for Lung Cancer 

Ian Thompson, MD 

University of Texas Health Science Center at San Antonio 

Prostate Cancer and Prostate-specific antigen: Our “Perfect Biomarker”—Fact or Fantasy? 

Robert C. Bast, MD 


Ovarian Cancer: CA-125 as a Prototype for an Early-diagnosis Biomarker—Do We Have 

Reasonable Expectations? 

Biologic, Clinical, and Psychosocial Correlates at the Interface of Aging and 

Cancer: Report from the National Institute on Aging (NIA)/National Cancer 

Institute (NCI) Conference on Geriatric Oncology Research to Improve Clinical 

Care 



Track(s): Geriatric Oncology 

William Dale, MD, PhD—Chair 

The University of Chicago Medical Center 

Psychosocial Factors at the Interface of Cancer and Aging 

Arti Hurria, MD 


Improving Geriatric Oncology Clinical Care through Research 

Harvey Jay Cohen, MD 

Duke University Medical Center 

Biologic Factors at the Interface of Cancer and Aging 

Supriya Gupta Mohile, MD, MS 


Clinical Factors at the Interface of Cancer and Aging 


83 

FRIDAY

FRIDAY 


Second Malignant Neoplasms: Epidemiology, Genetics, and Risk Prediction 



Track(s): Cancer Prevention/Epidemiology, Cancer Genetics, Patient and Survivor Care 

Lois B. Travis, MD, ScD—Chair 

University of Rochester School of Medicine and Dentistry 

Epidemiology of Second Malignant Neoplasms: An Overview 

Sophie D. Fossa, MD 

Oslo University Hospital, The Norwegian Radium Hospital 

Second Malignant Neoplasms in Survivors of Testicular Cancer 

M. Eileen Dolan, PhD 


Genomics and Late Effects of Treatment: Cisplatin as a Paradigm 

Margaret R. Spitz, MD 


Risk Prediction Models for Second Cancers: Synopsis of Ongoing Research and Genetic 

Predictors 

Andrea K. Ng, MD, MPH 

Brigham and Women’s Hospital and Harvard Medical School 

Screening for Second Cancers: Evidence-based Recommendations to Date 

Scott Michael Lippman, MD 


Chemoprevention and Interventional Strategies in Second Cancers: A Review of Evidencebased 

Recommendations 

84

4:00 PM - 6:00 PM 


Grant Writing Workshop II: Improving Your Grant Writing Skills (Mock Study 

Section and Small Group Discussions) 


CME credit: 2 

Track(s): Professional Development, Clinical Trials 

Bruce E. Johnson, MD—Chair 


Eric Jay Small, MD 

University of California, San Francisco 

Small Group Roundtable Discussant 

Alex A. Adjei, MD, PhD 

Roswell Park Cancer Institute 


Fabrice Andre, MD, PhD 

Institut Gustave-Roussy 


Dawn L. Hershman, MD, MS 

Columbia University Medical Center 


J. Jack Lee, PhD, DDS 



Wells A. Messersmith, MD 

University of Colorado Cancer Center 


Gary K. Schwartz, MD 



Lillian L. Siu, MD 

Princess Margaret Hospital 



85 

FRIDAY

FRIDAY 


4:30 PM - 5:45 PM 


Cancer Predisposition in Children, Adolescents, and Young Adults 



Track(s): Pediatric Oncology, Cancer Genetics 

David Malkin, MD—Chair 

The Hospital for Sick Children, University of Toronto 

Familial Cancer Syndromes: Moving past p53 

Stephen J. Chanock, MD 


Cancer Susceptibility: Methods for Identifying the Key Mutations 

Kenan Onel, MD, PhD 


Genetic Predisposition to Secondary Cancers in Survivors of Pediatric Cancer 

Updates in Triple-negative Breast Cancer 



Track(s): Breast Cancer, General Oncology, Tumor Biology 

Lisa A. Carey, MD—Chair 


Clinical and Molecular Biology of Triple-negative Breast Cancer 

William Foulkes, PhD 

McGill University 

Triple-negative Disease: Basal-like and BRCAness Findings and Implications of Epidemiologic 

Risk Factor Studies 

Andrew Nicholas James Tutt, PhD, MBChB 

Guy’s Hospital Breakthrough Breast Cancer Research Unit, Guy’s Hospital 

PARP Inhibitors and DNA Damage Repair as a Therapeutic Target 

86

4:30 PM - 5:45 PM 


Cancer Epidemiology for the Clinical Oncologist: When Should We Have 

Confidence in Studies and What Should We Tell Our Patients and Colleagues? 




Track(s): Cancer Prevention/Epidemiology 

Christine B. Ambrosone, PhD 



87 

FRIDAY

FRIDAY 


4:45 PM - 6:00 PM 

CLINICAL PROBLEMS IN ONCOLOGY SESSION 

Liver-directed Therapy in Colorectal Cancer: What Are the Options and When 

Should They Be Used? (C01)—Ticketed Session 



Track(s): Gastrointestinal (Colorectal) Cancer 

Alan Paul Venook, MD—Chair 


Under- and Overutilization of Liver-focused Treatments: The Medical Oncologist Perspective of 

When to Use and When Not to Use 

Kenneth Tanabe, MD 

Massachusetts General Hospital Cancer Center 

Which Patients Should Undergo Hepatic Metastasectomy and Which Should Not? 

Stephen Barnett Solomon, MD 


Radiofrequency Ablation, Cryoablation, Stereotactic Radiosurgery, External Beam Radiation: 

Lots of Choices, but Which to Use? 

88

7:30 AM - 8:15 AM 

EDUCATION SESSION 

How to Navigate the Annual Meeting (Fellows and Junior Faculty Only) 



John E. Pippen, MD—Chair 

Baylor Sammons Cancer Center and Texas Oncology/US Oncology 

Clifford Hudis, MD 


Saturday, June 4, 2011 

89 

SATURDAY

SATURDAY 


8:00 AM - 9:15 AM 


ASCO/Children’s Oncology Group (COG) Joint Session: Designing Trials to 

Test Novel Treatment Strategies for “Go” or “No Go” Decisions 



Track(s): Pediatric Oncology, Clinical Trials, Special Session 

Mark J. Ratain, MD—Chair 


Designing Early-phase Studies with “Go” versus “No Go” Rules 

Frank M. Balis, MD 


Early-phase Pediatric Studies: Identifying Valid Endpoints 

Susan Blaney, MD 

Texas Children’s Cancer Center 

Challenges of Conducting Early-phase Studies in Pediatrics 

Biomarkers in Genitourinary Cancers: Relevance to Clinical Practice 



Track(s): Genitourinary Cancer, Clinical Trials, Tumor Biology 

Nancy Ann Dawson, MD—Chair 

Georgetown University Hospital Lombardi Comprehensive Cancer Center 

Circulating Tumor Cells in Prostate Cancer 

Mark Garzotto, MD 

Portland Veterans Affairs Medical Center 

Prostate-specific Antigen Kinetics in Biochemically Recurrent Prostate Cancer 

(Castration-naive or -resistant): Does It Guide Management? 

Kimryn Rathmell, MD, PhD 


Renal Cell Cancer Biomarkers: Relevance to Clinical Practice 

Contemporary Topics in Ovarian Cancer Management 



Track(s): Gynecologic Cancer, Cancer Genetics, General Oncology 

Gottfried E. Konecny, MD—Chair 

University of California, Los Angeles 

Molecular Characterization of Ovarian Cancer: Where Are We Headed? 

Deborah Kay Armstrong, MD 


Doctor, I’m Confused: What Is the Best Treatment for My Advanced Ovarian Cancer? 

Martin Eric Gore, PhD 

Royal Marsden Hospital 

Bevacizumab Incorporation into Ovarian Cancer Treatment: Practical Considerations 

90

Etiology and Treatment of HPV-related Oropharyngeal Cancer 




Andy Trotti, MD—Chair 

H. Lee Moffitt Cancer Center and Research Institute 

Current Therapy and Modifications in HPV-related Oropharyngeal Cancer 

Sara Pai, MD, PhD 

The Johns Hopkins University School of Medicine 

Biology and Immune Therapy of HPV-related Oropharyngeal Cancer 

Maura L. Gillison, MD, PhD 

The Ohio State University 

Epidemiology and Etiology of HPV-related Oropharyngeal Cancer 

Identification of Molecular Signatures for Classification, Response, Outcomes, 

and Novel Targets 



Track(s): Sarcoma 

Paul S. Meltzer, MD, PhD—Chair 


Identification of Novel Targets through Genomics, Proteomics, and Metabolomics 

Matt Van De Rijn, MD, PhD 

Stanford University 

Molecular Signatures for Classification, Response, and Outcomes 

George D. Demetri, MD 


Molecular Translation: Bench to Bedside in Sarcomas 

PARP Inhibitors, DNA Repair, and Beyond: Theory Meets Reality in the Clinic 



Track(s): Tumor Biology, Developmental Therapeutics 

Michael B. Kastan, MD, PhD—Chair 


DNA Damage Response: Opportunities for Therapeutic Targeting 

Elizabeth R. Plummer, MD, DPhil 

Northern Centre for Cancer Care 

Development of PARP Inhibitors and Potential Roles in Chemotherapy Potentiation 

Judy Ellen Garber, MD, MPH 


Clinical Development of PARP Inhibitors: Current Status 


91 

SATURDAY

SATURDAY 


Running an Oncology Practice in 2011: Finance, Resourcing, and Ancillary 

Opportunities 



Track(s): Practice Management and Information Technology 

Dee Anna Smith—Chair 

Sarah Cannon Research Institute 

How to Understand the Financial Position of Your Practice: Financial Statements 101 

Jeffrey Patton, MD 

Tennessee Oncology 

How Do You Assess and Implement Ancillary Services That Will Enhance Your Practice? 

John Emmett Hennessy, CMPE 

Kansas City Cancer Center 

How Do You Manage the Resources in Your Office and How Does Technology Enable Efficient 

Formulary Management and Related Reimbursement Issues? 

92

8:00 AM - 9:15 AM 


Mechanisms of Metastasis (M04)—Ticketed Session 




Larry Norton, MD 


8:00 AM - 9:15 AM 



How to Manage Challenging Cases of Urothelial Cancer (C02)—Ticketed 

Session 



Track(s): Genitourinary Cancer, Geriatric Oncology 

Joaquim Bellmunt, MD, PhD—Chair 

University Hospital del Mar-IMIM 

Treatment Options for a Patient with Locally Advanced but Unresectable Bladder Cancer and 

for a Patient with Muscle-invasive but with Mixed Histology or Predominantly Nontransitional 

Cell 

Theresa M. Koppie, MD 

University of California, Davis 

Palliative Surgery in Patients with Advanced Bladder Cancer and Management of Upper Tract 

Tumors 

Daniel Peter Petrylak, MD 

Columbia University College of Physicians and Surgeons 

Systemic Therapy for Select Patient Subsets: Renal Dysfunction, Impaired Performance Status, 

Frail Elderly, or Platinum-refractory Disease 

93 

SATURDAY

SATURDAY 


8:00 AM - 9:30 AM 


Emerging Novel Targets for Lung Cancer 



Track(s): Lung Cancer 

George R. Simon, MD—Co-Chair 

Medical University of South Carolina 

Neeta Somaiah, MD—Co-Chair 

Fox Chase Cancer Center 

8:00 AM An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as 

monotherapy in patients with advanced non-small cell lung cancer (NSCLC). 


K. Wong, M. Koczywas, J. W. Goldman, E. H. Paschold, L. Horn, J. M. Lufkin, 

R. K. Blackman, F. Teofilovici, G. Shapiro, M. A. Socinski 

Discussion 

8:15 AM Suresh S. Ramalingam, MD (Abstract #7500) 

Winship Cancer Institute of Emory University 

Heat Shock Protein Inhibitors: Shock and Awe? 

8:30 AM Open-label, randomized multicenter phase II clinical trial of a toll-like 

receptor-2 (TLR2) agonist mycobacterium w (Cadi-05) in combination with 

paclitaxel plus cisplatin versus paclitaxel plus cisplatin in advanced nonsmall 

cell lung cancer (NSCLC). (Abstract #7501) 

C. P. Belani, D. Desai, B. M. Khamar, for the Cadi-05 Investigators Study Group 

Discussion 

8:45 AM Raffit Hassan, MD (Abstract #7501) 


Chemoimmunotherapy: A Light in the Darkness? 

9:00 AM Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) 

with or without the vascular disrupting agent vadimezan (ASA404) in 

advanced non-small cell lung cancer (NSCLC). (Abstract #7502) 

P. Lara, J. Douillard, K. Nakagawa, J. Von Pawel, M. J. McKeage, I. Albert, 

G. Losonczy, M. Reck, D. S. Heo, X. Fan, A. Fandi, G. Scagliotti 

Discussion 

9:15 AM Jean-Charles Soria, MD, PhD (Abstract #7502) 

Institut Gustave-Roussy 

Vascular Disrupting Agents: Is There a Future? 

94

8:00 AM - 9:30 AM 


Patient and Survivor Care and Health Services Research Session: 

Survivorship—Care Plans, Quality of Care, and Barriers to Care 





Wendy Demark-Wahnefried, PhD, RD—Co-Chair 


Lynne I. Wagner, PhD—Co-Chair 

Northwestern University 

8:00 AM Quality of care for comorbid conditions during the transition to survivorship. 


C. F. Snyder, K. D. Frick, R. J. Herbert, A. L. Blackford, B. A. Neville, 

A. C. Wolff, M. A. Carducci, C. Earle 

8:15 AM Results of a multicenter randomized trial to evaluate a survivorship care plan 

for breast cancer survivors. (Abstract #9005) 

E. Grunfeld, M. N. Levine, J. A. Julian, G. R. Pond, E. Maunsell, A. Folkes, 

S. F. Dent, A. Joy, L. F. Paszat, K. I. Pritchard, G. A. Porter, D. Rayson, 

A. Robidoux, S. Smith, J. Sussman, L. Provencher, J. Wiernikowski, J. J. Sisler, 

FUPII Trial Investigators, Ontario Clinical Oncology Group 

Discussion 

8:30 AM Lynne I. Wagner, PhD (Abstract #CRA9006) 


8:45 AM Barriers in providing breast and colorectal cancer survivorship care: 

Perceptions of U.S. primary care physicians (PCPs) and medical oncologists 

(MOs). (Abstract #CRA9006) 

K. S. Virgo, C. C. Lerro, C. N. Klabunde, C. Earle, P. A. Ganz 

9:00 AM Long-term consequences of treatment on paid work after diagnosis of breast 

cancer. (Abstract #9007) 

R. Jagsi, S. T. Hawley, P. Abrahamse, J. J. Griggs, A. S. Hamilton, S. J. Katz 

Discussion 

9:15 AM Wendy Demark-Wahnefried, PhD, RD (Abstract #9007) 


95 

SATURDAY

SATURDAY 


8:00 AM - 11:00 AM 


Designing Clinical Trials for Older Patients: Nuts and Bolts 


CME credit: 3 

Track(s): Geriatric Oncology, Clinical Trials, Professional Development 

Harvey Jay Cohen, MD—Co-Chair 


Hyman Bernard Muss, MD—Co-Chair 

University of North Carolina Lineberger Comprehensive Cancer Center 

Martine Extermann, MD 

H. Lee Moffitt Cancer Center & Research Institute 

Defining Eligibility Criteria: Healthy, Vulnerable, Frail 

Lazzaro Repetto, MD, PhD 

Istituto Nazionale Riposo E Cura Per Anziani 

Clinical Trial Recruitment 

Heidi D. Klepin, MD, MS 

Wake Forest University 

Acute Myeloid Leukemia: Bringing Theory to Practice 

William Thomas Barry, PhD 


Novel Design of Clinical Trials for Vulnerable Patients 

96

8:00 AM - 12:00 PM 

GENERAL POSTER SESSION 



Location: Hall A 


Brd. 1A Objective responses to chemotherapy in recurrent glioma: A prospective 

analysis from the German Glioma Network. (Abstract #2037) 

O. Baehr, B. Hentschel, E. Hattingen, S. Nussbaum, H. Berger, M. Tatagiba, 

J. Tonn, O. Schnell, M. Simon, T. Reithmeier, D. Krex, T. Pietsch, G. Reifenberger, 

O. Heese, M. Weller, J. Steinbach, M. Loeffler, German Glioma Network 

Brd. 1B Phase II study of dose-intense temozolomide in recurrent glioblastoma. 


S. Hammond, A. D. Norden, G. J. Lesser, J. Drappatz, C. E. Fadul, T. Batchelor, 

E. C. Quant, R. Beroukhim, A. Muzikansky, A. S. Ciampa, L. M. Doherty, 

D. C. LaFrankie, S. Ruland, C. A. Bochacki, K. Griffin, M. Gerard, C. Sceppa, 

M. R. Rosenfeld, P. Y. Wen 

Brd. 1C Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for 

recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor 

Consortium (NABTC) study 05-01. (Abstract #2039) 

L. Nayak, L. E. Abrey, J. Drappatz, M. R. Gilbert, D. A. Reardon, K. Lamborn, 

P. Y. Wen, M. Prados, L. M. DeAngelis, A. M. Omuro 

Brd. 1D Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or 

progressive meningioma. (Abstract #2040) 

A. D. Norden, S. Hammond, J. Drappatz, S. Phuphanich, D. A. Reardon, E. Wong, 

S. R. Plotkin, G. J. Lesser, J. J. Raizer, T. Batchelor, E. C. Quant, R. Beroukhim, 

T. J. Kaley, A. Muzikansky, A. S. Ciampa, L. M. Doherty, K. H. Smith, M. Gerard, 

C. Sceppa, P. Y. Wen 

Brd. 1E AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) 

and primary breast cancer (pBC) with eventual BM and association with 

outcome. (Abstract #2041) 

B. Adamo, A. M. Deal, C. Livasy, E. Burrows, K. Fritchie, K. L. Blackwell, 

E. P. Hamilton, J. Geradts, L. Thorne, A. Ugolkov, C. R. Miller, M. G. Ewend, 

L. A. Carey, C. M. Perou, V. L. Cryns, C. K. Anders 

Brd. 1F Glioma-associated antigens associated with prolonged survival in a phase I 

study of ICT-107 for patients with newly diagnosed glioblastoma. (Abstract 

#2042) 

S. Phuphanich, C. J. Wheeler, J. Rudnick, M. Mazer, M. Nuno, X. Fan, J. Bender, 

E. S. Hawkins, K. L. Black, J. Yu 

Brd. 1G Phase I study of aflibercept (VEGF Trap) and temozolomide in newly 

diagnosed, high-grade glioma. (Abstract #2043) 

J. F. De Groot, T. Cloughesy, F. S. Lieberman, S. M. Chang, A. M. Omuro, 

J. Drappatz, T. Batchelor, L. M. DeAngelis, M. R. Gilbert, W. A. Yung, J. D. Fisher, 

X. Ye, K. Lamborn, A. P. Chen, S. A. Grossman, M. Prados, P. Y. Wen 

Brd. 2A Circulating endothelial cells and progenitors in recurrent high-grade gliomas 

treated with bevacizumab and irinotecan. (Abstract #2044) 

M. Eoli, A. Calleri, L. Cuppini, E. Anghileri, S. Pellegatta, E. Prodi, M. Bruzzone, 

F. Bertolini, G. Finocchiaro 

Brd. 2B Effect of standard therapy on lymphocyte subsets and cytokines in newly 

diagnosed high-grade gliomas (HGG). (Abstract #2045) 

A. S. Balmanoukian, S. A. Grossman, C. Thoburn, F. Kos, M. Holdhoff, A. Hess 

Brd. 2C A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade 

meningioma. (Abstract #2046) 

S. A. Grimm, M. C. Chamberlain, J. Chandler, K. Muro, L. Rice, K. McCarthy, 

A. Rademaker, I. B. Helenowski, S. K. Johnston, M. M. Mrugala, J. J. Raizer 

97 

SATURDAY

SATURDAY 


Brd. 2D Vascular hemodynamic profiles of vestibular schwannomas and 

glioblastoma using MRI. (Abstract #2047) 

S. R. Plotkin, D. Jennings, K. Mouridsen, K. E. Emblem, A. G. Sorensen 

Brd. 2E FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following 

hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), 

and temozolomide (TMZ) for glioblastoma (GBM). (Abstract #2048) 

C. Grommes, S. Karimi, K. Beal, T. A. Chan, L. E. Abrey, P. H. Gutin, A. M. Omuro 

Brd. 2F CD44 as a prognostic and predictive marker for GBM. (Abstract #2049) 

B. D. Vaillant, K. Bhat, E. P. Sulman, V. Balasubramaniyan, S. Wang, K. D. Aldape, 

H. Colman 

Brd. 2G A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma 

(HGG). (Abstract #2050) 

J. Drappatz, J. J. Raizer, D. Schiff, A. S. Chi, T. Batchelor, S. M. Snodgrass, 

E. C. Quant, A. D. Norden, R. Beroukhim, S. A. Grimm, L. M. Doherty, 

A. S. Ciampa, D. C. LaFrankie, S. Ruland, M. Gerard, S. Hammond, P. Y. Wen 

Brd. 3A Concurrent temozolomide and radiation as the initial treatment for anaplastic 

glioma. (Abstract #2051) 

C. Tham, S. See, S. Tan, W. Ng, K. H. Lim, J. Thomas, E. Chua 

Brd. 3B Randomized phase II study of neoadjuvant bevacizumab and irinotecan 

versus bevacizumab and temozolomide followed by concomitant 

chemoradiotherapy in newly diagnosed primary glioblastoma multiforme. 


K. F. Hofland, S. Hansen, M. Sorensen, H. P. Schultz, A. Muhic, S. Engelholm, 

A. Ask, C. Kristiansen, C. Thomsen, H. Skovgaard Poulsen, U. N. Lassen 

Brd. 3C Prognostic factors in patients with WHO grade 3 gliomas: The Cleveland 

Clinic experience. (Abstract #2053) 

N. Hashemi-Sadraei, H. S. Bawa, A. Satra, G. Rahmathulla, M. Patel, G. Stevens, 

T. M. Tekautz, L. A. Rybicki, D. M. Peereboom, J. H. Suh, R. Weil, 

M. A. Vogelbaum, G. Barnett, M. S. Ahluwalia 

Brd. 3D Phase l study of sorafenib in combination with radiation therapy and 

temozolomide for the first-line treatment of patients with high-grade glioma. 


A. F. Hottinger, A. Ben Aissa, A. Bodmer, D. Squiban, N. Dunkel, N. Maradan, 

M. I. Vargas, D. C. Weber, E. Brendel, P. Dietrich 

Brd. 3E Upfront bevacizumab with temozolomide or with temozolomide and 

irinotecan for unresectable or multifocal glioblastoma. (Abstract #2055) 

E. Lou, D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, 

S. G. Turner, A. L. Sumrall, L. Bailey, H. S. Friedman, J. J. Vredenburgh 

Brd. 3F Phase II clinical trial of bortezomib and bevacizumab combination in 

recurrent glioblastoma. (Abstract #2056) 

D. A. Bota, Z. Eroglu, D. A. Reardon, B. D. Fu, J. Norfleet, A. Desjardins, 

M. E. Linskey, K. Peters, H. S. Friedman, J. J. Vredenburgh 

Brd. 3G Temozolomide-based chemoradiation in naive pure and mixed anaplastic 

astrocytoma: Long-term results of a phase II study. (Abstract #2057) 

S. Chiesa, G. Chiloiro, S. Manfrida, A. Mangiola, G. R. D’Agostino, G. Mantini, 

A. Albanese, P. De Bonis, C. Anile, M. Balducci 

Brd. 3H Prognostic factors in newly diagnosed glioblastoma: Have we missed 

gender? (Abstract #2058) 

E. Franceschi, A. Tosoni, S. Bartolini, L. Scopece, L. Lombardo, R. Poggi, 

V. Mazzocchi, L. La Torre, M. Ermani, A. A. Brandes 

Brd. 4A Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newly 

diagnosed glioblastoma. (Abstract #2059) 

F. Bach, M. Westphal, OSAG-101 Study Group 

98


Brd. 4B Efficacy of nitrosourea-based chemotherapy in recurrent malignant glioma 

according to time to adjuvant temozolomide failure: A pooled analysis. 


A. Paccapelo, I. Lolli, S. Scoccianti, B. Detti, G. Silvano, M. Fabrini, F. Perrone, 

G. Savio, S. Cascinu 

Brd. 4C Use of exosome analysis to reveal glioma-specific genetic changes in patient 

serum. (Abstract #2061) 

B. Carter, F. Hochberg, X. Breakefield, L. Balaj, S. Sivaraman, W. Curry, 

S. N. Kalkanis, L. Loguidice, L. M. Russo, M. Noerhelm, J. Skog 

Brd. 4D Neurotoxicity of intra-CSF liposomal cytarabine in the treatment of 

leptomeningeal metastases. (Abstract #2062) 

M. C. Chamberlain, S. K. Johnston 

Brd. 4E Glioblastoma in the elderly: Treatment planning, toxicity, and efficacy in an 

ambulatory practice. (Abstract #2063) 

W. P. Mason, Z. Lwin, D. MacFadden, A. AL-Zahrani, N. Laperriere, C. Menard, 

B. Millar, A. Sahgal, C. Massey, L. E. Coate 

Brd. 4F A phase I trial of laromustine (VNP40101M) and temozolomide for patients 

with malignant gliomas in first relapse or progression. (Abstract #2064) 

J. J. Raizer, L. Rice, A. Rademaker, J. Chandler, K. Muro, R. M. Levy, S. A. Grimm 

Brd. 4G A mathematical model of diffuse low-grade gliomas treated with PCV 

chemotherapy. (Abstract #2065) 

F. Ducray, M. Peyre, D. Ricard, B. Cajavec-Bernard, E. Grenier, M. Tod, V. Calvez, 

D. Frappaz, M. Sunyach, A. Vasiljevic, J. Pallud, S. Cartalat-Carel, J. Honnorat, 

B. Ribba 

Brd. 4H Glioblastoma in the elderly: The Cleveland Clinic experience (1992–2010). 


H. S. Bawa, N. Hashemi-Sadraei, J. H. Suh, G. Stevens, G. Rahmathulla, 

S. T. Chao, T. M. Tekautz, P. Elson, D. M. Peereboom, L. Angelov, R. Weil, 

M. A. Vogelbaum, G. Barnett, M. S. Ahluwalia 

Brd. 5A The effect of surgery in determining pseudoprogression and predicting 

outcome in adults with glioblastoma. (Abstract #2067) 

I. Melguizo, K. R. Hess, D. Blas-Boria, J. Bruner, N. Guha-Thakurta, V. K. Puduvalli 

Brd. 5B Survival after recurrence of medulloblastoma in the contemporary era. 


C. Koschmann, K. L. Schmidt, J. R. Geyer, S. Leary 

Brd. 5C Preliminary results from a multicenter, phase II, randomized, noncomparative 

clinical trial of radiation and temozolomide with or without vandetanib in 

newly diagnosed glioblastoma (GBM). (Abstract #2069) 

E. C. Quant, T. Batchelor, A. B. Lassman, D. Schiff, T. J. Kaley, E. Wong, 

T. Mikkelsen, J. Drappatz, A. D. Norden, R. Beroukhim, S. E. Weiss, 

B. M. Alexander, C. Sceppa, M. Gerard, S. D. Hallisey, C. A. Bochacki, 

K. H. Smith, A. Muzikansky, P. Y. Wen 

Brd. 5D A pharmacokinetic (PK) study of AC480 administered twice daily in patients 

with surgically resectable, recurrent malignant glioma (MG) not on enzymeinducing 

antiepileptic drug (EIAED). (Abstract #2070) 

A. Desjardins, D. A. Reardon, J. J. Vredenburgh, K. Peters, M. Trikha, J. James, 

M. Gardner, A. Brickhouse, J. E. Herndon, H. S. Friedman 

Brd. 5E Novel use of MR spectroscopy in detecting CSF lactate for diagnosis of 

neoplastic meningitis. (Abstract #2071) 

C. L. Weston, O. Zalatimo, J. Sheehan, R. Harbaugh, D. A. Bota, A. Shedden, 

M. J. Glantz 

Brd. 5F Clinical improvement and rapid radiographic regression induced by a MET 

inhibitor in a patient with MET-amplified glioblastoma. (Abstract #2072) 

A. S. Chi, E. L. Kwak, J. W. Clark, D. L. Wang, D. N. Louis, A. J. Iafrate, 

T. Batchelor 

99 

SATURDAY

SATURDAY 


Brd. 5G Concurrent, 3-times daily ultrafractionated radiation therapy and 

temozolomide for newly inoperable glioblastoma: TEMOFRAC—A phase II 

trial. (Abstract #2073) 

P. D. Beauchesnes, G. Faure, G. Noel, T. Schmitt, L. Martin, L. Taillandier, 

C. D. Carnin 

Brd. 5H Efficacy of radiation therapy on epileptic seizures of grade 2 and 3 gliomas: 

A retrospective study. (Abstract #2074) 

R. Ruda, E. Trevisan, U. Magliola, C. Mantovani, U. Ricardi, R. Soffietti 

Brd. 6A Value of CA 15–3 detection in cerebrospinal fluid (CSF) of breast cancer 

leptomeningeal metastases. (Abstract #2075) 

S. Salingue, M. Girot, I. Rodrigues, S. Taillibert, N. Kotecki, F. Zairi, M. Baranzelli, 

M. Faivre-Pierret, P. Devos, J. Bonneterre, F. Dubois, E. Le Rhun 

Brd. 6B Prognostic relevance of promoter methylation-associated loss of ID4 

expression in glioblastoma multiforme. (Abstract #2076) 

M. Martini, T. Cenci, N. Montano, V. Cesarini, R. Pallini, L. Larocca 

Brd. 6C Stereotactic volumetric resection, intracavitary carmustine wafers, and 

radiation therapy for brain metastases: The Moffitt Cancer Center 

experience. (Abstract #2077) 

S. Brem, R. Sampath, D. Yu, A. Staller, M. Obadia, M. G. Ewend 

Brd. 6D IDH mutation status impact on in vivo hypoxia biomarkers expression: New 

insights from a clinical, nuclear imaging, and immunohistochemical study in 

34 patients with glioma. (Abstract #2078) 

P. Metellus, C. Colin, D. Taieb, E. Guedj, I. Nanni-Metellus, B. Coulibaly, 

C. Colavolpe, S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, L. Ouafik, 

D. Figarella-Branger 

Brd. 6E Is cerebrospinal fluid cytology a useful test? (Abstract #2079) 

C. M. Zoccoli, O. Zalatimo, M. J. Glantz 

Brd. 6F Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: A 

phase II study. (Abstract #2080) 

F. Zustovich, L. Landi, G. Lombardi, L. Galli, C. Porta, D. Amoroso, A. Fontana, 

M. Andreuccetti, C. Galli, A. Falcone, V. Zagonel 

Brd. 6G Feasibility pilot of attenuated maintenance chemotherapy for adolescents 

and adults with newly diagnosed localized medulloblastoma and other 

primitive neuroectodermal tumors. (Abstract #2081) 

J. N. Dagri, A. Evans, J. Torkildson, J. Portnow, L. S. Ashby, B. Zakotnik, 

R. J. Brown, G. Dhall, J. L. Finlay 

Brd. 6H Safety results from a prospective study of concurrent radiosurgery and 

bevacizumab for recurrent malignant glioma. (Abstract #2082) 

K. C. Cuneo, A. R. Cabrera, J. H. Sampson, K. J. Allen, J. J. Vredenburgh, 

K. Peters, Z. Chang, J. E. Herndon, A. Desjardins, D. A. Reardon, J. Kirkpatrick 

Brd. 7A Chemotherapy plus concomitant low-dose fractionated radiotherapy as 

second-line treatment for recurrent or progressive glioblastoma after 

temozolomide-based chemoradiation: A pilot study. (Abstract #2083) 

G. R. D’Agostino, B. Diletto, S. Manfrida, A. Mangiola, S. Chiesa, L. De Filippo, 

V. Frascino, F. Miccichè, C. Anile, M. Balducci 

Brd. 7B Use of Tegwondo, a near-continuous temozolomide regimen, in high- and 

low-grade gliomas. (Abstract #2084) 

H. M. Strik, H. C. Bock, C. Marosi 

Brd. 7C Baseline and long-term cognition and neuroimaging in patients with primary 

CNS lymphoma (PCNSL) treated with enhanced chemotherapy (CHT) 

delivery. (Abstract #2085) 

N. D. Doolittle, M. A. Lubow, D. F. Kraemer, E. Dosa, N. A. Hedrick, R. Tyson, 

C. Lacy, L. M. Maron, R. W. Butler, E. A. Neuwelt 

100


Brd. 7D Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM): 

Results of a retrospective cohort study of the OMIT Bretagne and Pays de la 

Loire. (Abstract #2086) 

F. Grude, M. Campone, J. Frenel, P. Soulie, E. Vauleon, Y. Hadjarab, G. Ganem, 

F. Denis, J. Egreteau, A. Lortholary, M. Porneuf, H. Simon, P. DAM Hieu, V. Klein, 

B. Dominique, P. Deguiral, H. Desclos, P. Menei, S. Traoré 

Brd. 7E Functional and survival effect of bevacizumab and irinotecan administered at 

recurrence in a cohort of patients with GBM. (Abstract #2087) 

E. Tabouret, M. Barrie, C. Boucard, M. Matta, D. Autran, A. Loundou, O. L. Chinot 

Brd. 7F Phase II study of verubulin (MPC-6827) for the treatment of subjects with 

recurrent glioblastoma naive to treatment with bevacizumab. (Abstract 

#2088) 

L. J. Kim, M. C. Chamberlain, J. Zhu, J. J. Raizer, S. A. Grimm, S. Phuphanich, 

C. E. Fadul, S. Rosenfeld, A. H. Balch, C. C. Pope, M. Brulotte, A. A. Beelen, 

L. D. Recht 

Brd. 7G Prospective follow-up of 96 patients with breast cancer with leptomeningeal 

metastasis recruited from 2007 to 2010. (Abstract #2089) 

E. Le Rhun, N. Kotecki, F. Zairi, I. Rodrigues, A. Mailliez, M. Baranzelli, 

M. Faivre-Pierret, P. Devos, J. Cazin, J. Bonneterre, F. Dubois 

Brd. 8A Radiographic pattern of progression of recurrent GBM treated with 

bevacizumab with or without irinotecan. (Abstract #2091) 

P. Dory-Lautrec, E. Tabouret, M. Barrie, C. Boucard, M. Matta, D. Autran, 

N. Girard, O. L. Chinot 

Brd. 8B Clinical outcome of concomitant chemoradiotherapy followed by adjuvant 

temozolomide (TMZ) therapy for high-grade gliomas (HGG) in Colombia 

(RedLANO registry). (Abstract #2092) 

L. D. Ortiz, A. F. Cardona, C. E. Fadul, A. Londono, H. A. Becerra, 

E. Jimenez-Hakim, C. J. Yepes, H. Carranza, R. E. Bruges Maya, C. J. Castro, 

C. A. Vargas 

Brd. 8C Prognostic factors in elderly patients with grade 3 gliomas. (Abstract #2093) 

A. Satra, N. Hashemi-Sadraei, H. S. Bawa, D. M. Peereboom, G. Stevens, 

L. A. Rybicki, J. H. Suh, M. A. Vogelbaum, R. Weil, G. Barnett, M. S. Ahluwalia 

Brd. 8D Photodynamic therapy (PDT) in the multidisciplinary treatment of brain 

tumors: A feasibility study. (Abstract #2094) 

M. S. Gonzalez, V. Vanaclocha, I. Azinovic, J. Rebollo, R. Cañon, E. Calvo, 

A. Brugarolas 

Brd. 8E The role of plasma GFAP as a biomarker for glioblastoma. (Abstract #2095) 

H. Husain, W. Savage, A. Everett, X. Ye, C. Blair, K. E. Romans, C. Bettegowda, 

P. Burger, S. A. Grossman, M. Holdhoff 

Brd. 8G O(6)-methylguanine DNA-methyltransferase (MGMT) in glioblastoma: 

Analysis on first and following surgeries. (Abstract #2097) 

F. Bertolini, C. Baraldi, E. Zunarelli, A. Valentini, R. Depenni, A. Falasca, 

F. Bertoni, F. Cavalleri, A. Chiari, A. Fontana, P. F. Conte, G. Pinna, 

Gruppo Neuro-Oncologico Modena (GNO-MO) 

Brd. 8H Bevacizumab, temozolomide, and radiation therapy followed by 

bevacizumab, temozolomide, and oral topotecan for newly diagnosed 

glioblastoma multiforme (GBM). (Abstract #2098) 

J. J. Vredenburgh, A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, 

A. D. Coan, L. Bailey, D. Janney, C. Lu, H. S. Friedman 

Brd. 9A A review of how antineoplastic treatments impact the sexuality, fertility, and 

sexual function of adult patients with brain cancer: Implications for real-time 

treatment planning. (Abstract #2099) 

E. M. Dunbar, S. Savona, N. Ferree, P. A. Pumphrey 

101 

SATURDAY

SATURDAY 


Brd. 9B Treatment of patients with advanced neurofibromatosis type 2 (NF2) with 

novel molecularly targeted therapies. (Abstract #2100) 

V. Subbiah, J. M. Slopis, D. S. Hong, L. S. Angelo, I. E. McCutcheon, R. Kurzrock 

Brd. 9C A comparative study of pediatric CNS tumor activity as assessed by [18F]- 

FDG PET imaging and proton magnetic resonance spectroscopic imaging. 


S. J. Hipp, E. A. Steffen-Smith, P. Herscovitch, N. J. Patronas, J. M. Solomon, 

R. Bent, S. M. Steinberg, K. E. Warren 

102

8:00 AM - 12:00 PM 



Gastrointestinal (Colorectal) Cancer 



Brd. 10A The biology of early-onset colorectal cancer: An examination of tumor 

markers, pathology, and survival in a large cohort of patients. (Abstract 

#3537) 

S. A. Khan, M. Morris, K. Idrees, M. Gimbel, S. Rosenberg, Z. Zeng, J. Shia, 

M. P. La Quaglia, P. Paty 

Brd. 10B Colorectal cancer cases with de novo germ-line mutations in MLH1, MSH2, 

and MSH6 from the Colon Cancer Family Registry. (Abstract #3538) 

A. Win, M. A. Jenkins, D. D. Buchanan, J. P. Young, S. N. Thibodeau, 

J. L. Hopper, N. M. Lindor 

Brd. 10C Incidence and characteristics of BRAF V600E mutation in colorectal cancer 

(CRC) with mismatch repair (MMR) protein defect due to loss of MLH1: A 

prospective evaluation of 104 consecutive patients. (Abstract #3539) 

S. A. Mahesh, E. Hanna, M. Khan, P. Ravichandran, F. Slezak 

Brd. 10D The effect of screening on stage of disease and tumor characteristics in 

patients with operable colorectal cancer. (Abstract #3540) 

M. J. Proctor, E. Chrighton, C. H. Richards, D. C. Mcmillan, P. G. Horgan 

Brd. 10E Quality of life (QOL) for patients treated with FOLFOX with or without 

cetuximab (Cmab) following complete resection of colorectal cancer (CRC): 

Results from North Central Cancer Treatment Group (NCCTG) phase III trial 

N0147. (Abstract #3541) 

M. R. Mahoney, J. A. Sloan, J. M. Hubbard, H. Liu, A. F. Shields, E. Chan, 

R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. G. Nair, D. J. Sargent, S. R. Alberts 

Brd. 10F The final results of the SWOG S9304 phase III intergroup trial’s 

pharmacogenetic analysis: Association of polymorphisms with survival and 

toxicity in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) 

and pelvic radiation (RT). (Abstract #3542) 

P. M. Wilson, P. O. Bohanes, C. J. Rankin, J. K. Benedetti, C. M. Ulrich, 

S. R. Smalley, K. W. Makar, W. Zhang, T. Winder, Y. Ning, A. Gerger, 

L. Benhaim, R. El-Khoueiry, M. J. Labonte, C. D. Blanke, H. Lenz 

Brd. 10G Accuracy of endorectal ultrasonography in evaluation of response to 

chemoradiation in locally advanced rectal cancer. (Abstract #3543) 

B. Farnault, L. Moureau-Zabotto, C. de Chaisemartin, M. Giovannini, G. Monges, 

J. Delpero, P. Viens, M. Resbeut 

Brd. 10H Neoadjuvant chemoradiotherapy and multivisceral resection for primary 

locally advanced adherent colon cancer. (Abstract #3544) 

M. Cukier, H. Soliman, A. Smith, S. Wong 

Brd. 11A Neoadjuvant treatment response and outcomes in locally advanced rectal 

cancer: Establishing oncologic benchmarks. (Abstract #3545) 

G. J. Chang, I. Park, Y. You, C. Hu, S. R. Hamilton, C. Eng, B. W. Feig, P. Das, 

S. Krishnan, C. H. Crane, S. T. Nguyen, M. A. Rodriguez-Bigas, J. M. Skibber 

Brd. 11B Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in 

patients with K-ras-unmutated, locally advanced rectal cancer (LARC): A 

randomized multicenter phase II trial (SAKK 41/07). (Abstract #3546) 

D. Helbling, G. Bodoky, O. Gautschi, H. Sun, F. Bosman, B. Gloor, R. Burkhard, 

R. C. Winterhalder, A. Madlung, D. Rauch, P. Saletti, L. A. Widmer, M. M. Borner, 

D. Baertschi, P. Yan, D. Koeberle 

Brd. 11C Factors influencing histopathology-assessed TME quality after low anterior 

rectal resection: Results of a prospective multicenter observational trial. 


B. Garlipp, H. Ptok, U. Schmidt, P. Stuebs, F. Meyer, I. Gastinger, H. Lippert 

103 

SATURDAY

SATURDAY 


Brd. 11D Morbidity and mortality results from a prospective randomized trial 

comparing mesorectal excision with or without lateral lymph node dissection 

for clinical stage II and III lower rectal cancer: Japan Clinical Oncology Group 

study JCOG0212. (Abstract #3548) 

S. Fujita, S. Saito, Y. Moriya, J. Mizusawa, K. Nakamura, N. Saito, Y. Kinugasa, 

Y. Kanemitsu, M. Ohue, S. Fujii, Y. Akazai, M. Shiozawa, T. Yamaguchi, 

H. Bandou, T. Aoki, K. Murata, K. Shirouzu, N. Takiguchi, Y. Saida, Colorectal 

Cancer Study Group of Japan Clinical Oncology Group 

Brd. 11E Prospective analysis of KRAS, BRAF, and PIK3CA mutational status and 

EGFR copy number in patients (pts) with locally advanced rectal cancer: A 

translational substudy of a clinical trial (SAKK 41/07) evaluating the effect of 

neoadjuvant chemoradiation (CRT) with or without panitumumab. (Abstract 

#3549) 

D. Koeberle, S. Bougel, J. Benhattar, F. Bosman, O. Gautschi, H. Sun, G. Bodoky, 

R. von Moos, D. Helbling, for the Swiss Group for Clinical Cancer Research 

(SAKK) 

Brd. 11F Mortality risk after preoperative versus postoperative chemotherapy and 

radiotherapy in lymph node–positive rectal cancer. (Abstract #3550) 

T. E. Seery, A. Ziogas, B. S. Lin, C. G. Pan, M. J. Stamos, J. A. Zell 

Brd. 11G Results of a nationwide Japanese study on lateral pelvic lymph node 

metastasis in low rectal cancer: Is it regional or distant disease? (Abstract 

#3551) 

T. Akiyoshi, T. Watanabe, S. Miyata, K. Kotake, T. Muto, K. Sugihara 

Brd. 11H Three-year outcomes of GCR-3: A phase II randomized trial comparing 

conventional preoperative chemoradiation (CRT) followed by surgery and 

postoperative adjuvant chemotherapy (CT) with induction CT followed by 

CRT and surgery in locally advanced rectal cancer. (Abstract #3552) 

C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont, 

R. Vera, M. P. Escudero, J. Maurel, J. Aparicio 

Brd. 11H Three-year outcomes of GCR-3: A phase II randomized trial comparing 

conventional preoperative chemoradiation (CRT) followed by surgery and 

postoperative adjuvant chemotherapy (CT) with induction CT followed by 

CRT and surgery in locally advanced rectal cancer. (Abstract #3552) 

C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont, 

R. Vera, M. P. Escudero, J. Maurel, J. Aparicio 

Brd. 12A Oncologic and functional hazards of obesity among patients with locally 

advanced rectal cancer. (Abstract #3553) 

I. Park, C. Hu, M. A. Rodriguez-Bigas, Y. You, J. M. Skibber, C. Eng, R. A. Wolff, 

P. Das, C. H. Crane, G. J. Chang 

Brd. 12B Adherence to NCCN treatment guidelines for rectal cancer: Analysis of 

national practice patterns. (Abstract #3554) 

R. Chagpar, J. N. Cormier, B. W. Feig, G. J. Chang, Y. You, Y. Chiang, 

M. A. Rodriguez-Bigas, J. M. Skibber, Y. Xing 

Brd. 12C Comparison of outcomes of intensity-modulated radiotherapy and 3-D 

conformal radiotherapy for anal squamous cell carcinoma using a propensity 

score analysis. (Abstract #3555) 

D. A. Rothenstein, T. Dasgupta, J. F. Chou, Z. Zhang, J. L. Wright, L. K. Temple, 

L. Saltz, K. A. Goodman 

Brd. 12D Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer 

(CC): A pooled analysis of 16,425 patients from the ACCENT database. 


Q. Shi, J. M. Hubbard, G. A. Yothers, T. Andre, L. Saltz, G. Francini, B. M. Bot, 

C. Twelves, M. E. Buyse, A. Grothey, D. J. Sargent, for the ACCENT Collaborative 

Group 

104


Brd. 12E Survival rates among patients vaccinated following resection of colorectal 

cancer metastases in a phase II randomized study compared with 

contemporary controls. (Abstract #3557) 

M. Morse, D. Niedzwiecki, J. Marshall, C. R. Garrett, D. Z. Chang, M. Aklilu, 

T. S. Crocenzi, D. J. Cole, S. Dessureault, A. Hobeika, T. Osada, B. M. Clary, 

S. D. Hsu, G. Devi, A. Bulusu, R. Annechiarico, V. Chadaram, T. M. Clay, 

H. K. Lyerly 

Brd. 12F Independent validation of a prognostic classifier (Predictor-C) in a set of 292 

patients with colorectal cancer of UICC stage II. (Abstract #3558) 

H. Adams, T. Mayr, B. Hinzmann, A. Rosenthal 

Brd. 12G External validation of a tumor derived 5-gene prognostic signature 

(OncoDefender-CRC) for recurrence (R) of stages I/II colorectal cancer (CRC). 


P. F. Lenehan, L. A. Boardman, D. W. Fry, E. R. Heyman, J. Ohrnberger, 

W. P. Worzel 

Brd. 12H Microsatellite instability to predict the efficacy of adjuvant chemotherapy for 

stage II colon cancer. (Abstract #3560) 

J. Kim, H. Kim, Y. Hong, J. Lee, M. Ryu, H. Chang, S. Jang, M. Kim, C. Yu, T. Kim 

Brd. 13A Initial safety report of ACTS-CC trial (TRICC0706): A randomized phase III 

trial of UFT/LV versus S-1 as adjuvant therapy for stage III colon cancer. 


A. Takagane, H. Takiuchi, K. Ikejiri, I. Mochizuki, H. Mochizuki, K. Kotake, 

S. Kameoka, K. Takahashi, T. Watanabe, M. Watanabe, N. Boku, N. Tomita, 

Y. Matsubara, K. Sugihara 

Brd. 13B Updated results of the FIRIS study: A phase II/III trial of 

5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as 

second-line chemotherapy for metastatic colorectal cancer (mCRC). 


H. Baba, K. Muro, H. Yasui, Y. Shimada, A. Tsuji, S. Sameshima, T. Satoh, 

T. Denda, K. Ina, K. Sugihara 

Brd. 13C Carcinoma of unknown primary site (CUP): Outcomes in patients with a 

colorectal molecular profile treated with site-specific chemotherapy. 


F. A. Greco, W. J. Lennington, D. R. Spigel, G. R. Varadhachary, J. D. Hainsworth 

Brd. 13D Role of surgical resection among chemotherapy-treated patients with 

colorectal cancer with stage IV disease: A survival analysis. (Abstract #3564) 

B. S. Lin, A. Ziogas, T. E. Seery, M. J. Stamos, J. A. Zell 

Brd. 13E A randomized two-arm phase III study to investigate bevacizumab in 

combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX 

alone in post radical resection of patients with liver metastases of colorectal 


E. E. Voest, N. Snoeren, S. B. Schouten, A. M. Bergman, E. van Werkhoven, 

O. J. Loosveld, T. M. van Gulik, J. M. Smit, A. Cats, E. Boven, E. Hesselink, 

A. Rijken, M. Tol, O. Dalesio, H. M. Verheul, R. A. Tollenaar, J. van der Sijp, 

I. Borel Rinkes, R. van Hillegersberg 

Brd. 13F Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a 

randomized controlled trial in advanced colorectal cancer (aCRC). (Abstract 

#3566) 

G. W. Middleton, S. J. Gwyther, S. R. Brown, T. S. Maughan, C. Olivier, 

S. Richman, N. R. Maisey, M. Hill, S. Gollins, S. Myint, S. Slater, J. Wagstaff, 

J. A. Bridgewater, R. Glynne-Jones, G. Hemmings, H. Marshall, D. Blake, V. Napp, 

P. Quirke, M. T. Seymour, UK NCRI Colorectal Clinical Studies Group 

Brd. 13G Randomized phase III study of panitumumab (pmab) with FOLFOX4 

compared with FOLFOX4 alone as first-line treatment (tx) for metastatic 

colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group 

(ECOG) performance status (PS). (Abstract #3567^) 

S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, Y. Humblet, 

D. Cunningham, F. Xu, K. Krishnan, J. Douillard 

105 

SATURDAY

SATURDAY 


Brd. 13H FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) 

with or without an anti-EGFR monoclonal antibody for locally advanced, 

operable colon cancer: Planned interim report. (Abstract #3568) 

D. Morton, L. Magill, K. Handley, G. Brown, D. R. Ferry, Z. b. Gray, P. Quirke, 

M. T. Seymour, B. Warren, R. G. Gray, on behalf of the FOxTROT Collaborative 

Group 

Brd. 14A Initial change in tumor size as an imaging surrogate of outcomes in patients 

with metastatic colorectal cancer (mCRC) treated with first-line irinotecan 

and 5-FU combination chemotherapy. (Abstract #3569) 

C. Suzuki, L. Blomqvist, A. Sundin, P. Bystrom, A. Berglund, H. Jacobsson, 

P. Nygren, B. Glimelius 

Brd. 14B Can patients be cured after cytoreductive surgery plus intraperitoneal 

chemotherapy for colorectal peritoneal carcinomatosis? (Abstract #3570) 

D. Goéré, D. Tzanis, V. G. Gava, L. Maggiori Jr., F. Dumont, M. Ducreux, D. Elias 

Brd. 14C Treatment of colorectal peritoneal carcinomatosis with systemic 

chemotherapy: A pooled analysis of NCCTG’s phase III trials N9741 and 

N9841. (Abstract #3571) 

J. Franko, Q. Shi, C. D. Goldman, B. A. Pockaj, G. D. Nelson, R. M. Goldberg, 

H. C. Pitot, A. Grothey, S. R. Alberts, D. J. Sargent 

Brd. 14D Early tumor shrinkage and long-term outcome in metastatic colorectal 

cancer (mCRC): Assessment of predictive utility across treatment arms in 

the CRYSTAL and OPUS studies. (Abstract #3572) 

H. Piessevaux, E. Van Cutsem, C. Bokemeyer, M. Schlichting, S. Heeger, 

S. Tejpar 

Brd. 14E Phase II study of panitumumab with irinotecan for patients with KRAS 

wild-type metastatic colorectal cancer (MCRC) refractory to standard 

chemotherapy: A GERCOR study. (Abstract #3573) 

B. Chibaudel, C. Tournigand, M. Mabro, M. Bennamoun, P. Artru, S. Nguyen, 

J. Bachet, N. Aissat, H. Blons, P. Laurent-Puig, A. De Gramont, T. Andre, 

GERCOR 

Brd. 14F Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and 

irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with 

metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. 

(Abstract #3574^) 

M. Peeters, T. J. Price, A. H. Strickland, T. E. Ciuleanu, W. Scheithauer, 

S. O’Reilly, M. M. Keane, D. R. Spigel, Y. Tian, K. Krishnan 

Brd. 14G FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line 

treatment for patients with metastatic colorectal cancer (mCRC): Analysis of 

patients with KRAS mutated tumors in the randomized German AIO study 

KRK-0306. (Abstract #3575) 

S. Stintzing, J. Neumann, A. Jung, L. Fischer von Weikersthal, T. Decker, 

U. Vehling-Kaiser, E. Jaeger, T. Heintges, C. Stoll, D. P. Modest, T. Kirchner, 

W. Scheithauer, V. Heinemann 

Brd. 14H Efficacy of chemotherapy plus cetuximab according to metastatic site in 

KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL 

and OPUS studies. (Abstract #3576) 

C. Kohne, C. Bokemeyer, S. Heeger, U. Sartorius, P. Rougier, E. Van Cutsem 

Brd. 15A A multicenter, multinational retrospective analysis of mitomycin C (MMC) in 

refractory metastatic colorectal cancer (mCRC). (Abstract #3577) 

R. Ferrarotto, K. K. Machado, M. P. Mak, V. A. Vieira, T. K. Takahashi, 

D. Saragiotto, S. Kopetz, M. J. Overman, P. Hoff 

Brd. 15B Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in 

the front-line treatment of patients with metastatic colorectal cancer (mCRC) 

and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 

trial): Final results. (Abstract #3578) 

E. Mitry, O. Bouche, J. Seitz, P. Etienne, J. Legoux, T. Aparicio, G. Breysacher, 

C. Lecaille, T. Lecomte, J. Jouve, FFCD 

106


Brd. 15C Bevacizumab plus capecitabine as maintenance treatment after initial 

treatment with bevacizumab plus XELOX in previously untreated metastatic 

colorectal cancer: Updated findings from a randomized, multicenter phase III 


S. Yalcin, R. Uslu, F. Dane, U. Yilmaz, N. Zengin, E. Buyukunal, S. Buyukberber, 

C. Camci, O. Sencan, S. Kilickap 

Brd. 15D Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as 

first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic 

colorectal cancer (mCRC). (Abstract #3580) 

T. Ciuleanu, V. Nikolic, E. Shmueli, D. Vrbanec, S. Plate, Z. M. Krmpotic, M. Dank, 

G. Purkalne, T. Brodowicz, C. Zielinski 

Brd. 15E Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan 

(IRI) or with FOLFIRI � bevacizumab (BV) in previously treated patients (Pts) 

with metastatic colorectal cancer (mCRC). (Abstract #3581) 

A. D. Baron, C. L. O’Bryant, Y. Choi, A. Ashkenazi, S. Royer-Joo, C. C. Portera 

Brd. 15F Phase I results of the randomized, placebo controlled, phase I/II study of the 

novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) 

in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer 

(mCRC) who have received front-line systemic therapy. (Abstract #3582) 

A. Bessudo, J. C. Bendell, N. Gabrail, M. V. Kopp, L. Mueller, L. L. Hart, 

V. I. Vladimirov, A. U. Pande, I. Gorbatchevsky, C. Eng 

Brd. 15G Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with 

bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal 

cancer (CRC): AIO KRK 0205. (Abstract #3583) 

G. von Wichert, T. Hoehler, C. C. Schimanski, M. H. Moehler, R. Hofheinz, 

S. Kanzler, A. Hinke, T. Seufferlein, J. Siebler, A. Hochhaus, D. Arnold, M. Hallek, 

U. T. Hacker, Arbeitsgemeinschaft Internistische Onkologie (AIO) 

Brd. 15H A fixed-sequence, open-label study to determine the activity of SCH 717454 

(robatumumab) as assessed by positron emission tomography in patients 

with relapsed or recurrent colorectal cancer. (Abstract #3584) 

E. H. Lin, H. Lenz, M. N. Saleh, S. Badarinath, J. A. Knost, M. J. MacKenzie, 

B. N. Polite, P. Kavan, E. X. Chen, L. P. Leichman, K. Pathiraja, B. D. Lu 

Brd. 16A Phase I study of regorafenib sequentially administered with either FOLFOX 

or FOLFIRI in patients with first-/second-line colorectal cancer. (Abstract 

#3585) 

B. Schultheis, G. Folprecht, J. Kuhlmann, R. Ehrenberg, U. T. Hacker, C. Kohne, 

M. Kornacker, O. Boix, T. Lin, J. Krauss, R. Fischer, S. Hamann, D. Strumberg, 

K. B. Mross 

Brd. 16B Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and 

bevacizumab followed by an expanded cohort in previously untreated 

metastatic colorectal cancer. (Abstract #3586) 

J. H. Strickler, A. L. Cohn, C. Arrowood, S. Haley, M. Morse, H. Uronis, 

G. C. Blobe, S. D. Hsu, Y. Zafar, H. Hurwitz 

Brd. 16C Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) 

in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology 

Group GI05–102—Final report. (Abstract #3587) 

S. Shahda, M. Yu, J. Picus, J. A. Bufill, W. A. Harb, M. Burns, A. J. Spittler, 

J. Flynn, Y. Zeng, G. H. Vance, J. Wu, C. R. Currie, P. J. Loehrer, E. G. Chiorean 

Brd. 16D The relationship between the development of rash and clinical and healthrelated 

quality of life outcomes by KRAS mutation status in patients with 

colorectal cancer treated with cetuximab in NCIC CTG CO.17. (Abstract 

#3588) 

C. J. O’Callaghan, D. Tu, C. S. Karapetis, H. Au, M. J. Moore, N. C. Tebbutt, 

M. G. Trudeau, T. J. Price, D. Yip, D. J. Jonker 

107 

SATURDAY

SATURDAY 


Brd. 16E Correlation of capecitabine-induced skin toxicity with treatment efficacy in 

patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. 


V. Heinemann, L. Fischer von Weikersthal, U. Vehling-Kaiser, M. Stauch, H. Hass, 

H. F. Dietzfelbinger, D. V. Oruzio, S. Klein, K. Zellmann, T. Decker, M. Schulze, 

W. Abenhardt, G. Puchtler, H. W. Kappauf, J. Mittermueller, C. Haberl, 

C. A. Giessen, N. Moosmann, S. Stintzing 

Brd. 16F Association of baseline CEA, VEGF, and soluble VEGF receptor 2 with 

treatment outcomes in two randomized phase III trials of cediranib in 

metastatic colorectal cancer (mCRC). (Abstract #3590^) 

H. Schmoll, P. M. Hoff, J. D. Robertson, L. Pike, S. Morgan, D. Wilson, 

J. M. Jürgensmeier 

Brd. 16G Axitinib inhibition of [ 18 F] fluorothymidine (FLT) uptake in patients (pts) with 

colorectal cancer (CRC): Implications for cytotoxic chemotherapy 

combinations. (Abstract #3591) 

C. Hoh, J. R. Infante, H. A. Burris III, J. C. Tarazi, S. Kim, B. Rosbrook, T. R. Reid 

Brd. 16H Angiogenesis gene polymorphisms and clinical outcome of metastatic 

colorectal cancer treated with first-line bevacizumab and oxaliplatin-based 


A. Gerger, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, T. Winder, M. J. Labonte, 

P. M. Wilson, L. Benhaim, R. El-Khoueiry, G. Absenger, A. B. El-Khoueiry, S. Iqbal, 

H. Lenz 

Brd. 17A Serial FDG-PET/CT for early outcome prediction in patients with metastatic 

colorectal cancer undergoing chemotherapy. (Abstract #3593) 

A. Hendlisz, V. Golfinopoulos, C. Garcia, P. Emonts, A. Covas, L. Ameye, 

M. Paesmans, A. Deleporte, G. Machiels, E. Toussaint, B. Vanderlinden, 

A. Awada, M. Piccart, P. Flamen 

Brd. 17B Evaluation of the association between tagging polymorphisms of the MACC1 

locus and overall survival in patients with colorectal cancer. (Abstract #3594) 

A. Lang, S. Geller-Rhomberg, T. Winder, B. L. Hartmann, K. Gasser, B. Kohler, 

I. Grizelj, N. Stark, P. Tschann, H. Drexel, A. Muendlein 

Brd. 17C CpG island methylator phenotype and KRAS mutation status as prognostic 

markers in patients with resected colorectal cancer. (Abstract #3595) 

D. H. Koo, Y. Hong, K. Kim, J. Lee, H. Chang, Y. Kang, C. Yu, J. Kim, M. Kim, 

S. Jang, T. Kim 

Brd. 17D The prognostic influence and interrelationships of CD8 � T-cell infiltration in 

malignant colorectal tumors. (Abstract #3596) 

C. H. Richards, A. Powell, S. Platt, C. S. Roxburgh, D. C. Mcmillan, P. G. Horgan 

Brd. 17E Standardization of EGFR FISH in colorectal cancer: Results of an 

international, interlaboratory reproducibility ring study. (Abstract #3597) 

A. Sartore-Bianchi, S. Fieuws, S. Veronese, M. Moroni, N. Personeni, M. Frattini, 

V. Torri, F. Cappuzzo, S. Vander Borght, V. Martin, M. Skokan, A. Santoro, 

M. Gambacorta, S. Tejpar, M. Varella-Garcia, S. Siena 

Brd. 17F Determination of genomic profile to predict clinical response to FOLFOX plus 

bevacizumab in metastatic colorectal cancer. (Abstract #3598) 

T. J. George, H. Liu, L. V. Duckworth, J. E. Sullivan, J. Dong, C. Liu, L. H. Dang, 

K. Slentz-Kesler, C. J. Allegra 

Brd. 17G Cell-free DNA, KRAS, and BRAF mutations in plasma from patients with 

metastatic colorectal cancer treated with third-line cetuximab and irinotecan. 


N. Pallisgaard, K. G. Spindler, I. S. Vogelius, A. K. Jakobsen 

108


Brd. 17H The predictive value of single nucleotide polymorphisms in the vascular 

endothelial growth factor system in patients with metastatic colorectal 

cancer treated with bevacizumab plus chemotherapy as first-line treatment: 

Results of the phase III ACT trial NCT00598156 translational study. (Abstract 

#3600) 

T. Hansen, R. D. Christensen, R. F. Andersen, K. G. Spindler, A. Johnsson, 

A. K. Jakobsen 

Brd. 18A The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase 

III randomized study of cetuximab (CET) plus best supportive care (BSC) 

versus BSC: NCIC CTG/AGITG CO.17. (Abstract #3601) 

M. M. Vickers, C. S. Karapetis, D. Tu, C. J. O’Callaghan, T. J. Price, N. C. Tebbutt, 

G. Van Hazel, J. D. Shapiro, N. Pavlakis, P. Gibbs, J. Blondal, U. J. Yu Min Lee, 

J. M. Meharchand, R. L. Burkes, S. H. Rubin, J. Simes, J. R. Zalcberg, 

M. J. Moore, L. Zhu, D. J. Jonker 

Brd. 18B Early change in tumor size from waterfall plot analysis and RECIST response 

as predictor of overall survival (OS) in advanced, chemotherapy-refractory 

colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. (Abstract #3602) 

G. A. Van Hazel, D. Tu, N. C. Tebbutt, D. J. Jonker, T. J. Price, C. O’Callaghan, 

J. R. Zalcberg, M. Taylor, A. H. Strickland, A. T. Tomiak, D. Yip, J. Simes, 

S. K. Yadav, M. Links, M. J. Burnell, M. Jefford, C. S. Karapetis 

Brd. 18C The role of KRAS, BRAF, and PI3K mutations as markers of resistance to 

cetuximab in metastatic colorectal cancer. (Abstract #3603) 

A. Passardi, P. Ulivi, M. Valgiusti, E. Scarpi, R. Moscati, E. Chiadini, P. Rosetti, 

L. Saragoni, L. Capelli, A. Casadei Gardini, A. Ragazzini, M. Monti, S. Calpona, 

W. Zoli, C. Milandri, L. Frassineti 

Brd. 18D Prediction of tumor recurrence in stage II colon cancer through genetic 

variants in formyl peptide receptor 2 (FPR2). (Abstract #3604) 

R. D. Ladner, W. Zhang, M. J. Labonte, D. Yang, Y. Ning, A. Gerger, 

P. O. Bohanes, T. Winder, A. B. El-Khoueiry, S. Iqbal, N. Petasis, H. Lenz 

Brd. 18E Clinicopathological features of patients with colorectal cancer among KRAS 

wild-type p.G13D and other mutations: Results from a multicenter, crosssectional 

study by the Japan Study Group of KRAS Mutation in Colorectal 

Cancer. (Abstract #3605) 

H. Uetake, T. Watanabe, T. Yoshino, K. Yamazaki, M. Ishiguro, K. Sugihara, 

Y. Ohashi 

Brd. 18F Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping 

of DPYD in fluoropyrimidine therapy. (Abstract #3606) 

M. J. Deenen, A. Cats, M. K. Sechterberger, J. L. Severens, P. H. Smits, 

R. Bakker, C. M. Mandigers, M. Soesan, J. H. Beijnen, J. H. Schellens 

Brd. 18G Influence of KRAS and BRAF mutational status and rash on disease-free 

survival (DFS) in patients with resected stage III colon cancer receiving 

cetuximab (Cmab): Results from NCCTG N0147. (Abstract #3607) 

S. R. Alberts, S. N. Thibodeau, D. J. Sargent, M. R. Mahoney, F. Sinicrope, 

A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, 

J. T. Quesenberry, T. C. Smyrk, A. Grothey, S. G. Nair 

Brd. 18H CpG island methylation in PTEN, MGMT, and E/H cadherin promoters, 

mutations of K-ras and B-raf may indicate how progression in the colorectal 

adenocarcinoma sequence occurs. (Abstract #3608) 

B. Metzger, M. Dicato, G. Mahon 

Brd. 19A Genome-wide association study (GWAS) of the efficacy of capecitabine, 

oxaliplatin, and bevacizumab in metastatic colorectal cancer in the CAIRO2 

trial of the Dutch Colorectal Cancer Group (DCCG). (Abstract #3609) 

H. Guchelaar, J. Pander, S. Bohringer, T. van der Straaten, Y. Ariyurek, 

J. Houwing-Duistermaat, H. Gelderblom, C. J. Punt 

109 

SATURDAY

SATURDAY 


Brd. 19B A specific miRNA signature correlates with complete pathological response 

to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. 


G. Della Vittoria Scarpati, C. Carlomagno, S. Marchini, P. Ubezio, F. Falcetta, 

M. D’Incalci, S. De Placido, F. Sabbatino, C. Fusciello, S. Pepe 

Brd. 19C Clinical and prognostic relevance of methylation of circulating HLTF and 

HPP1 tumor DNA and CEA in serum of patients with colorectal carcinoma 

(CRC). (Abstract #3611) 

F. T. Kolligs, A. B. Philipp, D. Nagel, F. Spelsberg, A. Herbst, P. Stieber 

Brd. 19D Cancer stem cell gene variants associated with colon cancer recurrence. 


L. Benhaim, A. Gerger, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, T. Winder, 

M. J. Labonte, P. M. Wilson, R. El-Khoueiry, A. B. El-Khoueiry, S. Iqbal, H. Lenz 

Brd. 19E Use of KRAS mutation status to predict clinical outcomes in patients with 

metastatic colorectal cancer (mCRC) treated with the VEGF signaling 

inhibitor cediranib. (Abstract #3613^) 

J. M. Jürgensmeier, P. M. Hoff, L. Pike, J. D. Robertson, S. Morgan, G. McWalter, 

D. Wilson, J. Smith 

Brd. 19F Effects of a neurokinin-1 receptor (NK-1R) antagonist on colon cancer 

through suppression of colon tumor–initiating cells. (Abstract #3614) 

C. Polytarchou, J. M. Bugni, S. Dry, C. Pothoulakis, D. Iliopoulos 

Brd. 19G Effect of body mass index (BMI) and body surface area (BSA) on outcomes in 

early-stage colon cancer (CC). (Abstract #3615) 

S. Alipour, R. Woods, H. J. Lim, S. Gill, H. F. Kennecke, C. Speers, C. J. Brown, 

W. Y. Cheung 

Brd. 19H Comparison of innovative estimation of efficacy to standard using the 

ACCENT database. (Abstract #3616) 

J. W. Chapman, C. O’Callaghan, N. Hu, K. Ding, G. A. Yothers, P. J. Catalano, 

Q. Shi, R. G. Gray, M. J. O’Connell, D. J. Sargent, for the ACCENT collaborative 

group 

Brd. 20A Evaluating the relationship between progression-free survival (PFS) and 

overall survival (OS) in clinical trials of patients (pts) with metastatic 


R. Sidhu, A. Rong, S. Dahlberg 

Brd. 20B Survival advantage associated with metformin usage in patients with 

colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). 


H. M. Hassabo, M. Hassan, B. George, S. Wen, V. Baladandayuthapani, 

S. Kopetz, D. R. Fogelman, B. K. Kee, C. Eng, C. R. Garrett 

Brd. 20C Predictive and prognostic value of gender in early-stage colon cancer: A 

pooled analysis of 33,345 patients from the ACCENT database. (Abstract 

#3619) 

W. Y. Cheung, Q. Shi, M. O’Connell, J. Cassidy, C. D. Blanke, D. J. Kerr, 

E. Van Cutsem, S. R. Alberts, G. A. Yothers, D. J. Sargent, for the ACCENT 

Collaborative Group 

Brd. 20D Effect of VTE on mortality in patients with stage III colon cancer. (Abstract 

#3620) 

C. D. Mullins, K. A. Bikov, D. L. McNally, N. C. Onwudiwe, M. R. Dalal, N. Hanna 

Brd. 20E Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX 

phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in 

first-line metastatic colorectal cancer (CRC). (Abstract #3621) 

T. J. Price, D. Zannino, K. Wilson, J. Simes, G. A. Van Hazel, B. A. Robinson, 

A. Broad, V. Ganju, S. P. Ackland, N. C. Tebbutt 

Brd. 20F Short-term outcomes after colorectal cancer among the oldest old patients: 

A cross-national comparative study. (Abstract #3622) 

A. Syse, J. P. Bynum, H. G. Welch, S. Tretli, S. S. Soneji 

110


Brd. 20G Allergic reactions (ARs) induced by FOLFOX4 treatment in colorectal cancer: 

A comparative analysis between Asian and Western patients (pts). (Abstract 

#3623) 

K. Sugihara, A. Ohtsu, Y. Shimada, N. Mizunuma, P. Lee, A. De Gramont, 

R. M. Goldberg, M. L. Rothenberg, T. Andre, S. Brienza 

Brd. 20H Cetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis of 

timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial. 


E. Elimova, C. J. O’Callaghan, D. Tu, C. S. Karapetis, T. J. Price, L. Zhu, 

J. R. Zalcberg, J. Simes, D. J. Jonker 

Brd. 21A Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in 

elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an 

observational cohort study (OCS). (Abstract #3625) 

M. Kozloff, T. S. Bekaii-Saab, J. C. Bendell, A. L. Cohn, H. Hurwitz, N. Roach, 

H. Tezcan, S. Fish, E. D. Flick, Y. Mun, D. Dalal, A. Grothey 

Brd. 21B The effect of tumor response on quality of life (QoL) in patients with KRAS 

wild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL 


I. Griebsch, I. Lang, U. Sartorius, E. Van Cutsem 

Brd. 21C Effect of dose modification on the efficacy of capecitabine: Data from six 

randomized, phase III trials in patients with colorectal or breast cancer. 


J. Cassidy, J. O’Shaughnessy, H. Schmoll, C. Twelves, T. H. Cartwright, 

A. Buzdar, E. McKenna, F. Gilberg, N. Scotto, D. G. Haller 

Brd. 21D An analysis of the effect of stage at diagnosis of bowel cancer on survival: 

Findings from the South Australian Clinical Registry (SACR) for metastatic 


K. Jain, T. J. Price, C. Beeke, R. Padbury, G. P. Young, D. Roder, A. R. Townsend, 

S. Bishnoi, C. S. Karapetis 

Brd. 21E Surgical treatment of colorectal cancer in the advanced elderly: Does 

outcome justify treatment? (Abstract #3629) 

J. D. Cull, S. Kukreja, T. J. Hieken 

Brd. 21F Preoperative chemoradiation (CRT) with concurrent capecitabine (Cap), 

oxaliplatin (Ox), and bevacizumab (Bev) in patients with locally advanced 

rectal cancer (RC): Effects on pathological complete response (pCR) and 

surgical complications. (Abstract #3630) 

T. Hoehler, K. Dellas, D. Riesenbeck, T. Reese, F. Wuerschmidt, C. Roedel, 

W. Wagner, H. Zuehlke, M. Richter, J. Dunst 

Brd. 21G Colorectal cancer in African American and Caucasian patients: A 

comparison of an urban, university hospital with the National Cancer 

Institute SEER database. (Abstract #3631) 

E. P. Mitchell, A. Topham, R. Singla, S. Maron, J. Schoenfeld, F. Guiles, 

S. Goldstein, P. R. Anne, G. Isenberg, P. J. Maxwell IV, J. Palazzo 

Brd. 21H Could baseline health-related quality of life (QoL) improve prognostication of 

overall survival in metastatic colorectal cancer? Results from GERCOR 

OPTIMOX 1 study. (Abstract #3632) 

M. Diouf, F. Bonnetain, B. Chibaudel, C. Tournigand, L. Teixeira, H. Marijon, 

N. Perez-Staub, A. De Gramont 

Brd. 22A Application of adaptive study designs: Phase II and III results from the 

cediranib (CED) HORIZON (HZ) II and III studies. (Abstract #3633^) 

D. Wilson, P. M. Hoff, H. Schmoll, J. D. Robertson, A. Stone 

Brd. 22B The relationship between quality of life (QoL) and tumor response in patients 

(pts) with metastatic colorectal cancer (mCRC) receiving panitumumab 

(pmab) plus FOLFIRI as first-line therapy: An analysis of study 314. (Abstract 

#3634) 

M. Karthaus, J. Thaler, R. Hofheinz, L. Mineur, H. Letocha, R. Greil, E. Fernebro, 

E. Gamelin, A. Baños, C. Kohne 

111 

SATURDAY

SATURDAY 


Brd. 22C Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine 

survival differences in patients treated with anti-EGFR. (Abstract #3635) 

E. Canestrari, A. Ruzzo, B. Vincenzi, N. Galluccio, G. Perrone, F. Andreoni, 

P. Lorenzini, E. Rulli, S. d’Emidio, V. Catalano, F. Loupakis, R. Bisonni, I. Floriani, 

M. De Nictolis, D. Santini, L. Salvatore, G. Tonini, A. Falcone, 

M. Magnani, F. Graziano 

Brd. 22D miR128 and LET-7 microRNAs as potential biomarkers for selection of 

patients with metastatic colorectal cancer candidate to 

cetuximab/panitumumab therapy. (Abstract #3636) 

L. Landi, F. Biagioni, V. Ludovini, A. Sacconi, A. Destro, G. Blandino, M. Roncalli, 

L. Crinò, F. Cappuzzo 

112

8:00 AM - 12:00 PM 



Gastrointestinal (Noncolorectal) Cancer 


Track(s): Gastrointestinal (Noncolorectal) Cancer 

Brd. 23A Gemcitabine plus oxaliplatin (GemOx) in advanced hepatocellular carcinoma 

(HCC): A multicenter study of over 200 patients. (Abstract #4033) 

N. Williet, A. Zaanan, M. Hebbar, V. Boige, L. Fartoux, T. Mansourbakht, 

O. Dubreuil, O. Rosmorduc, F. Bonnetain, J. Taïeb 

Brd. 23B Phase II trial of concurrent chemoradiotherapy consisting of two courses 

with S-1 and cisplatin for locally advanced esophageal cancer. (Abstract 

#4034) 

H. Iwase, M. Shimada, T. Tsuzuki, N. Ryuge, H. Goto 

Brd. 23C Clinical significance of tumor markers as prognostic factors in patients with 

metastatic gastric cancer receiving first-line chemotherapy. (Abstract #4035) 

J. Jo, M. Ryu, D. Koo, B. Ryoo, H. Kim, J. Lee, H. Chang, T. Kim, K. Choi, G. Lee, 

H. Jung, K. Kim, J. Yook, S. Oh, B. Kim, J. Kim, Y. Kang 

Brd. 23D Effect of neoadjuvant chemotherapy on survival in patients with gastric 

signet ring cell adenocarcinoma: A multicentric comparative study. (Abstract 

#4036) 

C. Mariette, M. Messager, J. H. Lefevre, V. Pichot, A. Souadka, T. Thibot, 

D. Brachet, N. Carrere, M. Fernandez, J. Guiramand, B. Tsilividis, R. Flamein, 

K. Kraft, J. Balon, F. Borie, A. Glaise, X. d’Journo, F. Peschaud, F. Vandois, 

G. Piessen, FRENCH 

Brd. 23E Prediction of response and prognosis by a score including only 

pretherapeutic parameters in 410 neoadjuvant treated gastric cancer 

patients. (Abstract #4037) 

S. Lorenzen, S. Blank, K. Becker, R. Langer, F. Lordick, D. Jaeger, J. R. Siewert, 

K. Ott 

Brd. 23F C-MET gene copy number variation (CNV) analysis by quantitative PCR 

(qPCR) assay in Caucasian patients with gastric cancer (GC). (Abstract 

#4038) 

N. Galluccio, A. Ruzzo, E. Canestrari, P. Lorenzini, S. d’Emidio, V. Sisti, 

V. Catalano, F. Andreoni, C. Zingaretti, M. De Nictolis, C. Ligorio, F. Cappuzzo, 

M. Magnani, F. Graziano 

Brd. 23G Multicenter phase II trial to investigate safety and efficacy of an adjuvant 

therapy with gemcitabine and cetuximab in patients with R0 or R1 resected 

pancreatic cancer. (Abstract #4039) 

H. Fensterer, C. Schade-Brittinger, H. Mueller, B. Schupfner, J. Fass, U. Lindig, 

U. Settmacher, M. P. Ebert, M. Kornmann, R. Hofheinz, E. Endlicher, C. Brendel, 

P. J. Barth, D. K. Bartsch, T. M. Gress, Arbeitsgemeinschaft Internistische 

Onkologie (AIO) 

Brd. 23H The final analysis of a multicenter randomized controlled trial of gemcitabine 

(G) alone versus gemcitabine and S-1 combination therapy (GS) in patients 

with unresectable advanced pancreatic cancer (PC): GEMSAP study. 


H. Isayama, Y. Nakai, T. Sasaki, N. Sasahira, K. Hirano, T. Tsujino, M. Tada, 

M. Omata, K. Koike, GEMSAP study group 

Brd. 24A Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic 

pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 

479) or placebo (P) in combination with gemcitabine (G). (Abstract #4041) 

I. McCaffery, Y. Tudor, H. Deng, R. Tang, S. Badola, H. L. Kindler, C. S. Fuchs, 

E. Loh, S. D. Patterson, L. Chen, J. L. Gansert 

113 

SATURDAY

SATURDAY 


Brd. 24B Adjuvant treatments in pancreatic cancer: Preliminary data of a pooled 

analysis. (Abstract #4042) 

F. Drudi, D. Tassinari, C. Castellani, F. Carloni, C. Santelmo, E. Tamburini, 

M. Fantini, M. Papi, L. Gianni, A. Ravaioli 

Brd. 24C Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular 

carcinoma (HCC). (Abstract #4043) 

G. K. Abou-Alfa, B. Gansukh, J. F. Chou, J. Shia, M. Capanu, M. Kalin, H. X. Chen, 

N. J. Zojwalla, S. Katz, D. L. Reidy, D. P. Kelsen, L. Saltz 

Brd. 24E Screening for pancreatic cancer in a high-risk cohort: A 7-year experience. 


W. Al-Sukhni, A. Borgida, H. Rothenmund, S. Holter, S. Wilson, M. J. Moore, 

S. Narod, K. Jhaveri, M. A. Haider, S. Gallinger 

Brd. 24F Clinicopathologic features and treatment outcomes of patients (pts) with 

HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and 

gastroesophageal junction (GEJ). (Abstract #4046) 

B. E. Phillips, R. R. Tubbs, T. W. Rice, L. A. Rybicki, T. Plesec, C. P. Rodriguez, 

G. M. Videtic, J. P. Saxton, D. I. Ives, D. J. Adelstein 

Brd. 24G Molecular markers of the EGFR pathway in erlotinib-treated patients with 

advanced pancreatic cancer (APC): Translational analyses of a randomized, 

cross-over AIO phase III trial. (Abstract #4047) 

S. H. Boeck, A. Jung, R. P. Laubender, J. Neumann, R. Egg, C. Goritschan, 

U. Vehling-Kaiser, C. Winkelmann, L. Fischer von Weikersthal, M. R. Clemens, 

T. C. Gauler, A. Marten, S. Klein, G. Kojouharoff, M. Barner, M. Geissler, 

T. F. Greten, U. Mansmann, T. Kirchner, V. Heinemann 

Brd. 24H Lenalidomide for advanced hepatocellular cancer (HCC) in patients 

progressing on or intolerant to sorafenib. (Abstract #4048) 

H. Safran, K. Charpentier, A. Kaubisch, G. Dubel, G. Soares, 

K. E. Faricy-Anderson, T. J. Miner, Y. Eng, I. Ribizzi-Akhtar, A. M. Plette, 

N. J. Espat, D. Berz, A. Schumacher, D. Luppe, P. Bakalarski, P. Wingate, 

J. Victor, K. Rosati, D. Isdale 

Brd. 25A Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection 

for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat 

metastatic pancreatic cancer (mPC). (Abstract #4049) 

J. Lu, H. Deng, R. Tang, C. Hsu, H. L. Kindler, C. S. Fuchs, J. L. Gansert, S. Bray, 

S. S. Suzuki, E. Loh, M. Zhu 

Brd. 25B Adjuvant therapy in the treatment of biliary tract cancer (BTC): A systematic 

review and meta-analysis. (Abstract #4050) 

A. M. Horgan, E. Amir, T. Walter, J. J. Knox 

Brd. 25C An evaluation of cytoreductive surgery plus hyperthermic intraperitoneal 

chemotherapy on patients with peritoneal carcinomatosis: Final results of a 

phase II prospective and randomized clinical trial. (Abstract #4051) 

Y. Li, X. Yang, G. Yang, Y. Zhou, Y. Yonrmura 

Brd. 26A Comprehensive analysis of potential predictive biomarkers for insulin-like 

growth factor type 1 receptor (IGF-1R) targeted therapy in pancreatic cancer. 


R. T. Shroff, M. M. Javle, D. Li, R. A. Wolff, D. J. Mauro, G. Naumov, M. Nebozhyn, 

T. Zhang, Y. Li, S. Sathyanarayanan 

Brd. 26B Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine 

(DCX) in gastroesophageal adenocarcinoma: A phase II study of the 

Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4053) 

P. C. Thuss-Patience, R. Hofheinz, D. Arnold, A. Florschütz, S. Daum, 

A. Kretzschmar, L. Mantovani-Löffler, D. Bichev, B. Gahn, G. Schumacher, 

M. Kneba 

114


Brd. 26C Improved survival in patients with hepatocellular carcinoma over 30 years in 

Japan: Analysis of nationwide prospective registry of 148,161 patients. 


M. Kudo, N. Izumi, N. Kokudo, M. Sakamoto, Y. Matsuyama, T. Ichida, 

O. Nakashima, O. Matsui, Y. Ku, M. Makuuchi, for the Liver Cancer Study Group of 

Japan 

Brd. 27A Prognostic significance of post-treatment standardized uptake value (pSUV) 

of positron emission tomography (PET) to predict overall survival (OS) and 

relapse-free survival (RFS) in patients with esophageal or gastroesophageal 

cancer treated with definitive chemoradiotherapy. (Abstract #4055) 

A. Suzuki, L. Xiao, Y. Hayashi, J. Welsh, S. H. Lin, D. Maru, W. L. Hofstetter, 

R. J. Mehran, J. H. Lee, M. S. Bhutani, H. A. Macapinlac, Z. X. Liao, J. A. Ajani 

Brd. 27B Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal 

adenocarcinoma (GC): Combined U.S. experience. (Abstract #4056) 

E. C. Smyth, P. C. Enzinger, J. Li, M. Vincitore, J. Lacy, B. F. El-Rayes, P. L. Kunz, 

J. M. Ford, E. Robinson, D. P. Kelsen, M. A. Shah 

Brd. 27C A phase II study of neoadjuvant combination chemotherapy with docetaxel, 

cisplatin, and S-1 for locally advanced gastric cancer. (Abstract #4057) 

H. Ohnuma, Y. Sato, T. Takayama, T. Sagawa, M. Hirakawa, K. Harada, 

T. Nobuoka, K. Hirata, Y. Takahashi, S. Katsuki, S. Takahashi, M. Hirayama, 

M. Takahashi, M. Maeda, T. Sato, K. Miyanishi, M. Kobune, R. Takimoto, J. Kato 

Brd. 28A Quantitation of circulating methylated RASSF1A in prognostication and 

monitoring of treatment response in unresectable hepatocellular carcinoma 

(HCC). (Abstract #4058) 

S. L. Chan, A. K. Chan, E. P. Hui, S. Yu, L. Leung, H. H. Loong, B. Ma, T. Mok, 

A. T. Chan, W. Yeo 

Brd. 28B Prognostic factors in Japanese patients with advanced gastric cancer using 

the data from JCOG9912 study. (Abstract #4059) 

D. Takahari, A. Takashima, J. Mizusawa, Y. Yamada, T. Yoshino, K. Yamazaki, 

W. Koizumi, Y. Suzuki, N. Boku, A. Ohtsu 

Brd. 28C Final results of feasibility study of neoadjuvant chemotherapy with 

docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophageal 

squamous cell carcinoma. (Abstract #4060) 

H. Hara, H. Daiko, K. Kato, H. Igaki, S. Kadowaki, Y. Tanaka, Y. Hamamoto, 

H. Matsushita, M. Nagase, Y. Hosoya, M. Tahara 

Brd. 29A Prognostic microRNAs in patients operated for pancreatic cancer. (Abstract 

#4061) 

N. A. Schultz, K. K. Andersen, A. Roslind, H. Willenbrock, M. Wøjdemann, 

J. S. Johansen 

Brd. 29B An evaluation of microRNA signature and response of patients with gastric 

cancer to cisplatin and fluorouracil. (Abstract #4062) 

H. K. Kim, C. H. Kim, J. Kim, I. J. Choi, D. J. Munroe, J. E. Green 

Brd. 29C Effect of metformin on survival of diabetic patients with pancreatic 

adenocarcinoma. (Abstract #4063) 

N. Sadeghi, J. L. Abbruzzese, S. J. Yeung, M. Hassan, D. Li 

Brd. 30A Preliminary results of a randomized phase II study: Treatment of Chinese 

patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or 

the reverse sequence. (Abstract #4064) 

F. Bi, Q. Li, C. Zhou, J. Yu, X. Cai, M. Qiu, J. Liu, C. Yi, D. Luo, F. Xu, The Western 

Cooperative Gastrointestinal Oncology Group of China 

Brd. 30B Phase II single-arm, single institution trial of neoadjuvant gemcitabine and 

oxaliplatin treatment (NT) in patients (pts) with resectable pancreas 

adenocarcinoma (PC). (Abstract #4065) 

E. M. O’Reilly, W. R. Jarnagin, M. F. Brennan, C. Winston, L. H. Tang, M. Capanu, 

M. Schattner, L. Y. Chen, R. P. DeMatteo, C. J. DiMaio, M. I. D’Angelica, 

R. C. Kurtz, D. S. Klimstra, M. A. Lowery, D. G. Coit, D. L. Reidy, P. J. Allen 

115 

SATURDAY

SATURDAY 


Brd. 30C Correlation of HER2 and PTEN status with clinical outcome in esophageal 

(E), gastric (G), and gastroesophageal junction (GEJ) adenocarcinomas 

(ACs). (Abstract #4066) 

K. Linos, C. E. Sheehan, J. S. Ross 

Brd. 31A A new prognostic classification scheme with treatment guidelines for Asian 

patients with hepatocellular carcinoma (HCC): The Hong Kong Combined 

Liver Cancer (HKCLC) classification. (Abstract #4067) 

Y. Tang, T. Yao, C. C. Yau, S. Fan, R. Poon 

Brd. 31B Quality of lymphadenectomy for esophageal cancer in the United States: An 

analysis of the SEER database. (Abstract #4068) 

B. M. Stiles, A. Nasar, F. Mirza, J. L. Port, P. C. Lee, S. Paul, N. K. Altorki 

Brd. 31C A multinational phase II study of PEP02 (liposome irinotecan) for patients 

with gemcitabine-refractory metastatic pancreatic cancer. (Abstract #4069) 

A. H. Ko, M. A. Tempero, Y. Shan, W. Su, Y. Lin, E. Dito, A. Ong, Y. Wang, G. Yeh, 

L. Chen 

Brd. 31D Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of 

the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4070) 

S. Al-Batran, R. Hofheinz, N. Homann, G. Illerhaus, U. M. Martens, 

J. Stoehlmacher-Williams, H. Schmalenberg, K. B. Luley, N. Prasnikar, M. Egger, 

S. Probst, J. T. Hartmann, M. H. Moehler, D. Arnold, W. Fischbach, C. Pauligk, 

S. P. Moenig, P. Piso, E. Jaeger 

Brd. 31E CA19-9 for the prediction of efficacy of chemotherapy in patients with 

advanced pancreas cancer: A pooled analysis of six prospective trials. 


T. M. Bauer, T. S. Bekaii-Saab, X. Li, M. A. Villalona-Calero, P. A. Philip, 

A. F. Shields, M. M. Zalupski, N. Hammad, B. F. El-Rayes 

Brd. 31F Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or 

esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX). 


L. Dahan, B. Chibaudel, F. Di Fiore, P. Artru, L. Mineur, M. Galais, O. Dupuis, 

V. Blondin, S. Abdiche, M. Attia, A. De Gramont, G. Lledo, GERCOR 

Brd. 31G Prognostic values of microRNAs in phase III clinical trial gastric cancer 

patients treated with S-1/oxaliplatin or doxifluridine/oxaliplatin. (Abstract 

#4073) 

J. Jiang, C. Wu, X. Zheng, Q. Zhou, X. Zhang, X. Xu, B. Lu, J. Ju 

Brd. 31H Phase I study of everolimus in combination with sorafenib in patients with 

advanced hepatocellular carcinoma (HCC). (Abstract #4074) 

R. S. Finn, R. Poon, T. Yau, H. Klumpen, L. Chen, Y. Kang, T. Kim, 

C. Gomez-Martin, C. Rodriguez-Lope, T. Kunz, T. Paquet, K. Asubonteng, 

R. E. Winkler, O. Anak, D. B. Sellami, J. Bruix 

Brd. 32A Everolimus plus octreotide LAR versus placebo plus octreotide LAR in 

patients with advanced neuroendocrine tumors: Analysis by primary tumor 

site from RADIANT-2. (Abstract #4075) 

E. M. Wolin, N. Fazio, S. Saletan, R. E. Winkler, A. Panneerselvam, L. Kvols 

Brd. 32B Use of MTHFR A1298C polymorphism to predict response in a phase II 

international clinical trial of patients with advanced gastric (GC) or 

gastroesophageal junction (GEJ) adenocarcinoma treated with first-line 

lapatinib plus capecitabine. (Abstract #4076) 

M. J. Labonte, D. Yang, W. Zhang, P. M. Wilson, A. Gerger, P. O. Bohanes, 

Y. Ning, L. Benhaim, R. El-Khoueiry, Y. M. Nagarwala, A. M. Kemner, 

M. J. Pishvaian, R. K. Hsieh, O. Gladkov, S. Urba, S. Y. Rha, D. Sakaeva, S. Iqbal, 

A. B. El-Khoueiry, H. Lenz 

116


Brd. 32C A randomized, double-blind, multicenter phase II AIO trial with gemcitabine 

plus sorafenib versus gemcitabine plus placebo in patients with 

chemotherapy-naive advanced or metastatic biliary tract cancer: First safety 

and efficacy data. (Abstract #4077) 

M. H. Moehler, C. C. Schimanski, S. Kanzler, M. A. Woerns, U. Denzer, 

F. T. Kolligs, M. P. Ebert, A. Distelrath, M. Geissler, S. Zeuzem, F. Lammert, 

A. W. Lohse, M. M. Dollinger, U. Lindig, E. M. Duerr, N. Lubomierski, 

S. Zimmermann, M. Kabisch, S. Schadmann-Fischer, P. R. Galle, German AIO 

Brd. 32D Everolimus plus octreotide LAR versus placebo plus octreotide LAR in 

patients with advanced neuroendocrine tumors (NET): Effect of prior 

somatostatin analog therapy on progression-free survival in the RADIANT-2 


L. B. Anthony, M. Peeters, J. D. Hainsworth, E. Baudin, D. Hoersch, J. Klimovsky, 

K. Grouss, V. Jehl, M. E. Pavel, J. C. Yao 

Brd. 32E Circulating protein and cellular biomarkers of sunitinib in patients with 

advanced neuroendocrine tumors. (Abstract #4079) 

A. J. Zurita, J. Heymach, M. Khajavi, L. Tye, X. Huang, M. Kulke, H. Lenz, 

N. J. Meropol, W. Carley, S. E. DePrimo, C. S. Harmon 

Brd. 32F The role of cytoreductive surgery in patients with carcinomatosis from 

high-grade appendix cancer in the era of modern systemic chemotherapy. 


H. M. El Halabi, P. Ledakis, V. Gushchin, J. Francis, N. Athas, R. Macdonald, 

K. Studeman, A. Sardi 

Brd. 32G Final toxicity results of a phase I dose-escalation trial of tremelimumab 

(CP-675206) in combination with gemcitabine in chemotherapy-naive 

patients (pts) with metastatic pancreatic cancer. (Abstract #4081) 

M. Aglietta, C. Barone, M. B. Sawyer, M. J. Moore, W. H. Miller Jr., C. Bagalà, 

D. A. Ferraro, F. Colombi, C. Cagnazzo, L. Gioeni, K. D. Fly, B. Huang, F. Leone 

Brd. 32H Efficacy and safety of single-agent sunitinib in treating patients with 

advanced hepatocelluar carcinoma after sorafenib failure: A prospective, 

open-label, phase II study. (Abstract #4082) 

T. Yau, R. C. Leung, H. Wong, J. Chiu, P. Chan, R. Pang, S. Fan, R. Poon 

Brd. 33A The use of single-agent sorafenib in the treatment of patients with advanced 

hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis. 


J. Chiu, Y. Tang, T. Yao, A. Wong, H. Wong, R. C. Leung, P. Chan, T. Cheung, 

R. Poon, S. Fan, C. C. Yau 

Brd. 33B HER2 status as an independent prognostic marker in patients with advanced 

gastric cancer receiving adjuvant chemotherapy after curative gastrectomy. 


Y. Park, M. Ryu, H. Park, H. Kim, B. Ryoo, J. Yook, B. Kim, S. Jang, Y. Kang 

Brd. 33C A phase I study of GC33, a recombinant humanized antibody against 

glypican-3, in patients with advanced hepatocellular carcinoma (HCC). 


A. X. Zhu, P. J. Gold, A. B. El-Khoueiry, T. A. Abrams, H. Morikawa, T. Ohtomo, 

P. A. Philip 

Brd. 33D C-reactive protein as a biomarker to predict outcomes after liver 

transplantation for hepatocellular carcinoma. (Abstract #4086) 

H. An, J. Jang, M. Lee, S. Bae, J. Choi, S. Yoon, Y. You, D. Kim, E. Jeon, K. Park, 

S. Chun 

Brd. 33E Combination of exposure-response and case-control analyses in regulatory 

decision making. (Abstract #4087) 

J. Yang, Y. Wang, H. Zhao, C. Garnett, J. Gobburu, W. Pierce, G. Schechter, 

J. Summers, P. Keegan, B. Booth, N. Rahman 

117 

SATURDAY

SATURDAY 


Brd. 33F Fluoropyrimidine/platinum-based first-line chemotherapy in metastatic 

esophageal squamous cell carcinoma: Prognostic factor analysis in 239 


H. Jung, J. Lee, H. Ahn, S. Park, Y. Park, Y. Im 

Brd. 33G Clinical/pathologic features and survival of patients with fibrolamellarhepatocellular 

carcinoma (FLL-HCC): Data from the Fibrolamellar- 

Hepatocellular (FLL-HCC) Consortium. (Abstract #4089) 

C. Ang, A. P. Venook, M. A. Choti, R. P. DeMatteo, R. K. Kelley, D. Cosgrove, 

J. P. McGuire, M. S. Torbenson, T. M. Pawlik, W. R. Jarnagin, M. I. D’Angelica, 

Y. Fong, J. F. Chou, E. M. O’Reilly, D. S. Klimstra, A. C. Griffin, G. P. Vallarapu, 

M. Capanu, D. P. Kelsen, G. K. Abou-Alfa 

Brd. 33H The association between body mass index and baseline clinical stage of 

esophageal carcinoma. (Abstract #4090) 

Y. Hayashi, A. M. Correa, W. L. Hofstetter, A. A. Vaporciyan, D. C. Rice, 

G. L. Walsh, R. J. Mehran, A. Suzuki, J. H. Lee, M. S. Bhutani, S. H. Lin, J. Welsh, 

D. Maru, S. Swisher, J. A. Ajani 

Brd. 34A Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): 

Results of a phase II trial. (Abstract #4091) 

J. J. Knox, R. Wong, G. E. Darling, J. Lister, M. Guindi, G. Liu, W. Xu, J. J. Kim, 

D. J. Jonker, J. Wells, W. Kendal, H. Mackay, A. Visbal, R. E. Dinniwell, A. Pierre, 

R. Feld, S. Sundaresan, A. Bayley, Y. Shargall, A. M. Horgan 

Brd. 34B Safety results from a randomized trial of perioperative epirubicin, cisplatin 

plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) 

with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma. 


A. F. Okines, R. E. Langley, L. C. Thompson, S. P. Stenning, L. Stevenson, 

S. Falk, M. T. Seymour, F. Y. Coxon, G. W. Middleton, D. Smith, L. Evans, 

S. Slater, J. S. Waters, D. Ford, M. Hall, T. Iveson, R. D. Petty, C. Plummer, 

W. Allum, D. Cunningham, The National Cancer Research Institute (NCRI) Upper 

Gastrointestinal Cancers Clinical Studies Group 

Brd. 34C Utility of routine endoscopy in the follow-up of resected gastric carcinoma. 


M. Satolli, W. Evangelista, C. Mecca, R. Napoletano, A. Giacobino, A. Novarino, 

F. Brusa, J. Fiore, L. Pomba, M. Garino, G. Fronda, L. Ciuffreda 

Brd. 34D Phase II trial of postoperative adjuvant gemcitabine and cisplatin 

chemotherapy followed by chemoradiation with gemcitabine in patients with 

resected pancreatic cancer. (Abstract #4094) 

J. Kwon, E. Chie, J. Kim, S. Im, D. Oh, Y. Kim, S. Han, K. Lee, J. Jang, T. Kim, 

H. S. Han, S. Kim, Y. Yoon, Y. Bang, S. Ha 

Brd. 34E Progression-free survival as surrogate endpoint of overall survival in 

patients with advanced/recurrent gastric cancer: Individual patient data 

analysis on 4,102 patients from 20 randomized trials. (Abstract #4095) 

K. Shitara, T. Burzykowski, on behalf of GASTRIC project 

Brd. 34F Mature long-term outcome using a continuous 50-Gy shrinking field 

chemoradiation schedule for squamous cell carcinoma of the anus. (Abstract 

#4096) 

R. Cooper, K. Spindler, R. Prestwich, P. Byrnes, D. Sebag-Montefiore 

Brd. 34G Array-based comparative genomic hybridization analysis to identify 

prognostic markers for resected pancreatic cancer. (Abstract #4097) 

J. Lee, I. Petrini, J. Hwang, E. Giovannetti, J. Voortman, Y. Wang, S. M. Steinberg, 

N. Funel, P. S. Meltzer, G. Giaccone 

Brd. 34H Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim 

results of the French multicenter phase II trial ACCORD16. (Abstract #4098) 

E. Deutsch, C. Lemanski, E. Paris, A. Delarochefordiere, I. Martel-Lafay, E. Rio, 

L. Miglianico, Y. Becouarn, J. Pignon, J. Berille, P. Ezra, D. Azria 

118


Brd. 35A Impact of prior procedures on overall survival following radioembolization in 

patients with unresectable hepatocellular carcinoma (HCC). (Abstract #4099) 

G. M. Ettorre, B. Sangro, R. Cianni, D. Gasparini, R. Golfieri, S. Ezzidin, 

F. T. Kolligs, F. Izzo, on behalf of European Network for Radioembolization using 

Y90 microspheres (ENRY) 

Brd. 35B Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction 

(GEJ) cancer: Response and protracted stable disease observed in 


D. Ilson, Y. Y. Janjigian, M. A. Shah, D. P. Kelsen, L. H. Tang, J. Campbell, 

L. Fuqua, M. Capanu 

Brd. 35C Marker driven systemic treatment of inoperable cholangiocarcinomas: 

Panitumumab and combination chemotherapy in KRAS wild-type tumors. 


L. H. Jensen, J. Lindebjerg, J. Ploen, T. Hansen, A. K. Jakobsen 

Brd. 35D Pancreatic cancer and diabetes mellitus: A retrospective cohort study. 


A. Yacoub, E. Siegel, I. Makhoul 

Brd. 35E Impact of prior chemotherapy on progression-free survival in patients (pts) 

with advanced pancreatic neuroendocrine tumors (pNET): Results from the 

RADIANT-3 trial. (Abstract #4103) 

R. F. Pommier, E. M. Wolin, A. Panneerselvam, S. Saletan, R. E. Winkler, 

E. Van Cutsem 

Brd. 35F Epidemiology, treatment outcome, and survival of primary gallbladder 

cancer in the United States: A period prevalence SEER database study 

1973–2007. (Abstract #4104) 

A. M. Hossain, R. F. Khozouz, R. N. Rahman 

Brd. 35G Clinical factors and outcomes in HPV-associated anal canal cancer. 


J. Nair, Y. Hu, W. M. Mendenhall, C. Liu, C. G. Morris, R. Zlotecki, J. Kirwan, 

L. H. Dang, S. Tan, E. Huang, C. J. Allegra, T. J. George 

Brd. 35H Oxaliplatin, 5-FU, and leucovorin (FOLFOX) in advanced biliary tract cancer. 


S. Lee, K. Kim, H. Kim, S. Kim, S. Bae, C. Kim, N. Lee, K. Lee, S. Park, J. Won, 

J. Moon, D. Hong, H. Park 

Brd. 36A TACE plus sorafenib for the treatment of hepatocellular carcinoma: Final 

results of the multicenter SOCRATES trial. (Abstract #4107) 

A. Erhardt, F. T. Kolligs, M. M. Dollinger, E. Schott, H. Wege IV, M. Bitzer, C. Gog, 

J. Raedle, M. Schuchmann, C. Walter, D. Blondin, C. Ohmann, D. Haeussinger 

Brd. 36B FOLFIRI followed by radiochemotherapy and surgery in locally advanced 

gastric cancer: FFCD 0308 phase II trial. (Abstract #4108) 

P. Michel, G. Breysacher, F. Desseigne, L. Dahan, C. Petorin, D. Moussata, 

J. Grenier, S. Nguyen, F. Viret, N. Carrere, C. Mariette, C. Garnier Tixidre, 

K. Bouhier Leporrier, M. Galais, F. Fein, I. Iwanicki-Caron, E. Maillard, B. Dousset, 

F. Mornex, L. Bedenne 

Brd. 36C Meta-analyses of 22 randomized trials assessing the influence of 

chemotherapy in advanced/recurrent gastric cancer. (Abstract #4109) 

H. Bleiberg, D. J. Sargent, GASTRIC 

Brd. 36D Dose-ranging study of tesetaxel, a novel oral taxane, administered as 

second-line therapy at a flat dose to patients with advanced gastric cancer. 


J. S. Baker, A. Qureshi, L. Itri, W. Sun, M. F. Mulcahy, J. A. Ajani 

Brd. 36E Outcomes following sequential trials of stereotactic body radiotherapy 

(SBRT) for hepatocellular carcinoma (HCC). (Abstract #4111) 

A. Bujold, C. Massey, J. J. Kim, J. D. Brierley, R. Wong, C. Cho, Z. Kassam, 

R. E. Dinniwell, J. Ringash, B. Cummings, J. J. Knox, M. Sherman, L. A. Dawson 

119 

SATURDAY

SATURDAY 


Brd. 36F Association of the expression of the glioma-associated oncogene homolog 

(GLI) 1 with nuclear expression of NF-�B and unfavorable overall survival of 

patients with pancreatic cancer. (Abstract #4112) 

S. Yang, S. H. Kuo, C. Hsu, J. Lee, Y. Tien, A. Cheng 

Brd. 36G Sorafenib and bevacizumab combination targeted therapy in advanced 

neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine 

Tumor Group (GETNE0801). (Abstract #4113) 

D. E. Castellano, J. Capdevila, R. Salazar, J. Sastre, V. Alonso, M. Llanos, 

R. Garcia-Carbonero, A. Abad, I. Sevilla, I. Duran, Spanish Neuroendocrine Tumor 

Group (GETNE) 

Brd. 36H The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination 

with gemcitabine in patients (pts) with metastatic pancreatic cancer. 


J. Stephenson, D. A. Richards, B. M. Wolpin, C. R. Becerra, J. T. Hamm, 

W. A. Messersmith, S. Devens, J. Cushing, J. Goddard, T. Schmalbach, 

C. S. Fuchs 

Brd. 37A Phase II randomized trial on dose-escalated sorafenib (S) versus best 

supportive care (BSC) in patients with advanced hepatocellular carcinoma 

(HCC) with disease progression on prior S treatment. (Abstract #4115) 

T. Pressiani, L. Rimassa, C. Boni, R. Labianca, S. Fagiuoli, A. Ardizzoni, P. Foa, 

E. Cortesi, C. Porta, F. Artioli, L. Latini, C. Carnaghi, R. Lutman, G. Torzilli, 

M. Tommasini, R. Ceriani, G. Covini, L. Giordano, N. Locopo, A. Santoro 

Brd. 37B Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line 

therapy in hepatocellular cancer (HCC): North Central Cancer Treatment 

Group trial N0745. (Abstract #4116) 

J. M. Hubbard, S. R. Alberts, W. S. Loui, M. R. Mahoney, L. R. Roberts, 

T. C. Smyrk, Z. Gatalica, S. Kumar, S. R. Dakhil, P. J. Flynn, J. M. Lafky, 

M. J. Bury, NCCTG 

Brd. 37C Influence of tumor infiltrating Foxp3 � regulatory T cells on prognosis in 

resectable gastric cancer. (Abstract #4117) 

J. Kwon, M. Cho, E. Nam, J. Jo, S. Lee 

Brd. 37D S100A2 as a prognostic marker in patients receiving adjuvant therapy for 

pancreatic cancer (PC): A secondary analysis of RTOG 9704. (Abstract 

#4118) 

M. A. Tempero, K. A. Winter, G. E. Kim, S. Kakar, T. S. Hyun, W. Regine, 

R. B. Mowat, K. Charpentier, W. Small Jr., C. Guha, D. K. Chang, A. V. Biankin, 

RTOG 

Brd. 37E Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine 

and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with 

advanced gastric cancer (AGC). (Abstract #4119) 

Y. Kang, A. Ohtsu, E. Van Cutsem, L. Roman, J. Nunes, C. Li, D. Otero, F. Rivera, 

G. Aprile, P. R. Pimentel Alvarez, M. H. Moehler, J. Wu, B. Langer, M. A. Shah 

Brd. 37F Updated results of a phase I study of pasireotide (SOM230) in combination 

with everolimus (RAD001) in patients (pts) with advanced neuroendocrine 

tumors (NET). (Abstract #4120) 

J. A. Chan, D. P. Ryan, C. S. Fuchs, A. X. Zhu, T. A. Abrams, B. M. Wolpin, 

P. Malinowski, E. Regan, M. Kulke 

Brd. 37G Polymorphisms in EGF a�61G, GSTP1 Ile105Val, and MTHFR A1298C to 

predict response and survival in a phase II study for patients with metastatic 

or unresectable gastric (G) or gastroesophageal junction (GEJ) cancer 

treated with capecitabine, oxaliplatin (XELOX), and cetuximab. (Abstract 

#4121) 

S. Iqbal, M. J. Labonte, D. Yang, W. Zhang, P. O. Bohanes, Y. Ning, L. Benhaim, 

R. El-Khoueiry, P. M. Wilson, A. Gerger, A. B. El-Khoueiry, H. Lenz 

120


Brd. 37H Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study 

of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as 

first-line treatment in patients (pts) with advanced gastric or 

gastroesophageal junction (GEJ) cancer. (Abstract #4122) 

M. Alsina, A. H. Ko, M. Garcia De Paredes, F. Rivera, L. S. Schwartzberg, 

A. Fattaey, L. A. Kunkel, J. Tabernero, J. A. Ajani 

Brd. 38A Patients with carcinoma of unknown primary with isolated carcinomatosis on 

presentation: Clinicopathologic features and survival data. (Abstract #4123) 

H. R. Carlson, S. Karanth, M. A. Zarzour, R. Lenzi, M. N. Raber, 

G. R. Varadhachary 

Brd. 38B A phase I study of two different schedules of nab-paclitaxel (nab-P) with 

ascending doses of vandetanib (V) with expansion in patients (Pts) with 

pancreatic cancer (PC). (Abstract #4124) 

A. B. El-Khoueiry, S. Iqbal, H. Lenz, B. J. Gitlitz, D. Yang, S. Cole, V. Duddalwar, 

A. Garcia 

Brd. 38C BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with 

capecitabine compared to expectant treatment alone following curative 

surgery for biliary tract cancer. (Abstract #4125) 

J. A. Bridgewater, C. Stubbs, J. N. Primrose, National Cancer Research Institute 

(UK) Upper Gastrointestinal Studies Group 

Brd. 38E A randomized phase II study of gemcitabine (G) plus the cardiac glycoside 

huachansu (H) in the treatment of patients with locally advanced (LAPC) or 

metastatic pancreatic cancer (MPC). (Abstract #4127) 

Z. Meng, L. Liu, Y. Shen, P. Yang, L. Cohen, Y. Huo, Q. Zhao, C. S. Ng, 

D. Z. Chang, C. R. Garrett 

Brd. 38F Inactivation of BRCA2 cooperates with Trp53 R172H to induce invasive 

pancreatic ductal adenocarcinomas in mice: A mouse model of familial 


G. Feldmann, C. Karikari, M. dal Molin, S. Duringer, P. Volkmann, D. K. Bartsch, 

S. Bisht, J. Koorstra, P. Brossart, A. Maitra, V. Fendrich 

Brd. 38G Prevention of Barrett’s esophagus (BE) and esophageal adenocarcinoma 

(EAC) in the levrat rat model of EAC by treatment with a smoothened (SMO) 

inhibitor. (Abstract #4129) 

M. K. Gibson, A. H. Zaidi, J. M. Davison, B. Hough, A. F. Sanz, T. Foxwell, 

T. Hoppo, Y. Komatsu, K. S. Nason, C. Rotoloni, U. Malhotra, A. Atasoy, 

C. Smith, J. D. Luketich, B. A. Jobe, Pittsburgh Esophageal Neoplasia Group 

Brd. 38H Identification of a small and lethal subgroup of esophagogastric 

adenocarcinoma with evidence of responsiveness to crizotinib by MET 

amplification. (Abstract #4130) 

J. K. Lennerz, E. L. Kwak, M. Michael, S. B. Fox, A. Ackerman, K. Bergethon, 

G. Y. Lauwers, J. G. Christensen, K. D. Wilner, D. A. Haber, R. Salgia, Y. Bang, 

J. W. Clark, B. J. Solomon, A. J. Iafrate 

Brd. 39A REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, 

and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in 

advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and 

molecular analysis from phase II. (Abstract #4131) 

I. Chau, A. F. Okines, D. Gonzalez de Castro, C. Saffery, Y. Barbachano, 

A. Wotherspoon, L. Puckey, S. Hulkki Wilson, F. Y. Coxon, G. W. Middleton, 

D. R. Ferry, T. D. Crosby, S. Madhusudan, J. Wadsley, J. S. Waters, M. Hall, 

D. Swinson, A. Robinson, D. Smith, D. Cunningham, UK National Cancer 

Research Institute Upper Gastrointestinal Cancer Clinical Studies Group 

Brd. 39B FOLFIRI regimen as second-/third-line chemotherapy in patients with 

advanced pancreatic adenocarcinoma refractory to gemcitabine and 

platinum-salts: A retrospective series of 70 patients. (Abstract #4132) 

C. Neuzillet, O. Hentic, B. Rousseau, V. Rebours, L. Bengrine-Lefèvre, 

F. Bonnetain, E. Raymond, P. Ruszniewski, C. Louvet, P. Hammel 

121 

SATURDAY

SATURDAY 


8:00 AM - 12:00 PM 


Health Services Research 


Track(s): Health Services Research 

Brd. 40A Comparative analysis of lung cancer in a public hospital versus private 

hospitals in New York. (Abstract #6037) 

V. Gotlieb, V. Verma, J. Fogel, A. Multz, R. J. Gralla 

Brd. 40B The development of a value-based pricing index for new drugs in metastatic 

colorectal cancer. (Abstract #6038) 

G. Dranitsaris, I. Truter, M. Lubbe 

Brd. 40C The influence of self-reported conflicts of interest on the conclusions of 

editorial authors of phase III cancer trials. (Abstract #6039) 

M. C. Miranda, A. T. Lera, A. Ueda, B. Briones, T. Lerner, A. Del Giglio, 

R. P. Riechelmann 

Brd. 40D Perceptions of caregivers on the participation of cancer patients into clinical 

trials. (Abstract #6040) 

A. T. Lera, M. C. Miranda, P. Santi, G. Brito, P. Prestes, M. Oliveira, A. Del Giglio, 

R. P. Riechelmann 

Brd. 40E Factors influencing patient preferences for outpatient treatment of febrile 

neutropenia. (Abstract #6041) 

N. Lathia, P. K. Isogai, C. De Angelis, S. Walker, M. C. Cheung, N. Mittmann 

Brd. 40F Analysis of dermatologist density and melanoma mortality. (Abstract #6042) 

S. Aneja, J. S. Bordeaux 

Brd. 40G Changes in Medicaid reimbursements for cancer screening: Keeping pace 

with inflation? (Abstract #6043) 

M. T. Halpern, S. G. Haber, F. K. Tangka, D. H. Howard, L. C. Richardson, 

S. A. Sabatino, S. Sujha 

Brd. 40H Preferences of patients with metastatic breast cancer. (Abstract #6044) 

M. Smith, C. B. White, E. Railey, A. M. Storniolo, G. W. Sledge Jr. 

Brd. 41A A predictive model to identify cancer patients at risk for in-hospital mortality 

based on admission criteria. (Abstract #6045) 

K. Ramchandran, J. Shega, M. Schumacher, A. Rademaker, b. Weitner, 

E. Szmuilowicz, S. A. Weitzman 

Brd. 41B Discordance between conclusions in the abstract and conclusions stated in 

the body of the article: An analysis of randomized controlled trials (RCTs) of 

lung cancer. (Abstract #6046) 

A. K. Altwairgi, C. Booth, W. Hopman, T. D. Baetz 

Brd. 41C Assessing 2-month clinical prognosis in patients with solid tumors: First 

results of PRONOPALL study. (Abstract #6047) 

H. P. Bourgeois, S. Traoré, P. Solal-Celigny, O. Dupuis, P. Maillart, O. Capitain, 

R. Delva, P. Soulie, M. Marcq, E. Boucher, G. Ganem, E. Bourbouloux, J. Baudon, 

M. Kaassis, M. Zinger, C. Lafond, V. Berger, P. Mussault, P. Ingrand, F. Grude 

Brd. 41D Factors associated with histologic versus cytologic diagnosis of lung 


C. S. Lathan, A. Cronin, J. C. Weeks 

Brd. 41E Randomized controlled trials (RCTs) in the era of molecular oncology: 

Methodology, biomarkers, and endpoints. (Abstract #6049) 

A. Kay, J. Higgins, A. G. Day, R. M. Meyer, C. M. Booth 

Brd. 41F Socioeconomic position, stage of lung cancer, and time between referral and 

diagnosis in Denmark, 2001–2008. (Abstract #6050) 

S. O. Dalton, B. L. Frederiksen, E. Jakobsen, M. Steding-Jessen, K. Oesterlind, 

J. Schuz, M. Osler, C. Johansen 

122


Brd. 41G Are breast cancer quality metrics being met? (Abstract #6051) 

A. Murphy, G. Rauscher, D. Dupuy, R. Alvarez, T. Macarol, E. Knightly, D. Ansell, 

P. Grabler, P. A. Robinson, E. A. Marcus 

Brd. 41H Implementation of a prospective screening tool for breast cancer clinical trial 

eligibility at an NCI-designated cancer center. (Abstract #6052) 

K. H. Lethert, S. K. Cheng, D. J. Nauman, D. M. Dilts, A. Sandler, S. Y. Chui 

Brd. 42A Predictive markers of utilization of chemotherapy in patients with advanced 

colorectal cancer (CRC): A population-based study. (Abstract #6053) 

S. Ahmed, T. Zhu, R. Lee-Ying, C. Ubhi, V. Kundapur, R. Alvi, K. Haider 

Brd. 42B Assessing two meta-analysis (MA) methods: Individual patient data-based 

(IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002 

patients (pts)—Are there differences of concern? (Abstract #6054) 

E. Bria, R. J. Gralla, H. Raftopoulos, I. Sperduti, M. Milella, F. Cognetti, 

D. Giannarelli 

Brd. 42C Defining indicators for measuring the quality of systemic cancer therapy 

using administrative data. (Abstract #6055) 

M. K. Krzyzanowska, C. M. Booth, K. K. Chan, K. Enright, M. E. Trudeau 

Brd. 42D Attrition bias: Does the benefit of targeted agents (TA) increase the more we 

search for a selection biomarker? Meta-regression analysis of randomized 

clinical trials (RCTs) in advanced non-small cell lung and colorectal cancer 

(NSCLC/CRC). (Abstract #6056) 

D. Giannarelli, M. Milella, F. Loupakis, F. Cuppone, V. Vaccaro, I. Sperduti, 

P. Carlini, A. Falcone, F. Cognetti, E. Bria 

Brd. 42E SBRT for early NSCLC: Markov model insight for optimal patient selection. 


A. V. Louie, G. Rodrigues, M. Hannouf, D. Palma, G. Zaric, S. Senan 

Brd. 42F Pathways of care for adolescents with cancer in France. (Abstract #6058) 

E. Desandes, S. Bonnay, C. Berger, L. Brugieres, F. Isfan, V. Laurence, L. Mignot, 

D. Olive-Sommelet, I. Tron, J. Clavel, B. Lacour 

Brd. 42G Screening for hepatitis B virus (HBV) prior to chemotherapy: A 

cost-effectiveness analysis. (Abstract #6059) 

U. Zurawska, L. K. Hicks, G. Woo, C. M. Bell, M. Krahn, K. K. Chan, J. J. Feld 

Brd. 42H The cost-effectiveness of bevacizumab in combination with paclitaxel in 

first-line treatment of patients with metastatic breast cancer. (Abstract #6060) 

A. J. Montero, S. Gluck, G. D. Lopes Jr. 

Brd. 43A Prognostic significance of QOL deterioration during early lung cancer 

survivorship: Secondary analysis of RTOG 0212 and 0214. (Abstract #6061) 

V. Gondi, R. Paulus, D. Bruner, C. A. Meyers, E. Gore, A. H. Wolfson, 

M. Werner-Wasik, H. Choy, B. Movsas, Radiation Therapy Oncology Group 

(RTOG) 

Brd. 43B Smaller, faster trials: The right way to assess new targeted agents? A 

simulation study. (Abstract #6062) 

M. Le Deley, K. V. Ballman, D. J. Sargent 

Brd. 43C Utilization and clinical practice impact of an interactive tool for guiding 

choice of systemic adjuvant treatment (adj TX) for patients with early breast 

cancer (EBC). (Abstract #6063) 

P. Ravdin, S. Martino, M. D. Pegram, N. J. Robert, S. M. Swain, D. Janssen, 

A. Bowser, J. A. Mortimer, R. W. Carlson 

Brd. 43D Clinical practice guidelines (CPGs) for adjuvant chemotherapy (aCT) in 

colorectal cancer: A population-based analysis of adherence and nonreceipt. 


D. Rayson, R. Urquhart, E. Grunfeld, M. Cox, C. Kendell, M. Jorgensen, B. Colwell, 

G. A. Porter 

Brd. 43E Understanding patients’ attitudes toward communication about the cost of 

cancer care. (Abstract #6065) 

A. J. Bullock, E. W. Hofstatter, M. Yushak, M. K. Buss 

123 

SATURDAY

SATURDAY 


Brd. 43F Are African American men adequately represented in prostate cancer 

randomized controlled trials? A systematic review. (Abstract #6066) 

S. Galeb, T. Reljic, B. Djulbegovic, C. Gwede, N. B. Kumar, A. Kumar 

Brd. 43G Costs and utilization of oncology health care services at the end of life. 


B. Chastek, C. R. Harley, J. D. Kallich, L. N. Newcomer, C. J. Paoli, A. Teitelbaum 

Brd. 43H Willingness to pay to prevent chemotherapy-induced nausea and vomiting. 


P. Miller, S. Balu, D. Buchner, M. Walker, E. J. Stepanski, L. S. Schwartzberg 

Brd. 44A Meta analysis of behavioral interventions to reduce cancer pain. (Abstract 

#6069) 

S. S. Gorin, H. Badr, P. B. Jacobsen, E. Janke, H. S. Jim, P. Krebs 

Brd. 44B Analysis of minority-based community clinical oncology program (MBCCOP) 

accrual activity. (Abstract #6070) 

E. H. Williams, W. J. McCaskill-Stevens, T. E. Lad 

Brd. 44C Surgical treatment of colon cancer in patients older than age 80. (Abstract 

#6071) 

H. B. Neuman, E. S. O’Connor, J. Weiss, N. K. LoConte, D. Y. Greenblatt, 

M. Smith 

Brd. 44D Cancer in the adolescent and young adult (AYA) population in the United 

States: Current statistics and projections. (Abstract #6072) 

R. S. Go, J. D. Gundrum 

Brd. 44E A review of medical malpractice claims related to clinical genetic testing. 


R. A. Lindor, G. E. Marchant 

Brd. 44F ASCO Quality Oncology Practice Initiative (QOPI) quality measures for 

smoking cessation and survival in metastatic NSCLC. (Abstract #6074) 

I. T. Lennes, J. S. Temel, J. A. Greer, J. O. Jacobson, E. R. Park, 

V. A. Jackson, E. R. Gallagher, H. Bemis, W. F. Pirl 

Brd. 44G A clinical trial with culturally tailored video to increase participation of 

African Americans in cancer clinical trials. (Abstract #6075) 

D. R. Banda, M. Mete, R. Kapoor, S. M. Swain 

Brd. 44H Quantifying the personal financial impact of a career choice in academic 

hematology/oncology (AHO). (Abstract #6076) 

M. Palmeri, E. Stansfield, A. Stansfield, A. D. Fuld, J. M. Pipas, B. A. Arrick, 

E. Wadsworth, T. H. Davis 

Brd. 45A Comparison of beliefs of lung cancer providers and minority patients. 


C. B. Smith, N. Bickell, E. Halm, A. R. Berman, C. A. Powell, J. Salazar-Schicchi, 

J. E. Nelson, J. P. Wisnivesky 

Brd. 45B Impact of early prostate cancer diagnosis in the United States. (Abstract 

#6078) 

Y. Zhang, B. K. Hollenbeck, J. E. Montie, J. T. Wei 

Brd. 45C Predictors of successful breast-conserving surgery (BCS) in patients with 

ductal carcinoma in situ (DCIS). (Abstract #6079) 

J. J. Griggs, M. E. Sorbero, G. M. Ahrendt, L. M. Schiffhauer, A. Stark, A. W. Dick 

Brd. 45D Accelerated partial-breast irradiation using brachytherapy (APBIb) for breast 

cancer: Predictors of use and guideline concordance. (Abstract #6080) 

J. A. Hattangadi, N. Taback, B. A. Neville, J. R. Harris, R. S. Punglia 

Brd. 45E Cost-effectiveness of intraoperative radiation therapy for breast 

conservation. (Abstract #6081) 

M. Alvarado, E. Ozanne, A. Mohan, L. Esserman 

124


Brd. 45F Cost effectiveness of a survivorship care plan for breast cancer survivors. 


D. Coyle, E. Grunfeld, K. Coyle, J. A. Julian, G. R. Pond, A. Folkes, M. N. Levine, 

FUPII Trial Investigators, Ontario Clinical Oncology Group 

Brd. 45G Clinical outcome of advanced colorectal cancer patients pre and post 

bevacizumab therapy using the SEER database. (Abstract #6083) 

M. Choi, G. Dyson, P. A. Philip, A. F. Shields 

Brd. 45H How often are opioids prescribed for cancer patients reporting pain? Results 

of a population-based analysis. (Abstract #6084) 

L. C. Barbera, H. Seow, A. Husain, D. Howell, C. Atzema, C. Earle, Y. Liu, 

J. Sussman, R. Sutradhar, D. J. Dudgeon 

Brd. 46A Validation of a claims-based predicted performance status measure in 

SEER-Medicare. (Abstract #6085) 

F. Hendrick, I. H. Zuckerman, N. B. Pandya, X. Ke, M. J. Edelman, A. J. Davidoff 

Brd. 46B The cost-effectiveness of primary prophylaxis with granulocyte colonystimulating 

factor in docetaxel-containing adjuvant chemotherapy in early 

breast cancer: The impact of risk of febrile neutropenia and its mortality. 


K. K. Chan, M. E. Trudeau, A. Eisen, J. L. Verreault, C. A. Freedman, S. Dent 

Brd. 46C Correlates of poor surgical margins following initial surgery for ductal 

carcinoma in situ and receipt of additional surgery. (Abstract #6087) 

M. E. Sorbero, J. J. Griggs, G. M. Ahrendt, L. M. Schiffhauer, A. Stark, A. W. Dick 

Brd. 46D A year in the life of oncology health services research. (Abstract #6088) 

M. Brundage, C. F. Snyder, B. H. Bass 

Brd. 46E Changing prognosis of glioblastoma multiforme (GBM) in the 21st century: 

The influence of age and regional income. (Abstract #6089) 

M. V. Mishra, A. Dicker, M. Werner-Wasik, D. W. Andrews, X. Shen, 

T. N. Showalter, J. Glass, Z. Symon, Y. R. Lawrence 

Brd. 46F Reporting of cancer clinical trial adverse drug events: A RADAR report. 


S. M. Belknap, C. H. Georgopoulos, S. A. Weitzman, L. Qualkenbush, 

A. T. Samaras, J. M. McKoy, B. J. Edwards, S. T. Rosen, D. P. West 

Brd. 46G A national evaluation of response and factors affecting response to 

neoadjuvant therapy in breast and rectal cancer. (Abstract #6091) 

S. B. Edge, D. Gress, D. P. Winchester, A. Stewart 

Brd. 46H Evaluation of cancer trial eligibility criteria (with focus on non-AIDS–defining 

cancers) for inclusion of persons with HIV infection. (Abstract #6092) 

S. A. Weiss, S. Gajavelli, A. Negassa, J. A. Sparano, M. Haigentz Jr. 

Brd. 47A Predictors of accrual to clinical trials in an integrated health care delivery 

system. (Abstract #6093) 

C. P. Somkin, L. M. Ackerson, G. Husson, T. Kolevska, D. Goldstein, 

L. Fehrenbacher 

Brd. 47B Emerging trends in radiation therapy use among women older than age 70 

with stage I breast cancer from 2000–2007: A population-based analysis. 


X. Shen, A. P. Wojcieszynski, M. V. Mishra, P. R. Anne, T. N. Showalter 

Brd. 47C Assessment of clinical trials in oncology: An evaluation of 40,696 trials on 

ClinicalTrials.gov. (Abstract #6095) 

B. R. Hirsch, R. M. Califf, A. Tasneem, K. Chiswell, J. Bolte, K. A. Schulman, 

A. P. Abernethy 

Brd. 47D Therapeutic clinical trial enrolment among young adults diagnosed with 


P. S. Blanchette, M. Crump, A. A. Gupta 

125 

SATURDAY

SATURDAY 


Brd. 47E Use of radiation therapy after breast-conserving surgery among Medicaid 

recipients with early-stage breast cancer. (Abstract #6097) 

S. B. Wheeler, Y. Wu, A. Meyer, W. R. Carpenter, L. C. Richardson, J. L. Smith, 

M. A. Lewis, B. Weiner 

Brd. 47F Risks and benefits of phase I trials: Twelve-years experience from a single 

institution. (Abstract #6098) 

U. Swami, M. H. Ghalib, I. Chaudhary, J. Y. Hou, S. Aparo, M. H. Einstein, 

G. L. Goldberg, T. N. Elrafei, S. Gajavelli, B. Cohen, L. Rajdev, A. Kaubisch, 

M. Haigentz Jr., S. Mani, S. Goel 

Brd. 47G Framing the benefits of cancer treatment: How survival is described 

influences preferences for care. (Abstract #6099) 

P. Lin, T. W. Concannon, D. Greenberg, G. P. Rossi, J. Hille, C. Fang, 

H. R. Auerbach, P. J. Neumann 

Brd. 47H Doctor, what do I have? Limited-English–proficient patients and cancer 

diagnosis knowledge. (Abstract #6100) 

J. C. Leng, L. Yogendran, D. Massie, J. Ramirez, T. Lee, I. Lobach, F. Gany 

Brd. 48A The ASCO Breast Cancer Registry pilot: Implementation of a multisite 

community practice registry and treatment plan/summary program. (Abstract 

#6101) 

A. H. Partridge, V. W. Norris, V. S. Blinder, B. A. Cutter, M. T. Halpern, 

J. Malin, M. N. Neuss, A. C. Wolff, ASCO Breast Cancer Registry Pilot Steering 

Group 

Brd. 48B Health-related quality-of-life (HRQoL) reporting by randomized cancer trials 

(RCT): Pitfalls for interpretation. (Abstract #6102) 

L. Testa, C. C. Barbosa, A. C. Chaves, P. M. Hoff, R. P. Riechelmann 

Brd. 48C Prospective validation of risk prediction models for acute and delayed 

chemotherapy-induced nausea and vomiting (CINV). (Abstract #6103) 

N. Bouganim, G. Dranitsaris, L. Vandermeer, S. Hopkins, S. Dent, 

P. Wheatley-Price, S. Verreault, C. Young, M. J. Clemons 

Brd. 48D Pharmaceutical involvement in phase II breast cancer clinical trials. (Abstract 

#6104) 

A. Schneider, T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, J. M. Peppercorn 

Brd. 48E Shifting patterns in the interpretation of phase III clinical trial outcomes in the 

treatment of advanced NSCLC. (Abstract #6105) 

A. G. Sacher, N. B. Leighl 

Brd. 48F Relationship between physician characteristics and the use of newer 

chemotherapy for the treatment of colon cancer. (Abstract #6106) 

D. J. Becker, D. L. Hershman, B. J. Insel, A. I. Neugut 

Brd. 48G Uptake of bevacizumab for the treatment of colon cancer. (Abstract #6107) 

A. I. Neugut, D. J. Becker, B. J. Insel, D. L. Hershman 

Brd. 48H Population-based health care cost estimates related to breast cancer by 

staging. (Abstract #6108) 

N. Mittmann, P. K. Isogai, R. Saskin, N. Liu, J. Hoch, N. B. Leighl, M. C. Cheung, 

M. E. Trudeau, W. K. Evans, K. Dainty, C. Earle 

Brd. 49A Oncology appointment compliance in navigated and non-navigated patients 

receiving radiation therapy in an urban public hospital. (Abstract #6109) 

E. A. Marcus, N. Holloway, C. Galligan, R. Cheng, M. McDunn, P. A. Robinson, 

K. Devine 

Brd. 49B Early success in narrowing age, gender, and racial disparities in clinical trial 

accrual: Targeted screening efforts through the National Cancer Institute 

Community Cancer Centers Program (NCCCP). (Abstract #6110) 

S. S. Grubbs, R. S. Go, M. Z. Berger, M. Gonzalez, M. A. Thompson, R. Enos, 

D. C. St. Germain, A. Denicoff, C. Servididio, J. D. Bearden, H. Zaren, 

K. Wilkinson, M. Krasna, W. McCaskill-Stevens, M. Bell, R. K. Freeman, 

S. Miesfeldt, T. S. Ravikumar, S. G. Nair, A. Bashey 

126


Brd. 49C A cost benefit analysis of the 21-gene breast cancer assay within a Canadian 

health care system. (Abstract #6111) 

S. Hassan, N. Mittmann 

Brd. 49D Use of high-cost imaging in elderly patients with metastatic cancer. (Abstract 

#6112) 

Y. Hu, A. C. Kwok, W. Jiang, N. Taback, S. R. Lipsitz, G. V. Ting, E. T. Loggers, 

J. C. Weeks, C. C. Greenberg 

Brd. 49E The Cancer Therapy Evaluation Program’s (CTEP) implementation of the 

Operational Efficiency Working Group (OEWG) recommendations. (Abstract 

#6113) 

K. DiPiazza, E. Souhan, S. Finnigan, A. Denicoff, S. Friedman, M. Montello, 

M. M. Mooney, P. Schettino, J. A. Zwiebel, J. H. Doroshow, J. S. Abrams 

Brd. 49F Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. 


V. C. Tam, Y. Ko, N. Mittmann, K. Kumar, S. Hassan, M. C. Cheung, K. K. Chan 

Brd. 49G Financial implications of changes in the initial treatment of prostate cancer 

among Medicare beneficiaries. (Abstract #6115) 

M. A. Dinan, T. J. Robinson, T. M. Zagar, C. D. Scales Jr., L. H. Curtis, 

S. D. Reed, K. A. Schulman, W. Lee 

Brd. 49H The 2010 National Comprehensive Cancer Network (NCCN) research 

benchmarking survey (RBS): Clinical trials in the academic cancer center. 


S. L. Sherman, M. B. Waldinger, D. E. Paul 

Brd. 50A Survivorship care plan assessment checklist (SCPAC): A tool to evaluate 

breast cancer survivorship care plans. (Abstract #6117) 

C. T. Stricker, L. A. Jacobs, A. DeMichele, A. Jones, B. C. Risendal, S. C. Palmer 

Brd. 50B Survival trends and patterns of chemotherapy use in elderly metastatic 

colorectal cancer (mCRC) patients. (Abstract #6118) 

V. Shankaran, S. J. Beck, D. K. Blough, L. Koepl, Y. Yim, E. Yu, S. D. Ramsey 

Brd. 50C Clinical trial availability compared to incidence rates for adolescent and 

young adult cancer. (Abstract #6119) 

D. J. Indelicato, A. Bleyer, LIVESTRONG Young Adult Alliance 

Brd. 50D Conflict of interest in economic analyses of targeted therapies in oncology. 


A. D. Nearchou, A. Valachis, N. P. Polyzos, D. Mauri, P. A. Lind 

Brd. 50E Long-term surveillance and preventive practices among healthy young adult 

cancer survivors. (Abstract #6121) 

E. M. Del Giudice, L. F. Paszat, L. Rabeneck, R. Sutradhar, D. Urbach, D. Wilton, 

N. N. Baxter 

Brd. 50F Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: 

Results from North Central Cancer Treatment Group (NCCTG) phase III trial 

N0147. (Abstract #6122) 

J. A. Sloan, M. R. Mahoney, D. J. Sargent, J. M. Hubbard, H. Liu, E. M. Basch, 

A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. R. Alberts 

Brd. 50G Perspectives on electronic health information exchange among people 

affected by cancer. (Abstract #6123) 

E. B. Beckjord, R. Rechis, L. N. Shulman, B. Hesse 

Brd. 50H Does insurance coverage affect pancreatic cancer survival? The Medicare 

age threshold. (Abstract #6124) 

J. K. Smith, J. Dimick, E. R. Witkowski, E. Ragulin-Coyne, T. P. McDade, S. Ng, 

Z. Zhou, J. F. Tseng 

Brd. 51A The impact of time to adjuvant chemotherapy (AC) on survival in colorectal 

cancer (CRC): A systematic review and meta-analysis. (Abstract #6125) 

M. Raphael, J. J. Biagi, W. J. Mackillop, W. Kong, W. D. King, C. M. Booth 

127 

SATURDAY

SATURDAY 


Brd. 51B Two decades of oncology randomized controlled trials: Factors associated 

with CONSORT clinical trial reporting checklist compliance. (Abstract #6126) 

G. Rodrigues, I. Arra, V. Velker, B. Rotenberg, T. Sexton 

Brd. 51C Palliative chemotherapy: Does aggressive care beget aggressive care? 


A. A. Wright, H. G. Prigerson 

Brd. 51D Appointment (appt) access for new cancer patients (pts). (Abstract #6128) 

K. Gogineni, K. Armstrong 

Brd. 51E Impact of travel distance on early diagnosis of prostate cancer (CaP) and 

receipt of curative treatment. (Abstract #6129) 

J. A. Holmes, W. R. Carpenter, Y. Wu, S. P. Hinton, M. Massing, A. P. Schenck, 

A. Meyer, S. B. Wheeler, P. A. Godley, R. C. Chen 

Brd. 51F Calibrating clinically significant effects in survival and response endpoints in 

cancer clinical trials. (Abstract #6130) 

A. C. Dueck, D. J. Sargent, P. J. Novotny, P. A. Decker, H. Nelson, R. Qin, 

J. A. Sloan 

Brd. 51G Sponsor/research ethics boards (REB) communications about informed 

consent (IC) and time to local activation (LA): An NCIC CTG pilot study. 


M. Walker, A. Szeto, Z. Meng, B. E. Chen, R. M. Meyer 

Brd. 51H Managing specialty medication services through a network of specialty 

pharmacies: A case of oral oncology medications. (Abstract #6132) 

S. Aslam, S. Tschida, L. S. Lal, T. T. Khan, W. H. Shrank, G. R. Bhattarai, 

J. C. Montague- Clouse, L. N. Newcomer 

Brd. 52A Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, 

or FISH-negative early-stage breast cancer patients for HER2 status. 


L. P. Garrison, D. Lalla, M. G. Brammer, B. Wang, J. Babigumira, E. A. Perez 

Brd. 52B Rapid improvement in evidence-based, quality care of cancer patients with 

initiation of ASCO’s Quality Oncology Practice Initiative (QOPI). (Abstract 

#6134) 

M. A. Amin, M. H. Hashmi, S. A. Taylor 

Brd. 52C The effect of process engineering on the performance of a chemotherapy 

outpatient clinic (CC). (Abstract #6135) 

J. Latreille, C. Mimeault, N. Moreau, S. Parent, J. Savaria, J. Bastien, J. Lafreniere, 

C. C. Prady, O. Blaizel, G. Pie, M. Gannon 

Brd. 52D Computer-assisted outreach by patient care navigators using laptop wireless 

communication. (Abstract #6136) 

M. Castaldi, T. N. Elrafei, M. Broderick, H. Delany, Albert Einstein College of 

Medicine 

128

8:00 AM - 1:00 PM 



Developmental Therapeutics—Clinical Pharmacology and Immunotherapy 

Display Time: 8:00 AM - 12:00 PM 




CME credit: 1 


Jeffrey R. Infante, MD—Chair 

The Sarah Cannon Cancer Center 

Discussion 

12:00 PM Janet Dancey, MD (Abstracts #2515–2523) 

Ontario Institute for Cancer Research 

Discussion 

12:15 PM S. Percy Ivy, MD (Abstracts #2524–2529) 


Discussion 

12:30 PM George Coukos, MD, PhD (Abstracts #2530–2535) 

University of Pennsylvania, Abramson Cancer Center 

Discussion 

12:45 PM Jeffrey R. Infante, MD (Abstracts #2536–2539) 

The Sarah Cannon Cancer Center 

Brd. 1 First-in-human trial focusing on the immunologic effects of the survivinderived 

multiepitope vaccine EMD640744. (Abstract #2515) 

S. Gross, V. Lennerz, E. Gallerani, C. Sessa, N. Mach, S. Boehm, D. Hess, 

L. von Boehmer, A. Knuth, A. Ochsenbein, U. Gnad-Vogt, J. Zieschang, 

U. Forssmann, T. Woelfel, E. Kaempgen 

Brd. 2 The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results 

from phase I trial in Japanese patients with metastatic solid tumors. 


T. Nishina, T. Hirashima, K. Sugio, K. Muro, S. Akinaga, H. Maeda, T. Takahashi, 

T. Naito, H. Murakami, H. Yasui, N. Boku, N. Yamamoto 

Brd. 3 Phase I dose-finding study of trabectedin (T) in combination with cisplatin 

(C) in patients (pts) with advanced solid tumors. (Abstract #2517) 

C. Sessa, E. Gallerani, G. Del Conte, A. Christinat, A. Perotti, P. Lardelli, 

C. M. Kahatt, A. Florez, C. Fernandez, M. Miani, L. Gianni 

Brd. 4 A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in 

combination with docetaxel (D) in patients (pts) with solid tumors. (Abstract 

#2518) 

M. Puglisi, L. van Doorn, M. Blanco-Codesido, M. J. De Jonge, K. Moran, J. Yang, 

T. Busman, C. Franklin, M. Mabry, A. Krivoshik, R. Humerickhouse, L. R. Molife, 

F. Eskens 

Brd. 5 A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) 

administration of autologous TriMix-DC cellular therapy in patients with 

pretreated melanoma (TriMixIDIV). (Abstract #2519) 

B. Neyns, S. Wilgenhof, A. M. Van Nuffel, D. Benteyn, C. Heirman, I. Van Riet, 

A. Bonehill, J. Corthals, K. Thielemans 

Brd. 6 Phase I study of the PARP inhibitor olaparib (O) in combination with 

carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) 

cancer (Ca). (Abstract #2520) 

J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville, H. L. Kotz, 

J. Squires, N. D. Houston, J. J. Ji, M. Yu, J. H. Doroshow, E. C. Kohn 

129 

SATURDAY

SATURDAY 


Brd. 7 Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) 

in combination with sorafenib (S) in patients with advanced refractory solid 

tumors. (Abstract #2521) 

M. Simonelli, P. A. Zucali, R. De Sanctis, E. Lorenzi, F. De Vincenzo, L. Rimassa, 

M. C. Tronconi, N. Personeni, G. Masci, M. Zuradelli, M. Perrino, M. Bertossi, 

L. Giordano, A. Santoro 

Brd. 8 Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients 

with solid tumors. (Abstract #2522) 

P. A. Zucali, M. Simonelli, F. De Vincenzo, E. Lorenzi, L. Rimassa, L. Balzarini, 

V. Quagliuolo, A. Lambiase, C. Bordignon, A. Santoro 

Brd. 9 Is there a therapeutic benefit for patients participating in modern phase I 

trials? (Abstract #2523) 

M. N. Stein, A. R. Tan, J. M. Mehnert, D. Gibbon, R. S. DiPaola, R. A. Moss, 

E. Poplin, E. H. Rubin, B. Saraiya, M. P. Kane, P. Scott, M. LaRosiliere, H. Camisa, 

P. Kirin, C. M. Thomas, J. Aisner 

Brd. 10 Phase I open-label, dose-escalation study of ANA773 tosylate, an oral 

prodrug of a toll-like receptor-7 agonist, in patients with advanced solid 


G. A. Daniels, W. E. Carson III, A. C. Mita, K. L. Kendra, M. H. Rahimy, 

D. W. Inman, J. R. Appleman, J. L. Freddo, D. G. McNeel 

Brd. 11 Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen 

receptor– (ER) or androgen receptor (AR)–positive advanced breast 

carcinoma resistant to standard endocrine therapies. (Abstract #2525) 

B. Basu, J. Ang, D. Crawley, E. Folkerd, D. Sarker, M. Blanco-Codesido, K. Moran, 

S. Wan, N. Dobbs, F. Raynaud, S. R. Johnston, M. Dowsett, A. N. Tutt, 

J. F. Spicer, C. Swanton, J. S. De Bono 

Brd. 12 High efficacy and continued tumor shrinkage with cyclophosphamide, 

vincristine, and dacarbazine (CVD) in patients (Pts) with malignant 

pheochromocytoma/paraganglioma harboring succinate dehydrogenase 

subunit B (SDHB) mutations. (Abstract #2526) 

I. Jawed, L. Amiri-Kordestani, M. Velarde, K. Adams, S. Balasubramaniam, 

J. Reynolds, K. Pacak, A. T. Fojo 

Brd. 13 Early assessment of efficacy of ixabepilone (IXA) by analysis of the rate of 

tumor growth and decay using data from phase II and phase III clinical trials 

in metastatic breast cancer (MBC) patients (Pts). (Abstract #2527) 

L. Amiri-Kordestani, I. Jawed, J. Wilkerson, W. D. Stein, A. T. Fojo, S. M. Swain, 

S. E. Bates 

Brd. 14 Survival of 1,181 patients in a phase I clinic: The University of Texas 

University of Texas M. D. Anderson Cancer Center experience. (Abstract 

#2528) 

B. Stephen, J. J. Wheler, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, 

G. S. Falchook, S. A. Piha-Paul, S. Fu, F. Janku, S. L. Moulder, R. Kurzrock 

Brd. 15 Bevacizumab changes in patients with naive, stage II-III breast cancer 

assessed by 18F-fluoromisonidazole and 18F-fluorotymidine PET-CT. 


V. Boni, I. Dominguez, M. J. Garcia Velloso, J. Lopez Vega, P. Martinez, 

A. Plazaola, B. Hernando, A. Llombart Cussac, J. Lao, R. S. Gomez, I. Alvarez, 

J. J. Illarramendi, E. G. Calvo, S. Morales Murillo, T. Puertolas, L. J. Pina, 

E. Bernedo, G. Palacios, S. J. Scherer, J. Garcia-Foncillas 

Brd. 16 Intraprostatic PSA-TRICOM vaccine administration in patients with locally 

recurrent prostate cancer. (Abstract #2530) 

C. R. Heery, P. A. Pinto, J. Schlom, K. Y. Tsang, R. A. Madan, D. Poole, 

M. Vergati, B. Walter Rodriguez, M. Merino, J. L. Gulley 

130


Brd. 17 A dose confirmation and signal-generating study of the immunocytokine 

L19-IL2 in combination with dacarbazine in patients with metastatic 

melanoma. (Abstract #2531) 

T. K. Eigentler, B. Weide, G. Spitaleri, F. G. De Braud, A. Romanini, 

R. Gonzales-Inglesias, A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato, 

M. Kaspar, E. Trachsel, D. Neri, H. D. Menssen, C. Garbe 

Brd. 18 Monitoring T-cell responses in a phase II study of AGS-003, an autologous 

dendritic cell–based therapy in patients with newly diagnosed advanced 

stage renal cell carcinoma in combination with sunitinib. (Abstract #2532) 

R. A. Figlin, A. Amin, A. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, 

M. DeBenedette, S. K. Pal, V. Master, I. Y. Tcherepanova, R. Jain, W. L. Williams, 

T. Monesmith, F. Miesowicz, C. A. Nicolette 

Brd. 19 A dendritic cell–based vaccine effects on T-cell responses compared with a 

viral vector vaccine when administered to patients following resection of 

colorectal metastases in a randomized phase II study. (Abstract #2533) 

H. K. Lyerly, A. Hobeika, D. Niedzwiecki, T. Osada, J. Marshall, C. R. Garrett, 

D. Z. Chang, M. Aklilu, T. S. Crocenzi, D. J. Cole, S. Dessureault, 

S. D. Hsu, A. Bulusu, B. M. Clary, R. Annechiarico, G. Devi, 

V. Chadaram, T. M. Clay, M. Morse 

Brd. 20 Lymphodepletion and tumor burden govern clinical responses in patients 

with B-cell malignancies treated with autologous, CD19-targeted T cells. 


R. J. Brentjens, I. Riviere, J. Park, M. Davilla, X. Wang, R. Yeh, N. Lamanna, 

M. G. Frattini, M. Sadelain 

Brd. 21 A feasibility study of combination therapy with trastuzumab (T), 

cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor 

vaccine for the treatment of HER2� metastatic breast cancer. (Abstract 

#2535) 

L. A. Emens, R. Gupta, S. Petrik, M. Laiko, J. M. Leatherman, J. Levi, 

J. M. Asquith, M. M. Daphtary, E. Garrett-Mayer, B. J. Kobrin, N. E. Davidson, 

T. Dauses, S. Atay-Rosenthal, X. Ye, A. C. Wolff, V. Stearns, E. M. Jaffee 

Brd. 22 An umbrella protocol for histology-independent, phase I modular study 

based on EGFR mutation status: Using erlotinib alone or in combination with 

cetuximab, bortezomib, or dasatinib to overcome resistance. (Abstract 

#2536) 

J. Fok, R. Kurzrock, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, F. Janku, 

G. S. Falchook, S. A. Piha-Paul, R. Katz, S. Fu, S. L. Moulder, J. J. Wheler 

Brd. 23 Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) 

agonist, in patients with advanced solid tumors. (Abstract #2537) 

P. A. Cohen, D. W. Northfelt, G. J. Weiss, D. D. Von Hoff, K. Manjarrez, G. Dietsch, 

R. M. Hershberg, R. K. Ramanathan 

Brd. 24 Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in 

patients (pts) with advanced cancer: Updated results and assessment of 

human CSF distribution. (Abstract #2538) 

E. G. Chiorean, E. A. Sausville, E. I. Heath, A. Weise, J. Gomez-Navarro, 

K. Venkatakrishnan, S. Sankoh, J. Wu, M. Corvez, P. LoRusso 

Brd. 25 Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a 

pharmacodynamic (PD) biomarker in phase I trials of the humanized 

monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A). (Abstract #2539) 

J. Fredrickson, I. Chang, M. Friesenhahn, E. Ashton, P. N. Munster, M. S. Gordon, 

D. S. Chen, L. Naumovski, A. de Crespigny, L. S. Rosen 

131 

SATURDAY

SATURDAY 


8:00 AM - 1:00 PM 


Lymphoma and Plasma Cell Disorders 




Discussion Location: E354a 

CME credit: 1 


John Leonard, MD—Co-Chair 


Sonali M. Smith, MD—Co-Chair 


Discussion 

12:00 PM Ann S. LaCasce, MD (Abstracts #8015–8016, 8023) 


Discussion 

12:15 PM David G. Maloney, MD, PhD (Abstracts #8017–8019) 

Fred Hutchinson Cancer Research Center 

Discussion 

12:30 PM Suzanne Lentzsch, MD, PhD (Abstracts #8021–8022, 8024) 

University of Pittsburgh 

Discussion 

12:45 PM Jonathan L. Kaufman, MD (Abstracts #8025–8027) 

Emory University 

Brd. 1 Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for 

aggressive B-cell lymphomas: A phase I/II study. (Abstract #8015) 

G. S. Nowakowski, C. B. Reeder, B. LaPlant, T. M. Habermann, C. Rivera, 

W. R. Macon, D. J. Inwards, I. N. Micallef, P. B. Johnston, 

L. F. Porrata, S. M. Ansell, T. E. Witzig 

Brd. 2 Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in 

the first-line treatment of patients with intermediate- and high-risk diffuse 

large B-cell lymphoma (DLBCL): Preliminary analysis. (Abstract #8016) 

J. D. Hainsworth, E. Arrowsmith, M. McCleod, L. Fayad, O. Hamid, L. Davis, 

B. K. Lin 

Brd. 3 Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 

administered weekly to patients (pts) with relapsed/refractory B-cell non- 

Hodgkin lymphoma (NHL). (Abstract #8017) 

B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, 

C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir 

Brd. 4 Day 15 peripheral blood lymphocyte/monocyte ratio post-autologous 

peripheral hematopoietic stem cell transplantation and survival in diffuse 

large B-cell lymphoma. (Abstract #8018) 

L. F. Porrata, D. J. Inwards, S. M. Ansell, I. N. Micallef, P. B. Johnston, 

W. J. Hogan, S. Markovic 

Brd. 5 Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk 

CD20� NHL not eligible for standard ASCT: Five-year results. (Abstract 

#8019) 

L. Devizzi, A. Guidetti, C. Carlo-Stella, C. Tarella, E. Seregni, M. Magni, 

M. A. Di Nicola, E. Schiavello, P. Matteucci, S. Viviani, E. Bombardieri, 

A. M. Gianni 

132


Brd. 6 Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and 

autologous transplantation (MEL200) in newly diagnosed multiple myeloma 

(MM) patients: A phase III trial. (Abstract #8020) 

M. Boccadoro, F. Cavallo, A. Nagler, D. Ben Yehuda, P. Omedè, M. Cavalli, 

A. Levi, C. Crippa, A. Siniscalchi, P. Brasca, A. M. Carella, B. Zanetti, F. Patriarca, 

S. Pezzati, V. Montefusco, A. Stanevsky, B. Lupo, T. Caravita, F. Di Raimondo, 

A. P. Palumbo 

Brd. 7 Survival outcomes in elderly patients with plasma cell myeloma: The threedecade 

Eastern Cooperative Oncology Group (ECOG) experience. (Abstract 

#8021) 

E. L. Campagnaro, S. J. Jacobus, H. Uno, M. M. Oken, R. A. Kyle, S. V. Rajkumar, 

P. R. Greipp, D. H. Vesole, M. Weiss, R. Fonseca, H. M. Lazarus 

Brd. 8 Bortezomib plus DA-EPOCH-rituximab followed by bortezomib maintenance 

versus observation in previously untreated mantle cell lymphoma (MCL). 


C. Grant, K. Dunleavy, M. Tweito, S. M. Steinberg, S. Pittaluga, E. S. Jaffe, 

A. Wiestner, W. H. Wilson 

Brd. 9 Activity of vorinostat (SAHA), cladribine (2-CdA), and rituximab in previously 

untreated mantle cell lymphoma: A phase I/II study. (Abstract #8023) 

S. E. Spurgeon, A. I. Chen, B. Ratterree, C. Okada, G. Palmbach, K. Diaz, 

N. Subbiah, C. Capper, E. E. Epner 

Brd. 10 Generation of an automated tool for querying myeloma transcriptomics for 

multiple gene expression signatures used in risk stratification. (Abstract 

#8024) 

R. Fonseca, E. Braggio, J. J. Keats, G. J. Ahmann, J. Mantei, A. K. Stewart, 

P. L. Bergsagel 

Brd. 11 Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion 

study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone 

(loDex) in relapsed and/or refractory multiple myeloma (R/R MM). (Abstract 

#8025) 

M. Wang, W. Bensinger, T. Martin, M. Alsina, D. S. Siegel, N. Y. Gabrail, P. Hari, 

S. Singhal, R. A. Vescio, S. E. Assouline, L. A. Kunkel, M. Vallone, 

A. Wong, R. Niesvizky 

Brd. 12 The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive 

relapsed or refractory multiple myeloma (MM): Updated results from the 

PX-171–004 study. (Abstract #8026) 

A. K. Stewart, J. L. Kaufman, A. J. Jakubowiak, S. Jagannath, V. Kukreti, 

K. T. McDonagh, M. Alsina, N. J. Bahlis, A. Belch, N. Y. Gabrail, F. J. Reu, 

J. Matous, D. H. Vesole, R. Z. Orlowski, L. A. Kunkel, M. Le, P. Lee, M. Sebag, 

M. Wang, R. Vij, The Multiple Myeloma Research Consortium (MMRC) 

Brd. 13 PX-171–003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib 

(CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R 

MM): Long-term follow-up and subgroup analysis. (Abstract #8027) 

D. S. Siegel, T. Martin, M. Wang, R. Vij, S. Lonial, V. Kukreti, N. J. Bahlis, 

M. Alsina, G. Somlo, F. Buadi, F. J. Reu, K. W. Song, L. A. Kunkel, A. Wong, 

M. Vallone, R. Z. Orlowski, A. K. Stewart, S. Singhal, S. Jagannath, 

A. J. Jakubowiak, The Multiple Myeloma Research Consortium (MMRC) 

Brd. 14 Phase II study of carfilzomib (CFZ) in combination with current agents for 

relapsed and refractory multiple myeloma (RRMM). (Abstract #8028) 

J. Szymonifka, S. Z. Usmani, R. Sexton, S. Panozzo, B. P. Nair, S. Waheed, 

Y. Alsayed, J. Crowley, B. Barlogie 

133 

SATURDAY

SATURDAY 


8:00 AM - 1:00 PM 


Sarcoma 




Discussion Location: E354b 

CME credit: 1 


Robin L. Jones, MD—Co-Chair 


Christian Frederick Meyer, MD, PhD—Co-Chair 

The Johns Hopkins University 

Discussion 

12:00 PM Jayesh Desai, MBBS (Abstracts #10009–10017) 

Royal Melbourne Hospital 

Discussion 

12:15 PM Richard F. Riedel, MD (Abstracts #10019–10023) 


Discussion 

12:30 PM Warren Allen Chow, MD (Abstracts #10024–10028) 


Discussion 

12:45 PM Leo Mascarenhas, MBBS, MD, MS (Abstracts #10029–10033) 

Children’s Hospital Los Angeles 

Brd. 1 Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)resistant 

(RES) gastrointestinal stromal tumors (GIST): Final results of a 

University of Chicago Phase II Consortium trial. (Abstract #10009) 

H. L. Kindler, N. P. Campbell, K. Wroblewski, R. G. Maki, D. R. D’Adamo, 

W. A. Chow, D. R. Gandara, C. Antonescu, W. M. Stadler, E. E. Vokes 

Brd. 2 A phase II study of sorafenib in patients with metastatic or unresectable 

gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A 

KGSG study. (Abstract #10010) 

M. Ryu, S. Park, B. Ryoo, S. Im, H. Kwon, S. Lee, B. Kang, Y. Kang 

Brd. 3 An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in 

patients (pts) with metastatic and/or unresectable GIST. (Abstract #10011) 

G. D. Demetri, M. C. Heinrich, B. Chmielowski, J. A. Morgan, S. George, 

R. Bradley, R. K. Blackman, F. Teofilovici, J. A. Fletcher, W. D. Tap, 

M. von Mehren 

Brd. 4 The effect of crenolanib (CP-868596) on phosphorylation of the imatinibresistant 

D842V PDGFRA activating mutation associated with advanced 

gastrointestinal stromal tumors. (Abstract #10012) 

M. C. Heinrich, D. Griffith, A. McKinley, A. Presnell, A. Ramachandran 

Brd. 5 Definition of an imatinib trough concentration threshold in the treatment of 

advanced gastrointestinal stromal tumors (GIST). (Abstract #10013) 

M. Molimard, S. Bouchet, S. Poulette, E. Chauzit, K. Titier, N. Moore, R. Lassalle, 

A. Abouelfath, A. Italiano, C. Chevreau, F. Duffaud, M. Rios, D. Cupissol, 

A. Adenis, I. L. Ray-Coquard, O. Bouche, A. Le Cesne, J. Blay, B. Bui Nguyen 

Brd. 6 Correlation between imatinib trough levels and clinical benefit in 

gastrointestinal stromal tumors (GIST): Results of a prospective population 

pharmacokinetic study. (Abstract #10014) 

K. Eechoute, M. N. Fransson, U. De Giorgi, A. K. Reyners, F. A. de Jong, 

L. E. Friberg, W. Van Der Graaf, A. Sparreboom, J. Verweij, W. J. Loos, 

R. Mathijssen 

134


Brd. 7 Time to secondary resistance (TSR) after interruption of imatinib (IM) in 

advanced GIST: Updated results of the prospective French Sarcoma Group 

randomized phase III trial on long-term survival. (Abstract #10015) 

A. Le Cesne, I. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Bertucci, 

F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, A. Cioffi, S. Chabaud, D. Perol, 

J. Blay 

Brd. 8 Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of 

imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT� 

gastrointestinal stromal tumors (GIST). (Abstract #10016) 

M. von Mehren, M. C. Heinrich, H. Joensuu, C. D. Blanke, E. Wehrle, 

G. D. Demetri 

Brd. 9 An analysis of arterial hypertension and mutational status as predictive 

factors for results of sunitinib (SU) therapy in gastrointestinal stromal 

tumors (GIST). (Abstract #10017) 

P. Rutkowski, E. Bylina, T. Switaj, A. Klimczak, S. Falkowski, J. Kroc, 

I. A. Lugowska, M. Brzeskwiniewicz, A. Wozniak, J. Siedlecki, J. Limon 

Brd. 11 Tumor response and outcome in localized high-risk soft tissue sarcomas 

(STS) treated with preoperative chemotherapy (CHT) with or without 

radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group 

(ISG) and the Spanish Sarcoma Group (GEIS). (Abstract #10019) 

S. Stacchiotti, P. Verderio, A. Messina, C. Morosi, A. Ferraro, V. Quagliuolo, 

J. Martin, A. Comandone, G. Grignani, P. Picci, S. Frustaci, A. Gronchi, 

P. G. Casali 

Brd. 12 Preoperative chemoradiation therapy for localized retroperitoneal soft tissue 

sarcoma (RSTS): A phase II study from the Italian Sarcoma Group. (Abstract 

#10020) 

A. Gronchi, A. De Paoli, C. Dani, F. Merlo, V. Quagliuolo, G. Grignani, G. Bertola, 

P. Navarria, A. P. Dei Tos, P. G. Casali, Italian Sarcoma Group 

Brd. 13 Effect of FNCLCC grade 2 versus grade 3 on survival after neoadjuvant 

chemotherapy (NAC) plus or minus regional hyperthermia (RHT) in soft 

tissue sarcomas (STS): An analysis of the EORTC-ESHO Intergroup phase III 


R. D. Issels, R. P. Laubender, L. Lindner, U. Mansmann, E. Kampmann, J. Verweij, 

P. Reichardt, B. Schem, S. Daugaard, M. Niederhagen, Z. Vujaskovic, 

R. Wessalowski, C. M. Wendtner, K. Jauch, H. Duerr, R. Windhager, 

W. Hiddemann, J. Blay, P. Hohenberger 

Brd. 14 A randomized clinical trial of adjuvant chemotherapy with doxorubicin, 

ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 

randomized patients. (Abstract #10022) 

P. Pautier, A. Floquet, L. Gladieff, D. Berton-Rigaud, S. Piperno-Neumann, 

F. Selle, C. Guillemet, I. Ray-Coquard, B. Weber, P. Duvillard, C. Haie-Meder, 

A. Rey 

Brd. 15 Sensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) and 

myxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combined 

analysis from two European referral institutions. (Abstract #10023) 

R. Sanfilippo, A. Constantinidou, R. Bertulli, P. Coco, E. Fumagalli, M. Scurr, 

C. Morosi, S. Pilotti, I. R. Judson, P. G. Casali 

Brd. 16 A phase II dose expansion of TH-302 in combination with doxorubicin in soft 

tissue sarcoma. (Abstract #10024) 

L. D. Cranmer, K. N. Ganjoo, D. Adkins, D. R. Reed, S. H. Okuno, 

J. E. Butrynski, D. A. Rushing, G. A. Lorente, S. Kroll, S. P. Chawla 

Brd. 17 A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma 

(LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor 

(MPNST). (Abstract #10025) 

D. R. D’Adamo, M. Keohan, R. D. Carvajal, M. L. Hensley, C. Hirst, L. Qin, 

C. Antonescu, R. A. Lefkowitz, G. K. Schwartz, R. G. Maki 

135 

SATURDAY

SATURDAY 


Brd. 18 A dose-finding study of temsirolimus and liposomal doxorubicin for patients 

with advanced soft tissue or bone sarcoma. (Abstract #10026) 

D. M. Loeb, K. A. DeLorenzo, A. R. Chen, C. F. Meyer, J. Powell 

Brd. 19 Phase I study of irinotecan and temsirolimus in patients with refractory 

sarcomas. (Abstract #10027) 

S. Movva, T. Bocklage, B. Schmit, R. Quinn, B. J. Liem, C. F. Verschraegen 

Brd. 20 Phase II AIDS Malignancy Consortium trial of imatinib in AIDS-associated 

Kaposi’s sarcoma (KS). (Abstract #10028) 

H. B. Koon, K. Honda, J. Y. Lee, A. Noy, AIDS Malignancy Consortium 

Brd. 21 Use of cellular context to determine sarcoma phenotype in a new mouse 

sarcoma model. (Abstract #10029) 

S. Hettmer, J. Liu, C. M. Miller, R. T. Bronson, D. M. Langenau, A. J. Wagers 

Brd. 22 Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients 

with plexiform neurofibromas. (Abstract #10030) 

K. A. Robertson, D. C. Bowers, F. Yang, T. Vik, C. Ho, J. Croop, L. E. Walsh, 

C. Hingtgen, K. R. Pradhan, G. Hutchins, J. W. Fletcher, M. Cohen, 

M. Edwards-Brown, J. B. Travers, M. Yu, G. Nalepa, S. Denne, D. Ingram, 

W. Clapp 

Brd. 23 Cixutumumab combined with temsirolimus in patients with refractory 

Ewing’s sarcoma. (Abstract #10031) 

A. Naing, P. LoRusso, S. Fu, D. S. Hong, P. M. Anderson, R. S. Benjamin, 

J. A. Ludwig, H. X. Chen, L. A. Doyle, R. Kurzrock 

Brd. 24 Preliminary safety and outcome report of the metronomic therapy from the 

Latin American osteosarcoma treatment protocol 2006. (Abstract #10032) 

A. S. Petrilli, C. R. Macedo, S. R. Toledo, P. C. Pavoni-Ferreira, M. Grings, 

M. Scopinaro, S. Ferman, E. Boldrini, M. A. Almeida, C. T. de Oliveira, G. L. Rey, 

L. A. Castillo, M. Borsato, J. Barreto, V. L. Morais, A. L. Brunetto, D. Lustosa, 

Grupo Latino Americano para Tratamento de Osteosarcoma GLATO/GALOP 

Brd. 25 Activity of toremifene in sporadic desmoid-type fibromatosis. (Abstract 

#10033) 

M. Fiore, C. Colombo, S. Radaelli, P. Prestianni, R. Sanfilippo, C. Morosi, 

F. Perrone, S. Stacchiotti, P. G. Casali, A. Gronchi 

136

9:30 AM - 12:00 PM 


Opening Session with Presidential Address, NCI Director’s Address, David A. 

Karnofsky Memorial Award and Lecture, ASCO Humanitarian Award, and the 

Conquer Cancer Foundation Donor Recognition Awards 

Location: Hall B1 


Track(s): Special Session 

Kenneth Carl Anderson, MD—Karnofsky Award Recipient 


Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma 


137 

SATURDAY

SATURDAY 


9:45 AM - 11:00 AM 


The Role of Prevention Services in U.S. Health Care Reform (M01)—Ticketed 

Session 



Track(s): Cancer Prevention/Epidemiology, Health Services Research 

Steven Stranne, MD, JD 

Polsinelli Shughart 

The Role of Prevention in the New Health Care Reform Bill 

138

9:45 AM - 11:00 AM 


Practical Approaches to the Patient with Complex Gynecologic Cancer 

(C03)—Ticketed Session 




Nadeem Abu-Rustum, MD—Chair 


Practical Management of Late-stage Complications of Ovarian Cancer 


Krishnansu Sujata Tewari, MD 

University of California, Irvine Medical Center 

Treatment Challenges in the Management of the Advanced Cervical Cancer Patient 

Linda R. Duska, MD 

University of Virginia Health System 

Conservative Management of a Young Patient with Endometrial Cancer: Fertility-sparing 

Options 

139 

SATURDAY

SATURDAY 


1:00 PM - 4:00 PM 

ORAL ABSTRACT SESSION 



CME credit: 3 


Michael J. Hall, MD—Co-Chair 


John S. Kauh, MD—Co-Chair 


1:00 PM The impact of capecitabine and oxaliplatin in the preoperative multimodality 

treatment in patients with carcinoma of the rectum: NSABP R-04. (Abstract 

#3503) 

M. S. Roh, G. A. Yothers, M. J. O’Connell, R. W. Beart, H. C. Pitot, 

A. F. Shields, D. S. Parda, S. Sharif, C. J. Allegra, N. J. Petrelli, J. C. Landry, 

D. P. Ryan, A. Arora, T. L. Evans, G. S. Soori, L. Chu, R. V. Landes, M. Mohiuddin, 

S. Lopa, N. Wolmark 

1:15 PM Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant 

chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Longterm 

results of a randomized, phase III trial. (Abstract #3504) 

R. Hofheinz, F. K. Wenz, S. Post, A. Matzdorff, S. Laechelt, J. T. Hartmann, 

L. Müller, H. Link, M. H. Moehler, E. Kettner, E. Fritz, U. Hieber, H. Lindemann, 

M. Grunewald, S. Kremers, C. Constantin, M. Hipp, D. Gencer, I. Burkholder, 

A. Hochhaus 

1:30 PM Preoperative chemoradiotherapy and postoperative chemotherapy with 

5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced 

rectal cancer: First results of the German CAO/ARO/AIO-04 randomized 

phase III trial. (Abstract #LBA3505) 

C. Roedel, H. Becker, R. Fietkau, U.Graeven, W. Hohenberger, T. Hothorn, 

M. Lang-Welzenbach, T. Liersch, L. Staib, H. Christiansen, C. Wittekind, R. Sauer 

1:45 PM An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3–4 

rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 

9203 trials: Surrogacy in question? (Abstract #3506) 

F. Bonnetain, J. Bosset, J. Gerard, G. Calais, T. Conroy, L. Mineur, O. Bouche, 

P. Maingon, O. Chapet, L. Radosevic-Jelic, N. Methy, L. Collette 

Discussion 

2:00 PM Robert Glynne-Jones, MD (Abstracts #3503–3506) 

Mount Vernon Centre for Cancer Treatment 

2:15 PM The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin 

(FU/L) in stage II colon cancer. (Abstract #3507) 

G. A. Yothers, C. J. Allegra, M. J. O’Connell, T. J. George, S. Sharif, N. J. Petrelli, 

S. Lopa, N. Wolmark 

2:30 PM Overall survival (OS) and updated disease-free survival (DFS) results of the 

NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. 


C. J. Allegra, G. A. Yothers, M. J. O’Connell, S. Sharif, N. J. Petrelli, 

L. H. Colangelo, N. Wolmark 

2:45 PM A multinational, randomized phase III study of bevacizumab (Bev) with 

FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon 

cancer (CC): Subgroup analyses from the AVANT trial. (Abstract #3509) 

T. Andre, E. Van Cutsem, H. Schmoll, J. Tabernero, S. Clarke, M. J. Moore, 

D. Cunningham, T. H. Cartwright, J. R. Hecht, F. Rivera, S. Im, G. Bodoky, 

R. Salazar, F. Maindrault-Goebel, E. Shmueli, E. Bajetta, M. Makrutzki, 

A. Shang, A. De Gramont, P. M. Hoff 

140


Discussion 

3:00 PM Howard S. Hochster, MD (Abstracts #3507–3509) 


3:15 PM Final results from PRIME: Randomized phase III study of panitumumab 

(pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). 


J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, 

Y. Humblet, D. Cunningham, F. Xu, K. Krishnan 

3:30 PM Influence of KRAS G13D mutations on outcome in patients with metastatic 

colorectal cancer (mCRC) treated with first-line chemotherapy with or 

without cetuximab. (Abstract #3511) 

S. Tejpar, C. Bokemeyer, I. Celik, M. Schlichting, U. Sartorius, E. Van Cutsem 

Discussion 

3:45 PM Tanios S. Bekaii-Saab, MD (Abstracts #3510^–3511) 

The Ohio State University Medical Center 

141 

SATURDAY

SATURDAY 


1:15 PM - 2:30 PM 


Pediatric Oncology Award and Lecture 



Track(s): Special Session, Pediatric Oncology 

Lee J. Helman, MD 

Center for Cancer Research, National Cancer Institute 

Pathways to New Targets for Pediatric Sarcomas 

142

1:15 PM - 2:30 PM 


Direct-to-Consumer Genetic Testing for Cancer: What Physicians Need to 

Know 



Track(s): Cancer Genetics, General Oncology 

Sancy Ann Leachman, MD—Chair 

University of Utah Hospitals and Clinics 

Direct-to-Consumer Genetic Testing for Cancer: The Consumer Perspective 

Daniel B. Vorhaus, JD 

Robinson, Bradshaw, & Hinson, P.A. 

A Guide to the (Current) Direct-to-Consumer Genetic Testing Landscape 

Stacy W. Gray, MD 


Direct-to-Consumer Genetic Testing: What We Know about Consumer Attitudes and Behavior 

Angela R. Bradbury, MD 


Direct-to-Consumer Genetic Testing for Cancer: Clinical Implications and Challenges 

Management of Prostate Cancer in Older Adults: To Treat or Not to Treat 



Track(s): Geriatric Oncology, Genitourinary Cancer 

Anthony Victor D’Amico, MD, PhD—Chair 

Dana-Farber Cancer Institute/Brigham and Women’s Hospital 

Localized Disease 

William Dale, MD, PhD 


Screening 

Shabbir M. H. Alibhai, MD, MSc 

University Health Network 

Biochemical Recurrence 

Newer Techniques and Controversies in Breast and Lung Imaging for Cancer 

Screening and Prevention 



Track(s): Cancer Prevention/Epidemiology, Breast Cancer, Lung Cancer 

Denise R. Aberle, MD—Chair 

University of California, Los Angeles David Geffen School of Medicine 

Lung Cancer Screening and CT Imaging 


Constance D. Lehman, MD, PhD 


Breast Cancer Screening: Magnetic Resonance Imaging, Ultrasound, Mammography—Where 

Do We Stand? 

143 

SATURDAY

SATURDAY 


Post–Health Care Reform: Facing the New Reality 



Track(s): Practice Management and Information Technology, Health Services Research 

Tom Main, MBA—Chair 

Oliver Wyman 

Preparing Your Practice for Post–Health Care Reform: How Do Accountable Care 

Organizations Work? How Do We Define and Manage Risk? 

Lee Nisley Newcomer, MD 

United Health Group 

Payer Perspectives in Oncology 

Cecil Wilson, MD 

American Medical Association 

Response from the Medical Community 

The Therapy of High-risk Patients with Lung Cancer 



Track(s): Lung Cancer, Geriatric Oncology 

Jeffrey Bogart, MD—Chair 

State University of New York Upstate Medical University 

Tailoring Radiotherapy for High-risk/Compromised Patients with Early-stage or Locally 

Advanced Non-small Cell Lung Cancer 

Cesare Gridelli, MD 

SG Moscati Hospital 

Therapy of Elderly Patients with Advanced Lung Cancer 

Rogerio Lilenbaum, MD 

Cleveland Clinic Florida 

Implications of Comorbidities and Performance Status in Patients with Advanced Lung Cancer 

144

1:15 PM - 2:30 PM 


Circulating Tumor Cells: We Have the Technology, But What Do We Do with 

the Information? (M06)—Ticketed Session 



Track(s): Developmental Therapeutics, Breast Cancer, Genitourinary Cancer 

Daniel F. Hayes, MD 


1:15 PM - 2:30 PM 


Subsequent Therapy after Treatment of Lung Cancer: Consensus? 





Kenneth Rosenzweig, MD—Chair 

Mount Sinai Medical Center 

The Role of Postoperative Radiation Therapy in the Patient with Resected Lung Cancer: When, 

Why, and How? 

Jessica S. Donington, MD 


Surgical Concerns for Adjuvant Therapy 

Joan H. Schiller, MD 


Adjuvant Therapy: Who, What, When, and Why? 


145 

SATURDAY

SATURDAY 


1:15 PM - 2:45 PM 


Ovarian Cancer: Novel Approaches to Improve Treatment Outcomes 




Amit M. Oza, MD—Chair 


1:15 PM Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 

363 formalin-fixed paraffin embedded (FFPE) specimens. (Abstract #5000) 

C. Gourley, C. O. Michie, K. E. Keating, S. Deharo, E. J. O’Brien, A. Winter, 

F. A. McDyer, J. M. Mulligan, L. A. Hill, T. S. Davison, T. Halsey, L. McCoy, 

C. Wilson, A. Williams, D. J. Harrison, D. P. Harkin, R. D. Kennedy 

Discussion 

1:30 PM Patricia Shaw, MD (Abstract #5000) 

University Health Network 

1:45 PM Effect of screening on ovarian cancer mortality in the Prostate, Lung, 

Colorectal, and Ovarian (PLCO) cancer randomized screening trial. (Abstract 

#5001) 

S. S. Buys, E. Partridge, A. Black, C. Johnson, L. Lamerato, C. Isaacs, D. Reding, 

R. Greenlee, B. Kessel, M. Fouad, D. Chia, L. Ragard, J. Rathmell, P. Hartge, 

P. Pinsky, G. Izmirlian, J. Xu, P. Prorok, C. D. Berg 

Discussion 

2:00 PM Usha Menon, PhD, RN (Abstract #5001) 

UCL Elizabeth Garrett Institute of Women’s Health 

2:15 PM Randomized double-blind placebo-controlled international trial of 

abagovomab maintenance therapy in patients with advanced ovarian cancer 

after complete response to first-line chemotherapy: The Monoclonal 

Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous 

Abagovomab (MIMOSA) Trial. (Abstract #LBA5002) 

J. Pfisterer, J. S. Berek, A. Casado, K. Cwiertka, T. Pinter, A. Pluzanska, 

E. Pujade-Lauraine, G. Scambia, J. B. Vermorken, C. Simonelli, M. Bertolotti, 

A. Capriati, P. Sabbatini, AGO-OVAR, COGI, GEICO, GINECO 

Discussion 

2:30 PM George Coukos, MD, PhD (Abstract #LBA5002) 

University of Pennsylvania, Abramson Cancer Center 

146

1:15 PM - 2:45 PM 


Translational Science Advancing AR Targeting in Prostate Cancer 



Track(s): Genitourinary Cancer 


Mark Garzotto, MD—Co-Chair 

Portland Veterans Affairs Medical Center 

William Kevin Kelly, DO—Co-Chair 

Thomas Jefferson University Hospital 

1:15 PM Abiraterone acetate (AA) in patients with metastatic castration-resistant 

prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate 

Cancer Clinical Trials Consortium study. (Abstract #4500) 

C. J. Ryan, A. L. Harzstark, A. M. Lin, L. Fong, K. Grycz, R. Z. Szmulewitz, 

V. K. Weinberg, A. Molina, E. J. Small 

Discussion 

1:30 PM Mary-Ellen Taplin, MD (Abstract #4500) 


1:45 PM MDV3100 effects on androgen receptor (AR) signaling and bone marrow 

testosterone concentration modulation: A preliminary report. (Abstract 

#4501) 

E. Efstathiou, M. A. Titus, D. Tsavachidou, A. Hoang, M. Karlou, S. Wen, 

P. Troncoso, R. Ashe, C. J. Berman, J. Mohler, C. Logothetis 

Discussion 

2:00 PM Christopher P. Evans, MD (Abstract #4501) 


2:15 PM An evaluation of clusterin antisense inhibitor OGX-011 in combination with 

the second-generation antiandrogen MDV3100 in a castrate-resistant 

prostate cancer model. (Abstract #4502) 

H. Matsumoto, H. Kuruma, A. Zoubeidi, L. Fazli, M. E. Gleave 

Discussion 

2:30 PM Peter Nelson, MD (Abstract #4502) 


147 

SATURDAY

SATURDAY 


1:30 PM - 4:00 PM 


Lymphoma 




Myron Stefan Czuczman, MD—Co-Chair 


Gilles A. Salles, MD, PhD—Co-Chair 

Hospices Civils de Lyon and Universite de Lyon 

1:30 PM R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the 

treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin 

lymphoma. (Abstract #8000) 

D. Cunningham, P. Smith, P. Mouncey, W. Qian, A. S. Jack, C. Pocock, 

K. Ardeshna, J. A. Radford, A. J. Davies, A. McMillan, M. D. Linch 

1:45 PM Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) 

comparing CHOP�R for eight cycles to CHOP with or without R for six cycles 

followed by autotransplant for patients with high-intermediate (H-Int) or high 

IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). (Abstract #8001) 

P. J. Stiff, J. M. Unger, J. Cook, L. S. Constine, S. Couban, T. C. Shea, 

J. N. Winter, T. P. Miller, R. R. Tubbs, D. C. Marcellus, J. W. Friedberg, K. Barton, 

G. M. Mills, M. L. LeBlanc, L. Rimsa, S. J. Forman, R. I. Fisher 

2:00 PM Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy 

(R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell 

lymphoma: Final results of the randomized Mega-CHOEP trial of the German 

High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). (Abstract 

#8002) 

N. Schmitz, M. Nickelsen, M. Ziepert, M. Haenel, P. Borchmann, C. Schmidt, 

A. Viardot, M. Bentz, N. Peter, G. Ehninger, G. Doelken, L. H. Truemper, 

M. Loeffler, M. Pfreundschuh, B. Glass 

2:15 PM First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for 

young adults with diffuse large B-cell lymphoma: Preliminary results of the 

GOELAMS 075 prospective multicenter randomized trial. (Abstract #8003) 

S. Le Gouill, N. Milpied, T. Lamy, V. Delwail, R. Gressin, D. Guyotat, G. Damaj, 

C. Foussard, G. Cartron, H. Maisonneuve, E. Deconinck, F. Dreyfus, E. Gyan, 

L. Sutton, N. Morineau, M. Alexis, F. Perry, M. Sauvezie 

Discussion 

2:30 PM Julie Vose, MD (Abstracts #8000–8003) 

University of Nebraska Medical Center 

2:45 PM Maintenance with rituximab after autologous stem cell transplantation in 

relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL 

final analysis. (Abstract #8004) 

C. Gisselbrecht, B. Glass, G. Laurent, D. S. Gill, M. D. Linch, M. Trneny, D. Bron, 

O. Shpilberg, H. Hagberg, M. Bargetzi, D. Ma, J. Briere, C. Moskowitz, N. Schmitz 

3:00 PM Systemic and intrathecal chemotherapy followed by high-dose 

chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS 

relapse of aggressive lymphomas: A potentially curative approach? 


L. Fischer, M. Haenel, R. Moehle, R. Schroers, T. Elter, M. Reiser, M. H. Dreyling, 

G. Illerhaus, J. Eucker, C. W. Scholz, B. Metzner, A. Roeth, J. Birkmann, 

U. Schlegel, P. Martus, E. Thiel, A. Korfel 

Discussion 

3:15 PM James L. Rubenstein, MD, PhD (Abstracts #8004–8005) 


148


3:30 PM Predictors of early response and event-free survival in Hodgkin lymphoma 

(HL): PET versus CT imaging. (Abstract #8006) 

C. L. Schwartz, D. L. Friedman, K. McCarten, S. L. Wolden, S. Voss, 

L. S. Constine, L. Chen, Children’s Oncology Group 

Discussion 

3:45 PM Bruce D. Cheson, MD (Abstract #8006) 

Georgetown University Medical Center 

149 

SATURDAY

SATURDAY 


1:30 PM - 4:30 PM 


Melanoma/Skin Cancers 


CME credit: 3 

Track(s): Melanoma/Skin Cancers 

Paolo Antonio Ascierto, MD—Co-Chair 

Istituto Nazionale Tumori 

Caroline Robert, MD, PhD—Co-Chair 

Institute Gustave-Roussy 

1:30 PM A population-based, case-control study of MC1R variants, ultraviolet light 

exposure, and melanoma. (Abstract #8504) 

E. Ng, E. Vega-Saenz de Miera, B. Tan, W. Gai, J. D. Goldberg, I. Osman, 

M. Berwick, D. Lazovich, D. Polsky 

1:45 PM Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks 

induction only in patients with intermediate- and high-risk melanoma 

(Intergroup trial E 1697). (Abstract #8505) 

S. S. Agarwala, S. J. Lee, L. E. Flaherty, M. Smylie, R. F. Kefford, W. E. Carson III, 

G. Cohen, J. M. Kirkwood 

2:00 PM Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant 

treatment of stage III melanoma: A randomized phase III Italian Melanoma 

Intergroup (IMI) trial (ISRCTN75125874). (Abstract #8506) 

V. Chiarion-Sileni, M. Guida, A. Romanini, R. Ridolfi, M. Mandala, P. Del Bianco, 

B. Silvestri, M. Medici, M. Michiara, M. Dalla Palma, O. Puccetti, J. Pigozzo, 

F. Laveder, G. De Salvo, Italian Melanoma Intergroup 

2:15 PM EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-a2b 

(PEG-IFN) versus observation in resected stage III melanoma: Long-term 

results at 7.6-years follow-up. (Abstract #8506b) 

A. M. Eggermont, S. Suciu, M. Santinami, W. Kruit, A. Testori, J. Marsden, C. J. A. 

Punt, M. E. Gore, R. MacKie, R. Dummer, D. Schadendorf, P. Patel, A. Spatz, and 

U. Keilholz 

Discussion 

2:30 PM Helen Gogas, MD (Abstracts #8504–8506b) 

Hellenic Cooperative Oncology Group (HeCOG) 

2:45 PM Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes 

(young TIL) in metastatic melanoma patients. (Abstract #8510) 

R. Shapira-Frommer, M. Besser, I. Kuchuk, R. Nave, D. Zippel, A. Treves, 

A. Nagler, S. Apter, A. Shimoni, R. Yerushalmi, E. Ben-Ami, A. Ben-Nun, 

G. Markel, O. Itzhaki, R. Catane, J. Schachter 

3:00 PM A phase I trial of ipilimumab plus bevacizumab in patients with unresectable 

stage III or stage IV melanoma. (Abstract #8511) 

F. S. Hodi, P. A. Friedlander, M. B. Atkins, D. F. McDermott, D. P. Lawrence, 

N. Ibrahim, X. Wu, J. Zhou, A. Giobbie-Hurder, G. Murphy, T. Hollman, 

E. Velazquez, S. Russell, P. Dipiro, J. T. Yap, A. D. Van Den Abbeele 

Discussion 

3:15 PM Mario Sznol, MD (Abstracts #8510–8511) 


3:30 PM BRAF mutation by age-decade and body mass index in metastatic 


A. M. Menzies, L. Visintin, M. D. Chatfield, M. S. Carlino, J. R. Howle, 

R. A. Scolyer, J. F. Thompson, R. F. Kefford, G. V. Long 

150


3:45 PM Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor 

RAF265 administered daily to patients with advanced cutaneous melanoma. 


W. H. Sharfman, F. S. Hodi, D. P. Lawrence, K. T. Flaherty, R. K. Amaravadi, 

K. B. Kim, R. Dummer, S. Gobbi, I. Puzanov, J. A. Sosman, K. Dohoney, L. P. Lam, 

S. Kakar, Z. Tang, O. Krieter, M. B. Atkins 

4:00 PM BRIM-2: An open-label, multicenter phase II study of vemurafenib in 

previously treated patients with BRAF V600E mutation-positive metastatic 


A. Ribas, K. B. Kim, L. M. Schuchter, R. Gonzalez, A. C. Pavlick, J. S. Weber, 

G. A. McArthur, T. E. Hutson, K. T. Flaherty, S. J. Moschos, D. P. Lawrence, 

P. Hersey, R. F. Kefford, B. Chmielowski, I. Puzanov, J. Li, K. B. Nolop, R. J. Lee, 

A. K. Joe, J. A. Sosman 

Discussion 

4:15 PM Gary K. Schwartz, MD (Abstracts #8507–8509) 


151 

SATURDAY

SATURDAY 


2:00 PM - 6:00 PM 


Breast Cancer—Triple-negative/Cytotoxics/Local Therapy 




Discussion Location: Hall B1 

CME credit: 1 


Fatima Cardoso, MD—Co-Chair 

Champalimaud Cancer Center 

Karen A. Gelmon, MD—Co-Chair 

British Columbia Cancer Agency 

Discussion 

5:00 PM Reshma Jagsi, MD, DPhil (Abstracts #1011–1014) 

University of Michigan 

Discussion 

5:15 PM George Somlo, MD (Abstracts #1015–1021) 


Discussion 

5:30 PM Stephen K. L. Chia, MD (Abstracts #1022–1027) 


Discussion 

5:45 PM Ian E. Krop, MD, PhD (Abstracts #1028–1033) 


Brd. 1 Early toxicity results with 3D conformal external beam therapy (CEBT) from 

the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. 


T. B. Julian, J. P. Costantino, F. A. Vicini, J. R. White, K. A. Winter, D. W. Arthur, 

R. R. Kuske, R. Rabinovitch, D. S. Parda, E. P. Mamounas, W. J. Curran Jr., 

N. Wolmark 

Brd. 2 Observation or standard axillary dissection after sentinel-node biopsy in 

breast cancer: Final results from the German KISS study. (Abstract #1012) 

C. Schem, W. Jonat, H. Ostertag, on behalf of the German KISS study group 

Brd. 3 Contralateral breast cancer risk in patients with familial breast cancer tested 

negative for BRCA1 and BRCA2. (Abstract #1013) 

K. Rhiem, C. Engel, M. Graeser, W. Janni, M. Kiechle, N. Ditsch, C. Mundhenke, 

R. Kreienberg, J. Tio, M. Golatta, A. Honig, D. Gadzicki, D. Speiser, K. Kast, 

S. Briest, A. Meindl, R. Schmutzler 

Brd. 4 Patient and tumor characteristics associated with contralateral breast cancer 

in a nested population-based case-control study. (Abstract #1014) 

M. J. Junqueira, M. Morrow, A. S. Reiner, K. Malone, C. Lynch, J. L. Bernstein, 

The WECARE Study Collaborative Group 

Brd. 5 Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in 

patients with basal-like breast cancer. GEICAM 2006-03: A multicenter, 

randomized phase II study. (Abstract #1015) 

E. Alba, J. Chacon, A. Lluch, L. Garcia-Estevez, A. Anton, B. Cirauqui, 

J. Lopez Garcia-Asenjo, E. M. Carrasco, C. Rodriguez, M. Escudero, A. Sanchez, 

N. Ribelles, C. Romero, J. Alvarez, J. Albanell, on behalf of Spanish Breast Cancer 

Research Group (GEICAM) 

152


Brd. 6 Open label, randomized clinical trial of standard neoadjuvant chemotherapy 

with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel 

and RAD001 followed by FEC (TR-FEC) in women with triple receptornegative 

breast cancer (TNBC). (Abstract #1016) 

A. M. Gonzalez-Angulo, M. C. Green, J. L. Murray, S. L. Palla, K. H. Koenig, 

A. M. Brewster, V. Valero, N. K. Ibrahim, S. L. Moulder, J. K. Litton, D. J. Crawford, 

P. R. Flores, M. J. Dryden, W. F. Symmans, S. H. Giordano, L. Pusztai, A. Buzdar, 

G. B. Mills, G. N. Hortobagyi, F. Meric-Bernstam 

Brd. 7 A randomized study of individually tailored toxicity-based dosage of 

fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early 


H. Lindman, M. Andersson, P. Edlund, K. D. Bjerre, T. Hatschek, H. T. Mouridsen, 

H. Anderson, B. Ejlertsen, S. Møller, E. Lidbrink, C. Kamby, J. Ahlgren, J. Bergh, 

C. Blomqvist 

Brd. 8 Intense dose-dense (idd) sequential chemotherapy with epirubicin (E), 

paclitaxel (T), and cyclophosphamide (C) (ETC) compared with 

conventionally scheduled chemotherapy in high-risk breast cancer patients 

(> 3�LN): Eight-year follow-up analysis. (Abstract #1018) 

V. Moebus, C. Thomssen, H. Lueck, W. Kuhn, A. Junker-Stein, C. M. Kurbacher, 

U. Nitz, R. Kreienberg, M. Untch, C. Jackisch, J. B. Huober, A. Hinke, A. Du Bois, 

A. Schneeweiss 

Brd. 9 Anthracyline (A) use among women with breast cancer (BC). (Abstract #1019) 

S. H. Giordano, Y. Lin, Y. Kuo, G. N. Hortobagyi, J. S. Goodwin 

Brd. 10 Final multivariate analysis of obesity and survival in patients with nodalpositive 

primary breast cancer: The ADEBAR trial. (Abstract #1020) 

J. W. Janni, P. G. Hepp, U. Andergassen, N. Harbeck, B. K. Rack, 

J. K. Neugebauer, K. Annecke, A. Wischnik, W. Simon, M. Rezai, T. N. Fehm, 

A. Schneeweiss, P. A. Fasching, B. Gerber, T. Zwingers, H. L. Sommer, K. Friese, 

M. Kiechle 

Brd. 11 Molecular subtypes, body mass index (BMI), and their time-varying 

prognostic impact in node-positive breast cancer (BC): Pooled analysis from 

the WSG AM-01 and -02 trials. (Abstract #1021) 

O. Gluz, C. Liedtke, R. E. Kates, J. B. Huober, S. Mohrmann, A. Hartmann, 

C. Thomssen, V. Moebus, U. Nitz, N. Harbeck, West German Study Group 

Brd. 12 Local versus central laboratory discrepancies in the determination of 

triple-negative breast cancer (TNBC) status in a large phase III 

(CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) 

maintenance therapy after standard chemotherapy (CT) in early breast 

cancer (EBC) patients (pts). (Abstract #1022) 

M. Ruiz-Borrego, C. H. Barrios, A. Lluch, J. Bines, J. Segalla, A. Ruiz, 

L. Torrecillas, A. Llombart-Cussac, R. Torres, J. Garcia Saenz, 

J. Lopez Garcia-Asenjo, H. L. Gomez, J. De la Haba, S. Reyes, E. Martinez, 

J. Baena, L. Perez-Michell, A. Rodriguez-Lescure, A. Anton, M. Martin, 

on behalf of CIBOMA/GEICAM 

Brd. 13 Impact of low estrogen- and progesterone-receptor expression on survival 

outcomes in breast cancers previously classified as triple-negative breast 

cancers. (Abstract #1023) 

K. P. Raghav, L. F. Hernandez-Aya, X. Lei, M. Chavez-Mac Gregor, 

F. Meric-Bernstam, T. A. Buchholz, A. A. Sahin, K. Do, G. N. Hortobagyi, 

A. M. Gonzalez-Angulo 

Brd. 14 Bcl2 as a surrogate prognostic and predictive marker in triple-negative 


T. M. Abdel-Fatah, P. D. Dickinson, P. Moseley, J. S. Reis-Filho, A. R. Green, 

I. O. Ellis, S. Chan 

153 

SATURDAY

SATURDAY 


Brd. 15 TBCRC009: A multicenter phase II study of cisplatin or carboplatin for 

metastatic triple-negative breast cancer and evaluation of p63/p73 as a 

biomarker of response. (Abstract #1025) 

S. J. Isakoff, P. E. Goss, E. L. Mayer, T. A. Traina, L. A. Carey, K. Krag, 

H. S. Rugo, M. C. Liu, V. Stearns, S. E. Come, D. R. Borger, C. A. Quadrino, 

D. Finkelstein, J. E. Garber, P. D. Ryan, E. P. Winer, L. W. Ellisen, on behalf of the 

Translational Breast Cancer Research Consortium 

Brd. 16 Foxp3 expression in breast cancer cells: A new predictor of response to 

anthracycline versus docetaxel in primary breast cancer treated with 

adjuvant chemotherapy in the phase III trial FNCLCC/PACS-01. (Abstract 

#1026) 

F. Ghiringhelli, P. Fumoleau, L. Arnould, G. Mignot, C. Dalban, F. Bonnetain, 

H. H. Roche, M. Spielmann, C. Levy, A. Lortholary, F. Eichler, C. Mesleard, 

S. Ladoire 

Brd. 17 Use of topoisomerase 2 alpha (TOP2A) protein overexpression to predict 

response to anthracycline-based chemotherapy. (Abstract #1027) 

S. Chan, J. S. Reis-Filho, P. D. Dickinson, P. Moseley, A. R. Green, I. O. Ellis, 

T. M. Abdel-Fatah 

Brd. 18 Correlation of various pathological complete response (pCR) definitions with 

long-term outcome and the prognostic value of pCR in various breast cancer 

subtypes: Results from the German neoadjuvant meta-analysis. (Abstract 

#1028) 

G. Von Minckwitz, M. Kaufmann, S. Kuemmel, P. A. Fasching, W. Eiermann, 

J. U. Blohmer, S. D. Costa, J. Hilfrich, C. Jackisch, B. Gerber, A. Du Bois, 

J. B. Huober, C. A. Hanusch, G. E. Konecny, W. Fett, E. Stickeler, N. Harbeck, 

K. Mehta, S. Loibl, M. Untch, GBG and AGO-B study groups 

Brd. 19 Multigene predictors developed on breast cancer cell lines to predict patient 

chemotherapy response: A validation study on the NSABP B-27 trial. 


K. Shen, G. Tang, J. P. Costantino, S. J. Anderson, C. Kim, K. L. Pogue-Geile, 

N. Song, M. J. Gabrin, C. E. Geyer, N. Wolmark 

Brd. 20 Blinded validation study of genomic predictions for survival following 

adjuvant sequential anthracycline-docetaxel chemotherapy �/- endocrine 

therapy. (Abstract #1030) 

W. F. Symmans, F. Andre, M. C. Liu, J. Delacruz, F. Peintinger, S. Borstnar, 

H. Wang, P. Regitnig, M. Ota, S. Seevaratnam, S. Delaloge, C. Hatzis 

Brd. 21 Benefit from CMF with or without anthracyclines in relation to biologic 

profiles in early breast cancer. (Abstract #1031) 

A. Rocca, A. Paradiso, P. Sismondi, E. Scarpi, A. Mangia, L. Medri, S. Bravaccini, 

D. Casadei Giunchi, D. Amadori, R. Silvestrini 

Brd. 22 The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus 

nonanthracyclines in NCIC.CTG MA.5 randomized trial. (Abstract #1032) 

M. Cheang, D. Voduc, D. Tu, S. Jiang, S. Leung, S. K. Chia, L. E. Shepherd, 

M. N. Levine, K. I. Pritchard, T. Vickery, S. Davies, I. J. Stijleman, 

C. Davis, J. S. Parker, M. J. Ellis, P. S. Bernard, C. M. Perou, T. O. Nielsen 

Brd. 23 Prognostic relevance of circulating tumor cells (CTC) before adjuvant 

chemotherapy in patients with breast cancer patients: Results of the German 

SUCCESS trial. (Abstract #1033) 

J. K. Jueckstock, B. K. Rack, T. Zwingers, P. G. Hepp, A. Schneeweiss, 

M. W. Beckmann, W. Lichtenegger, H. L. Sommer, K. Pantel, H. Tesch, 

H. Forstbauer, R. Lorenz, M. Rezai, J. K. Neugebauer, U. Andergassen, K. Friese, 

W. Janni, SUCCESS Study Group 

154


Brd. 24 Antitumor activity in a randomized phase II study comparing two schedules 

of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC). 


A. Awada, S. Chan, G. H. Jerusalem, R. E. Coleman, M. T. Huizing, A. Mehdi, 

S. M. O’Reilly, J. T. Hamm, P. J. Barrett-Lee, V. Cocquyt, K. Sideras, D. E. Young, 

M. Brown, C. Zhao, A. L. Hannah, L. K. Masuoka, A. Garcia, E. A. Perez, 

NKTR-102 Study Group 

Brd. 25 Relationship between OS and PFS in metastatic breast cancer (MBC): Review 

of FDA submission data. (Abstract #1035) 

P. Cortazar, J. J. Zhang, R. Sridhara, R. L. Justice, R. Pazdur 

155 

SATURDAY

SATURDAY 


2:00 PM - 6:00 PM 


Developmental Therapeutics—Experimental Therapeutics 





CME credit: 1 


R. Donald Harvey, PharmD—Co-Chair 

Winship Cancer Institute at Emory University 

Jan H. M. Schellens, MD, PhD—Co-Chair 

Netherlands Cancer Institute 

Discussion 

5:00 PM Patrick Schoffski, MD, MPH (Abstracts #3011–3016) 

University Hospitals Leuven 

Discussion 

5:15 PM Lillian L. Siu, MD (Abstracts #3017–3024) 


Discussion 

5:30 PM Carlos L. Arteaga, MD (Abstracts #3025–3029) 

Vanderbilt-Ingram Cancer Center 

Discussion 

5:45 PM Mark J. Ratain, MD (Abstracts #3030–3032) 


Brd. 1 First human dose (FHD) study of the oral transforming growth factor-beta 

receptor I kinase inhibitor LY2157299 in patients with treatment-refractory 

malignant glioma. (Abstract #3011) 

J. Rodon Ahnert, J. Baselga, E. Calvo, J. Seoane, I. Brana, E. Sicart, 

I. Gueorguieva, A. Cleverly, M. M. Lahn, S. Pillay, M. Holdhoff, J. O. Blakeley, 

M. A. Carducci 

Brd. 2 A first-in-human phase I dose-escalation study of MK-1496, first-in-class 

orally available novel PLK1 inhibitor, in patients with advanced solid tumors. 


T. Doi, H. Murakami, K. Wan, M. Miki, H. Kotani, N. Sakamoto, N. Yamamoto, 

A. Ohtsu 

Brd. 3 MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in 

patients (pts) with advanced solid tumors: Phase I study of multiple 

treatment schedules. (Abstract #3013) 

J. S. Kauh, G. Shapiro, R. B. Cohen, J. W. Clark, R. Harvey, J. M. Cleary, 

D. Mahalingam, S. Kuan, A. McDonald, A. Berger, B. Dezube, J. Sarantopoulos 

Brd. 4 A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients 

(pts) with advanced or metastatic solid tumors. (Abstract #3014) 

C. M. Rudin, A. Jimeno, W. H. Miller Jr., B. J. Eigl, S. N. Gettinger, A. L. Chang, 

K. Faia, J. Sweeney, G. Loewen, R. W. Ross, G. J. Weiss 

Brd. 5 Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell 


D. Mahadevan, E. G. Chiorean, W. Harris, D. D. Von Hoff, A. Younger, 

D. M. Rensvold, F. Cordova, W. Qi, C. F. Shelton, M. D. Becker, J. R. Garlich, 

R. K. Ramanathan 

Brd. 6 Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized 

dose-ranging trial of sorafenib (S). (Abstract #3016) 

M. L. Maitland, T. Karrison, G. L. Bakris, K. Fox, L. A. Janisch, S. Karovic, 

M. R. Levine, L. House, J. J. Wright, E. E. Cohen, G. F. Fleming, T. Y. Seiwert, 

V. M. Villaflor, W. M. Stadler, M. J. Ratain 

156


Brd. 7 Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial 

of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic 

solid tumor. (Abstract #3017) 

S. Leijen, M. R. Middleton, P. Tresca, F. Kraeber-Bodere, V. Dieras, 

M. E. Scheulen, J. Tessier, Z. X. Xu, E. Shochat, A. Walz, J. Deutsch, S. Blotner, 

V. Lopez Valverde, V. M. Naegelen, J. H. Schellens, W. E. Eberhardt 

Brd. 8 Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 

(GSK458) in patients with advanced solid tumors (study P3K112826). 


P. N. Munster, R. van der Noll, E. E. Voest, E. C. Dees, A. R. Tan, J. M. Specht, 

G. S. Falchook, A. Daud, M. P. Lolkema, J. E. Grilley-Olson, E. Y. Yu, S. Fu, 

E. K. Bergsland, J. Kleha, S. Peng, D. A. Smith, T. A. Lampkin, J. H. Schellens, 

S. R. Morris, R. Kurzrock 

Brd. 9 Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in 

patients with advanced malignancies. (Abstract #3019) 

N. Houede, S. J. Faivre, A. Awada, E. Raymond, A. Italiano, T. Besse-Hammer, 

M. Donica, N. Rejeb, C. Luepfert, S. Ongarello, J. Delord 

Brd. 10 A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR 

inhibitor, administered QD in patients with advanced solid tumors. (Abstract 

#3020) 

A. J. Wagner, J. C. Bendell, S. Dolly, J. A. Morgan, J. A. Ware, J. Fredrickson, 

K. E. Mazina, J. O. Lauchle, H. A. Burris III, J. S. De Bono 

Brd. 11 A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase 

(PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. 


V. Moreno Garcia, R. D. Baird, K. J. Shah, B. Basu, N. Tunariu, M. Blanco, 

P. A. Cassier, J. V. Pedersen, M. Puglisi, D. Sarker, D. Papadatos-Pastos, 

A. G. Omlin, A. Biondo, J. A. Ware, H. Koeppen, G. G. Levy, K. E. Mazina, 

J. S. De Bono 

Brd. 12 First-in-human phase I study evaluating the safety, pharmacokinetics (PK), 

and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive 

Akt inhibitor GDC-0068. (Abstract #3022) 

J. Tabernero, C. Saura, D. Roda Perez, R. Dienstmann, S. Rosello, L. Prudkin, 

J. A. Perez-Fidalgo, B. Graña, C. Jones, L. Musib, Y. Yan, P. H. Patel, J. Baselga, 

A. Cervantes 

Brd. 13 Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of 

AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients. (Abstract 

#3023) 

H. A. Henary, R. Kurzrock, G. S. Falchook, A. Naing, S. L. Moulder, J. J. Wheler, 

A. M. Tsimberidou, J. Durand, P. Yang, M. Johansen, R. Newman, R. Khan, 

U. Patel, D. S. Hong 

Brd. 14 A first-in-human phase I study of JNJ-26481585, a novel oral histone 

deacetylase inhibitor (HDACi), in patients with advanced cancer with 

evidence of target modulation and antitumor activity. (Abstract #3024) 

R. D. Baird, B. Venugopal, R. S. Kristeleit, J. Charlton, M. Blanco-Codesido, 

E. Saunders, K. J. Shah, D. Crawford, P. Stephens, D. Wilkins, L. Sweeting, 

A. Forslund, J. W. Smit, P. A. Palmer, N. Fourneau, P. Hellemans, J. S. De Bono, 

R. Plummer, U. Banerji, T. Evans 

Brd. 15 Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for 

solid tumors with liver involvement. (Abstract #3025) 

A. Cervantes, M. Alsina, J. Tabernero, J. R. Infante, P. LoRusso, G. Shapiro, 

L. G. Paz-Ares, R. Falzone, J. Hill, J. Cehelsky, A. White, I. Toudjarska, 

D. Bumcrot, R. Meyers, G. Hinkle, N. Svrzikapa, D. W. Sah, A. Vaishnaw, 

J. Gollob, H. A. Burris III 

Brd. 16 A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in 

patients (pts) with advanced solid tumors. (Abstract #3026) 

J. Berlin, V. L. Keedy, P. A. Janne, L. Yee, N. A. Rizvi, X. Jin, C. Copigneaux, 

T. Hettmann, D. M. Beaupre, P. LoRusso 

157 

SATURDAY

SATURDAY 


Brd. 17 Two-dimensional phase I study of neratinib (NER) combined with 

temsirolimus (TEM) in patients (Pts) with solid tumors. (Abstract #3027) 

L. Gandhi, R. Bahleda, J. M. Cleary, A. Hollebecque, E. L. Kwak, S. Pandya, 

S. Tolaney, R. Abbas, R. Ananthakrishnan, A. Berkenblit, J. Boni, J. Clancy, 

K. W. Turnbull, M. VoVan, G. Shapiro, J. Soria 

Brd. 18 A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab 

and lapatinib in patients with HER2-positive solid tumors. (Abstract #3028) 

H. S. Han, C. Swanton, Y. Y. Janjigian, S. C. Sutherland, S. Chandarlapaty, 

R. Lehman, N. Hamilton, J. Knowles, R. Lee, L. Yan, D. Sullivan, C. Hudis 

Brd. 19 A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in 

patients with advanced solid tumors. (Abstract #3029) 

C. Mamot, R. Ritschard, B. Vogel, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, 

R. Herrmann, C. Rochlitz 

Brd. 20 A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic 

(PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in 

combination with pemetrexed and carboplatin. (Abstract #3030) 

L. H. Brail, J. E. Gray, H. Burris, G. R. Simon, J. Cooksey, S. F. Jones, 

D. Farrington, T. Lam, K. Jackson, K. Chow, J. T. Brandt, J. R. Infante 

Brd. 21 Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in 

combination with cisplatin or carboplatin in patients with advanced solid 


A. Deleporte, H. Dumez, A. Awada, J. Costermans, M. Meeus, T. Berghmans, 

M. Ould Kaci, N. Juhel, A. Berge, T. Taube, P. Schöffski 

Brd. 22 Determination of the maximum tolerated dose (MTD) of MGCD265, an oral 

Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination 

with docetaxel. (Abstract #3032) 

D. W. Rasco, A. Patnaik, R. K. Amaravadi, K. P. Papadopoulos, N. B. Haas, 

A. W. Tolcher, M. Beeram, K. Harlacker, M. A. Drouin, M. Tawashi, J. Wang, 

A. Karam, C. R. Maroun, C. Bonfils, M. Mehran, J. M. Besterman, P. J. O’Dwyer 

158

2:00 PM - 6:00 PM 


Genitourinary (Prostate) Cancer 




Discussion Location: Hall D2 

CME credit: 1 



Leonard Joseph Appleman, MD, PhD—Co-Chair 


Iwona Anna Skoneczna, MD—Co-Chair 

Institute of Oncology 

Discussion 

5:00 PM Daniel W. Lin, MD (Abstracts #4521–4524) 


Discussion 

5:15 PM William K. Oh, MD (Abstracts #4525^–4530) 

Mount Sinai Medical Center 

Discussion 

5:30 PM Charles J. Ryan, MD (Abstracts #4531–4535) 


Discussion 

5:45 PM Philip W. Kantoff, MD (Abstracts #4536–4545) 


Brd. 1 Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in 

localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 

14 randomized trial (EU-20503/NCT00104741). (Abstract #4521) 

B. M. Dubray, V. Beckendorf, S. Guerif, E. Le Prise, A. Reynaud-Bougnoux, 

J. Hannoun Levi, T. D. Nguyen, C. Hennequin, J. Cretin, M. Fayolle-Campana, 

J. Lagrange, J. Bachaud, D. Azria, A. Grangirard, P. Pommier, J. Simon, V. Harter, 

M. Habibian, Groupe d’Etude des Tumeurs Uro-Genitales 

Brd. 2 A phase II study of pomegranate extract for men with rising prostate-specific 

antigen following primary therapy. (Abstract #4522^) 

C. J. Paller, X. Ye, P. Wozniak, B. Gillespie, P. Sieber, R. Greengold, B. Stockton, 

B. Hertzman, M. Efros, R. Roper, H. Liker, M. A. Carducci 

Brd. 3 Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus 

HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final 

results on PSA progression-free survival (Abstract #4523) 

S. Oudard, I. Latorzeff, P. Beuzeboc, E. Banu, A. Caty, E. Sevin, R. Delva, 

F. Rolland, F. Priou, R. Elaidi, S. Culine 

Brd. 4 PSA response and early PSA progression evaluated in patients randomized 

in a phase III trial comparing androgen deprivation therapy (ADT) plus 

docetaxel versus ADT alone in hormone-naive metastatic prostate cancer 

(GETUG-AFU 15/0403). (Abstract #4524) 

G. Gravis, K. Fizazi, F. Joly, S. Oudard, F. Priou, I. Latorzeff, R. Delva, B. Esterni, 

M. Habibian, M. Soulie 

Brd. 5 Survival benefit from first docetaxel treatment for cabazitaxel plus 

prednisone compared with mitoxantrone plus prednisone in patients with 

metastatic castration-resistant prostate cancer (mCRPC) enrolled in the 

TROPIC trial. (Abstract #4525^) 

A. O. Sartor, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen, 

J. S. De Bono, For the TROPIC investigators 

159 

SATURDAY

SATURDAY 


Brd. 6 A subgroup analysis of the TROPIC trial exploring reason for discontinuation 

of prior docetaxel and survival outcome of cabazitaxel in metastatic 

castration-resistant prostate cancer (mCRPC). (Abstract #4526^) 

J. S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen, 

A. O. Sartor, for the TROPIC investigators 

Brd. 7 Phase III, randomized, open-label study of triweekly versus biweekly 

docetaxel (T) as a treatment for advanced hormone-refractory prostate 

cancer (HRPC): Final analysis of the Finnish Uro-oncological Group Study 

1-2003. (Abstract #4527) 

P. Kellokumpu-Lehtinen, U. Harmenberg, T. K. Joensuu, R. McDermott, 

P. Hervonen, C. Ginman, M. Luukkaa, P. Nyandoto, T. Luukkaala, H. Joensuu, 

Prosty study group 

Brd. 8 A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) 

combined with either AT-101 or placebo for the first-line therapy of 

metastatic castration-resistant prostate cancer (CRPC) (Abstract #4528) 

G. Sonpavde, V. B. Matveev, J. M. Burke, J. R. Caton, M. T. Fleming, P. A. Karlov, 

J. Holmlund, B. A. Wood, M. Brookes, L. H. Leopold 

Brd. 9 Final results on phase II study of a weekly schedule of ixabepilone in patients 

with metastatic castrate-refractory prostate cancer (E3803): A trial of the 

Eastern Cooperative Oncology Group. (Abstract #4529) 

G. Liu, Y. Chen, R. S. DiPaola, M. A. Carducci, G. Wilding, Eastern Cooperative 


Brd. 10 Tolerability and efficacy of chemotherapy in older men with metastatic 

castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. (Abstract 

#4530) 

B. Seruga, A. M. Horgan, G. R. Pond, S. M. Alibhai, E. Amir, R. De Wit, 

M. A. Eisenberger, I. Tannock 

Brd. 11 Safety, efficacy, and pharmacodynamics of the investigational agent TAK- 

700 in metastatic castration-resistant prostate cancer (mCRPC): Updated 

data from a phase I/II study. (Abstract #4531) 

D. B. Agus, W. M. Stadler, D. H. Shevrin, L. Hart, G. R. MacVicar, O. Hamid, 

J. D. Hainsworth, M. E. Gross, J. Wang, L. de Leon, D. MacLean, R. Dreicer 

Brd. 12 A noncomparative randomized phase II study of two dose levels of 

itraconazole in men with metastatic castration-resistant prostate cancer 

(mCRPC): A DOD/PCCTC trial. (Abstract #4532) 

E. S. Antonarakis, E. I. Heath, D. C. Smith, D. E. Rathkopf, A. L. Blackford, 

D. C. Danila, S. King, A. Frost, M. A. Carducci, Prostate Cancer Clinical Trials 

Consortium (PCCTC) 

Brd. 13 Effect of denosumab versus zoledronic acid in patients with castrateresistant 

prostate cancer and bone metastases: Subgroup analyses by prior 

SRE and baseline pain. (Abstract #4533) 

N. D. Shore, M. R. Smith, M. Jievaltas, K. Fizazi, R. Damião, J. Chin, K. Miller, 

J. P. Maroto, Y. Qian, A. Feng, K. Chung, C. D. Goessl 

Brd. 14 Post-progression treatment with APC8015F may have prolonged survival of 

subjects in the control arm of sipuleucel-T phase III studies. (Abstract #4534) 

L. G. Gomella, C. Nabhan, J. B. Whitmore, M. W. Frohlich, D. J. George 

Brd. 15 Final analysis of a phase I/IIa study with CV9103, an intradermally 

administered prostate cancer immunotherapy based on self-adjuvanted 

mRNA. (Abstract #4535) 

H. Kübler, T. Maurer, A. Stenzl, S. Feyerabend, U. Steiner, M. Schostak, 

W. Schultze-Seemann, F. vom Dorp, L. Pilla, G. Viatali, C. Hampel, S. Wedel, 

L. Trojan, K. Hiller, M. Sommerauer, D. Jocham, B. Scheel, T. Lander, K. Kallen, 

K. Miller 

Brd. 16 Molecular characterization of neuroendocrine prostate cancer (NEPC) and 

identification of new drug targets. (Abstract #4536) 

H. Beltran, D. Rickman, K. Park, A. Sboner, T. Macdonald, S. T. Tagawa, 

M. B. Gerstein, F. Demichelis, D. M. Nanus, M. A. Rubin 

160


Brd. 17 Validation of NF-kappaB p65 as a prostate cancer prognostic marker on a 

large European cohort. (Abstract #4537) 

P. O. Gannon, L. Lessard, V. Forest, L. R. Begin, T. Schlomm, S. Minner, 

M. Graefen, A. Mes-Masson, F. Saad 

Brd. 18 Association of angiotensin II blockers with survival among men with prostate 

cancer: Results from CaPSURE. (Abstract #4538) 

A. Bardia, J. E. Cowan, P. Carroll, A. V. D’Amico, M. A. Carducci 

Brd. 19 A six-gene panel that predicts survival in men with castration-resistant 

prostate cancer. (Abstract #4539) 

S. K. Subudhi, G. Heller, A. Anand, D. C. Danila, M. Fleisher, H. I. Scher 

Brd. 20 Genomic analysis of circulating tumor cells (CTC) from patients with 

castration-resistant prostate cancer (CRPC) as predictive biomarkers. 


D. C. Danila, A. Anand, J. Yao, M. Gierszewska, M. Kramer, S. Muller, M. Fleisher, 

W. R. McCombie, H. I. Scher 

Brd. 21 Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression 

to predict clinical recurrence after radical prostatectomy. (Abstract #4541) 

S. M. Falzarano, C. Magi-Galluzzi, W. F. Novotny, T. Maddala, D. B. Cherbavaz, 

C. Millward, E. A. Klein 

Brd. 22 Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature 

for prostate cancer death in a conservatively managed watchful waiting 

needle biopsy cohort. (Abstract #4542) 

J. M. Cuzick, G. Fisher, D. Berney, D. Mesher, H. Møller, J. E. Reid, A. Gutin, 

J. S. Lanchbury, S. Stone 

Brd. 23 Risk of second primary malignancy in U.S. men diagnosed with prostate 

cancer from 1992 to 2007. (Abstract #4543) 

E. Davis, C. A. Salinas, L. A. Okoth, K. A. Cooney 

Brd. 24 Racial disparities in prostate cancer treatment: The contribution of 

inappropriate care. (Abstract #4544) 

C. J. Presley, A. C. Raldow, L. D. Cramer, P. R. Soulos, J. B. Long, 

D. V. Makarov, J. B. Yu, C. P. Gross 

Brd. 25 PARP inhibition reverses radiation resistance conferred by ETS fusions in 


F. Y. Feng, S. Han, C. Brenner, A. Sabolch, D. A. Hamstra, T. S. Lawrence, 

A. Chinnaiyan 

161 

SATURDAY

SATURDAY 


2:00 PM - 6:00 PM 


Tumor Biology 




Discussion Location: S100bc 

CME credit: 1 

Track(s): Tumor Biology 

Charles D. Lopez, MD, PhD—Co-Chair 

Oregon Health Science University 

Joseph A. Sparano, MD—Co-Chair 

Albert Einstein College of Medicine 

Discussion 

5:00 PM Matthew James Ellis, MB, BChir, PhD (Abstracts #10509–10516) 

Washington University Medical Center 

Discussion 

5:15 PM Robert Arthur Kratzke, MD (Abstracts #10517–10521) 


Discussion 

5:30 PM David B. Solit, MD (Abstracts #10522–10527) 


Discussion 

5:45 PM Ravi Salgia, MD, PhD (Abstracts #10528–10533) 


Brd. 1 Use of gene expression patterns post neoadjuvant chemotherapy to identify 

a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a 

stem-like phenotype in basal-like breast cancer (BLBC). (Abstract #10509) 

J. M. Balko, R. S. Cook, T. W. Miller, N. E. Bhola, M. Sanders, 

N. M. Granja-Ingram, V. Sanchez, I. M. Meszoely, J. Salter, M. Dowsett, 

K. Stemke-Hale, A. M. Gonzalez-Angulo, G. B. Mills, C. L. Arteaga 

Brd. 2 Early drop of circulating tumor cells (CTC) and increase of circulating 

endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined 

with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in 

multicenter phase II trial BEVERLY 1. (Abstract #10510) 

J. Pierga, F. Bidard, F. Andre, T. Petit, F. Dalenc, T. Delozier, G. Romieu, 

J. Bonneterre, J. Ferrero, P. Kerbrat, A. Martin, P. Viens 

Brd. 3 Identification of a novel breast cancer molecular subgroup associated with a 

deficiency in DNA-damage response. (Abstract #10511) 

J. M. Mulligan, L. A. Hill, S. Deharo, F. A. McDyer, T. S. Davison, M. Bylesjo, 

N. M. Lindor, L. Galligan, T. Delaney, I. A. Halfpenny, V. Farztdinov, N. Goffard, 

V. Proutski, K. E. Keating, P. B. Mullan, J. E. Quinn, P. G. Johnston, F. J. Couch, 

D. P. Harkin, R. D. Kennedy 

Brd. 4 Improving detection methods for PIK3CA mutations in breast cancer using 

peripheral blood from patients with metastastic breast cancer (MBC). 


M. J. Higgins, D. Jelovac, E. Barnathan, B. Blair, S. Slater, P. Powers, J. Zorzi, 

S. C. Jeter, G. R. Oliver, F. Diehl, P. Angenendt, P. Huang, P. Argani, K. Murphy, 

A. C. Wolff, B. H. Park 

Brd. 5 Quantitative copy number analysis by multiplex ligation-dependent probe 

amplification (MLPA) of BRCA1-associated breast cancer regions identifies 

BRCAness, and as such treatment response. (Abstract #10513) 

E. H. Lips, L. Mulder, S. A. Joosse, S. Savola, M. A. Vollebergh, L. F. Wessels, 

J. Wesseling, P. M. Nederlof, S. Rodenhuis 

162


Brd. 6 Separation of breast cancer from normal tissues using GC-MS-based 

metabolite profiling. (Abstract #10514) 

J. Budczies, C. Denkert, B. Mueller, S. F. Brockmoeller, M. Dietel, C. Radke, 

S. Loibl, G. Von Minckwitz, J. L. Griffin, M. Oresic, G. Wohlgemut, O. Fiehn 

Brd. 7 Global gene expression analysis of heterotypic interaction between cancer 

cells and osteoblasts in vitro to detect signaling pathways relevant for bone 

metastasis in breast cancer patients. (Abstract #10515) 

M. Buess, M. Rajski, B. Vogel, C. Rochlitz 

Brd. 8 Targeting �-catenin/CBP interaction in breast cancer. (Abstract #10516) 

A. Ring, O. Evgrafov, J. Knwoles, M. Kahn 

Brd. 9 Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell 


J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. Wu 

Brd. 10 Changes in molecular profile following platinum chemotherapy in NSCLC. 


W. Huang, M. Skokan, Y. Chang, C. Wu, J. Lee, W. Feser, A. E. Barón, P. A. Bunn, 

M. Varella-Garcia 

Brd. 11 Insulin-like growth factor receptor-1 (IGF1R) and epidermal growth factor 

receptor (EGFR) amplification and expression in surgically resected NSCLC. 


V. Ludovini, A. Flacco, F. Bianconi, F. R. Tofanetti, M. Ragusa, J. Vannucci, 

G. Bellezza, M. G. Mameli, R. Chiari, V. Minotti, L. Pistola, A. Siggillino, E. Baldelli, 

A. Sidoni, F. Puma, M. Varella-Garcia, L. Crinó 

Brd. 12 Large-scale screening of ALK fusion oncogene transcripts in archival 

NSCLC tumor specimens using multiplexed RT-PCR assays. (Abstract 

#10520) 

T. Li, P. C. Mack, S. Desai, K. Kelly, J. Cooc, P. V. Danenberg, K. D. Danenberg, 

D. R. Gandara 

Brd. 13 Blind prediction of response to erlotinib in early-stage non-small cell lung 

cancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles. 


R. Hilhorst, E. Schaake, R. van Pel, P. M. Nederlof, L. Houkes, M. Mommersteeg, 

R. de Wijn, M. van den Heuvel, P. Baas, R. Ruijtenbeek, H. M. Klomp 

Brd. 14 Evaluation of p53 mutation as a predictive biomarker for outcome to 

chemotherapy in ovarian cancer. (Abstract #10522) 

A. H. Calvert, J. C. Jackson, C. Hutton, A. Swart, W. Qian, C. Kwakye, R. Fossati, 

A. Lissoni, P. G. Harper, N. Colombo, R. J. Edmondson, J. Lunec 

Brd. 15 Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAF 

inhibitor vemurafenib in metastatic melanoma. (Abstract #10523) 

K. J. Bloom, S. M. Anderson, R. C. Schilling, J. Lee, H. Halait, S. Cheng, 

R. A. Langland, H. Lawrence 

Brd. 16 Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 


M. Del Re, F. Loupakis, A. Michelucci, A. Di Paolo, A. Falcone, P. Simi, G. Bocci, 

M. Cantore, R. Bordonaro, A. Di Leo, C. Barbara, F. Cappuzzo, F. G. De Braud, 

R. Danesi 

Brd. 17 Circulating protein biomarkers of sunitinib (SU) and interferon-� (IFN-�) 

efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell 

carcinoma (mRCC). (Abstract #10525) 

C. S. Harmon, R. A. Figlin, T. E. Hutson, M. D. Michaelson, S. Négrier, S. T. Kim, 

X. Huang, J. A. Williams, R. J. Motzer 

Brd. 18 RNA-based molecular tumor typing and immunological infiltrate as response 

predictors to neoadjuvant chemotherapy: Prospective validation in the 

GeparQuinto-PREDICT substudy. (Abstract #10526) 

C. Denkert, R. Kronenwett, S. Loibl, V. Nekljudova, S. Darb-Esfahani, B. Gerber, 

B. Sinn, C. Petry, I. Bauerfeind, J. Budczies, M. Rezai, M. Dietel, I. Schrader, 

G. Kunz, G. Von Minckwitz, GBG and AGO-B study groups 

163 

SATURDAY

SATURDAY 


Brd. 19 Effect of everolimus plus octreotide LAR treatment on chromogranin A and 

5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine 

tumors: Phase III RADIANT-2 study results. (Abstract #10527) 

E. Baudin, E. M. Wolin, D. E. Castellano, G. Kaltsas, J. Lebrec, Z. Tsuchihashi, 

J. Klimovsky, S. Saletan, J. C. Yao, D. Gross 

Brd. 20 A hepatocyte growth factor antagonist engineered by site-directed 

mutagenesis. (Abstract #10528) 

F. Cecchi, D. Pajalunga, A. Fowler, D. C. Rabe, B. Peruzzi, N. J. MacDonald, 

D. K. Blackman, S. J. Stahl, A. Byrd, D. P. Bottaro 

Brd. 21 Activity of the cancer metabolism inhibitor MPC-9528 in xenograft models: 

Comparison of different dosing schedules. (Abstract #10529) 

V. R. Baichwal, J. A. Willardsen, J. W. Lockman, B. R. Murphy, R. Gordillo, 

T. C. Fleischer, C. Bradford, D. I. Papac, G. G. Mather, R. O. Carlson 

Brd. 22 In vivo tumor growth inhibition by novel PKM2 cancer metabolism 

modulators. (Abstract #10530) 

O. M. Becker, V. Behar, O. Bohana-Kashtan, A. Shitrit, D. Sherman, E. Ben-Zeev, 

R. Ozeri, N. C. Schutz, A. Yacovan 

Brd. 23 New microRNA-based diagnostic test for lung cancer classification. 


T. B. Edmonston, H. Gibori, M. Kushnir, G. Lithwick Yanai, H. Benjamin, M. Bibbo, 

C. Thurm, L. Horowitz, Y. Huang, M. Feinmesser, I. Barshack, S. J. Hou, S. Gilad, 

S. Benjamin, K. Ashkenazi, M. Ezagouri, Y. Goren, C. Hogan, A. Chajut 

Brd. 24 The effect of fish oil on chemotherapy activity in mice: Clinical implications. 


L. G. Daenen, J. M. Roodhart, E. C. Stigter, M. G. Gerritsen, R. H. Medema, 

A. B. Brenkman, E. E. Voest 

Brd. 25 The effects of targeting stromal and tumor cell platelet-derived growth factor 

receptor (PDGFR) in non-small cell lung cancer (NSCLC). (Abstract #10533) 

D. E. Gerber, P. Gupta, M. T. Dellinger, J. Toombs, I. Valencia, M. Peyton, 

N. Loizos, R. A. Brekken 

164

2:00 PM - 6:00 PM 



Cancer Prevention/Epidemiology 



Brd. 1A Gender, age, and ethnic representation in non-small cell lung cancer 

(NSCLC) U.S. registration trials: FDA review. (Abstract #1530) 

S. M. Malik, A. T. Farrell, Q. Xu, R. Sridhara, R. Pazdur 

Brd. 1B Recruitment in the Internet era: An efficient strategy for a study of breast 

cancer risk. (Abstract #1531) 

L. M. Yackowski, F. R. Schnabel, R. Oratz, D. Roses, R. Wieder, C. Kowalczyk, 

H. Ostrer 

Brd. 1C Clinical characteristics of affected BRCA1 and BRCA2 mutation carriers in an 

underserved population. (Abstract #1532) 

M. El-Masry, C. Ricker, D. V. Spicer, D. Tripathy 

Brd. 1D Prophylactic oophorectomy for patients with breast cancer with BRCA 

results. (Abstract #1533) 

J. C. Schink, K. M. Doll, C. B. Weldon, J. R. Trosman, H. H. Wetzel, 

T. J. Fallen, W. J. Gradishar 

Brd. 1E Prevalence of recognized bone metastases in the U.S. adult population. 


S. Li, Y. Peng, E. D. Weinhandl, A. H. Blaes, K. Cetin, V. M. Chia, S. Stryker, 

J. J. Pinzone, J. F. Acquavella, T. J. Arneson 

Brd. 1F Suicide in patients with cancer in California: 2000–2005. (Abstract #1535) 

H. R. Mirshahidi, K. Nasseri, P. K. Mills 

Brd. 1G Perceptions and practices of dietary cancer prevention: Comparison 

between physicians and patients. (Abstract #1536) 

V. W. Li, J. Ko, W. W. Li 

Brd. 2A Cancer in young adults: Characteristics of a cohort of Brazilian patients. 


C. S. Souza, A. V. Melo Mendes, S. D. Simon 

Brd. 2B Gestational diabetes and risk of incident primary cancer: A large populationbased 

cohort study in Israel. (Abstract #1538) 

T. Sella, G. Chodick, M. Barchana, A. D. Heymann, A. Porath, E. Kokia, V. Shalev 

Brd. 2C Antioxidant supplement use after diagnosis and breast cancer outcomes. 


H. Greenlee, M. L. Kwan, L. Kushi, J. Song, A. Castillo, E. Weltzien, 

C. Quesenberry, B. J. Caan 

Brd. 2D Outcome of effective intervention to improve screening colonoscopy in a 

downtown Brooklyn community hospital. (Abstract #1540) 

K. Veerabhadrappa, Z. M. Bo, K. T. Lyar, R. Sultana, G. M. Villani 

Brd. 2E Diagnosis of breast cancer metastases with PET/TC in patients with elevation 

of tumor markers: First data update. (Abstract #1541) 

A. Mafodda, A. Prestifilippo, D. Aricò, A. Vadalà, M. Mare, C. Fornito, D. Giuffrida 

Brd. 2F Cancer with diabetes: Prevalence, metabolic control, and survival in a 

general oncology practice. (Abstract #1542) 

N. J. Karlin, A. C. Dueck, C. Cook 

Brd. 2G The prevalence of human papillomavirus types 52 and 58 in uterine cervical 

lesions from Japanese women. (Abstract #1543) 

K. Takehara, T. Nishimura, J. Sakane, Y. Kawakami, T. Mizunoe, M. Nishiwaki, 

K. Taniyama 

Brd. 3A Gender disparities in colorectal cancer screening. (Abstract #1544) 

S. Yager, W. Y. Cheung 

165 

SATURDAY

SATURDAY 


Brd. 3B Environmental organochlorine pesticide pollutants in patients with benign 

and malignant breast disease. (Abstract #1545) 

K. S. Sodhi, I. D. Sharma, A. Chaturvedi 

Brd. 3C Early adulthood obesity, cumulative smoking, and esophageal cancer 

survival. (Abstract #1546) 

L. E. Coate, R. Zhai, W. Xu, Z. Chen, K. Asomaning, M. Kulke, R. S. Heist, 

D. Christiani, G. Liu 

Brd. 3D Breast cancer survival: The association of age within stage of disease. 


C. Parise, K. Bauer, V. Caggiano 

Brd. 3E Trends in survival by race for stomach cancer patients from the U.S. SEER 

cancer registry. (Abstract #1548) 

L. Chu, L. Wang, M. Shing, W. Dong 

Brd. 3F Long-term history of fasting blood glucose level and the risk of pancreatic 

cancer: A nested case-control study. (Abstract #1549) 

K. Stefani, H. Kim, S. Ahn, K. Choi, I. Suh 

Brd. 3G Does breast cancer in Asian geriatric patients have the same biological 

characteristics as in their Western counterparts? A comparison between 

Shanghai and Vienna. (Abstract #1550) 

M. M. Tea, L. Tang, G. Di, Z. Shao, C. F. Singer 

Brd. 3H Stroger Hospital of Cook County (CCH) AIDS malignancy project: The 

CHAMP study—A 13-year, single-institution retrospective study of cancers in 

patients infected with HIV. (Abstract #1551) 

S. Gupta, H. Poola, K. K. Batra, J. M. Orsi, S. Velinova, S. Jain, 

S. B. Sreenivasappa, M. C. Telfer, M. R. Mullane, A. L. French, P. G. Rubinstein 

Brd. 4B The influence of sociodemographic factors on breast cancer tumor biology. 


K. A. Dookeran, K. Ferrer, M. Sekosan, N. Holloway, W. J. McCaskill-Stevens, 

S. J. Gehlert 

Brd. 4C Multicenter, prospective, case-control, observational study on the influence 

of venous thromboembolism on patient outcome. (Abstract #1554) 

M. Mandala, R. Labianca, G. Agnelli, L. Crino, E. Maiello, A. Santoro, D. Fagnani, 

for the MASTER ONCOLOGY Investigators 

Brd. 4D Compliance to adjuvant hormone therapy for black and white women with 


S. Bhatta, N. Hou, D. Huo, B. N. Polite, G. F. Fleming, O. I. Olopade, S. Hong 

Brd. 4E The accuracy of tobacco assessment during definitive radiotherapy or 

chemoradiotherapy in patients with head and neck cancer. (Abstract #1556) 

M. R. Kudrimoti, S. M. Arnold, J. Valentino, T. Gal, A. Hyland, A. Singh, 

V. Rangnekar, K. M. Cummings, J. R. Marshall, G. W. Warren 

Brd. 4F Prospective structured smoking behavior assessment at diagnosis and 

long-term cancer survival. (Abstract #1557) 

G. W. Warren, K. Kasza, M. E. Reid, K. M. Cummings, J. R. Marshall 

Brd. 4G Factors associated with on-time regular screening among the Korean 

population eligible to be screened for gastric cancer: A nationwide 

retrospective cohort study based on National Cancer Screening Program 

(NCSP) data. (Abstract #1558) 

M. Hahm, K. Choi, H. Lee, J. Jun, E. Park 

Brd. 4H Gynecological cancer screening in women at high risk of Lynch syndrome. 


C. Guillen-Ponce, C. Martinez-Sevila, R. Perea, M. Arenas, M. Molina-Garrido, 

M. Goicoechea, D. Salas, A. Carrato, Hereditary Cancer Group of the Comunindad 

Valenciana (Spain) 

166


Brd. 5A An analysis of colorectal cancer (CRC) following a diagnosis of prostate 

cancer (CaP): Is it due to earlier diagnosis or increased incidence? (Abstract 

#1560) 

S. Bae, M. Asadi, J. L. Millar, I. Jones, S. McLaughlin, A. Bui, M. Steele, 

M. W. Chao, D. English, P. Gibbs 

Brd. 5B The role of HPV genotypes and persistence in follow-up of cervical 

intraepithelial neoplasia after treatment. (Abstract #1561) 

Y. Huang, L. Wu, J. Zuo, N. Li, J. An, J. Hu, M. Huang 

Brd. 5C Multidisciplinary high-risk program: A community hospital’s experience. 


H. Lowry, N. Dekhne, D. Fend, R. Lerman, N. Gregory, J. Boura 

Brd. 5D Results from a longitudinal breast MRI surveillance study: Psychological 

impact for high-risk women. (Abstract #1563) 

L. J. Patrick-Miller, A. R. Bradbury, R. Pius, K. Wroblewski, M. S. Verp, S. Jackson, 

C. Gulden, G. Newstead, H. Abe, O. I. Olopade 

Brd. 5E Racial differences in early-stage colorectal cancer outcomes and prognostic 

factors. (Abstract #1564) 

J. D. Acoba, C. D. Chong 

Brd. 5F Isolation of equol-producing bacterium to realize chemoprevention of 


H. Tsuji, K. Moriyama, K. Nomoto, N. Miyanaga, H. Akaza 

Brd. 5G Management of breast cancer after childhood cancer and Hodgkin 


M. Terenziani, S. Viviani, M. Massimino, A. Moliterni, M. Gennaro, L. Gandola, 

L. Boschetti, S. Catania, G. Cefalo, A. Di Russo, G. Goisis, G. Mariani, 

F. Spreafico, M. Zambetti, P. Valagussa, G. Bonadonna 

Brd. 5H Impact of dietary habits on epidermal growth factor receptor (EGFR) 

mutation status of Japanese patients with lung adenocarcinomas. (Abstract 

#1567) 

Y. Yamane, M. Iwasaki, A. Kawase, K. Tsuchihara, G. Ishii, H. Ohmatsu, S. Niho, 

K. Yoh, K. Nagai, Y. Ohe, S. Tsugane, A. Ochiai, H. Esumi, K. Goto 

Brd. 6A Metachronous contralateral breast cancer: An analysis of risk factors and 

prognosis in 42,670 women in Sweden. (Abstract #1568) 

V. Vichapat, H. Garmo, M. Holmqvist, L. Holmberg, G. Liljegren, F. Warnberg, 

M. Lambe, T. Fornander, J. Adolfsson, M. Lüchtenborg 

Brd. 6B The burden of cancer in Japan, the United States, France, Germany, Italy, 

Spain, Sweden, and the United Kingdom. (Abstract #1569) 

N. Koinuma, N. E. Wilking, B. Jonsson, D. Hogberg 

Brd. 6C Preventing cancer in the colon: Effect of ginger root extract on markers of 

inflammation in colon mucosa in people at high risk for colorectal cancer. 


S. M. Zick, D. K. Turgeon, S. Vareed, M. T. Ruffin IV, Z. Djuric, A. J. Litzinger, 

B. Wright, D. P. Normolle, D. E. Brenner 

Brd. 6D The new generation of combined hormone contraceptives and risk of 

gynecologic cancers. (Abstract #1571) 

R. Haque, G. Inzhakova, J. M. Shi, J. Chung, F. Niu, C. T. Cheetham 

Brd. 6E Disparities of incidence and survival in lung cancer: A SEER-based analysis 

on Asian living in the United States 1973–2007. (Abstract #1572) 

R. N. Rahman, S. Rastogi, A. M. Hossain 

Brd. 6F Determining the impact of the U.S. mammography screening guidelines on 

patient survival in a predominantly African American population treated in a 

public hospital. (Abstract #1573) 

I. Habtes, C. Raskind-Hood, K. Adams, E. R. Becker, C. D’Orsi, G. Birdsong II, 

K. Gundry, R. O’Regan, S. G. Gabram 

167 

SATURDAY

SATURDAY 


Brd. 6G Fetal microchimerism in breast and colon cancer. (Abstract #1574) 

M. Kamper-Jørgensen, R. J. Biggar, C. L. Stamper, H. Hjalgrim, A. Tjønneland, 

A. Olsen, A. N. Andersen, K. Rostgaard, N. Kroman, V. K. Gadi 

Brd. 7A Global cancer mortality: The effect of health care system resources on 

survival from cancer. (Abstract #1576) 

A. Batouli, P. Jahanshahi, J. B. Yu 

Brd. 7B Observations on cancer of the breast among Arab-American women. 


O. R. Signori, K. A. Schwartz, H. Dakhlallah, R. M. Pandit, E. E. Signori 

Brd. 7C Association between contralateral prophylactic mastectomy and breast 

cancer outcomes. (Abstract #1578) 

A. M. Brewster, P. A. Parker, I. Bedrosian, W. Dong, S. K. Peterson, S. B. Cantor, 

M. Crosby, Y. Shen 

Brd. 7D Impact on stage distribution of gastric cancer by the National Cancer 

Screening Program (NCSP) in Korea. (Abstract #1579) 

J. Jun, K. Choi, H. Lee, E. Park 

Brd. 7E A combination of fecal tests for the detection of colon cancer: A new strategy 

for appropriate prioritization of referrals to colonscopy—A prospective 

Italian study. (Abstract #1580) 

A. Ardizzoia, F. Parente, B. Marino, A. Ilardo, F. Perna, I. Saracino, A. Zullo, 

C. Hassan, P. Fracasso, R. A. Moretti, M. Cremaschini, D. Vaira, G. Ucci 

Brd. 7F Knowledge and perceptions of breast cancer risk in adolescent girls at high 

risk and population risk for breast cancer. (Abstract #1581) 

A. R. Bradbury, L. J. Patrick-Miller, L. Tuchman, C. Moore, P. Rauch, C. B. Sands, 

R. Shorter, B. Rowan, S. Malhotra, S. Van Decker, L. Bealin, H. Schmidheiser, 

M. B. Daly 

Brd. 7G A dose-finding clinical trial of mushroom powder in postmenopausal breast 

cancer survivors for secondary breast cancer prevention. (Abstract #1582) 

M. R. Palomares, J. Rodriguez, S. Phung, F. Z. Stanczyk, S. F. Lacey, 

T. W. Synold, S. Denison, P. H. Frankel, S. Chen 

Brd. 7H Peripheral blood eosinophil counts and risk of colorectal cancer mortality in 

a large general population-based cohort study. (Abstract #1583) 

N. Taghizadeh, J. M. Vonk, H. M. Boezen 

Brd. 8A Meta-analysis of insulin glargine and cancer risk. (Abstract #1584) 

P. Boyle, A. Koechlin, P. Boffetta, M. Boniol, G. Bolli, J. Rosenstock 

Brd. 8B Healthcare service barriers to breast cancer screening among Egyptian 

females. (Abstract #1585) 

H. M. El-Mansy, H. M. Ismail, I. F. Kharboush, M. M. Tawfik, O. G. El Sharkawy, 

H. Mamdouh, H. Sallam 

Brd. 8C Prospective analysis of association between use of statins or other lipid 

lowering agents and melanoma risk in the Women’s Health Initiative. 


D. B. Jagtap, C. A. Rosenberg, L. Martin, M. Pettinger, P. Greenland, 

J. D. Khandekar, R. Levy, D. Lane, M. S. Simon 

Brd. 8D Breast ductal lavage (DL) and P16 immunocytochemistry. (Abstract #1587) 

C. Casadio, S. Di Vincenzo Jr., L. Chiapparini, B. Bonanni, M. Cazzaniga 

Brd. 8E Risk of lymphoma in women with breast implants: Analysis of clinical 

studies. (Abstract #1588) 

J. A. Largent, M. Oefelein, H. M. Kaplan, T. Okerson, P. Boyle 

Brd. 8F Incidence of Kaposi sarcoma in HIV-infected patients receiving antiretroviral 

therapy: A prospective multicohort study from southern Africa. (Abstract 

#1589) 

J. Bohlius, F. Valeri, M. Maskew, H. Prozesky, C. Chimbetete, P. Lumano-Mulenga, 

T. Gsponer, M. Egger, International epidemiologic Database to Evaluate AIDS 

(IeDEA) 

168


Brd. 8G Racial variation of leptin levels in women with breast cancer. (Abstract 

#1590) 

T. P. Avery, K. R. Sexton, A. Brewster, R. El-Zein, M. Bondy 

Brd. 8H Time since last pregnancy and breast cancer survival: A systematic review 

and meta-analysis. (Abstract #1591) 

A. Valachis, A. D. Nearchou, D. Mauri, P. A. Lind, N. P. Polyzos 

Brd. 9A Aristolochic acid nephropathy in Taiwan: Harbinger of a global iatrogenic 

disease. (Abstract #1592) 

A. P. Grollman, C. Chen, M. Moriya, K. Dickman, L. Wu, G. Mihalyne, 

K. L. Edwards, K. Snappin, Y. Pu 

Brd. 9B Classification of the components of the MedDietScore in relation to 

colorectal cancer prevalence. (Abstract #1593) 

N. Kontou, D. B. Panagiotakos, T. Psaltopoulou, N. Soupos, E. Polychronopoulos, 

D. Xynopoulos, D. Dimitroulopoulos, A. Linos, E. Paraskevas, M. A. Dimopoulos 

Brd. 9D What we know from the semiannually repeated CT screening in a high-risk 

cohort over 15 years: Update of the Anti-lung Cancer Association Project. 


N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui, 

M. Kusumoto, T. Tsuchida, H. Nishiyama, N. Moriyama 

Brd. 9E MRI characteristics of BRCA-associated breast cancers. (Abstract #1596) 

A. K. Kelekar, S. Mukherjee, C. Mitri, F. Khan, W. Ducaine, L. Dohany, D. Zakalik 

Brd. 9F Do cancer survivors follow screening guidelines better? (Abstract #1597) 

A. B. Chagpar, T. B. Sanft, C. P. Gross 

Brd. 9G The impact of screening mammography in breast cancer patients age 40–49 

at an urban city hospital. (Abstract #1598) 

C. Checka, S. Dhage, S. Adams, E. Samii, T. Shah, S. Shaylor, K. P. Joseph 

Brd. 9H Body mass index: A potential risk factor for breast cancer in minority 


V. Sharma, D. Patel, A. Abichandani, P. Saraf, A. J. Cohen 

Brd. 10A Breast cancer characteristics among Hispanic women from a Southwestern 

county hospital. (Abstract #1600) 

M. N. Kundranda, S. Amar 

Brd. 10B Patterns of treatment in young women with early-stage cervical cancer. 


S. Grover, L. L. Lin, G. Suneja 

Brd. 10C A survey of suspected familial breast cancer in Iraqi Kurdish women. 


A. M. Saaed, A. K. Sheikha, S. S. Mohammed, H. A. Ameen, S. Y. Sheet, 

M. Khasraw 

Brd. 10D Clinical and pathological profile of breast cancer in a tertiary cancer center in 

Saudi Arabia. (Abstract #1603) 

S. AlShehri, O. A. Abulkhair, A. Al Kushi, S. Musaad, A. Al Olayan, A. R. Jazieh 

Brd. 10E Pattern of malignant diseases in Lagos, Nigeria. (Abstract #1604) 

O. F. Adetayo 

169 

SATURDAY

SATURDAY 


2:00 PM - 6:00 PM 





Brd. 11A Long-term results from EORTC24971/TAX323: Comparing TPF to PF in 

patients with unresectable squamous cell carcinoma of the head and neck 

(SCCHN). (Abstract #5530) 

J. B. Vermorken, E. Remenar, C. Van Herpen, M. Degardin, J. S. Stewart, 

R. Karra Gurunath, C. Fortpied 

Brd. 11B Prognostic factors of overall survival in head and neck cancer: Post-hoc 

exploratory results from the SPINNAKER trial—A phase III randomized 

clinical trial of pemetrexed plus cisplatin versus cisplatin monotherapy. 


S. Urba, J. Gatz, W. Shen, A. Hossain, K. Winfree, A. Koustenis, P. Peterson 

Brd. 11C The effect of cisplatin dose administered during concurrent 

chemoradiotherapy in patients with locoregionally advanced 

nasopharyngeal carcinoma. (Abstract #5532) 

H. H. Loong, B. Ma, F. Mo, S. Leung, E. P. Hui, M. K. Kam, S. L. Chan, A. T. Chan 

Brd. 11D Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): 

Analysis of disparities in care. (Abstract #5533) 

B. A. Murphy, A. Y. Chen, W. J. Curran Jr., A. S. Garden, P. M. Harari, 

S. J. Wong, L. A. Bellm, M. Schwartz, J. Newman, D. Adkins, 

D. N. Hayes, U. Parvathaneni, D. Brachman, B. Ghabach, C. Schneider, 

M. Greenberg, A. Abitbol, P. R. Anne, K. Ang 

Brd. 11E Concomitant chemoradiation in locally advanced head and neck squamous 

cell carcinoma: A literature-based metanalysis on the platinum concomitant 


M. G. Ghi, A. Paccagnella, I. Floriani, D. Garavaglia 

Brd. 11F Long-term toxicity: A comparison between surgery plus radiotherapy and 

exclusive chemoradiation therapy regimes in oropharyngeal cancer patients. 


L. Raimondo, M. Garzaro, G. Riva, G. Pecorari, C. Giordano, M. Airoldi 

Brd. 11G Neoadjuvant chemotherapy and prognostic subgroups defined by survival 

benefit in paitents with locoregionally advanced nasopharyngeal carcinoma. 


X. Ji, Y. Zhong, Y. Zhou, F. Zhou, G. Zhang, G. Chen, D. Deng, H. Liu, J. Zhang, 

C. Xie 

Brd. 11H Quality of life, physical, and psychologic functioning in patients affected by 

end-stage head and neck cancer. (Abstract #5537) 

M. Airoldi, M. Garzaro, L. Raimondo, G. Riva, G. Pecorari, C. Giordano 

Brd. 12A A phase II study of pemetrexed combined with cisplatin in patients (pts) with 

recurrent or metastatic nasopharyngeal carcinoma. (Abstract #5538) 

A. W. Lee, T. Yau, T. C. Shum, W. Ng, L. L. Chan, R. M. Yeung 

Brd. 12B Long-term symptom burden after radiation treatment for oropharynx cancer: 

A comparison of 3D and IMRT techniques. (Abstract #5539) 

D. I. Rosenthal, G. B. Gunn, T. R. Mendoza, A. S. Garden, B. M. Beadle, 

W. H. Morrison, X. S. Wang, S. J. Frank, R. S. Weber, K. Ang, C. S. Cleeland 

Brd. 12C Clinical characteristics of an incident cohort of patients with resected 

squamous cell carcinoma of the head and neck (SCCHN) in the United 

Kingdom. (Abstract #5540) 

K. Kim, M. Amonkar, D. Högberg, F. Kasteng 

170


Brd. 12D Pretreatment PET and posttreatment pathologic nodal status as a predictor 

for distant metastasis in locally advanced head and neck squamous cell 

carcinoma treated with definitive concurrent chemoradiotherapy. (Abstract 

#5541) 

K. Hu, W. F. Mourad, M. Perksy, M. Urken, A. Jacobson, B. Culliney, T. Tran, 

S. P. Schantz, P. Costantino, L. B. Harrison 

Brd. 12E Comparison of two schedules in locally advanced nasopharyngeal 

carcinoma observed in a nonendemic population. (Abstract #5542) 

M. Garzaro, L. Raimondo, G. Pecorari, F. Pedani, C. Giordano, M. Airoldi 

Brd. 12F A phase II trial of induction chemotherapy with cisplatin, docetaxel, and 

capecitabine followed by concurrent cisplatin-radiotherapy in advanced 

nasopharyngeal carcinoma. (Abstract #5543) 

M. Yamouni, Y. Beldjilali, K. Benhadji, H. Khellafi, F. Betkaoui, Y. Kaid, L. Benchlef, 

F. Z. Daim, S. Toubal, A. Boukerche, A. Abdelaoui, L. Djellali 

Brd. 12G Exploring factors in diagnostic delays of head and neck cancer at a public 

hospital. (Abstract #5544) 

D. W. Lai, S. A. Buckley, B. L. Schmidt, C. Viet, F. Muggia, I. Belitskaya-Levy, 

R. F. Cohen, M. D. DeLacure, N. Sanfilippo, D. Myssiorek, D. Hirsch, 

N. Seetharamu 

Brd. 12H Incidence of esophageal cancers among oral cavity and pharynx cancer 

patients: A review of the SEER database (1973–2007). (Abstract #5545) 

E. Kim, N. Chandra, J. Kim 

Brd. 13A Chemoselection with induction chemotherapy followed by chemoradiation or 

surgery versus chemoradiation for patients (pts) with locally advanced 

squamous cell carcinoma of the oropharynx (LASCCOP). (Abstract #5546) 

I. Y. Dobrosotskaya, E. Light, J. M. Maxwell, S. A. Byrd, M. E. Spector, B. Kumar, 

F. Y. Feng, A. Eisbruch, G. T. Wolf, M. Prince, J. Moyer, T. N. Teknos, 

D. B. Chepeha, H. M. Walline, J. B. McHugh, K. G. Cordell, S. Urba, 

C. R. Bradford, T. Carey, F. P. Worden 

Brd. 13B Measurement of distress in patients with nasopharyngeal carcinoma. 


Y. Jiang, Y. Deng 

Brd. 13C Concomitant chemoradiation using weekly cisplatin for advanced squamous 

cell carcinoma of head and neck: Experience from a tertiary cancer center in 

India. (Abstract #5548) 

A. Sharma, B. K. Mohanti, A. Thakar, S. P. Chaudhary, S. Bhasker, S. Bahadur 

Brd. 13D Paclitaxel (TLX) and cetuximab (CTX) combination efficiency after failure of a 

platinum-based chemotherapy in recurrent/metastatic head and neck 

squamous cell carcinoma (RMHNSCC). (Abstract #5549) 

P. Ceruse, E. Lavergne, G. Buiret, B. Pham, S. Chabaud, B. Favier, D. Girodet, 

P. Zrounba, J. Fayette 

Brd. 13E Recurrence of T1N0 oral tongue squamous cell carcinoma in Stockholm, 

Sweden 2000–2009. (Abstract #5550) 

M. Ryott 

Brd. 13F Comprehensive volume hyperfractionated (HFx) re-irradiation (Re-RT) of 

recurrent head and neck (H/N) cancer is feasible. (Abstract #5551) 

P. Kumar, U. K. Sinha 

Brd. 13G Survival, tumor control, and toxicity with TPF before accelerated 

radiotherapy potentiated with cetuximab for stage III-IV unresectable head 

and neck cancer: A phase II study. (Abstract #5552^) 

C. Mercke, H. Sjödin, H. Haugen, G. Adell, G. Wickart-Johansson, 

E. M. Munck-Wikland, G. von Dobeln, J. Nyman 

Brd. 13H Concurrent chemoradiotherapy with or without induction chemotherapy for 

locally advanced head and neck cancer. (Abstract #5553) 

J. J. Caudell, S. Spencer, R. Meredith, L. Nabell, J. A. Bonner 

171 

SATURDAY

SATURDAY 


Brd. 14A Kinetic analysis of 18 f-fluoroerythronitroimidazole PET/CT during 

radiotherapy correlates with outcome in head and neck cancer. (Abstract 

#5554) 

M. Hu, J. Yu, L. Kong, Z. Fu 

Brd. 14B Weekly and 3-weekly cisplatin concurrent with intensity-modulated 

radiotherapy in locally advanced head and neck squamous cell cancer. 


V. Espeli, E. Zucca, M. E. Ghielmini, A. Richetti, O. Giannini, F. Martucci 

Brd. 14C Chemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxia 

imaging with F18 misonidazole PET scanning. (Abstract #5556) 

A. D. Colevas, A. Quon, A. McMillan, Q. Le 

Brd. 14D Multiple cases of squamous cell carcinoma of the tongue and oral cavity in 

patients treated with long-term pegylated liposomal doxorubicin (PLD) for 

ovarian cancer. (Abstract #5557) 

T. L. Cannon, F. Muggia, D. Hirsch, E. A. Andreopoulou, A. R. Kerr, 

M. D. DeLacure 

Brd. 14E Influence of induction chemotherapy on patient’s compliance to radiotherapy 

in patients with locally advanced head and neck squamous cell carcinoma. 


B. Atassi, O. Ozgursoy, G. H. Yoo, J. R. Jacobs, N. Bhatti, M. Mal, H. Kim, H. Lin, 

A. Sukari 

Brd. 14F Use of buccal fat pad to correct defects in the oral cavity after excision of 

cheek cancer: A prospective study. (Abstract #5559) 

S. K. Agrawala, S. Gosh 

Brd. 14G Clinical response rate at primary tumor site (PTS) following a novel 

induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound 

(nab-)paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) 

versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF � C) in patients with 

locally advanced head and neck squamous cell carcinoma (HNSCC). 


D. Adkins, J. Ley, B. Nussenbaum, J. Diaz, R. Paniello, W. L. Thorstad, H. A. Gay, 

J. Subramanian, T. M. Wildes, J. Mathai, T. Rachocki, D. I. Kuperman 

Brd. 14H Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor 

PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) 

squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5561) 

L. L. Siu, S. J. Hotte, S. A. Laurie, S. Singh, E. Winquist, S. K. Chia, 

E. X. Chen, K. K. Chan, T. Wang, I. Taylor, A. Ruiz-Garcia, C. Mormont, 

D. Soulieres 

Brd. 15A Phase II trial of sorafenib in patients with advanced thyroid cancer. (Abstract 

#5562) 

S. M. Keefe, A. B. Troxel, S. Rhee, K. Puttaswamy, P. J. O’Dwyer, L. A. Loevner, 

S. J. Mandel, M. S. Brose 

Brd. 15B A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 

750 mg/m 2 for patients (Pts) with recurrent or metastatic (R/M) head and neck 

squamous cell cancer (HNSCC). (Abstract #5563) 

M. G. Fury, E. J. Sherman, D. M. Lisa, N. Agarwal, K. M. Algazy, B. Brockstein, 

C. J. Langer, D. Lim, R. Mehra, S. K. Rajan, N. Jafri, S. Korte, B. Lipson, F. Yunus, 

T. Tanvetyanon, S. Smith-Marrone, K. K. Ng, H. Xiao, S. Haque, D. G. Pfister 

Brd. 15C Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic 

squamous cell carcinoma of the head and neck (SCCHN): Final results. 


A. Argiris, A. P. Kotsakis, S. Kim, F. P. Worden, P. Savvides, M. K. Gibson, 

G. R. Blumenschein Jr., H. X. Chen, J. R. Grandis, M. S. Kies 

Brd. 15D Phase I/II trial of vandetanib and bortezomib in adults with locally advanced 

or metastatic medullary thyroid cancer: Phase I results. (Abstract #5565) 

A. W. Gramza, S. A. Wells, S. Balasubramaniam, A. T. Fojo 

172


Brd. 15E A phase II study of VEGF trap in patients with radioactive iodine 

(RAI)–refractory thyroid carcinoma. (Abstract #5566) 

E. J. Sherman, A. L. Ho, S. Haque, R. M. Tuttle, R. A. Ghossein, H. Schöder, 

M. S. Baum, K. Kelly, A. P. Chen, A. R. Shaha, D. G. Pfister 

Brd. 15F Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients 

with recurrent or metastatic (R/M) squamous cell carcinoma of the head and 

neck (SCCHN): First results of phase II trial GORTEC 2008-03. (Abstract 

#5567) 

J. Guigay, J. Fayette, A. Dillies, C. Sire, J. N. Kerger, I. Tennevet, J. H. Machiels, 

S. Zanetta, Y. Pointreau, L. Bozec Le Moal, L. Brugel Ribere, S. Henry, 

S. Temam, GORTEC 

Brd. 15G Pilot study to evaluate the effect of erlotinib (E) administered before surgery 

in operable patients with squamous cell carcinoma of the head and neck 

(SCCHN). (Abstract #5568) 

M. Porosnicu, J. D. Waltonen, C. Sullivan, L. McWilliams, G. L. Kucera, A. Thomas, 

R. Plasser, J. D. Browne 

Brd. 15H Prospective phase II study of tumor response assessment by CT and FDG- 

PET/CT following 8 weekly doses of cetuximab in patients with 

metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). 


J. Ley, B. A. Siegel, F. Dehdashti, J. Subramanian, G. Ansstas, T. Rachocki, 

J. Mathai, T. M. Wildes, D. I. Kuperman, D. Adkins 

Brd. 16A Treatment (T) of T2 N0-1 larynx cancer (LC) with hyperfractionated 

radiotherapy (HRT) and cetuximab (C): Final report. (Abstract #5570) 

R. E. Giglio, A. Navigante, M. D. Pereira, L. Califano, B. M. Roth, P. Saco, 

M. A. Castro, P. Menendez, P. Aguerre, R. Adan, C. Brosio, C. Pogany 

Brd. 16B Human papillomavirus (HPV)–related, p16 positive head and neck squamous 

cell carcinomas (HNSCCs) after stem cell transplantation (SCT) and solid 

organ transplantation (SOT). (Abstract #5571) 

C. P. Rodriguez, D. Chute, R. Seth, B. Burkey, J. Scharpf, A. P. Hoschar, D. I. Ives, 

D. J. Adelstein 

Brd. 16C Different cellular p16 localization may signal different survival outcomes in 

head and neck cancer. (Abstract #5572) 

D. N. Hayes, N. Zhao, M. Ang, M. Patel, M. D. Wilkerson, X. Yin, M. C. Hayward, 

W. K. Funkhouser Jr., A. Olshan 

Brd. 16D Prognostic role of PI3KCA and TP53 in HPV-negative oropharyngeal cancers 

(OPCs). (Abstract #5573) 

P. Bossi, F. Perrone, R. Miceli, L. Locati, C. Bergamini, A. Mirabile, R. Granata, 

C. Resteghini, B. Cortelazzi, M. Orsenigo, C. Fallai, E. Orlandi, S. Pilotti, 

L. F. Licitra 

Brd. 16E HPV prevalence and prognostic value in a prospective cohort of 255 patients 

with locally advanced squamous cell carcinoma of the head and neck treated 

with chemoradiation therapy at Centre Hospitalier de l’Université de 

Montréal: A single-center experience. (Abstract #5574) 

E. Thibaudeau, D. Soulieres, B. Fortin, F. Coutlee, P. Nguyen-Tan, X. Weng, 

M. Audette, O. Abboud, L. Guertin, A. Christopoulos, J. Tabet 

Brd. 16F Factors predicting survival outcomes for patients with HPV-positive base of 

tongue cancer. (Abstract #5575) 

P. Attner 

Brd. 16G Lymph node density and response to induction TPF in patients with HPVrelated 

head and neck cancer. (Abstract #5576) 

H. C. Agbahiwe, S. Marur, A. A. Forastiere, G. Sanguineti 

Brd. 16H Effects of human papillomavirus (HPV) and other potential risk factors on 

survival in patients with oropharyngeal cancer. (Abstract #5577) 

M. Knoedler, A. Zakarneh, U. Zimmermann, K. Woelke, O. Kaschke, U. Keilholz 

173 

SATURDAY

SATURDAY 


Brd. 17A Association of p16 and pEGFR expression with high-risk HPV in head and 

neck squamous cell carcinoma. (Abstract #5578) 

R. Altaha 

Brd. 17B Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by 

SNaPshot analysis. (Abstract #5579) 

L. J. Wirth, V. Nardi, D. Juric, A. K. Cosper, K. Bergethon, V. Scialabba, 

D. R. Borger, A. J. Iafrate, L. W. Ellisen, D. Deschler, D. Zhao, P. M. Sadow, 

D. Dias-Santagata 

Brd. 17C Adenoid cystic carcinoma of the head and neck (ACCHN) incidence and 

survival trends. (Abstract #5580) 

C. L. Ellington, S. A. Kono, T. K. Owonikoko, S. S. Ramalingam, F. R. Khuri, 

D. M. Shin, N. F. Saba 

Brd. 17D High-grade transformation in acinic cell carcinoma of the salivary glands: A 

rare but important clinical entity. (Abstract #5581) 

K. A. Price, W. Shon, J. A. Davidson, J. E. Lewis, D. L. Price, J. J. Garcia 

Brd. 17E 17-allylaminogeldanamycin in advanced medullary and differentiated thyroid 

carcinoma. (Abstract #5582) 

J. F. Moley, D. Adkins, K. C. Bible, A. M. Traynor, J. R. Molina, G. Colon-Otero, 

T. J. Pluard, M. H. Shah, R. Suresh, C. Erlichman, S. P. Ivy, V. Suman, 

S. M. Geyer, P. M. Fracasso, M. S. Cohen, H. Tang, E. Fialkowski, A. Traugott, 

R. C. Smallridge, P2C 

Brd. 17F Preoperative recombinant adeno-viral human p53 gene (rAd-p53) therapy in 

treatment of locally advanced locally advanced papillary thyroid cancer 

(PTC) and folliculary thyroid cancer (FTC). (Abstract #5583) 

J. Zhu 

Brd. 17G Prognostic factors of adenoid cystic carcinoma of head and neck. (Abstract 

#5584) 

Y. Choi, S. Kim, S. Nam, S. Choi, J. Roh, J. Lee, S. Lee, K. Cho 

Brd. 17H Comparison of native and adaptive immunity profiles of healthy volunteers 

and patients with well-differentiated thyroid cancer. (Abstract #5585) 

S. Hossain, C. Bhimani, Z. Chen, S. S. Ramalingam, D. M. Shin, C. Cohen, 

F. R. Khuri, E. Waller, T. K. Owonikoko 

Brd. 18A Pharmacogenetic variations in ABCG2 are associated with cisplatin toxicity 

in patients with head and neck squamous cell carcinoma. (Abstract #5586) 

B. Lee, R. Slack, J. J. Hwang, K. Steadman, W. Harter, B. J. Davidson, 

K. A. Newkirk, P. G. Shields, R. Goldman, J. F. Deeken 

Brd. 18B ERCC1 and XPF protein expression in patients with nasopharyngeal 

carcinoma (NPC) undergoing curative intent radiation with or without 

platinum chemotherapy. (Abstract #5587) 

A. Jagdis, T. Phan, A. C. Klimowicz, J. J. Laskin, H. Lau, S. K. Petrillo, 

J. E. Siever, T. A. Thomson, A. M. Magliocco, D. Hao 

Brd. 18C Association of increased lymphocyte infiltration with outcome in patients 

with head and neck cancer treated with the IRX-2 regimen. (Abstract #5588) 

P. Naylor 

Brd. 18D Gene expression profiling predicts nonresponders to chemoradiation in 

HPV16-positive head and neck squamous cell carcinoma. (Abstract #5589) 

B. J. Thibodeau, T. J. Geddes, S. Ahmed, B. L. Pruetz, P. Y. Chen, G. D. Wilson, 

J. A. Akervall 

Brd. 18E Serum C18-ceramide as a biomarker for response: Phase II trial of 

gemcitabine plus doxorubicin in patients with HNSCC. (Abstract #5590) 

K. Shirai, S. Saddoughi, P. E. O’Brien, L. Afrin, E. Garrett-Mayer, G. R. Simon, 

U. B. Chaudhary, B. Ogretmen 

174


Brd. 18F Identification of signaling pathways involved in the mechanism of action of 

the immunomodulatory peptide gamma-D-glutamyl-L-tryptophan. (Abstract 

#5591) 

J. Papkoff, H. Lee, G. Singh, S. Singh, S. Chitta, K. Andrew, P. Quintel, 

J. S. Rosenberg, B. A. Watkins, S. T. Sonis, C. W. Tuthill 

Brd. 18G The effect of the immunomodulatory peptide 

gamma-D-glutamyl-L-tryptophan in leukemia, lymphoma, and head and neck 

cancer xenograft models. (Abstract #5592) 

C. W. Tuthill, J. Papkoff, B. A. Watkins, S. T. Sonis 

Brd. 18H High dose rate intraoperative radiation therapy for recurrent head and neck 

cancer: The importance of in-field control on survival. (Abstract #5593) 

L. B. Harrison, W. F. Mourad, M. Perksy, M. Urken, A. Jacobson, B. Culliney, 

T. Tran, S. P. Schantz, P. Costantino, K. Hu 

Brd. 19A Efficacy and safety of weekly paclitaxel combined with cetuximab in the 

treatment of pretreated recurrent/metastatic head and neck cancer patients. 


B. Jimenez, J. Trigo Perez, M. Saez Medina, C. Quero Blanco, B. Pajares, 

A. Rueda, E. Alba 

175 

SATURDAY

SATURDAY 


2:00 PM - 6:00 PM 


Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell 



Brd. 20A Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFRmutant 

lung cancers that recur after adjuvant TKI. (Abstract #7029) 

G. R. Oxnard, Y. Y. Janjigian, M. E. Arcila, M. G. Kris, M. Ladanyi, 

C. G. Azzoli, V. A. Miller 

Brd. 20B Tumor response and toxicity in neoadjuvant erlotinib in early-stage NSCLC 


H. M. Klomp, E. Schaake, NEL Study group 

Brd. 20C Chemotherapy influence EGFR mutation status for Chinese patients with 

regionally advanced non-small cell lung cancer. (Abstract #7031) 

J. Wang, K. Chen, H. Bai, J. Zhao, Z. Wang, M. Zhuo, T. An, J. Duan, L. Yang, 

M. Wu, Q. Guo, X. Liu, S. Wang, Y. Wang 

Brd. 20D The role of EGFR mutation status in patients with stage III nonsquamous 

non-small cell lung cancer treated with chemoradiotherapy. (Abstract #7032) 

F. Li, G. y. Zhu, X. N. Li, R. Yu, A. Shi, L. Yin 

Brd. 20E Mutations of EGFR, K-ras, and EML-4ALK genes in resected lung 

adenocarcinoma and their clinical significance. (Abstract #7033) 

T. Ohba, K. Sugio, T. Kometani, M. Yamaguchi, M. Hamatake, K. Nosaki, 

H. Takeoka, H. Kitajima, F. Hirai, T. Seto, Y. Ichinose 

Brd. 20F The association of epidermal growth factor receptor (EGFR) mutation and 

survival in N2(�) non-small cell lung cancer patients treated with platinumbased 

neoadjuvant concurrent chemoradiotherapy. (Abstract #7034) 

H. Ahn, Y. Choi, J. Sun, Y. Ahn, K. Kim, J. Kim, Y. Shim, J. Ahn, K. Park, M. Ahn 

Brd. 20G Detection of EGFR mutations with mutation-specific antibodies in primary 

lesions of non-small cell lung cancer. (Abstract #7035) 

X. Zhang, L. Yin, X. Yang, J. Yang, Q. Zhou, J. Xu, Z. Xie, S. An, S. Chen, 

R. Wang, G. Zhu, Y. Gu, Y. Wu 

Brd. 20H Impact of EGFR mutation status in patients with completely resected lung 

adenocarcinoma treated with adjuvant platinum-based chemotherapy. 


K. Yoh, K. Goto, S. Niho, H. Ohmatsu, K. Nagai, Y. Ohe 

Brd. 21A Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer 

(NSCLC) patients (pts). (Abstract #7037) 

E. Felip, M. Salcedo, N. Murtra-Garrell, A. Navarro, C. Teixido, J. Hernandez-Losa, 

S. Cedres, P. Martinez, E. Lopez, M. Montero, V. Freixinos, G. Argiles, I. Nuñez, 

V. Peg, E. Pallisa, M. Canela, J. Tabernero, S. Ramon y Cajal, N. Tallada 

Brd. 21B Initial experience with erlotinib in advanced non-small cell lung cancer in the 

kingdom of Saudi Arabia. (Abstract #7038) 

A. A. Alolayan, S. Musaad, H. Bamefleh, M. Nounou, A. R. Jazieh 

Brd. 21C SOCCAR: Sequential or concurrent chemotherapy and hypofractionated 

accelerated radiotherapy in inoperable stage III NSCLC. (Abstract #7039) 

J. Maguire, R. McMenemin, N. O’Rourke, C. Peedell, M. Snee, S. McNee, V. Kelly 

Brd. 21D Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) 

for poor-risk stage III non-small cell lung cancer (NSCLC). (Abstract #7040) 

Y. Chen, J. Moon, K. J. Pandya, K. Kelly, L. E. Gaspar, D. Lau, F. R. Hirsch, 

D. R. Gandara 

176


Brd. 21E Predictive factors for symptomatic radiation pneumonitis in 293 

consecutively treated non-small cell lung cancer (NSCLC) patients receiving 

definitive radiation therapy. (Abstract #7041) 

A. Orisamolu, E. Xanthopoulos, A. Fernandes, J. P. Christodouleas, 

S. Apisarnthanarax, N. Mitra, F. Wan, C. J. Langer, T. L. Evans, J. Stevenson, 

D. Sterman, A. Vachani, A. R. Haas, R. Rengan 

Brd. 21F Long-term survival (LTS) and competing risks within a prospective 

multicenter German randomized trial comparing induction chemotherapy 

(CTx) followed by concurrent (cc) chemoradiation (CTx/RTx) plus surgery 

(SURG) (� TRIMODALITY) supplemented by PCI versus local treatment (Tx) 

alone (SURG � RTx) in operable IIIA NSCLC. (Abstract #7042) 

T. C. Gauler, C. Poettgen, H. Wagner, S. Korfee, R. Hepp, G. Stamatis, 

J. Von Pawel, B. Passlick, V. Budach, H. Wilke, S. Seeber, M. Stuschke, 

W. E. Eberhardt 

Brd. 21G Endostar in combination with radiotherapy and paclitaxel/carboplatin in 

patients with unresectable non-small cell lung cancer of stage III: Preliminary 

results of a phase II study. (Abstract #7043) 

S. Ma, Y. Xu, X. Sun, Y. Ji, Y. Zheng, S. Wang, J. Chen 

Brd. 21H Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR) 

followed by gemcitabine and carboplatin consolidation in patients with 

unresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657. 


J. Zhang, S. M. Russo, H. A. Gay, T. Parent, Z. Nelson, S. Eubanks, P. R. Walker 

Brd. 22A Oral vinorelbine (NVBo) at 3 weekly flat-dose intakes (FDI) as single agent or 

with cisplatin (CDDP) concomitantly with thoracic radiotherapy (RT) in stage 

III NSCLC: Escalation-dose phase I trial results. (Abstract #7045) 

D. M. Kowalski, M. J. Krzakowski, K. Zajda, C. Lucas 

Brd. 22B A phase I study of nab-paclitaxel (nP) with carboplatin (C) and thoracic 

radiation (TRT) in patients with locally advanced NSCLC. (Abstract #7046) 

V. L. Keedy, B. Lu, L. Horn, Y. Shyr, C. F. Winkler, D. P. Carbone, A. Sandler 

Brd. 22C Long-term survival (S) of induction chemotherapy (CTx) with three cycles 

cisplatin (cis)/paclitaxel (pac) followed by concurrent (cc) chemoradiation 

(CTx/RTx) cis/etoposide (eto) and 45 Gy (1.5 Gy bid) plus surgery (SURG): 

Phase II results (CISTAXOL). (Abstract #7047) 

W. E. Eberhardt, T. C. Gauler, C. Le Pechoux, R. Hepp, S. Welter, B. Fischer, 

S. Bildat, D. Grunenwald, G. Stamatis, M. Stuschke, C. Poettgen 

Brd. 22D Long-term follow-up of phase III trial of docetaxel and cisplatin (DP) versus 

mitomycin, vindesine, and cisplatin (MVP) with concurrent thoracic radiation 

therapy (TRT) for locally advanced non-small cell lung cancer (OLCSG 0007). 


K. Kiura, N. Takigawa, K. Matsuo, S. Kuyama, S. Hosokawa, K. Fujiwara, 

A. Hisamoto, T. Kozuki, H. Ueoka, M. Tanimoto, Okayama Lung Cancer Study 

Group 

Brd. 22E Stereotactic body radiation therapy versus high-dose conventional radiation 

therapy in early-stage NSCLC: A retrospective study on local failure and 

survival rates. (Abstract #7049) 

S. Jeppesen, T. Schytte, H. R. Jensen, C. Brink, O. Hansen 

Brd. 22F Fiducial-less stereotactic radiotherapy for early-stage lung cancer: Efficacy 

and toxicity evaluation. (Abstract #7050) 

J. Bibault, B. Prevost, E. Dansin, X. Mirabel, T. Lacornerie, F. Dubus, E. Lartigau 

Brd. 22G Outcomes of stereotactic body radiotherapy in patients with clinical stage I 

non-small cell lung cancer who are fit to undergo surgery. (Abstract #7051) 

S. Senan, N. E. Verstegen, C. J. Haasbeek, B. J. Slotman, F. J. Lagerwaard 

Brd. 22H Clinical outcome of cN0 non-small cell lung cancer patient staged by thin 

slice CT, FDG-PET, and EBUS-TBNA. (Abstract #7052) 

Y. Sakairi, H. Hoshino, T. Nakajima, T. Fujiwara, F. Ishibashi, H. Tamura, H. Wada, 

T. Iwata, T. Okamoto, T. Mizobuchi, Y. Moriya, S. Yoshida, K. Yasufuku, I. Yoshino 

177 

SATURDAY

SATURDAY 


Brd. 23A Biologic risk model for recurrence in resected early-stage non-small cell lung 

cancer (ES NSCLC). (Abstract #7053) 

K. A. Gold, J. Lee, Y. Ping, C. Behrens, D. Liu, H. Lee, J. S. Koo, R. Lotan, L. Solis, 

W. Rinsurongkawong, D. J. Stewart, W. L. Hofstetter, S. Swisher, S. M. Lippman, 

I. I. Wistuba, W. K. Hong, E. S. Kim 

Brd. 23B Survival analysis of patients with/without lymph node examination after lung 

cancer resection. (Abstract #7054) 

R. U. Osarogiagbon, R. A. Ramirez, C. Wang, L. E. Miller, M. Ul-Haq, A. Farooq, 

J. W. Allen, D. Spencer, A. Berry, A. B. Weir III, H. Cole, T. O’Brien 

Brd. 23C Final results of a trial comparing two neoadjuvant chemotherapy (CT) 

regimens followed by surgery in patients with resectable non-small cell lung 

cancer (NSCLC): A phase II randomized study by the European Lung Cancer 

Working Party. (Abstract #7055) 

T. Berghmans, J. Lafitte, V. Giner, M. Berchier, A. Scherpereel, M. Paesmans, 

A. Meert, T. Bosschaerts, N. Leclercq, J. P. Sculier 

Brd. 23D BRCA1 mRNA expression patterns in a large lung cancer cohort. (Abstract 

#7056) 

K. Kelly, P. Mack, X. Huang, P. Lara Jr., P. V. Danenberg, K. D. Danenberg, 

D. R. Gandara 

Brd. 23E PI3K pathway and downstream signaling analysis in malignant pleural 

mesothelioma (MPM). (Abstract #7057) 

S. Cedres Perez, M. Montero, D. Torrejon, P. Martinez, V. Freixinos, 

N. Mulet-Margalef, G. Argiles, I. Nuñez, E. Lopez, L. Prudkin, M. Salcedo, 

N. Tallada, S. Ramon y Cajal, E. Felip 

Brd. 23F Role of solid tumor size compared with whole tumor size to predict 

pathological malignant grade or prognosis in clinical stage IA lung 

adenocarcinoma: A multicenter study. (Abstract #7058) 

Y. Tsutani, Y. Ibuki, T. Ikeda, Y. Miyata, H. Nakayama, M. Okada 

Brd. 23G Molecular studies support the association between germline genetic variants 

in the vascular endothelial growth factor (VEGF) pathway and survival in 

non-small cell lung cancer (NSCLC) patients. (Abstract #7059) 

D. M. Glubb, W. Zhang, K. Owzar, C. Jiang, O. Mirza, S. Kashyap, W. Rzyman, 

J. Jassem, F. R. Hirsch, R. Dziadziuszko, F. Innocenti 

Brd. 23H Characteristics of the ground-glass opacity nodules showing growth during 


H. Matsuguma, A. Ui, N. Oohata, R. Nakahara, T. Kasai, Y. Kamiyama, S. Igarashi, 

K. Mori, T. Kodama, K. Yokoi 

Brd. 24A Incomplete intrapulmonary lymph node retrieval with routine pathology 

evaluation of resected lung cancer. (Abstract #7061) 

R. A. Ramirez, C. Wang, L. E. Miller, C. A. Adair, T. O’Brien, A. Berry, 

R. U. Osarogiagbon 

Brd. 24B A window-of-opportunity trial of vorinostat (V) in patients with resectable 

non-small cell lung cancer (NSCLC). (Abstract #7062) 

K. H. Dragnev, T. Ma, F. Galimberti, C. P. Erkmen, V. Memoli, W. Nugent, 

J. R. Rigas, D. Johnstone, A. Frandsen, S. Simeone, J. Czum, H. Li, J. DiRenzo, 

S. Freemantle, E. Dmitrovsky 

Brd. 24C Induction chemotherapy with gemcitabine-carboplatin-paclitaxel (GEMCAP) 

in stage III non-small cell lung cancer (NSCLC). (Abstract #7063) 

G. L. Banna, H. Lipari, C. Buscarino, A. Seca, A. Basile, M. Ippolito, G. Novello, 

R. Condorelli, S. Cavallaro, G. Squadrito, M. D’Arrigo, V. Gebbia, A. Terminella, 

S. Saita 

Brd. 24D Prognostic role of nitrotyrosines in surgically resected non-small cell lung 

cancer (NSCLC). (Abstract #7064) 

L. Toschi, P. Colombo, C. Soldani, L. Giordano, G. Finocchiaro, L. Siracusano, 

L. Gianoncelli, M. Incarbone, A. Destro, M. Alloisio, L. Terracciano, 

M. Varella-Garcia, F. Cappuzzo, M. Roncalli, A. Viola, A. Santoro 

178


Brd. 24E Hedgehog inhibition and radiation therapy in non-small cell lung cancer. 


J. Zeng, K. Aziz, M. Armour, B. Aftab, R. Gajula, S. Chettair, T. Salih, C. M. Rudin, 

P. T. Tran, R. Hales 

Brd. 24F Incidence and predictors of venous thromboembolism (VTE) among 

ambulatory patients with lung cancer. (Abstract #7066) 

G. C. Connolly, M. R. Dalal, J. Lin, A. A. Khorana 

Brd. 24G Factors associated with adherence to chemotherapy guidelines in patients 

with non-small cell lung cancer (NSCLC). (Abstract #7067) 

R. G. Salloum, T. J. Smith, J. Elston-Lafata, G. Jensen 

Brd. 24H Examination of 12-lipoxygenase (12-LOX) as a therapeutic target in nonsmall 

cell lung cancer (NSCLC): Mechanisms controlling survival and 

induction of apoptosis following selective inhibition. (Abstract #7068) 

M. Cathcart, V. Campbell, K. Gately, E. Kay, G. P. Pidgeon, K. J. O’Byrne 

Brd. 25A Smoking, passive smoking and lung cancer cell types among women in 

Morocco: Analysis of epidemiological profiling of 101 cases. (Abstract 

#7069) 

H. Errihani, S. Ouaouch, H. Abahssain, R. Razine, H. Mrabti, R. Abouqal, M. Ichou, 

N. Benjaafar, F. Zakkouri 

Brd. 25B Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy 

following definitive treatment in patients with stage I-III adenocarcinoma of 

the lung with G12C, G12D, or G12V KRAS mutations. (Abstract #7070) 

S. P. D’Angelo, B. J. Park, L. M. Krug, C. Crevar, C. E. Medina, D. K. Sumner, 

J. Richman, C. Coeshott, D. Apelian, A. Cohn, M. G. Kris, C. G. Azzoli 

Brd. 25C Prognostic role of integrin �1, E-cadherin, and rac1 expression in small cell 


M. Chang, K. Lee, Y. Kim, J. Kang 

Brd. 26A Liposomal cisplatin in cancer patients with renal failure. (Abstract #7072) 

G. Stathopoulos, S. Rigatos, J. Stathopoulos, S. Batzios 

Brd. 26B Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety of 

amrubicin in patients (pts) with advanced solid tumors. (Abstract #7073) 

N. Chen, S. P. Chawla, E. G. Chiorean, W. L. Read, M. Gorbaty, A. C. Mita, 

L. Yung, R. McNally, M. F. Renschler, S. Sharma 

Brd. 26C Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): 

Findings from a North Central Cancer Treatment Group (NCCTG) pooled 


S. E. Schild, N. R. Foster, J. P. Meyers, K. R. Olivier, H. J. Ross, J. R. Molina, 

P. J. Stella, L. R. Past, Y. I. Garces, A. A. Adjei, North Central Cancer Treatment 

Group 

Brd. 27A Retrospective review of extrapulmonary small cell carcinoma and prognostic 

factors. (Abstract #7075) 

J. E. Brammer, P. D. Lulla, M. A. Bilen, G. R. Lynch 

Brd. 27B A pilot study of adjuvant chemotherapy with cisplatin and irinotecan for 

high-grade pulmonary neuroendocrine carcinona (large cell neuroendocrine 

carcinoma and small cell lung cancer). (Abstract #7076) 

H. Kenmotsu, S. Niho, T. Ito, Y. Ishikawa, H. Tada, I. Sekine, S. Watanabe, 

M. Yoshimura, N. Yamamoto, F. Oshita, K. Kubota, K. Nagai 

Brd. 27C Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer 

(SCLC). (Abstract #7077) 

M. G. Viganò, R. Cavina, S. Novello, F. Grossi, A. Santoro, V. Gregorc, 

G. Scagliotti, I. M. Garassino, G. Rossoni, M. G. Levra, C. Genova, 

F. Caligaris-Cappio, A. Lambiase, C. Bordignon 

179 

SATURDAY

SATURDAY 


Brd. 28A Predictors of pulmonary toxicity in limited-stage (LS) small cell lung cancer 

(SCLC) patients treated with concurrent chemotherapy (CTX) and high-dose 

(70 Gy) daily radiotherapy (RT): A pooled analysis of three CALGB studies. 


J. K. Salama, L. Hodgson, H. Pang, M. R. Green, J. J. Urbanic, A. W. Blackstock, 

J. Crawford, J. Bogart, E. E. Vokes, CALGB 

Brd. 28B Phase II study of NK012 in relapsed small cell lung cancer. (Abstract #7079) 

E. Raefsky, D. R. Spigel, J. R. Infante, J. C. Bendell, S. F. Jones, A. J. Lipman, 

D. Trent, S. Kawamura, F. A. Greco, J. D. Hainsworth, H. A. Burris III 

Brd. 28C Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and 

invasion of small cell lung cancer (SCLC) cells. (Abstract #7080) 

Z. Wang 

Brd. 29A A phase I study of weekly oral topotecan in patients (pts) with relapsed small 

cell lung cancer (SCLC). (Abstract #7081) 

E. Kontopodis, L. Vamvakas, K. Kalbakis, N. K. Vardakis, G. Sfakiotaki, 

V. Georgoulias, S. Agelaki 

Brd. 29B A phase I study of amrubicin (AMR) and cyclophosphamide in patients with 

advanced solid organ malignancies: A trial from the Hoosier Oncology 

Group. (Abstract #7082) 

S. I. Jalal, J. A. Bufill, G. A. Masters, N. Somaiah, K. Koneru, J. McClean, 

R. E. Sanborn, J. Wu, Z. Yu, L. H. Einhorn 

Brd. 29C Determinants of chemotherapy administration and effects of chemotherapy 

on survival in elderly patients with small cell lung cancer (SCLC): A SEER- 

Medicare analysis. (Abstract #7083) 

L. C. Caprario, D. M. Kent, T. A. Trikalinos, G. M. Strauss 

Brd. 30A Phase II study of sunitinib in patients with relapsed or refractory small cell 

lung cancer (SCLC). (Abstract #7084) 

J. Han, K. Lim, H. Kim, S. Oh, T. Yun, J. Lee 

Brd. 30B Systemic therapy usage and outcomes for patients diagnosed with 

malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, 

Canada. (Abstract #7085) 

A. Hasani, B. Sun, G. Liu, W. Xu, R. Feld, N. B. Leighl 

Brd. 30C Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as 

markers of patient response and outcome in malignant pleural 

mesothelioma. (Abstract #7086) 

K. Hollevoet, K. Nackaerts, R. Gosselin, W. De Wever, L. Bosquée, P. De Vuyst, 

P. R. Germonpre, E. Kellen, C. Legrand, Y. Kishi, J. R. Delanghe, 

J. P. Van Meerbeeck 

Brd. 31A Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated 

malignant pleural mesothelioma (MPM) patients (Italian SoMe Study). 


V. Mutri, C. Pinto, S. Giaquinta, P. Di Tullio, V. Torri, B. Melotti, F. Sperandi, 

F. Di Fabio, F. L. Rojas Llimpe, S. Pini, F. Massari, A. Martoni 

Brd. 31B Repeated ambulatory intrapleural chemotherapy for malignant pleural 

mesothelioma. (Abstract #7088) 

J. Javidfar, J. R. Sonett, M. E. Ginsburg, J. Miller, E. Hare, M. Bacchetta, 

R. Fawwaz, R. N. Taub 

Brd. 31C NGR-hTNF in previously treated patients with malignant pleural 


F. De Vincenzo, G. Rossoni, A. Santoro, V. Gregorc, P. A. Zucali, G. Citterio, 

M. Simonelli, G. Petrella, F. Caligaris-Cappio, A. Lambiase, C. Bordignon 

Brd. 31D Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery 

and radiation in the treatment of malignant pleural mesothelioma (MPM). 


F. Rea, A. G. Favaretto, G. Marulli, L. Spaggiari, T. M. De Pas, A. Ceribelli, 

A. Paccagnella, G. Crivellari, F. Russo, M. Ceccarelli, F. Facciolo 

180


Brd. 31E Imatinib mesylate in thymic epithelial malignancies. (Abstract #7091) 

C. Buonerba, M. Marino, S. Sioletic, S. Conti, L. Petillo, P. Federico, V. Damiano, 

G. Merola, A. Evoli, M. Lalle, A. Ceribelli, M. Milella, G. Palmieri 

181 

SATURDAY

SATURDAY 


2:00 PM - 6:00 PM 


Lung Cancer—Metastatic/Non-small Cell 



Brd. 32A Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small 

cell lung cancer (mNSCLC): A National Comprehensive Cancer Network 

(NCCN) outcomes database analysis. (Abstract #7537) 

K. E. Bickel, J. C. Niland, R. Mamet, C. C. Zornosa, D. S. Ettinger, K. Pisters, 

G. A. Otterson, M. Koczywas, M. E. Reid, M. S. Rabin, T. A. D’Amico, C. Earle, 

T. M. Pini, G. P. Kalemkerian 

Brd. 32B Guideline adherence rates and costs of chemotherapy treatment for NSCLC 

patients treated in U.S. community oncology practices. (Abstract #7538) 

Z. Wang, I. Aksamit, L. Tuscher, B. S. Tom, C. B. Del Buono, U. Campbell, 

S. Shields, T. Lam, K. B. Whitlock, M. Mayo, J. Huang, A. M. Christman, 

K. A. Bergstrom 

Brd. 32C The effect of 3 months of integrative cancer treatment on quality of life for 

patients with lung cancer. (Abstract #7539) 

E. D. Staren, D. Gupta, J. F. Grutsch, D. P. Braun 

Brd. 32D Influence of crossover therapy on the association between progression-free 

survival (PFS) and overall survival (OS) in randomized trials of moleculartargeted 

agents for advanced non-small cell lung cancer (NSCLC). (Abstract 

#7540) 

K. Hotta, K. Kiura, E. Suzuki, N. Takigawa, Y. Fujiwara, E. Ichihara, M. Tabata, 

M. Tanimoto 

Brd. 32E Factors influencing a specific histological diagnosis of non-small cell lung 


J. A. Sulpher, S. P. Owen, H. Hon, K. Tobros, F. A. Shepherd, E. Sabri, G. Liu, 

C. M. Canil, P. Wheatley-Price 

Brd. 32F Surgical, histopathologic, and patient-related factors associated with 

isolated brain metastases (IBM) in patients with stages I-IIIA non-small cell 

carcinoma (NSCLC) undergoing surgical resection in comparison to patients 

developing other distal metastases (ODM). (Abstract #7542) 

J. M. Varlotto, L. N. Medford-Davis, J. Shelkey, J. C. Flickinger, A. Recht, 

M. Nikolov, M. Reed, J. Toth, M. M. DeCamp 

Brd. 32G Retrospective review of MRIs in lung cancer patients with brain metastases: 

An assessment of early response. (Abstract #7543) 

R. Zinner, M. Debnam, G. W. Gladish, B. Konda, J. M. Hanneken, D. J. Stewart, 

R. F. Munden, L. Chi 

Brd. 32H Clinical outcome of patients with leptomeningeal metastasis from non-small 

cell lung cancer: Okayama Lung Cancer Study Group. (Abstract #7544) 

S. Umemura, K. Kiura, K. Tsubouchi, N. Takigawa, K. Fujiwara, N. Horita, 

Y. Segawa, N. Hamada, I. Takata, M. Tanimoto 

Brd. 33A Prospective study on incidence of bone metastasis (BM) and skeletal-related 

events (SREs) in patients (pts) with stage IIIB and IV lung cancer (CSP- 

HOR13). (Abstract #7545) 

N. Katakami, A. Hata, H. Kunikane, K. Takeda, K. Eguchi, K. Takayama, T. Sawa, 

H. Saito, M. Harada, S. Yokota, K. Ando, Y. Ohashi 

Brd. 33B Can we really treat patients over 70 years old with a chemotherapy doublet 

for non-small cell lung cancer (NSCLC)? (Abstract #7546) 

M. G. Zauderer, C. S. Sima, B. Korc-Grodzicki, M. G. Kris, L. M. Krug 

Brd. 33C Meta-analysis of efficacy and safety of single-agent and doublet 

chemotherapy with or without platinum in advanced non-small cell lung 

cancer in the elderly. (Abstract #7547) 

G. Des Guetz, B. Uzzan, P. Nicolas, K. Chouahnia, G. Sebbane, J. F. Morere 

182


Brd. 33D Phase II study of bevacizumab and erlotinib in treatment-naive elderly 

patients (older than age 65) with advanced non-small cell lung cancer 

(NSCLC). (Abstract #7548) 

H. Borghaei, R. Mehra, M. M. Millenson, H. Tuttle, K. Ruth, A. J. Magdalinski, 

D. M. Mintzer, J. Lee, J. Stevenson, C. J. Langer 

Brd. 33E Results of a phase II study of single-agent sunitinib in elderly non-small cell 

lung cancer patients. (Abstract #7549) 

C. Reynolds, A. I. Spira, W. L. Gluck, R. E. Pluenneke, K. A. Boehm, F. Zhan, 

L. Asmar 

Brd. 33F Do elderly chemorefractory NSCLC patients derive benefit from salvage 

targeted therapy? Subgroup analysis of clinical outcome and toxicity from 

the BATTLE trial. (Abstract #7550) 

A. S. Tsao, S. Liu, J. Lee, C. M. Alden, E. S. Kim, G. R. Blumenschein Jr., 

R. S. Herbst, S. M. Lippman, I. I. Wistuba, W. K. Hong 

Brd. 33G Survival results of a randomized, phase III trial of nab-paclitaxel and 

carboplatin compared with cremophor-based paclitaxel and carboplatin as 

first-line therapy in advanced non-small cell lung cancer. (Abstract #7551) 

M. A. Socinski, I. N. Bondarenko, N. A. Karaseva, A. Makhson, I. Vynnychenko, 

I. Okamoto, J. K. Hon, V. Hirsh, P. Bhar, G. I. Berk, J. L. Iglesias 

Brd. 33H Phase III study comparing the effects of carboplatin plus S-1 and carboplatin 

plus paclitaxel in chemotherapy-naive patients with advanced non-small cell 

lung cancer: An updated report of the LETS study (WJTOG3605). (Abstract 

#7552) 

T. Hirashima, I. Okamoto, H. Yoshioka, S. Morita, M. Ando, K. Takeda, T. Seto, 

N. Yamamoto, H. Saka, K. Asami, S. Kudoh, M. Satouchi, N. Ikeda, Y. Iwamoto, 

T. Sawa, M. Miyazaki, K. Tamura, T. Kurata, M. Fukuoka, K. Nakagawa, 

West Japan Oncology Group 

Brd. 34A Single-agent maintenance therapy for advanced-stage non-small cell lung 

cancer: A meta-analysis. (Abstract #7553) 

M. Behera, T. K. Owonikoko, Z. Chen, S. A. Kono, F. R. Khuri, C. P. Belani, 

S. S. Ramalingam 

Brd. 34B Results of a randomized phase IIb study estimating overall survival of 

pralatrexate versus erlotinib in platinum-pretreated NSCLC. (Abstract #7554) 

J. D. Patel, C. G. Azzoli, G. A. Weems, A. Koutsoukos, P. Zatloukal, K. Kelly 

Brd. 34C Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with 

advanced non-small cell lung cancer (NSCLC): Pooled analysis of two 

randomized trials. (Abstract #7555) 

A. Ardizzoni, L. Boni, M. Tiseo, A. Vincent, R. Passalacqua, A. Camerini, 

R. Labianca, G. Genestreti, F. Zanelli, L. Ciuffreda, F. Di Costanzo, F. De Marinis, 

L. Crinò, A. Santo, A. Pazzola, F. Barbieri, N. Zilembo, I. Colantonio, C. Tibaldi, 

E. F. Smit 

Brd. 34D Prognostic score for second-line chemotherapy of advanced non-small cell 

lung cancer (NSCLC): External validation in a phase III trial comparing 

vinflunine with docetaxel. (Abstract #7556) 

M. J. Krzakowski, M. Di Maio, K. Perraud, D. M. Kowalski, C. Gridelli 

Brd. 34E The role of gender in predicting for reduced drug clearance and increased 

toxicity in non-small cell lung cancer (NSCLC) patients receiving carboplatin 

and paclitaxel. (Abstract #7557) 

V. H. Phan, C. Tan, J. L. Vardy, A. Rittau, H. Xu, F. Zhang, A. J. McLachlan, 

P. J. Beale, S. J. Clarke 

Brd. 34F Standard chemotherapy strategy versus changing chemotherapy strategy as 

to FDG-PET response after first cycle of standard chemotherapy for 

advanced NSCLC. (Abstract #7558) 

S. Kim, J. Kim, K. Kim, D. Lee, C. Choi, D. Moon, J. Ryu, S. Oh, C. Suh, J. Lee 

183 

SATURDAY

SATURDAY 


Brd. 34G A randomized phase II trial of a vascular disrupting agent (VDA) 

fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), 

bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer 

(NSCLC): Analysis of safety and activity of the FALCON trial. (Abstract 

#7559) 

E. B. Garon, F. F. Kabbinavar, J. A. Neidhart, J. D. Neidhart, N. Y. Gabrail, 

M. R. Oliveira, S. Lu, J. Balkissoon 

Brd. 34H Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin 

(C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or 

recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update on 

maintenance treatment and progression-free and overall survival (PFS, OS). 


J. Aisner, J. Manola, S. R. Dakhil, P. J. Stella, J. H. Schiller, PrECOG, LLC 

Brd. 35A Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic 

nonsquamous non-small cell lung cancer (NSCLC) followed by platinumbased 

chemotherapy (CT) at disease progression (PD): A multicenter phase II 

trial SAKK 19/05. (Abstract #7561) 

F. Zappa, C. Droege, D. C. Betticher, R. von Moos, M. H. Brutsche, F. Baty, 

L. Bubendorf, A. Ochsenbein, E. Oppliger Leibundgut, O. Gautschi, P. Froesch, 

R. A. Stahel, D. Rauch, P. Schmid, M. Mayer, S. Crowe, P. Brauchli, K. Ribi, 

M. Pless 

Brd. 35B AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without 

pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small 

cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)pem: 

Interim safety data. (Abstract #7562) 

F. Barlesi, A. Scherpereel, R. Gervais, V. A. Gorbunova, A. Vikström, M. J. Ahn, 

J. H. Kim, A. Chella, J. Aerts, N. Ferrer, J. M. Trigo Perez, B. Lutiger, A. Rittmeyer 

Brd. 35C Phase II study of topotecan and bevacizumab in advanced refractory nonsmall 

cell lung cancer (NSCLC). (Abstract #7563) 

S. F. Powell, A. Beitinjaneh, R. L. Bliss, R. A. Kratzke, J. W. Leach, A. Dudek 

Brd. 35D Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients 

(pts) with recurrent non-small cell lung cancer (NSCLC). (Abstract #7564) 

S. M. Gadgeel, J. C. Ruckdeschel, A. J. Wozniak, W. Chen, D. Hackstock, 

C. Galasso, A. Burger, S. P. Ivy, P. LoRusso, M. J. Edelman 

Brd. 35E Phase I dose-escalation study of sorafenib in combination with bevacizumab 

(B), paclitaxel (P), and carboplatin (C) for the treatment of advanced 

nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7565) 

G. R. Blumenschein, J. R. Molina, C. D. Lathia, T. J. Ong, D. Roth, P. Rajagopalan, 

F. V. Fossella, M. S. Kies, R. S. Marks, A. A. Adjei, P. R. Sundaresan 

Brd. 35F ALK rearrangement in a selected population of advanced non-small cell lung 

cancer patients: FISH and inmunohistochemistry diagnostic methods, 

prevalence and clinical outcomes. (Abstract #7566) 

P. Martinez, J. Hernandez-Losa, J. Castellvi, N. Tallada, S. Cedres, M. Montero, 

V. Rodriguez-Freixinos, I. Nuňez, G. Argiles, N. Mulet-Margalef, D. Torrejon, 

S. Ramon y Cajal, E. Felip 

Brd. 35G Vorinostat (V) and bortezomib (B) as third-line treatment in patients with 

advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology 

Network Phase II Study. (Abstract #7567) 

M. W. Jones, C. Zhang, K. R. Oettel, J. H. Blank, E. G. Robinson, H. G. Ahuja, 

R. J. Kirschling, P. H. Johnson, M. S. Huie, J. Kolesar, M. Wims, H. Hernan, 

T. C. Campbell, A. M. Traynor, T. Hoang 

Brd. 35H Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapynaive 

patients with non-small cell lung cancer (NSCLC): Preliminary results. 


V. Gregorc, N. Zilembo, F. Grossi, G. Rossoni, F. Pietrantonio, E. Rijavec, 

A. Bulotta, M. Vitali, G. Barletta, L. Bergamaschi, M. Platania, F. Caligaris-Cappio, 

A. Lambiase, C. Bordignon 

184


Brd. 36A The effect of talactoferrin on overall survival in prognostically important 

NSCLC subsets in a randomized, placebo-controlled phase II trial. (Abstract 

#7569) 

P. M. Parikh, A. Ranade, A. K. Vaid, S. H. Advani, A. Bapna, J. Zhu, Y. Wang, 

P. M. Ismail, R. K. Malik 

Brd. 36B A phase IB trial of iniparib (BSI-201) in combination with carboplatin 

(C)/paclitaxel (P) in patients with non-small cell lung cancer (NSCLC). 


A. C. Mita, M. M. Mita, C. Rocha, C. R. Bradley, J. Sarantopoulos, P. O’Rourke, 

S. M. Gadgeel, A. J. Wozniak, E. I. Heath 

Brd. 36C Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth 

factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in 

Asian patients (pts) with NSCLC. (Abstract #7571) 

E. Tan, K. Park, W. T. Lim, M. Ahn, Q. Ng, J. Ahn, D. S. Tan, J. Sun, J. Jac, 

M. Han, F. C. Payumo, M. Credi, K. McKee, M. M. Cotreau, P. Bhargava, 

W. Slichenmyer 

Brd. 36D A phase I study of MM-10–001 in advanced non-small cell lung cancer. 


M. C. Cristea, M. Koczywas, K. L. Reckamp, S. F. Lacey, A. Rotter, P. H. Frankel, 

S. Fouladi Rad, X. Liu, V. Tran, E. Reorizo, M. Kalos 

Brd. 36E Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell 

lung cancer (NSCLC). (Abstract #7573) 

P. C. Mack, N. Farneth, C. Mahaffey, P. Lara Jr., D. R. Gandara 

Brd. 36F Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy 

for patients with advanced and previously treated non-small cell lung cancer 


G. R. Simon, S. Saddoughi, A. Mukhopadhyay, Y. Peterson, C. E. Senkal, J. Oaks, 

D. Perrotti, Y. Hannun, B. Ogretmen 

Brd. 36G DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer 

Treatment—A catalogue of clinically relevant somatic mutations in lung 


L. Horn, H. Chen, C. M. Lovly, J. Andrews, P. Yeh, M. A. Levy, W. Pao 

Brd. 36H My Cancer Genome: Web-based clinical decision support for genome 

directed lung cancer treatment. (Abstract #7576) 

M. A. Levy, C. M. Lovly, L. Horn, R. Naser, W. Pao 

Brd. 37A Screening for mutations in Colombian metastatic non-small cell lung cancer 

(NSCLC) patients (ONCOLGroup). (Abstract #7577) 

A. F. Cardona, P. L. Ramos, R. Duarte, H. Carranza, C. J. Castro, M. Lema, 

C. A. Vargas, A. Jimenez, H. A. Becerra, R. Rosell 

Brd. 37B Development of prognostic biomarker in pathologic stage I NSCLC patients: 

Protein expressions involving in DNA damage response. (Abstract #7578) 

J. Ryu, C. Choi, S. Yang, H. Nam, H. Kim, M. H. Lee 

Brd. 37C Significance of thymidylate synthase and thyroid transcription factor 1 

expression in patients with nonsquamous non-small cell lung cancer treated 

with pemetrexed-based chemotherapy. (Abstract #7579) 

J. Sun, J. Ahn, K. Park, J. Han, M. Ahn 

Brd. 37D Clinical outcome of KRAS mutated advanced non-small cell lung cancer 

(NSCLC) patients (pts): A mono-institutional analysis. (Abstract #7580) 

R. Chiari, V. De Angelis, C. Bennati, C. Molica, G. Metro, S. Duranti, 

F. R. Tofanetti, V. Ludovini, V. Minotti, L. Crino 

Brd. 37F Role of basal inflammatory status as a predictor of survival in bevacizumab 

treated advanced non-small cell lung cancer (NSCLC) patients. (Abstract 

#7582) 

C. Botta, A. Guglielmo, E. Bestoso, S. Apollinari, A. Licchetta, P. Blardi, 

P. Tassone, G. Chiriaco, V. Barbieri, G. Mantovani, P. Tagliaferri, P. Correale 

185 

SATURDAY

SATURDAY 


Brd. 37G Circulating endothelial cells, endothelial progenitor cells, microparticles, and 

markers of inflammation and coagulation in advanced non-small cell lung 


T. Fleitas, G. Reynes, V. Martinez-Sales, V. Vila, E. Reganon, D. Mesado, 

M. Martin, J. Gómez-Codina, J. Montalar 

Brd. 37H Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in 

patients with advanced non-small cell lung cancer with progression after 

first-line chemotherapy. (Abstract #7584) 

K. Habben, P. Delmar, C. M. Brownstein, W. Koehler, K. Kuenkele, O. Splesis, 

S. S. Ramalingam, J. A. Engelman, D. Chen 

Brd. 38A Influence of expression of estrogen (ERS-1) and progesterone (PGR) 

receptors on metastatic spread and outcome in non-small cell lung cancer 


W. M. Brueckl, C. Eschbach, G. H. Wiest, J. H. Ficker, S. Zirlik, R. Hake, S. Eidt, 

A. Hartmann, R. M. Wirtz 

Brd. 38B The nuclear factor kb (NFkB) and Notch signalling pathways and BRCA1 

mRNA expression in stage IV non-small cell lung cancer (NSCLC) patients 

(p). (Abstract #7586) 

M. Santarpia, M. Sanchez-Ronco, I. Magri, S. Viteri, C. Costa, A. Gasco, 

M. Gonzalez Cao, N. Mederos, F. Salazar, J. Bertran-Alamillo, 

A. Gimenez Capitan, G. Altavilla, S. Benlloch, Z. Yeste, E. Aldeguer, M. Taron, 

R. Rosell 

Brd. 38C Clinical, pathological, and molecular characteristics of patients with nonsmall 

cell lung cancer harboring mutations in PIK3CA. (Abstract #7587) 

M. Pietanza, M. E. Arcila, J. E. Chaft, M. F. Zakowski, M. Ladanyi, G. J. Riely, 

M. G. Kris 

Brd. 38D Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated 

non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor 

receptor (EGFR) mutations. (Abstract #7588) 

E. Carcereny, M. A. Molina, J. Sanchez, J. Bertran-Alamillo, C. Mayo, E. Aldeguer, 

A. Gimenez Capitan, Z. Yeste, C. Costa, S. Benlloch, A. Martinez, C. Buges, 

J. Bosch, D. Isla, M. Domine, M. Provencio, C. Camps, M. Taron, R. Rosell 

Brd. 38E Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in 

EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple 

target profiling. (Abstract #7589) 

M. Taron, S. Benlloch, R. Rosell, J. Sanchez, C. Costa, A. Gimenez Capitan, 

C. Mayo, J. Bertran-Alamillo, M. A. Molina, B. Massuti, C. Camps, M. Majem, 

D. Isla, M. Santarpia, S. Viteri, A. Gasco, T. Moran, E. Carcereny, C. Queralt, 

I. de Aguirre 

Brd. 38F Initial detection of the double epidermal growth factor receptor (EGFR) 

mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell 

lung cancer (NSCLC) patients (p) with brain metastases (mets) and the 

influence of first-line chemotherapy on outcome to erlotinib. (Abstract #7590) 

T. Moran, J. Sanchez, M. A. Molina, J. Bertran-Alamillo, A. Gimenez Capitan, 

S. Benlloch, M. Taron, B. Massuti, C. Camps, R. Porta, D. Isla, G. Lopez-Vivanco, 

I. Bover, M. Garcia-Campelo, C. D. Rolfo, F. Salazar, E. Carcereny, F. Cardenal, 

I. Magri, R. Rosell 

Brd. 38G [ 18 F]fluoro-L-thymidine (FLT) uptake in baseline positron emission 

tomography (PET) as a prognostic marker in patients with advanced nonsmall 

cell lung cancer (NSCLC) treated first-line with erlotinib. (Abstract 

#7591) 

M. Scheffler, T. Zander Jr., L. Nogova, C. Kobe, D. Kahraman, M. Dietlein, 

I. Papachristou, S. Querings, E. Stoelben, W. Engel-Riedel, B. Neumaier, J. Wolf 

Brd. 38H Association of CA repeat number and R497K with PFS to EGFR TKIs in 

NSCLC patients having sensitive mutation of EGFR. (Abstract #7592) 

J. Kang, E. Jeon, J. Shin, J. Kim, M. Lee, Y. Kim, K. Lee, Y. Wang, E. Cho 

186


Brd. 39A DAB2 interactive protein (DAB2IP) methylation in serum DNA of non-small 

cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor 

(EGFR) mutations. (Abstract #7593) 

J. Wei, J. Ramirez, M. Taron, J. Sanchez, S. Benlloch, R. Rosell, M. Botia, 

M. Perez-Cano, P. Mendez, M. Tierno, C. Queralt, I. de Aguirre, B. Sanchez, 

A. Martinez, C. Buges, J. Bosch, B. Massuti, C. Camps, T. Moran 

Brd. 39B Quantitative detection of the T790M EGFR mutation in circulating tumor DNA 

of lung cancer patients subjected to EGFR-TKI treatment. (Abstract #7594) 

J. Uchida, K. Taniguchi, F. Imamura, K. Nishino, T. Kumagai, Y. Akazawa, 

T. Okuyama, K. Kato 

Brd. 39C Circulating tumor cells and detection of EGFR mutation in cell-free tumor 

DNA in blood plasma in metastatic non-small cell lung cancer with EGFR 

mutation. (Abstract #7595) 

K. Isobe, Y. Hata, S. Sakaguchi, K. Sato, K. Sugino, G. Sano, S. Sakamoto, 

Y. Takai, K. Shibuya, K. Takagi, S. Homma 

Brd. 39D The surfactant protein B (SFTPB) as a surrogate of circulating tumor cells 

(CTC) with prognostic value in advanced-stage NSCLC. (Abstract #7596) 

R. Sirera, E. Jantus-Lewintre, A. Timon, M. Usó, A. Berrocal, S. Borrego, 

G. Marcaida, E. Sanmartin, R. Rosell, C. Camps 

Brd. 39E First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying 

an activating EGFR mutation: A multicenter academic phase II study in 

caucasian patients (pts) (NCT00339586)—FIELT study group. (Abstract 

#7597) 

J. De Greve, J. P. Van Meerbeeck, J. F. Vansteenkiste, E. Teugels, C. Geers, 

A. Meert, P. Vuylsteke, C. N. Focan, J. Canon, Y. Humblet, G. J. Berchem, 

B. Colinet, D. Galdermans, L. Bosquée, C. A. Dooms, L. Decoster, J. Vermeij, 

A. Dewaele, D. C. Schallier 

Brd. 39F Epidermal growth factor receptor (EGFR) mutation testing and first-line 

treatment with gefitinib as a strategy in the treatment of patients with 

advanced non-small cell lung cancer (NSCLC). (Abstract #7598) 

G. Lopes, J. Segel, D. S. Tan, Y. Do, T. Mok, E. Finkelstein 

Brd. 39G Targeting therapies influence survival of refractory patients with lung 

advanced adenocarcinoma: A phase III randomized trial. (Abstract #7599) 

K. Zarogoulidis, E. Boutsikou, T. Kontakiotis, P. Zarogoulidis, E. Eleftheriadou, 

L. Sacas, G. Galaktidou 

Brd. 39H Meta-analysis of the chemotherapy versus EGFR-TKI in different selections 

of patients. (Abstract #7600) 

C. Xu, Q. Zhou, Y. Wu 

Brd. 40A Phase II study of dose-dense chemotherapy followed by dose-intense 

erlotinib for initial treatment of metastatic NSCLC. (Abstract #7601) 

L. L. Waller, A. A. Miller, N. P. Streer, J. F. Lovato, W. J. Petty 

Brd. 40B Systematic comparative analysis of efficacy of EGFR tyrosine kinase 

inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC. (Abstract 

#7602) 

T. K. Owonikoko, M. Behera, H. N. Tran, Z. Chen, R. P. Chowdry, N. F. Saba, 

S. S. Ramalingam, F. R. Khuri 

Brd. 40C Randomized phase III trial of gefitinib or pemetrexed as second-line 

treatment in patients with non-small cell lung cancer previously treated with 

platinum-based chemotherapy (KCSG-LU08-01). (Abstract #7603) 

M. Ahn, J. Sun, J. Ahn, S. Kim, K. Lee, Y. Min, H. Yun, H. Kim, H. Song, Y. H. Kim, 

B. Kim, I. Hwang, I. S. Woo, H. Ryoo, H. Yi, J. Jang, J. Kwon, K. Park 

Brd. 40D Safety data and patterns of progression in met diagnostic subgroups in 

OAM4558g: A phase II trial evaluating MetMAb in combination with erlotinib 

in advanced NSCLC. (Abstract #7604) 

A. Vashishtha, P. H. Patel, W. Yu, J. G. Bothos, J. Simpson, T. Maneatis, 

L. Doessegger, A. C. Peterson, C. Clement-Duchene, G. Robinet, M. Krzakowski, 

G. R. Blumenschein Jr., J. H. Goldschmidt Jr., D. B. Daniel, D. R. Spigel 

187 

SATURDAY

SATURDAY 


Brd. 40E A phase II study (CTONG0803) of erlotinib as second-line treatment in 

advanced non-small cell lung cancer (NSCLC) patients (pts) with 

asymptomatic brain metastases (BM) after first-line chemotherapy (CT). 


Y. Wu, C. Zhou, Y. Cheng, S. Lu, G. Chen, C. Huang, Y. Huang, H. Yan, J. Yang, 

Chinese Thoracic Oncology Group 

Brd. 40F Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for 

brain metastasis in non-small cell lung cancer patients harboring either exon 

19 or 21 mutations. (Abstract #7606) 

K. Kim, D. Lee, J. Lee, C. Suh, S. Kim, C. Choi, S. Jang, J. Choi 

Brd. 40G Rates of central nervous system (CNS) metastases in patients with advanced 

non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially 

treated with gefitinib or erlotinib versus chemotherapy. (Abstract #7607) 

S. Heon, B. Y. Yeap, N. I. Lindeman, M. S. Rabin, D. M. Jackman, B. E. Johnson 

Brd. 40H Cerebral penetration of gefitinib in patients with lung adenocarcinoma. 


M. Wang, Z. Jing, C. Minjiang 

Brd. 41A How sensitive are epidermal growth factor receptor-tyrosine kinase 

inhibitors for squamous cell carcinoma of the lung harboring epidermal 

growth factor receptor gene sensitive mutations? (Abstract #7609) 

A. Hata, N. Katakami, K. Kunimasa, H. Yoshioka, S. Fujita, R. Kaji, Y. Imai, 

K. Tomii, M. Iwasaku, A. Nishiyama, T. Ishida 

Brd. 41B Time course of skin toxicity (tox) secondary to erlotinib (E) therapy in 

patients (pts) with non-small cell lung cancer (NSCLC) enrolled in the 

SATURN study. (Abstract #7610) 

R. Perez-Soler, F. Cappuzzo, L. Leon, S. Wojtowicz-Praga 

Brd. 41C Implementation of adherence to erlotinib by a treatment-monitoring program. 


V. Gebbia, M. Bellavia, P. Russo, G. L. Banna, F. Ferraù, P. Tralongo, 

N. Borsellino 

188

2:00 PM - 6:00 PM 



Patient and Survivor Care 


Track(s): Patient and Survivor Care 

Brd. 42A Incidence and predictors of delayed congestive heart failure (CHF) after 

hematologic malignancies treated with autologous hematopoietic cell 

transplantation (aHCT). (Abstract #9042) 

S. Armenian, C. Sun, T. Shannon, M. Shangguan, G. MIlls III, L. Francisco, 

F. L. Wong, S. J. Forman, S. Bhatia 

Brd. 42B The risk of subsequent malignancies in cervical cancer survivors as 

compared with breast and colorectal cancer survivors: United States 

1992–2007. (Abstract #9043) 

J. Underwood, S. Rim, E. Tai, T. Fairley 

Brd. 42C Prevalence and correlates of suicidal ideation among outpatients at a 

comprehensive cancer center. (Abstract #9044) 

J. M. Randall, L. Bazhenova, M. White, A. A. Bharne, K. A. Shimabukuro, 

Y. Matusov, K. Messer, A. Lowery, M. Loscalzo, K. Clark, W. Bardwell 

Brd. 42D Long-term effects of the diagnosis and treatment of breast cancer upon 

young breast cancer survivors. (Abstract #9045) 

P. H. Morrow, A. C. Broxson, M. Munsell, K. Basen-Engquist, C. K. Rosenblum, 

L. H. Nguyen, L. R. Schover, K. Hahn, J. K. Litton, G. N. Hortobagyi 

Brd. 42E An evaluation of serum cytokine levels and fatigue and depression in ECOG 

E4Z02. (Abstract #9046) 

T. A. Rich, J. Manola, D. Cella, R. A. Cruciani, M. Fisch, Eastern Cooperative 


Brd. 42F Paclitaxel-associated acute pain syndrome (P-APS) and its association on 

the development of peripheral neuropathy: NCCTG trial N08C1. (Abstract 

#9047) 

B. Reeves, S. R. Dakhil, J. A. Sloan, K. N. Burger, N. A. Le-Lindqwister, 

G. S. Soori, A. J. Jaslowski, J. Kelaghan, D. H. Lachance, C. L. Loprinzi 

Brd. 42G Survival effect of darbepoetin alfa in patients with diffuse large B-cell 

lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B 


R. Delarue, C. Haioun, B. Coiffier, L. Fornecker, M. Fournier, N. Mounier, 

T. J. Molina, S. Bologna, C. Fruchart, S. Picard, H. Tilly, A. Bosly 

Brd. 42H Randomized, multicenter, phase II trial of compound Chinese herbal extract 

LC09 versus placebo for external treatment of hand-foot syndrome induced 

by anticancer therapy. (Abstract #9049) 

L. Jia, Y. Lou, A. Tian, S. Zhu, X. Zhang 

Brd. 43A Structural and functional MRI of the brain as biomarker for postcancer 

fatigue. (Abstract #9050) 

H. Prinsen, A. Heerschap, G. Bleijenberg, M. Zwarts, M. van der Graaf, 

M. Rijpkema, H. Van Laarhoven 

Brd. 43B Long-term survival rates of older breast cancer patients: Population-based 

estimates over three decades. (Abstract #9051) 

B. Kanapuru, A. Jemal, C. S. Hesdorffer, W. B. Ershler, J. W. Yates 

Brd. 43C A risk stratification schema for predicting diabetes mellitus in cancer 

survivors. (Abstract #9052) 

A. Moghaddamjou, A. Y. Tashakkor, P. Birks, W. Y. Cheung 

Brd. 43D Quality-of-life concordance between patients with malignant gliomas and 

their caregivers: Updated data. (Abstract #9053) 

B. V. Stell, D. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, M. A. Schwartz, 

K. Muro, M. H. Marymont, J. Chandler, I. B. Helenowski, L. I. Wagner, J. J. Raizer, 

C. L. Bennett 

189 

SATURDAY

SATURDAY 


Brd. 43E Cost-effectiveness of universal hepatitis B virus screening in patients 

beginning chemotherapy for solid tumors. (Abstract #9054) 

F. L. Day, J. Karnon, D. Rischin 

Brd. 43F A prospective, observational study of medication use among outpatients 

with common solid tumors. (Abstract #9055) 

M. Weiss, J. Manola, M. A. Thompson, M. L. Thomas, M. Fisch 

Brd. 43G Reactivation of hepatitis B infection among patients with cancer. (Abstract 

#9056) 

J. Hwang, M. Fisch, H. Zhang, M. Kallen, M. Routbort, L. S. Lal, J. Vierling, 

M. Suarez-Almazor 

Brd. 43H Analysis of overall survival and self-reported fatigue in patients with locally 

advanced esophageal cancer: A Mayo Clinic Esophageal Adenocarcinoma 

and Barrett’s Esophagus Registry Consortium study. (Abstract #9057) 

M. C. Stauder, Y. Romero, B. Kabat, P. J. Atherton, M. B. Fredericksen, 

C. Deschamps, A. Jatoi, J. A. Sloan, M. Botros, R. C. Miller 

Brd. 44A Accrual of underrepresented minority women to breast cancer clinical trials 

in the Inland Empire, California. (Abstract #9058) 

Y. Yuan, P. Uppala, S. S. Lum, C. Garberoglio, H. R. Mirshahidi, R. Cassady, 

J. Morgan, C. Chen 

Brd. 44B Incidence and risk factors predictive of recurrent venous thromboembolism 

in patients with cancer at a comprehensive cancer center. (Abstract #9059) 

S. Vadhan-Raj, X. Zhou, R. S. Benjamin, G. W. Gladish 

Brd. 44C Achievement of personalized pain goal (PPG) in cancer patients referred to a 

supportive care clinic. (Abstract #9060) 

S. Dalal, D. Hui, L. M. Nguyen, R. Chacko, E. Bruera 

Brd. 44D Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a 

university-based breast oncology clinic. (Abstract #9061) 

A. Soni, A. Brufsky, R. C. Jankowitz, P. Rastogi, V. G. Vogel, S. Puhalla 

Brd. 44E Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general 

population case-control study. (Abstract #9062) 

M. A. van der Kaaij, N. Heutte, P. Meijnders, J. M. Raemaekers, 

E. Abeilard-Lemoisson, A. Allgeier, B. Meulemans, A. H. Simons, N. Mounier, 

M. Henry-Amar, J. C. Kluin-Nelemans, European Organization for Research and 

Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d’Etude des 

Lymphomes de l’Adulte (GELA) 

Brd. 44F Is there an advantage to adding inferior vena cava filter (IVCF) placement to 

anticoagulation with fondaparinux in patients with cancer and venous 

thromboemboli (VTE): Results of the Cancer and Thrombosis (CAT) 

prospective randomized clinical trial (RCT). (Abstract #9063) 

M. F. Barginear, R. J. Gralla, M. Akerman, M. Lesser, T. P. Bradley, I. Shapira, 

N. J. Nier-Shoulson, C. R. Greben, D. R. Budman 

Brd. 44G Symptom burden and change among adolescent/young adult (AYA) patients 

with breast, lung, colorectal, or prostate cancer. (Abstract #9064) 

V. T. Chang, F. Zhao, L. I. Wagner, S. D. Sanford, J. Salsman, M. Fisch 

Brd. 44H Prognostic value of multidimensional geriatric assessment (MGA) on 

survival of a prospective cohort of 880 elderly cancer patients (ECP). 


U. Basso, C. Falci, A. Brunello, V. Zafferri, P. Fiduccia, G. Sergi, S. Lonardi, 

E. Lamberti, E. Castegnaro, C. Soldà, F. Cossutta, V. Chiarion-Sileni, 

S. Monfardini, V. Zagonel 

Brd. 45A OVERcome: An intervention study to improve sexual function in women with 


I. Juraskova, S. Jarvis, K. Mok, M. Peate, B. Meiser, S. Mireskandari, 

M. Friedlander 

190


Brd. 45B Recalling breast cancer presentation and therapy: Associations between 

patient inaccuracy and demographic characteristics. (Abstract #9067) 

W. C. Mertens, C. Loke, D. Katz, R. Barham, G. Makari-Judson 

Brd. 45C Understanding the psychosocial needs of young adults with cancer: 

Identifying targets for clinical intervention. (Abstract #9068) 

K. M. Trevino, K. Fasciano, A. H. Partridge, P. Maciejewski, E. Kacel, R. Jimenez, 

S. Block, H. G. Prigerson 

Brd. 45D Sleep disturbance in patients with advanced cancer: Frequency and factors 

associated with response to specialist-based outpatient supportive care. 


S. Yennurajalingam, G. Chisholm, S. L. Palla, E. Bruera 

Brd. 45E Quality-of-life (QOL) evaluation within a randomized phase III study of 

gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in 

unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST 


Y. Ohashi, M. Tanaka, N. Boku, H. Ueno, T. Okusaka 

Brd. 45F Predicting the risk of cardiovascular comorbidity in cancer survivors. 


A. Y. Tashakkor, A. Moghaddamjou, W. Y. Cheung 

Brd. 45G Cancer-related fatigue and sexual functioning in women with early breast 

cancer: Is there a link? (Abstract #9072) 

K. Webber, K. Mok, B. K. Bennett, I. Juraskova, D. Goldstein, M. Friedlander, 

A. R. Lloyd, FOLCAN study group 

Brd. 45H Clinical trial participation among patients with advanced cancer: What 

characteristics most influence enrollment? (Abstract #9073) 

R. Jimenez, B. Zhang, M. E. Nilsson, S. Joffe, C. Lathan, H. G. Prigerson 

Brd. 46A Stage I lung cancer survivorship: Incidence of secondary malignancies and 

need for individualized care plan. (Abstract #9074) 

R. Surapaneni, K. Rajagopalan, A. Hageboutros 

Brd. 46B Zoledronic acid inhibits adjuvant letrozole-associated bone loss in 

postmenopausal Japanese women with early breast cancer. (Abstract #9075) 

S. Takahashi, T. Iwase, N. Kohno, T. Ishikawa, T. Taguchi, M. Takahashi, 

J. Horiguchi, S. Nakamura, M. Fukunaga, S. Noguchi 

Brd. 46C Does time-to-antibiotics predict outcome of febrile neutropenia in pediatric 

cancer? (Abstract #9076) 

M. B. Fletcher, H. Hodgkiss, R. Browning, T. Hoffman, C. Hadden, N. J. Winick, 

T. L. McCavit 

Brd. 46D Health-related quality of life (HRQOL) of patients 3 years after radiation 

therapy (RT) for early head and neck cancer (HNC). (Abstract #9077) 

I. Bairati, F. Meyer 

Brd. 46E Aprepitant is active in biologic therapies induced severe pruritus: Proof of 

concept study. (Abstract #9078) 

D. Santini, B. Vincenzi, F. Guida, A. Frezza, O. Venditti, M. Silletta, G. Tonini 

Brd. 46F Antiemetic control of palonosetron in patients with gastrointestinal cancer 

receiving a fluoropyrimidine-based regimen containing either irinotecan or 

oxaliplatin. (Abstract #9079) 

M. A. Blazer, J. Reardon, D. Efries, Y. T. Smith, L. M. Weatherby, K. Juergens, 

T. Criswell, J. S. Rose, G. S. Phillips, N. Griffith, T. S. Bekaii-Saab 

Brd. 46G A randomized, double-blind, active control, multicenter, dose-finding study 

of XM22, glycopegfilgrastim, in patients with breast cancer receiving 

myelosuppressive therapy. (Abstract #9080) 

A. Buchner, P. Bias, M. Kaufmann 

Brd. 46H Frequency and predictors of patient deviation from prescribed opioids and 

barriers to opioid pain management in patients (pts) with advanced cancer. 


L. M. Nguyen, M. De la Cruz, D. Hui, J. L. Palmer, H. A. Parsons, E. Bruera 

191 

SATURDAY

SATURDAY 


Brd. 47A A population-based study of metastatic colorectal cancer (mCRC) in people 

age 80 or older: Findings from the South Australian Clinical Registry (SACR) 

for mCRC. (Abstract #9082) 

C. Beeke, K. Jain, T. J. Price, R. Padbury, D. Roder, G. P. Young, M. Ly, 

M. A. Khattak, A. Richards, A. R. Townsend, C. S. Karapetis 

Brd. 47B A randomized, noninferiority study of recombinant human G-CSF/human 

serum albumin fusion (CG-10639) and pegfilgrastim in patients with breast 

cancer receiving myelosuppressive therapy. (Abstract #9083) 

O. Gladkov, V. Moiseyenko, I. N. Bondarenko, J. V. Shparyk, S. Barash, 

J. M. Herpst 

Brd. 47C Cancer-related memory problems, demographic, and socioeconomic 

backgrounds: A cross-sectional study of the United States population. 


P. Jean-Pierre, P. Winters, T. Ahles, M. Antoni, D. Armstrong, F. Penedo, 

S. E. Lipshultz, T. L. Miller, K. Fiscella 

Brd. 47D Prospective cohort study of depression during androgen deprivation therapy 

(ADT) for nonmetastatic prostate cancer. (Abstract #9085) 

N. Timilshina, H. Breunis, S. M. Alibhai 

Brd. 47E Mammography-detected breast cancer over time among patients age 75 and 

older at a community-based cancer center: 1990–2008. (Abstract #9086) 

J. A. Malmgren, M. K. Atwood, H. G. Kaplan 

Brd. 47F CD4� T-cell count to predict the response to new H1N1 vaccination in 

pediatric patients with cancer. (Abstract #9087) 

A. M. Mavinkurve-Groothuis, M. van der Flier, F. Stelma, C. van Leer-Buter, 

F. Preijers, P. Hoogerbrugge 

Brd. 47G Age-dependent effects of intensive chemotherapy (IC) on quality of life (QOL) 

and physical function in patients with acute myeloid leukemia (AML). 


H. Z. Mohamedali, H. Breunis, J. Brandwein, M. Li, N. Timilshina, M. Minden, 

G. A. Tomlinson, S. M. Alibhai 

Brd. 47H Survivors’ perspectives on cancer: Results from a LIVESTRONG survey. 


R. Rechis, E. B. Beckjord, S. Nutt, B. M. Hayes-Lattin 

Brd. 48A Venous thromboembolic complications in patients with malignant glioma 

treated on a bevacizumab clinical trial. (Abstract #9090) 

A. L. Sumrall, D. A. Reardon, A. Desjardins, K. Peters, E. Lou, S. G. Turner, 

L. Bailey, H. S. Friedman, J. J. Vredenburgh 

Brd. 48B Analysis of phase III clinical studies for palonosetron, ondansetron, 

dolasetron, and granisetron in the prevention of chemotherapy-induced 

nausea and vomiting (CINV). (Abstract #9091) 

S. Y. Barbour, G. R. Morrow, R. Ahmed, G. Ballinari, M. D. Thorn, D. Cox, 

L. S. Schwartzberg 

Brd. 48C Developing a community-based screening instrument that measures 

problem-related distress. (Abstract #9092) 

M. Golant, J. S. Buzaglo, M. Miller, K. Clark, M. Loscalzo, V. Kennedy, 

K. R. Dougherty, J. Taylor 

Brd. 48D An analysis of the prognostic value of handgrip strength and its 

incorporation into the comprehensive geriatric assessment (CGA) in elderly 

Asian patients with cancer. (Abstract #9093) 

R. Kanesvaran, K. Koo, W. Chen, D. Poon 

Brd. 48E Inflammatory cytokines and toxic effects of oxaliplatin-based chemotherapy 

in patients with colorectal cancer. (Abstract #9094) 

X. S. Wang, C. S. Cleeland, V. E. Johnson, J. M. Reuben, D. R. Fogelman, 

M. Malekifar, K. E. Liao, P. Liu, E. N. Cohen, K. R. Gilmore, C. Eng 

192


Brd. 48F Barriers to care faced by newly diagnosed patients with cancer. (Abstract 

#9095) 

S. K. Hendren, P. C. Raich, P. Winters, W. Thorland, S. Loader, S. Rousseau, 

P. Valverde, E. Whitley, K. Fiscella 

Brd. 48G Health-related quality of life in patients with advanced renal cell carcinoma 

receiving pazopanib or placebo in a randomized phase III trial. (Abstract 

#9096) 

A. Pickard, D. Cella, M. S. Duh, A. Guerin, N. Mishagina, L. Antràs, M. Neary, 

L. McCann, R. Hodge, C. Sternberg 

Brd. 48H Effect of a nurse practitioner (ARNP)–directed intervention on the quality of 

life of patients with metastatic cancer: Results of a randomized pilot study. 


S. H. Dyar, M. Lesperance, R. P. Shannon, J. A. Sloan, G. Colon-Otero 

Brd. 49A To follow up or not? A new model of supportive care for early breast cancer. 


J. Dent, A. Topping, C. Ferguson, J. Stephenson, M. McCoy, V. Allinson, 

S. Brayford 

Brd. 49B The influence of age on intensity of care at the end of life among older 

patients with advanced cancer. (Abstract #9099) 

J. A. Zerillo, A. K. Smith, M. A. Schonberg, E. P. McCarthy 

Brd. 49C Functional impairment (FI) after hematopoietic cell transplantation (HCT) and 

impact on quality of life (QOL). (Abstract #9100) 

A. Bosworth, F. L. Wong, H. Kim, R. Ferrer Danao, J. Gyorffy, S. Patel, 

S. J. Forman, S. Bhatia 

Brd. 49D Deep vein thrombosis (DVT) and pulmonary embolism (PE): Awareness and 

prophylaxis practices reported by patients with cancer. (Abstract #9101) 

F. R. Rickles, E. Varga, A. Brownstein, R. J. Friedman, G. A. Maynard, J. Ansell 

Brd. 49E Bupropion for hot flashes control in breast cancer survivors: A prospective, 

double-blind, randomized cross-over pilot phase II trial. (Abstract #9102) 

G. R. Nuňez, A. Del Giglio, H. Pinczowski, R. M. Zanellato, L. C. Tateyama, 

F. Schindler, F. A. Fonseca 

Brd. 49F Preventive skin care among cancer survivors. (Abstract #9103) 

S. C. Lau, W. Y. Cheung 

Brd. 49G Quality of life in patients with dermatologic toxicities: Experience from the 

SERIES clinic. (Abstract #9104) 

J. Gordon, Y. Balagula, S. W. Dusza, D. Chen, S. Berg, D. P. West, 

M. E. Lacouture 

Brd. 49H The effect of a 3-day oral aprepitant regimen on the prevention of CINV over 

standard therapy in Chinese patients receiving high-dose cisplatin. (Abstract 

#9105) 

Y. Cheng, L. Zhang, H. Zhang, C. Zhou, B. Han, Y. Zhang, C. Huang, J. Chang, 

X. Song, J. Liang, H. Liang, J. Hu, S. Yu, J. Chen, J. Wang, H. Pan, A. Carides, 

D. Chitkara 

Brd. 50A Agreement between breast cancer survivors and oncologists on treatments 

received. (Abstract #9106) 

T. B. Sanft, V. Northrup, A. B. Chagpar, M. Irwin 

Brd. 50B What topics do patients and caregivers consider most important for support 

groups? An evidence-based analysis of 3,728 participants. (Abstract #9107) 

R. J. Gralla, K. D. Morse, C. N. Rittenberg, J. A. Petersen, K. Burg, B. J. Davis, 

C. Sison, L. M. Rosen, M. Lesser 

Brd. 50C Assessing patients’ values when standard-of-care options are exhausted. 


R. D. Pentz, Z. L. Farmer, M. J. Green, C. Daugherty, F. J. Hlubocky, 

S. K. Peterson, C. C. Sun, C. M. Lewis, T. K. Owonikoko, F. R. Khuri, R. D. Harvey 

193 

SATURDAY

SATURDAY 


Brd. 50D Fertility preservation treatment options: What do patients actually 

understand about their choices? (Abstract #9109) 

J. Mersereau, L. Kondapalli, U. Balthazar 

Brd. 50E Predictors of quality of life (QOL) and mental health (MH) in caregivers of 

patients with advanced cancer. (Abstract #9110) 

D. Wadhwa, D. Burman, N. Swami, C. Zimmermann 

Brd. 50F Geriatric factors to predict toxicity and dose-intensity reduction in FFCD 

2001–02 phase III study comparing a first-line chemotherapy of LV5FU2 or 

FOLFIRI in treatment of metastatic colorectal cancer (mCRC) in elderly 


T. Aparicio, J. Jouve, L. Teillet, D. Gargot, V. Le Brun Ly, J. Cretin, C. Locher, 

O. Bouche, G. Breysacher, J. Charneau, J. Seitz, M. Gasmi, F. Ricard, F. Subtil, 

E. Mitry, Federation Francophone de Cancerologie Digestive 

Brd. 50G Association between a validated symptom assessment tool and nurse 

clinical impression in patients with cancer admitted to a palliative care unit. 


W. Rhondali, D. Hui, S. Kim, K. L. Kilgore, J. Kang, L. M. Nguyen, E. Bruera 

Brd. 50H Quality-of-life assessment in patients with malignant ascites: Results of a 

multicenter phase II/III study comparing paracentesis plus catumaxomab 

with paracentesis alone. (Abstract #9113) 

A. Gonschior, M. M. Heiss, M. H. Moehler, S. L. Parsons, H. Gilet 

Brd. 51A Prevalence of psychosocial distress in a rural community oncology practice 

and impact of interventions. (Abstract #9114) 

J. S. Smith, D. L. Limesand, M. A. Alikhan 

Brd. 51B Denosumab versus zoledronic acid in patients with bone metastases from 

solid tumors other than breast and prostate cancers or multiple myeloma: A 

number needed to treat (NNT) analysis. (Abstract #9115) 

G. E. Richardson, T. E. Ciuleanu, L. Costa, S. J. Gans, J. Garcia Saenz, V. Hirsh, 

V. Hungria, M. Krzakowski, C. Manegold, H. Nahi, S. Novello, A. L. Petzer, 

M. E. Rader, P. Solal-Celigny, S. Vadhan-Raj, J. F. Vansteenkiste, P. J. Woll, 

C. Ke, K. Chung, H. Yeh 

Brd. 51C Results from a randomized phase II study to evaluate the safety and efficacy 

of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral 

neuropathy (REASON). (Abstract #9116) 

C. Lhomme, D. Berton-Rigaud, F. Joly, J. Baurain, F. Rolland, A. Stenzl, 

T. Schmelter, M. Campone 

Brd. 51D The impact of less than 8% weight loss on overall survival in subjects with 

non-small cell lung cancer (NSCLC) treated in a phase IIb trial of GTx-024. 


S. Dodson, A. Dobs, M. L. Hancock, M. A. Johnston, M. S. Steiner 

Brd. 51E A multicenter analysis of the predictors of fertility preservation in women 

with breast cancer: Role of neoadjuvant chemotherapy. (Abstract #9118) 

J. Kim, K. Oktay, C. Gracia, S. Lee, C. Morse, J. Mersereau 

Brd. 51F Cognitive difficulties among patients with cancer receiving chemotherapy 

affects quality of life: A University of Rochester Clinical Community 

Oncology Program study of 439 patients. (Abstract #9119) 

M. C. Janelsins, K. Devine, K. M. Mustian, S. G. Mohile, L. J. Peppone, L. Sprod, 

M. Weiss, V. Vinciguerra, A. Jacobs, G. R. Morrow 

Brd. 51G Sexual side effects (SSE) reported by adolescent/young adult (AYA) versus 

older cancer survivors. (Abstract #9120) 

C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, G. A. Di Lullo, J. M. Metz 

Brd. 51H Serum 25-hydroxyvitamin D testing at Memorial Sloan-Kettering Cancer 

Center. (Abstract #9121) 

K. M. Wesa, K. Yeung, G. Jacobs, M. Coleton, B. R. Cassileth 

194


Brd. 52A Impact of geriatric vulnerability parameters on pegylated liposomal 

doxorubicin (PLD) tolerance and outcome in elderly patients with metastatic 

breast cancer: Results of the DOGMES multicenter phase II GINECO trial. 


C. Falandry, E. Brain, M. Bonnefoy, F. Mefti, A. Savoye, O. Rigal, 

S. Oddou-Lagranière, C. El Kouri, L. Uwer, S. Abadie-Lacourtoisie, J. Cretin, 

J. Jacquin, G. Freyer 

Brd. 52B The status of oncofertility resources at NCI-designated comprehensive 

cancer centers. (Abstract #9123) 

M. L. Clayman, M. Harper, G. P. Quinn, S. Shah, J. Reinecke 

Brd. 52C Safety and efficacy of implanted central venous catheters during adjuvant 

treatment of breast cancer and in a general oncology population. (Abstract 

#9124) 

M. Wilson, D. J. Porter, A. Maher 

Brd. 52D Quality of life in male patients with hormone-independent cancers: The role 

of testosterone. (Abstract #9125) 

P. Homel, S. B. Fleishman, M. Suhail, V. Rosenwald 

Brd. 52F Do high symptom scores trigger clinical actions by providers? Assessing the 

effect of standardized symptom screening. (Abstract #9127) 

J. Sussman, H. Seow, D. Bainbridge, G. R. Pond, L. Martelli-Reid 

Brd. 52G Physician preferences and knowledge gaps regarding the care of childhood 

cancer survivors: A survey of the American Academy of Family Physicians 

(AAFP). (Abstract #9128) 

T. O. Henderson, P. C. Nathan, M. Kigin, F. J. Hlubocky, K. Wroblewski, 

T. V. Stewart, J. M. Galliher, K. C. Oeffinger, C. Daugherty 

Brd. 52H The trajectory of physical functioning during breast cancer treatment of older 

women. (Abstract #9129) 

C. Owusu, M. D. Schluchter, S. M. Koroukian, N. A. Berger 

Brd. 53A Documenting the complete resolution rates of venous thromboemboli (VTE) 

with the factor Xa inhibitor fondaparinux sodium (FS) in patients with cancer. 


D. R. Budman, M. F. Barginear, R. J. Gralla, T. P. Bradley, I. Shapira, 

N. J. Nier-Shoulson, C. R. Greben, M. Akerman, M. Lesser 

Brd. 53B Survivorship care plans for colorectal cancer survivors: What do primary 

care providers want and need? (Abstract #9131) 

T. Salz, K. C. Oeffinger, P. R. Lewis, R. Rhyne, R. L. Williams, M. W. Yeazel 

Brd. 53C Intensity of end-of-life cancer care among seniors: Variations by principal 

health care provider. (Abstract #9132) 

K. Murray, L. Lucas, S. Miesfeldt 

Brd. 53D Comparison of patient-reported symptoms and health behaviors to clinician 

documentation among patients with breast cancer in follow-up care. 


M. E. Melisko, M. Bock, D. H. Moore, D. Hamolsky, M. Mendelsohn, L. Lawson, 

H. Orlando, H. S. Rugo, A. J. Chien, J. W. Park, M. M. Moasser, P. N. Munster, 

A. Goga, L. Esserman 

Brd. 53E Geriatric assessment (GA) of older patients with cancer in Australia: A 

national, multicenter audit. (Abstract #9134) 

S. S. Joshi, C. B. Steer, J. Yoong, R. Lakhanpal, S. Kirsop, T. Dunlop, 

L. R. Mileshkin, D. Yip, G. M. Marx, E. J. Hovey, S. Della-Fiorentina, 

Clinical Oncology Society of Australia 

Brd. 53F Aggressiveness of end-of-life care before and after the utilization of a 

palliative care service. (Abstract #9135) 

W. Gonsalves, T. Tashi, T. Davies, S. Ortman, R. Thota, J. Krishnamurthy, 

I. T. Aldoss, M. Kalaiah, A. Ganta, N. Didwaniya, C. Eberle, A. Ganti, S. Subbiah, 

P. T. Silberstein 

195 

SATURDAY

SATURDAY 


Brd. 53G Patient experience with survivorship care plans: Findings from an online 

registry of breast cancer survivors. (Abstract #9136) 

J. S. Buzaglo, K. R. Dougherty, M. Amsellem, M. Golant 

Brd. 53H Prospective assessment of symptom burden among cancer survivors with 

common solid tumors: Results from ECOG trial E2Z02. (Abstract #9137) 

L. I. Wagner, L. Zickl, M. Smith, D. Cella, C. Coles, L. J. Patrick-Miller, J. Manola, 

M. Fisch 

Brd. 54A Hodgkin lymphoma of the elderly veterans: Veterans Affairs Cancer Registry 


J. Krishnamurthy, T. Tashi, W. Gonsalves, R. Thota, P. T. Silberstein, S. Subbiah 

Brd. 54B BRCA mutation carriers: Risk factors for psychosocial and physiologic 

disruption. (Abstract #9139) 

L. B. Wenzel, K. Osann, J. Gross, R. Kurz, E. L. Nelson, B. Y. Karlan 

Brd. 54C The effectiveness of a structured exercise and education program on clinical 

and quality-of-life outcomes in patients with cancer who are actively 

undergoing therapy compared with patients not currently receiving therapy. 


L. M. Leach, A. Kleski, K. Spencer, J. Anthony, M. LaLonde, T. J. Sweeney, 

T. Caulin-Glaser 

196

3:00 PM - 4:15 PM 


ASCO/Radiological Society of North America (RSNA) Joint Session: Cancer 

Screening—Can We See Clearly Now? 



Track(s): Practice Management and Information Technology, Cancer Prevention/Epidemiology, 

Special Session 



N. Reed Dunnick, MD—Co-Chair 


Denise R. Aberle, MD 

University of California, Los Angeles David Geffen School of Medicine 

Lung Cancer Screening: Results and Implications of the National Lung Screening Trial (NLST) 

Mark Helvie, MD 


Breast Cancer Screening: U.S. Preventive Services Task Force Recommendations—Why the 

Controversy? 

Elizabeth Burnside, MD, MPH 

University of Wisconsin 

Evaluating Screening Studies: Translating the Science to Practice 


197 

SATURDAY

SATURDAY 


3:00 PM - 4:15 PM 


Immunologics and Biologics for Sarcomas: Is There a Role? 



Track(s): Sarcoma, Pediatric Oncology 

Peter Houghton, PhD—Chair 

Nationwide Children’s Hospital 

Emerging Biologic Strategies for Sarcomas 

Paul Robbins, PhD 

National Cancer Institute Center for Cancer Research 

Adoptive Immunotherapy of Synovial-cell Sarcoma Targeting Cancer/Testis Antigens 

Crystal Mackall, MD 


The Future of Immunotherapy for Sarcomas 

Lung Cancer Whole-genome Sequencing: What a Clinician Should Know 



Track(s): Lung Cancer, Tumor Biology 

Ramaswamy Govindan, MD—Chair 


Whole-genome Sequencing of Lung Cancer: Update and Implications for Clinical Research 

Elaine Mardis, PhD 

Washington University 

Whole-genome Sequencing: A Primer for the Clinicians 

Neil Caporaso, MD 


Lung Cancer Whole-genome Sequencing: Insights into Lung Cancer Biology 

Next-generation Sequencing in Cancer Genetics 



Track(s): Cancer Genetics 

Stephen B. Gruber, MD, PhD, MPH—Chair 


Next-generation Sequencing: What Are the Clinical Implications? 

Veda N. Giri, MD 


Beyond Genome-wide Association Studies in Cancer Susceptibility 

Arul Chinnaiyan, MD, PhD 


Next-generation Sequencing and Susceptibility to Prostate Cancer 

198

Prediction, Prevention, and Treatment of Chemotherapy Toxicity in Older 

Patients 



Track(s): Geriatric Oncology, General Oncology 

Supriya Gupta Mohile, MD, MS—Chair 


Prevention and Management of Nonhematologic Toxicity in Elderly Patients Receiving 

Chemotherapy 



Prediction of Chemotherapy Toxicity in Elderly Patients 


Gary H. Lyman, MD, MPH 

Duke University 

Prevention and Management of Hematologic Toxicity in Elderly Patients Receiving 

Chemotherapy 

199 

SATURDAY

SATURDAY 


3:00 PM - 4:15 PM 


Issues in Therapy for Rectal Cancer (M07)—Ticketed Session 




Blase N. Polite, MD, MPH 


Which Chemotherapy and When: Understanding the Timing and Type of Chemotherapy in 

Patients with Rectal Cancer 

Claus Roedel, MD 

University of Frankfurt 

Radiation Therapy for Rectal Cancer: When Can It Be Omitted or Shortened? 

200

3:00 PM - 4:15 PM 


Integrative Oncology: A Mainstream Look at Approaches for Patients with 

Advanced Cancer (C06)—Ticketed Session 



Track(s): Professional Development, Cancer Prevention/Epidemiology, Patient and Survivor 

Care 

Nancy E. Davidson, MD—Chair 

University of Pittsburgh Cancer Institute 

Clinical Trial Design in Integrative Oncology: Advanced Cancer 

Edith P. Mitchell, MD 

Kimmel Cancer Center at Thomas Jefferson University 

Evidence-based Interventions in Integrative Oncology for Patients with Metastatic Cancer 

Brent Bauer, MD 

Mayo Clinic 

What Alternative Therapies Are Hot for Advanced Cancer Patients? 


201 

SATURDAY

SATURDAY 


3:00 PM - 4:30 PM 


Host Genomics and Treatment Outcomes in Breast Cancer 




Christos Sotiriou, MD, PhD—Chair 


Discussion 

3:00 PM Mark J. Ratain, MD 


3:15 PM Genetic associations with taxane-induced neuropathy by genome-wide 

association study (GWAS) in E5103. (Abstract #1000) 

B. P. Schneider, L. Li, K. Miller, D. Flockhart, M. Radovich, B. A. Hancock, 

N. Kassem, T. Foroud, D. L. Koller, S. S. Badve, Z. Li, A. H. Partridge, 

A. M. O’Neill, J. A. Sparano, C. T. Dang, D. W. Northfelt, M. Smith, E. Railey, 

G. W. Sledge Jr. 

Discussion 

3:30 PM Howard L. McLeod, PharmD (Abstract #1000) 

University of North Carolina Eshelman School of Pharmacy 

3:45 PM Genes regulating estradiol and estrone-conjugate levels in postmenopausal 

women with resected early-stage breast cancer detected by a genome-wide 

association study (GWAS). (Abstract #1001) 

J. N. Ingle, B. L. Fridley, A. Buzdar, M. E. Robson, M. Kubo, M. Liu, 

I. Ibrahim-Zada, A. Batzler, G. D. Jenkins, M. P. Goetz, D. W. Northfelt, 

E. A. Perez, C. V. Williard, L. Wang, D. J. Schaid, Y. Nakamura, 

R. M. Weinshilboum 

4:00 PM ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) 

versus tamoxifen (T) or their sequence for early breast cancer. (Abstract 

#1002) 

M. Bouzyk, K. P. Gray, M. M. Regan, O. Pagani, W. Tang, R. Kammler, 

R. Maibach, G. Viale, P. Dell’Orto, B. J. Thurlimann, E. Hitre, M. Lyng, H. J. Ditzel, 

P. Neven, G. MacGrogan, K. N. Price, R. D. Gelber, A. S. Coates, A. Goldhirsch, 

B. Leyland-Jones, BIG 1-98 Collaborative and International Breast Cancer Study 

Groups 

Discussion 

4:15 PM James M. Rae, MD (Abstracts #1001–1002) 


202

3:00 PM - 5:30 PM 


Pediatric Oncology I 



Track(s): Pediatric Oncology 


Paul C. Nathan, MD, MSc—Co-Chair 

The Hospital for Sick Children 

Jennifer Lynn McNeer, MD—Co-Chair 


3:00 PM Results of a prospective clinical trial for VAMP alone without irradiation for 

pediatric favorable, early-stage Hodgkin lymphoma patients who achieve an 

early complete response. (Abstract #9503) 

M. Metzger, H. J. Weinstein, M. M. Hudson, A. Billett, E. C. Larsen, 

A. M. Friedmann, S. S. Donaldson, M. J. Krasin, L. E. Kun, K. C. Marcus, 

T. I. Yock, N. Tarbell, C. Billups, J. Wu, M. P. Link 

3:15 PM Dexamethasone (DEX) versus prednisone (PRED) during induction for 

children with high-risk acute lymphoblastic leukemia (HR-ALL): A report 

from the Children’s Oncology Group Study AALL0232. (Abstract #9504) 

N. J. Winick, W. L. Salzer, M. Devidas, J. B. Nachman, E. A. Raetz, M. L. Loh, 

N. A. Heerema, A. J. Carroll, J. M. Gastier-Foster, M. J. Borowitz, B. L. Wood, 

C. L. Willman, S. Hunger, W. L. Carroll, E. C. Larsen 

Discussion 

3:30 PM Andrea Biondi, MD (Abstract #9504) 

University of Milano-Bicocca 

3:45 PM Relationship of CRLF2 expression and outcome in pediatric B-cell precursor 

acute lymphoblastic leukemia (BCP-ALL): A report from the Children’s 

Oncology Group. (Abstract #9505) 

I. Chen, R. Harvey, C. G. Mullighan, M. L. Loh, M. Devidas, M. J. Borowitz, 

S. K. Tasian, D. Payne-Turner, W. Wharton, J. Pullen, A. J. Carroll, W. L. Carroll, 

B. M. Camitta, S. Hunger, N. J. Winick, C. L. Willman 

4:00 PM Treatment outcomes in older adolescent and young adult (AYA) patients with 

newly diagnosed AML. (Abstract #9506) 

J. A. Canner, T. A. Alonzo, J. Franklin, D. R. Freyer, A. S. Gamis, R. B. Gerbing, 

B. Lange, S. Meshinchi, W. G. Woods, J. P. Perentesis, J. Horan 

4:15 PM Impact of traditional cardiovascular disease risk factors on long-term 

cardiovascular outcome in adult survivors of childhood cancer: A report 

from the Childhood Cancer Survivor Study. (Abstract #9507) 

G. T. Armstrong, Y. Chen, T. Kawashima, C. A. Sklar, D. A. Mulrooney, E. J. Chow, 

W. Border, J. Durand, A. Mertens, M. Stovall, W. Leisenring, Y. Yasui, 

L. L. Robison, K. C. Oeffinger, L. Meacham 

4:30 PM Impact of HFE mutations on cardiac status in survivors of childhood highrisk 

ALL: Dana-Farber Cancer Institute Childhood ALL 05–159. (Abstract 

#9508) 

S. E. Lipshultz, S. R. Lipsitz, J. Kutok, T. L. Miller, S. D. Colan, D. S. Neuberg, 

S. E. Dahlberg, L. B. Silverman, J. M. Henkel, V. I. Franco, S. E. Sallan, 

Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium 

4:45 PM Cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic 

leukemia (ALL). (Abstract #9509) 

K. C. Oeffinger, P. G. Snell, C. S. Moskowitz, J. F. Chou, D. A. Kent, 

E. S. Tonorezos, A. L. Dunn, S. M. Smith, T. S. Church 

203 

SATURDAY

SATURDAY 


5:00 PM Melanoma as a subsequent neoplasm in survivors of childhood cancer: A 

report from the Childhood Cancer Survivor Study. (Abstract #9510) 

A. S. Pappo, G. T. Armstrong, W. Liu, D. K. Srivastava, W. Leisenring, 

S. Hammond, M. Stovall, J. P. Neglia, L. L. Robison 

Discussion 

5:15 PM Louise C. Strong, MD (Abstract #9510) 


204

3:00 PM - 6:00 PM 




CME credit: 3 



Ronald J. Buckanovich, MD—Co-Chair 


Gottfried E. Konecny, MD—Co-Chair 


3:00 PM Phase II randomized placebo-controlled study of olaparib (AZD2281) in 

patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). 


J. A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. B. Vergote, G. J. Rustin, 

C. Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, E. Macpherson, 

C. Watkins, J. Carmichael, U. Matulonis 

3:15 PM A phase II trial of iniparib (BSI-201) in combination with 

gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent 


R. T. Penson, C. Whalen, B. Lasonde, C. N. Krasner, P. Konstantinopoulos, 

T. E. Stallings, C. R. Bradley, M. J. Birrer, U. Matulonis 

3:30 PM A phase II trial of iniparib (BSI-201) in combination with 

gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent 


M. J. Birrer, P. Konstantinopoulos, R. T. Penson, M. Roche, A. Ambrosio, 

T. E. Stallings, U. Matulonis, C. R. Bradley 

Discussion 

3:45 PM Stanley B. Kaye, MD (Abstracts #5003–5005) 

The Royal Marsden Hospital 

4:00 PM Result of interim analysis of overall survival in the GCIG ICON7 phase III 

randomised trial of bevacizumab in women with newly diagnosed ovarian 

cancer. (Abstract #LBA5006) 

G. Kristensen, T. Perren, W. Qian, J. Pfisterer, J. A. Ledermann, F. Joly, 

M. S. Carey, P. J. Beale, A. Cervantes, A. M. Oza 

4:15 PM OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of 

chemotherapy with or without bevacizumab (BEV) in patients with platinumsensitive 

recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or 

fallopian tube cancer (FTC). (Abstract #LBA5007) 

C. Aghajanian, N. J. Finkler, T. Rutherford, D. A. Smith, J. Yi, H. Parmar, 

L. R. Nycum, M. A. Sovak 

4:30 PM Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): 

Results from a phase II randomized discontinuation trial (RDT). (Abstract 

#5008) 

R. J. Buckanovich, R. Berger, A. Sella, B. I. Sikic, X. Shen, D. A. Ramies, 

D. C. Smith, I. B. Vergote 

Discussion 

4:45 PM Anil Sood, MD (Abstracts #LBA5006–5008) 


5:00 PM A randomized phase II (RP2) trial of ridaforolimus (R) compared with 

progestin (P) or chemotheraphy (C) in female adult patients with advanced 

endometrial carcinoma. (Abstract #5009) 

A. M. Oza, A. Poveda, A. R. Clamp, S. Pignata, G. Scambia, J. Del Campo, 

M. McCormack, L. Sevcik, B. M. Schwartz, S. Guan, R. Lee, J. D. Cheng, 

F. G. Haluska 

205 

SATURDAY

SATURDAY 


5:15 PM A comparative randomized, placebo-controlled, double-blind phase II study 

with and without enzastaurin in combination with paclitaxel and carboplatin 

as first-line treatment for advanced ovarian cancer. (Abstract #5010) 

I. B. Vergote, P. Harter, N. Kovalenko, T. Bauknecht, K. Mansouri, Y. Zhang, 

J. Sehouli 

5:30 PM A phase II study of decitabine and carboplatin in recurrent platinum (Pt)resistant 

ovarian cancer (OC). (Abstract #5011) 

D. Matei, C. Shen, F. Fang, J. Schilder, M. Li, A. Arnold, Y. Zeng, J. M. Pilrose, 

C. Kulesavage, C. Balch, W. Berry, P. Wulfridge, T. H. Huang, K. P. Nephew 

Discussion 

5:45 PM Helga B. Salvesen, MD, PhD (Abstracts #5009–5011) 

Haukeland University Hospital, The University of Bergen 

206

4:30 PM - 6:00 PM 


Finding the Targets, Restoring the Vision 





Ravi Salgia, MD, PhD—Chair 


4:30 PM A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab 

(AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients 

(pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary 

and biomarker analyses. (Abstract #3500) 

C. Eng, E. Van Cutsem, E. Nowara, A. Swieboda-Sadlej, N. C. Tebbutt, 

E. P. Mitchell, I. Davidenko, K. Oliner, L. Chen, J. Huang, I. McCaffery, E. Loh, 

D. Smethurst, J. Tabernero 

Discussion 

4:45 PM Ravi Salgia, MD, PhD (Abstract #3500) 


Colorectal Cancer: Exploiting the Targets 

5:00 PM A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 

(dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the 

treatment of chemorefractory metastatic colorectal cancer (mCRC) with 

wild-type (wt) KRAS status. (Abstract #3501) 

D. J. Watkins, J. Tabernero, H. Schmoll, T. Trarbach, F. J. Ramos, J. Howe, 

H. M. Brown, J. Clark, K. Hsu, B. D. Lu, D. Cunningham 

Discussion 

5:15 PM Margaret M. Mooney, MD, MBA (Abstract #3501) 


The Importance of Biomarker Codevelopment to Success 

5:30 PM A phase II study of the PARP inhibitor ABT-888 plus temozolomide in 

patients with heavily pretreated, metastatic colorectal cancer. (Abstract 

#3502) 

M. J. Pishvaian, R. Slack, A. Witkiewicz, A. R. He, J. J. Hwang, A. Hankin, 

K. Dorsch-Vogel, D. Kuda, T. McAndrew, L. M. Weiner, J. Marshall, J. R. Brody 

Discussion 

5:45 PM Andrew Nicholas James Tutt, PhD, MBChB (Abstract #3502) 

Breakthrough Breast Cancer Research Unit, Guy’s Hospital 

207 

SATURDAY

SATURDAY 


4:45 PM - 6:00 PM 


ASCO/American Society of Hematology (ASH) Joint Session 



Track(s): Leukemia, Myelodysplasia, and Transplantation, Lymphoma and Plasma Cell 

Disorders, Special Session 



Welcome and Introduction 

Armand Keating, MD—Co-Chair 



Anna Jankowska, MSc 


Impaired Hydroxylation of 5-Methylcytosine in TET2-mutated Patients with Myeloid 

Malignancies (ASH #33807) 

Menno Volkert Huisman, MD, PhD 

Leiden University Medical Center 

Outpatient Treatment in Patients with Acute Pulmonary Embolism: The Hestia Study (ASH 

#34998) 

Kaan Boztug, MD 

CeMM Research Center for Molecular Medicine 

Correction of Wiskott-Aldrich Syndrome by Hematopoietic Stem Cell Gene Therapy (ASH 

#33064) 

Kirit Ardeshna, MD 

University College London Hospitals 

An Intergroup Randomized Trial of Rituximab versus a Watch-and-Wait Strategy in Patients 

with Stage II, III, IV, Asymptomatic, Nonbulky Follicular Lymphoma (Grades 1, 2, and 3a). A 

Preliminary Analysis (ASH #27692) 

208

4:45 PM - 6:00 PM 


Design and Interpretation of Randomized Controlled Trials in Oncology to 

Achieve Meaningful Benefits for Patients and Society 



Track(s): Clinical Trials, Ethics 

Ralph M. Meyer, MD—Chair 

NCIC Clinical Trials Group, Queen’s University 

Explanatory versus Pragmatic Randomized Controlled Trials in Oncology: How and Why to 

Make This Distinction in the Design and Interpretation of Clinical Trials 

Antonio Tito Fojo, MD, PhD 

National Cancer Institute, National Institutes of Health 

How Much Is Life Worth: The Multibillion Dollar Question in Contemporary Oncology 

Alberto F. Sobrero, MD 

Ospedale San Martino 

Raising the Bar for Efficacy in Cancer Therapeutics 

New Developments in Lynch Syndrome and DNA Mismatch Repair: Screening, 

Genetics, Prognosis, and Treatment 



Track(s): Cancer Genetics, Gastrointestinal (Colorectal) Cancer 

Michael J. Hall, MD—Chair 


Controversies in Screening for Lynch Syndrome 


Noralane M. Lindor, MD 

Mayo Clinic 

Update on the Genetics of Lynch Syndrome: New Genes, New Mechanisms, New Insights 

Zsofia Kinga Stadler, MD 


The Importance of DNA Mismatch Repair in the Prognosis and Treatment of Colorectal Cancer 

209 

SATURDAY

SATURDAY 


Nonphysician Providers in Oncology: Examining Collaborative Approaches 

and Next Steps 



Track(s): Practice Management and Information Technology, Patient and Survivor Care, 

Professional Development 

Dean F. Bajorin, MD—Chair 


Elaine L. Towle, CMPE 

Oncology Metrics 

Partnering with Nonphysician Providers in the Community Setting: Results of the Study of 

Collaborative Practice Arrangements Funded by Susan G. Komen for the Cure ® 

Shirley Shuster, APRN, BC, OCN 

Commonwealth Hematology Oncology 

Successful Implementation of the Nonphysician Provider in the Community Setting 

Michael Goldstein, MD 

Beth Israel Deaconess Medical Center/Harvard Medical School 

The Past Will Not Predict the Future of the Oncology Workforce 

210

4:45 PM - 6:00 PM 


Initial Management of Hepatocellular Carcinoma (M08)—Ticketed Session 




Jeff H. Geschwind, MD 


Nonsurgical Strategies for Hepatocellular Carcinoma 

Timothy M. Pawlik, MD, MPH 


What Are the Upfront Surgical Options for Hepatocellular Cancer? 

4:45 PM - 6:00 PM 


Multimodality Approach to Mucosal Melanoma (C05)—Ticketed Session 




Vernon Keith Sondak, MD—Chair 


Role of Surgery for Subtypes of Mucosal Melanoma 

Bryan Burmeister, MBBS 

Princess Alexandra Hospital 

Radiotherapy for Primary and Advanced Mucosal Melanoma 

Leslie Anne Fecher, MD 

University of Pennsylvania Abramson Cancer Center 

Systemic Therapy for Advanced Mucosal Melanoma 


211 

SATURDAY

SUNDAY 

Sunday, June 5, 2011 

7:30 AM - 9:00 AM 

HIGHLIGHTS OF THE DAY SESSION 

Highlights of the Day I Including Clinical Trials Participation Awards 



Track(s): Special Session, General Oncology 

Douglas W. Blayney, MD—Co-Chair 


Daniel F. Hayes, MD—Co-Chair 


7:30 AM 

Clinical Trials Participation Awards 

7:45 AM 

Joel E. Tepper, MD 

University of North Carolina at Chapel Hill School of Medicine 


8:00 AM 

Gottfried E. Konecny, MD 



8:15 AM 

Bruce D. Cheson, MD 

Georgetown University Medical Center 

Lymphoma 

8:30 AM 

Antoni Ribas, MD 

Jonsson Comprehensive Cancer Center, University of California, Los Angeles 


212

8:00 AM - 9:15 AM 


ASCO–American Cancer Society Award and Lecture 




Jamie Von Roenn, MD 


Personalized Medicine: A Comprehensive Definition 


213 

SUNDAY

SUNDAY 


8:00 AM - 9:15 AM 


Diffuse Large B-cell Lymphoma: Present and Future 




Jeremy S. Abramson, MD—Chair 


Treatment of Diffuse Large B-cell Lymphoma in 2011 

Ari Melnick, MD 


Transcript Profiling and Novel Targets in Diffuse Large B-cell Lymphoma 

Christian Gisselbrecht, MD 

Hopital Saint Louis 

Novel Therapies for Diffuse Large B-cell Lymphoma 

Improving Drug Safety: From Toxicity Assessment to Post-marketing 

Surveillance 




David Cella, PhD—Chair 

Robert H. Lurie Comprehensive Cancer Center of Northwestern University 

Using Patient-reported Outcomes to Measure Toxicities in Clinical Trials 

Richard Pazdur, MD 


Improving Drug Safety: The U.S. Food and Drug Administration Past and Future 

Julia Bohlius, MD, MScPH 

Institute for Social and Preventive Medicine, University of Bern 

The Importance of Post-marketing Pharmacovigilance 

Molecular and Pathologic Controversies for Potentially Curative Lung Cancers 




Elisabeth Brambilla, MD—Chair 

CHU Grenoble 

The Histologic Reclassification of Adenocarcinoma of the Lung: Implications for Diagnosis and 

Therapy 

David Harpole Jr., MD 


Genomic Prognostication in Early-stage Non-small Cell Lung Cancer: Past, Present, and Future 

Ethan Dmitrovsky, MD 

Dartmouth Medical School 

MicroRNA Profiling: Clinical Studies in Lung Cancer 

214

Oncology Practice Models: Strategies to Overcome Competitive 

Disadvantages 



Track(s): Practice Management and Information Technology, Professional Development 

Harvey D. Bichkoff, MPH—Chair 

California Cancer Care 

Practice Model for Success: Community-based/Single-specialty 

Denis Brin Hammond, MD 

New Hampshire Oncology-Hematology 

Practice Model for Success: Hospital/University-affiliated 

R. Steven Paulson, MD 

Texas Oncology 

Practice Model for Success: Regional/Multispecialty 

Standard Management of Stage IV Colorectal Cancer: Start and Stop, 

Maintenance, Bevacizumab beyond Progression? (eQuestions Session) 




Axel Grothey, MD—Chair 

Mayo Clinic 

Bevacizumab beyond Progression 

Jeffrey A. Meyerhardt, MD, MPH 


Start and Stop, Maintenance, Chemotherapy Holiday 

Wells A. Messersmith, MD 


Toxicity of Chemotherapy 

The Molecular Biology, New Targets, and Pathways in Head and Neck Cancer 



Track(s): Head and Neck Cancer, Developmental Therapeutics, Tumor Biology 

David Sidransky, MD—Chair 


Genetic and Epigenetic Targets, High-throughput Technology 

Christine H. Chung, MD 


Targeted Pathways from Bench to Clinic 

Ezra E. W. Cohen, MD 


Clinical Advances in Targeted Therapies 


215 

SUNDAY

SUNDAY 


8:00 AM - 9:15 AM 


Bone Protection in Prostate Cancer: Benefits and Pitfalls (M09)—Ticketed 

Session 




Matthew Raymond Smith, MD, PhD 


Bisphosphonates, RANK-ligand Inhibitors, and Other “Bone Protecting” Agents: The Standard 

of Care 

Ian Tannock, MD, PhD 

Princess Margaret Hospital and University of Toronto 

Bone-protective Agents: Do They Have Questionable Efficacy and Unacceptable Cost? 

8:00 AM - 9:15 AM 


Soft-tissue Sarcomas: A Continuing Clinical Conundrum for the Clinician? 





Raphael E. Pollock, MD, PhD—Chair 


Surgery for Soft-tissue Sarcomas 

Thomas F. DeLaney, MD 


Radiation for Soft-tissue Sarcomas 

Rashmi Chugh, MD 


Chemotherapy for Soft-tissue Sarcomas 

216

8:00 AM - 10:00 AM 


Training Program Directors’ Breakfast (Training Program Directors Only) 


Track(s): Special Session, Professional Development 

Thomas H. Davis, MD—Chair 

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center 

ACGME Open Discussion; MATCH Update; How Can ASCO Recognize Teachers? 

Michael P. Kosty, MD 

Scripps Clinic 

Informational Items: WAG, Classic References, QOPI for Fellows 

Frances A. Collichio, MD 

University of North Carolina at Chapel Hill School of Medicine 

ASCO MedOnc In-training Exam Statistics 

Howard R. Terebelo, DO 

Providence Hospital 

My Experience with Education Essentials for Oncology Fellows (EEOF) 


217 

SUNDAY

SUNDAY 


8:00 AM - 11:00 AM 




CME credit: 3 


Eric L. Chang, MD—Co-Chair 


Martin Nicholas, MD, PhD—Co-Chair 


8:00 AM Prognostic factors for response and survival in primary central nervous 

system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG- 

1). (Abstract #2004) 

K. Jahnke, A. Korfel, P. Martus, S. Lokka, R. Moehle, F. Griesinger, M. Rauch, 

A. Roeth, B. Hertenstein, T. Fischer, T. Hundsberger, H. Mergenthaler, 

M. Leithäuser, T. Birnbaum, U. Herrlinger, J. Schubert, A. Florschütz, L. Fischer, 

M. Weller, E. Thiel 

8:15 AM Prognostic factors for chemotherapy-related toxicity in primary central 

nervous system lymphoma (PCNSL) treated with high-dose methotrexate 

(HDMTX) with or without ifosfamide: Results from a German phase III trial 

(G-PCNSL-SG-1). (Abstract #2005) 

P. Martus, K. Jahnke, A. Korfel, T. Rose, L. Fischer, R. Moehle, H. A. Klasen, 

M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, T. Hundsberger, H. Mergenthaler, 

M. Leithäuser, T. Birnbaum, U. Herrlinger, J. Schubert, J. Birkmann, M. Weller, 

E. Thiel 

Discussion 

8:30 AM Lisa Marie DeAngelis, MD (Abstracts #2004–2005) 


8:45 AM RTOG 0525: A randomized phase III trial comparing standard adjuvant 

temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed 


M. R. Gilbert, M. Wang, K. D. Aldape, R. Stupp, M. Hegi, K. A. Jaeckle, 

T. S. Armstrong, J. S. Wefel, M. Won, D. T. Blumenthal, A. Mahajan, 

C. J. Schultz, S. C. Erridge, P. D. Brown, A. Chakravarti, W. J. Curran Jr., 

M. P. Mehta 

9:00 AM Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) 

followed by ENZ maintenance therapy in patients with newly diagnosed 

glioblastoma (GBM) without hypermethylation of the O 6 -methylguanyl 

DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, 

uncontrolled phase II study. (Abstract #2007) 

W. Wick, J. Steinbach, S. E. Combs, M. Platten, C. Hartmann, F. K. Wenz, 

U. Boecker, C. Stoffregen 

Discussion 

9:15 AM Jeffrey S. Abrams, MD (Abstracts #2006–2007) 


9:30 AM Correlation of treatment effects on progression-free survival at 6 months 

(PFS-6) and overall survival (OS) in patients with newly diagnosed 


X. Ye, S. A. Grossman, S. Desideri, S. Piantadosi, for the ABTC CNS Consortium 

Discussion 

9:45 AM Martin J. Van Den Bent, MD (Abstract #2008) 

Daniel den Hoed Cancer Center 

218


10:00 AM Magnetic resonance (MR) perfusion imaging to differentiate early 

progression from pseudoprogression following chemoradiotherapy for 


J. J. Graber, R. J. Young, A. Gupta, A. D. Shah, T. A. Chan, Z. Zhang, W. Shi, 

K. Beal, A. M. Omuro 

10:15 AM A phase II study of daily afatinib (BIBW 2992) with or without temozolomide 

(21/28 days) in the treatment of patients with recurrent glioblastoma. 


D. D. Eisenstat, L. B. Nabors, W. P. Mason, J. R. Perry, W. R. Shapiro, P. Kavan, 

S. Phuphanich, Y. Fu, X. J. Cong, M. Shahidi, D. A. Reardon 

10:30 AM Outcome of infants and young children with newly diagnosed 

medulloblastoma treated on Head Start III protocol. (Abstract #2011) 

G. Dhall, L. Ji, K. Haley, J. P. Grimm, F. H. Gilles, S. L. Gardner, J. C. Allen, 

A. Cornelius, K. R. Pradhan, J. H. Garvin, R. S. Olshefski, J. Hukin, M. Comito, 

S. Goldman, S. J. Thompson, A. Hirt, M. P. Atlas, A. W. Walter, R. Sposto, 

J. L. Finlay 

Discussion 

10:45 AM Marc C. Chamberlain, MD (Abstracts #2009-2011) 


219 

SUNDAY

SUNDAY 


8:00 AM - 12:00 PM 


Genitourinary Cancer 



Brd. 1A Identification of mutations of the SWI/SNF complex gene PBRM1 by exome 

sequencing in renal carcinoma. (Abstract #4571) 

B. T. Teh, I. Varela, P. Tarpey, K. Raine, D. Huang, C. Ong, K. A. Furge, 

P. J. Campbell, M. R. Stratton, P. Futreal 

Brd. 1B The asociation between the number of nodes removed at retroperitoneal 

lymph node dissection and overall- and cancer-specific survival in patients 

with nonseminomatous germ cell tumor. (Abstract #4572) 

D. Lewinshtein, A. Schatz, C. R. Porter 

Brd. 1C CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 

inhibition in prostate cancer. (Abstract #4573) 

F. Lamoureux, M. Yin, A. Zoubeidi, M. E. Gleave 

Brd. 1D Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and 

prednisone (P) in patients (pts) with metastatic castration-resistant prostate 

cancer (mCRPC). (Abstract #4574) 

X. Huang, Y. M. Ning, M. Mulquin, R. A. Madan, J. L. Gulley, P. G. Kluetz, 

D. Adelberg, P. M. Arlen, H. L. Parnes, B. Adesunloye, S. M. Steinberg, 

J. J. Wright, J. B. Trepel, C. Chen, C. Bassim, A. B. Apolo, W. D. Figg, W. L. Dahut 

Brd. 1E A phase II trial of dasatinib in subjects with hormone-refractory prostate 

cancer previously treated with chemotherapy. (Abstract #4575) 

P. Twardowski, C. Chen, A. S. Kraft, G. S. Chatta, E. Alexson, M. Mitsuhashi, 

W. Ye, M. Lilly 

Brd. 1F The association of PTEN loss on outcome in patients with early high-risk 

prostate cancer (CaP) treated with adjuvant docetaxel following radical 

prostatectomy (RP). (Abstract #4576) 

D. Keizman, Z. Zhang, V. J. Sinibaldi, A. DeMarzo, B. Gurel, T. Lotan, J. Hicks, 

E. Rosenbaum, E. S. Antonarakis, J. J. Kim, M. A. Carducci, M. A. Eisenberger 

Brd. 1G An evaluation of blood mRNA expression array signatures derived from 

unsupervised analyses in the identification of prostate cancers with poor 


D. Olmos, J. Clark, D. Brewer, L. Barwell, G. Attard, A. H. Reid, S. K. Sandhu, 

A. Zivi, D. Bianchini, N. Babu Oomen, E. Thompson, L. R. Molife, S. B. Kaye, 

C. Parker, C. Cooper, R. J. Jones, J. S. De Bono 

Brd. 2A The effect of tobacco exposure in renal cell carcinoma (RCC) overall and 

cancer-specific survival. (Abstract #4578) 

N. Kroeger, T. Klatte, F. D. Birkhaeuser, E. N. Rampersaud, D. B. Seligson, 

N. Zomorodian, F. F. Kabbinavar, A. S. Belldegrun, A. J. Pantuck 

Brd. 2B Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic 

germ cell tumors (GCT). (Abstract #4579) 

A. Jain, M. J. Brames, D. J. Vaughn, L. H. Einhorn 

Brd. 2C Phase III trial comparing long-term versus short-term androgen deprivation 

combined with high-dose radiotherapy for localized prostate cancer: GICOR 

protocol DART01/05. (Abstract #4580) 

A. Zapatero, A. Guerrero, X. Maldonado, A. Alvarez, C. González San Segundo, 

A. Cabeza, V. Macías, F. Casas, A. Pedro-Olivé, S. Villa, A. Boladeras, 

M. Vazquez de La Torre, C. Martin de Vidales, F. A. Calvo, GICOR (Grupo 

Investigacion Clinica Oncologia Radioterapica) 

Brd. 2D Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in 

prevention of skeletal-related events (SREs) in castration-resistant prostate 

cancer metastatic to the bone (mCRPC). (Abstract #4581) 

S. J. Snedecor, J. A. Carter, S. Kaura, M. Botteman 

220


Brd. 2E Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 

cycles in men with metastatic castration-resistant prostate cancer (mCRPC). 


G. R. Pond, A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, W. R. Berry, 

R. De Wit, M. A. Eisenberger, I. Tannock, G. Sonpavde 

Brd. 2F Association of progression-free survival (PFS) at 2 or 3 years with overall 

survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation 

of individual patient data (IPD) from seven randomized trials comparing local 

therapy with or without neoadjuvant chemotherapy (NC). (Abstract #4583) 

G. J. Chen, G. Sonpavde, C. L. Vale, D. Fisher, T. Powles, Advanced Bladder 

Cancer Meta-analysis Collaborators (ABCMAC) 

Brd. 2G The prognostic significance of LDH levels in patients with 

relapsed/refractory seminoma and their predictive value of the new 

international prognostic score. (Abstract #4584) 

T. Powles, C. Mollevi, A. Kramar, A. Lorch, J. Beyer, for the International 

Prognostic Factors Study Group (IPFSG) 

Brd. 3A The interval to biochemical failure versus biochemical failure as predictors 

for cause-specific and overall survival following dose-escalated external 

beam radiation therapy for prostate cancer. (Abstract #4585) 

N. S. Kapadia, F. Y. Feng, K. B. Olson, H. M. Sandler, D. A. Hamstra 

Brd. 3B Prognostic factors in second-line treatment of urothelial cancers with 

gemcitabine and paclitaxel: German Association of Urological Oncology 

(AUO) trial AB 20/99. (Abstract #4586) 

G. Niegisch, R. Fimmers, R. Siener, S. Park, P. Albers, German Association of 

Urological Oncology (AUO) 

Brd. 3D Everolimus as first-line therapy in nonrapidly progressive metastatic 

castration-resistant prostate cancer (mCRPC): A multicenter phase II trial 

(SAKK 08/08). (Abstract #4588) 

A. Templeton, C. Rothermundt, R. Cathomas, D. Baertschi, C. Droege, 

O. Gautschi, M. M. Borner, E. Fechter, F. Stenner, R. C. Winterhalder, B. Mueller, 

V. Dutoit, P. Dietrich, R. Schiess, P. Wild, G. N. Thalmann, D. Klingbiel, 

S. Gillessen 

Brd. 3E Increased risk of overall and cardiovascular mortality after radical 

nephrectomy for renal cell carcinoma less than or equal to 2 cm. (Abstract 

#4589) 

M. Kates, G. M. Badalato, N. Sadeghi, M. S. Pitman, J. M. McKiernan 

Brd. 3F An analysis of STAT3 polymorphism on outcomes of interferon-alpha 

treatment in patients with metastatic renal cell carcinoma. (Abstract #4590) 

M. Eto, T. Kamba, H. Miyake, M. Fujisawa, K. Yoshida, H. Uemura, T. Tsukamoto, 

Y. Katsuoka, A. Matsubara, K. Nishimura, T. Nakamura, O. Ogawa, S. Naito 

Brd. 3G Progression-free survival (PFS) of first-line VEGF-targeted therapy as a 

prognostic parameter for overall survival (OS) in patients with metastatic 

renal cell carcinoma (mRCC). (Abstract #4591) 

C. Seidel, M. Fenner, C. W. Reuter, A. Ganser, V. Gruenwald 

Brd. 3H Interim results of a randomized phase II study with window-design to 

evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) 

LY2181308 in combination with docetaxel for first-line treatment of castrateresistant 

prostate cancer (CRPC). (Abstract #4592) 

P. J. Wiechno, P. Chlosta, J. Smok-Kalwat, J. Pikilel, D. H. Henry, 

D. F. Christianson, B. G. Somer, B. Mellado, I. Duran, D. E. Castellano, S. Callies, 

V. Andre, K. Hurt, M. M. Lahn, M. Stöckle, C. Reuter, B. Heinrich 

Brd. 4A Impact of carboplatin plus weekly docetaxel as salvage chemotherapy in 

docetaxel-resistant and castration-resistant prostate cancer (DRPC) on free 

testosterone levels. (Abstract #4593) 

C. W. Reuter, M. A. Morgan, M. Fenner, P. Ivanyi, V. Gruenwald, A. Ganser 

221 

SUNDAY

SUNDAY 


Brd. 4B Prognositic value of suppressed markers of bone turnover (BTO) after 6 

months of androgen deprivation therapy (ADT) in prostate cancer. (Abstract 

#4594) 

J. Sharma, C. T. Yiannoutsos, N. M. Hahn, C. Sweeney 

Brd. 4C Risk of high-grade liver toxicity with pazopanib in patients with cancer: A 

meta-analysis. (Abstract #4595) 

S. Kapadia, S. Hapani, S. Wu 

Brd. 4D Observation versus adjuvant radiation or chemotherapy in the management 

of stage I seminoma. (Abstract #4596) 

M. S. Soper, J. R. Hastings, M. Tome, K. Lodin 

Brd. 4E LH-receptor polymorphisms and response to androgen deprivation therapy 

in prostate cancer. (Abstract #4597) 

S. V. Liu, T. B. Dorff, Q. Wang, S. Xiong, E. Thara, M. Keng, S. A. Ingles, 

J. K. Pinski 

Brd. 4F Cytokines’ profiles to predict chemotherapy outcome in castration-resistant 

prostate cancer (CRPC). (Abstract #4598) 

K. L. Mahon, M. D. Chatfield, M. Lee-Ng, S. N. Breit, D. A. Brown, M. P. Molloy, 

G. M. Marx, N. Pavlakis, M. J. Boyer, M. R. Stockler, R. Wykes, S. M. Henshall, 

R. L. Sutherland, L. Horvath 

Brd. 4G A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone, 

and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory, 

and angiostatic treatment in patients (pts) with castration-refractory prostate 

cancer (CRPC) . (Abstract #4599) 

A. Reichle, M. Vogelhuber, S. Feyerabend, T. Suedhoff, M. Schulze, J. Hubner, 

R. Oberneder, M. Baier, A. Ruebel, K. Birkholz, A. Bakhshandeh-Bath, 

R. Andreesen 

Brd. 4H Sorafenib and sunitinib in renal cell cancer: A study based on register data. 


A. E. Ambring, U. K. Stierner, A. S. Oden, I. N. Bjorholt 

Brd. 5A Final results of the international, expanded-access program of everolimus in 

patients with advanced renal cell carcinoma who progress after prior 

vascular endothelial growth factor receptor–tyrosine kinase inhibitor 

(VEGFr-TKI) therapy. (Abstract #4601) 

V. Grünwald, P. I. Karakiewicz, S. E. Bavbek, K. Miller, J. H. Machiels, S. Lee, 

J. M. Larkin, P. Bono, S. Y. Rha, D. E. Castellano, C. U. Blank, J. J. Knox, 

R. Hawkins, R. R. Yuan, M. Rosamilia, J. L. Booth, I. Bodrogi, on behalf of the 

REACT Study Group 

Brd. 5B Quantifying the effect of everolimus on both tumor growth and new 

metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor 

model of the RECORD-1 phase III trial. (Abstract #4602^) 

A. M. Stein, A. Carter, N. Hollaender, R. J. Motzer, C. Sarr 

Brd. 5C A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential 

plasma epigenetic marker of response to chemotherapy and prognosis in 

men with castration-resistant prostate cancer (CRPC). (Abstract #4603) 

L. Horvath, K. L. Mahon, W. Qu, J. Devaney, M. D. Chatfield, C. Paul, R. Wykes, 

M. J. Boyer, M. R. Stockler, G. M. Marx, R. L. Sutherland, S. J. Clark 

Brd. 5D A pooled analysis of the efficacy and safety of sunitinib in elderly patients 

(pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4604) 

T. E. Hutson, R. M. Bukowski, B. I. Rini, M. E. Gore, J. M. Larkin, R. A. Figlin, 

C. H. Barrios, B. Escudier, X. Lin, K. D. Fly, B. Martell, E. Matczak, R. J. Motzer 

Brd. 5E Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in 

combination with docetaxel-prednisone regimen for patients (pts) with 

castration-resistant prostate cancer (CRPC). (Abstract #4605) 

J. Medioni, J. Ferrero, G. Deplanque, T. Maurina, J. P. Rodier, E. Raymond, 

J. Allyon, S. Renaux, J. Dufour-Lamartinie, S. Oudard 

222


Brd. 5F Final results of a phase II study of everolimus (RAD001) in metastatic 

transitional cell carcinoma (TCC) of the urothelium. (Abstract #4606) 

M. I. Milowsky, A. M. Regazzi, I. R. Garcia-Grossman, A. Trout, A. Flaherty, 

S. Gerst, H. Al-Ahmadie, I. Ostrovnaya, D. F. Bajorin 

Brd. 5G Does enrollment setting influence patient attributes and outcomes in RTOG 

prostate cancer trials? (Abstract #4607) 

W. Lee, J. Dignam, D. Bruner, J. A. Efstathiou, Y. Yan, G. E. Hanks, M. Roach III, 

M. V. Pilepich, H. M. Sandler 

Brd. 5H Late toxicity rates following definitive radiotherapy for prostate cancer: A 

meta-analysis revealing interactions between dose and technique. (Abstract 

#4608) 

N. Ohri, W. Shi, A. Dicker, T. N. Showalter 

Brd. 6A Efficacy and safety of intrapatient dose escalation of sorafenib as first-line 

treatment for metastatic renal cell carcinoma (mRCC). (Abstract #4609^) 

M. E. Gore, R. J. Jones, A. Ravaud, M. Kuczyk, T. Demkow, A. Bearz, 

N. Laferriere, U. P. Strauss, C. Porta 

Brd. 6B Analysis of the relationship between Karnofsky performance status (KPS) 

and tumor response in the RECORD-1 phase III trial of everolimus in patients 

with advanced renal cell carcinoma (RCC). (Abstract #4610) 

C. Porta, B. Escudier, T. E. Hutson, R. A. Figlin, E. Calvo, V. Grünwald, S. Osanto, 

A. Ravaud, A. Panneerselvam, J. J. Knox, R. J. Motzer 

Brd. 6C Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide 

synthase (NOS3) and vascular endothelial growth factor (VEGF) and its 

relationship to sunitinib-induced hypertension. (Abstract #4611) 

A. A. van der Veldt, K. Eechoute, S. Oosting, M. H. Kappers, J. B. Haanen, 

A. K. Reyners, H. Gelderblom, H. Guchelaar, C. Van Herpen, E. Boven, 

R. Mathijssen 

Brd. 6D Tumor marker rise during second course high-dose chemotherapy in 

recurrent testicular cancer: Outcome analysis. (Abstract #4612) 

M. Pant-Purohit, M. J. Brames, R. Abonour, L. H. Einhorn 

Brd. 6E Final results of a risk-adapted policy of adjuvant chemotherapy (ACT) in 

patients with invasive bladder carcinoma (IBC). (Abstract #4613) 

J. Arranz Arija, Y. Jerez Gilarranz, A. Soria Lovelle, C. López López, 

P. Sabin Dominguez, M. Riesco, J. Adeva Alfonso, D. Urosa Velasco, 

E. López Juárez, R. González Beca, M. Martin 

Brd. 6F The ZOTECT study: Effect of intravenous zoledronic acid on bone 

metabolism in patients with metastatic bone disease in prostate cancer (PC) 

and breast cancer (BC). (Abstract #4614) 

P. Hadji, M. Ziller, T. Maurer, M. Muth, A. Ruebel, C. May, K. Birkholz, 

J. E. Gschwend 

Brd. 6G Long-term response to sunitinib for metastatic renal cell carcinoma (mRCC) 

patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center. 


A. M. Molina, X. Jia, M. S. Ginsberg, S. Velasco, D. R. Feldman, S. Patil, 

R. J. Motzer 

Brd. 6H Does absolute neutrophil count predict adverse tumor grade in African 

American men with prostate cancer? (Abstract #4616) 

N. Sadeghi, G. M. Badalato, G. W. Hruby, V. R. Grann, J. M. McKiernan 

Brd. 7A Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel 

(TAX) in previously treated metastatic (MET) urothelial cancer. (Abstract 

#4617) 

Y. Wong, S. Litwin, D. J. Vaughn, E. R. Plimack, W. Song, J. W. Lee, 

M. B. Dabrow, M. Brody, H. Tuttle, G. R. Hudes 

Brd. 7B Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy 

for patients with relapsed/refractory urothelial cancer (UC). (Abstract #4618) 

A. Necchi, N. Nicolai, C. Ortega, T. Sava, C. Messina, C. Sacco, F. Crippa, 

C. Morosi, R. Lanocita, M. Colecchia, L. Mariani, N. Zaffaroni, R. Salvioni 

223 

SUNDAY

SUNDAY 


Brd. 7C Presurgical docetaxel (Doc) and androgen deprivation therapy (ADT) in 

lymph node-positive prostate cancer (PCa). (Abstract #4619) 

L. C. Pagliaro, A. J. Zurita, J. C. Araujo, J. F. Ward, J. W. Davis, C. A. Pettaway, 

S. Tu, J. Kim, P. Dieringer, C. Logothetis, L. L. Pisters 

Brd. 7D Alkaline phosphatase (ALP) normalization and overall survival in patients 

with bone metastases from castration-resistant prostate cancer (CRPC) 

treated with radium-223. (Abstract #4620^) 

S. Nilsson, C. G. O’Bryan-Tear, B. Bolstad, A. Lokna, C. C. Parker 

Brd. 7E The association of pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) 

with outcome of sunitinib tx in patients (pts) with metastatic renal cell 

carcinoma (mRCC). (Abstract #4621) 

P. Huang, M. A. Carducci, M. A. Eisenberger, R. Pili, J. J. Kim, E. S. Antonarakis, 

H. J. Hammers, D. Keizman 

Brd. 7F Phase II trial of everolimus monotherapy in the palliative treatment of 

patients with metastatic transitional cell carcinoma (TCC) after failure of 

platinum-based therapy: Activity and biomarkers. . (Abstract #4622) 

E. Seront, B. Sautois, S. Rottey, L. A. D’Hondt, J. Canon, J. Vandenbulcke, 

N. Whenham, J. Goeminne, O. Feron, J. H. Machiels 

Brd. 7G Thioredoxin reductase RNA levels in expressed prostatic secretions as 

prognostic indicators of prostate cancer. (Abstract #4623) 

J. A. Linehan, R. Torrey, J. P. Clark, G. Babilonia, D. D. Smith, K. Chan, C. Lau, 

D. Y. Josephson, M. H. Kawachi, T. G. Wilson, S. S. Smith 

Brd. 7H A multicenter, randomized phase II study of the second-line maximum 

androgen blockade with an alternative antiandrogen combined with tegafururacil 

(UFT) for prostate cancer with relapse after initial hormonal therapy. 


M. Takahashi, R. Kawabata, A. Kawano, Y. Murakami, Y. Sutou, T. Inai, 

S. Akazawa, T. Hamao, H. Hayashi, T. Fukawa, M. Takemura, Y. Yamamoto, 

K. Yamaguchi, H. Nakatsuji, T. Kishimoto, H. Izaki, T. Fukumori, H. Kanayama 

Brd. 8A Phase II trial of sunitinib in renal cell cancer with untreated brain metastases. 


C. Chevreau, A. Ravaud, B. Escudier, A. Caty, R. Delva, F. Rolland, S. Oudard, 

R. Herve, E. Blanc, C. Ferlay, N. Lignon, S. Negrier, French Group on Renal 

Cancer 

Brd. 8B Analysis of blood-derived circulating microvesicles for microRNA 

biomarkers of metastatic and nonmetastatic prostate cancer. (Abstract 

#4626) 

F. C. Hamdy, R. J. Bryant, T. L. Pawlowski, G. Marsden, S. Smith, R. Vessella, 

C. D. Kuslich 

Brd. 8C Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the 

assessment of vascular response to sunitinib in renal cell carcinoma (RCC). 


G. A. Bjarnason, R. Williams, J. M. Hudson, C. Bailey, C. R. Lee, B. A. Lloyd, 

S. Kandel, J. M. Ebos, A. Kiss, R. S. Kerbel, L. M. Milot, M. Atri, G. J. Stanisz, 

P. Burns 

Brd. 8D Randomized phase II study of danusertib (D) in second-line metastatic 


J. P. Bleuse, H. J. Meulenbeld, E. M. Vinci, E. Raymond, G. Vitali, A. Santoro, 

L. Dogliotti, R. Berardi, F. Cappuzzo, S. T. Tagawa, C. N. Sternberg, M. Jannuzzo, 

M. Mariani, A. Petroccione, R. De Wit 

Brd. 8E Sorafenib and everolimus (RAD001) in the treatment of patients with 

advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research 

Institute phase I/II trial. (Abstract #4629) 

D. M. Waterhouse, W. C. Penley, C. D. Webb, F. A. Greco, H. A. Burris III, 

J. D. Hainsworth 

224


Brd. 8F Observation prior to systemic therapy in patients with metastatic renal cell 

carcinoma in the kinase inhibitor era. (Abstract #4630) 

R. A. Fisher, A. Pender, K. Thillai, S. Chowdhury, L. M. Pickering, S. St. Rose, 

M. E. Gore, J. M. Larkin 

Brd. 8G Association of Raynaud’s phenomenon after bleomycin etoposide cisplatin 

(BEP) chemotherapy for testicular cancer (TC) with accelerated 

atherosclerosis. (Abstract #4631) 

R. Altena, H. Boer, C. Meijer, J. Nuver, A. M. van Roon, N. Zwart, E. De Vries, 

J. D. Lefrandt, A. J. Smit, J. A. Gietema 

Brd. 8H Relationship of T lymphocytes, T regulatory cells, and B lymphocytes to 

clinical outcome in prostate cancer. (Abstract #4632) 

M. Trepel, A. Flammiger, L. Weisbach, T. Schlomm, H. Huland, S. Minner, 

P. Tennstaedt, C. Bokemeyer, G. Sauter 

Brd. 9A Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients 

treated with pazopanib in prospective clinical trials. (Abstract #4633) 

P. Wolter, L. McCann, C. N. Sternberg, T. E. Hutson, F. Mehmud, L. N. Pandite, 

P. Schoffski 

Brd. 9B Effect of sunitinib (SU) administration on post-treatment survival in patients 

with metastatic renal cell carcinoma (mRCC) treated on the upfront 

randomized phase III trial of sunitinib or interferon alfa (IFN). (Abstract #4634) 

K. B. Blagoev, J. Wilkerson, W. D. Stein, R. J. Motzer, S. E. Bates, A. T. Fojo 

Brd. 9C The PCCTC imaging data capture toolset: An analysis of its impact on 

prostate cancer clinical trial accuracy and workload. (Abstract #4635) 

E. R. Dennis, J. J. Fox, S. M. Larson, J. S. Farrelly, L. H. Schwartz, 

H. Schöder, E. C. Haupt, L. S. Borwick, H. I. Scher, M. J. Morris 

Brd. 9D Quantifying the tradeoffs of active surveillance for low-risk prostate cancer: 

A clinical decision analysis. (Abstract #4636) 

D. Liu, H. P. Lehmann, K. D. Frick, B. Carter 

Brd. 9E Prevalence of prostate cancer (PC) clinical states (CS) in the United States: 

Estimates using a dynamic progression model. (Abstract #4637) 

K. Solo, M. Mehra, R. Dhawan, J. Valant, H. I. Scher 

Brd. 9F A phase II multicenter evaluation of ARQ 197 monotherapy in patients with 

relapsed or refractory germ cell tumors (GCTs). (Abstract #4638) 

D. R. Feldman, L. H. Einhorn, D. I. Quinn, A. Horwich, Y. Loriot, J. K. Joffe, 

D. J. Vaughn, A. Flechon, J. Hajdenberg, A. U. Pande, K. Liu, 

I. Gorbatchevsky, R. J. Motzer 

Brd. 9G Pilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advanced 

squamous cell carcinoma (SCC) of the penis. (Abstract #4639) 

R. Salvioni, N. Nicolai, L. Piva, M. Catanzaro, T. Torelli, D. Biasoni, S. Stagni, 

A. Milani, A. Necchi 

Brd. 9H Impact of 24 months of androgen deprivation therapy (ADT) on physical 

function in men with nonmetastatic prostate cancer. (Abstract #4640) 

S. M. Alibhai, H. Breunis, N. Timilshina, S. Duff Canning, N. Fleshner, M. Krahn, 

I. Tannock, G. A. Tomlinson, P. R. Warde, G. Naglie 

Brd. 10A The prognostic significance of prenephrectomy absolute lymphocyte count 

in clear cell renal cell carcinoma. (Abstract #4641) 

S. Saroha, R. Uzzo, G. R. Hudes, E. R. Plimack, K. Ruth, T. I. Al-Saleem 

Brd. 10B A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in 

patients (pts) with high-risk localized prostate cancer. (Abstract #4642) 

W. K. Oh, M. D. Galsky, M. Barry, F. Fennessey, J. P. Richie, J. H. Hayes, 

R. S. Bhatt, M. Taplin, P. G. Febbo, R. W. Ross 

Brd. 10C Randomized phase II trial evaluating different schedules of zoledronic acid 

administration on bone mineral density in patients with stage D prostate 

cancer beginning androgen deprivation. (Abstract #4643) 

J. M. Lang, J. C. Eickhoff, N. C. Binkley, M. J. Staab, G. Liu, G. Wilding, 

D. G. McNeel 

225 

SUNDAY

SUNDAY 


Brd. 10D Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for 

bladder cancer: A population-based study. (Abstract #4644) 

C. M. Booth, D. R. Siemens, I. Tannock, Y. Peng, G. Li, W. J. Mackillop 

Brd. 10E A case-control study examining associations of germ-line oxidative DNA 

repair single-nucleotide polymorphisms (SNPs) with lethal prostate cancer 

(PCa) risk. (Abstract #4645) 

N. M. Hahn, J. Jung, J. Dantzer, S. Philips, Y. R. Patel, K. A. Carr, Y. Mohammadi, 

D. Magjuka, C. Camp, M. Bolden, E. F. Dropcho, J. A. Knight II, M. L. Moore, 

A. D. Reed, M. J. Waddell, J. E. Klaunig, L. Li, C. Sweeney, T. C. Skaar 

Brd. 10F Efficacy and safety of sunitinib in patients with metastatic renal cell 

carcinoma on hemodialysis. (Abstract #4646) 

J. Casper, D. Goebel, V. Gruenwald, A. Flörcken, D. Mueller, K. Toussaint, 

B. Metzner 

Brd. 10G Variation in sex steroid methyl transferases associated with androgen 

deprivation therapy (ADT) efficacy in advanced prostate cancer. (Abstract 

#4647) 

M. Kohli, D. W. Mahoney, H. S. Chai, D. W. Hillman, D. R. Rider, B. A. Costello, 

J. R. Cerhan 

Brd. 10H Quality-of-life assessment in a randomized, double-blind study of sipuleucel- 

T in men with androgen-dependent prostate cancer. (Abstract #4648) 

T. M. Beer, P. F. Schellhammer, J. M. Corman, L. M. Glode, S. Hall, Y. Xu, 

M. W. Frohlich, D. F. Penson 

Brd. 11A A randomized phase II study of bone-targeted therapy in advanced 

androgen-dependent prostate cancer. (Abstract #4649) 

M. A. Bilen, D. Liu, P. Mathew, L. C. Pagliaro, C. Logothetis, J. C. Araujo, 

A. Aparicio, P. G. Corn, J. Hajdenberg, S. R. Dakhil, S. Tu 

Brd. 11B Prostate-specific membrane antigen antibody–drug conjugate (PSMA ADC): 

A phase I trial in taxane-refractory prostate cancer. (Abstract #4650) 

D. P. Petrylak, P. W. Kantoff, R. C. Frank, N. D. Shore, Y. Rotshteyn, 

R. J. Israel, W. C. Olson, T. Ramakrishna, S. Morris 

Brd. 11C Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by 

FISH and immunohistochemistry to address intra- and intertissue 

heterogeneity and disease progression. (Abstract #4651) 

A. M. Joshua, A. Evans, J. Squire, M. Yoshimoto, O. Ludkovski, S. Tan, A. Dobi, 

B. Furusato, G. Petrovics, S. Srivastava, I. Sesterhenn 

Brd. 11D 9q32-q33.1 amplification as a prognostic factor for overall survival in 

metastatic germ cell tumors. (Abstract #4652) 

J. M. Piulats, A. Vidal, M. Nadal, A. Pisa, J. R. Germa-Lluch, E. Condom, 

A. Villanueva, X. Garcia del Muro 

Brd. 11E Use of P63 expression to define a lethal subset of muscle-invasive bladder 


W. Choi, J. B. Shah, M. Tran, R. S. Svatek, L. Marquis, I. C. Lee, D. Yu, L. Adam, 

J. E. Bondaruk, S. Wen, Y. Shen, C. P. Dinney, B. Czerniak, D. J. McConkey, 

A. O. Siefker-Radtke 

Brd. 11F Lymphovascular invasion in clinical stage I testicular nonseminoma: 

Potential marker of more aggressive relapses and implications for active 

surveillance. (Abstract #4654) 

C. R. Nichols, S. Daneshmand, S. Tyldesley, K. N. Chi, N. Murray, A. I. So, 

P. C. Black, B. M. Hayes-Lattin, C. K. Kollmannsberger 

Brd. 11G Detection of metastatic disease as a leading cause of screening failure in a 

phase III trial of zibotentan versus placebo in patients with nonmetastatic 


E. Y. Yu, F. E. Nathan, C. S. Higano 

226


Brd. 11H Clinical features of germ cell tumors (GCT) in men age 50 or older: 

Successful outcome and tolerability to chemotherapy for advanced disease. 


M. H. Voss, E. P. Jacobsen, S. Patil, S. Turkula, X. Jia, J. Sheinfeld, D. F. Bajorin, 

G. J. Bosl, R. J. Motzer, D. R. Feldman 

Brd. 12A Follow-up study of chemotherapy plus hormone therapy for biochemical 

relapse after definitive local therapy for prostate cancer. (Abstract #4657) 

M. Nakabayashi, W. Xie, G. Buckle, G. Bubley, M. S. Ernstoff, W. V. Walsh, 

D. Morganstern, P. W. Kantoff, M. M. Regan, M. Taplin 

Brd. 12B Prostate-specific membrane antigen (PSMA)–targeted imaging of metastatic 

prostate cancer (PCa) via small molecule inhibitors: Comparison to bone 

scan, CT/MRI, and 111 In capromab. (Abstract #4658) 

R. Coleman, J. A. Barrett, A. Hussain, K. M. Slawin, T. Armor, N. D. LaFrance, 

J. W. Babich 

Brd. 12C Pazopanib in patients with metastatic renal cell carcinoma previously treated 

with sunitinib or bevacizumab: A Sarah Cannon Research Institute phase II 


J. A. Reeves, D. R. Spigel, D. B. Daniel, E. K. Friedman, H. A. Burris III, 

J. D. Hainsworth 

Brd. 12D Comparison of two major prognostic models for patients with metastatic 

renal cell carcinoma treated in the contemporary era of targeted therapies. 


M. Crepel, B. J. Escudier, J. H. Machiels, M. D. Staehler, A. Ravaud, G. Gravis, 

F. Joly, C. Chevreau, L. Zini, H. Lang, L. Salomon, P. Bigot Jr., J. Rigaud, 

J. Patard Sr. 

Brd. 12E Time to disease-related pain after sipuleucel-T in asymptomatic patients with 

metastatic castrate-resistant prostate cancer (mCRPC): Results from three 

randomized phase III trials. (Abstract #4661) 

E. J. Small, C. S. Higano, P. W. Kantoff, J. B. Whitmore, M. W. Frohlich, 

D. P. Petrylak 

Brd. 12F Phase I/II study of neoadjuvant docetaxel plus intensity-modulated 

radiotherapy (IMRT) prior to surgery for high-risk prostate cancer. (Abstract 

#4662) 

M. Garzotto, A. Hung, T. M. Beer, J. J. Alumkal, J. N. Graff, P. E. Farris, 

J. F. Flamiatos, S. Mongoue-Tchokote, S. N. Carter 

Brd. 12G Quantitative gene expression in primary and highest Gleason pattern cancer 

specimens identifies genes associated with clinical recurrence and prostate 

cancer–specific survival after radical prostatectomy. (Abstract #4663) 

E. A. Klein, S. M. Falzarano, T. Maddala, M. Lee, R. J. Pelham, W. F. Novotny, 

S. Shak, C. Magi-Galluzzi 

Brd. 12H Investigator-initiated pilot study of sunitinib malate in patients with newly 

diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF 

Prostate Cancer Clinical Trials Consortium. (Abstract #4664) 

D. J. George, S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, 

S. E. Yenser Wood, A. J. Armstrong, R. J. Varley, J. Madden, J. W. Moul 

Brd. 13A Does prostate brachytherapy that avoids the central zone prevent long-term 

urinary incontinence? Five-year results of a multi-institutional comparative 

cohort study. (Abstract #4665) 

J. A. Talcott, A. L. Zietman, I. D. Kaplan, J. A. Clark, A. V. D’Amico 

Brd. 13B Characterization of the anaplastic prostate carcinomas: A prospective 

two-stage phase II trial of frontline carboplatin and docetaxel (CD) and 

salvage etoposide and cisplatin (EP). (Abstract #4666) 

A. Aparicio, A. L. Harzstark, E. Lin, P. G. Corn, J. C. Araujo, S. Tu, L. C. Pagliaro, 

R. E. Millikan, W. Arap, J. Kim, C. J. Ryan, A. J. Zurita, N. M. Tannir, A. M. Lin, 

E. J. Small, P. Mathew, D. M. Jones, P. Troncoso, P. F. Thall, C. Logothetis, 

Prostate Cancer Clinical Trials Consortium 

227 

SUNDAY

SUNDAY 


Brd. 13C Agent Orange as a risk factor for high-grade prostate cancer detected on 

initial prostate biopsy. (Abstract #4667) 

N. J. Ansbaugh, J. Shannon, M. Mori, P. E. Farris, L. Collins, M. Garzotto 

Brd. 13D Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in 

metastatic renal cell carcinoma (mRCC). (Abstract #4668) 

A. Finelli, A. M. Horgan, A. Evans, T. Kim, K. Durrant, S. Yap, C. A. Cassol, 

W. Dubinski, N. Fleshner, M. A. Jewett, A. M. Joshua, S. S. Sridhar, 

A. Zlotta, J. J. Knox 

11 

Brd. 13E C-choline-PET/CT (C-PET) versus transrectal ultrasound–guided prostate 

biopsies (TRUS-BP) to diagnose locally recurrent prostate cancer (PCA) 

following radiation therapy (RT). (Abstract #4669) 

A. Heidenreich, B. Brehmer, R. Epplen, D. J. Pfister, EURO Prostate Center 

Aachen 

Brd. 13F Results of a phase I/II clinical trial of BPX-101, a novel drug-activated 

dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer 

(mCRPC). (Abstract #4670) 

K. M. Slawin, G. Sonpavde, J. D. McMannis, Y. Bai, M. Seethammagari, J. M. Bull, 

V. Hawkins, T. Dancsak, N. Lapteva, J. M. Levitt, D. M. Spencer 

228

8:00 AM - 12:00 PM 






Brd. 14A A phase I/II study of cisplatin and radiation in combination with sorafenib in 

cervical cancer: Evaluation of biomarkers. (Abstract #5037) 

C. A. Townsley, M. Milosevic, M. A. Haider, H. Mackay, I. Yeung, S. Kim, W. Levin, 

L. Manchul, S. Bindra, K. MacAlpine, L. M. Tinker, L. Wang, J. Quintos, 

A. W. Fyles, A. M. Oza 

Brd. 14B Response rate and toxicity of primary concomitant radiochemotherapy in 

locally advanced cervical cancer: Results of an open prospective, 

multicenter phase II study of the NOGGO. (Abstract #5038) 

A. Mustea, A. Belau, J. Sehouli, K. Drzewiecki, M. H. Eichbaum, K. Bartz, 

E. Angelidou, S. Saegner, M. O. Langenbruch, P. Ledwon, M. Zygmunt, 

G. Koehler, D. Koensgen, North-Eastern Society of Gynaecological Oncology 

Brd. 14C Expression of embryonic stem cell factor SOX2 in serous ovarian 

carcinomas. (Abstract #5039) 

T. N. Fehm, D. Pham, V. Scheible, C. Lengerke, S. Perner, H. Neubauer, 

A. Staebler 

Brd. 14D Akt-mTOR pathway in uterine leiomyosarcoma. (Abstract #5040) 

G. Garg, A. Short, J. Liu, A. R. Munkarah, R. Morris, R. Ali-Fehmi 

Brd. 14E Treatment of cervical intraepithelial neoplasia with topical imiquimod. 


S. Polterauer, C. Grimm, C. Natter, J. Rahhal, L. Hefler, A. Reinthaller, P. Speiser 

Brd. 14F MRI prior to systematic lymphadenectomy in patients with locally advanced 

cervical cancer. (Abstract #5042) 

M. Gold, Z. Zhang, H. Marques, J. Gorelick, L. M. Landrum, R. S. Mannel, 

L. T. Chuang, J. Q. Yu, C. K. McCourt, M. Harisinghani, A. Sohaib, D. Koh, 

S. Raman, M. S. Gee, H. Choi, M. Atri 

Brd. 14G Treatment and outcome of patients with invasive extramammary Paget’s 


A. Karam, O. Dorigo 

Brd. 14H Confirmatory factor analysis of the sexual adjustment and body image scale 

in women with a diagnosis of gynecologic cancer. (Abstract #5044) 

S. E. Ferguson, C. Massey, C. Classen, M. Wegener, N. Quartey, M. Pulandiran, 

D. Wiljer, S. Urowitz 

Brd. 15A PRECEDENT: A randomized phase II trial comparing EC145 and pegylated 

liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects 

with platinum-resistant ovarian cancer. (Abstract #5045) 

R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris, 

E. A. Sausville, E. Kutarska, S. A. Ghamande, N. Y. Gabrail, S. De Pasquale, 

E. Nowara, L. Gilbert, J. R. Caton, R. H. Gersh, M. G. Teneriello, W. A. Harb, 

P. Konstantinopoulos, J. T. Symanowski, C. Lovejoy, R. A. Messmann 

Brd. 15B Final survival results of the randomized phase III study of trabectedin with 

pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian 


B. J. Monk, T. J. Herzog, S. B. Kaye, C. N. Krasner, J. B. Vermorken, F. Muggia, 

E. Pujade-Lourraine, P. Zintl, T. V. Parekh, A. Poveda 

Brd. 15C The role of NKTR-102 in women with platinum resistant/refractory ovarian 

cancer and failure on pegylated liposomal doxorubicin (PLD). (Abstract 

#5047) 

A. A. Garcia, I. B. Vergote, J. P. Micha, C. H. Pippitt Jr., G. G. Rao, D. L. Spitz, 

N. Reed, G. G. Dark, E. N. Ibrahim, V. A. Armenio, L. R. Duska, C. J. Poole, 

C. Gennigens, L. Y. Dirix, J. West, C. Zhao, A. C. Leung, L. K. Masuoka, 

G. J. Rustin 

229 

SUNDAY

SUNDAY 


Brd. 15D Catumaxomab treatment of malignant ascites in patients with chemotherapyrefractory 

ovarian cancer: A phase II study. (Abstract #5048) 

J. S. Berek, R. P. Edwards, L. Parker, L. R. DeMars, T. J. Herzog, S. S. Lentz, 

R. Morris, W. L. Akerley, R. W. Holloway, M. Method, S. C. Plaxe, J. L. Walker, 

T. Schindler, E. Schulze, C. N. Krasner, Cooperative Ovarian Cancer Group 

(COGI) 

Brd. 15E Fibroblast growth factor receptor 4 (FGFR4) expression as a prognostic 

indicator in high-grade serous ovarian carcinoma (HGSC): Signaling 

pathway, mechanism, and implication for therapeutic targeting. (Abstract 

#5049) 

T. M. Zaid, M. Thompson, K. Wong, T. Yeung, Z. Yeung, D. M. Gershenson, 

M. J. Birrer, S. C. Mok 

Brd. 15F The relationship of polymorphism Mad1 1673 G>A on outcomes in patients 

with advanced ovarian cancer treated with carboplatine-paclitaxel. (Abstract 

#5050) 

M. Santibañez, D. Prada, C. Diaz, C. Castro, F. Morales-Vasquez, 

D. Gallardo Rincon, L. A. Herrera 

Brd. 15G Analysis of polymorphisms in sodium channel, voltage-gated, type I, alpha 

subunit (SCN1A) as predictors of clinical outcome and toxicity in advanced 

ovarian cancer patients enrolled in a phase III trial treated with patupilone. 


Y. Ning, W. Zhang, D. Yang, D. Weber, F. Souami, P. O. Bohanes, A. Gerger, 

M. J. Labonte, L. Benhaim, H. Lenz 

Brd. 15H Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel 

and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients 

(pts): Treatment at recurrence and overall survival (OS) final analysis from 

CALYPSO phase III GCIG trial. (Abstract #5052) 

C. Marth, J. Alexandre, L. C. Hanker, C. Brown, J. Kaern, M. Heywood, 

A. Bonaventura, I. B. Vergote, S. Pignata, A. Ferrero, V. Gebski, M. Gropp, 

T. Skeie-Jensen, C. Giede, P. A. Vasey, C. Schauer, N. Reed, G. Ferrandina, 

R. Fossati, E. Pujade-Lauraine 

Brd. 16A A risk model for secondary cytoreductive surgery in recurrent ovarian 

cancer: An evidence-based proposal for patient selection. (Abstract #5053) 

W. Tian, D. Chi, J. Sehouli, C. Trope, R. Jiang, A. Ayhan, G. Cormio, Y. Xing, 

G. Breitbach, E. I. Braicu, C. A. Rabbitt, H. Oksefjell, C. Fotopoulou, H. Meerpohl, 

A. Du Bois, J. S. Berek, R. Zang, P. Harter 

Brd. 16B Intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin in patients 

with epithelial ovarian, fallopian tube, or peritoneal carcinoma: A feasibility 


S. Nagao, T. Nishikawa, A. Kurosaki, R. Ohishi, N. Iwasa, K. Hasegawa, 

K. Fujiwara 

Brd. 16C Multimodality evaluation of excision repair cross-complementation 1 

(ERCC1) expression as a predictive biomarker for platinum resistance in 

epithelial ovarian cancer (EOC). (Abstract #5055) 

C. O. Michie, L. Song, D. Faratian, J. Orr, T. Rye, J. Clark, J. M. Bartlett, 

D. J. Harrison, D. Melton, A. Williams, C. Gourley 

Brd. 16D Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal 

doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian 

cancer (EOC). (Abstract #5056) 

D. Jelovac, D. K. Armstrong, S. Weil, M. Phillips, B. M. Schwartz, J. M. Estes, 

R. D. Alvarez 

Brd. 16E Age-specific prognostic factors for survival in patients with advanced 

ovarian cancer (OC) treated with platinum/taxane-based primary 

chemotherapy: A combined explorative analysis of three prospective phase 

III trials from the AGO study group. (Abstract #5057) 

F. Hilpert, A. Hempel, J. Hedderich, O. Junge, P. Harter, A. Du Bois, J. Pfisterer, 

AGO Study Group 

230


Brd. 16F Expression profiles in matched primary and recurrent serous ovarian 


D. A. Zajchowski, B. Y. Karlan, L. K. Shawver 

Brd. 16G Carboplatin and pegylated liposomal doxorubicin versus carboplatin and 

paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a 

subset analysis of the CALYPSO phase III GCIG trial. (Abstract #5059) 

S. Mahner, W. Meier, A. Du Bois, C. Brown, D. Lorusso, A. Ferrero, J. Cretin, 

H. Havsteen, P. Bessette, L. Angleitner-Boubenizek, I. B. Vergote, P. A. Vasey, 

V. Gebski, B. Slama, J. Herrstedt, L. Kaizer, A. Georgoulopoulos, N. Reed, 

U. Wagner 

Brd. 16H Phase II trial of trabectedin (T) in heavily pretreated recurrent ovarian cancer 

(ROC) patients. (Abstract #5060) 

D. Lorusso, P. Malaguti, V. Masciullo, S. Mainenti, A. di Legge, M. Ludovisi, 

A. Pesce, F. Mascilini, E. Fusco, G. Scambia 

Brd. 17A Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in 

patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary 

peritoneal cancers: Results of a phase II study. (Abstract #5061) 

M. G. del Carmen, J. P. Micha, L. A. Small, D. G. Street, A. Londhe, T. McGowan 

Brd. 17B A North American population-based outcome for early-stage ovarian clear 

cell carcinoma (OCCC). (Abstract #5062) 

P. Hoskins, J. S. Albarrak, N. Le, A. Tinker, K. Swenerton, J. Santos, C. B. Gilks 

Brd. 17C Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in 

patients (pts) with advanced ovarian cancer. (Abstract #5063) 

D. S. Tan, T. A. Yap, M. M. Hutka, P. Roxburgh, E. Grzybowska, C. Gourley, 

M. E. Gore, S. B. Kaye 

Brd. 17D Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat 

doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with 


H. Gungor, A. Saleem, R. Agarwal, S. P. Blagden, A. Michael, E. A. Stronach, 

M. Chen, E. Pickford, N. R. Rama, Y. L. Lewis, S. C. Carme, C. Salinas, 

D. A. Smith, E. Krachey, A. Santiago-Walker, R. N. Gunn, M. El-Bahrawy, 

S. A. Babar, S. R. Morris, H. Gabra 

Brd. 17E Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) 

patients treated with chemotherapy and predictive value of early modeled 

kinetic parameters in CALYPSO trial: A GCIG study. (Abstract #5065) 

B. You, O. Colomban, M. Heywood, C. Lee, M. Davy, N. Reed, S. Pignata, 

R. Fossati, G. Emons, K. L. Rehman, K. D. Steffensen, E. Petru, V. Gebski, 

A. Burges, N. Tubiana-Matthieu, M. Hansen, P. A. Vasey, U. Denison, 

P. De Bruyne, A. M. Oza 

Brd. 17F Phase I feasibility study of intraperitoneal cisplatin and intravenous 

paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, 

fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology 

Group study 9921. (Abstract #5066) 

D. S. Dizon, M. Sill, N. S. Gould, S. C. Rubin, S. D. Yamada, R. DeBernardo, 

R. S. Mannel, E. L. Eisenhauer, L. R. Duska, P. M. Fracasso, Gynecologic 


Brd. 17G Prediction of progression-free survival (PFS) adjusted by continuous 

platinum-free interval (PFI) at fixed timepoints in patients with recurrent 

ovarian cancer (ROC): Results from OVA-301. (Abstract #5067) 

A. Poveda, B. J. Monk, S. B. Kaye, J. B. Vermorken, I. B. Vergote, 

I. B. Runnebaum, E. Pujade-Lauraine, T. V. Parekh, A. Nieto, J. Gomez, 

Y. C. Park, N. Colombo 

Brd. 17H Acquired drug resistance in gynecologic cancer detected by drug response 

marker testing. (Abstract #5068) 

I. Benjamin, H. J. Dalton, B. J. Monk 

231 

SUNDAY

SUNDAY 


Brd. 18A A novel plasma amino acid profile-based biomarker for early detection of 


E. Miyagi, R. Numazaki, Y. Ihata, T. Muramatsu, A. Imaizumi, H. Yamamoto, 

M. Yamakado, N. Okamoto, M. Asai-Sato, F. Hirahara 

Brd. 18B Operative morbidity and mortality in octogenarians and nonagenarians with 


C. L. Walters, K. E. Schneider, J. M. Whitworth, J. M. Fauci, J. M. Straughn, 

M. N. Barnes 

Brd. 18C First quality-of-life data of a sequential dose-dense regimen in advanced 

ovarian cancer: A multicenter phase II study of the Northeastern German 

Society of Gynecological Oncology. (Abstract #5071) 

G. Oskay-Özcelik, R. Richter, K. Pietzner, H. Hindenburg, H. L. Sommer, 

R. Chekerov, O. Camara, E. Keil, J. Einenkel, W. Lichtenegger, J. Sehouli 

Brd. 18D Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and 

peritoneal cancers treated with intraperitoneal chemotherapy. (Abstract 

#5072) 

K. M. Esselen, N. Rodriguez, N. S. Horowitz, S. M. Campos 

Brd. 18E Extended duration of response with second-line intraperitoneal platinumbased 

therapy for epithelial ovarian cancer. (Abstract #5073) 

M. E. Skaznik-Wikiel, J. L. Lesnock, W. C. McBee Jr., S. D. Richard, J. L. Kelley, 

K. K. Zorn, T. C. Krivak, R. P. Edwards 

Brd. 18F Regulation of the tumor suppressor gene PAEP in the transition from serous 

borderline ovarian tumors to low-grade serous ovarian carcinomas. 


E. R. King, Y. T. Tsang, Z. Zu, D. M. Gershenson, S. C. Mok, K. Wong 

Brd. 18G Increased expression of C-terminal binding protein-2 in epithelial ovarian 

carcinoma modulates DNA repair pathways and decreases tumor response 

to histone deacetylase inhibitors. (Abstract #5075) 

T. May, L. M. Barroilhet, J. Yang, M. Singh, W. R. Welch, S. P. Sugrue, 

R. S. Berkowitz, S. Ng 

Brd. 18H Use of contrast-enhanced ultrasound imaging with microbubbles targeted to 

�v�3 integrins to enhance detection of early-stage ovarian tumors. (Abstract 

#5076) 

A. Barua, A. Yellapa, P. Bitterman, J. M. Bahr, S. Sharma, D. B. Hales, 

J. L. Luborsky, J. S. Abramowicz 

Brd. 19A Surveillance for ovarian carcinoma patients after curative-intent treatment. 


F. E. Johnson, K. S. Virgo, F. Gao, D. G. Mutch 

Brd. 19B Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with 

advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary 

peritoneal cancer (PPC), or fallopian tube cancer (FTC). (Abstract #5078) 

O. Smaletz, M. Diz, C. C. Carmo, J. Sabbaga, G. F. Cunha, S. J. Azevedo, 

F. C. Maluf, C. H. Barrios, R. L. Costa, A. G. Fontana, V. A. Alves, A. M. Moro, 

A. M. Scott, E. W. Hoffman, L. J. Old 

Brd. 19C Is there a place for neoadjuvant chemotherapy in the management of 

advanced malignant germ cell tumors of the ovary? (Abstract #5079) 

L. Kumar, S. Talukdar, R. Hariprasad, A. Gupta, A. Mookerjee, S. Kumar, 

N. Bhatla, S. Mathur 

Brd. 19D FDG-PET/CT imaging in gynecologic cancers: Is there an advance on patient 

management? (Abstract #5080) 

M. Dalla Palma, M. Gregianin, L. Evangelista, A. Cervino, G. Saladini, L. Borgato, 

M. O. Nicoletto, V. Zagonel 

Brd. 19E Prognostic significance of serum HE4 in epithelial ovarian cancer. (Abstract 

#5081) 

M. Marinaccio, E. Mele, V. Lorusso, A. Larocca, C. Pellegrino, R. Chiappetta, 

F. Sozzi 

232


Brd. 19F Intra- and postoperative catumaxomab in patients with epithelial ovarian 

cancer: Two-year efficacy results from a multicenter, single-arm, phase II 


J. Sehouli, A. Reinthaller, C. Marth, D. Reimer, T. Reimer, W. Stummvoll, 

L. Angleitner-Boubenizek, B. Lehnert, M. Marquardt, M. M. Essing, R. Chekerov 

Brd. 19G Assessing the value of weekly full blood counts (FBC) in patients with 

advanced serous gynecologic cancers receiving weekly 

carboplatin/paclitaxel (wCP) chemotherapy. (Abstract #5083) 

D. Ulahannan, G. J. Rustin, M. Hall 

Brd. 19H Relationship between relative dose intensity and mortality in women 

receiving combination chemotherapy for stage III-IV epithelial ovarian 


L. J. Havrilesky, R. K. Hanna, M. S. Poniewierski, R. Laskey, A. A. Secord, 

P. A. Gehrig, M. A. Lopez, A. Shafer, L. Van Le, D. C. Dale, J. Crawford, 

G. H. Lyman 

Brd. 20A Effects of weekly bevacizumab and paclitaxel/carboplatin with or without 

sorafenib on heavily pretreated patients with recurrent or persistent cervical 


Y. Kikuchi, M. Takano, T. Goto, H. Kouta, R. Kikuchi, K. Kudoh, T. Kita, K. Furuya, 

K. Umayahara, K. Takizawa 

Brd. 20B Cyclin D1 and p57 expression in advanced ovarian epithelial carcinoma: A 

GOG study. (Abstract #5086) 

E. Hill, W. Brady, M. J. Birrer, K. M. Darcy, W. P. McGuire III, W. J. Hoskins, 

D. P. Warshal, R. D. Drake, P. Hanjani, J. Hurteau 

Brd. 20C The phase II study of efficacy and safety of oxaliplatin with doxorubicin in 

recurrent ovarian cancer (OC). (Abstract #5087) 

I. Pokataev, G. M. Manikhas, V. Borisov, M. Stenina, A. Tjulandina, S. Tjulandin 

Brd. 20D The impact of dose intensity on the efficacy of gemcitabine plus carboplatin 

(GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A 

retrospective analysis of AGO-OVAR 2.5. (Abstract #5088) 

C. Kurzeder, L. Zhao, E. A. Eisenhauer, I. B. Vergote, A. Du Bois, D. Tai, Y. Wang, 

J. F. Gill, H. W. Hirte, B. Richter, L. C. Hanker, J. Bentley, U. A. Wagner, M. Plante, 

R. Kimmig, J. Pfisterer 

Brd. 20E Phase II trial of weekly irinotecan and carboplatin for relapsed ovarian 

cancer: A Kansai Clinical Oncology Group study. (Abstract #5089) 

H. Tsubamoto, K. Inoue, R. Kawaguchi, K. Ito, S. Takeuchi, T. Shiozaki, Y. Itani, 

A. Arakawa, T. Tabata, S. Toyoda 

Brd. 20F Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive 

ovarian cancer: A phase II study, CTEP #7431. (Abstract #5090) 

M. L. Hensley, S. J. Kravetz, X. Jia, W. P. Tew, L. Pereira, P. Sabbatini, C. Whalen, 

C. Aghajanian, C. Zarwan, S. T. Berlin 

Brd. 20G Large international multicenter evaluation of the clinical significance of 

L1-CAM expression in FIGO stage I, type 1 endometrial cancer. (Abstract 

#5091) 

A. G. Zeimet, S. Abdel-Azim, D. Reimer, E. Mueller-Holzner, B. Winterhoff, 

U. Puistola, A. Ben-Arie, L. vanKempen, F. Amant, E. Petru, S. Jahn, 

S. Polterauer, P. Oppelt, M. Weigert, P. Altevogt, M. Huszar, C. Marth, M. Fogel 

Brd. 20H Impact of the MDM2 promoter polymorphisms SNP285 and SNP309 on 

endometrial cancer risk among Caucasians. (Abstract #5092) 

S. Knappskog, J. Trovik, J. Marcickiewisz, S. Tingulstad, A. Staff, K. Hveem, 

L. Vatten, H. B. Salvesen, P. Lonning 

Brd. 21A Pegylated liposomal doxorubicin and carboplatin in malignant mixed 

epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II 

trial of the AGO study group. (Abstract #5093) 

P. Harter, U. Canzler, H. Lueck, A. Reuss, W. Meier, T. N. Fehm, A. Staehle, 

A. Burges, C. Kurzeder, J. Sehouli, K. H. Baumann, L. C. Hanker, P. Wimberger, 

W. Schroeder, M. Gropp, S. Mahner, A. Du Bois 

233 

SUNDAY

SUNDAY 


Brd. 21B The presence of racial disparities in histopathologic characteristics of 

uterine cancer in an equal-access environment. (Abstract #5094) 

K. E. Oliver, L. Enewold, K. Zhu, T. P. Conrads, G. S. Rose, G. L. Maxwell, 

J. H. Farley 

Brd. 21C Molecular analysis of endometrial pathogenesis in Lynch syndrome. 


M. Huang, B. Djordjevic, D. Urbauer, S. N. Westin, C. C. Sun, J. K. Burzawa, 

L. Meyer, D. C. Bodurka, R. Broaddus, K. H. Lu 

Brd. 21D Recombinant adenovirus-p53 (rAd-p53) in combination with radiotherapy for 

treating cervical cancer. (Abstract #5096) 

S. Zhang 

Brd. 21E A phase II study of recombinant adeno-viral human p53 gene combined with 

radiotherapy in treatment of patients with locally advanced cervical 


J. Pan 

Brd. 21F Gemcitabine for advanced endometrial carcinoma (EMC): A review of the 

MSKCC experience. (Abstract #5098) 

R. N. Grisham, C. H. Adaniel, D. M. Hyman, W. Ma, A. Iasonos, C. Aghajanian, 

J. A. Konner 

Brd. 21G Validation of the predictive value of modeled hCG decline profiles in low-risk 

gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX). 


G. Freyer, B. You, R. Harvey, F. Golfier, H. Mitchell, P. Savage, M. Tod, C. Philip, 

T. Hajri, M. Seckl 

Brd. 21H Exploration of biomarkers for lymph node metastasis in patients with 

endometrial cancer using exon-expression microarray. (Abstract #5100) 

S. Sudo, Y. Konno, T. Odagiri, T. Kato, M. Hosaka, M. Takeda, H. Watari, 

M. Kaneuchi, N. Sakuragi 

Brd. 22A The use of bevacizumab and concurrent radiation for recurrent gynecologic 


A. N. Viswanathan, J. Szymonifka, C. Tanaka, S. T. Berlin, S. M. Campos, 

N. S. Horowitz, J. Lee, C. Whalen, U. Matulonis 

Brd. 22B Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent 

uterine cervical cancer: A Kansai Clinical Oncology Group study. (Abstract 

#5102) 

M. Takekuma, Y. Hirashima, K. Ito, H. Tsubamoto, T. Tabata, A. Arakawa, Y. Itani, 

N. Furukawa, H. Murakoshi, S. Takeuchi 

Brd. 22C Paradigm shift in the management of high intermediate–risk stage I 

endometrial cancer. (Abstract #5103) 

J. O. Schorge, A. H. Russell, L. A. Garrett, A. Goodman, M. G. del Carmen, 

W. B. Growdon, D. M. Boruta II 

Brd. 22D Laparoscopic intraoperative sentinel lymph node detection by technetium-99 

hysteroscopically injected in endometrial cancer patients. (Abstract #5104) 

G. Favero 

Brd. 22E Genome-wide single nucleotide polymorphism (SNP) arrays as a novel 

diagnostic tool in synchronous carcinomas. (Abstract #5105) 

Y. Ikeda, K. Oda, S. Nakagawa, S. Murayama-Hosokawa, K. Shoji, S. Yamamoto, 

S. Ishikawa, Y. Uehara, Y. Miyamoto, M. Tanikawa, T. Kashiyama, Y. Takazawa, 

D. Maeda, O. Hiraike-Wada, K. Miyagawa, F. McCormick, M. Fukayama, 

H. Aburatani, T. Yano, Y. Taketani 

Brd. 22F Ovarian preservation in premenopausal patients with early-stage 

endometrial cancer: A multicenter retrospective matched cohort study. 


T. Lee, S. Seong, J. Kim, J. Lee, H. Ryu 

234


Brd. 22G Factors associated with synchronous ovarian and endometrial cancer: A 

population-based case control study. (Abstract #5107) 

M. M. AlHilli, S. C. Dowdy, A. Weaver, J. St. Sauver, G. L. Keeney, A. Mariani, 

K. C. Podratz, J. N. Bakkum-Gamez 

Brd. 22H Endometrial cancer screening in patients with Lynch syndrome. (Abstract 

#5108) 

A. Bats, M. Le Frere-Belda, U. Metzger, P. Laurent-Puig, F. Lecuru 

Brd. 23A Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: 

Results of a prospective, multicenter phase II study of the NOGGO. (Abstract 

#5109) 

D. Koensgen, A. Belau, J. Sehouli, H. L. Sommer, K. Bartz, S. Markmann, 

L. Schneidewind, J. P. Scharf, M. Ehmke, D. Stengel, P. Ledwon, H. Guba, 

M. Zygmunt, G. Koehler, A. Mustea, North-Eastern Society of Gynaecological 

Oncology 

Brd. 23B Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, 

and an mTOR inhibitor, RAD001, in endometrial carcinomas. (Abstract #5110) 

K. Oda, K. Shoji, S. Nakagawa, T. Kashiyama, Y. Ikeda, Y. Miyamoto, 

M. Tanikawa, H. Kuramoto, M. Nishida, O. Hiraike-Wada, T. Yano, S. Kozuma, 

Y. Taketani 

Brd. 23C Obesity, diabetes, and race in Type 1 and Type 2 endometrial cancers. 


E. M. Ko, J. Franasiak, K. Sink, W. R. Brewster, P. A. Gehrig, V. L. Bae-Jump 

235 

SUNDAY

SUNDAY 


8:00 AM - 12:00 PM 





Brd. 24A IL-6 as a prognostic biomarker in patients with metastatic melanoma. 


L. Hoejberg, L. Bastholt, J. S. Johansen, K. Fode, H. Schmidt 

Brd. 24B Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of 

oncogenic mutant BRAF kinase in BRAF-mutant metastatic melanoma. 


M. S. Carlino, C. A. Saunders, V. Gebski, A. M. Menzies, B. Ma, P. F. Lebowitz, 

R. Kefford, G. V. Long 

Brd. 24C Distinguishing between nodular and superficial spreading melanoma using 

specific microRNA alterations. (Abstract #8540) 

L. Poliseno, A. Haimovic, D. Hanniford, M. F. Segura, P. J. Christos, R. L. Shapiro, 

A. C. Pavlick, R. S. Berman, E. Hernando, J. Zavadil, I. Osman 

Brd. 24D An analysis of altered melanoma matrix metalloproteinase-23 (MMP-23) 

expression and response to immune biologic therapy. (Abstract #8541) 

M. Krogsgaard, M. W. Ma, E. B. Friedman, E. Vega-Saenz de Miera, F. Darvishian, 

A. Perez-Garcia, R. S. Berman, R. L. Shapiro, P. J. Christos, I. Osman, 

A. C. Pavlick 

Brd. 24E Morphologic and immunohistochemical (IHC) changes in metastatic 

melanoma (MM) tissue and associations with clinical outcome in patients 

(pts) on BRAF inhibitors (BRAFi). (Abstract #8542) 

G. V. Long, J. S. Wilmott, J. R. Howle, M. D. Chatfield, V. Tembe, J. F. Thompson, 

P. Hersey, G. J. Mann, G. A. McArthur, H. Rizos, R. J. Young, L. L. Scurr, 

R. N. Sharma, R. F. Kefford, R. A. Scolyer 

Brd. 24F Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in 

patients with unresectable melanoma. (Abstract #8543) 

P. Boasberg, R. W. Weber, S. Cruickshank, O. Hamid, S. O’Day, L. E. Spitler 

Brd. 24G A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose 

interferon alfa-2b in high-risk acral melanoma patients. (Abstract #8544) 

L. Si, L. L. Mao, Z. H. Chi, C. L. Cui, X. N. Sheng, S. M. Li, B. X. Tang, J. Guo 

Brd. 24H Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of 

toxicity and clinical efficacy in metastatic melanoma patients with normal 

lactate dehydrogenase (LDH). (Abstract #8545) 

J. L. Chang, P. A. Ott, C. Sorlie, C. Escano, E. Yepes, S. Mendoza, A. Gandhi, 

L. Liebes, A. C. Pavlick 

Brd. 25A A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in 

stage IV melanoma. (Abstract #8546) 

J. P. Fruehauf, Z. Eroglu, K. M. Kong, J. G. Jakowatz, W. L. Akerley, 

W. E. Samlowski 

Brd. 25B Health-related quality of life (HRQOL) in the Nordic randomized trial of 

adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma. 


J. Hansson, S. Aamdal, L. Bastholt, M. Hernberg, B. Nilsson, U. K. Stierner, 

H. von der Maase, Y. Brandberg, Nordic Melanoma Cooperative Group 

Brd. 25C An open-label pilot study of vemurafenib in previously treated metastatic 

melanoma patients with brain metastases. (Abstract #8548) 

R. Dummer, J. Rinderknecht, S. M. Goldinger, I. Wagner, L. Mitchell, M. Veronese, 

S. Nick, P. Hilfiker, S. Gobbi 

236


Brd. 26A MicroRNA oncogenes and tumor suppressors controlling malignant 

melanoma cell growth, apoptosis, migration, and invasion. (Abstract #8549) 

R. W. Georgantas, K. Streicher, W. Zhu, R. Carrasco, Z. Xiao, Z. Liu, P. Brohawn, 

C. Morehouse, D. Tice, B. W. Higgs, L. Richman, P. Kiener, B. Jallal, Y. Yao 

Brd. 26B Ultrasound (US)-guided fine-needle aspiration cytology (FNAC) for the 

prediction of sentinel node (SN) metastases and its effect on the nomogram 

for melanoma patients. (Abstract #8550) 

C. A. Voit, A. C. Van Akkooi, P. Siegel, W. Sterry, A. Schoengen, 

G. Schaefer-Hesterberg, A. M. Eggermont 

Brd. 26C A gene expression profile associated with clinical outcome in stage III 


J. Falkenius, J. Lindberg, H. Johansson, M. Frostvik-Stolt, J. Lundeberg, 

J. Hansson, S. Egyhazi 

Brd. 27A Somatostatin receptor scintigraphy in patients with metastatic uveal 


M. E. Valsecchi, D. Summers, C. M. Intenzo, S. Kim, M. J. Mastrangelo, T. Sato 

Brd. 27B Intratumoral neutrophils, plasmacytoid dendritic cells, and pSTAT3 in AJCC 

stage I/II melanoma prognosis. (Abstract #8553) 

T. O. Jensen, H. Schmidt, H. J. Moller, F. Donskov, M. Hoyer, P. Sjoegren, 

I. J. Christensen, T. Steiniche 

Brd. 27C Effectiveness of treatment guidance on diarrhea and colitis across 

ipilimumab studies. (Abstract #8554) 

S. O’Day, J. S. Weber, J. D. Wolchok, J. M. Richards, P. Lorigan, D. F. McDermott, 

W. J. Urba, V. DePril, K. N. Heller, R. A. Ibrahim, A. Hauschild 

Brd. 28A Two phase I studies of PTI-188, a radiolabeled murine antimelanin antibody, 

in patients with metastatic melanoma (MM). (Abstract #8555) 

M. Lotem, T. Peretz, S. Mizrachi, Y. Liberman, E. Dadachova, A. Casadevall, 

A. de Kater, N. Friedmann, G. B. Thornton, M. Klein 

Brd. 28B Association of CT antigen expression and survival in stage III melanoma. 


N. H. Turner, T. John, S. Deb, A. M. Campbell, A. Azad, P. C. Boutros, Y. Chen, 

J. S. Cebon 

Brd. 28C A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 

(GRM1) signaling, in advanced melanoma. (Abstract #8557) 

J. M. Mehnert, Y. Wen, J. H. Lee, L. Dudek, L. Pruski-Clark, W. Shih, S. Chen, 

J. S. Goydos 

Brd. 29A A germ-line polymorphism in the RET proto-oncogene predicts risk and 

recurrence in desmoplastic melanoma. (Abstract #8558) 

N. Kounalakis, C. M. Amato, J. Barr, W. Robinson 

Brd. 29B Exploratory analysis of technical factors that influence sentinel lymph node 

biopsy (SLNB) performance. (Abstract #8559) 

D. Silbermins, M. E. Valsecchi, N. de Rosa, S. L. Wong, G. H. Lyman 

Brd. 29C Primary melanoma features associated with increased risk of brain 

metastasis. (Abstract #8560) 

M. W. Ma, M. Qian, D. Lackaye, R. S. Berman, R. L. Shapiro, A. C. Pavlick, 

J. Golfinos, E. Parker, E. Hernando, Y. Shao, I. Osman 

Brd. 30A Impact of immune modulation on sentinel lymph node positivity and 

outcome in melanoma patients. (Abstract #8561) 

R. C. Medicherla, M. W. Ma, M. Qian, E. Vega-Saenz de Miera, R. S. Berman, 

R. L. Shapiro, A. C. Pavlick, N. Bhardwaj, Y. Shao, I. Osman, F. Darvishian 

Brd. 30B The prognostic relevance of altered antiglycan antibody profiles in the sera 

of primary melanoma patients. (Abstract #8562) 

A. Haimovic, M. W. Ma, M. I. Vuskovic, T. Miller, M. DiBenedetto, J. Grossman, 

R. L. Shapiro, A. C. Pavlick, R. S. Berman, H. I. Pass, M. Huflejt, I. Osman 

237 

SUNDAY

SUNDAY 


Brd. 30C Melanoma pigmentation affects melanoma-specific survival and provides a 

potential target for radiopharmaceutical-based imaging and therapy. 


D. Kee, W. Liu, B. A. Devitt, R. Wolfe, R. Ware, R. Salemi, A. Dobrovic, 

S. Brglevska, J. Kelly, J. Callahan, A. Katsifis, P. Roselt, O. C. Neels, T. Bourdier, 

R. J. Hicks, G. A. McArthur 

Brd. 31A Clinical outcome of patients with metastasic melanoma undergoing phase I 

clinical trials. (Abstract #8564) 

M. Blanco-Codesido, A. Brunetto, S. Frentzas, V. Moreno Garcia, 

D. Papadatos-Pastos, J. V. Pedersen, L. Trani, M. Puglisi, D. Sarker, L. R. Molife, 

U. Banerji 

Brd. 31B The burden of metastatic melanoma (mM): Treatment patterns, healthcare 

use, and costs. (Abstract #8565) 

C. Reyes, S. DaCosta Byfield, S. Satram-Hoang, A. H. Teitelbaum 

Brd. 31C The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on 

BRAF wild-type melanoma. (Abstract #8566) 

Y. Funahashi, J. Matsui, Y. Minoshima, A. Yokoi, T. Abe, K. Okamoto, 

K. Takahashi, T. Kadowaki, G. Kuznetsov, S. Agoulink 

Brd. 31D Mechanism of antitumor activity of E7080, a selective VEGFR and FGFR 

tyrosine kinase inhibitor (TKI), in combination with selective mutant BRAF 

inhibition. (Abstract #8567) 

J. Matsui, Y. Narita, T. Semba, Y. Adachi, T. Kadowaki, J. Oestreicher, 

M. Matijevic, M. Byrne, Y. Funahashi 

Brd. 31E Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese melanoma 

patients and their significance: Large-scale analysis of 644 patients. 


Y. Kong, L. Si, J. Guo, Z. H. Chi, C. L. Cui, X. N. Sheng, B. X. Tang 

Brd. 31G Potency of new duplex drugs linking 3�-C-ethynylcytidine and 5-fluoro-2�deoxyuridine 

against human melanoma in vitro and in vivo. (Abstract #8570) 

S. Schott, H. Niessner, T. Sinnberg, S. Venturelli, A. Berger, S. Noor, 

D. Mailaender-Sanchez, C. Garbe, C. Busch 

Brd. 31H Phase I trial of temozolomide, thalidimide, and lomustine in patients with 

metastatic melanoma in the brain. (Abstract #8571) 

N. E. Papadopoulos, W. Hwu, S. Cain, L. Posada, K. B. Kim, J. Homsi, 

A. Y. Bedikian, M. A. Davies, P. Hwu 

Brd. 32A Association of response and survival in Allovectin melanoma trials. 


D. D. Kharkevitch, A. Chu, L. G. Strause, L. R. Muenz, R. T. Kenney, A. Rolland 

Brd. 32B A phase I, open-label, cohort study of two doses of coxsackievirus A21 given 

intratumorally in stage IV melanoma. (Abstract #8573) 

D. Shafren, B. M. Smithers, M. Formby 

Brd. 32C Mutation frequency in BRAF and NRAS genes among primary tumors and 

different types of metastasis from melanoma patients. (Abstract #8574) 

M. Colombino, M. Capone, M. Maio, V. De Giorgi, A. Cossu, A. Lissia, C. Rubino, 

B. Massidda, S. Staibano, O. Nappi, G. Botti, C. Caraco, N. Mozzillo, A. Manca, 

M. Sini, P. A. Ascierto, G. Palmieri, Italian Melanoma Intergroup (IMI) 

Brd. 32D Feasability and reliabity of the assessment of BRAF and c-KIT mutations in 

cytologic samples from metastatic melanoma. (Abstract #8575) 

M. D. Lozano, T. Labiano, J. I. Echeveste, M. Montana, N. Gomez, 

M. F. Sanmamed, A. Gurpide, M. A. Idoate, S. Martin-Algarra 

Brd. 32E Routine imaging to detect recurrences in high-risk melanoma patients. 


T. S. Park, K. H. Lagisetty, R. M. Sherry, J. C. Yang, M. S. Hughes, K. Morton, 

D. E. White, Y. Klionsky, S. A. Rosenberg, G. Q. Phan 

238


Brd. 32F The results of a randomized phase II study using embolization with or 

without granulocyte-macrophage colony-stimulating factor (GM-CSF) in 

uveal melanoma patients with hepatic metastasis. (Abstract #8577) 

D. J. Eschelman, C. F. Gonsalves, M. Terai, M. Laudadio, K. L. Sullivan, 

M. J. Mastrangelo, T. Sato 

Brd. 32G Identification of predictive biomarkers for dasatinib treatment of metastatic 


A. J. Eustace, S. Kennedy, A. Larkin, T. Mahgoub, D. Tryfonopoulos, L. O’Driscoll, 

M. Clynes, J. Crown, N. O’Donovan 

Brd. 32H Ipilimumab plus temozolomide in metastatic melanoma. (Abstract #8579) 

S. P. Patel, A. Y. Bedikian, N. E. Papadopoulos, W. Hwu, K. B. Kim, J. Homsi, 

M. A. Davies, S. E. Woodman, L. G. Radvanyi, K. Woodard, S. Mahoney, P. Hwu 

Brd. 33A Overall survival (OS) in the management of pretreated patients with 

unresectable stage III/IV melanoma: A systematic literature review and 

meta-analysis. (Abstract #8580) 

S. Kotapati, P. Dequen, M. Ouwens, M. van Baardewijk, R. A. Ibrahim, S. Wagner, 

J. P. Jansen 

Brd. 33B Safety and survival analysis of ipilimumab therapy in patients with stable 

asymptomatic brain metastases. (Abstract #8581) 

K. N. Heller, A. C. Pavlick, F. S. Hodi, J. A. Thompson, K. A. Margolin, 

D. P. Lawrence, D. F. McDermott, W. E. Samlowski, T. Michener, M. Karasarides 

Brd. 33C Plasma Tie-2 and its ligand Ang-2 in metastatic malignant melanoma: 

Relationships to clinicopathological parameters and tumor burden. (Abstract 

#8582) 

R. Mouawad, J. Thery, S. Vignot, R. Conforti, D. Khayat, J. Spano 

Brd. 33D Ipilimumab safety profile: Summary of findings from completed trials in 

advanced melanoma. (Abstract #8583) 

R. A. Ibrahim, D. M. Berman, V. DePril, R. W. Humphrey, T. Chen, M. Messina, 

K. M. Chin, H. Y. Liu, M. Bielefield, A. Hoos 

Brd. 33E Multicohort model of prevalence estimation of advanced malignant 

melanoma in the United States: An increasing public health concern. 


A. Y. Lin, P. F. Wang, J. Kolker 

Brd. 33F Correlation between lymphocyte counts and response to outpatient 

intravenous interleukin-2 preceded by famotidine in metastatic melanoma. 


W. Quan, K. N. Donkor, F. M. Quan 

Brd. 33H Sentinel lymph node detection using laser-assisted indocyanine green dye 

lymphangiography in melanoma and breast cancer patients. (Abstract #8587) 

B. Phillips, V. Jain, N. Conkling, C. R. Pameijer 

Brd. 34A Analysis of CTLA-4 gene polymorphisms in patients with advanced 

melanoma treated with anti-CTLA-4 therapy. (Abstract #8588) 

P. Queirolo, A. Morabito, P. Piccioli, S. Lastraioli, S. Callegari, M. Camoriano, 

P. A. Ascierto, S. Laurent, B. Dozin, M. Pistillo 

Brd. 34B BRAF, NRAS, and KIT mutational analysis of spindle cell melanoma. 


S. J. Dorkhom, J. Kim, A. J. Lazar, M. A. Davies, J. Homsi, N. E. Papadopoulos, 

W. Hwu, A. Y. Bedikian, S. E. Woodman, S. P. Patel, P. Hwu, K. B. Kim 

Brd. 34C The prognostic utility of LDH and disease-specific graded prognostic 

assessment for melanoma brain metastases. (Abstract #8590) 

M. Lowe, A. Cavitt, J. Shelton, N. Maynard, I. R. Crocker, G. W. Carlson, 

K. A. Delman, D. H. Lawson, M. Rizzo 

239 

SUNDAY

SUNDAY 


Brd. 34D Use of microRNA signature to predict patient sensitivity to dendritic cell 

vaccination in metastatic melanoma. (Abstract #8591) 

L. Ridolfi, I. Vannini, F. Fanini, L. Fiammenghi, M. Petrini, V. Ancarani, A. Granato, 

M. Guidoboni, E. Pancisi, A. Riccobon, R. Ridolfi, C. Fernandez-Cymering, 

S. Volinia, C. Milandri, C. M. Croce, M. Fabbri 

Brd. 34E Acral lentiginous melanoma in Hawaii: Characterization of the mTOR 

pathway in the non-Caucasian population. (Abstract #8592) 

S. Y. Morita, S. Jim, C. A. Lum, D. E. Hemmings, J. Davis 

Brd. 34F A pilot study of endogenous heat shock protein vaccines for metastatic 


J. M. Heun, W. K. Nevala, J. B. Allred, V. Suman, M. R. Callstrom, T. D. Atwell, 

M. A. Farrell, E. Galanis, L. A. Erickson, W. J. Charboneau, S. Markovic 

Brd. 34G Antitumor activity of MLN4924, an investigational inhibitor of NEDD8activating 

enzyme (NAE), in preclinical models of melanoma. (Abstract 

#8594) 

T. Traore, M. Mihollen, J. Garnsey, A. Berger, M. Manfredi, K. Cosmopolous, 

J. Donelan, P. G. Smith 

Brd. 34H Molecular profiling of melanoma tumor biopsies to identify a response 

signature to the multi-RTK inhibitor, E7080. (Abstract #8595) 

J. J. Nemunaitis, D. S. Hong, R. Kurzrock, N. N. Senzer, N. C. Twine, T. Kadowaki, 

M. Ren, Y. Funahashi, J. P. O’Brien, J. S. Simon, A. Eisen 

Brd. 35A Adjuvant GM-CSF therapy for patients with resected stage III/IV melanoma: A 

retrospective review of a single-center experience. (Abstract #8596) 

S. Markovic, P. A. Burch, B. LaPlant, J. M. Heun, R. Bradshaw 

Brd. 35B Frequency of mutations associated with targeted therapy in malignant 

melanoma patients. (Abstract #8597) 

S. Cheng, P. Chu, M. Hinshaw, K. Smith, J. Maize, A. Sferruzza 

240

8:00 AM - 12:00 PM 



Pediatric Oncology 



Brd. 38A The impact of surveillance imaging on overall survival in patients with 

recurrent Wilms tumor: A report from the Children’s Oncology Group. 


E. A. Mullen, J. R. Anderson, K. J. Steacy, J. I. Geller, D. M. Green, P. Norkool, 

C. V. Fernandez, G. Khanna, M. H. Malogolowkin, J. Dome 

Brd. 38B Association of GSTP1 hypermethylation with reduced protein expression 

and its correlation with clinical stage in neuroblastoma. (Abstract #9537) 

F. Gumy-Pause, B. Pardo, M. Khoshbeen-Boudal, M. Ansari, E. F. Attiyeh, 

H. Ozsahin 

Brd. 38C BMP signaling activity in pediatric germ cell tumors. (Abstract #9538) 

N. J. Fustino, D. Rakheja, J. F. Amatruda 

Brd. 38D Ewing sarcoma prognostic score (ESPS) at diagnosis, based on fever and 

metastatic status. (Abstract #9539) 

N. Gaspar, G. Le Teuff, A. Defachelles, C. Schmitt, D. Levy, M. Castex, O. Lejars, 

C. Verite, E. Plouvier, L. Claude, O. Oberlin 

Brd. 38E The effect of topotecan in advanced intraocular retinoblastoma with 

manageable toxicity. (Abstract #9540) 

I. A. Qaddoumi, C. Billups, C. F. Stewart, J. Wu, K. Helton, B. McCarville, 

T. E. Merchant, R. C. Brennan, B. Haik, C. Rodriguez-Galindo, M. W. Wilson 

Brd. 38F Pilot immunotherapy trial in high-risk pediatric sarcomas. (Abstract #9541) 

M. O. Amoako, M. S. Merchant, D. B. Bernstein, K. Baird, C. Mackall 

Brd. 38G Changes in incidence of infant cancer: Analysis of SEER data 1992–2007. 


G. A. Pereira, K. B. Ribeiro, C. Rodriguez-Galindo, L. G. Spector, A. L. Frazier 

Brd. 38H A comparison of safety and efficacy of cytotoxic versus molecularly targeted 

drugs in pediatric phase I solid tumor oncology trials. (Abstract #9543) 

K. M. Dorris, T. R. Hummel, A. M. Ingle, M. Kim, J. P. Perentesis, M. Fouladi 

Brd. 39A Incidence and outcomes of patients with late recurrence of Wilms tumor 

(WT): The international experience. (Abstract #9544) 

M. H. Malogolowkin, F. Spreafico, J. Dome, N. Breslow, H. van Tinteren, 

K. Pritchard-Jones, M. van den Heuvel, C. Bergeron, J. De Kraker, N. Graf, 

COG Renal Tumors Committee and SIOP Renal Tumors Study Group 

Brd. 39B A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric 

patients with refractory solid tumors. (Abstract #9545) 

L. M. McGregor, S. L. Spunt, D. Ward, J. Wu, C. Billups, S. P. Ivy, V. M. Santana, 

M. Fouladi, W. L. Furman 

Brd. 39C Cell cycle and apoptotic effects of PM00104 in pediatric cell lines and 

xenographs. (Abstract #9546) 

A. Beaugrand, C. Lanvers-Kaminsky, P. Aviles Marin, C. Cuevas Marchante, 

P. Opolon, L. Le Dret, A. Verschuur, G. Vassal, B. Geoerger, ITCC Biology and 

Preclinical Evaluation Committee 

Brd. 39D Quantifying alkylating agent exposure: Evaluation of the cyclophosphamide 

equivalent dose—A report from the Childhood Cancer Survivor Study. 


D. M. Green, V. G. Nolan, D. K. Srivastava, W. Leisenring, J. P. Neglia, C. A. Sklar, 

M. M. Hudson, L. Diller, M. Stovall, L. L. Robison 

Brd. 39F Toxicity of 131 I-MIBG combined with high-dose chemotherapy in children 

with refractory neuroblastoma. (Abstract #9549) 

L. Amoroso, G. Villavecchia, M. Cabria, A. Piccardo, M. Conte, M. Nantron, 

A. Garaventa, B. De Bernardi 

241 

SUNDAY

SUNDAY 


Brd. 39G Exposure-response analysis as evidence for antitumor activity of everolimus 

in the treatment of patients with subependymal giant-cell astrocytoma 

(SEGA) associated with tuberous sclerosis (TS). (Abstract #9550) 

N. Mehrotra, E. Pfuma, C. Garnett, Q. Liu, B. Booth, N. Rahman, A. H. Shahlaee, 

K. Liu 

Brd. 39H Changes in cardiovascular signaling proteins during doxorubicin treatment 

in children with high-risk ALL. (Abstract #9551) 

T. L. Miller, S. E. Lipshultz, R. E. Scully, D. Sawyer, S. R. Lipsitz, 

L. B. Silverman, H. Smith, J. M. Henkel, V. I. Franco, L. L. Cushman, S. E. Sallan 

Brd. 40A Allogeneic transplantation for patients with high-risk or refractory 

neuroblastoma. (Abstract #9552) 

T. A. Driscoll, P. L. Martin, J. Moffet, M. Daniel, K. Page, S. Parikh, V. Prasad, 

P. Szabolcs, J. Kurtzberg 

Brd. 40B Reversal of glucocorticoid resistance by the g-secretase inhibitor PF- 

03084014 in T-cell acute lymphoblastic leukemia. (Abstract #9553) 

J. B. Samon, M. Castillo-Martin, J. L. Jakubczak, S. Randolph, C. Cordon-Cardo, 

A. A. Ferrando 

Brd. 40C Phase I trial of TPI 287 as a single agent and in combination with 

temozolomide (TMZ) in patients with refractory or recurrent neuroblastoma 

(NB) or medulloblastoma (MB). (Abstract #9554) 

G. L. Saulnier Sholler, D. Eslin, W. D. Roberts, J. Kaplan, G. Bergendahl, 

T. Ashikaga, T. Higgins, S. Lenox, S. Silberman, W. Ferguson 

Brd. 40D NOTCH1 inhibition by the gamma-secretase inhibitor RO4929097 in pediatric 

glial tumors. (Abstract #9555) 

G. Berghtold, C. Dantas Barbosa, G. Dieffenbach, E. Daudigeos-Dubus, H. Blokus, 

C. Ferreira, J. Boylan, M. Abely, G. Vassal, J. Grill, B. Geoerger 

Brd. 40E INI1 and mib-1 expression in childhood chordomas. (Abstract #9556) 

H. Yin, K. M. Dorris, L. M. Wagner, M. H. Collins, A. Towbin, R. Nagarajan 

Brd. 40F Nimotuzumab and vinorelbine concomitantly to radiation and as 

maintenance for diffuse pontine glioma in childhood: Results from a series 

of 12 patients. (Abstract #9557) 

M. Massimino, V. Biassoni, L. Gandola, E. Schiavello, E. Pecori, F. Bach 

Brd. 40G Survivin expression in Ewing sarcoma family of tumors. (Abstract #9558) 

P. Hingorani, D. Azorsa, A. white-Collins, P. Dickman, M. Seidel 

Brd. 40H PARP-1 inhibitor MK-4827 in combination with radiation as a treatment 

strategy for metastatic neuroblastoma. (Abstract #9559) 

S. Bhargava, S. Mueller, L. Wehmeijer, X. Yang, A. Gragg, K. K. Matthay, 

W. A. Weiss, D. A. Haas-Kogan 

Brd. 41A Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in 

children and adolescents: Analysis of growth signaling pathways expression 

and clinical outcome. (Abstract #9560) 

J. Mora, C. de Torres, E. Rodriguez, T. M. Cardesa, E. de Alava, O. Cruz 

Brd. 41B Oncologic outcomes of partial versus radical nephrectomy for unilateral 

Wilms tumor. (Abstract #9561) 

N. G. Cost, J. D. Lubahn, H. A. Penn, C. F. Granberg, B. J. Schlomer, 

J. E. Wickiser, D. Rakheja, P. C. Gargollo, D. Leonard, L. A. Baker, G. Raj, 

V. Margulis 

Brd. 41C Back pain and hip pain among survivors of childhood acute lymphoblastic 

leukemia. (Abstract #9562) 

D. C. Bowers, T. Griffith, L. Gargan, C. Cochran, B. Kleiber, A. Foxwell, 

A. Farrow-Gillespie, A. Orlino, J. N. Germann 

Brd. 41D A phase I study of temsirolimus and valproic acid for refractory solid tumors 

in children. (Abstract #9563) 

D. W. Coulter, S. H. Gold, B. Weston, I. Davis, J. Blatt 

242


Brd. 41E Feasibility and pharmacokinetic study of potential ABCG2 inihibitor, gefitinib 

(GB), in combination with irinotecan (IRN) for adolescents and young adults 

(AYA). (Abstract #9564) 

H. Kawamoto, Y. Tabei, T. Kimura, K. Hishima, A. Makimoto 

Brd. 41F Randomized double-blind controlled trial (RCT) of pegfilgrastim as 

prophylactic therapy in pediatric patients with solid tumors during 

myelosuppressive chemotherapy. (Abstract #9565) 

S. Anaya Aguirre, V. Wanzke Del Angel, H. Rivera Marquez, M. Villasis Keever, 

E. Lopez Aguilar, F. Cerecedo Diaz 

Brd. 41G Characteristics of childhood cancer survivors who attend long-term followup 

(LTFU) clinic. (Abstract #9566) 

K. Devine, J. R. Andolina, N. Murray, G. R. Morrow, O. J. Sahler 

Brd. 41H Central nervous system relapse in pediatric acute lymphoblastic leukemia: 

Should we be making the diagnosis sooner? (Abstract #9567) 

A. E. Aguilar, A. K. Agrawal, J. H. Feusner 

Brd. 42A A survey of insurance retention in pediatric patients diagnosed with 

malignancies in a vertically integrated health care system. (Abstract #9568) 

R. M. Cooper, V. Y. Chiu 

Brd. 42B B-cell non-Hodgkin lymphomas in childhood: Twenty years experience in a 

single institution. (Abstract #9569) 

A. Pourtsidis, M. Servitzoglou, M. Baka, D. Bouhoutsou, M. Varvoutsi, D. Doganis, 

C. Strantzia-Michail, H. Kosmidis 

Brd. 42C Effect of selenium supplemantation on anthracycline-induced cardiac 

toxicity in children treated for cancer: Correlation with pro-brain natriuretic 

peptide levels. (Abstract #9570) 

N. Tacyildiz, D. Ozyoruk, G. Ozelci Kavas, H. Dincaslan, G. Yavuz, E. Unal, 

S. Atalay, A. Ikinciogullari, T. Ucar, B. Doganay, G. Oktay, A. Cavdar, O. Kucuk 

Brd. 42D Surviving childhood cancer: What next? Challenges in developing countries. 


P. Kurkure, V. Dhamankar, S. Goswami, N. Dalvi, E. Rawat-Pawar 

Brd. 42E Influence of prognostic factors in pediatric high-grade osteosarcoma 

survival. (Abstract #9572) 

A. Castellanos-Toledo, R. Rivera-Luna, R. Cardenas-Cardos, J. Figueroa Carbajal, 

C. Leal-Cavazos 

Brd. 42F Second malignant tumors in childhood cancer survivors. (Abstract #9573) 

R. Kebudi, I. Ayan, O. Gorgun, F. Y. Agaoglu, G. N. Ozdemir, Y. Dizdar, B. Zulfikar, 

E. Darendeliler 

Brd. 42H Sorafenib (Soraf) and bevacizumab (Beva) for recurrent metastatic 

hepatoblastoma (HB). (Abstract #9575) 

A. Marsh, L. Lo, J. H. Feusner 

Brd. 43A Long-term echocardiogram monitoring and cardiac outcomes of childhood 

cancer survivors with exposure to high doses of anthracyclines. (Abstract 

#9576) 

R. Nagarajan, J. Correll, D. A. Kent, N. Bakeer, J. P. Perentesis, K. C. Burns 

Brd. 43B Secondary leukemia 15 years or more after treatment for childhood cancer: A 

report from the Childhood Cancer Survivor Study. (Abstract #9577) 

K. Nottage, J. Lanctot, Z. Li, J. P. Neglia, S. Bhatia, S. Hammond, W. Leisenring, 

A. T. Meadows, D. K. Srivastava, L. L. Robison, G. T. Armstrong 

Brd. 43C Cardiopulmonary outcomes in pediatric surivors of Hodgkin’s lymphoma. 


K. C. Burns, J. Correll, D. A. Kent, N. Bakeer, J. P. Perentesis, R. Nagarajan 

243 

SUNDAY

SUNDAY 


Brd. 43D A pediatric phase I trial of vorinostat and temozolomide in relapsed or 

refractory primary brain or spinal cord tumors: A Children’s Oncology Group 

Phase I Consortium Study. (Abstract #9579) 

T. R. Hummel, L. M. Wagner, C. H. Ahern, R. M. McGovern, M. M. Ames, 

R. J. Gilbertson, T. M. Horton, A. M. Ingle, B. Weigel, S. Blaney, 

Children’s Oncology Group 

Brd. 43E Evaluation of traditional and novel measures of cardiac function to detect 

anthracycline-induced cardiotoxicity in survivors of childhood cancer. 


A. C. Dietz, S. Sivanandam, C. Kaufman, A. Kelly, J. P. Neglia, P. R. Gaillard, 

D. A. Mulrooney 

Brd. 43F School attendance in childhood cancer survivors. (Abstract #9581) 

A. E. French, E. Tsangaris, S. Guger, M. Barrera, R. Brown, S. Urbach, 

D. Stephens, P. C. Nathan 

244

8:00 AM - 12:00 PM 



Sarcoma 



Brd. 44A Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim 

results from a phase II study. (Abstract #10034) 

J. Blay, S. P. Chawla, J. Martin Broto, E. Choy, M. Dominkus, J. Engellau, 

R. Grimer, R. M. Henshaw, E. Palmerini, P. Reichardt, P. Rutkowski, K. M. Skubitz, 

D. M. Thomas, Y. Zhao, Y. Qian, I. A. Jacobs 

Brd. 44B A novel combined radiologic method for evaluation of the response to 

chemotherapy for primary bone sarcoma. (Abstract #10035) 

S. Miwa, T. Shirai, J. Taki, N. Yamamoto, H. Nishida, K. Hayashi, H. Kimura, 

A. Takeuchi, K. Igarashi, H. Tsuchiya 

Brd. 44C Primary osteosarcomas of the mandible: Joint study of the Groupe Sarcome 

Francais (GSF), Rare Cancer Network, and Groupe d’Etude des Tumeurs de 

la Tete et du Cou (GETTEC). (Abstract #10036) 

J. Thariat, I. Ray-Coquard, A. Thyss, A. Italiano, J. Sarini, R. C. Miller, E. Bompas, 

A. Brouchet, O. Dassonville, S. Salas, P. Maingon, J. Kurtz, H. Reychler, 

T. de La Motte Rouge, K. Aldabbagh, J. Usseglio, P. Kerbrat, J. Lotz, 

L. Chaigneau, M. Julieron, Groupe Sarcome Francais-Groupe d’Etude des 

Tumeurs Ossseuses (GSF-GETO), Rare Cancer Network, Groupe d’Etude des 

Tumeurs de la Tete et du Cou (GETTEC) 

Brd. 44D Effects of denosumab on pain reduction in giant cell tumor of bone (GCTB): 

Interim phase II study results. (Abstract #10037) 

C. S. Cleeland, A. P. Staddon, S. Schuetze, A. Powell, A. Lopez Pousa, A. Cioffi, 

J. R. Kroep, S. Stacchiotti, K. Chung, C. Atchison, Y. Qian, Y. Zhao, I. A. Jacobs 

Brd. 44E Functional characterization of IGFBP5 in the inhibition of osteosarcoma 

tumorgenicity. (Abstract #10038) 

G. Luther, E. Wagner, H. Luu, R. Haydon, T. He 

Brd. 44F Osteosarcoma of the pelvis and sacrum: A retrospective analysis of 73 


E. Palmerini, N. Fabbri, E. L. Staals, E. Marchesi, M. Alberghini, A. Tienghi, 

F. Fagioli, P. Picci, M. Mercuri, S. Ferrari 

Brd. 44G Phase II study of 153-samarium-EDTMP followed by haematopoietic stem cell 

for patients with osteosarcoma with bone metastasis. (Abstract #10040) 

B. Massimo, G. Grignani, A. Giostra, M. Pagano, S. Ferrari, B. Elia, 

F. Carnevale-Scianca, M. Aglietta, R. Pellerito, F. Fagioli 

Brd. 44H Clinical outcomes of adult patients with relapsed Ewing sarcoma: A 30-year 

single institution experience. (Abstract #10041) 

S. I. Robinson, S. K. Ahmed, N. N. Laack, P. S. Rose, S. H. Okuno 

Brd. 45A High-dose chemotherapy plus autologous stem cell transplation (HDCT/ 

SCT) in patients with sarcoma: A single institution experience. (Abstract 

#10042) 

A. Stradella, A. Lopez-Pousa, M. Quintana, P. Murata, M. Ortin, O. Gallego, 

I. Sullivan, L. Robert, A. Sebio, I. Gracia, J. De Vega, A. Barnadas 

Brd. 45B Prevalence of hereditary GIST susceptibility in adults with GIST. (Abstract 

#10043) 

I. R. Rainville, E. J. Root, M. Salerno, L. DiGianni, D. A. Nelson, C. L. Corless, 

M. C. Heinrich, M. E. Robson, J. E. Garber 

245 

SUNDAY

SUNDAY 


Brd. 45C Patterns of care, prognosis, and survival of patients with metastatic 

gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and 

second-line sunitinib. (Abstract #10044) 

A. Italiano, A. Cioffi, R. G. Maki, P. Schoffski, P. Rutkowski, A. Le Cesne, 

F. Duffaud, A. Adenis, N. Isambert, E. Bompas, J. Blay, P. G. Casali, P. Coco, 

D. R. D’Adamo, M. Keohan, M. Toulmonde, C. Antonescu, M. Debiec-Rychter, 

J. Coindre, B. Bui Nguyen 

Brd. 45D Identification of SDHA (subunit A of the succinate dehydrogenase) mutations 

in KIT/PDGFRA WT gastrointestinal stromal tumors (GISTs). (Abstract 

#10045) 

M. A. Pantaleo, A. Astolfi, V. Indio, P. Paterini, S. Formica, R. Casadio, P. Martelli, 

A. Maleddu, M. Nannini, A. P. Dei Tos, M. C. Heinrich, D. Santini, F. Catena, 

C. Ceccarelli, M. Fiorentino, M. di Battista, R. Moore, N. Thiessen, C. Gnocchi, 

G. Biasco 

Brd. 45E Identification of single nucleotide variants in gastrointestinal stromal tumor 

KIT/PDGFRA wild-type (WT GISTs) by massively parallel sequencing. 


V. Indio, M. A. Pantaleo, A. Astolfi, R. Casadio, P. Paterini, S. Formica, P. Martelli, 

R. Moore, N. Thiessen, M. di Battista, F. Catena, D. Santini, M. C. Heinrich, 

C. Gnocchi, A. P. Dei Tos, G. Biasco 

Brd. 45F KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two 

different subpopulations in KIT-negative GIST-like (KNGL) patients. (Abstract 

#10047) 

J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano, 

J. Rubió, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda, 

M. Ramirez, R. Cubedo, J. Lopez-Guerrero, Spanish Group for Sarcoma Research 

(GEIS) 

Brd. 45G Who are the long responders to imatinib (IM) in patients with advanced 

GIST? Results of the BFR14 prospective French Sarcoma Group randomized 

phase III trial. (Abstract #10048) 

A. Blesius, P. A. Cassier, I. Ray-Coquard, A. Italiano, A. Adenis, M. Rios, 

F. Bertucci, T. Huynh, D. Cupissol, Y. Berge, E. Bompas, J. Emile, S. Chabaud, 

D. Perol, A. Le Cesne 

Brd. 45H Mechanism of early radiographic response to imatinib in GIST. (Abstract 

#10049) 

J. Gao, J. C. McAuliffe, A. J. Lazar, W. Wang, H. Choi, K. Hunt, D. M. Araujo, 

R. E. Pollock, R. S. Benjamin, J. C. Trent 

Brd. 46A Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase 

II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) 

following failure of standard therapy (Rx). (Abstract #10050) 

A. D. Van Den Abbeele, Y. Tanaka, T. Locascio, C. Sakellis, M. C. Heinrich, 

M. von Mehren, E. Choy, W. D. Tap, J. Manola, G. D. Demetri, S. George, 

J. T. Yap 

Brd. 46B FDG-PET as a predicitve marker for primary resistance to imatinib (IM) in 

patients with gastrointestinal stromal tumors (GIST) (Abstract #10051) 

S. Oosting, M. W. Den Hollander, B. Rikhof, D. B. Rouw, J. R. De Jong, 

P. L. Jager, A. H. Brouwers, W. Van Der Graaf, E. De Vries, J. A. Gietema, 

A. K. Reyners 

Brd. 46C Outcome of adjuvant imatinib in patients with gastrointestinal stromal tumor: 

Results of a population-based, matched cohort study. (Abstract #10052) 

H. T. Hatoum, J. C. Trent, A. Guo, S. Lin, L. A. Sirulnik, M. Sasane 

Brd. 46D Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma 

Group (FSG) retrospective review of 90 patients (pts). (Abstract #10053) 

F. Duffaud, I. Ray-Coquard, A. Blesius, T. Huynh, E. Boucher, O. Bouche, J. Bay, 

F. Marchal, J. Spano, F. Bertucci, B. Bui Nguyen, O. Collard, L. Chaigneau, 

N. Isambert, A. Adenis, J. Mancini, A. Le Cesne, J. Blay, French Sarcoma Group 

(GSF-GETO) 

246


Brd. 46E Influence of imatinib interruption and imatinib rechallenge on the residual 

tumor volume in patients with advanced GIST: Results of the BFR14 

prospective French Sarcoma Group randomized phase III trial. (Abstract 

#10054) 

J. Domont, J. Blay, I. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Bertucci, 

F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, V. Bourne-Branchu, 

S. Chabaud, A. Le Cesne 

Brd. 46F Retrospective analysis of surgery in metastatic GIST patients sensitive to 

imatinib: A Spanish Group for Research on Sarcoma (GEIS) study. (Abstract 

#10055) 

J. Rubió, J. Martinez-Trufero, A. Lopez-Pousa, X. Garcia del Muro, J. Fra, 

A. Redondo, N. Lainez, A. Poveda, A. Casado, C. M. Valverde, A. De Juan, 

I. Sevilla, R. Andres, J. Cruz, M. Safont, J. Martin Broto, X. Garcia-Albeniz, 

J. Maurel 

Brd. 46G MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation 

with KIT/PDGFRA kinase genotype. (Abstract #10056) 

S. Formica, A. Astolfi, M. Nannini, M. A. Pantaleo, M. Ferracin, B. Zagatti, 

M. Negrini, D. Santini, P. Paterini, M. di Battista, A. Maleddu, M. Saponara, 

M. Pallotti, A. Mandrioli, C. Lolli, F. Catena, A. P. Dei Tos, G. Biasco 

Brd. 46H Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced 

primary and metastatic/recurrent operable gastrointestinal stromal tumor 

(GIST): Long-term follow-up results of RTOG 0132. (Abstract #10057) 

D. Wang, Q. Zhang, C. D. Blanke, G. D. Demetri, M. C. Heinrich, J. C. Watson, 

J. P. Hoffman, S. H. Okuno, J. M. Kane, M. vonMehren, B. L. Eisenberg 

Brd. 47A Exploring the relation between overall survival (OS) and progression-free 

survival (PFS) in gastrointestinal stromal tumor (GIST) via meta-analysis. 


R. L. Keyser, K. E. Tranbarger Freier, D. C. Hoaglin, S. Tzivelekis, D. Muston, 

I. Ozer-Stillman 

Brd. 47B Tumor volumes measurement (3D) versus Response Evaluation Criteria in 

Solid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessing 

response of gastrointestinal stromal tumors (GIST) to imatinib (IM). (Abstract 

#10059) 

G. Schiavon, A. Ruggiero, S. Sleijfer, K. Eechoute, G. P. Krestin, J. Verweij, 

R. Mathijssen 

Brd. 47C Validating innovation: A population-based study of gastrointestinal stromal 

tumors (GIST) to estimate the survival benefit of imatinib. (Abstract #10060) 

D. Goldstein, C. Lee, E. Tracey, C. Cook-Yarborough, S. Lord 

Brd. 47D Hypertension monitoring as a tool to predict congestive heart failure (CHF) 

during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC). 


D. Galizia, C. Ortega, E. Palesandro, V. Prati, S. Gallo, L. D’Ambrosio, A. Bonzano, 

D. Rota Scalabrini, S. Aliberti, G. Grignani, M. Aglietta 

Brd. 47E Study of dynamic contrast-enhanced ultrasound (DCE-US) for the early 

evaluation of imatinib. (Abstract #10062) 

G. Abboud, N. Lassau, S. Koscielny, B. Benatsou, F. Tabarout, L. Chami, 

E. Girard, S. Bidault, J. Domont, A. Cioffi, S. Bonvalot, A. Le Cesne 

Brd. 47F Imatinib efficacy by tumor genotype in Asian patients with metastatic or 

recurrent gastrointestinal stromal tumors (GISTs): A retrospective study of 

Korean GIST Study Group (KGSG). (Abstract #10063) 

H. Kang, M. Ryu, K. Kim, Y. Park, W. Kim, S. Im, S. Park, K. Lee, H. Song, Y. Kang 

Brd. 47G A phase II study of low-dose protracted irinotecan in patients with advanced 

sarcomas. (Abstract #10064) 

S. N. Dumont, J. C. Trent, S. Patel, D. M. Araujo, A. G. Dumont, R. S. Benjamin 

247 

SUNDAY

SUNDAY 


Brd. 47H High rates of histopathologic discordance in sarcoma with implications for 

clinical care. (Abstract #10065) 

C. P. Raut, S. George, J. L. Hornick, J. E. Butrynski, J. A. Morgan, J. Ready, 

A. F. Nascimento, C. D. Fletcher, G. D. Demetri, E. H. Baldini 

Brd. 48A Differences between neurofibromatosis-1-associated malignant peripheral 

nerve sheath tumors (MPNST) and sporadic MPNST: The Mayo Clinic 


K. N. Johnson, C. H. Stucky, B. A. Pockaj, R. J. Gray, P. S. Rose, N. Wasif 

Brd. 48B Multicentric phase II clinical trial evaluating the role of everolimus (RAD001) 

in endemic or classic Kaposi’s sarcoma (C06–46). (Abstract #10067) 

R. Porcher, D. Kerob, N. Dupin, B. Guillot, T. Jouary, A. Mathieu-Boue, K. Slimane, 

V. Furlan, M. Battistella, F. Agbalika, S. Mourah, C. Lebbé 

Brd. 48C Effect of Notch3 to regulate rhabdomyosarcoma growth in vitro and in vivo. 


R. Rota, L. Raimondi, R. Ciarapica, F. Verginelli, M. Gueguen, R. Boldrini, 

L. De Sio, A. Inserra, M. Locatelli, T. Dang, L. Miele, S. Stifani, I. Limon, F. Locatelli 

Brd. 48D Quantitative analysis of IGF-1R expression in FFPE human 

rhabdomyosarcoma tumor tissue by mass spectrometry. (Abstract #10069) 

S. Malempati, T. A. Hembrough, S. Thyparambil, L. Cao, M. Darfler, D. Krizman, 

D. S. Hawkins, S. Skapek, L. J. Helman, J. Burrows 

Brd. 48E Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective 

study from the French Group Sarcoma (GSF-GETO). (Abstract #10070) 

E. Bompas, L. Campion, A. Italiano, A. l. Cesne, M. Giaj Levra, C. Chevreau, 

S. Piperno-Neumann, N. Isambert, A. Thyss, M. Rios, J. Kurtz, C. Delcambre, 

J. Bay, F. Duffaud, M. Trassard, P. Soulie, J. Blay 

Brd. 48F Advanced well-differentiated/dedifferentiated liposarcomas: Role of 

chemotherapy and survival. (Abstract #10071) 

M. Toulmonde, A. Italiano, N. Penel, A. Cioffi, A. Le Cesne, N. Isambert, 

E. Bompas, F. Duffaud, A. Patrikidou, R. G. Maki, J. Coindre, J. Blay, 

B. Bui Nguyen 

Brd. 48G A phase II study of a new formulation of nonpegylated liposomal doxorubicin 

(doxorubicin GP-pharm) as first-line treatment in patients with advanced 

soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial. (Abstract 

#10072) 

A. Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balañá, 

J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra, 

J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo, J. Blay 

Brd. 48H A phase I dose-escalation study of azacitidine in combination with 

temozolomide in patients with soft tissue sarcomas. (Abstract #10073) 

I. Matushansky, K. E. Coakley, T. S. Uldrick, R. N. Taub 

Brd. 49A Expression of MGMT and response to treatment with temozolomide in 

patients with leiomyosarcoma. (Abstract #10074) 

A. Marrari, J. L. Hornick, N. H. Ramaiya, J. Manola, A. J. Wagner 

Brd. 49B A phase II consortium trial of vorinostat and bortezomib for advanced soft 

tissue sarcomas. (Abstract #10075) 

S. Attia, M. R. Mahoney, S. H. Okuno, D. Adkins, H. G. Ahuja, T. P. Ducker, 

W. J. Maples, L. Ochs, N. L. Wentworth-Hartung, C. Erlichman, H. H. Bailey 

Brd. 49C A phase II trial evaluating efficacy of neo-/adjuvant EIA CTX, surgery, and 

radiation therapy in high-risk soft tissue sarcoma. (Abstract #10076) 

T. Schmitt, B. Kasper, M. Bischof, B. Lehner, S. Dietrich, A. Dimitrakopoulou- 

Strauss, L. G. Strauss, G. Mechtersheimer, P. Wuchter, A. D. Ho, G. Egerer 

Brd. 49D Growth factor receptors and cell cycle proteins as new molecular prognosis 

markers in high-grade undifferentiated pleomorphic sarcoma (HGUPS). 


C. Serrano, S. Simonetti, C. M. Valverde, R. Morales, C. Suarez, T. Moline, 

J. Carles, S. Ramon y Cajal, C. Romagosa 

248


Brd. 49E Adjuvant and neoadjuvant chemotherapy (NAC) with ifosfamide (IFO) and 

doxorubicin hydrochloride (ADM) for high-grade soft tissue sarcomas (STS) 

in the extremities: Japan Clinical Oncology Group study JCOG030404. 


K. Tanaka, J. Mizusawa, H. Fukuda, N. Araki, H. Chuuman, M. Takahashi, 

T. Ozaki, T. Hiruma, H. Tsuchiya, H. Morioka, T. Morita, T. Wada, M. Hatori, 

Y. Yoshida, J. Toguchida, S. Abe, A. Matsumine, R. Yokoyama, Y. Iwamoto 

Brd. 49F Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic 

therapy and survival. (Abstract #10079) 

A. Cioffi, A. Italiano, N. Penel, Y. Berge, M. Toulmonde, S. Salas, C. Chevreau, 

A. Le Cesne, F. Duffaud, D. R. D’Adamo, M. Keohan, C. Genebes, C. Antonescu, 

J. Coindre, B. Bui Nguyen, R. G. Maki 

Brd. 49G Effect of the combination of mTOR inhibitor ridaforolimus and HDAC 

inhibitor vorinostat on in vitro synergism in synovial sarcoma, 

osteosarcoma, and a range of other tumor subtypes. (Abstract #10080) 

S. S. Morgan, L. D. Cranmer 

Brd. 49H Identification of potential molecular candidate lesions by molecular analysis 

of desmoid tumors with QRT-PCR and high-density SNP arrays. (Abstract 

#10081) 

P. Erben, D. Nowak, W. Hofmann, R. Hofheinz, P. Hohenberger, B. Kasper 

Brd. 50A Heterogeneity of metastatic behavior among high-grade pleomorphic soft 

tissue sarcomas identified by gene expression analysis. (Abstract #10082) 

K. M. Skubitz, P. Francis, A. Skubitz, X. Luo, M. Nilbert 

Brd. 50B Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) 

chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose 

intensity (DI). (Abstract #10083) 

Y. Kojima, K. Hashimoto, M. Ando, K. Yonemori, H. Yamamoto, M. Kodaira, 

M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto, Y. Fujiwara 

Brd. 50C Topoisomerase-based chemotherapy in adults with relapsed or refractory 

pediatric-type sarcoma: A retrospective analysis of the German AIO Sarcoma 

Group/BMBF SAREZ registry. (Abstract #10084) 

J. T. Hartmann, I. Sturm, R. D. Issels, S. W. Krause, V. Gruenwald, A. Kunitz, 

L. Lindner, K. San Nicolo, F. Mayer, B. Hertenstein, L. Mueller, U. Kontny, 

J. Topaly, R. U. Trappe, W. Grothe 

Brd. 50D Metastatic angiosarcomas (mAS): Identification of treatments that 

significantly improve the outcome. (Abstract #10085) 

E. Amela, A. Italiano, I. Ray-Coquard, L. Chaigneau, C. Delcambre, B. Bui Nguyen, 

F. Bertucci, N. Isambert, D. Cupissol, E. Bompas, J. Bay, F. Duffaud, C. Guillemet, 

N. Corradini, P. A. Cassier, C. Chevreau, J. Blay, N. Penel, French Sarcoma Group 

(GSF/GETO) 

Brd. 50E Predictive role of topoisomerase II�, gp170, Bcl-2, tumor burden, and 

histology in neoadjuvant chemotherapy for soft tissue sarcomas of the 

extremities. (Abstract #10086) 

A. Comandone, P. Porrino, E. Berardengo, A. Linari, A. Boglione, C. Oliva, 

G. Gino, C. Faletti, P. Bergnolo, P. Pochettino, A. Bernardi, E. M. Brach del Prever, 

R. Piana 

Brd. 50F Creatinine clearance and serum albumin as factors for encephalopathy with 

ambulatory 14-day infusional ifosfamide for advanced liposarcomas. 


S. M. Alam, C. Benson, R. L. Jones, E. Thanopoulou, S. Mitchell, O. Al-Muderis, 

A. Dunlop, C. Propert-Lewis, I. R. Judson, M. R. Scurr 

Brd. 50G Pulmonary metastasectomy in soft tissue sarcomas (STS): A singleinstitution 


M. Glogowski, L. Talarek, I. A. Lugowska, S. Falkowski, T. Switaj, M. Zmijewski, 

R. Wlodarczyk, H. Kosela, M. Turski, M. J. Krzakowski, P. Rutkowski 

249 

SUNDAY

SUNDAY 


Brd. 50H Histology and outcome in localized high-risk soft tissue sarcomas (STS) 

treated with preoperative chemotherapy (CHT) with or without radiation 

therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and 

the Spanish Sarcoma Group (GEIS). (Abstract #10089) 

P. G. Casali, S. Stacchiotti, P. Verderio, P. Collini, A. P. Dei Tos, M. Alberghini, 

A. Llombart-Bosch, C. Morosi, A. Messina, M. Mercuri, A. Gronchi 

Brd. 51A Exploratory analysis of prognostic factors for patients (pts) with advanced 

soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined 

study of the EORTC Soft Tissue and Bone Sarcoma Group and the French 

Sarcoma Group. (Abstract #10090) 

N. Penel, M. M. Van Glabbeke, B. Bui Nguyen, M. Ouali, S. Mathoulin-Pelissier, 

S. Marreaud, A. Italiano, V. Brouste, P. C. Hogendoorn, J. Coindre, J. Blay, 

P. Hohenberger 

Brd. 51B Mucocutaneous angiosarcoma (MC-AS) versus non-MC-AS: Clinicopathologic 

features and treatment outcomes in 44 patients (pts). (Abstract 

#10091) 

R. H. Quek, M. R. Harunal Rashid, W. Ong, M. J. Lee, R. Jeevan, Z. Ho, F. Chin, 

L. Soh, D. Poon, M. Teo 

Brd. 51C Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated 

with vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-like 


K. Harano, Y. Kojima, K. Hashimoto, M. Ando, A. Hirakawa, K. Yonemori, 

M. Kodaira, M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto, 

Y. Fujiwara 

Brd. 51D Management and outcomes for primary cardiac sarcomas (PCS): A 

retrospective study of the French Sarcoma Group (FSG). (Abstract #10093) 

N. Isambert, I. Ray-Coquard, B. Bui Nguyen, M. Rios, P. Kerbrat, A. Blouet, 

L. Chaigneau, F. Duffaud, S. Piperno-Neumann, J. Kurtz, J. Thariat, N. Girard, 

O. Collard, E. Bompas, N. Penel, J. Bay, C. Guillemet, F. Collin, J. Blay, 

A. Le Cesne 

Brd. 51E Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients 

(pts) with locally advanced or metastatic leiomyosarcoma (LMS) and 

liposarcoma (LPS). (Abstract #10094) 

U. Bitz, D. Pink, C. Busemann, P. Reichardt 

Brd. 51F Prognostic factors in leiomyosarcoma (LMS): Does primary site influence 

outcome? (Abstract #10095) 

M. R. Harunal Rashid, W. Ong, M. Teo, M. Tan, L. Foo, Y. Lim, F. Chin, M. J. Lee, 

Z. Ho, R. Jeevan, J. W. Chia, L. Soh, D. Poon, R. H. Quek 

Brd. 51G The role of E-cadherin expression in response and outcome in patients with 

leiomyosarcoma treated with chemotherapy. (Abstract #10096) 

V. Ravi, J. Yang, D. M. Araujo, M. S. Park, R. S. Benjamin, W. Zhang, J. C. Trent, 

S. Patel 

Brd. 51H The role of chemotherapy in advanced hemangiopericyoma/solitary fibrous 

tumor. (Abstract #10097) 

M. S. Park, S. Patel, V. Ravi, A. P. Conley, J. C. Trent, A. J. Lazar, D. Lev, 

X. Wang, R. S. Benjamin, D. M. Araujo 

Brd. 52A Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) 

evaluation of preoperative therapy for extremity soft tissue sarcomas (STS). 


J. M. Meyer, K. S. Perlewitz, S. L. Hemmingson, J. B. Hayden, A. Hung, 

A. Mansoor, M. L. Holtorf, W. J. Woodward, C. S. Springer, W. Huang, C. W. Ryan 

250

8:00 AM - 12:30 PM 





Discussion Time: 11:30 AM - 12:30 PM 

Discussion Location: S100bc 

CME credit: 1 



Thomas J. Smith, MD—Chair 

Massey Cancer Center of Virginia Commonwealth University 

Discussion 

11:30 AM James Lloyd Wade, MD (Abstracts #9017–9022) 

Cancer Care Specialists of Central Illinois 

Discussion 

11:45 AM Pamela Jean Goodwin, MD (Abstracts #9023–9029) 

Mount Sinai Hospital 

Discussion 

12:00 PM Patricia A. Ganz, MD (Abstracts #9030–9035) 

University of California, Los Angeles Schools of Medicine and Public Health 

Discussion 

12:15 PM Teresa Gilewski, MD (Abstracts #9036–9041) 


Brd. 1 Gabapentin for the prevention of chemotherapy-induced nausea and 

vomiting: A pilot study. (Abstract #9017) 

F. M. Cruz, A. Del Giglio, D. d. Cubero, P. Taranto, T. Lerner, A. T. Lera, 

M. C. Miranda, M. C. Vieira, A. B. Fede, F. Schindler, S. O. Afonseca, 

H. Pinczowski 

Brd. 2 Antiemetic choice based on economic advantage. (Abstract #9018) 

E. Z. Touloukian, A. Yakan, R. E. Bloom 

Brd. 3 Phase III study of single-dose casopitant in combination with ondansetron 

and dexamethasone for the prevention of oxaliplatin-induced nausea and 

vomiting. (Abstract #9019) 

P. J. Hesketh, V. Moiseyenko, G. Rosati, A. Makhson, J. Levin, M. W. Russo 

Brd. 4 A randomized, double-blind, placebo-controlled cross over trial of the effect 

on quality of life (QOL) of continuing dexamethasone beyond 24 hours 

following moderately emetogenic chemotherapy in women with breast 


J. L. Vardy, G. R. Pond, A. Dodd, D. Warr, B. Seruga, M. J. Clemons, L. Bordeleau, 

I. Tannock 

Brd. 5 Testing the cutaneous absorption of lorazepam, diphenhydramine, and 

haloperidol gel (ABH gel) used for cancer-related nausea. (Abstract #9021) 

T. J. Smith, J. K. Ritter, P. J. Coyne, G. L. Parker, P. Dodson, D. S. Fletcher 

Brd. 6 Effect of GTx-024, a selective androgen receptor modulator (SARM), on 

physical function in patients with non-small cell lung cancer (NSCLC) with 

cancer cachexia. (Abstract #9022) 

M. S. Steiner, A. Dobs, M. L. Hancock, M. A. Johnston, G. Barnette, S. Dodson 

Brd. 7 Buspirone treatment of dyspnea in outpatients receiving chemotherapy: A 

University of Rochester Cancer Center Community Clinical Oncology 

Program (URCC CCOP) study. (Abstract #9023) 

P. W. Bushunow, J. A. Roscoe, D. J. Dudgeon, J. J. Kirshner, C. E. Heckler, 

G. R. Morrow, S. R. Dakhil, T. S. Collins, D. A. Churchill, University of Rochester 

Cancer Center Community Clinical Oncology Program (URCC CCOP) 

251 

SUNDAY

SUNDAY 


Brd. 8 Mortality reduction by talactoferrin alfa (TLF) in severe sepsis with different 

types of infections. (Abstract #9024) 

J. Crawford, K. K. Guntupalli, N. C. Dean, P. E. Morris, R. K. Malik, 

J. P. Schaumberg 

Brd. 9 Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in 

prevention of skeletal-related events (SREs) in metastatic breast cancer 

(mBC). (Abstract #9025) 

J. A. Carter, S. J. Snedecor, S. Kaura, M. Botteman 

Brd. 10 Vitamin D repletion and prevention of bone loss in nonosteoporotic women 

with breast cancer. (Abstract #9026) 

S. Servitja, D. Prieto-Alhambra, M. Martinez-Garcia, L. Garrigos, M. J. Pena, 

A. Diez-Perez, J. Albanell, X. Nogues, I. Tusquets 

Brd. 11 Phase III randomized, double-blind, placebo-controlled trial of soy protein 

and venlafaxine for treatment of hot flashes in men with prostate cancer. 


M. Vitolins, L. Griffin, W. V. Tomlinson, J. Vuky, D. B. Fried, P. T. Adams, 

D. Moose, B. Frizzell, J. E. Radford, T. Shah, E. G. Shaw 

Brd. 12 Final results of a randomized phase II trial (NCT00637975) evaluating activity 

and toxicity of fixed-dose oxycodone and increasing dose of pregabalin 

versus increasing dose of oxycodone and fixed-dose pregabalin for the 

treatment of oncologic neuropathic pain (NEUROPAIN-01). (Abstract #9028) 

M. C. Garassino, A. Bianchi, A. Febbraro, I. Spagnoletti, V. Iorno, A. Bramati, 

C. Carbone, L. Isa, E. Breda, R. Magarotto, V. Torri, G. Farina 

Brd. 13 Acupuncture for chemotherapy-induced fatigue: A randomized controlled 


G. E. Deng, Y. Chan, K. Yeung, A. J. Vickers, B. R. Cassileth 

Brd. 14 Long-term protective effects of the angiotensin-receptor blocker telmisartan 

on epirubucin-induced inflammation, oxidative stress, and myocardial 

dysfunction. (Abstract #9030) 

G. Mantovani, C. Madeddu, M. Dessì, E. Massa, G. Antoni, A. Piras, C. Cadeddu, 

M. Deidda, G. Mercuro 

Brd. 15 The relationship between serum hepcidin levels and clinical outcomes in 

patients with chemotherapy-associated anemia treated in a controlled trial. 


D. P. Steensma, B. J. Sasu, J. A. Sloan, D. Tomita, C. L. Loprinzi 

Brd. 16 Role of hypoalbuminemia in the development of venous thromboembolism in 

cancer chemotherapy patients. (Abstract #9032) 

Z. Li, W. B. Webb III, J. Mao, S. Gautam, S. Singh, G. H. Lyman 

Brd. 17 Molecular diagnosis of bacteriemia in patients with neutropenic febrile 

oncohematologic. (Abstract #9033) 

E. Gimeno, L. Sorli, E. Abella, A. Alvarez-Larran, J. Horcajada, L. Garrigos, 

A. Taus, A. Salar, B. Sanchez, C. Pedro, C. Besses, M. Salvado 

Brd. 18 Effect of YOCAS yoga on circadian rhythm, anxiety, and mood: A URCC 

CCOP randomized, controlled clinical trial among 410 cancer survivors. 


K. M. Mustian, L. Sprod, L. J. Peppone, S. G. Mohile, M. C. Janelsins, O. Palesh, 

K. Devine, P. S. Reddy, M. Melnik, J. K. Giguere, G. R. Morrow 

Brd. 19 Effect of medical Qigong on cognitive function, quality of life, and a 

biomarker of inflammation in patients with cancer: A randomized controlled 


B. Oh, P. Butow, N. Pavlakis, P. J. Beale, S. J. Clarke, D. S. Rosenthal, L. Larkey, 

J. L. Vardy 

Brd. 20 Exercise and side effects among 417 older patients with cancer during and 

after cancer treatment: A URCC CCOP study. (Abstract #9036) 

L. Sprod, S. G. Mohile, K. Devine, M. C. Janelsins, L. J. Peppone, G. R. Morrow, 

R. S. Lord, H. M. Gross, K. M. Mustian 

252


Brd. 21 Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) 

older than age 65 with advanced cancer (Ca) and toxicity outcomes. 


A. Gajra, M. Hardt, W. P. Tew, S. G. Mohile, C. Owusu, H. D. Klepin, C. P. Gross, 

S. M. Lichtman, R. Ramani, J. Brown, V. Katheria, R. Jayani, K. Hansen, 

K. Togawa, S. Klapper, A. Hurria, Cancer and Aging Research Group 

Brd. 22 Scarring, disfigurement, and quality of life in long-term survivors of 

childhood cancer: A report from the Childhood Cancer Survivor Study. 


K. E. Kinahan, L. K. Sharp, A. Didwania, K. Seidel, W. Leisenring, M. E. Lacouture, 

M. Stovall, L. L. Robison, K. R. Krull 

Brd. 23 Disability pension among patients with breast cancer: A Norwegian 

population-based controlled study. (Abstract #9039) 

B. Hauglann, J. Sˇ altytë Benth, S. D. Fossa, A. A. Dahl 

Brd. 24 What leads to better quality of life at the end of life? (Abstract #9040) 

M. E. Nilsson, B. Zhang, E. Reitschuler-Cross, A. A. Wright, X. Gao, J. S. Temel, 

T. A. Balboni, H. G. Prigerson 

Brd. 25 Do the preferences of patients with terminal cancer or their family caregivers 

and end-of-life care discussions influence utilization of hospice-palliative 

care? (Abstract #9041) 

A. An, Y. Yun, W. Lee, K. Jung, Y. Do, S. Kim, D. S. Heo, J. Choi, S. Park, 

H. Jeong, J. Kang, J. Ro 

253 

SUNDAY

SUNDAY 


8:00 AM - 12:30 PM 




Display Location: Hall A 



CME credit: 1 


Birgit Geoerger, MD, PhD—Chair 

Institut Gustave Roussy 

Discussion 

11:30 AM Julia Lynne Glade Bender, MD (Abstracts #9520–9523) 


Discussion 

11:45 AM Paul Graham Fisher, MD (Abstract #9524) 

Stanford Cancer Center 

Discussion 

12:00 PM William D. Tap, MD (Abstracts #9526–9531) 


Discussion 

12:15 PM Lillian Sung, MD, PhD (Abstracts #9532–9535) 


Brd. 36A A phase I trial of IMC-A12 and temsirolimus in children with refractory solid 

tumors: A Children’s Oncology Group Study. (Abstract #9520) 

M. Fouladi, J. P. Perentesis, L. M. Wagner, A. M. Ingle, J. Gammon, G. Thomas, 

D. A. Krueger, P. Houghton, S. Vinks, B. Weigel, S. Blaney 

Brd. 36B Phase I study of clofarabine and liposomal daunorubicin in childhood acute 

myeloid leukemia. (Abstract #9521) 

P. Kearns, N. J. Graham, M. Cummins, B. Gibson, J. D. Grainger, R. Keenan, 

D. Lancaster, G. Shenton, J. Vormoor, D. Webb, I. Hawley, P. J. Johnson 

Brd. 36C A phase I trial of vorinostat and bortezomib in children with refractory or 

recurrent solid tumors: A Children’s Oncology Group study. (Abstract #9522) 

J. A. Muscal, P. A. Thompson, T. M. Horton, A. M. Ingle, C. H. Ahern, 

R. M. McGovern, J. M. Reid, M. M. Ames, B. Weigel, S. Blaney 

Brd. 36D A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children 

with refractory or recurrent neuroblastoma: Early-phase evaluation. 


F. Navid, R. C. Barfield, R. Handgretinger, P. M. Sondel, B. L. Shulkin, 

R. Kaufman, C. Billups, J. Wu, W. L. Furman, L. M. McGregor, M. Otto, S. Gillies, 

V. M. Santana 

Brd. 36E Vinorelbine in progressive unresectable low-grade glioma in children. 


A. M. Cappellano, E. Bouffet, F. Silva, P. Paiva, M. d. Alves, S. Cavalheiro, 

N. S. Silva 

Brd. 36G Pilot study of adding vincristine, topotecan, and cyclophosphamide to 

interval-compressed chemotherapy in newly diagnosed patients with 

localized Ewing sarcoma family of tumors: A Children’s Oncology Group 


L. Mascarenhas, J. L. Felgenhauer, M. C. Bond, J. D. Femino, N. N. Laack, 

S. Ranganathan, M. D. Krailo, N. Marina, Children’s Oncology Group 

Brd. 36H The management of pulmonary nodules at diagnosis in patients with Ewing 

sarcoma (ES). (Abstract #9527) 

C. Owens, M. Le Deley, J. M. Michon, I. Marzouk, E. Thebault, P. Marec Bérard, 

O. Oberlin 

254


Brd. 37A Proposal of a prognostic score system for the Brazilian Osteosarcoma 

Treatment Group (BOTG) patients. (Abstract #9528) 

M. Cypriano, A. Ferraro, C. M. Costa, V. Odone, D. Lustosa, M. Borsato, 

A. L. Brunetto, L. Calheiros, J. Barreto, S. Epelman, E. Carvalho, W. V. Pereira, 

E. M. Pontes, R. J. Garcia Filho, M. d. Alves, C. R. Macedo, O. P. de Camargo, 

P. Pericles, V. Penna, A. S. Petrilli, Sociedade Brasileira de Oncologia Pediatrica 

(SOBOPE) 

Brd. 37B Parameningeal rhabdomyosarcoma: Results of a pooled analysis from U.S. 

and European Cooperative Groups. (Abstract #9529) 

J. H. Merks, G. De Salvo, C. Bergeron, G. Bisogno, A. Rey, O. Oberlin, A. Kelsey, 

I. Zanetti, J. M. Michalski, D. S. Hawkins, J. R. Anderson 

Brd. 37C Anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma. (Abstract #9530) 

J. C. van Gaal, U. E. Flucke, M. H. Roeffen, E. S. de Bont, A. J. Suurmeijer, 

W. Van Der Graaf, Y. M. Versleijen-Jonkers 

Brd. 37D Can the well-credentialed neuroblastoma tumor antigen GD2 be exploited for 

T-cell-based immunotherapy of pediatric sarcomas? (Abstract #9531) 

S. Ramakrishna, S. Gottschalk, R. Morgan, G. Dotti, M. K. Brenner, R. Orentas, 

C. Mackall 

Brd. 37E Performance-based physical function in long-term survivors of Hodgkin 


K. K. Ness, M. Metzger, T. T. Huang, G. T. Armstrong, L. L. Robison, 

M. M. Hudson 

Brd. 37F Risk factors for clostridium difficile infection in children with malignancy. 


P. M. De Blank, T. Zaoutis, B. Fisher, A. B. Troxel, J. Kim, R. Aplenc 

Brd. 37G L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large 

compassionate-use protocol. (Abstract #9534) 

P. V. Plourde, S. Jeha, L. B. Silverman, J. B. Nachman, S. R. Rheingold, 

G. V. Dahl, E. A. Raetz, T. Mercedes, T. Corn 

Brd. 37H Palonosetron in the prevention of chemotherapy-induced nausea and 

vomiting in children with acute lymphoblastic leukemia treated with high 

dose methotrexate. (Abstract #9535) 

H. Schroeder, S. Nadaraja, S. Rosthoej, P. S. Wehner, H. Thomassen 

255 

SUNDAY

SUNDAY 


9:00 AM - 12:00 PM 


Breast Cancer—HER2/ER 


CME credit: 3 


Harold J. Burstein, MD, PhD—Co-Chair 


Rebecca Alexandra Dent, MD—Co-Chair 

Sunnybrook Health Sciences Centre 

9:00 AM Exemestane for primary prevention of breast cancer in postmenopausal 

women: NCIC CTG MAP.3—A randomized placebo-controlled clinical trial. 


P. E. Goss, J. N. Ingle, J. Ales-Martinez, A. Cheung, R. T. Chlebowski, 

J. Wactawski-Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin, 

E. Winquist, G. Sarto, J. E. Garber, C. J. Fabian, P. Pujol, E. Maunsell, P. Farmer, 

K. A. Gelmon, D. Tu, H. Richardson 

Discussion 

9:15 AM Andrea Decensi, MD (Abstract #LBA504) 

Ente Ospedaliero Ospedali Galliera 

9:30 AM TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and 

trastuzumab in patients with HER2-overexpressing breast cancer. (Abstract 

#505) 

J. C. Chang, I. A. Mayer, A. Forero-Torres, R. Nanda, M. P. Goetz, 

A. A. Rodriguez, A. C. Pavlick, T. Wang, S. G. Hilsenbeck, C. Gutierrez, R. Schiff, 

C. K. Osborne, M. F. Rimawi, on behalf of the Translational Breast Cancer 

Research Consortium 

9:45 AM Correlation of molecular effects and pathologic complete response to 

preoperative lapatinib and trastuzumab, separately and combined, prior to 

neoadjuvant breast cancer chemotherapy. (Abstract #506) 

F. A. Holmes, Y. M. Nagarwala, V. A. Espina, L. A. Liotta, M. A. Danso, 

R. I. Gallagher, K. McIntyre, C. R. Osborne, J. M. Mahoney, A. M. Florance, 

T. C. Anderson, J. O’Shaughnessy 

10:00 AM Final results of a phase II randomized trial of neoadjuvant anthracyclinetaxane 

chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive 

breast cancer (CHER-LOB trial). (Abstract #507) 

V. Guarneri, A. Frassoldati, A. Bottini, D. G. Generali, K. Cagossi, F. Artioli, 

G. Bisagni, C. Boni, A. Ravaioli, D. Amadori, A. Musolino, L. Cavanna, M. Untch, 

L. Orlando, G. Giardina, F. Piacentini, E. Tagliafico, M. Bagnalasta, 

R. D’Amico, P. F. Conte 

Discussion 

10:15 AM Gunter Von Minckwitz, MD, PhD (Abstracts #505–507) 

German Breast Group 

10:30 AM A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in 

FGFR1 amplified and nonamplified metastatic breast cancer. (Abstract #508) 

F. Andre, T. D. Bachelot, M. Campone, F. Dalenc, J. M. Perez-Garcia, 

S. A. Hurvitz, N. C. Turner, H. S. Rugo, M. M. Shi, Y. Zhang, A. C. Kay, 

A. J. Yovine, J. Baselga 

10:45 AM LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine 

(C) in patients with brain metastases (BM) from HER2-positive (�) metastatic 

breast cancer (MBC) before whole brain radiotherapy (WBR). (Abstract #509) 

T. D. Bachelot, G. Romieu, M. Campone, V. Dieras, C. Cropet, H. H. Roche, 

M. Jimenez, E. Le Rhun, J. Pierga, A. Gonçalves, M. Leheurteur, J. Domont, 

M. Gutierrez, H. Cure, J. Ferrero, C. Labbe 

256


Discussion 

11:00 AM Nancy U. Lin, MD (Abstract #509) 


11:15 AM Patterns and correlates of adjuvant breast cancer endocrine therapy use. 


T. M. Pini, J. J. Griggs, A. S. Hamilton, S. J. Katz 

11:30 AM When to intervene to increase use of adjuvant hormone therapy among 

women with hormone-sensitive breast cancer. (Abstract #511) 

V. P. Quinn, J. A. Strauss, J. E. Schottinger, C. T. Cheetham, R. Haque 

Discussion 

11:45 AM Dawn L. Hershman, MD, MS (Abstracts #510–511) 

Columbia University Medical Center 

257 

SUNDAY

SUNDAY 


9:30 AM - 12:30 PM 




CME credit: 3 


Patricia LoRusso, DO—Co-Chair 

Karmanos Cancer Institute 

E. Gabriela Chiorean, MD—Co-Chair 

Indiana University Melvin and Bren Simon Cancer Center 

Discussion 

9:30 AM Sarat Chandarlapaty, MD, PhD 


9:45 AM Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity 

of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human 


H. A. Burris, L. L. Siu, J. R. Infante, J. J. Wheler, C. Kurkjian, J. Opalinska, 

D. A. Smith, J. M. Antal, J. L. Gauvin, T. Gonzalez, L. M. Adams, P. Bedard, 

J. F. Gerecitano, R. Kurzrock, K. N. Moore, S. R. Morris, C. Aghajanian 

10:00 AM A phase I dose escalation study of oral MK-2206 (allosteric AKT inhibitor) 

with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or 

metastatic solid tumors. (Abstract #3004) 

A. W. Tolcher, R. D. Baird, A. Patnaik, V. Moreno Garcia, K. P. Papadopoulos, 

C. R. Garrett, D. Olmos, K. A. Shannon, V. Zazulina, E. H. Rubin, I. C. Smith, 

J. Ryan, P. D. Smith, A. Taylor, M. Learoyd, L. Lupinacci, L. Yan, J. S. De Bono 

10:15 AM Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor 

GDC-0941: A first-in-human phase Ib study testing daily and intermittent 

dosing schedules in patients with advanced solid tumors. (Abstract #3005^) 

G. Shapiro, P. LoRusso, E. L. Kwak, J. M. Cleary, L. Musib, C. Jones, 

A. de Crespigny, M. Belvin, M. McKenzie, M. R. Gates, I. T. Chan, J. C. Bendell 

Discussion 

10:30 AM Pasi A. Janne, MD, PhD (Abstracts #3003–3005 ∧ ) 


10:45 AM First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) 

trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with 

advanced or metastatic solid tumors. (Abstract #3006^) 

S. O. Dolly, J. Albanell, F. Kraeber-Bodere, U. Banerji, R. Bahleda, 

M. Martinez Garcia, Z. X. Xu, E. Guarin, J. Tessier, E. Shochat, J. Deutsch, 

S. Blotner, V. Meresse, J. Soria 

11:00 AM Safety, pharmacokinetics, and pharmacodynamics results from a phase I 

trial of BAY 86–9766 (RDEA119), a MEK inhibitor, in patients with advanced 


L. Gore, K. Lewis, D. D. Von Hoff, G. J. Weiss, R. K. Ramanathan, A. A. Adjei, 

G. K. Dy, W. Ma, N. J. Clendeninn, D. P. Leffingwell, B. Sheedy, C. Iverson, 

J. N. Miner, Z. Shen, L. Yeh, R. L. Dubowy, M. Jeffers, P. Rajagopalan, 

C. D. Weekes 

Discussion 

11:15 AM Patrick G. Johnston, MD, PhD (Abstracts #3006 ∧ –3007) 

Queen’s University Belfast 

11:30 AM Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an 

inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced 

solid tumors: Results of a phase I study. (Abstract #3008) 

B. I. Sikic, S. G. Eckhardt, G. Gallant, H. A. Burris III, D. R. Camidge, 

A. D. Colevas, S. F. Jones, W. A. Messersmith, H. A. Wakelee, H. Li, 

P. G. Kaminker, S. Morris, J. R. Infante 

258


11:45 AM Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF� 

receptor involved in tumor angiogenesis. (Abstract #3009) 

L. W. Goff, R. B. Cohen, J. Berlin, C. Noberasco, H. Borghaei, C. Gallo-Stampino, 

E. Wang, D. Hu Lowe, W. J. Levin, F. G. De Braud 

12:00 PM Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II 

randomized discontinuation trial (RDT) in patients (pts) with advanced solid 


M. S. Gordon, N. J. Vogelzang, P. Schoffski, A. Daud, A. I. Spira, B. A. O’Keeffe, 

T. Rafferty, Y. Lee, R. Berger, G. Shapiro 

Discussion 

12:15 PM Jaap Verweij, MD, PhD (Abstracts #3008–3010) 

Erasmus University Medical Center 

259 

SUNDAY

SUNDAY 


9:30 AM - 12:30 PM 




CME credit: 3 


D. Ross Camidge, MD, PhD—Co-Chair 

University of Colorado Denver 

Scott Arthur Kono, DO—Co-Chair 

Winship Cancer Institute at Emory University 

9:30 AM Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer 

(NSCLC) patients (p) with epidermal growth factor receptor (EGFR) 

mutations: Interim results of the European erlotinib versus chemotherapy 

(EURTAC) phase III randomized trial. (Abstract #7503) 

R. Rosell, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, F. Cardenal, 

R. Garcia Gomez, C. Pallares, J. Sanchez, R. Porta, M. Cobo, M. Di Seri, 

P. Garrido Lopez, A. Insa, F. De Marinis, R. Corre, M. Carreras, E. Carcereny, 

M. Taron, L. G. Paz-Ares, Spanish Lung Cancer Group 

9:45 AM Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) 

compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of 

advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). (Abstract 

#7504) 

M. Thomas, A. Reuss, J. R. Fischer, S. Andreas, C. Kortsik, C. Grah, M. H. Serke, 

M. von Eiff, C. Witt, J. Kollmeier, E. Müller, L. Müller, M. Schenk, R. Heine, 

D. M. Behringer, M. Schroeder, N. Reinmuth, P. Schnabel, T. Acker, M. Wolf 

10:00 AM Final efficacy results from OAM4558g, a randomized phase II study 

evaluating MetMAb or placebo in combination with erlotinib in advanced 

NSCLC. (Abstract #7505) 

D. R. Spigel, T. J. Ervin, R. Ramlau, D. B. Daniel, J. H. Goldschmidt Jr., 

G. R. Blumenschein Jr., M. J. Krzakowski, G. Robinet, C. Clement-Duchene, 

F. Barlesi, R. Govindan, T. Patel, S. V. Orlov, M. S. Wertheim, J. Zha, A. Pandita, 

W. Yu, R. L. Yauch, P. H. Patel, A. C. Peterson 

Discussion 

10:15 AM Tony Mok, MD (Abstracts #7503–7505) 

Prince of Wales Hospital 

10:30 AM Identification of driver mutations in tumor specimens from 1,000 patients 

with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium 

(LCMC). (Abstract #CRA7506) 

M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, 

S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, 

W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, 

J. D. Minna, P. A. Bunn 

10:45 AM Impact of crizotinib on survival in patients with advanced, ALK-positive 

NSCLC compared with historical controls. (Abstract #7507) 

A. T. Shaw, B. Y. Yeap, B. J. Solomon, G. J. Riely, A. J. Iafrate, G. Shapiro, 

D. B. Costa, M. Butaney, S. I. Ou, R. G. Maki, Y. Bang, M. Varella-Garcia, 

R. Salgia, K. D. Wilner, K. Kulig, P. Selaru, Y. Tang, E. L. Kwak, J. W. Clark, 

D. R. Camidge 

Discussion 

11:00 AM Ramaswamy Govindan, MD (Abstracts #CRA7506–7507) 


260


11:15 AM Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) 

combination with triweekly D alone in elderly patients (pts) with advanced 

non-small cell lung cancer (NSCLC): An intergroup trial of 

JCOG0803/WJOG4307L. (Abstract #7509) 

T. Abe, A. Yokoyama, K. Takeda, Y. Ohe, S. Kudoh, Y. Ichinose, H. Okamoto, 

N. Yamamoto, H. Yoshioka, K. Minato, T. Sawa, Y. Iwamoto, H. Saka, 

J. Mizusawa, T. Shibata, S. Nakamura, M. Ando, K. Nakagawa, N. Saijo, 

T. Tamura 

11:30 AM PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best 

supportive care (BSC) versus placebo plus BSC immediately following 

induction treatment with pem plus cisplatin for advanced nonsquamous 

non-small cell lung cancer (NSCLC). (Abstract #CRA7510) 

L. G. Paz-Ares, F. De Marinis, M. Dediu, M. Thomas, J. Pujol, P. Bidoli, O. Molinier, 

T. P. Sahoo, E. Laack, M. Reck, J. Corral, S. A. Melemed, W. J. John, N. Chouaki, 

A. Zimmerman, C. M. Visseren Grul, C. Gridelli 

11:45 AM Efficacy, tolerability and biomarker analyses from a phase III, randomized, 

placebo-controlled, parallel group study of gefitinib as maintenance therapy 

in patients with locally advanced or metastatic non-small cell lung cancer 

(NSCLC; INFORM; C-TONG 0804). (Abstract #LBA7511) 

L. Zhang, M. Shenglin, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Q. Liu, 

L. Yun-Peng, M. Wang, and X. Zhang 

Discussion 

12:00 PM Martin J. Edelman, MD (Abstracts #7509–LBA7511) 

University of Maryland Greenebaum Cancer Center 

261 

SUNDAY

SUNDAY 


9:30 AM - 12:30 PM 


Myeloma 


CME credit: 3 


Andrzej J. Jakubowiak, MD, PhD—Co-Chair 


Taimur Sher, MBBS—Co-Chair 


9:30 AM Incidence of second primary malignancy (SPM) in melphalan-prednisonelenalidomide 

combination followed by lenalidomide maintenance (MPR-R) in 

newly diagnosed multiple myeloma patients (pts) age 65 or older. (Abstract 

#8007) 

A. P. Palumbo, M. Delforge, J. Catalano, R. Hajek, M. Kropff, M. Petrucci, Z. Yu, 

J. M. Mei, M. A. Dimopoulos 

9:45 AM Incidence of second primary malignancies (SPM) after 6-years follow-up of 

continuous lenalidomide in first-line treatment of multiple myeloma (MM). 


A. C. Rossi, T. M. Mark, D. Jayabalan, P. J. Christos, F. Zafar, K. Pekle, T. Shore, 

R. N. Pearse, J. Leonard, S. Chen-Kiang, M. Coleman, R. Niesvizky 

10:00 AM Lenalidomide and dexamethasone (LEN plus DEX) treatment in 

relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of 

second primary malignancies (SPM): Analysis of MM-009/010. (Abstract 

#8009) 

M. A. Dimopoulos, R. Z. Orlowski, R. Niesvizky, S. Lonial, N. A. Brandenburg, 

D. M. Weber 

Discussion 

10:15 AM Ola Landgren, MD, PhD (Abstracts #8007–8009) 


10:30 AM Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and 

improve progression-free survival (PFS) in patients (Pts) with multiple 

myeloma (MM) with or without bone disease? MRC myeloma IX study results. 


K. Boyd, G. Morgan, F. Davies, P. Wu, W. Gregory, S. E. Bell, A. Szubert, 

N. Navarro Coy, M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, 

H. Roddie, C. Rudin, G. Cook, G. H. Jackson, J. A. Child 

10:45 AM Are there temporal benefits to long-term bisphosphonate treatment in 

multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid 

(ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial. (Abstract #8011) 

F. Davies, G. Morgan, P. Wu, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, 

M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie, 

C. Rudin, G. Cook, G. H. Jackson, K. Boyd, J. A. Child 

Discussion 

11:00 AM G. David Roodman, MD, PhD (Abstracts #8010–8011) 

University of Pittsburgh Medical Center 

11:15 AM Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in 

patients with previously treated multiple myeloma. (Abstract #8012) 

N. S. Raje, R. J. Hohl, E. A. Faber, P. G. Richardson, A. Forero-Torres, 

G. J. Schiller, A. D. Cohen, S. P. Carpenter, D. Cronier, M. Pashkevich, 

J. Wooldridge, K. C. Anderson 

262


11:30 AM Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination 

with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56positive 

relapsed or relapsed/refractory multiple myeloma (MM). (Abstract 

#8013) 

J. G. Berdeja, S. Ailawadhi, S. D. Weitman, S. Zildjian, J. J. O’Leary, J. O’Keeffe, 

R. Guild, K. Whiteman, A. A. Chanan-Khan 

11:45 AM Elotuzumab with lenalidomide and low-dose dexamethasone in patients with 

relapsed multiple myeloma: A randomized phase II study. (Abstract #8014) 

P. G. Richardson, P. Moreau, A. J. Jakubowiak, T. Facon, S. Jagannath, R. Vij, 

D. E. Reece, D. White, M. Raab, L. Benboubker, J. Rossi, C. Tsao, T. Parli, 

D. M. Berman, A. K. Singhal, S. Lonial 

Discussion 

12:00 PM Asher Alban Akmal Chanan-Khan, MD (Abstracts #8012–8014) 


263 

SUNDAY

SUNDAY 


9:45 AM - 11:00 AM 


Innovation in Delivering Quality Care in Low-resource Scenarios 



Track(s): Health Services Research, International, Special Session 

Clement Adebayo Adebamowo, MD, ScD—Chair 

Institute of Human Virology, University of Maryland School of Medicine 

Challenges for Improving the Quality of Care in Low-resource Scenarios 

Benjamin O. Anderson, MD 


Lessons from the Breast Health Global Initiative 

William Tierney, MD 

Indiana University School of Medicine 

Solutions for Improving Quality in Low-resource Areas: Lessons Learned from HIV 

264

9:45 AM - 11:00 AM 


Dutasteride, Fenasteride, Micronutrients, and Vitamins for Prostate Cancer 

Prevention: How Do We Apply What We Have Learned to the Community? 



Track(s): Cancer Prevention/Epidemiology, Genitourinary Cancer 

Ian Thompson, MD—Chair 


PCPT and SELECT: The Southwest Oncology Group Experience 

Gerald L. Andriole, MD 


Dutasteride and Prostate Cancer Prevention 

Otis W. Brawley, MD 

American Cancer Society 

Translating Prostate Cancer Prevention Research to the Community: Barriers to Uptake 

Integration of Molecularly Targeted Therapy and Chemotherapy in the 

Treatment of Advanced Head and Neck Cancers 




David G. Pfister, MD—Chair 


Updates on Concomitant Chemoradiation 

David Raben, MD 


Integration of Targeted Therapy with Radiation 

Athanassios Argiris, MD, PhD 


Molecularly Targeted Therapy and Combinations with Chemotherapy for Recurrent/Metastatic 


Moving the Bar in Upper Gastrointestinal Malignancies: A Review of Recent 

Upper Gastrointestinal Phase III Studies—Clinically Meaningful or Just 

Statistically Positive? (eQuestions Session) 




Eileen Mary O’Reilly, MD—Chair 


Review of Recent Phase III Studies in Upper Gastrointestinal Malignancies 

Neal J. Meropol, MD 


Health Care Economics in Relation to Upper Gastrointestinal Cancers 

Donna Niedzwiecki, PhD 

Duke University 

Statistical Review of the Benefit: Is It Meaningful? 


265 

SUNDAY

SUNDAY 


Weight of Evidence: Associations between Body Weight and Health Outcomes 

(Including Survival) in Cancer Populations 



Track(s): Patient and Survivor Care, Cancer Prevention/Epidemiology, General Oncology 

Jennifer A. Ligibel, MD—Chair 


Overview of the Current Evidence Supporting Body Weight Status, Adiposity, and Weight Loss 

on Cancer Outcomes 

Rudolf Kaaks, PhD 

German Cancer Research Center DKFZ 

Biological Mechanisms whereby Weight Status and Weight Loss Affects Cancer Progression 

Cheryl L. Rock, PhD 

University of California, San Diego 

Presentation of the ENERGY Trial in Terms of Rationale, Design, Methods, and Outcomes 

266

9:45 AM - 11:00 AM 


CA-125 Use in Practice: The Promise and Pitfalls (M10)—Ticketed Session 




Robert C. Bast, MD 


Current State and Future Use of CA-125 in the Management of Ovarian Cancer 

M. E. L. Van Der Burg, MD, PhD 


Breaking the Addiction to CA-125 

9:45 AM - 11:00 AM 


Treatment of HIV-related Lymphomas: Integration of New Strategies to Control 

and Monitor HIV while Treating High-risk Lymphomas (C08)—Ticketed Session 




Amrita Y. Krishnan, MD—Chair 


Stem Cell Transplantation for Treatment of HIV-related Malignancies 

Steven G. Deeks, MD 

University of California, San Francisco School of Medicine 

Therapy of HIV Infection: New Antiretrovirals and Monitoring Strategies 

Wyndham Hopkins Wilson, MD, PhD 


Overview of HIV-related Lymphoma 


267 

SUNDAY

SUNDAY 


10:30 AM - 12:30 PM 


Training Program Directors Session: Talking Business—The Finances of Your 

Program and Teaching Interprofessional Communication Skills (Training 

Program Directors Only) 


CME credit: 2 

Track(s): Special Session, Professional Development 

Thomas H. Davis, MD—Chair 

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center 


Walter F. Baile, MD 


The Principles of Communication Mentoring 

Daniel E. Epner, MD 


Measuring Competency in Communication 

Lori K. Mihalich-Levin, JD 

Association of American Medical Colleges 

Medicare Funding of Graduate Medical Education: Fundamentals and the Future 

Robert A. Wolff, MD 


The Business of Running a Training Program: Microeconomics 

268

11:30 AM - 12:45 PM 


Advanced Renal Cell Cancer: Which Drug to Use and in What Way? 

(eQuestions Session) 




Sandy Srinivas, MD—Chair 

Stanford Medical Center 

Today’s Renal Cell Cancer Therapeutic Landscape 

Thomas E. Hutson, DO, PharmD 

Baylor Sammons Cancer Center-Texas Oncology PA 

Management of Unique Subsets of Patients with Renal Cell Cancer 

Eric Jonasch, MD 


Sequential versus Combination Therapy: Which One Wins? 

Diabetes and Antidiabetic Drugs: Association with Cancer Risk and Potential 

for Primary and Secondary Prevention 




Pamela Jean Goodwin, MD—Chair 


Metformin and Cancer Prevention 

Lorraine Lipscombe, MD 

University of Toronto 

Association of Diabetes and Cancer: Epidemiology Data 

Ann D. Thor, MD 


Metformin: In Vivo and in Vitro Studies 

Is Patient and Physician Acceptance of Palliative and End-of-Life Care Socially 

and Culturally Determined? 



Track(s): Ethics, Patient and Survivor Care, Professional Development 

Antonella Surbone, MD, PhD—Chair 

New York University 

Variables in Patients’ and Caregivers’ Acceptance of Palliative and End-of-Life Care 

Guido Biasco, MD 

University of Bologna 

Cultural Dynamics in Providing Palliative Care 


Marjorie Kagawa-Singer, PhD, MA, MN, RN 

University of California, Los Angeles School of Public Health 

Overcoming Patients, Caregivers, and Health Professionals Cross-cultural Differences at the 

End of Life 

269 

SUNDAY

SUNDAY 


Melanoma: Therapeutic Decisions for the Practicing Oncologist in 2011 



Track(s): Melanoma/Skin Cancers, General Oncology 

Antoni Ribas, MD—Chair 

Jonsson Comprehensive Cancer Center, University of California, Los Angeles 

Immunotherapeutic Options in Advanced Melanoma (IL-2, Ipilimumab, Adoptive Cell Therapy, 

GM-CSF) 

Jeffrey Alan Sosman, MD 

Vanderbilt University Medical Center 

State of Targeted Therapy and How Testing and Treatment Can Be Incorporated into the Care 

of Patients with Melanoma in 2011 

Christopher D. Lao, MD 


When Is Cytotoxic Therapy or Palliative Therapy Indicated in the Era of Increasing Therapeutic 

and Clinical Trial Options 

270

11:30 AM - 12:45 PM 


Prognostic Utility of B-RAF Mutation in the Management of Papillary Thyroid 

Cancer (M11)—Ticketed Session 




Michael Xing, MD, PhD 


Prognostic Utility of B-RAF Mutation in the Management of Papillary Thyroid Cancer 

11:30 AM - 12:45 PM 


Doctor, Is There Any Hope? Communicating Prognosis while Maintaining Hope 

at the End of Life (C09)—Ticketed Session 



Track(s): Professional Development, Ethics, Patient and Survivor Care 

Ross C. Donehower, MD—Chair 

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University 

Developing Effective Communication Strategies to Discuss Poor Prognosis 

Philip C. Hoffman, MD 

University of Chicago Medical Center 

Managing End-of-Life Decisions 


271 

SUNDAY

SUNDAY 


1:00 PM - 4:00 PM 

PLENARY SESSION 

Plenary Session Including Science of Oncology Award and Lecture 


CME credit: 3 


Kathy Miller, MD—Co-Chair 



Indiana University of Simon Cancer Center 

1:00 PM Robert Weinberg, PhD—Science of Oncology Award Recipient 

Whitehead Institute for Biomedical Research, Massachusetts Institute of 

Technology 

The EMT and the Pathogenesis of High-grade Carcinomas 

1:45 PM Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable 

GIST with a high risk of recurrence: Final results of a randomized trial 

(SSGXVIII/AIO). (Abstract #LBA1) 

H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, 

M. Schlemmer, E. Wardelmann, G. Ramadori, S. E. Al-Batran, B. E. Nilsson, 

O. Monge, R. Kallio, M. Sarlomo-Rikala P. Bono, M. Leinonen, P. Hohenberger, 

T. Alvegard, P. Reichardt 

Discussion 

2:00 PM Charles D. Blanke, MD (Abstract #LBA1) 

University of British Columbia/British Columbia Cancer Agency 

2:15 PM Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk 

neuroblastoma: Results from the HR-NBL1/SIOPEN trial. (Abstract #2) 

R. L. Ladenstein, U. Poetschger, R. Luksch, P. Brock, V. Castel, I. Yaniv, 

V. Papadakis, G. Laureys, J. Malis, W. Balwierz, E. Ruud, P. Kogner, 

H. Schroeder, A. Forjaz De Lacerda, M. Beck Popovic, P. Bician, M. Garami, 

T. Trahair, A. D. Pearson, D. Valteau Couanet 

Discussion 

2:30 PM Julie R. Park, MD (Abstract #2) 

Seattle Children’s Hospital 

2:45 PM Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate 

plus asparaginase (C-MTX/ASNase) in children and young adults with 

high-risk acute lymphoblastic leukemia (HR-ALL): A report from the 

Children’s Oncology Group Study AALL0232. (Abstract #3) 

E. C. Larsen, W. L. Salzer, M. Devidas, J. B. Nachman, E. A. Raetz, M. L. Loh, 

N. A. Heerema, A. J. Carroll, J. M. Gastier-Foster, M. J. Borowitz, B. L. Wood, 

C. L. Willman, N. J. Winick, S. Hunger, W. L. Carroll 

Discussion 

3:00 PM Martin S. Tallman, MD (Abstract #3) 


3:15 PM Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF 

inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAFmutated 

melanoma. (Abstract #LBA4) 

P. B. Chapman, A. Hauschild, C. Robert, J. M. G. Larkin, J. B. A. G. Haanen, 

A. Ribas, D. Hogg, S. O’Day, P. A. Ascierto, A. Testori, P. Lorigan, R. Dummer, 

J. A. Sosman, C. Garbe, R. J. Lee, K. B. Nolop, B. Nelson, J. Hou, K. T. Flaherty, 

and G. A. McArthur 

272


3:30 PM Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) 

versus DTIC alone as first-line treatment in patients with unresectable stage 

III or IV melanoma. (Abstract #LBA5) 

J. D. Wolchok, L. Thomas, I. N. Bondarenko, S. O’Day, J. S. Weber, C. Garbe, 

S. Francis, R. A. Ibrahim, A. Hoos, and C. Robert 

Discussion 

3:45 PM Kim Allyson Margolin, MD (Abstracts #LBA4–LBA5) 


273 

SUNDAY

SUNDAY 


4:30 PM - 5:30 PM 


Antiangiogenic Therapies and Biomarkers in Pediatric Cancer 


CME credit: 1 


Steven G. DuBois, MD—Chair 


4:30 PM Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide 

(CYC) in children and young adults with refractory solid tumors. (Abstract 

#9500) 

V. M. Santana, S. D. Baker, B. McCarville, C. F. Stewart, J. Wu, C. Billups, 

S. L. Spunt, W. L. Furman, L. M. McGregor, S. Hu, J. C. Panetta, W. E. Reddick, 

A. Davidoff, W. H. Leung, F. Navid 

4:45 PM Phase I study of pazopanib in children with relapsed or refractory solid 

tumors (ADVL0815): A Children’s Oncology Group Phase I Consortium Trial. 


J. L. Glade Bender, A. Lee, P. C. Adamson, A. M. Ingle, C. H. Ahern, B. Wu, 

S. Baruchel, P. J. Harris, M. M. Ames, B. Weigel, S. Blaney, Children’s Oncology 

Group 

5:00 PM Surrogate biomarkers of antiangiogenesis in Children’s Oncology Group 

(COG) phase I trials. (Abstract #9502) 

S. Baruchel, B. Wu, R. B. Mokhtari, J. L. Glade Bender, S. G. DuBois, 

B. C. Widemann, J. R. Park, D. Stempak, C. H. Ahern, B. Weigel 

Discussion 

5:15 PM Michael L. Maitland, MD, PhD (Abstracts #9500–9502) 


274

4:30 PM - 6:00 PM 



Geriatric Biology, Screening Tools, Dose Intensity, and Impact on Survival 



Track(s): Patient and Survivor Care, Geriatric Oncology 

Gretchen Genevieve Kimmick, MD, MS—Co-Chair 


Christine Ritchie, MD, MSPH—Co-Chair 


4:30 PM Relationship between components of the comprehensive geriatric 

assessment (CGA), chemotherapy dose intensity, and overall survival in a 

colorectal cancer (CRC) cohort age 65 and older. (Abstract #9000) 

E. E. Ramsdale, B. N. Polite, K. A. Bylow, H. L. Kindler, W. Dale 

4:45 PM Validation of the G8 screening tool in geriatric oncology: The ONCODAGE 

project. (Abstract #9001) 

P. Soubeyran, C. Bellera, J. Goyard, D. Heitz, H. Cure, H. Rousselot, G. Albrand, 

V. Servent, O. Saint Jean, C. Roy, S. Mathoulin-Pelissier, M. Rainfray 

Discussion 

5:00 PM Gretchen Genevieve Kimmick, MD, MS (Abstract #9001) 


5:15 PM P16 INK4a expression after chemotherapy in older women with early-stage 


H. B. Muss, J. Krishnamurthy, S. M. Alston, A. C. Lacy, T. A. Jolly, G. Williams, 

L. A. Carey, E. C. Dees, C. K. Anders, W. J. Irvin Jr., N. E. Sharpless 

5:30 PM Predictors of primary dose reduction (PDR) among patients (pts) age 65 and 

older receiving adjuvant chemotherapy (chemo). (Abstract #9003) 

H. D. Klepin, A. Gajra, M. Hardt, W. P. Tew, S. G. Mohile, C. Owusu, C. P. Gross, 

S. M. Lichtman, R. Ramani, V. Katheria, J. Brown, R. Jayani, K. Hansen, 

K. Togawa, S. Klapper, F. L. Wong, A. Hurria, on behalf of the Cancer and Aging 

Research Group 

Discussion 

5:45 PM Matti S. Aapro, MD (Abstracts #9002–9003) 

Clinique De Genolier 

275 

SUNDAY

SUNDAY 


4:30 PM - 6:00 PM 


PK/PD According to Dr. Merrill Egorin: A Tribute to a Great Translational 

Scientist 




Duncan Ian Jodrell, MSc, DM, MRCP—Co-Chair 

NIHR Cambridge Biomedical Research Centre 

S. Percy Ivy, MD—Co-Chair 


4:30 PM Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics 

(PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; 

V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced 

solid tumors. (Abstract #3000) 

P. LoRusso, J. J. Ji, J. Li, L. K. Heilbrun, G. Shapiro, E. A. Sausville, S. A. Boerner, 

D. W. Smith, M. Pilat, J. Zhang, A. P. Chen, N. Nechiporchik, R. E. Parchment 

Discussion 

4:45 PM James H. Doroshow, MD (Abstract #3000) 


5:00 PM Final results of a translational phase l study assessing a QOD schedule of 

the potent AKT inhibitor MK-2206 incorporating predictive, 

pharmacodynamic (PD), and functional imaging biomarkers. (Abstract 

#3001^) 

T. A. Yap, L. Yan, A. Patnaik, D. Olmos, I. Fearen, R. D. Baird, 

K. P. Papadopoulos, N. Tunariu, A. Biondo, H. Keilhack, L. M. Delgado, A. Taylor, 

S. C. Blackman, C. L. Carpenter, S. Decordova, S. Heaton, M. D. Garrett, 

D. Sullivan, J. S. De Bono, A. W. Tolcher 

Discussion 

5:15 PM Jerry M. Collins, PhD (Abstract #3001 ∧ ) 


5:30 PM Phase I study of PF-04554878, a second-generation focal adhesion kinase 

(FAK) inhibitor, in patients with advanced solid tumors. (Abstract #3002) 

S. F. Jones, G. Shapiro, J. C. Bendell, E. X. Chen, P. Bedard, J. M. Cleary, 

S. Pandya, K. J. Pierce, B. Houk, N. Hosea, K. S. Zandi, W. G. Roberts, 

S. M. Shreeve, L. L. Siu 

Discussion 

5:45 PM Alan Hilary Calvert, MD (Abstract #3002) 

University College London 

276

4:30 PM - 6:00 PM 



Predictive Markers in Breast Cancer: How Many Tests Do We Need, and What 

Do They Tell Us? 




Harold J. Burstein, MD, PhD—Chair 


4:30 PM Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide 

(AC) 3 docetaxel (T) with or without capecitabine (X), in high-risk EBC: 

Exploratory Ki-67 analyses. (Abstract #500) 

J. E. Pippen, D. Paul, C. T. Stokoe, J. L. Blum, L. Krekow, F. A. Holmes, 

D. L. Lindquist, S. M. Sedlacek, R. R. Rivera, R. J. Brooks, S. J. Vukelja, 

K. McIntyre, C. Lopez-Diaz, J. O’Shaughnessy 

4:45 PM Neoadjuvant anastrozole or tamoxifen for premenopausal breast cancer: 

Ki67 expression data from the STAGE study. (Abstract #501^) 

T. Kinoshita, N. Masuda, Y. Sagara, H. Iwata, S. Nakamura, Y. Yanagita, 

R. Nishimura, H. Iwase, S. Kamigaki, H. Takei, H. Tsuda, S. Noguchi 

Discussion 

5:00 PM Mitchell Dowsett, PhD (Abstracts #500–501 ∧ ) 


5:15 PM Concordance among gene-expression-based predictors for ER-positive 

breast cancer treated with adjuvant tamoxifen. (Abstract #502) 

A. Prat, J. S. Parker, C. Fan, M. Cheang, L. D. Miller, J. Bergh, S. K. Chia, 

P. S. Bernard, T. O. Nielsen, M. J. Ellis, L. A. Carey, C. M. Perou 

5:30 PM Using the PAM50 breast cancer intrinsic classifier to assess risk in ER� 

breast cancers: A direct comparison to Oncotype DX. (Abstract #503) 

R. R. Bastien, M. T. Ebbert, K. M. Boucher, C. M. Kelly, B. Wang, T. Iwamoto, 

S. Krishnamurthy, L. Pusztai, P. S. Bernard 

Discussion 

5:45 PM Daniel F. Hayes, MD (Abstracts #502–503) 


277 

SUNDAY

SUNDAY 


4:45 PM - 6:00 PM 


B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric 

Oncology 



Track(s): Special Session, Geriatric Oncology 

John M. Bennett, MD 


Enhancing Geriatric Oncology Training to Care for Elders with Malignancies 

278

4:45 PM - 6:00 PM 


Chronic Lymphocytic Leukemia Therapy: An Update on Frontline and Novel 

Therapies 




Susan Mary O’Brien, MD—Chair 


Novel Therapies in Chronic Lymphocytic Leukemia 

Michael J. Hallek, MD 

University of Cologne 

Update on Frontline Therapy for Chronic Lymphocytic Leukemia: Is Fludarabine, 

Cyclophosphamide, and Rituximab (FCR Regimen) the Treatment of Choice? 

John C. Byrd, MD 

The Ohio State University Comprehensive Cancer Center and Arthur G. James Cancer Hospital 

and Solove Research Institute 

Molecular, Biochemical, and Clinical Predictive Factors in Chronic Lymphocytic Leukemia: An 

Update 

Clinical Problems in Management of Multiple Myeloma (eQuestions Session) 



Track(s): Lymphoma and Plasma Cell Disorders, General Oncology 

Asher Alban Akmal Chanan-Khan, MD—Chair 


Complications of Antimyeloma Therapies 

Ivan Borrello, MD 


Smoldering and Asymptomatic Myeloma 

G. David Roodman, MD, PhD 


Bone Disease and Its Management in Multiple Myeloma 

Early-phase Cancer Clinical Trials: Are the Goals Therapeutic or Scientific? 



Track(s): Ethics, Clinical Trials, Developmental Therapeutics 

Steven Joffe, MD, MPH—Chair 


Introduction to the Ethics of Early-phase Clinical Trials 

Nancy King, JD 

Wake Forest University School of Medicine 

The Need to Emphasize the Research Orientation of Early-phase Clinical Trials 

Razelle Kurzrock, MD 


Early-phase Trials as Optimal Therapy in Some Settings 


279 

SUNDAY

SUNDAY 


Genetic Syndromes in Upper Gastrointestinal Cancer for the Clinical 

Oncologist: Syndromes, Testing, and Screening 



Track(s): Gastrointestinal (Noncolorectal) Cancer, Cancer Genetics 

Manish A. Shah, MD—Chair 


Incidence of Hereditable Upper Gastrointestinal Cancers: How Common Are They and What 

Are the Genetic Considerations? 

Zsofia Kinga Stadler, MD 


Genetic Testing: Indications, Insurance/Legal Ramifications, and What Tests Should Be Done 

Marcia Canto, M.D. 


Indications for Screening: Pancreatic, Esophageal, and Stomach Cancers 

Inclusion of Patients with Brain Metastases in Clinical Trials 



Track(s): Clinical Trials, Central Nervous System Tumors, Developmental Therapeutics 

Lauren E. Abrey, MD—Chair 


Overview of the Treatment of Brain Metastases in Patients with Solid Tumors 

Karen Kelly, MD 

University of California, Davis Cancer Center 

Pharmacokinetic/Pharmacodynamic Issues in the Treatment of Brain Metastases 

Minesh P. Mehta, MD 


Radiation Therapy for Brain Metastases: Techniques, Trials, and Outcomes 

Next-generation Therapeutic Targets and Drugs 




Kapil N. Bhalla, MD—Chair 

University of Kansas Cancer Center 

Molecular Chaperones in Tumor Biology and Therapy 

Jean-Pierre J. Issa, MD 


Deregulated Epigenetic Mechanisms: Developing Therepeutic Opportunities 

Anil Sood, MD 


siRNA and miRNA Therapeutics: Rapid Translation from Bench to Bedside 

280

You Can Write an Outstanding Manuscript 




Daniel G. Haller, MD—Chair 

University of Pennsylvania 

An Editor’s Perspective 

Stephen A. Cannistra, MD 

Beth Israel Deaconess Medical Center 

How to Reach Meaningful Conclusions 

Cynthia Dunbar, MD 

National Heart, Lung, and Blood Institute 

How to Present Data Effectively 


281 

SUNDAY

SUNDAY 


4:45 PM - 6:00 PM 


Therapy of the Elderly Patient with Acute Myeloid Leukemia (M12)—Ticketed 

Session 



Track(s): Leukemia, Myelodysplasia, and Transplantation, Geriatric Oncology 

Charles Alan Schiffer, MD 

Wayne State University 

Therapy of the Elderly Patient with Acute Myeloid Leukemia 

Harry Paul Erba, MD, PhD 


Controversies in Treating the Elderly Patient with Acute Myeloid Leukemia 

4:45 PM - 6:00 PM 


Current State of Neuro-oncology: Successes, Failures, and the Future 





John L. Villano, MD, PhD—Chair 

University of Illinois 

Henry S. Friedman, MD 


Jan C. Buckner, MD 

Mayo Clinic 

282

7:30 AM - 9:00 AM 


Highlights of the Day II Including Partners in Progress Award 




Charles D. Blanke, MD—Chair 

University of British Columbia/British Columbia Cancer Agency 

7:30 AM 

Benjamin O. Anderson, MD—Partners in Progress Award Recipient 


7:40 AM 

Stepen R. D. Johnston, MA, MD, PhD 



7:55 AM 

Jyoti D. Patel, MD 



8:10 AM 

Ivan Borrello, MD 


Myeloma 

8:25 AM 

Gregory T. Armstrong, MD, MSCE 



Monday, June 6, 2011 

283 

MONDAY

MONDAY 


8:00 AM - 9:15 AM 


ASCO/European Society for Medical Oncology (ESMO) Joint Session: Cancer 

in Low- and Middle-income Countries 



Track(s): Developmental Therapeutics, Clinical Trials, International, Special Session 

David J. Kerr, MD, PhD—Co-Chair 

University of Oxford 



Peter Boyle, PhD 

International Prevention Research Institute 

Epidemiologic Overview of Cancer in Low- and Middle-income Countries 

Jan Agosti, MD 

Bill and Melinda Gates Foundation 

Cervical Cancer and HPV Vaccines in Low- and Middle-income Countries 

Henry L. Y. Chan, MD 

Chinese University of Hong Kong 

Hepatocellular Carcinoma: Prevention and Control in Low- and Middle-income Countries 

284

8:00 AM - 9:15 AM 


Breast Cancer in Older Women: The Whole Picture 



Track(s): Breast Cancer, Geriatric Oncology, International 

Richard C. Zellars, MD—Chair 


Locoregional Implications for Therapy in Older Women 



Patterns of Care and Outcomes Disparities in Older Patients inside and outside of the 

United States 

Hyman Bernard Muss, MD 

University of North Carolina Lineberger Comprehensive Cancer Center 

Overview and Medical Therapeutic Implications of Breast Cancer in Elderly Patients 

Communicating Effectively across the Trajectory of Cancer Care and 

Survivorship (eQuestions Session) 




Edward G. Shaw, MD—Chair 


Communication from the Perspective of the Physician 


Neeraj Arora, PhD 


Enhancing the “Patient Centeredness” of Communication between the Care Team and Patients 

and Their Family Members: Understanding Patient Perspectives 

Jessie Gruman, PhD 

Center for Advancing Health 

Communication on Both the Giving and Receiving End: Perspectives from a Physician and a 

Patient 

Intraperitoneal Chemotherapy and Cytoreductive Surgery in Colon Cancer: A 

Debate 




David P. Ryan, MD—Chair 

Massachusetts General Hospital and Harvard Medical School 

Surgical Debulking and Hyperthermic Chemotherapy for Metastatic Colon Cancer: Stop 

Selecting Patients and Start Proving Efficacy 

Paul H. Sugarbaker, MD 

Washington Hospital Center 

Surgical Debulking and Hyperthermic Chemotherapy for Metastatic Colon Cancer: If You Select 

the Right Patients, Long-term Survival Can Be Achieved 

285 

MONDAY

MONDAY 


Optimizing the Use of Alkylators in Neuro-oncology 




James R. Perry, MD—Chair 

Sunnybrook Health Sciences Centre 

Temozolomide in Upfront Therapy for Low- and High-grade Gliomas 

Wolfgang Wick, MD 

University Hospital Heidelberg 

Temozolomide in Refractory Disease-alternative Schedules 

Michael Weller, MD 

University Hospital Zurich 

What about the Older Generation Alkylators? Revisiting the Role of Nitrosoureas in Neurooncology 

The Patient Protection and Affordable Care Act of 2010: Reform Initiatives and 

Their Implications 



Track(s): Health Services Research, Practice Management and Information Technology 

David Christopher Miller, MD, MPH—Chair 


ACOs and Their Implications for Cancer-related Quality and Spending 

Lee Nisley Newcomer, MD 

United Health Group 

Payment Bundling and Its Implications for Improving Cancer-related Quality 

Scott Gottlieb, MD 

American Enterprise Institute for Public Policy Research 

The IPAB and Implications for Cancer-related Medicare Spending 

Transition from Therapy Improvement to Potential Cure for Chronic 

Myelogenous Leukemia: Roadblocks and Opportunities 




Moshe Talpaz, MD—Chair 


The Frontline Therapy of Chronic Myelogenous Leukemia: Nilotinib or Imatinib? 

Jorge E. Cortes, MD 


Resistant Disease: Assessment, Monitoring, and Therapy 

Ravi Bhatia, MD 


The Chronic Myelogenous Leukemia Stem Cell: The Roadblock to Cure? 

286

8:00 AM - 9:15 AM 

MEET THE PROFESSOR SESSIONS 

Management of Neuroendocrine Tumors of the Lung Exclusive of Small Cell 

Lung Cancer (M13)—Ticketed Session 




William D. Travis, MD 


Neuroendocrine Tumors of the Lung: Update on Histology 

Update in Hereditary Renal Cancer (M20)—Ticketed Session 



Track(s): Cancer Genetics, Genitourinary Cancer 

W. Marston Linehan, MD 

National Institutes of Health 


287 

MONDAY

MONDAY 


8:00 AM - 11:00 AM 


Genitourinary (Nonprostate) Cancer 


CME credit: 3 


Evan Y. Yu, MD—Co-Chair 


Carsten Bokemeyer, MD—Co-Chair 

University Medical Center Hamburg-Eppendorf 

8:00 AM Axitinib versus sorafenib as second-line therapy for metastatic renal cell 

carcinoma (mRCC): Results of phase III AXIS trial. (Abstract #4503) 

B. I. Rini, B. Escudier, P. Tomczak, A. Kaprin, T. E. Hutson, C. Szczylik, 

J. C. Tarazi, B. Rosbrook, S. Kim, R. J. Motzer 

8:15 AM Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus 

sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). 


D. Cella, B. Escudier, B. I. Rini, C. Chen, H. Bhattacharyya, J. C. Tarazi, 

B. Rosbrook, S. Kim, R. J. Motzer 

8:30 AM Final results from an EORTC (GU Group)/NCRI randomized phase III trial of 

adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a 

high risk of relapse after nephrectomy for renal cell carcinoma (RCC). 


M. Aitchison, C. A. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, 

L. McMahon, P. A. Vasey 

8:45 AM Do genetic polymorphisms predict risk of recurrence in patients with 

localized renal cell carcinoma? Results from a cohort study. (Abstract #4506) 

F. A. Schutz, K. P. Gray, M. Pomerantz, M. B. Atkins, J. E. Rosenberg, 

M. S. Hirsch, D. F. McDermott, G. M. Lee, S. Signoretti, P. W. Kantoff, 

M. L. Freedman, T. K. Choueiri 

Discussion 

9:00 AM Bruce G. Redman, DO (Abstracts #4503–4506) 


9:15 AM Superior survival after sequential high-dose chemotherapy (HDCT) as 

compared to single HDCT in patients with relapsed or refractory germ cell 

tumors (GCT): Six-year long-term follow-up of a prospective, randomized 

phase II trial. (Abstract #4507) 

A. Lorch, A. Kleinhans, A. Kramar, J. T. Hartmann, C. Bokemeyer, O. Rick, 

J. Beyer, for the German Testicular Cancer Study Group 

9:30 AM A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) 

and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 

05/014, ISRCTN53643604). (Abstract #4508) 

R. A. Huddart, R. Gabe, F. Cafferty, P. Pollock, J. D. White, J. Shamash, 

S. P. Stenning, TE23 Trial Management Group and Collaborators, NCRI Testis 

Cancer Clinical Studies Group 

9:45 AM A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard 

BEP in patients with in intermediate prognosis germ cell cancer (GCC): An 

intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC 

group (EORTC 30983). (Abstract #4509) 

R. De Wit, I. A. Skoneczna, K. Gedske Daugaard, M. de Santis, A. Garin, N. Aass, 

J. A. Witjes, P. Albers, J. White, J. Germa-Lluch, S. Osanto, S. Marreaud, 

L. Collette 

Discussion 

10:00 AM Christopher Sweeney, MBBS (Abstracts #4507–4509) 


288


10:15 AM Prospective, randomized phase III study comparing two intensified regimens 

(methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] 

versus gemcitabine/cisplatin) in patients with inoperable or recurrent 

urothelial cancer. (Abstract #4510) 

A. Bamias, A. Karadimou, S. Lampaki, G. Aravantinos, I. Xanthakis, 

C. Papandreou, G. Lainakis, F. Zagouri, N. Soupos, E. Kostouros, E. Samantas, 

C. Hatzimouratidis, C. Konstantinidis, C. Deliveliotis, D. G. Pectasides, 

G. Fountzilas, M. A. Dimopoulos, Hellenic Cooperative Oncology Group 

10:30 AM Association of germ-line variation with platinum-based chemotherapy 

response in patients (pts) with urothelial carcinoma (UC). (Abstract #4511) 

D. J. Gallagher, V. Joseph, R. J. Hamilton, I. Ostrovnaya, I. R. Garcia-Grossman, 

J. C. Riches, A. M. Regazzi, J. A. Przybylo, M. Gaudet, M. I. Milowsky, K. Offit, 

D. F. Bajorin 

Discussion 

10:45 AM Maria De Santis, MD (Abstracts #4510–4511) 

KFJ Spital Austria 

289 

MONDAY

MONDAY 


8:00 AM - 11:00 AM 


Pediatric Oncology II 


CME credit: 3 


Edward F. Attiyeh, MD—Co-Chair 

Children’s Hospital of Philadelphia 

Alejandro Gutierrez, MD—Co-Chair 

Dana-Farber Cancer Center 

8:00 AM The prognostic value of semi-quantitative 123 I mIBG scintigraphy at 

diagnosis in high-risk neuroblastoma: Validation of the SIOPEN score 

method. (Abstract #9511) 

V. Lewington, U. Poetschger, A. Boubaker, Z. Bar-Sever, B. Drake, 

A. Staudenherz, M. Castellani, B. Lambert, K. Grange, P. Brock, A. Garaventa Sr., 

I. Yaniv, D. Valteau Couanet, V. Castel, A. Forjaz De Lacerda, J. Malis, 

H. Schroeder, R. Luksch, K. Beiske, R. L. Ladenstein 

8:15 AM Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added 

iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy 

(NANT) study. (Abstract #9512) 

K. K. Matthay, B. D. Weiss, J. Villablanca, J. M. Maris, G. A. Yanik, S. G. Groshen, 

H. Jackson, R. Hawkins, F. Goodarzian, A. Panigrahy, S. G. DuBois, J. Stubbs, 

A. Towbin, J. A. Barrett, N. D. LaFrance, J. W. Babich 

8:30 AM Phase I study of vincristine, irinotecan, and 131 I-MIBG for patients with 

relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma 

Therapy (NANT) study. (Abstract #9513) 

S. G. DuBois, L. Chesler, S. G. Groshen, R. Hawkins, F. Goodarzian, G. A. Yanik, 

C. F. Stewart, Y. P. Mosse, J. M. Maris, J. Villablanca, K. K. Matthay 

Discussion 

8:45 AM Mark Gaze, MD (Abstracts #9511–9513) 

University College London 

9:00 AM Stratification of patients with neuroblastoma for targeted ALK inhibitor 

therapy. (Abstract #9514) 

D. Weiser, M. Laudenslager, E. Rappaport, E. Carpenter, E. F. Attiyeh, S. Diskin, 

W. B. London, J. M. Maris, Y. P. Mosse 

9:15 AM Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk 

factors, and concordance of grading scales—A report from the Children’s 

Oncology Group (COG). (Abstract #9515) 

W. Landier, K. R. Knight, F. L. Wong, J. K. Lee, O. Thomas, H. Kim, 

S. G. Kreissman, M. L. Schmidt, L. Chen, W. B. London, S. Bhatia, 

J. G. Gurney, Children’s Oncology Group 

9:30 AM Shorter duration therapy that includes vincristine (V), dactinomycin (A), and 

lower doses of cyclophosphamide (C) with or without radiation therapy for 

patients with newly diagnosed low-risk embryonal rhabdomyosarcoma 

(ERMS): A report from the Children’s Oncology Group (COG). (Abstract 

#9516) 

D. Walterhouse, A. S. Pappo, J. L. Meza, J. C. Breneman, A. A. Hayes-Jordan, 

D. Parham, T. P. Cripe, W. H. Meyer, D. S. Hawkins 

9:45 AM Randomized comparison of VAC versus VAI chemotherapy (CT) as 

consolidation for standard risk (SR) Ewing sarcoma tumor (ES): Results of 

the Euro-EWING.99-R1 trial. (Abstract #9517) 

O. Oberlin, M. Le Deley, U. Dirksen, I. J. Lewis, A. Ranft, J. M. Michon, 

M. Paulussen, J. Whelan, R. L. Ladenstein, B. Brennan, P. Marec Bérard, 

V. Laurence, H. Van Den Berg, L. Hjorth, C. Douglas, K. Wheatley, 

M. M. Van Glabbeke, I. R. Judson, A. W. Craft, H. Juergens, European Ewing 

Tumour Working Initiative of National Groups 

290


10:00 AM Outcome of Head Start III multinational protocol for newly diagnosed central 

nervous system (CNS) primitive neuroectodermal tumors (pnet) of young 

children. (Abstract #9519) 

T. B. Davidson, L. Ji, K. Haley, G. Dhall, J. P. Grimm, F. H. Gilles, S. L. Gardner, 

J. C. Allen, A. A. Bedros, M. M. Etzl, R. S. Olshefski, A. Cornelius, J. Torkildson, 

G. A. Kennedy, J. R. Fangusaro, S. R. Rassekh, M. J. Joyce, S. J. Bertolone, 

R. Sposto, J. L. Finlay 

Discussion 

10:15 AM Roger Packer, MD (Abstract #9519) 

Children’s National Medical Center 

10:30 AM Relevance of germ-line genetic variations for treatment response in pediatric 

osteosarcoma patients. (Abstract #9518) 

M. Hagleitner, P. Hoogerbrugge, B. W. Schreuder, U. E. Flucke, M. J. Coenen, 

D. M. Te Loo 

291 

MONDAY

MONDAY 


8:00 AM - 12:00 PM 





Brd. 1A Immunotherapy of advanced melanoma by intratumoral injections of 

autologous, purified dendritic cells transduced with gene construct of 

interleukin-12, with dose-dependent expression under the control of an oral 

activator ligand. (Abstract #2540) 

D. J. Schwartzentruber, J. M. Kirkwood, M. J. Guarino, J. M. Richards, O. Hamid, 

S. O’Day, J. J. Nemunaitis, J. E. Talmadge, S. Chada, K. B. Menander, 

K. Shafer-Weaver, J. H. Senesac, M. O. Thornton, J. J. Lewis, R. B. Herberman 

Brd. 1B Effect of a costimulatory endodomain on the performance of T cells 

expressing CD19-directed chimeric antigen receptors (CARs) in subjects 

with relapsed/refractory B-cell malignancies (Abstract #2541) 

C. A. Ramos, B. Savoldo, E. Liu, C. M. Bollard, M. P. Mims, M. J. Keating, 

A. P. Gee, Z. Mei, C. M. Rooney, H. E. Heslop, M. K. Brenner, G. Dotti 

Brd. 1C Identification of pre- and post-treatment markers of efficacy in patients with 

renal cancer treated with MVA-5T4 in a phase III study. (Abstract #2542) 

R. Harrop, W. H. Shingler, M. McDonald, P. Treasure, R. J. Amato, R. E. Hawkins, 

H. Kaufman, J. de Belin, M. Goonewardena, S. Naylor 

Brd. 1D Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma 

(RCC): Analysis of pts receiving extended therapy. (Abstract #2543) 

E. M. Posadas, N. M. Tannir, Y. Wong, M. S. Ernstoff, C. K. Kollmannsberger, 

J. Qian, P. J. Ansell, E. M. McKeegan, M. D. McKee, J. L. Ricker, D. M. Carlson, 

D. Michaelson 

Brd. 1E Eribulin dosing in patients with advanced solid tumors and hepatic 

impairment. (Abstract #2544) 

L. A. Devriese, P. Witteveen, E. E. Voest, E. N. Overkleeft, M. Langenberg, 

J. H. Beijnen, L. Reyderman, J. Wanders, D. R. Mould, A. Gupta, Z. Hussein, 

J. H. Schellens 

Brd. 1F The role of the electrocardiogram (ECG) in phase I drug development in 

patients with cancer: The University of Texas M. D. Anderson Cancer Center 

experience with 8,966 ECGs. (Abstract #2545) 

H. Veasey Rodrigues, A. Naing, D. S. Hong, G. S. Falchook, S. Fu, J. J. Wheler, 

A. M. Tsimberidou, S. L. Moulder, F. Janku, S. Wen, S. N. Fessahaye, 

E. C. Golden, D. I. Westerhold, M. Ewer, R. Kurzrock 

Brd. 1G A phase I study of once-weekly aminoflavone prodrug (AFP464) in solid 

tumor patients. (Abstract #2546) 

M. P. Goetz, J. M. Reid, Y. Qi, A. Chen, R. M. McGovern, M. J. Kuffel, 

P. D. Scanlon, C. Erlichman, M. M. Ames 

Brd. 2A The effect of enoxaparin on inflammatory and thrombotic mediators in 

cancer patients as studied using protein and biochip array approaches. 


D. Hoppensteadt, E. Litinas, H. Khan, J. Cunanan, I. Thethi, J. Fareed 

Brd. 2B T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatment 

of women with stage IV breast cancer (phase I): Clinical and immune function 


L. G. Lum, R. Rathore, Z. Al-Kadhimi, P. Davol, A. Thakur, C. Pray, Q. Liu, 

E. Tomaszewski, F. Cummings, P. Steele, J. Wedge, N. Kouttab, A. Maizel, 

W. Colaiace, R. Joyrich, V. Ratanatharathorn, J. P. Uberti 

Brd. 2C Population pharmacokinetics and pharmacogenomics of erlotinib: Effect of 

drug exposure on treatment outcomes in Japanese patients with non-small 

cell lung cancer. (Abstract #2549) 

M. Fukudo, Y. Ikemi, Y. Togashi, K. Masago, Y. Kim, T. Mio, M. Mishima, K. Inui, 

T. Katsura 

292


Brd. 2D Cellular function of the mononuclear phagocyte system (MPS) as a 

phenotypic probe for pegylated liposomal doxorubicin (PLD) 

pharmacokinetics (PK) in patients with recurrent ovarian cancer. (Abstract 

#2550) 

W. P. Caron, J. C. Lay, A. M. Fong, N. M. La-Beck, S. E. Newman, 

D. L. Clarke-Pearson, W. R. Brewster, L. Van Le, V. L. Bae-Jump, 

P. A. Gehrig, W. Zamboni 

Brd. 2E Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in adults 

with solid tumor malignancy (STM). (Abstract #2551) 

K. M. Mullane, M. R. Mullane, B. M. Wong, Y. Zhao, T. Sterling, S. Manoff, 

P. W. Annunziato 

Brd. 2F Evaluation of response rate and disease control rate as potential predictors 

of overall survival in anthracycline-pretreated women receiving first-line 

chemotherapy for metastatic breast cancer (MBC). (Abstract #2552) 

J. Liu, K. S. Albain, S. Chan, A. D. Seidman, D. Tai, Y. Wang, L. Zhao 

Brd. 2G Procoagulant and inflammatory mediators in small cell lung carcinoma: 

Potential role in thromboembolic complications. (Abstract #2553) 

I. Thethi, D. Hoppensteadt, H. Khan, M. Demir, C. Adiguzel, E. Litinas, J. Fareed 

Brd. 3A Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC 

inhibitor valproic acid in patients with advanced cancers. (Abstract #2554) 

J. J. Wheler, F. Janku, T. Jackson, S. Fu, M. Sun, H. Yang, A. Naing, 

S. L. Moulder, A. M. Tsimberidou, D. S. Hong, G. S. Falchook, S. A. Piha-Paul, 

G. Garcia-Manero, R. Kurzrock 

Brd. 3B Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I 

(Ph I) oncology trial as markers of prognosis and treatment benefit. (Abstract 

#2555) 

J. Ang, D. Olmos, V. Moreno Garcia, A. Brunetto, D. Papadatos-Pastos, 

H. Arkenau, M. Blanco, R. D. Baird, P. A. Cassier, D. S. Tan, R. S. Kristeleit, 

S. Dolly, K. J. Shah, B. Amin, B. G. Anghan, L. R. Molife, U. Banerji, J. S. De Bono, 

S. B. Kaye 

Brd. 3C Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients 

with EpCAM-positive advanced solid tumors. (Abstract #2556) 

J. P. Connor, R. Stupp, M. C. Cristea, N. Lewis, L. D. Lewis, M. R. Mattiacci, 

M. Felder, S. Stewart, J. Henslee-Downey, R. Neugebauer, P. B. Komarnitsky 

Brd. 3D Adoptive immunotherapy with autologous CD3/CD28-costimulated T-cells 

after fludarabine-based chemotherapy in patients with chronic lymphocytic 


S. J. Schuster, C. Hosing, E. J. Shpall, B. Levine, N. Aqui, E. A. Chong, 

J. Svoboda, A. Gordon, J. D. McMannis, D. Bosque, J. Cotte, A. Brennan, 

Z. Zheng, L. Leinbach, Y. Xu, E. A. Veloso, W. Decker, C. M. Bollard, 

M. J. Keating, C. H. June 

Brd. 3E Effect of cellular vaccination of prostate cancer patients on IgG responses to 

peptide epitopes predicted from prostate tumor–associated autoantigens. 


G. P. Hemstreet, V. M. Pisarev, C. A. Enke, R. J. Hauke, G. R. Rossi, 

L. Tennant, W. J. Ramsey, N. N. Vahanian, C. J. Link 

Brd. 3F Blinded independent radiologic review (BIRR) versus investigator radiologic 

evaluation (IRE) for response assessment in metastatic colorectal cancer 

(mCRC): Systematic review and meta-analysis. (Abstract #2559) 

J. S. Lima, F. M. Carcano, F. H. Souza, L. V. dos Santos 

Brd. 3G Clinical effects of Wilms tumor protein (WT) 1 peptide vaccination in patients 

with WT1-expressing solid tumors as compared to patients with AML/MDS. 


A. Letsch, C. Scheibenbogen, A. Asemissen, K. Zimmermann, S. Bauer, 

M. Voelker-Call, D. Stather, E. Thiel, U. Keilholz 

293 

MONDAY

MONDAY 


Brd. 3H Posterior reversible encephalopathy syndrome in patients with cancer. 


A. M. Paker, L. Chi, M. C. Ruiz, M. E. Loghin 

Brd. 4A Expected benefits versus actual outcomes in oncology phase III randomized 

controlled trials (RCTs). (Abstract #2562) 

H. K. Gan, B. You, G. R. Pond, E. X. Chen 

Brd. 4B RECIST 1.0 versus 1.1: Implications for trial interpretation and design in 

advanced prostate cancer. (Abstract #2563) 

C. I. Piatek, B. B. Desai, D. Wei-Tsao, R. Tang, F. Acosta, J. K. Pinski, T. B. Dorff, 

A. Goldkorn, H. Jadvar, D. I. Quinn 

Brd. 4C A dose-finding study of a MUC-1 vaccine in conjunction with poly-IC:LC 

(polyinosinic-polycytidylic acid stabilized with polylysine and carboxy 

methylcellulose) in immunosuppressed (IS) patients (pts) with advanced 

prostate cancer (PCa) . (Abstract #2564) 

A. K. Patel, L. J. Appleman, W. E. Gooding, D. Friedland, J. McKolanis, 

A. M. Salazar, O. J. Finn, G. S. Chatta 

Brd. 4D Autologous heat shock protein vaccine (HSPPC-96) for patients with 

recurrent glioblastoma (GBM): Results of a phase II multicenter clinical trial 

with immunological assessments. (Abstract #2565) 

A. Parsa, C. Crane, S. Han, V. Kivett, A. Fedoroff, N. A. Butowski, S. M. Chang, 

J. L. Clarke, M. S. Berger, M. McDermott, M. Aghi, C. Yanes, M. Prados, 

A. E. Sloan, J. N. Bruce 

Brd. 4E Incidence of hypersensitivity reactions (HSRs) to albumin-bound paclitaxel 

(ABI) in patients (pts) with a history of HSR to cremophor-based paclitaxel 

(P). (Abstract #2566) 

J. P. Timoney, D. McGuffy, D. DeRitis, E. Tyler, J. Sumka, M. Pozotrigo, V. Bhatt, 

A. Chan, N. T. Sklarin 

Brd. 4F Comparison of 12 current staging systems for advanced hepatocellular 

carcinoma not amendable to locoregional therapy as inclusion criteria for 

clinical trials. (Abstract #2567) 

X. Li, Q. Lin, M. Dong, X. Wu, L. Wei, J. Wen, X. Ma, Z. Chen 

Brd. 4G First-in-human phase I study of the antiangiogenic vaccine (OTS11101) 

targeting VEGFR-1 in patients with solid tumors. (Abstract #2568) 

H. Hayashi, T. Kurata, Y. Fujisaka, T. Satoh, M. Takeda, M. Miyazaki, T. Okabe, 

H. Kiyota, K. Tanaka, T. Tsunoda, K. Nakagawa 

Brd. 4H Pro- versus antitumor effects of bisphosphonate-activated �� T cells in 

cancer immunotherapy. (Abstract #2569) 

V. Kunzmann, M. Smetak, B. Kimmel, K. Weigang-Koehler, M. Goebeler, 

J. Birkmann, J. Becker, I. Schmidt-Wolf, H. Einsele, M. Wilhelm 

Brd. 5A Influence of renal dysfunction on the pharmacokinetic of intravenous 

vinflunine: Results of a phase I trial in patients with cancer. (Abstract #2570) 

J. Delord, N. Isambert, P. Fumoleau, A. Ravaud, T. Nguyen, P. Ferre, S. Favrel, 

M. Pinel, J. Tourani 

Brd. 5B Population pharmacokinetic analysis from phase I and phase II studies of the 

humanized monovalent antibody, MetMAb, in patients with advanced solid 


S. Bai, Y. Xin, D. Jin, S. Kaur, I. Nijem, J. G. Bothos, A. C. Peterson, P. H. Patel 

Brd. 5C The effect of elotuzumab on natural killer (NK) cell function against multiple 

myeloma (MM). (Abstract #2572) 

S. M. Collins, C. E. Bakan, Y. Alghothani, H. Kwon, B. Balasa, G. Starling, A. Rice, 

D. M. Benson Jr. 

Brd. 5D Melphalan and whole-blood stem cell reinfusion in castration-resistant 

prostate cancer (CRPC): A phase I/II study. (Abstract #2573) 

J. Shamash, J. Jacob, T. Powles, S. Agrawal, K. Mutsvangwa, N. Saunders, 

P. Wilson, J. Stebbing 

294


Brd. 5E Systemic immune responses induced by intratumoral plasmid IL-12 

electroporation in patients with melanoma. (Abstract #2574) 

E. Cha, A. Daud, D. G. McNeel, R. Heller, L. Fong 

Brd. 5F Humoral tumor-associated immune responses induced by catumaxomab in 

patients with malignant ascites. (Abstract #2575) 

P. Ruf, M. Jäger, B. Foerster, H. Martinius, D. Seimetz, H. Lindhofer 

Brd. 5G Reduction of toxicity by reversing the order of infusion in docetaxel and 

cyclophosphamide (TC). (Abstract #2576) 

D. Miura, M. Fujii, T. Iwatani, T. Takano, H. Kawabata 

Brd. 5H A phase I clinical trial of a genetically modified and imageable oncolytic 

vaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP) 

imaging. (Abstract #2577) 

J. V. Pedersen, E. M. Karapanagiotou, A. Biondo, N. Tunariu, M. Puglisi, 

K. A. Denholm, S. Sassi, D. Mansfield, T. A. Yap, J. S. De Bono, K. J. Harrington 

Brd. 6A A phase 0 microdosing trial of an in vivo assay for predicting 

chemoresistance to platinum. (Abstract #2578^) 

C. Pan, S. Wang, R. deVere White, D. R. Gandara, P. Lara Jr., T. Li, P. Mack, 

A. Rodriguez-Fahrni, J. S. Lee, M. Malfatti, K. Turteltaub, P. T. Henderson 

Brd. 6B New lesions versus growth of existing disease: Does it impact prognosis? 


A. Grothey, J. M. Heun, M. Branda, R. M. Goldberg, D. J. Sargent 

Brd. 6C Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a 

multicenter, open-label, single-dose, phase I trial. (Abstract #2580) 

J. T. Lettieri, A. L. Mazzu, L. Huang, C. D. Lathia 

Brd. 6D Functional and clinical evidence of the influence of sorafenib binding to 

albumin on sorafenib disposition in adult patients with cancer with advanced 


A. Thomas-Schoemann, M. Tod, O. Mir, N. Bancelin, R. Coriat, F. Taieb, 

P. Boudou-Rouquette, H. Abbas, S. Ropert, J. Durand, A. Dauphin, F. Goldwasser, 

B. Blanchet 

Brd. 6E Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the 

pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal 

doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer 

(EOC). (Abstract #2582) 

M. D. Walsh, H. Giovinazzo, A. Sheikh, M. Ivanovic, A. B. Whitlow, S. E. Newman, 

N. M. La-Beck, R. J. Kowalsky, B. A. Zamboni, D. L. Clarke-Pearson, 

W. R. Brewster, L. Van Le, V. L. Bae-Jump, P. A. Gehrig, W. Zamboni 

Brd. 6F Meta-analysis of the pharmacokinetic variability of liposomal anticancer 

agents compared with nonliposomal anticancer agents. (Abstract #2583) 

B. Sidone, B. A. Zamboni, W. Zamboni 

Brd. 6G Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical 


M. Sebastian, L. von Boehmer, A. Zippelius, F. Mayer, M. Reck, D. Atanackovic, 

M. Thomas, F. Schneller, J. Stoehlmacher, E. Goekkurt, H. Bernhard, 

A. Groeschel, R. Bals, S. Schmidt, B. Scheel, S. D. Koch, T. Lander, K. Kallen, 

A. Knuth 

Brd. 6H Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) 

with intravenous weekly vinorelbine in advanced solid tumors. (Abstract 

#2585) 

R. Bahleda, J. Soria, Y. Berge, C. Massard, S. Wind, M. M. Uttenreuther-Fischer, 

F. Fleischer, H. De-Montserrat, F. Solca, I. Tschoepe, J. Delord 

Brd. 7A Population pharmacokinetic (PK) analysis supports fixed dosing for the 

humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) 

administered intravenously in patients with advanced solid tumors. (Abstract 

#2586) 

Y. Xin, M. S. Gordon, D. Jin, E. Wakshull, D. S. Chen, L. S. Rosen, P. N. Munster, 

L. Naumovski, S. Bai 

295 

MONDAY

MONDAY 


Brd. 7B Assessment of association between BRAF mutation status in melanoma 

tumors and response to ipilimumab. (Abstract #2587) 

J. Jackson, G. Whitney, O. Hamid, H. Schmidt, S. D. Chasalow, S. Alaparthy, 

Y. Bao, V. Shahabi 

Brd. 7C Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to 

reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and 

esophagogastric cancer (EGC). (Abstract #2588) 

R. F. Gabitass, N. E. Annels, J. Crawshaw, H. S. Pandha, G. W. Middleton 

Brd. 7D Tumor-targeted cancer vaccination (GeneVieve Protocol): A phase I/II study 

of intravenous Rexin-G and Reximmune-C for chemotherapy-resistant 


J. G. Ignacio, H. Bruckner, R. E. Manalo, F. S. San Juan, L. Baniqued, 

A. Madamba, E. M. Gordon, F. L. Hall 

Brd. 7E Outcomes in phase II trials of metastatic breast cancer: Where is the bar? 


A. Kamal, T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, 

J. M. Peppercorn 

Brd. 7F AIDS malignancy consortium (AMC) study 061: A phase I/PK study of 

sunitinib (S) with highly active antiretroviral therapy (HAART) in HIV� 

patients with solid tumors. (Abstract #2591) 

J. F. Deeken, M. A. Rudek, D. M. Aboulafia, R. J. Sullivan, J. F. Gerecitano, 

M. E. Cianfrocca, D. H. Henry, L. Ratner, B. J. Dezube, K. Mosby, M. Tibbals, 

R. F. Little, S. P. Ivy, P. C. Moore, R. T. Mitsuyasu 

Brd. 7G A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine 

encoding Epstein-Barr virus (EBV) antigens. (Abstract #2592) 

E. P. Hui, G. S. Taylor, B. Ma, S. L. Chan, R. Ho, W. Wong, H. Jia, C. Edwards, 

A. B. Rickinson, A. T. Chan, N. M. Steven 

Brd. 7H Metabolic profiles as predictive biomarkers of erlotinib-induced adverse 

effects in patients with non-small cell lung cancer. (Abstract #2593) 

A. Hamada, J. Sasaki, S. Saeki, N. Iwamoto, M. Inaba, S. Ushijima, H. Kishi, 

S. Fujii, H. Semba, K. Kashiwabara, Y. Tsubata, Y. Kai, T. Isobe, H. Kohrogi, 

H. Saito 

Brd. 8A An evaluation of plasma homocysteine levels and the hematological toxicity 

of pemetrexed even with folate supplementation. (Abstract #2594) 

A. Horiike, H. Tanaka, T. Sakatani, R. Saito, K. Kaburaki, N. Yanagitani, K. Kudo, 

F. Ohyanagi, S. Hagiwara, T. Horai, M. Nishio 

Brd. 8B Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in 

patients with solid tumors: Results from two phase Ib trials. (Abstract #2595) 

F. G. De Braud, C. Catania, A. Onofri, C. Pierantoni, S. Cascinu, M. Maur, 

C. Masini, P. F. Conte, L. Giovannoni, A. Tasciotti, V. Lovato, D. Neri, 

H. D. Menssen 

Brd. 8C NAD(P)H oxidase genetic polymorphisms and anthracyclines-induced 

cardiac lesions in patients with cancer. (Abstract #2596) 

A. Cascales, F. Pastor, B. Sanchez-Vega, J. Corral, A. Vicente, T. Garcia, 

V. Vicente, F. Ayala 

Brd. 8D Key drug development features in the design of early-phase oncology trials: 

An FDA perspective. (Abstract #2597) 

R. Charlab Orbach, G. M. Blumenthal, P. Cortazar, K. K. Filipski, C. Grimstein, 

L. Zhang, P. Mummaneni, B. Booth, I. Zineh 

Brd. 8E Population pharmacokinetics of NKTR-102, a topoisomerase I inhibitorpolymer 

conjugate, in patients with advanced solid tumors. (Abstract #2598) 

M. A. Eldon, U. Hoch 

Brd. 8F A pilot study of vaccination with sialyl Lewis a (sLe a )–keyhole limpet 

hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21 in 

metastatic breast cancer patients (pts). (Abstract #2599) 

A. Diab, G. Ragupathi, W. W. Scholz, K. Panageas, C. Hudis, P. O. Livingston, 

T. Gilewski 

296


Brd. 8G A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered 

either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim 

(peg) every 21 days (NCT01214642). (Abstract #2600) 

K. C. Shih, J. R. Infante, K. P. Papadopoulos, J. C. Bendell, A. W. Tolcher, 

H. A. Burris III, M. Beeram, L. Jackson, R. Arcos, E. H. Westin, D. Farrington, 

A. McGlothlin, S. Hynes, J. Leohr, J. T. Brandt, A. Nasir, A. Patnaik 

Brd. 8H The effect of the trifunctional anti-EpCAM antibody catumaxomab on the 

development of tumor-specific immune responses in patients with gastric 


H. Reinhard, S. K. Meyer, K. Bartels, R. Fischer, D. Seimetz, C. Bokemeyer, 

D. Atanackovic 

Brd. 9A Correlation between adverse event reports of hypothyroidism and clinical 

response in patients treated with vascular endothelial growth factor receptor 

inhibitors (VEGFR-I). (Abstract #2602) 

G. Speranza, L. Rubinstein, S. P. Ivy, P. J. Harris 

Brd. 9B Added value of pre- and on-treatment tumor growth kinetics assessment to 

RECIST in patients (pts) treated with molecularly targeted agents (MTAs). 


C. Le Tourneau, V. Servois, L. Ollivier, X. Paoletti 

Brd. 9C A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA. 


R. A. Madan, M. Bilusic, J. W. Hodge, K. Y. Tsang, P. M. Arlen, C. R. Heery, 

M. Rauckhorst, S. McMahon, C. Intrivici, T. A. Ferrara, A. Cohn, D. Apelian, 

A. Franzusoff, Z. Guo, J. Schlom, J. L. Gulley 

Brd. 9D Development and validation of a prediction tool for hand-foot skin reaction 

(HFSR) in patients receiving sorafenib. (Abstract #2605) 

J. Yu, G. Dranitsaris, M. D. Vincent, L. Huang, F. Fang, M. E. Lacouture 

Brd. 9E Understanding the role of carbonyl reductase polymorphisms on 

doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK). 


G. J. Fetterly, K. E. Thudium, J. Kalabus, M. Murphy, P. D. Zagst, J. Prey, 

E. Kittleman, A. A. Adjei, T. L. O’Connor, J. G. Blanco 

Brd. 9F A phase I dose escalation study of NKP-1339 in patients with advanced solid 

tumors refractory to treatment. (Abstract #2607) 

N. R. Dickson, S. F. Jones, H. A. Burris III, R. K. Ramanathan, G. J. Weiss, 

J. R. Infante, J. C. Bendell, W. McCulloch, D. D. Von Hoff 

Brd. 9G The effect of metformin (M) on overall survival (OS) of patients (Pts) with 

colorectal cancer (CRC) treated with chemotherapy (CTX). (Abstract #2608) 

M. Bansal, E. Siegel, R. Govindarajan 

Brd. 9H Phase I study of ATI-1123, a novel human serum albumin-stabilized 

docetaxel liposomal formulation, in patients with advanced solid 


S. Vemulapalli, A. C. Mita, N. S. Gallegos, G. Anderson, J. Charles, J. M. Rogers, 

A. Kousba, K. K. Sankhala, J. J. Nemunaitis 

Brd. 10A Enrichment of allogeneic tumor antigen-specific T-cells from bone marrow 

(BM) of patients treated with high-dose post-transplant cyclophoshamide 

(Cy): A novel approach to adoptive immunotherapy. (Abstract #2610) 

K. Noonan, L. Luznik, I. Borrello 

Brd. 10B Returning research results to clinical trial participants: A survey of patients 

with cancer. (Abstract #2611) 

K. Elzinga, C. V. Fernandez, D. Y. Heng, P. A. Tang 

Brd. 10C Phase I study evaluating the pharmacokinetics (PK) of components of S-1 in 

patients with impaired hepatic function. (Abstract #2612) 

D. Mahalingam, J. Sarantopoulos, M. S. Gordon, N. B. Pandya, B. R. Tan, 

A. C. Mita, C. Zergebel, K. Saito, C. H. Takimoto, M. Saif 

297 

MONDAY

MONDAY 


Brd. 10D Phase II, open-label trial to assess the effect of continuous oral afatinib 

(BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy 

in relapsed or refractory solid tumors including brain metastases and 

glioblastoma that is not amenable to other therapy. (Abstract #2613^) 

H. Kristeleit, M. Puglisi, G. W. Middleton, D. Propper, M. T. Kelleher, L. Trani, 

K. A. Denholm, G. Wallenstein, P. Stopfer, S. Buschke, M. M. Uttenreuther- 

Fischer, E. Bent, D. O’Brien, J. F. Spicer, L. R. Molife 

Brd. 10E A first-in-human phase Ia open-label dose-escalation study of the safety, 

pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized 

monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered 

intravenously in patients with advanced solid tumors. (Abstract #2614) 

L. S. Rosen, M. S. Gordon, S. Bai, P. Hegde, J. Fredrickson, D. S. Chen, I. Chang, 

R. P. Funke, G. S. Chandler, L. Naumovski, P. N. Munster 

298

8:00 AM - 12:00 PM 






Brd. 10F Phase I, open-label, dose-escalation study of AZD7762 in combination with 

irinotecan (irino) in patients (pts) with advanced solid tumors. (Abstract 

#3033) 

A. L. Ho, J. C. Bendell, J. M. Cleary, G. K. Schwartz, H. A. Burris III, P. Oakes, 

F. Agbo, P. N. Barker, A. M. Senderowicz, G. Shapiro 

Brd. 10G Efficacy in selected tumor types in a phase I study of the c-MET inhibitor 

ARQ 197 in combination with sorafenib. (Abstract #3034) 

A. A. Adjei, J. A. Sosman, R. E. Martell, G. K. Dy, L. W. Goff, W. Ma, L. Horn, 

G. J. Fetterly, S. A. Michael, J. A. Means, F. Chai, M. Lamar, G. M. Strauss, 

W. Chiang, J. Jarboe, B. E. Schwartz, I. Puzanov 

Brd. 10H A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in 

patients with advanced solid tumors: Results of dose-escalation phase. 


A. Patnaik, L. J. Appleman, J. M. Mountz, R. K. Ramanathan, M. Beeram, 

A. W. Tolcher, K. P. Papadopoulos, M. T. Lotze, D. P. Petro, C. Laymon, L. Paige, 

P. Rajagopalan, M. Jeffers, D. Roth, R. L. Dubowy 

Brd. 11A A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) 

and epirubicin in patients with solid tumor malignancies. (Abstract #3036) 

A. P. Moore, S. Thomas, C. J. Ryan, T. M. Jahan, S. G. DuBois, J. K. Chan, 

K. T. Thurn, E. A. Collisson, A. Reinert, A. Daud, P. N. Munster 

Brd. 11B Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once 

weekly (QW) dose regimen in patients with advanced solid tumors. (Abstract 

#3037^) 

A. Biondo, T. A. Yap, L. Yan, A. Patnaik, I. Fearen, R. D. Baird, 

K. P. Papadopoulos, L. M. Delgado, A. Taylor, L. Lupinacci, S. C. Blackman, 

S. Decordova, M. Tall, S. Heaton, M. D. Garrett, D. Sullivan, 

J. S. De Bono, A. W. Tolcher 

Brd. 11C A phase I trial of VB-111, a tissue- and condition-specific dual action vascular 

disruptive and antiangiogenic agent, for treatment of patients with advanced 

metastatic cancer. (Abstract #3038) 

A. J. Brenner, Y. Cohen, F. J. Giles, E. C. Borden, E. Breitbart, L. Bangio, N. Sher, 

P. L. Triozzi 

Brd. 11D Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral 

murine double minute 2 (MDM2) antagonist, in patients with leukemias and 


A. Beryozkina, G. L. Nichols, M. Reckner, L. T. Vassilev, R. Rueger, L. Jukofsky, 

S. Middleton, M. Andreeff, S. Padmanabhan, R. Strair, M. L. Delioukina, 

P. G. Maslak, P. Hillmen, R. Kurzrock, L. Gore, A. Patnaik, R. G. Maki, 

G. K. Schwartz, A. J. Wagner, J. Zhi 

Brd. 11E A phase I study of R-(-)-gossypol (AT-101) in combination with cisplatin (P) 

and etoposide (E) in patients (pts) with advanced solid tumors and extensivestage 

small cell lung cancer (ES-SCLC). (Abstract #3040) 

A. M. Traynor, J. Kolesar, R. M. Marnocha, J. C. Eikhoff, D. B. Alberti, N. Takebe, 

G. Wilding, G. Liu, W. R. Schelman 

Brd. 11F Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) 

inhibitor, in combination with doxorubicin and cyclophosphamide in breast 

cancer and other solid tumors. (Abstract #3041) 

A. R. Tan, D. Toppmeyer, M. N. Stein, R. A. Moss, M. Gounder, D. C. Lindquist, 

J. J. Ji, A. P. Chen, M. J. Egorin, B. Kiesel, J. H. Beumer, R. S. DiPaola 

299 

MONDAY

MONDAY 


Brd. 11G Development and validation of biomarker assays to assess 

pharmacodynamic modulation of MET. (Abstract #3042) 

A. K. Srivastava, M. G. Hollingshead, J. Weiner, S. Khin, S. Borgel, P. Risbood, 

T. D. Pfister, S. M. Lawrence, R. J. Kinders, D. P. Bottaro, 

J. E. Tomaszewski, R. E. Parchment, J. H. Doroshow 

Brd. 11H Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with 

advanced solid tumors: An update on safety and efficacy. (Abstract #3043) 

B. Grana, H. A. Burris III, J. Rodon Ahnert, A. R. Abdul Razak, M. J. De Jonge, 

F. Eskens, L. L. Siu, Q. C. Ru, N. F. Homji, D. Demanse, E. Di Tomaso, 

J. G. Cosaert, C. Quadt, J. Baselga, J. C. Bendell 

Brd. 12A A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with 

paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in 

patients with advanced non-small cell lung cancer (NSCLC). (Abstract #3044) 

B. Besse, J. Soria, C. Gomez-Roca, J. A. Ware, A. A. Adjei, G. K. Dy, G. Shankar, 

R. K. Brachmann, H. J. Groen 

Brd. 12B Genetic correlations with chemotherapy-induced hepatic injury. (Abstract 

#3045) 

C. H. Pilgrim, K. Brettingham-Moore, A. Pham, W. Murray, E. Link, M. Smith, 

V. Usatoff, P. M. Evans, S. Banting, B. N. Thomson, M. Michael, W. A. Phillips 

Brd. 12C A phase I dose escalation study of the polo-like kinase 1 inhibitor volasertib 

(BI 6727) with two different dosing schedules in patients with advanced solid 


C. Lin, W. Su, C. Yen, A. Cheng, Y. Lu, C. Hsu, D. C. Huang, H. Fritsch, F. Voss, 

R. Schreck, T. Taube, C. Yang 

Brd. 12D Angiogenic factors and soluble receptors in NCIC CTG BR.24. (Abstract 

#3047) 

C. L. Addison, K. Ding, H. Zhao, A. Le Maitre, S. A. Laurie, G. D. Goss, 

F. A. Shepherd, P. A. Bradbury, L. Seymour 

Brd. 12E Imaging with [ 18 f]-fluorodeoxyglucose positron emission tomography 

(FDG-PET) and dynamic contrast enhanced magnetic resonance imaging 

(DCE-MRI) as markers of drug effect in a phase I dose-escalation study of 

combined RAD 001 and cetuximab. (Abstract #3048) 

C. A. Martin, R. F. Perini, A. N. Avadhani, M. Redlinger, K. Harlacker, 

K. T. Flaherty, M. A. Rosen, C. R. Divgi, P. J. O’Dwyer 

Brd. 12F A phase I schedule optimization study of pegylated glutaminase (PEG-PGA) 

plus 6-diazo-5-oxo-l-norleucine (DON) in patients (pts) with advanced solid 


C. Unger, C. Mueller, M. P. Bausch, K. Krzemieniecki, S. Ochenduszko, B. Wilk, 

E. Jaeger, S. Al-Batran 

Brd. 12G A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously 

with bevacizumab with or without paclitaxel to patients with advanced solid 

tumors. (Abstract #3050^) 

C. D. Weekes, P. LoRusso, V. Ramakrishnan, L. M. Shih, W. C. Darbonne, 

P. Hegde, Y. Xin, R. Yu, H. Xiang, R. K. Brachmann, A. Patnaik 

Brd. 12H A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA- 

9090) administered twice weekly in patients with solid tumors: Updated 

report. (Abstract #3051) 

D. C. Cho, E. I. Heath, J. M. Cleary, E. L. Kwak, L. Gandhi, D. P. Lawrence, 

C. Zack, F. Teofilovici, R. Bradley, M. D. Karol, G. Shapiro, P. LoRusso 

Brd. 13A A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, 

administered QD or BID in patients with advanced or metastatic solid tumors. 


D. D. Von Hoff, P. LoRusso, G. D. Demetri, G. J. Weiss, G. Shapiro, 

R. K. Ramanathan, J. A. Ware, R. Raja, J. Jin, G. G. Levy, K. E. Mazina, 

A. J. Wagner 

300


Brd. 13B Integrated research platform (iGXT) for enhancing drug development and 

personalizing cancer therapy: Pilot study results. (Abstract #3053) 

D. R. Gandara, T. A. Van Dyke, Z. Weaver Ohler, T. Li, P. Lara Jr., P. C. Mack, 

R. F. Calhoun, R. Gandour-Edwards, K. D. Danenberg, R. de Vere White, 

N. Goodwin 

Brd. 13C Poly (ADP ribose) polymerase (PARP) inhibition in peripheral blood 

lymphocytes (PBLs): Does it reflect PARP inhibition in tumor? (Abstract 

#3054) 

D. R. Shalinsky, D. D. Wang, K. A. Kern, P. English, N. J. Curtin, R. Plummer 

Brd. 13D First-in-human dose-escalation safety and PK trial of a novel humanized 

monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular 

endothelial growth factor. (Abstract #3055) 

D. S. Mendelson, L. S. Rosen, M. S. Gordon, J. W. Goldman, A. J. Olszanski, 

H. Dai, R. Perea, A. Gollerkeri 

Brd. 13E Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the 

novel dual PI3K/mTOR inhibitor BEZ235. (Abstract #3056) 

D. Bottino, J. Tabernero, H. A. Burris III, C. Britten, L. Chen, J. C. Bendell, 

O. Chiparus, V. Duval, E. Di Tomaso, C. Sarr, W. Hackl, J. Baselga, 

J. Rodon Ahnert 

Brd. 13F First-in-human phase I study of Atu027, a liposomal small interfering RNA 

formulation, targeting protein kinase N3 (PKN3) in patients with advanced 


D. Strumberg, B. Schultheis, U. Traugott, C. Vank, A. Santel, O. Keil, K. Giese, 

J. Kaufmann, J. Drevs 

Brd. 13G Phase I dose-escalation study of AZD7762 in combination with gemcitabine 

(gem) in patients (pts) with advanced solid tumors. (Abstract #3058) 

E. A. Sausville, P. LoRusso, M. A. Carducci, P. N. Barker, F. Agbo, P. Oakes, 

A. M. Senderowicz 

Brd. 13H Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug 

delivery of 11 C-labeled docetaxel in patients with non-small cell lung cancer 

(NSCLC): Implications for scheduling of antiangiogenic agents. (Abstract 

#3059) 

E. F. Smit, M. Lubberink, I. Bahce, M. Walraven, M. P. de Boer, H. N. Greuter, 

N. Hendrikse, J. Eriksson, A. D. Windhorst, P. E. Postmus, H. M. Verheul, 

E. H. Serne, A. A. Lammertsma, A. A. van der Veldt 

Brd. 14A Early targeted drug development: Pilot FDA review of PI3K inhibitor phase I 

studies using a knowledge management database. (Abstract #3060) 

G. M. Blumenthal, R. Charlab Orbach, I. Zineh, P. Cortazar, R. L. Justice, 

R. Pazdur 

Brd. 14B Investigation of hand-foot syndrome (HFS) observed in pazopanib (P)-treated 

patients (pts) with renal cell carcinoma (RCC). (Abstract #3061) 

H. A. Ball, Y. Lin, Z. Xue, B. Suttle, C. Xu, L. Huang, L. McCann, T. E. Hutson, 

C. N. Sternberg, L. N. Pandite 

Brd. 14C Phase I study of LDE225 in advanced solid tumors: Updated analysis of 

safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic 

correlation. (Abstract #3062) 

H. A. Tawbi, J. Rodon Ahnert, R. Dummer, A. L. Thomas, C. Granvil, Y. Shou, 

J. Dey, M. M. Mita, D. D. Amakye, A. C. Mita 

Brd. 14D A first-in-human phase I clinical trial of CXR1002 in patients (pts) with 

advanced cancer. (Abstract #3063) 

I. R. MacPherson, D. Bissett, R. D. Petty, B. Tait, L. M. Samuel, J. MacDonald, 

M. Smith, J. A. Birse-Archbold, A. L. Barnett, C. R. Wolf, C. R. Elcombe, 

A. Jeynes-Ellis, T. Evans 

301 

MONDAY

MONDAY 


Brd. 14E A phase I study of CAL-101, an isoform-selective inhibitor of 

phosphatidylinositol 3-kinase P110�, in combination with anti-CD20 

monoclonal antibody therapy and/or bendamustine in patients with 

previously treated B-cell malignancies. (Abstract #3064) 

I. W. Flinn, M. T. Schreeder, S. E. Coutre, J. Leonard, N. D. Wagner-Johnston, 

S. De Vos, R. V. Boccia, L. Holes, S. Peterman, L. L. Miller, A. S. Yu 

Brd. 14F Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib 

in advanced solid tumors. (Abstract #3065) 

I. Garrido-Laguna, R. Kurzrock, J. J. Wheler, G. S. Falchook, S. A. Piha-Paul, 

S. Fu, A. Naing, C. Hinojosa, R. Mistry, A. Scamardo, K. S. Culotta, 

S. Ekmekcioglu, S. Wen, L. H. Camacho, S. P. Ivy, D. S. Hong 

Brd. 14G A dose-escalation study with the novel formulation of the oral pan-class I 

PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with 

advanced solid tumors. (Abstract #3066) 

J. D. Peyton, J. Rodon Ahnert, H. Burris, C. Britten, L. Chen, J. Tabernero, 

V. Duval, N. Rouyrre, A. P. Silva, C. Quadt, J. Baselga 

Brd. 14H Combination study of navitoclax with gemcitabine (G) in patients (pts) with 


J. M. Cleary, C. S. Rocha Lima, H. Hurwitz, A. J. Montero, G. Shapiro, C. Franklin, 

J. Yang, A. M. Graham, T. Busman, M. Mabry, K. D. Holen, A. Krivoshik, 

R. Humerickhouse, H. Uronis 

Brd. 15A Update on a phase I pharmacologic and pharmacodynamic study of MK- 

1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with 

gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. 


J. H. Schellens, G. Shapiro, A. C. Pavlick, R. Tibes, S. Leijen, S. M. Tolaney, 

I. Diaz-Padilla, R. K. Ramanathan, T. Demuth, J. Viscusi, J. D. Cheng, 

R. Lam, Y. Xu, A. M. Oza 

Brd. 15B Results of a study of the oral inhibitor PTC299 on tumor VEGF synthesis. 


J. J. Luke, L. A. Callahan, C. H. Darby, E. Moss, J. Winkelman, J. Barth, 

G. L. Elfring, A. Ogden, G. K. Schwartz, M. M. Gounder 

Brd. 15C Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, 

in patients with advanced solid tumors. (Abstract #3070) 

J. C. Bendell, M. S. Gordon, H. Hurwitz, C. H. Condon, Y. Yang, D. Wilson, 

K. M. Attie, M. L. Sherman, S. Sharma 

Brd. 15D The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of 

patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A 

phase I study. (Abstract #3071) 

J. A. Thompson, A. Forero-Torres, E. I. Heath, S. M. Ansell, S. K. Pal, J. R. Infante, 

S. De Vos, P. A. Hamlin, B. Zhao, K. Klussman, N. C. Whiting 

Brd. 15E Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with 

advanced malignancies and normal and impaired liver function: An NCI 

Organ Dysfunction Working Group (ODWG) study. (Abstract #3072) 

J. Sarantopoulos, H. Lenz, P. LoRusso, S. Shibata, S. Kummar, D. Mulkerin, 

R. K. Ramanathan, M. M. Mita, P. O’Rourke, S. C. Remick, S. Goel, M. Gutierrez, 

S. S. Ramalingam, A. Murgo, A. M. Davies, S. Mani, J. Boni, M. Shapiro, S. P. Ivy, 

C. H. Takimoto, National Cancer Institute Organ Dysfunction Working Group 

Brd. 15F A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced 


J. W. Goldman, M. S. Gordon, H. Hurwitz, R. Pili, D. S. Mendelson, B. J. Adams, 

D. Alvarez, B. K. Seon, C. P. Theuer, B. R. Leigh, L. S. Rosen 

Brd. 15G Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA 

repair: Final results from a 100-patient, 5-arm phase Ib trial in combination 

with five standard of care (SOC) anticancer regimens. (Abstract #3074) 

K. K. Sankhala, A. W. Tolcher, M. M. Mita, M. S. Gordon, L. S. Rosen, 

K. P. Papadopoulos, A. Patnaik, R. L. Drengler, A. C. Mita, J. Sarantopoulos, 

R. G. Bristow, G. Fine, G. S. Choy, M. Azab 

302


Brd. 15H A phase I, open-label, dose-escalation study of the novel oral proteasome 

inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid 


K. P. Papadopoulos, D. S. Mendelson, A. W. Tolcher, A. Patnaik, H. A. Burris III, 

D. W. Rasco, J. C. Bendell, M. S. Gordon, G. Kato, H. Wong, D. Bomba, S. Lee, 

H. H. Gillenwater, T. Woo, J. R. Infante 

Brd. 16A First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results 

from the solid tumors cohort. (Abstract #3076) 

L. Chen, L. S. Rosen, T. Iyengar, J. W. Goldman, R. Savage, J. Kazakin, 

T. C. Chan, B. E. Schwartz, G. Abbadessa, D. D. Von Hoff 

Brd. 16B Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine 

in a cohort of patients (pts) with advanced breast, ovarian, and uterine 


L. H. Camacho, S. Pant, M. N. Saleh, G. Abbadessa, J. Kazakin, B. E. Schwartz, 

J. C. Bendell 

Brd. 16C Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as 

monotherapy in subjects with previously treated advanced solid tumors. 


M. A. Dickson, P. LoRusso, E. A. Sausville, N. Rao, E. Kobayashi, M. R. Kurman, 

S. Akinaga, G. K. Schwartz 

Brd. 16D Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II 

randomized discontinuation trial (RDT). (Abstract #3079) 

M. J. Ratain, G. K. Schwartz, A. M. Oza, C. M. Rudin, S. B. Kaye, M. J. De Jonge, 

D. Khayat, A. Awada, M. B. Sawyer, J. C. Obel, J. Medioni, T. Evans, J. De Greve, 

P. M. Soetekouw, J. Baurain, P. J. O’Dwyer, C. Hartman, V. Poulart, I. B. Walters 

Brd. 16E A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered 

every 3 weeks in patients (pts) with advanced malignancies: Final results. 


M. M. Mita, A. C. Mita, J. Moseley, J. Poon, K. A. Small, Y. Jou, P. Kirschmeier, 

D. Zhang, P. Statkevich, K. K. Sankhala, J. Sarantopoulos, J. M. Cleary, 

L. R. Chirieac, S. Rodig, R. Bannerji, G. Shapiro 

Brd. 16F Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in 

advanced solid tumors (STs). (Abstract #3081) 

M. Kittaneh, A. J. Montero, K. Kovacs, V. D. Guardiola Amado, A. M. Flores, 

A. Ferrell, M. Vulfovich, M. D. Pegram, P. W. Benedetto, C. S. Rocha Lima, 

J. R. Merchan 

Brd. 16G Quality appraisal of clinical validation studies for multigene prediction 

assays of chemotherapy response in early-stage breast cancer. (Abstract 

#3082) 

N. M. Kuderer, E. Culakova, M. Huang, M. S. Poniewierski, G. S. Ginsburg, 

W. T. Barry, P. K. Marcom, N. Ready, A. P. Abernethy, G. H. Lyman 

Brd. 16H MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase 

inhibitor, in combination with erlotinib: Phase I clinical experience. (Abstract 

#3083) 

P. J. O’Dwyer, K. P. Papadopoulos, A. W. Tolcher, U. R. Teitelbaum, K. Harlacker, 

M. Beeram, D. Sohal, M. Mehran, M. Tawashi, M. A. Drouin, C. R. Maroun, 

J. Wang, M. Fournel, A. Karam, J. M. Besterman, A. Patnaik 

Brd. 17A Dose-response relationship in phase I clinical trials: A European Drug 

Development Network (EDDN) collaboration study. (Abstract #3084) 

P. A. Cassier, V. Moreno Garcia, C. Gomez-Roca, D. Olmos, R. Morales, 

G. Del Conte, E. Gallerani, A. Brunetto, P. Schoffski, S. Marsoni, J. H. Schellens, 

N. Penel, E. E. Voest, T. Evans, R. Plummer, R. H. Wilson, J. Soria, J. Tabernero, 

J. Verweij, S. B. Kaye, European Drug Development Network 

303 

MONDAY

MONDAY 


Brd. 17B Phase I dose escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) 

dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). 


R. Kurzrock, A. Patnaik, L. Rosenstein, S. Fu, K. P. Papadopoulos, D. A. Smith, 

G. S. Falchook, G. Chambers, J. L. Gauvin, A. Naing, L. S. Smith, 

T. Gonzalez, A. M. Tsimberidou, T. A. Mays, D. S. Cox, D. S. Hong, D. J. DeMarini, 

N. T. Le, S. R. Morris, A. W. Tolcher 

Brd. 17C A first-in-human phase I study of MORAb-004 (MOR4), a humanized 

monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid 


R. D. Carvajal, M. M. Gounder, C. M. Coughlin, J. Fishel, J. Heyburn, 

D. O’Shannessy, L. Grasso, C. Schweizer, J. Parno, L. J. Old, N. S. Azad, 

L. A. Diaz Jr. 

Brd. 17D Findings from the phase I clinical trials of CX-4945, an orally available 

inhibitor of CK2. (Abstract #3087) 

R. F. Marschke, M. J. Borad, R. W. McFarland, R. H. Alvarez, J. K. Lim, 

C. S. Padgett, D. D. Von Hoff, S. E. O’Brien, D. W. Northfelt 

Brd. 17E Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, 

germ cell, and epithelial tumors containing amplification of CCND1. (Abstract 

#3088) 

R. F. Perini, A. DeMichele, D. J. Vaughn, M. Gallagher, W. Sun, B. J. Giantonio, 

U. R. Teitelbaum, S. Randolph, J. G. Christensen, R. D. Courtney, D. A. Pryma, 

C. R. Divgi, P. J. O’Dwyer 

Brd. 17F Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients 

with advanced solid tumors. (Abstract #3089) 

R. Dienstmann, A. W. Tolcher, K. P. Papadopoulos, D. W. Rasco, J. Tabernero, 

I. Brana, A. Piera, N. Skartved, H. Aladdin, J. Petersen, A. Patnaik 

Brd. 17G A phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor) 

in subjects with solid tumors. (Abstract #3090) 

R. J. Kelly, A. Rajan, G. Chun, A. Lopez-Chavez, G. Giaccone 

Brd. 17H A phase I dose escalation study of INCB028060, an inhibitor of c-MET 

receptor tyrosine kinase, in patients with advanced solid tumors. (Abstract 

#3091) 

R. C. Donehower, A. Scardina, M. Hill, J. Bowman, R. C. Newton, X. Liu, 

P. Scherle, Q. Wang, S. Diamond, J. Boer, F. Lee, T. Gau, H. A. Burris III, 

J. C. Bendell, S. F. Jones, J. R. Infante 

Brd. 18A Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. 


S. R. Palmer, C. Erlichman, M. Fernandez-Zapico, Y. Qi, L. Almada, 

A. McCleary-Wheeler, M. J. Borad, J. R. Molina, A. Grothey, H. C. Pitot, 

A. Jatoi, D. W. Northfelt, R. R. McWilliams, S. H. Okuno, P. Haluska, G. P. Kim, 

G. Colon-Otero 

Brd. 18B Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective 

inhibitor of FMS and Kit. (Abstract #3093) 

S. P. Anthony, I. Puzanov, P. S. Lin, K. B. Nolop, B. West, D. D. Von Hoff 

Brd. 18C Phase I dose-escalation study of the investigational Aurora A kinase (AAK) 

inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients 

with nonhematologic malignancies. (Abstract #3094) 

S. Sharma, R. Kurzrock, L. Gouw, D. S. Hong, K. Jones, X. Zhou, H. Shi, 

H. Fingert, G. S. Falchook 

Brd. 18D A phase I/II study of the hypomethylating agent azacitadine with the 

nanoparticle albumin bound paclitaxel in the treatment of patients with 

advanced or metastatic solid tumors. (Abstract #3095^) 

T. L. Dumlao, T. W. Butler, D. L. Dyess, H. T. Khong 

304


Brd. 18E First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 

inhibitor. (Abstract #3096) 

U. Banerji, C. Aghajanian, E. Raymond, R. Kurzrock, M. Blanco-Codesido, 

E. Oelmann, L. Grinsted, W. Burke, S. B. Kaye, A. Naing 

Brd. 18F Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of 

ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors. 


U. Keilholz, V. Moiseyenko, A. Makhson, V. Semiglazov, M. Learoyd, A. Saunders, 

M. Stuart, S. Tjulandin 

Brd. 18G Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth 

factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with 

erlotinib (E) in patients with advanced solid tumors. (Abstract #3098^) 

V. M. Macaulay, M. R. Middleton, S. G. Eckhardt, R. A. Juergens, C. M. Rudin, 

A. Manukyants, S. Gogov, S. Poondru, R. Gedrich, S. M. Gadgeel 

Brd. 18H A phase I study evaluating the combination of OSI-906, a dual inhibitor of 

insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with 

weekly paclitaxel (PAC) in patients with advanced solid tumors. (Abstract 

#3099) 

W. A. Harb, C. Sessa, H. W. Hirte, S. B. Kaye, R. Simantov, S. N. Banerjee, 

A. Christinat, D. W. Sternberg, M. Singh, R. Light, S. Poondru 

Brd. 19A A phase I dose-escalation study of the novel gamma secretase inhibitor 

PF-03084014 in patients (pts) with advanced solid tumors. (Abstract #3100) 

W. A. Messersmith, P. LoRusso, J. M. Cleary, A. Dasari, X. Zhang, M. N. Shaik, 

R. D. Courtney, S. Randolph, G. Shapiro 

Brd. 19B Final results of a phase I study of the combination of a novel cell cycle 

inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic 

and other solid tumors. (Abstract #3101) 

W. Ma, W. A. Messersmith, G. K. Dy, E. Freas, A. Whitworth, F. Wilhelm, 

S. G. Eckhardt, A. A. Adjei, A. Jimeno 

Brd. 19C First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor 

MK-4827 in advanced cancer patients with antitumor activity in BRCAdeficient 

tumors and sporadic ovarian cancers (soc). (Abstract #3102) 

W. R. Schelman, S. K. Sandhu, V. Moreno Garcia, G. Wilding, L. Sun, C. Toniatti, 

M. Stroh, N. Kreischer, C. L. Carpenter, L. R. Molife, S. B. Kaye, J. S. De Bono, 

R. M. Wenham 

Brd. 19D Predictive value of Fc gamma receptor IIIa genotype in response to 

conatumumab in three phase II studies. (Abstract #3103) 

Y. Pan, V. Haddad, T. Sabin, N. Baker, Y. Hei, F. Galimi, J. Graves, C. Huang, 

S. Cottrell 

Brd. 19E Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 

in BRCA 1 and 2–mutated, advanced ovarian and/or locally advanced or 

metastatic breast cancer. (Abstract #3104) 

Y. Drew, J. A. Ledermann, A. Jones, G. Hall, G. C. Jayson, M. Highley, D. Rea, 

R. M. Glasspool, S. E. Halford, G. Crosswell, S. Colebrook, 

A. V. Boddy, N. J. Curtin, E. R. Plummer 

Brd. 19F Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 

receptor signaling, in combination with paclitaxel (P). (Abstract #3105) 

J. A. Lopez-Martin, M. Vidal Losada, J. Cortes, B. Bermejo, A. Lluch Fernandez, 

M. Learoyd, A. Saunders, M. Stuart, J. Baselga 

Brd. 19G FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors. 


J. Chang, M. Rand, G. M. Blumenthal, P. Cortazar, C. Kulick, E. Hausman, 

S. Chang, R. Pratt, B. Habtemarium, Y. Chen, J. Bullock, R. Charlab Orbach, 

I. Zineh, R. L. Justice, R. Pazdur 

305 

MONDAY

MONDAY 


8:00 AM - 12:00 PM 


Tumor Biology 



Brd. 20A Evaluation of the prognostic significance of human mammaglobin 

expression in pleural effusion from patients with negative thoracoscopy. 


A. Vigani, P. A. Canessa, C. Manta, P. Ferro, M. C. Franceschini, A. Morabito, 

M. Sivori, V. Fontana, F. Fedeli, M. Pistillo, S. Roncella 

Brd. 20B Clinical characterstics and outcomes of patients with BRAF-mutant 

advanced cancer in a phase I clinic: The University of Texas M. D. Anderson 

Cancer Center experience. (Abstract #10535) 

H. E. El-Osta, G. S. Falchook, A. M. Tsimberidou, D. S. Hong, A. Naing, K. B. Kim, 

S. Wen, F. Janku, R. Kurzrock 

Brd. 20C The association of long pentraxin 3 on prognosis in pancreatic carcinoma 

patients on gemcitabine-based chemotherapy. (Abstract #10536) 

S. Kondo, H. Ueno, C. Morizane, F. Koizumi, K. Tamura, T. Okusaka 

Brd. 20D The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on 

epithelial–mesenchymal transition (EMT) in non-small cell lung cancer 

(NSCLC) cells lines and its effect on erlotinib and cisplatin. (Abstract #10537) 

M. Maitah, S. Ali, P. LoRusso, F. H. Sarkar, S. M. Gadgeel 

Brd. 20E Indoleamine 2,3-dioxygenase activity and clinical outcome following 

induction chemotherapy and concurrent chemoradiation in stage III nonsmall 

cell lung cancer. (Abstract #10538) 

B. C. Creelan, G. Bepler, S. Antonia, T. Garrett, H. H. Soliman 

Brd. 20F The predictive role of midtreatment changes in survivin, GSTP1, and 

topoisomerase 2 alpha expressions for pathologic complete response to 

neoadjuvant chemotherapy in patients with locally advanced breast cancer. 


S. Keskin, Y. Eralp, E. Akisik, A. Igci, M. Muslumanoglu, S. Yilmaz, M. Tunaci, 

H. Camlica, S. Tuzlali, P. Saip, N. Dalay, V. Ozmen, E. Topuz 

Brd. 20G Role of the type III TGF-� receptor in modulating antitumor immunity during 

breast cancer progression. (Abstract #10540) 

B. A. Hanks, O. M. Campbell, J. D. Lee, M. Morse, T. M. Clay, H. K. Lyerly, 

G. C. Blobe 

Brd. 20H Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung 

cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) 

mutations. (Abstract #10541) 

S. Viteri, R. Rosell, C. Costa, M. Taron, J. Sanchez, S. Benlloch, T. Moran, 

B. Massuti, C. Camps, M. Majem, E. Carcereny, F. Cardenal, A. Gasco, 

N. Mederos, I. Magri, C. D. Rolfo, M. Garcia-Campelo, A. Gimenez Capitan, 

I. de Aguirre, C. Queralt 

Brd. 21A The relationship between the number of aberrantly methylated regions and 

the methylation status of p73 and RARB genes and prognosis in patients 

with breast cancer. (Abstract #10542) 

D. M. Marzese, F. Gago, J. I. Orozco, O. M. Tello, L. M. Vargas-Roig, M. Roqué 

Brd. 21B An evaluation of molecular imaging with 11 c-PD153035 PET/CT and its 

association in predicting outcomes in non-small cell lung cancer treated with 

EGFR-TKI. (Abstract #10543) 

X. Meng, J. Yu, B. W. Loo, L. Ma, X. Sun, J. D. Murphy, S. Q. Zhao, L. Kong, 

G. R. Yang, W. L. Li, X. G. Zhao 

306


Brd. 21C A metabolic phenotyping approach to understanding relationships between 

metabolic syndrome and breast tumor responses to chemotherapy. (Abstract 

#10544) 

J. Stebbing, A. Sharma, B. North, T. J. Athersuch, A. Zebrowski, D. Pchejetski, 

R. C. Coombes, J. K. Nicholson, H. C. Keun 

Brd. 21D The prognostic role of calretinin expression and neutrophil-to-lymphocyte 

ratio (NLR) in patients with malignant pleural mesothelioma (MPM) 

undergoing extrapleural pneumonectomy (EPP). (Abstract #10545) 

S. C. Kao, S. Klebe, D. Henderson, G. Reid, M. D. Chatfield, N. Armstrong, T. Yan, 

J. L. Vardy, S. J. Clarke, N. Van Zandwijk, B. McCaughan 

Brd. 21E The relationship of HOXB9 expression promoting tumor cell proliferation and 

angiogenesis to clinical outcomes of patients with breast cancer. (Abstract 

#10546) 

T. Hayashida, H. Jinno, H. Seki, M. Takahashi, M. Sakata, S. Hirose, M. Mukai, 

Y. Kitagawa 

Brd. 21F Correlation of 18F-FDG uptake and EGFR/KRAS mutations in surgically 

resected lung cancer. (Abstract #10547) 

K. Takamochi, S. Oh, M. Fukui, K. Suzuki 

Brd. 21G The potential of circulating microRNA (miRNA) levels as a biomarker in drug 

development: An analysis of tumor-serum samples from patients on a phase 

I trial of saracatinib-paclitaxel (P)-carboplatin (C). (Abstract #10548) 

D. S. Tan, S. Aamdal, G. Freyer, R. J. Jones, S. B. Kaye, E. Pujade-Lauraine, 

J. Fog, M. Wrang Teilum, C. Glue, A. Baker, U. A. Emeribe, P. Elvin, C. Stephens, 

M. Stuart, J. Walker, E. Boven 

Brd. 21H Molecular characterization of primary breast cancer in older women using 

partitional clustering and correlation with long-term clinical outcome. 


B. M. Syed, A. R. Green, D. Soria, E. C. Paish, J. Garibaldi, D. A. Morgan, 

I. O. Ellis, K. Cheung 

Brd. 22A Single molecule RNA sequencing of formalin-fixed paraffin-embedded tissue 

derived from lung cancer patients. (Abstract #10550) 

A. J. Yee, T. Raz, A. Amzallag, D. Lipson, E. Giladi, H. Lopez, D. R. Borger, 

M. Mino-Kenudson, J. F. Thompson, A. J. Iafrate, P. Milos, D. A. Haber, 

S. Ramaswamy 

Brd. 22B MicroRNA expression patterns in lobular neoplasia. (Abstract #10551) 

L. A. Stead, A. Ramnauth, S. Fineberg, O. Loudig 

Brd. 22C Identification of LASEP3 as a new serological and prognostic biomarker for 


A. Takano, Y. Nakamura, Y. Daigo 

Brd. 22D Clinical relevance of circulating CK-19mRNA-positive tumor cells at first 

diagnosis in patients with metastatic breast cancer. (Abstract #10553) 

N. E. Androulakis, M. Perraki, S. Apostolaki, V. Bozionelou, A. G. Pallis, 

K. Kalbakis, S. Agelaki, A. Xyrafas, D. Mavroudis, V. Georgoulias 

Brd. 22E Differential effect of adjuvant taxane-based and taxane-free chemotherapy 

regimens on the CK-19 mRNA-positive circulating tumor cells in patients 

with early breast cancer. (Abstract #10554) 

N. Xenidis, M. Perraki, S. Apostolaki, S. Agelaki, K. Kalbakis, N. K. Vardakis, 

A. Kalykaki, A. Xyrafas, S. Kakolyris, D. Mavroudis, V. Georgoulias 

Brd. 22F Microarray-based gene expression profiles reliably predict ELISA-derived 

uPA and PAI-1 levels in breast cancer biopsies, a comparison between fresh 

frozen (FF) and formalin-fixed paraffin-embedded (FFPE) samples. (Abstract 

#10555) 

C. Matuschek, H. Prisack, E. Boelke, W. Budach, M. Peiper, M. Rezai, W. Janni, 

H. Bojar 

307 

MONDAY

MONDAY 


Brd. 22G The role of IGF-1R in EGFR TKI resistance in NSCLC using IHC and AQUA 

technology. (Abstract #10556) 

Y. Kato, C. Mascaux, M. W. Wynes, B. Reyna Asuncion, C. Tran, K. Yoshida, 

J. Matsubayashi, E. Nakajima, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda, 

F. R. Hirsch 

Brd. 22H Clinical relevance of mesenchymal stem cell–induced resistance to 


J. M. Roodhart, L. G. Daenen, E. C. Stigter, R. H. Medema, A. C. Martens, 

A. B. Brenkman, E. E. Voest 

Brd. 23A A polymorphism in the coding sequence of WT1 is an independent 

prognostic marker in 1,101 patients with lobular breast cancer. (Abstract 

#10558) 

M. Heuser, F. Damm, P. Schuermann, M. Zucknick, M. Shah, P. Harrington, 

P. Pharoah, M. Schmidt, A. Broeks, R. van Hien, R. A. Tollenaar, H. Nevanlinna, 

T. Heikkinen, K. Aittomaki, C. Blomqvist, J. Krauter, P. Hillemanns, A. Ganser, 

T. Park-Simon, T. Dork 

Brd. 23B The prognosic value of the downregulation of leukocyte cell–derived 

chemotaxin 2 gene of hepatocellular carcinoma. (Abstract #10559) 

C. Yang, M. Ho, C. Chen, H. Hsu, P. Lee, M. Kuo 

Brd. 23C Molecular tumor profiling (MTP) in cancer of unknown primary site (CUP): A 

complement to standard pathologic diagnosis. (Abstract #10560) 

D. S. Thompson, J. D. Hainsworth, C. M. Lane, W. J. Lennington, D. R. Spigel, 

F. A. Greco 

Brd. 23D Non-small cell lung cancer biomarkers: Discovery using mab proteomics. 


L. Takacs, M. Guergova-Kuras, I. Kurucz, N. Tardieu, J. Kadas, 

C. Malderez-Bloes, A. Jullien, Y. Kieffer, B. Dezso, B. Karger 

Brd. 23E Performance characteristics and validation of automated tumor-infiltrating 

lymphocyte counting. (Abstract #10562) 

C. C. Hoyt, I. S. Hagemann, A. R. Hagemann, L. Wang, E. Hung, K. Lane, 

G. Coukos, M. D. Feldman 

Brd. 23F Thymidylate synthase expression in adenosquamous carcinoma of lung. 


C. Shu, H. Cheng, A. Wang, M. Mansukhani, C. A. Powell, B. Halmos, 

A. C. Borczuk 

Brd. 23G Comprehensive next-generation sequencing for clinically actionable 

mutations from formalin-fixed cancer tissues. (Abstract #10564) 

J. S. Ross, D. Lipson, R. Yelensky, M. Jarosz, A. Parker, C. E. Sheehan, F. Juhn, 

Z. Zwirko, K. Brennan, T. Bloom, S. Downing, J. Curran, M. T. Cronin 

Brd. 23H Modulation of angiogenic biomarkers in patients treated on a phase I study 

of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors. 


Y. Liu, M. Starr, H. Pang, J. Marcello, B. R. Leigh, C. P. Theuer, H. Hurwitz, 

A. B. Nixon 

Brd. 24A Disparities in the prognostic significance of proliferation amongst different 

molecular subtypes in node-negative breast cancer. (Abstract #10566) 

M. Schmidt, I. Petry, D. Boehm, A. Lebrecht, S. Gebhard, H. Koelbl, M. Gehrmann, 

J. G. Hengstler 

Brd. 24B SmgGDS splice variants: Potential novel targets for breast cancer 

therapeutics. (Abstract #10567) 

C. Bergom, A. Hauser, E. L. Lorimer, R. Li, A. C. Mackinnon, C. L. Williams 

Brd. 24C Discovery of oncoproteins as cancer biomarkers and molecular targets for 

antibody-based immunotherapy. (Abstract #10568) 

Y. Daigo, A. Takano, Y. Nakamura 

308


Brd. 24E Exonic expression variations of EGFR and KRAS in small bronchoscopic 

biopsies from patients with advanced non-small cell lung cancer treated by 

combined bevacizumab/erlotinib therapy followed by platinum-based 

chemotherapy at disease progression: A multicenter phase II trial 

SAKK19/05. (Abstract #10570) 

M. H. Brutsche, M. Frueh, S. Crowe, K. Na, C. Droege, D. C. Betticher, 

R. von Moos, F. Zappa, M. Pless, L. Bubendorf, F. Baty, on behalf of the Swiss 

Group for Clinical Cancer Research (SAKK) 

Brd. 24F An integrated analysis of three distinct IBC/non-IBC affymetrix gene 

expression data sets to study the transcriptional heterogeneity both between 

IBC and non-IBC and within IBC. (Abstract #10571) 

S. J. Van Laere, N. T. Ueno, P. Finetti, P. B. Vermeulen, A. Lucci Jr., D. Birnbaum, 

F. Robertson, T. Iwamoto, P. A. van Dam, W. A. Woodward, P. Viens, L. Y. Dirix, 

J. M. Reuben, F. Bertucci 

Brd. 24G Circulating tumor cell (CTC) as a clinical marker in malignant pleural 


F. Tanaka, K. Yoneda, N. Kondo, M. Hashimoto, T. Takuwa, S. Matsumoto, 

S. Hasegawa, Y. Okumura, T. Tsujimura, K. Fukuoka, T. Nakano 

Brd. 24H Pathway analysis of primary human non-small cell lung cancer (NSCLC). 


N. Daraselia, Y. Wang, A. Budoff, A. Lituev, O. Potapova, J. Monforte, 

V. Ossovskaya 

Brd. 25B A second generation microRNA-based assay for diagnosing tumor tissue 

origin. (Abstract #10575) 

R. T. Aharonov, S. Rosenwald, T. B. Edmonston, I. Barshack, M. Feinmesser, 

M. Huszar, W. C. Mueller, F. Fogt, H. Shomin, L. Cohen, I. Burnstein, E. Goren, 

B. St. Cyr, Y. Spector, N. Dromi, E. Meiri 

Brd. 25C NY-ESO-1 as a predictive marker for neoadjuvant chemotherapy in stage IIIa 


T. John, Y. Chen, M. H. Starmans, M. Walkiewicz, P. Russell, A. Azad, S. Deb, 

N. K. Altorki, P. C. Boutros, P. Mitchell, J. S. Cebon 

Brd. 26A Circulating endothelial cell (CEC), a surrogate of tumor angiogenesis, as a 

diagnostic and prognostic marker in malignant pleural mesothelioma (MPM). 


K. Yoneda, F. Tanaka, N. Kondo, H. Orui, M. Hashimoto, T. Takuwa, 

S. Matsumoto, Y. Okumura, A. Sato, T. Tsujimura, N. Tsubota, K. Kuribayashi, 

K. Fukuoka, T. Nakano, S. Hasegawa 

Brd. 26B A microRNA-based diagnostic test for kidney tumor classification. (Abstract 

#10578) 

A. Chajut, E. Fridman, I. Barshack, Z. A. Dotan, M. Zepeniuk, S. Tabak, 

D. Lebanony, E. Klinke, S. Rosenwald, O. Zion, A. Faerman, M. Ben-David, 

A. Bokish, Y. Spector 

Brd. 26C Use of immunohistochemical evaluation of DNA repair proteins to 

demonstrate cisplatin response prediction in resected NSCLC squamous cell 


W. E. Pierceall, K. M. Sprott, E. Brambilla, R. Pirker, H. H. Popper, X. Wang, 

Y. Chen, S. Quan, M. Filipits, L. Alaparthi, J. Kutok, D. T. Weaver, M. Al-Adhami, 

F. Andre, T. Le Chevalier, B. E. Ward, J. Soria 

Brd. 27A MYC and human telomerase gene (TERC) gene copy number gain in resected 

in non-small cell lung cancer (NSCLC). (Abstract #10580) 

A. Flacco, V. Ludovini, F. R. Tofanetti, F. Bianconi, G. Bellezza, M. G. Mameli, 

G. Metro, C. Bennati, L. Cagini, N. Daddi, L. Pistola, A. Siggillino, E. Baldelli, 

A. Sidoni, F. Puma, M. Varella-Garcia, L. Crinò 

Brd. 27B A novel inflammatory-based prognostic score in hepatocellular carcinoma. 


D. J. Pinato, H. S. Wasan, L. Maslen, B. North, R. Sharma 

309 

MONDAY

MONDAY 


Brd. 27C Disseminated tumor cells in the bone marrow of ductal carcinoma in situ 


N. Sänger, K. E. Effenberger, S. Riethdorf, E. Ruckhäberle, L. C. Hanker, 

I. Wiegratz, K. Strebhardt, K. Pantel, M. Kaufmann 

Brd. 28A SOX2-related micrornas, miR-145 and miR-367, as prognostic markers of 

time to recurrence (TTR) in surgically resected non-small cell lung cancer 

(NSCLC) patients (p). (Abstract #10583) 

A. Navarro, M. Campayo, N. Vinolas, V. Ciria, T. Diaz, R. M. Marrades, L. Molins, 

J. Ramirez, M. Monzo 

Brd. 28B Evaluation of anti-CTLA4 treatment in a murine model of intestinal polyposis. 


J. D. Phillips, N. R. Blatner, M. F. Mulcahy, P. Beckhove, D. J. Bentrem, K. Khazaie 

Brd. 28C ALK chromosomal alterations in neuroendocrine tumors. (Abstract #10585) 

C. Montagut, E. Arriola, A. B. Galvan, F. G. Rojo, M. Salido, M. Gallen, M. Garcia, 

A. Martinez, F. Pons, S. Servitja, M. Iglesias, S. Menendez, S. Serrano, F. Sole, 

A. Rovira, J. Albanell, J. Bellmunt 

Brd. 29A Correlation of high levels of immature blood vessels in colorectal tumors 

with longer survival following bevacizumab treatment. (Abstract #10586) 

S. Noonan, P. Martin, M. Biniecka, A. Maguire, M. Tosetto, J. Hyland, K. Sheahan, 

D. O’Donoghue, H. Mulcahy, D. Fennelly, J. O’Sullivan 

Brd. 29B A single nucleotide polymorphism (SNP) in a microRNA (miRNA)-binding site 

of KRT81 and time to recurrence (TTR) in patients (p) with surgically resected 


M. Campayo, A. Navarro, N. Vinolas, R. Tejero, C. Munoz, T. Diaz, R. M. Marrades, 

M. L. Cabanas, J. M. Gimferrer, J. Ramirez, P. Gascon, M. Monzo 

Brd. 29C Gastrin-releasing peptide receptor expression in Brazilian and Japanese 

patients with lung cancer and normal lung tissue samples from healthy 

individuals. (Abstract #10588) 

J. Mattei, Y. Kato, M. W. Wynes, C. Cano, R. D. Achcar, B. Reyna Asuncion, 

B. R. de Macedo, L. Meurer, J. Kulczynski, R. Roesler, K. Yoshida, 

J. Matsubayashi, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda, A. Brunetto, 

G. Schwartsmann 

Brd. 30A Prognostic value of CA27.29 trend during adjuvant chemotherapy and until 2 

years thereafter in patients with primary breast cancer. (Abstract #10589) 

B. K. Rack, P. G. Hepp, U. Andergassen, J. K. Neugebauer, J. Salmen, 

G. Heinrich, J. Schreier, A. Hoenig, D. Finas, T. Zwingers, R. Kreienberg, 

M. W. Beckmann, W. Lichtenegger, H. L. Sommer, K. Friese, W. Janni, SUCCESS 

Study Group 

Brd. 30B Body mass index (BMI) and DNA mismatch repair status in colon cancers 

from patients treated in adjuvant therapy trials. (Abstract #10590) 

N. R. Foster, F. Sinicrope, G. A. Yothers, C. J. Allegra, D. J. Sargent 

Brd. 30C Reactivation of oncogene-induced senescence in KRAS mutant non-small 

cell lung cancer by inhibition of TWIST1. (Abstract #10591) 

T. F. Burns, I. Dobromilskaya, S. Murphy, S. Thiyagarajan, S. Das, P. T. Tran, 

C. M. Rudin 

Brd. 31A Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects 

with metastatic breast cancer (MBC). (Abstract #10592) 

M. C. Liu, M. Mego, S. Nakamura, F. Nole, J. Pierga, M. Toi, E. Munzone, 

H. Yagata, M. T. Sandri, F. Bidard, H. Wang, D. F. Hayes, M. Cristofanilli 

Brd. 31B Computer-aided volumetry analysis in assessing pulmonary chemotherapy 

response in advanced NSCLC comparing with RECIST criteria. (Abstract 

#10593) 

L. Ding, R. L. Bliss, M. Ingebrand, T. Allen, P. Ives, A. Dudek, R. A. Kratzke 

310


Brd. 31C Prospective comparison of recurrence score, uPA/PAI-1, central grade and 

molecular classification in early breast cancer: Interim results from the 

WSG-Plan B trial. (Abstract #10594) 

T. Degenhardt, O. Gluz, H. H. Kreipe, R. E. Kates, C. Liedtke, S. Shak, 

M. R. Clemens, D. Augustin, U. Nitz, N. Harbeck, on behalf of the Plan B 

investigators 

Brd. 31D Association of the MDM2 T309G polymorphism and gastroesophageal reflux 

disease (GERD) with overall survival (OS) in esophageal adenocarcinoma 

(EAC). (Abstract #10595) 

D. J. Renouf, B. Sun, R. Zhai, W. Xu, R. S. Heist, M. Kulke, L. Su, D. C. Christiani, 

G. Liu 

Brd. 31E Molecular and clinicopathologic characteristics of HER2-mutant lung 

adenocarcinoma (ADC). (Abstract #10596) 

M. E. Arcila, J. E. Chaft, K. Nafa, M. G. Kris, M. F. Zakowski, M. Ladanyi 

Brd. 31F PAM50 breast cancer intrinsic classifier: Clinical validation of a multianalyte 

laboratory developed test. (Abstract #10597) 

M. T. Ebbert, R. R. Bastien, L. R. Rowe, P. A. Miller, D. Anderson, K. M. Boucher, 

L. M. Pappas, C. Fauron, B. W. Lyons, T. Dowell, D. E. Wall, L. Barley, 

P. S. Bernard 

Brd. 31G Activation of the mTOR pathway in primary medullary thyroid carcinoma and 

lymph node metastases. (Abstract #10598) 

A. Tamburrino, A. A. Molinolo, P. Salerno, R. Chernock, M. Raffeld, L. Xi, 

J. S. Gutkind, J. F. Moley, S. A. Wells, M. Santoro 

Brd. 31H Molecular predictors of metastases and stage of thymoma. (Abstract #10599) 

S. S. Badve, C. Goswami, Y. Gokmen-Polar, R. P. Nelson Jr., J. Henley, N. Miller, 

R. K. Jain, R. J. Mehta, N. A. Zaheer, G. W. Sledge Jr., L. Li, K. Kesler, 

P. J. Loehrer 

Brd. 32A Expression of Adam28 as a prognostic biomarker of survival in patients with 

early-stage non-small cell lung cancer. (Abstract #10600) 

Y. Zhang, X. Zhang, Y. Wu, G. Zhang, H. Cheng, S. Dong 

Brd. 32B An analysis of serum heparan sulfate concentration and EGFR tyrosine 

kinase inhibitor treatment in patients with non-small cell lung 


M. Nishio, T. Yamanaka, K. Matsumoto, H. Kimura, K. Sakai, A. Sakai, T. Sone, 

A. Horiike, F. Koizumi, K. Kasahara, T. Ohira, N. Ikeda, N. Saijo, T. Arao, K. Nishio 

Brd. 32C Signatures of drug sensitivity in non-small cell lung cancer. (Abstract 

#10602) 

H. Gong, D. G. Beer, S. Singh 

Brd. 32D Elucidating the biological basis of prognosis in young women with early 

breast cancer (BC) using gene expression profiling. (Abstract #10603) 

H. A. Azim, S. Michels, P. Bedard, D. Fumagalli, S. K. Singhal, B. Haibe-Kains, 

M. Piccart, C. Sotiriou, S. Loi 

Brd. 32E A mouse model of rectal cancer that mimics the clinical disease. (Abstract 

#10604) 

H. Kishimoto, M. Momiyama, R. Aki, H. Kimura, A. Suetsugu, M. Bouvet, 

T. Fujiwara, R. M. Hoffman 

Brd. 32F MicroRNA analysis as a potential diagnostic tool in the cytological diagnosis 

of non-small cell lung cancer. (Abstract #10605) 

A. Fassina, R. Cappellesso, A. Olivotto, M. Fassan 

Brd. 32G TGF�1 gene polymorphisms with the risk of radiation pneumonitis in nonsmall 

cell lung cancer in different ethnic study. (Abstract #10606) 

X. Niu, S. Lu, H. Li, Y. Liu, Z. Chen, D. Zhou, M. Kan, Z. Li, Y. Yu, C. LV 

Brd. 32H Functional metabolic tomographic optical breast imaging (TOBI) to monitor 

response to neoadjuvant therapy in breast cancer. (Abstract #10607) 

S. Carp, C. Wanyo, M. Specht, L. Schapira, B. Moy, D. Finkelstein, D. Boas, 

S. J. Isakoff 

311 

MONDAY

MONDAY 


Brd. 33A Diagnostic and therapeutic significance of the cerebrospinal fluid (CSF) 

EGFR mutation analysis for the patients with NSCLC suffering meningitis 

carcinomatosa harboring active EGFR mutation, after gefitinib therapy 

failure. (Abstract #10608) 

S. Sasaki, Y. Yoshioka, R. Ko, Y. Katsura, Y. Namba, K. Koike, M. Yoshioka, 

S. Tominaga 

Brd. 33B KRAS and BRAF mutation analysis on paired biopsy and resection 

specimens of patients with colorectal cancer: Molecular analysis using 

high-resolution melting, direct sequencing, KRAS ARMS-scorpion PCR and 

BRAF pyrosequencing. (Abstract #10609) 

L. C. Krol, N. A. Hart, N. Methorst, A. J. Knol, C. Prinsen, J. E. Boers 

Brd. 33C An evaluation of bone marrow stromal-derived growth factor-1 and 

interleukin-8 levels in stage I-III breast cancer patients with disseminated 

tumor cells. (Abstract #10610) 

C. Hall, S. Krishnamurthy, A. Lodhi, A. Bhattacharyya, A. Anderson, H. M. Kuerer, 

I. Bedrosian, A. Lucci Jr. 

Brd. 33D Circulating levels of RANK/RANKL and OPG in patients with bone metastasis 

treated with zoledronic acid: A prospective study. (Abstract #10611) 

T. Ibrahim, L. Mercatali, E. Sacanna, R. Ricci, E. Scarpi, P. Serra, F. Fabbri, 

C. Tison, D. Amadori 

Brd. 33E Differential efficacy of pemetrexed in non-squamous NSCLC based on 

human cytokeratin fragment antigen 21-1 (CYFRA21–1) serum levels. 


K. Kaburaki, A. Horiike, T. Sakatani, R. Saito, H. Tanaka, N. Yanagitani, K. Kudo, 

F. Ohyanagi, S. Hagiwara, T. Horai, M. Nishio 

Brd. 33F Combined use of MammaPrint and molecular subtyping profile (BluePrint) to 

identify subgroups with marked differences in response to neoadjuvant 

treatment. (Abstract #10613) 

F. De Snoo, P. Roepman, O. Krijgsman, R. A. Bender, R. Bernards, A. Glas 

Brd. 33G A miRNA assay for the classification of benign and neoplastic lesions in 

pancreatic fine needle aspirates. (Abstract #10614) 

A. E. Schwarzbach, A. Adai, M. Lloyd, B. F. Andruss 

Brd. 33H Collecting tissue for research purposes: A survey of 16 institutions in the 

Translational Breast Cancer Research Consortium (TBCRC). (Abstract 

#10615) 

E. S. Frank, R. T. Burns, N. E. Carbine, L. Cargen, C. Chauhan, D. K. Cline, 

R. Kleban, S. A. Mertz, A. H. Meyn, J. Perlmutter, C. A. Rufenbarger, M. Smith, 

P. A. Spears, L. V. Vincent, A. C. Wolff 

Brd. 34A Use of the DEPArray platform to detect, isolate, and molecularly characterize 

pure tumor cells from peripheral blood samples enriched using the 

CellSearch system. (Abstract #10616) 

G. Medoro, S. Gross, N. Manaresi, M. Sergio, F. Fontana, S. Gianni, A. Calanca, 

E. Peruzzi, M. Banzi, G. Signorini, C. Rao, J. Patel, J. Karkera, G. Giorgini, 

M. Mata, M. C. Connelly 

Brd. 34B The prognostic impact of circulating tumor cells in patients with small cell 


T. Naito, F. Tanaka, K. Yoneda, T. Takahashi, H. Murakami, Y. Nakamura, 

A. Tsuya, M. Endo, H. Kenmotsu, K. Kaira, T. Shukuya, A. Ono, H. Akamatsu, 

S. Miura, M. Kimura, N. Yamamoto 

Brd. 34C Significance of FANCJ expression as a predictive marker of sensitivity to 

5-fluorouracil in colorectal cancer. (Abstract #10618) 

R. Nakanishi, H. Kitao, N. Yamashita, N. Kubo, Y. Fujinaka, M. Iimori, E. Oki, 

M. Morita, Y. Kakeji, Y. Maehara 

312


Brd. 34D Implications of specific T-cell responses by different novel and known 

immunogenic tumor-associated antigens (TAA) in patients with metastatic 


A. M. Babiak, M. Steinhauser, S. Hofmann, J. Conzelmann, V. Schneider, 

M. Goetz, L. Zhang, H. Dohner, J. Greiner 

Brd. 34E Influence of KRAS status of colorectal cancer liver metastases in patients 

receiving neoadjuvant chemotherapy including bevacizumab prior liver 

resection. (Abstract #10620) 

S. Stremitzer, J. Maresch, T. Aschacher, B. Wolf, F. Wrba, T. Gruenberger, 

B. Gruenberger 

Brd. 34F Intravital evaluation of time-course efficacy of anticancer drugs on colorectal 

liver metastases in the same living mice using two-photon laser scanning 

microscopy. (Abstract #10621) 

K. Tanaka, Y. Morimoto, Y. Toiyama, S. Saigusa, Y. Okugawa, Y. Inoue, 

K. Uchida, K. Matsushita, M. Kawamura, A. Mizoguchi, M. Kusunoki 

Brd. 34G Clinical, biological, and pathological features predicting non-sentinel lymph 

node (NSLN) status in breast cancer (BC). (Abstract #10622) 

J. Furlanetto, E. Fiorio, G. Pollini, Z. Franchini, P. Pietrarota, Q. Piubello, 

F. Bonetti, R. Micciolo, E. Manfrin, G. L. Cetto, A. Molino 

Brd. 34H Prognostic role of interleukin-1B and interleukin-1-receptor antagonist 

polymorphisms in localized gastric cancer. (Abstract #10623) 

E. Goekkurt, G. Folprecht, S. Lehmann, L. Obermann, M. Kramer, A. Rentsch, 

S. Wilop, G. Ehninger, T. H. Brummendorf, J. Stoehlmacher-Williams 

Brd. 35A Effect of everolimus treatment on chromogranin A, neuron-specific enolase, 

gastrin, and glucagon levels in patients with advanced pancreatic 

neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. (Abstract 

#10624) 

E. De Vries, L. B. Anthony, L. Sideris, L. Chen, J. Lebrec, Z. Tsuchihashi, 

R. E. Winkler, J. C. Yao, K. E. Oberg 

Brd. 35B Comparison of predictive and prognostic impact of molecular subtypes and 

central grade regarding taxane-based therapy in intermediate-risk breast 

cancer: Results from the EC-Doc trial. (Abstract #10625) 

U. Nitz, O. Gluz, C. Liedtke, J. B. Huober, A. Hartmann, R. E. Kates, H. H. Kreipe, 

E. Pelz, W. Kuhn, N. Harbeck, on behalf of the EC-Doc investigators (West 

German Study Group/AGO-B) 

Brd. 35C Correlation of CA 27.29 and circulating tumor cells before, at the end, and 2 

years after adjuvant chemotherapy in patients with primary breast cancer: 

The SUCCESS trial. (Abstract #10626) 

P. G. Hepp, B. K. Rack, H. Tesch, M. Rezai, T. Beck, J. Salmen, U. Andergassen, 

U. Ortmann, T. Zwingers, M. W. Beckmann, W. Lichtenegger, J. W. Janni, 

SUCCESS Study Group 

Brd. 35D Determining argininosuccinate synthetase (ASS) expression in melanoma 

patients treated with arginine depleting therapy. (Abstract #10627) 

V. Dinh, M. You, N. Savaraj, C. Wu, M. T. Kuo, M. Wangpaichitr, L. G. Feun 

Brd. 35E Pathoepidemiological patterns of contralateral breast cancers in Black and 

White women. (Abstract #10628) 

H. Nsouli-Maktabi, A. M. Schwartz, S. D. Cleary, N. Younes, H. A. Young, 

D. E. Henson 

Brd. 35F Thymidilate synthase gene copy number as predictive marker of 

capecitabine efficacy in patients with breast cancer. (Abstract #10629) 

R. Audet, R. Duchnowska, K. Adamowicz, J. Zok, W. Rogowski, M. M. Litwiniuk, 

S. Debska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft, K. Zabkowska, 

C. Shen, S. Edgerton, K. V. Nielsen, A. D. Thor, J. C. Chang, K. Miller, J. Jassem, 

G. W. Sledge Jr., B. Leyland-Jones 

Brd. 35G Biomarkers affecting metastasis and survival in paired tissues of 107 

patients with metastatic breast cancer. (Abstract #10630) 

E. Kim, H. Lee, G. Gong, K. Jung, J. Ahn, B. Son, S. Ahn, H. Kim, S. Kim 

313 

MONDAY

MONDAY 


Brd. 35H Redefining CTCs: Detection of additional circulating tumor cells using an 

antibody capture cocktail and HER2 FISH. (Abstract #10631) 

F. Z. Bischoff, T. J. Pircher, T. Pham, K. Wong, S. Mikolajczyk, P. Cotter, 

J. A. Mayer 

Brd. 36A Proof of concept of immuno-PET molecular imaging of met using 76 Br- and 

89 

Zr-labeled MetMAb. (Abstract #10632) 

M. Merchant, J. Marik, J. Peng, S. P. Williams, A. Ogasawara, J. N. Tinianow, 

V. Bhadrasetty, L. Lang, S. M. Lee, I. Kim, M. Williams, L. Szajek, 

K. E. Raffensperger, F. Cecchi, E. Jagoda, P. L. Choyke, C. Paik, D. P. Bottaro 

314

8:00 AM - 12:00 PM 

TRIALS IN PROGRESS POSTER SESSION 


Trials in Progress Poster Session 


Track(s): Clinical Trials; Special Session 

Brd. 36B A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 

4/6 inhibitor, in combination with letrozole for first-line treatment of patients 

with postmenopausal, estrogen receptor (ER)-positive, human epidermal 

growth factor receptor 2 (HER2)-negative advanced breast cancer. (Abstract 

#TPS100) 

R. S. Finn, K. Boer, I. Lang, R. J. Parikh, R. Patel, M. Schmidt, C. T. Hagenstad, 

H. J. Lim, T. Pinter, D. Amadori, D. Chan, R. Dichmann, S. T. Kim, 

S. Randolph, D. J. Slamon, J. P. Crown 

Brd. 36C Incorporating comparative effectiveness research study endpoints into the 

treatment for positive-node, endocrine-responsive breast cancer 

(RxPONDER) study. (Abstract #TPS101) 

S. D. Ramsey, W. E. Barlow, C. Moinpour, A. M. Gonzalez-Angulo, 

G. N. Hortobagyi, D. L. Veenstra, L. P. Garrison, S. R. Tunis, L. H. Baker 

Brd. 36D MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with 

or without pertuzumab (P) compared with trastuzumab (H) plus taxane for 

first-line treatment of HER2-positive, progressive, or recurrent locally 

advanced or metastatic breast cancer (MBC). (Abstract #TPS102) 

P. A. Ellis, C. H. Barrios, Y. Im, M. Patre, F. Branle, E. A. Perez 

Brd. 36E A phase III randomized trial of metformin versus placebo on recurrence and 

survival in early-stage breast cancer (BC; NCIC Clinical Trials Group MA.32). 

(Abstract #TPS103) 

W. Parulekar, B. E. Chen, C. Elliott, L. E. Shepherd, K. A. Gelmon, K. I. Pritchard, 

T. J. Whelan, J. A. Ligibel, D. L. Hershman, I. A. Mayer, T. J. Hobday, P. Rastogi, 

J. Lemieux, P. A. Ganz, V. Stambolic, P. J. Goodwin 

Brd. 36F SWOG S1007: A phase III, randomized clinical trial of standard adjuvant 

endocrine therapy with or without chemotherapy in patients with one to three 

positive nodes, hormone receptor (HR)-positive, and HER2-negative breast 

cancer with recurrence score (RS) of 25 or less. (Abstract #TPS104) 

A. M. Gonzalez-Angulo, W. E. Barlow, J. Gralow, F. Meric-Bernstam, D. F. Hayes, 

C. Moinpour, S. D. Ramsey, A. F. Schott, D. B. Sparks, K. S. Albain, 

G. N. Hortobagyi 

Brd. 36G Ongoing clinical development of lapatinib in HER2-positive (HER2�) 

metastatic breast cancer (MBC): An innovative approach to recruit patients in 

clinical studies. (Abstract #TPS105) 

S. R. Johnston, K. A. Gelmon, X. B. Pivot, W. J. Gradishar, A. Conner, D. Kothari, 

P. Legenne, M. Leigh, L. O’Rourke, R. Parikh 

Brd. 36H A phase I dose-escalation study of ABT-888 (veliparib) in combination with 

carboplatin in HER2-negative metastatic breast cancer (MBC). (Abstract 

#TPS106) 

S. Viswanathan, R. Wesolowski, R. M. Layman, G. Alejandra, B. Miller, 

J. J. Chalmers, S. Bejastani, W. Zhao, G. Pierluigu, J. Cotrill, M. A. Phelps, 

L. J. Schaaf, S. M. Geyer, N. Hall, M. V. Knopp, C. L. Shapiro, 

M. A. Villalona-Calero, A. Chen, M. R. Grever, B. Ramaswamy 

Brd. 37A An open-label positron emission tomography (PET) study to investigate and 

quantify brain and tumor penetration of carbon-11 labeled lapatinib in 

patients with HER2-overexpressing (HER2�) advanced or metastatic breast 

cancer (MBC). (Abstract #TPS107) 

R. C. Coombes, J. A. Reise, M. Lau, S. C. Carme, G. E. Searle, M. Huiban, 

P. Burgess, K. Koch, A. Das-Gupta, A. Saleem 

315 

MONDAY

MONDAY 


Brd. 37B Phase III study of taxane chemotherapy with lapatinib or trastuzumab as 

first-line therapy for women with HER2/neu-positive metastatic breast cancer 

(BC) (NCIC Clinical Trials Group (NCICCTG )MA.31/GSK EGF 108919). 


W. Parulekar, J. W. Chapman, S. Aparicio, Y. Murray, F. M. Boyle, A. Di Leo, 

B. Kaufman, C. Levy, A. Manikhas, M. Martin, K. I. Pritchard, L. S. Schwartzberg, 

M. J. Burnell, S. Dent, S. Ellard, K. S. Tonkin, T. J. Whelan, J. Lemieux, 

L. Bordeleau, K. A. Gelmon 

Brd. 37C Safety and efficacy of single-agent adjuvant trastzumab in older women with 

breast cancer. (Abstract #TPS109) 

C. Owusu, H. D. Klepin, G. G. Kimmick, L. Sutton, A. Brufsky 

Brd. 37D A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in 

estrogen receptor-positive (ER�) breast cancer. (Abstract #TPS110) 

S. Ebbinghaus, J. L. Blum, J. Cortes, H. S. Rugo, C. Swanton, L. Eaton, Y. Song, 

T. Zhang, J. Baselga 

Brd. 37E Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without 

letrozole in aromatase inhibitor-resistant breast cancer. (Abstract #TPS111) 

P. Haluska, A. Dhar, X. Hou, F. Huang, D. S. Nuyten, J. Park, A. H. Brodie, 

J. N. Ingle, J. M. Carboni, M. M. Gottardis, A. C. Wolff, F. G. Finckenstein 

Brd. 37F A randomized, double-blind phase II trial of exemestane with or without 

MM-121 in postmenopausal women with locally advanced or metastatic 

estrogen receptor-positive (ER�) and/or progesterone receptor-positive 

(PR�), HER2-negative breast cancer. (Abstract #TPS112) 

V. M. Moyo, M. J. Higgins, R. Aravelo-Araujo, N. Iannotti, V. Charu, N. Dhindsa, 

P. E. Goss 

Brd. 37G HER2 suppression with the addition of lapatinib to trastuzumab in HER2positive 

metastatic breast cancer (LPT112515). (Abstract #TPS113) 

N. U. Lin, M. A. Danso, A. K. David, J. J. Muscato, C. E. Ellis, S. Lahiri, 

T. Sessa, Y. M. Nagarwala, E. Winer 

Brd. 37H Randomized, double-blind, placebo-controlled phase II trial of low-dose 

metronomic cyclophosphamide alone or in combination with veliparib 

(ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neunegative 

metastatic breast cancer: New York Cancer Consortium trial P8853. 


E. Andreopoulou, A. P. Chen, J. Zujewski, M. Kim, D. L. Hershman, K. Kalinsky, 

T. Cigler, L. T. Vahdat, G. Raptis, B. Ramaswamy, Y. Novik, F. Muggia, 

J. A. Sparano 

Brd. 38A A phase III, multicenter, double-blind, randomized trial of celecoxib versus 

placebo in primary breast cancer patients: Randomized European Celecoxib 

Trial (REACT). (Abstract #TPS115) 

R. C. Coombes, G. Von Minckwitz, J. Hicks, P. Klare, A. A. Evans, M. Schmidt, 

A. Makris, R. Grieve, S. Loibl, L. Maher, K. Mousa, K. Buchsenscuhtz, R. A’Hern, 

J. M. Bliss 

Brd. 38B EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 

(T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with 

HER2-positive locally advanced or metastatic breast cancer (MBC) and 

previously treated with a trastuzumab-based regimen. (Abstract #TPS116) 

S. Verma, V. Dieras, L. Gianni, D. Miles, M. Welslau, M. D. Pegram, J. Baselga, 

E. Guardino, L. Fang, C. M. Linehan, K. L. Blackwell 

Brd. 38C Trial of perioperative endocrine therapy: Individualizing care (POETIC). 


I. E. Smith, L. Johnson, M. Dowsett, J. F. Robertson, L. E. Robison, J. S. Kokan, 

A. A. Evans, C. Holcombe, K. Horgan, A. Skene, R. Prasad, M. S. Absar, R. Vidya, 

N. J. Bundred, C. Harding-Mackean, D. A. Wheatley, M. W. Kissin, I. F. Pinhel, 

L. S. Kilburn, J. M. Bliss, on behalf of the POETIC Trialists 

316


Brd. 38D Trastuzumab plus capecitabine with or without pertuzumab in patients with 

HER2-positive MBC whose disease has progressed during or following 

trastuzumab-based therapy for first-line metastatic disease: A multicenter, 

randomized, two-arm, phase II study (PHEREXA). (Abstract #TPS118) 

M. Munoz-Mateu, A. Urruticoechea, R. Separovic, J. Erfán, T. D. Bachelot, 

J. Canon, N. Kovalenko, E. Staroslawska, B. Pikó, C. Veyret, O. Pribylova, 

D. L. Ciule, J. Ratnayake, S. Das, K. Mayne, G. Ross 

Brd. 38E A phase I/II study of MM-111, a novel bispecific antibody that targets the 

ErB2/ErB3 heterodimer, in combination with trastuzumab in advanced 

refractory HER2-positive breast cancer. (Abstract #TPS119) 

M. J. Higgins, N. Y. Gabrail, K. Miller, S. V. Agresta, S. Sharma, C. McDonagh, 

J. Murray, K. Andreas, S. Frye, V. M. Moyo, C. Niyikiza, P. D. Ryan 

Brd. 38F A randomized trial assessing the use of electro-acupuncture for aromatase 

inhibitor-induced arthralgia. (Abstract #TPS120) 

J. M. Beith, E. Segelov, K. Orme, A. McLean, B. Oh 

Brd. 38G Serum NT pro-BNP and individual genetic polymorphisms as predictors of 

trastuzumab-related cardiotoxicity. (Abstract #TPS121) 

S. Goel, J. Lynch, L. A. Chantrill, J. J. Rutovitz, B. Murray, E. A. Abdi, R. Bell, 

A. L. Sullivan, A. Goldrick, T. M. Hayes, G. Asghari, N. Wilcken, N. J. McCarthy, 

J. M. Beith 

Brd. 38H TBCRC 011: Targeting the androgen receptor (AR) for the treatment of 

AR�/ER-/PR- metastatic breast cancer (MBC). (Abstract #TPS122) 

A. Gucalp, S. M. Tolaney, S. J. Isakoff, J. N. Ingle, M. C. Liu, L. A. Carey, 

K. L. Blackwell, H. S. Rugo, L. Nabell, A. Abbruzzi, J. Gonzalez, D. D. Giri, S. Patil, 

K. Feigin, G. D’Andrea, M. Theodoulou, P. Drullinsky, N. T. Sklarin, C. Hudis, 

T. A. Traina, Translational Breast Cancer Research Consortium 

Brd. 39A Tesetaxel, an advanced-generation oral taxane, as first-line treatment in 

women with metastatic breast cancer. (Abstract #TPS123) 

L. S. Schwartzberg, M. Beeram, A. Patnaik, A. W. Tolcher, L. Itri, A. L. Olson, 

A. D. Seidman 

Brd. 39B Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in 

combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally 

advanced (adv) or metastatic HER2-negative breast cancer (BC). (Abstract 

#TPS124) 

J. Baselga, L. S. Schwartzberg, O. Petrenciuc, M. Shan, W. J. Gradishar 

Brd. 39C ACRIN 6688 phase II study of fluorine-18 3-deoxy-3 fluorothymidine (FLT) in 

invasive breast cancer. (Abstract #TPS125) 

P. R. Jolles, L. Kostakoglu, H. D. Bear, M. O. Idowu, K. A. Kurdziel, L. Shankar, 

D. A. Mankoff, F. Duan, D. L’Heureux 

Brd. 39D ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of 

Tamoxifen—A single-arm, phase II study of the efficacy of tamoxifen in 

triple-negative but oestrogen receptor beta-positive metastatic breast 

cancer. (Abstract #TPS126) 

B. E. Kiely, K. Phillips, P. A. Francis, F. M. Boyle, J. F. Forbes, S. B. Fox, 

L. Murphy, V. Gebski, D. F. Lindsay, R. L. Sutherland, H. Badger 

Brd. 39E TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triplenegative 

breast cancer (TNBC) brain metastases (BM). (Abstract #TPS127) 

C. K. Anders, R. Nanda, M. C. Liu, K. L. Blackwell, C. H. Van Poznak, 

V. G. Abramson, A. M. Storniolo, N. U. Lin, V. Stearns, A. Melhem, S. Puhalla, 

J. T. Carpenter, M. E. Melisko, A. M. Deal, C. Hudis, E. P. Winer, C. M. Perou, 

C. R. Bradley, A. C. Wolff, L. A. Carey, Translational Breast Cancer Research 

Consortium 

317 

MONDAY

MONDAY 


Brd. 39F TBCRC 019: An open-label, randomized, phase II trial of nanoparticle 

albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) 

monoclonal antibody tigatuzumab in patients with metastatic, triple-negative 

(ER, PR, and HER2-negative) breast cancer. (Abstract #TPS128) 

A. Forero-Torres, N. U. Lin, M. C. Liu, H. S. Rugo, S. Puhalla, R. Nanda, 

I. A. Mayer, A. M. Storniolo, T. A. Traina, D. F. Hayes, M. F. Rimawi, M. P. Goetz, 

F. J. Esteva, W. J. Irvin Jr., A. C. Wolff, on behalf of the Translational Breast 

Cancer Research Consortium 

Brd. 39G An observational study using �-H2AX foci to investigate cardiac doses of 

radiation following adjuvant radiotherapy for breast cancer: Standard 

external beam radiotherapy to the breast versus intraoperative radiotherapy. 


D. Woolf, R. Bakhshi, S. Fawcitt, M. Worku, D. B. Ghosh, S. Sivabalasingham, 

N. R. Williams, S. Short, K. Pigott, M. R. Keshtgar 

Brd. 39H PARP inhibition after preoperative chemotherapy in patients with triplenegative 

breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier 

Oncology Group BRE09-146. (Abstract #TPS130) 

S. R. Malireddy, S. M. Perkins, S. S. Badve, G. W. Sledge Jr., K. Miller 

Brd. 40A Phase III randomized French multicentric study to evaluate the impact of a 

localized 16-Gy boost after conservative surgery and a 50-Gy whole-breast 

irradiation in breast ductal carcinoma in situ (the BONBIS trial). (Abstract 

#TPS131) 

D. Azria, D. Cowen, C. Bourgier, B. de la Lande, S. Gourgou-Bourgade, 

Z. Douadi Gaci, M. Leblanc-Onfroy, I. Latorzeff, O. Pradier, P. Maingon, 

I. Lecouillard, P. Bontemps, S. Ellis, C. Levy, A. Benyoucef, S. Racadot, 

H. Laharie-Mineur, P. Lagarde, C. Marchal, C. Lemanski 

Brd. 40B A phase IIa clinical biomarker trial of aspirin and dietary arginine restriction 

in colorectal cancer patients. (Abstract #TPS132) 

J. A. Zell, C. E. McLaren, C. G. Albers, E. W. Gerner, L. B. Wenzel, F. L. Meyskens 

Brd. 40C Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB) and the integrin 

inhibitor cilengitide in patients with glioblastoma (GBM) without methylation 

of the MGMT gene promoter (ExCentric). (Abstract #TPS133^) 

M. Khasraw, S. McCowatt, Z. Kerestes, M. E. Buyse, M. Back, H. Wheeler 

Brd. 40D CeCil: A randomized, noncomparative phase II clinical trial of the effect of 

radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or 

cetuximab on the 1-year overall survival of patients with newly diagnosed 

MGMT-promoter unmethylated glioblastoma. (Abstract #TPS134) 

V. Verschaeve, L. A. D’Hondt, L. M. Verbeke, F. Van Fraeyenhove, S. Du Four, 

J. Duerinck, B. Neyns 

Brd. 40E A phase II and pharmacodynamic trial of RO4929097 for patients with 

recurrent/progressive glioblastoma. (Abstract #TPS135) 

D. M. Peereboom, J. N. Rich, J. G. Supko, K. Lamborn, X. Ye, A. E. Sloan, 

M. Prados, S. A. Grossman, Adult Brain Tumor Consortium (ABTC) 

Brd. 40F AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and 

temozolomide in patients with newly diagnosed glioblastoma. (Abstract 

#TPS136) 

O. L. Chinot, W. Wick, F. Saran, W. P. Mason, R. Henriksson, R. Nishikawa, 

A. H. Zeaiter, N. Moore, A. Das, T. F. Cloughesy 

Brd. 40G A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in 

women with early-stage HER2� breast cancer (BC). (Abstract #TPS137) 

P. E. Goss, C. H. Barrios, A. Chan, S. K. Chia, S. Delaloge, B. Ejlertsen, 

J. N. Ingle, B. Moy, H. Iwata, F. A. Holmes, J. Mansi, G. Von Minckwitz, L. Han, 

A. Thiele, V. Agrapart, A. Freyman, J. Truscello, A. Berkenblit, D. Finkelstein 

318


Brd. 40H A phase II randomized study of lenalidomide or lenalidomide and rituximab 

as maintenance therapy following standard chemotherapy for patients with 

high/high-intermediate risk diffuse large B-cell lymphoma. (Abstract 

#TPS138) 

N. M. Reddy, R. Simmons, M. Caldwell, M. H. Jagasia, D. S. Morgan, S. I. Park, 

J. P. Greer, K. L. Richards 

Brd. 41A Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as 

adjuvant therapy in patients with malignant pleural mesothelioma (MPM). 


L. M. Krug, A. S. Tsao, S. Kass, V. W. Rusch, W. D. Travis, K. Panageas, 

P. S. Adusumili, M. G. Kris, P. G. Maslak, D. A. Scheinberg 

Brd. 41B CYPTAM-BRUT 2: A prospective multicenter observational study in the 

neoadjuvant and metastatic setting investigating tamoxifen response 

between women with a favorable versus unfavorable endoxifen profile. 


A. Dieudonné, H. Wildiers, D. Lambrechts, H. Guchelaar, V. O. Dezentje, 

M. Joerger, K. Zaman, I. B. Vergote, P. Neven 

Brd. 41C A phase I study of NPC-1C, a novel therapeutic antibody to treat pancreas 

and colorectal cancers. (Abstract #TPS141) 

N. S. Azad, L. A. Diaz Jr., C. E. Devoe, D. Laheru, D. T. Le, D. Cosgrove, L. Zheng, 

A. De Jesus-Acosta, R. C. Donehower, P. M. Arlen, J. A. Bristol 

Brd. 41D A pilot study of the safety, efficacy, and effects on functional imaging of the 

combination of cG250 and sunitinib in patients (pts) with advanced renal cell 

carcinoma (RCC). (Abstract #TPS142) 

M. Ciprotti, I. D. Davis, D. W. Pook, F. T. Lee, T. Cavicchiolo, S. Lee, B. Chappell, 

G. J. O’Keefe, H. Tochon-Danguy, F. E. Smyth, W. Hopkins, A. M. Scott 

Brd. 41E Validation of the phase 0 concept. (Abstract #TPS143) 

J. R. Westin, S. Fu, D. S. Hong, T. Helgason, F. Ouyang, L. S. Angelo, 

K. S. Culotta, S. N. Westin, R. Kurzrock 

Brd. 41F A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine 

in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and 

low tumor expression of human equilibrative nucleoside transporter-1 

(hENT1) determined by metastasis biopsy. (Abstract #TPS144) 

T. Ikdahl, I. Davidenko, C. Bassi, E. Tomasetto, L. Smith, S. McLachlan, S. Jones, 

M. Raponi, J. Isaacson, C. Voong, L. Rolfe, A. R. Allen, E. Poplin 

Brd. 41G First-in-human, multicenter, dose-escalation, phase I study of the 

investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with 

advanced nonhematologic malignancies and melanoma. (Abstract #TPS145) 

J. A. Sosman, A. A. Adjei, P. LoRusso, S. A. Michael, G. K. Dy, A. Bowditch, 

B. Chmielowski, S. Lee, R. M. Walker, S. Faucette, E. S. Izmailova, V. Bozon, 

A. Ribas 

Brd. 41H A phase I clinical trial of QBI-139, a human ribonuclease variant, in solid 

tumors. (Abstract #TPS146) 

L. E. Strong, J. A. Kink, B. Mei, M. N. Shahan, R. T. Raines 

Brd. 42A Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable 

invasive breast cancer. (Abstract #TPS147) 

K. Kalinsky, J. A. Sparano, M. Kim, K. D. Crew, M. A. Maurer, B. Taback, 

S. M. Feldman, H. Hibshoosh, L. Wiechmann, K. B. Adelson, D. L. Hershman 

Brd. 42B Valproic Acid Signature Trial (VAST): A proof-of-principle study correlating 

pharmacology, pathology, and advanced imaging with genomic prediction of 

drug sensitivity in breast cancer. (Abstract #TPS148) 

A. L. Cohen, M. Schabel, A. Bild, T. L. Werner 

Brd. 42C First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients 

with advanced solid tumors. (Abstract #TPS149) 

J. Soria, F. G. De Braud, R. Cereda, R. Bahleda, A. Delmonte, E. Angevin, 

A. Varga, C. Noberasco, E. Dall’O’, N. Lassau, C. Dromain, M. Bellomi, F. Farace, 

F. Bertolini, M. Zucchetti, S. Marsoni, M. G. Camboni 

319 

MONDAY

MONDAY 


Brd. 42D Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects 

with advanced solid tumors refractory to standard therapy or for which no 

standard therapy is available. (Abstract #TPS150) 

R. E. Martell, E. G. Chiorean, H. Youssoufian, M. D. Rutstein, B. Pytowski, 

L. Benjamin, L. Abad, J. Patel, T. Steele, M. Dowd, A. Qin, C. F. Kukel, F. E. Fox, 

A. Dontabhaktuni, A. Morozov 

Brd. 42E Randomized phase II study of capecitabine with or without ramucirumab 

(IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or 

metastatic breast cancer (mBC) previously treated with anthracycline and 

taxane therapy (CP20–0903/NCT01234402). (Abstract #TPS151) 

L. T. Vahdat, K. Miller, J. A. Sparano, H. Youssoufian, J. D. Schwartz, S. Nanda, 

W. Wang, L. Abad, A. Dontabhaktuni, M. D. Rutstein 

Brd. 42F A randomized, double-blind, placebo-controlled multicenter phase III study 

comparing denosumab with placebo as adjuvant treatment for women with 

early-stage breast cancer who are at high risk of disease recurrence (D- 

CARE). (Abstract #TPS152) 

P. E. Goss, C. H. Barrios, R. Bell, D. Finkelstein, H. Iwata, M. Martin, A. H. Braun, 

R. D. Dansey, R. E. Coleman 

Brd. 42G Integrative and multidisciplinary clinical trial using imaging, molecular, and 

dynamic biomarkers to predict bevacizumab plus chemotherapy response in 

breast cancer. (Abstract #TPS153) 

J. Lopez Vega, E. G. Calvo, A. Plazaola, B. Hernando, S. Morales Murillo, 

A. Anton, R. S. Gomez, I. Alvarez, J. J. Illarramendi, A. De Juan, P. Martinez, 

A. Llombart, S. J. Scherer, L. Sabariz, A. la Huerta, L. J. Pina, I. Dominguez, 

M. J. Garcia Velloso, V. Boni, J. Garcia-Foncillas 

Brd. 42H Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion 

and tissue diffusivity as biomarkers of response of renal cell carcinoma 

(RCC) to treatment with sunitinib. (Abstract #TPS154) 

A. Leary, L. M. Pickering, J. M. Larkin, M. O. Leach, M. E. Gore, A. Sohaib, 

D. J. Collins, D. Koh 

Brd. 43A Pharmacodynamic study of antiangiogenic therapy in patients with renal cell 

carcinoma. (Abstract #TPS155) 

G. Anandappa, E. Sala, H. K. Cheow, N. J. Bird, A. Shaw, A. N. Priest, A. Gill, 

T. Fryer, Y. T. Hong, R. Smith, A. Backen, B. Whitcher, A. Jonson, D. Richards, 

L. Cookson, W. M. Lee, C. Dive, K. M. Fife, D. I. Jodrell, T. Eisen 

Brd. 43B A phase I, single-institution open label, dose-escalation trial with an 

expansion cohort evaluating the safety and tolerability of AZD6244 and 

IMC-A12 in subjects with advanced solid malignancies. (Abstract #TPS156) 

S. R. Ahmed, D. Cosgrove, D. Ball, R. C. Donehower, B. Nelkin, E. Petito, 

M. Downs, H. X. Chen, A. Doyle, A. Scardina, M. A. Carducci, N. S. Azad 

Brd. 43C Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with 

advanced solid tumors and colorectal cancer (CRC). (Abstract #TPS157) 

M. R. Khawaja, A. Younger, J. M. Funke, M. J. Waddell, D. R. Jones, K. Pollok, 

N. K. Prasad, W. Berry, G. Sandusky, E. G. Chiorean 

Brd. 43D A pharmacokinetics/pharmacodynamics study of sequence specificity of the 

PARP inhibitor olaparib with carboplatin in refractory/recurrent women’s 

cancers: NCT01237067. (Abstract #TPS158) 

J. Lee, J. Squires, J. L. Hays, H. L. Kotz, D. Nielsen, N. D. Houston, E. C. Kohn 

Brd. 43E A phase I first-in-human study of REGN910, a fully human and selective 

angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor 

malignancies. (Abstract #TPS159) 

K. P. Papadopoulos, N. G. Chau, A. Patnaik, L. Adriaens, A. S. Lalani, C. Daly, 

L. L. Siu 

320


Brd. 43F A phase 0 exploratory study to assess the pharmacodynamic effects of 

single intratumoral dose of a novel bispecific targeting/immune-activating 

agent on the melanoma tumor microenvironment. (Abstract #TPS160) 

L. A. Fecher, Y. McGrath, D. D. Williams, N. J. Hassan, M. Kalos, L. M. Schuchter, 

R. K. Amaravadi, A. Chew, E. A. Veloso, B. J. Czerniecki, G. Karakousis, 

G. P. Linette, B. K. Jakobsen, C. H. June 

Brd. 43G A randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid 

(FOLFIRI) with or without the addition of an endothelin receptor antagonist in 

patients with metastatic colorectal cancer after failure of 

oxaliplatin-containing chemotherapy. (Abstract #TPS161) 

A. L. Thomas, R. H. Wilson, W. P. Steward, R. A. Adams, S. E. Bridges, 

A. C. Casbard, T. S. Maughan, G. Griffiths, NCRI Colorectal Clinical Studies Group 

Brd. 43H A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and 

everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT). 


A. R. Townsend, L. Pirc, J. Hardingham, C. S. Karapetis, N. C. Tebbutt, N. Singhal, 

T. J. Price 

Brd. 44A A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) 

versus placebo in patients with chemotherapy-refractory KRAS wild-type 

(WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial. 


J. D. Shapiro, L. L. Siu, J. R. Zalcberg, M. J. Moore, J. Ringash, N. Mittmann, 

J. Simes, C. J. O’Callaghan, D. Tu, I. B. Walters, N. Magoski, P. Smith, 

D. Nomikos, L. Zhu, M. Savoie, S. Virk, F. El-Tahche, R. Gill, T. J. Price, 

D. J. Jonker 

Brd. 44B PULSE: An open-label, phase II study assessing double positivity (phosphoinsulin-growth 

factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) 

expression, as a predictive marker of resistance in previously untreated 

metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated 

with panitumumab plus mFOLFOX6—A GEMCAD study. (Abstract #TPS164) 

J. Maurel, X. Garcia-Albeniz, C. Méndez Méndez, M. Martin-Richard, C. Pericay, 

R. Vera, J. Aparicio, M. Rubini, M. Cuatrecasas, on behalf of the GEMCAD 

Cooperative Group 

Brd. 44C Developing a biomarker-stratified trial design in advanced colorectal cancer: 

The MRC FOCUS 3 feasibility study. (Abstract #TPS165) 

T. S. Maughan, R. H. Wilson, G. T. Williams, M. T. Seymour, S. Richman, 

P. Quirke, M. Pope, J. Pope, M. Parmar, A. Nelson, A. M. Meade, S. L. Kenny, 

B. Jasani, E. Hodgkinson, D. Fisher, R. Butler, J. A. Bridgewater, R. A. Adams, 

R. S. Kaplan 

Brd. 44D LICC: L-BLP25 in patients with colorectal carcinoma after curative resection 

of hepatic metastases—A randomized, double-blind, placebo-controlled, 

multicenter, multinational, phase II trial. (Abstract #TPS166) 

C. C. Schimanski, P. R. Galle, H. Lang, M. Schoen, M. H. Moehler 

Brd. 44E The PARSC trial, a prospective study for the assessment of recurrence risk 

in stage II colon cancer (CC) patients using ColoPrint. (Abstract #TPS167) 

R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall, J. J. Van Der Hoeven, 

B. Glimelius, F. Bibeau, L. Stork-Sloots, R. A. Bender, J. Capdevila 

Brd. 44F A phase II, multicenter, randomized, double-blind, placebo-controlled, 

ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with 

refractory symptomatic carcinoid syndrome. (Abstract #TPS168) 

M. Kulke, T. M. O’Dorisio, A. T. Phan, R. M. Langdon Jr., B. J. Marek, N. Iklaque, 

E. K. Bergsland, J. Freiman, K. Frazier, J. Jackson, B. Zambrowicz 

Brd. 44G IMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advanced 

gastroesophageal cancer. (Abstract #TPS169) 

S. A. Szyldergemajn, A. Gonçalves, J. Metges, K. Gunzer, C. Montagut, 

R. Salazar, M. Alsina, T. Evans, D. Swinson, R. D. Petty, H. Singer, C. M. Kahatt 

321 

MONDAY

MONDAY 


Brd. 44H A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and 

oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic 


M. J. Pishvaian, R. Slack, A. Witkiewicz, A. R. He, J. J. Hwang, A. Hankin, L. Ley, 

S. K. Apte, S. J. Littman, L. M. Weiner, J. Marshall, J. R. Brody 

Brd. 45A PAZONET: A phase II trial of pazopanib in patients with metastatic 

neuroendocrine tumors (NETs) who may have previously received 

antiangiogenic or mTOR treatment. (Abstract #TPS171) 

J. Capdevila, A. Teule, D. E. Castellano, J. Sastre, R. Garcia-Carbonero, I. Sevilla, 

I. Duran, P. Escudero, J. Fuster, E. Grande Pulido 

Brd. 45B Phase I trial of sorafenib in hepatocellular carcinoma (HCC) patients after 

liver transplantation (LT). (Abstract #TPS172) 

A. B. Siegel, R. Hidalgo, D. Tsushima, J. Zaretsky, J. Emond, T. Kato, 

R. S. Brown Jr. 

Brd. 45C A randomized, double-blind placebo-controlled phase II study of FOLFOX 

with or without GDC-0449 (vismodegib) in patients with advanced gastric and 

gastroesophageal junction carcinoma (NCI 8376). (Abstract #TPS173) 

D. J. Cohen, L. Liebes, R. Xu, N. Takebe, J. A. Sparano, New York Cancer 

Consortium 

Brd. 45D A phase I study of dovitinib in combination with capecitabine and oxaliplatin 

in upfront treatment of advanced colorectal and gastric cancer with a dose 

expansion cohort in advanced gastric cancer. (Abstract #TPS174) 

W. M. D. Tai, W. S. Ooi, J. Y. Ngeow, N. Deng, H. Wang, C. K. Tham, H. Y. Lim, 

S. P. Choo, P. Tan, H. C. Toh, I. B. Tan 

Brd. 45E Evaluation of sorafenib in combination with local microtherapy guided by 

gadolinium-EOB-DTPA enhanced MRI in patients with inoperable 

hepatocellular carcinoma. (Abstract #TPS175) 

J. Ricke, K. Schuette, I. W. Graziadei, A. Jakob, C. Verslype, B. Sangro, 

J. Walecki, H. Klümpen, B. Peynircioglu, S. Yalcin, C. Bartolozzi, H. Amthauer, 

P. Malfertheiner 

Brd. 45F Randomized phase II study of the efficacy and safety of gemcitabine plus 

TH-302 versus gemcitabine alone in previously untreated patients with 

advanced pancreatic cancer. (Abstract #TPS176) 

M. J. Borad, D. Sigal, H. Uronis, J. Stephenson Jr., N. Bahary, M. U. Rarick, 

L. C. DeMarco, T. J. Finnegan, E. G. Chiorean, D. P. Ryan, A. L. Cohn, 

B. K. Ulrich, V. C. Harish, E. N. Anderes, W. Ma, P. P. Yu, F. Sinicrope, C. Eng, 

U. K. Sunkara, S. G. Reddy 

Brd. 45G ACRIN 6690: Can contemporary imaging reduce false-positive rate in liver 

transplant (LT) allocation? A multicenter comparison of CT and MRI for 

diagnosis of hepatocellular carcinoma (HCC). (Abstract #TPS177) 

C. Wald, M. Nalesnik, E. A. Pomfret, M. Russo, M. A. Rosen, D. M. Hartfeil, P. Fox, 

M. L. Heckel, C. Gatsonis 

Brd. 45H Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): 

FOLFOX alone or in combination with AMG 102 or panitumumab as first-line 

treatment in patients with advanced gastroesophageal adenocarcinoma: 

FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase 

II trial. (Abstract #TPS178) 

D. Malka, S. Gourgou-Bourgade, J. Emile, P. Laurent-Puig, J. Taïeb 

Brd. 46A The Personalized RNA Interference to Enhance the Delivery of Individualized 

Cytotoxic and Targeted Therapeutics (PREDICT) approach to biomarker 

discovery in renal cell carcinoma. (Abstract #TPS179) 

M. Gerlinger, L. Albiges, on behalf of the PREDICT Consortium 

(www.predictconsortium.eu) 

Brd. 46B SYNERGY: A randomized phase III study comparing first-line 

docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic 

castrate-resistant prostate cancer (mCRPC). (Abstract #TPS180) 

K. N. Chi, J. S. De Bono, C. S. Higano 

322


Brd. 46C A randomized, double-blind, phase III trial comparing ipilimumab versus 

placebo following radiotherapy (RT) in patients (pts) with castration-resistant 

prostate cancer (CRPC) who have received prior treatment with docetaxel 

(D). (Abstract #TPS181) 

C. G. Drake, H. I. Scher, W. R. Gerritsen, R. Ezzeddine, T. F. Fitzmaurice, 

J. Cuillerot, K. M. Chin, P. Gagnier 

Brd. 46D Randomized, double-blind, phase III trial to compare the efficacy of 

ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic 

patients (pts) with metastatic chemotherapy-naïve castration-resistant 

prostate cancer (CRPC). (Abstract #TPS182) 

T. M. Beer, C. Logothetis, P. Sharma, W. R. Gerritsen, R. Ezzeddine, 

J. P. Fairchild, P. Gagnier, K. M. Chin, J. Cuillerot 

Brd. 46E IMA901 Multipeptide Vaccine Randomized International Phase III Trial 

(IMPRINT): A randomized, controlled study investigating IMA901 

multipeptide cancer vaccine in patients receiving sunitinib as first-line 

therapy for advanced/metastatic RCC. (Abstract #TPS183) 

B. I. Rini, T. Eisen, A. Stenzl, W. Brugger, T. Weinschenk, A. Mahr, J. Fritsche, 

N. Hilf, R. Mendrzyk, J. Lindner, A. Schmid, A. Kirner, S. Walter, H. Singh, 

C. Reinhardt 

Brd. 46F A phase III, randomized study of the investigational agent TAK-700 plus 

prednisone for patients with chemotherapy-naive metastatic castrationresistant 

prostate cancer (mCRPC). (Abstract #TPS184) 

F. Saad, H. Akaza, M. A. Eisenberger, J. Nelson, H. I. Scher, K. Suzuki, M. Wirth, 

I. J. Webb, J. Wang, D. MacLean, R. De Wit 

Brd. 46G Phase I/II trial to establish the safety and preliminary efficacy of the 

combination of docetaxel, prednisone, and SOM 230 in metastatic castrateresistant 


H. M. Vankayala, L. K. Heilbrun, J. A. Fontana, U. N. Vaishampayan 

Brd. 46H A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced 

urothelial carcinoma patients with either mutated or wild-type FGFR3. 


M. I. Milowsky, G. L. Carlson, M. M. Shi, G. Urbanowitz, Y. Zhang, C. N. Sternberg 

Brd. 47A Design of a phase II randomized, open-label trial of DN24–02, an autologous 

cellular immunotherapy targeting HER2/neu, in patients with surgically 

resected urothelial cancer at high risk of recurrence. (Abstract #TPS187) 

D. F. Bajorin, P. Sharma, R. B. Sims, A. Sandler, S. P. Lerner 

Brd. 47B A randomized, controlled phase III global trial comparing sipuleucel-T plus 

androgen deprivation therapy versus androgen deprivation therapy alone in 

men with metastatic androgen dependent (hormone sensitive) prostate 


K. Fizazi, T. Powles, D. J. George, C. H. Poehlein 

Brd. 47C Design of an open-label randomized phase II trial examining the effect of 

sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on 

immune markers in prostate cancer patients with a rising prostate-specific 

antigen (PSA) after primary therapy. (Abstract #TPS189) 

E. S. Antonarakis, A. S. Kibel, D. W. Lin, R. C. Tyler, M. Tabesh, C. G. Drake 

Brd. 47D A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-ofconcept 

study of ARN-509 in patients with progressive advanced castrationresistant 


D. E. Rathkopf, D. C. Danila, S. F. Slovin, M. J. Morris, J. E. Steinbrecher, Y. Chen, 

M. Fleisher, S. M. Larson, C. L. Sawyers, H. I. Scher 

Brd. 47E Predicting response to platinum chemotherapy in metastatic castrationresistant 

prostate cancer (mCRPC) using a genomic signature for 

“BRCAness”: A phase II clinical trial of satraplatin in men with mCRPC who 

have progressed on docetaxel. (Abstract #TPS191) 

S. M. Seng, M. D. Galsky, C. Tsao, J. Li, P. G. Febbo, W. K. Oh 

323 

MONDAY

MONDAY 


Brd. 47F A randomized phase II study of MK-2206 in comparison with everolimus in 

refractory renal cell carcinoma (NCI 8727). (Abstract #TPS192) 

E. Jonasch, P. Lara Jr., N. M. Tannir 

Brd. 47G Radiolabeled antiprostate specific membrane antigen (PSMA) monoclonal 

antibody J591 ( 177 Lu-J591) for nonmetastatic castration-resistant prostate 

cancer (CRPC): A randomized phase II trial. (Abstract #TPS193) 

S. T. Tagawa, N. M. Hahn, D. A. Vaena, D. I. Quinn, W. K. Kelly, P. J. Christos, 

J. Osborne, S. Vallabhajosula, K. Nadeau, G. Mileo, L. Tyrell, A. Saran, C. Ecker, 

H. Beltran, S. J. Goldsmith, D. M. Nanus 

Brd. 47H Phase I/II study of BNC105P in combination with everolimus or following 

everolimus for progressive metastatic renal cell carcinoma following prior 

tyrosine kinase inhibitors. (Abstract #TPS194) 

T. E. Hutson, J. Sarantopoulos, T. Logan, G. Sonpavde, M. D. Galsky, 

C. Sweeney, D. C. Bibby, G. Kremmidiotis, E. E. Doolin, N. M. Hahn, 

Hoosier Oncology Group 

Brd. 48A A phase II study to evaluate the efficacy and safety of catumaxomab as 

consolidation treatment in patients with epithelial ovarian cancer in second 

or third complete remission. (Abstract #TPS195) 

A. M. Oaknin, L. Chiva, I. Romero, A. Romero, M. M. Essing, A. González-Martín, 

GEICO 

Brd. 48B Concomitant chemoradiation or RT/cetuximab versus induction TPF 

followed by chemoradiation or RT/cetuximab in locally advanced head and 

neck squamous cell carcinoma: A randomized phase III factorial study. 


A. Paccagnella, M. G. Ghi, I. Floriani, A. Gava, A. Buffoli, on behalf of the GSTTC 

Italian Collaborative Group 

Brd. 48C EORTC 22071–24071: Randomized, phase III trial of EGFR-antibody 

combined with adjuvant chemoradiation for patients with head and neck 

squamous cell carcinoma (HNSCC) at high risk of recurrence. (Abstract 

#TPS197) 

C. Liberatoscioli, J. A. Langendijk, C. Van Herpen, L. Collette, E. M. Ozsahin, 

R. Karra Gurunath, D. A. Lacombe, A. Gulyban, N. Gosselin, W. Budach 

Brd. 48D PAPILLOPHAR: Impact of the human papillomavirus (HPV) status in the 

prognosis of oropharynx squamous cell carcinoma (OSCC). (Abstract 

#TPS198) 

J. Lacau Saint Guily, J. Pretet, G. Agius, A. Rousseau, B. Barry, X. Dufour, 

S. Perie, M. Lefevre, P. Birembaut, C. Mougin, T. Simon, C. Clavel, 

PAPILLOPHAR Group 

Brd. 48E CALGB 10603 (RATIFY): A randomized phase III study of induction 

(daunorubicin/cytarabine) and consolidation (high-dose cytarabine) 

chemotherapy combined with midostaurin or placebo in treatment-naïve 

patients with FLT3 mutated AML. (Abstract #TPS199) 

R. M. Stone, H. Dohner, G. Ehninger, M. Villeneuve, T. Teasdale, J. D. Virkus, 

L. R. Bressler, M. M. Seiler, G. Marcucci, R. A. Larson, on behalf of all study 

investigators 

Brd. 48F A global phase II, single-arm, open-label study to determine the efficacy of 

midostaurin in patients with aggressive systemic mastocytosis (ASM) or 

mast cell leukemia (MCL) with or without an associated hematologic clonal 

nonmast cell lineage disease (AHNMD). (Abstract #TPS200) 

J. R. Gotlib, H. Kluin-Nelemans, M. J. Mauro, O. Hermine, E. O. Hexner, 

J. H. Lipton, F. T. Awan, Z. G. Nikolova, S. H. Gross, C. Dutreix, B. Dharan, 

T. George, P. Horny, C. Akin, K. Hartmann, P. Valent, A. Reiter, on behalf of all 

PKC412 D2201 study investigators 

324


Brd. 48G Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in 

combination with cytarabine for patients with first relapsed or refractory 

acute myeloid leukemia. (Abstract #TPS201) 

C. R. Mehta, G. Michelson, M. Salganik, J. Feaster, R. Allen, A. L. Cahill, J. A. Fox, 

S. B. Ketchum, F. Ravandi, H. P. Erba, G. J. Schiller, R. K. Stuart, N. Vey, 

E. J. Feldman 

Brd. 48H Multicenter, single-arm phase II study of nilotinib in Philadelphia 

chromosome-positive (Ph�) chronic myeloid leukemia in chronic-phase 

(CML-CP) patients with low imatinib trough plasma concentrations. (Abstract 

#TPS202) 

S. Lim, R. C. Holdridge, M. Talpaz, C. N. Abboud, S. Yi, E. Noon, S. Ericson, 

M. Jones 

Brd. 49A RESPONSE: A randomized, open label, phase III study of INC424 in 

polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea 

(HU). (Abstract #TPS203) 

S. Verstovsek, J. Kiladjian, R. J. Waltzman, V. Sandor, J. Lukawy, W. M. Garrett, 

K. Malek, R. M. Huber, A. M. Vannucchi 

Brd. 49B A single-arm, open-label, multicenter study of complete molecular response 

(CMR) in patients with newly diagnosed Philadelphia-chromosome positive 

(Ph�) chronic myeloid leukemia in chronic phase (CML-CP) treated with 

nilotinib. (Abstract #TPS204) 

I. W. Flinn, S. Goldberg, R. L. Robles, D. Rizzieri, J. P. Radich, M. J. Mauro, 

S. Ericson, J. E. Cortes 

Brd. 49C Prospective, observational registry of branded imatinib and nilotinib 

exposure in pregnant women: Voluntary postauthorization safety study. 


M. Juma, S. Ericson, D. Eng, A. Adeoye 

Brd. 49D A randomized phase III study of elacytarabine versus limited investigator’s 

choice in patients with refractory acute myeloid leukemia (AML). (Abstract 

#TPS206) 

D. Rizzieri, N. Vey, M. Gobbi, D. L. Selleslag, M. W. Dennis, K. Kuliczkowski, 

U. Krug, F. Moscardo, D. Bron, A. D. Moicean, A. Venditti, T. F. Jacobsen, 

O. Foss, F. J. Giles 

Brd. 49E A phase II study of elacytarabine plus idarubicin as second-course 

remission-induction therapy in patients with acute myeloid leukemia. 


D. Rizzieri, U. Krug, R. F. Schlenk, N. Vey, X. G. Thomas, F. Huguet, M. Johansen, 

T. F. Jacobsen 

Brd. 49F SCAT trial: Phase III Spanish customized adjuvant treatment according 

BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer. (Abstract 

#TPS208) 

B. Massuti, U. Jimenez, J. M. Rodriguez Paniagua, Y. W. Pun, M. Cobo, 

E. Carcereny Costa, R. Arrabal, J. Astudillo, I. Barneto, R. De Las Penas, 

C. Baamonde, G. Sales, J. Gonzalez-Larriba, G. Lopez-Vivanco, 

F. Hernando-Trancho, J. Pac, A. Artal-Cortes, J. Rivas, R. Rosell, J. Sanchez, 

Spanish Lung Cancer Group / SLCG-GECP 

Brd. 49G The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in 

patients with resected, early-stage non-small cell lung cancer (NSCLC) and 

confirmed mutations in the epidermal growth factor receptor (EGFR). 


N. A. Pennell, J. W. Neal, R. Govindan, P. A. Janne, T. L. Evans, D. B. Costa, 

R. P. Rosovsky, M. Lanuti, C. G. Azzoli, L. V. Sequist 

325 

MONDAY

MONDAY 


Brd. 49H MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy 

(ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA 

NSCLC. (Abstract #TPS210) 

P. Therasse, J. F. Vansteenkiste, M. Zielinski, T. M. De Pas, D. Atanackovic, 

L. V. Sequist, E. Vallieres, S. Swisher, S. Adams, B. Passlick, W. E. Eberhardt, 

D. Grunenwald, T. Mok, M. Boyer, A. Katz, J. Douillard, M. Debois, V. G. Brichard, 

N. K. Altorki 

Brd. 50A Erlotinib beyond progression study: Randomized phase II study comparing 

chemotherapy plus erlotinib with chemotherapy alone in EGFR 

TKI-responsive, advanced non-small cell lung cancer (NSCLC) that 

subsequently progresses. (Abstract #TPS211) 

B. Halmos, P. Fu, N. A. Pennell, G. A. Otterson, T. Mekhail, M. R. Snell, 

J. P. Kuebler, S. M. Gadgeel, A. Conrad, A. T. Stefanski, A. Dowlati 

Brd. 50B A phase II randomized trial of anastrozole (A) and fulvestrant (F) as 

consolidation therapy in postmenopausal women with advanced non-small 

cell lung cancer who have received first-line platinum-based chemotherapy 

with or without bevacizumab. (Abstract #TPS212) 

B. T. McLaughlin, S. Land, A. A. Tarhini, J. Siegfried, A. Argiris 

Brd. 50C Randomized phase II study of ficlatuzumab (formerly AV-299), an antihepatocyte 

growth factor (HGF) monoclonal antibody (MAb) in combination 

with gefitinib (G) in Asian patients (pts) with NSCLC. (Abstract #TPS213) 

T. Mok, E. Tan, K. Park, J. Jac, M. Han, F. C. Payumo, M. Credi, K. McKee, 

M. M. Cotreau, P. Bhargava, W. Slichenmyer 

Brd. 50D PROSE: Randomized proteomic stratified phase III study of second-line 

erlotinib versus chemotherapy in patients with inoperable non-small cell 

lung cancer (NSCLC). (Abstract #TPS214) 

C. Sorlini, S. Barni, F. Petrelli, S. Novello, F. De Marinis, T. M. De Pas, F. Grossi, 

A. Bearz, M. Mencoboni, M. Aieta, A. Caprioli, P. Antonelli, N. Zilembo, A. Bachi, 

I. Floriani, H. Roder, J. Roder, J. Grigorieva, C. Lazzari, V. Gregorc 

Brd. 50E A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with 

non-small cell lung cancer (NSCLC). (Abstract #TPS215) 

L. V. Sequist, W. A. Harb, M. Modiano, D. M. Jackman, K. Wong, J. A. Engelman, 

R. Nering, M. Onsum, V. M. Moyo 

Brd. 50F Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant 

(F) in previously treated advanced non-small cell lung cancer (NSCLC). 


E. B. Garon, S. M. Dubinett, F. F. Kabbinavar, K. L. Reckamp, 

D. C. Marquez-Garban, L. Goodglick, S. Sharma, L. P. Stabile, J. Siegfried, 

R. J. Pietras 

Brd. 50G A phase III, randomized, double-blind, placebo-controlled study of erlotinib 

plus ARQ 197 versus erlotinib plus placebo in previously treated subjects 

with locally advanced or metastatic, nonsquamous, non-small cell lung 

cancer (NSCLC) . (Abstract #TPS217) 

A. Sandler, J. H. Schiller, V. Hirsh, L. V. Sequist, J. Soria, J. Von Pawel, Q. Wang, 

A. U. Pande, B. E. Schwartz, E. G. Garmey, I. Gorbatchevsky, G. Scagliotti 

Brd. 50H A randomized phase III study of maintenance therapy with bevacizumab (B), 

pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) 

following carboplatin, paclitaxel, and bevacizumab (PCB) for advanced 

nonsquamous NSCLC: ECOG trial 5508 (NCT01107626). (Abstract #TPS218) 

S. E. Dahlberg, S. S. Ramalingam, C. P. Belani, J. H. Schiller 

326


Brd. 51A Study ESOGIA-GFPC 08–02: Phase III, randomized, multicenter trial 

involving subjects over age 70 with stage IV non-small cell lung cancer and 

comparing a “classical” strategy of treatment allocation (dual-agent therapy 

based on carboplatin or monotherapy with docetaxel alone), based on 

performance status and age, with an “optimized” strategy allocating the 

same treatments according to a simplified geriatric screening scale, plus a 

more thorough geriatric evaluation if necessary. (Abstract #TPS219) 

R. Corre, C. Chouaid, F. Barlesi, H. Le Caer, E. Dansin, A. Vergnenegre, 

P. Fournel, GFPC 

Brd. 51B Randomized phase III trial of gemcitabine/carboplatin with or without iniparib 

(BSI-201) in patients with previously untreated stage IV squamous non-small 

cell lung cancer (NSCLC). (Abstract #TPS220) 

D. R. Spigel, P. G. Harper, J. D. Hainsworth, F. De Marinis, F. F. Kabbinavar, 

E. S. Kim, T. J. Lynch, R. Rosell, F. A. Shepherd, M. A. Socinski, A. Vergnenegre 

Brd. 51C E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and 

bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with 

advanced nonsquamous, non-small cell lung cancer (NSCLC). (Abstract 

#TPS221) 

A. Argiris, J. Lee, J. H. Schiller, Eastern Cooperative Oncology Group 

Brd. 51D Randomized phase IV trial comparing efficacy and tolerability of 

temsirolimus with and without an elevated starting dose in patients with 

relapsed, refractory mantle cell lymphoma. (Abstract #TPS222) 

A. Bair, G. Hess, J. Boni, F. Offner 

Brd. 51E A phase II trial of bortezomib plus lenalidomide for relapsed/refractory 

mantle cell lymphoma (MCL) (CALGB 50501). (Abstract #TPS223) 

V. A. Morrison, S. Jung, J. L. Johnson, J. Leonard, B. D. Cheson, 

Cancer and Leukemia Group B 

Brd. 51F An open-label phase II study of intravenous bortezomib and oral 

panobinostat (LBH589) in adult patients with relapsed/refractory peripheral 

T-cell lymphoma (PTCL) or NK/T-cell lymphoma (NKL) after failure of 

conventional chemotherapy. (Abstract #TPS224) 

D. C. Tan, P. Chan, B. L. Ng, B. K. Yap, Y. H. Chan, L. P. Koh, F. A. Wahid, 

S. Lim, N. S. Chin, W. Kim, S. Y. Tan, Y. T. Goh 

Brd. 51G A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), 

lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients 

(Pts) with relapsed multiple myeloma (MM). (Abstract #TPS225) 

P. Moreau, A. P. Palumbo, A. K. Stewart, V. Rajkumar, A. J. Jakubowiak, K. Halka, 

S. Goranov, H. Bumbea, K. B. Pendergrass, A. Lupu, A. Dimopoulos, 

A. O. Rocafiguera, J. G. Gandhi, G. Mihaylov, T. Masszi, J. Matous, G. Fonseca, 

R. Bryce, D. S. Siegel 

Brd. 51H PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib 

with or without immunochemotherapy in newly diagnosed nongerminal 

center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including 

rapid prospective non-GCB subtype identification. (Abstract #TPS226) 

J. Leonard, J. Reeves, B. Ferhanoglu, K. T. Doner, H. Eom, I. W. Flinn, J. Raposo, 

N. M. Chowhan, C. Suh, S. Noga, G. Tumyan, S. Aung, J. Hajdenberg, 

B. K. Ulrich, K. B. Pendergrass, G. Mulligan, A. Rizo, S. Kussick, F. Offner 

Brd. 52A PANORAMA1: A randomized, double-blind, placebo controlled phase III 

study of panobinostat in combination with bortezomib and dexamethasone 

in patients with relapsed multiple myeloma. (Abstract #TPS227) 

J. F. San-Miguel, S. Lonial, V. Hungria, P. Moreau, H. Einsele, J. Lee, S. Yoon, 

P. Corradini, W. W. Jedrzejczak, D. C. Tan, K. Yong, A. Guenther, 

M. M. Wroclawska-Swacha, H. J. Weber, P. M. Bourquelot, P. G. Richardson 

327 

MONDAY

MONDAY 


Brd. 52C A phase II trial of nilotinib in the treatment of patients with KIT mutated 

advanced acral and mucosal melanoma (NICAM). (Abstract #TPS229) 

J. M. Larkin, S. Turajlic, P. D. Nathan, P. Lorigan, G. Stamp, 

D. Gonzalez de Castro, N. Martin, J. Griffiths, K. Edmonds, S. Sarker, 

M. G. James, R. A’Hern, G. Coombes, C. Snowdon, J. M. Bliss, M. E. Gore, 

R. Marais 

Brd. 52D A phase II study combining ipilimumab and fotemustine in patients with 

metastatic melanoma: The NIBIT-M1 trial. (Abstract #TPS230) 

A. Di Giacomo, P. A. Ascierto, E. Fonsatti, E. Pittiglio, P. Queirolo, L. Pilla, 

R. Ridolfi, M. Santinami, A. Testori, G. Parmiani, M. Maio 

Brd. 52E PREDICT phase II: A trial to prospectively validate a gene signature 

associated with clinical benefit from MAGE-A3 antigen-specific cancer 

immunotherapeutic (ASCI) in patients with unresected metastatic cutaneous 

melanoma. (Abstract #TPS231) 

P. Saiag, J. S. Weber, B. Dreno, A. Hauschild, C. Jamoul, O. Peeters, P. Therasse 

Brd. 52F DERMA phase III trial of MAGE-A3 antigen-specific cancer 

immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3positive 

resected stage III melanoma. (Abstract #TPS232) 

J. M. Kirkwood, B. Dreno, A. Hauschild, D. Schadendorf, A. Testori, P. Hersey, 

C. Jamoul, O. Peeters, P. Therasse 

Brd. 52G A randomized multicenter phase II trial on efficacy of high-slip skin care pad 

for hand-foot skin reaction caused by sorafenib in patients with renal cell 

carcinoma. (Abstract #TPS233) 

N. Shinohara, N. Nonomura, G. Kimura, M. Eto, H. Minami, N. Yamazaki, S. Naito, 

Japanese Society of Renal Cancer 

Brd. 52H The use of subcutaneous natural ghrelin to treat cachexia (CC) related 

symptom distress, nutritional intake (NI), and physical functioning: A 

two-step phase I/II study with an intrapatient dose escalation followed by 

maintenance treatment. (Abstract #TPS234) 

F. Strasser, D. Blum, R. Oberholzer, S. deWolf-Linder, C. Driessen, T. Cerny 

Brd. 53A A phase II/III study of sotatercept (ACE-011), an activin antagonist, for 

chemotherapy-induced anemia in patients with metastatic non-small cell 

lung cancer treated with first-line platinum-based chemotherapy. (Abstract 

#TPS235) 

H. Raftopoulos, A. Laadem, M. Puccio, R. D. Knight 

Brd. 53B Phase II trial of subcutaneous methylnaltrexone in the treatment of severe 

opioid-induced constipation in cancer patients. (Abstract #TPS236) 

M. Mori, T. Ashikaga, S. M. Grunberg 

Brd. 53C Randomized clinical trial to evaluate an e-health intervention for fear of 

cancer recurrence, anxiety, and depression among cancer survivors. 


L. I. Wagner, J. Duffecy, K. A. Lehman, S. D. Sanford, M. Begale, E. Nawacki, 

D. C. Mohr 

Brd. 53D A randomized placebo-controlled trial of testosterone replacement for 

fatigue in male hypogonadic patients with advanced cancer. (Abstract 

#TPS238) 

E. Del Fabbro, J. Garcia, R. Dev, J. L. Palmer, C. Klingner-Winton, L. E. Roberts, 

J. Allo, G. Cardwell, E. Bruera 

Brd. 53E Lenalidomide in solid tumor patients with inflammatory cancer cachexia: A 

multicenter, randomized, double-blind, proof-of-concept study of fixed dose 

or CRP-response-guided dose or placebo. (Abstract #TPS239) 

F. Strasser, R. Oberholzer, D. Blum, M. Joerger, C. Driessen, S. deWolf-Linder, 

S. R. Haile, R. von Moos, N. Zerkiebel, A. Jatoi, R. Woelky, K. Fearon, T. Cerny, 

Swiss Group for Clinical Cancer Research (SAKK 96/10) 

328


Brd. 53F A longitudinal study of alterations in cognitive function and brain 

metabolites among women receiving chemotherapy for primary breast 


S. Kohli, J. C. Buckner, J. H. Cerhan, K. Kantarci, D. L. Barton, J. A. Sloan, 

P. J. Novotny 

Brd. 53G Measuring subjective improvement as well as objective response to estimate 

the benefit of palliative chemotherapy in women with platinum-resistant or 

refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/ 

GCIG/PoCoG). (Abstract #TPS241) 

M. Friedlander, M. R. Stockler, M. King, A. M. Oza, M. Voysey, J. Martyn, K. Gillies, 

K. M. Sjoquist, P. Butow, Australia New Zealand Gynaecological Oncology Group 

(ANZGOG), Psycho-Oncology Group (PoCoG), Gynecologic Cancer Intergroup 

(GCIG) 

Brd. 53H A multicenter study assessing 12-weekly intravenous bisphosphonate 

therapy in women with low-risk bone metastases from breast cancer: The 

TRIUMPH trial. (Abstract #TPS242) 

N. Bouganim, J. F. Hilton, L. Vandermeer, S. Hopkins, D. Robbins, E. Amir, 

S. Dent, C. Milano, O. C. Freedman, R. A. Dent, G. Dranitsaris, M. J. Clemons 

Brd. 54A Effect of Chinese herbal medicine JDXZO on epidermal growth factor 

receptor inhibitor (EGFRIs)–related skin toxicity. (Abstract #TPS243) 

H. Lin, J. Li 

Brd. 54B Clinical performance, efficacy, and safety of the DigniCap system, a scalphypothermia 

system, in preventing chemotherapy (CTX)-induced alopecia in 

patients (pts) with early-stage breast cancer (BC). (Abstract #TPS244) 

A. Glencer, M. E. Melisko, L. Esserman, S. A. Melin, H. S. Rugo 

Brd. 54C A single-arm multicenter proof-of-concept study of denosumab to treat 

hypercalcemia of malignancy in patients who are refractory to IV 

bisphosphonates. (Abstract #TPS245) 

M. I. Hu, R. Gucalp, K. L. Insogna, I. Glezerman, H. G. Bone, A. Jaccard, 

W. Misiorowski, B. W. Yu, H. Yeh 

Brd. 54D AMC 070: A phase I/II study of lenalidomide in patients with AIDS-associated 

Kaposi sarcoma (Abstract #TPS246) 

K. A. Shimabukuro, E. G. Reid, AMC 070 Study Team 

Brd. 54E Cancer Research UK Stratified Medicine Programme. (Abstract #TPS247) 

J. Peach, A. Tuff, J. Bull, F. Hemsley, L. Jones, M. Jones, C. Westwood, 

P. W. Johnson 

Brd. 54F A pilot study of tumor-derived exosomes as diagnostic and prognostic 

markers in breast cancer patients receiving neoadjuvant chemotherapy. 


R. E. Raab, T. L. Pawlowski, D. Spetzler, M. R. Klass, C. D. Kuslich, 

L. S. Bellin, J. H. Wong, A. S. Asch 

Brd. 54G ACRIN 6691 monitoring and predicting breast cancer neoadjuvant 

chemotherapy response using diffuse optical spectroscopic imaging (DOSI). 


B. J. Tromberg, J. A. Butler, D. A. Mankoff, S. J. Isakoff, N. M. Hylton, A. G. Yodh, 

D. Boas, K. Paulsen, B. W. Pogue, P. A. Kaufman, R. S. Mehta, P. M. Carpenter, 

A. Cerussi, Z. Zhang, D. M. Hartfeil, D. L’Heureux 

329 

MONDAY

MONDAY 


8:00 AM - 12:30 PM 






Discussion Location: S100a 

CME credit: 1 


Gary E. Goodman, MD—Co-Chair 

Swedish Cancer Institute 

Marie Wood, MD—Co-Chair 

University of Vermont 

Discussion 

11:30 AM Claudine Isaacs, MD (Abstracts #1509–1513) 

Lombardi Comprehensive Cancer Center 

Discussion 

11:45 AM Susan M. Domchek, MD (Abstracts #1514–1518) 

Abramson Cancer Center, University of Pennsylvania 

Discussion 

12:00 PM Stephen B. Gruber, MD, PhD, MPH (Abstracts #1519–1524) 


Discussion 

12:15 PM Kala Visvanathan, MD, MHS (Abstracts #1525–1529) 

The Johns Hopkins University Bloomberg School of Public Health 

Brd. 1 Feasibility and yield of offering genetic counseling to all patients with newly 

diagnosed high-grade epithelial ovarian cancer. (Abstract #1509) 

A. G. Arnold, J. Bhatia, M. F. Phillips, G. J. Gardner, K. M. Bell-McGuinn, 

C. Aghajanian, R. R. Barakat, K. Offit, N. D. Kauff 

Brd. 2 Does maternal or paternal inheritance of BRCA mutation affect the age of 

cancer diagnosis? (Abstract #1510) 

I. Shapira, R. J. Gralla, M. Akerman, L. R. Weiselberg, V. S. John, H. Raftopoulos, 

V. Vinciguerra, J. L. Lovecchio, A. Menzin, S. Cohen 

Brd. 3 Effect of rapid genetic testings on the rate of bilateral prophylactic 

mastectomy in BRCA1/2 mutation carriers. (Abstract #1511) 

L. Cortesi, E. De Matteis, E. Razzaboni, V. Medici, G. Tazzioli, A. Andreotti, 

M. Federico 

Brd. 4 Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal 

carcinoma in situ. (Abstract #1512) 

N. Elsayegh, S. Bayraktar, A. M. Gutierrez-Barrera, H. Lin, H. M. Kuerer, 

K. I. Muse, K. Ready, J. K. Litton, F. Meric-Bernstam, G. N. Hortobagyi, B. Arun 

Brd. 5 Identification of BRCA1/BRCA2 carriers by screening in the healthy 

population and its implications. (Abstract #1513) 

E. Levy-Lahad, E. Gabai-Kapara, B. Kaufman, R. Catane, S. Segev, P. Renbaum, 

U. Beller, M. King, A. Lahad 

Brd. 6 Prevalence and ancestral origin of hispanic BRCA mutations: Insights for 

ancestry-informed genetic cancer risk assessment. (Abstract #1514) 

J. N. Weitzel, J. N. DeHart, R. M. Ogaz, A. E. Martir-Negron, J. Herzog, C. Ricker, 

J. Congleton, C. Cina, P. R. Duncan, G. W. Unzeitig, J. Saldivar, M. Beattie, 

N. R. Feldman, S. Sand, D. Port, E. M. John, C. Haiman, R. Varma, 

S. L. Neuhausen, G. P. Larson, Cancer Genetics Community Research Network 

Brd. 7 Analysis of genomic ancestry in a sample of hereditary breast cancer high 

risk patients from Bahia, Brazil. (Abstract #1515) 

I. O. Nascimento, T. B. Machado, B. Toralles, L. A. Ferreira, M. Romeo, 

C. A. Sandes, L. Meyer, B. Garicochea, R. Meyer, S. Freire, K. Abe-Sandes 

330


Brd. 8 Prospective study of breast cancer risk in mutation-negative women from 

BRCA1 or BRCA2 mutation-positive families in the Kathleen Cuningham 

Foundation Consortium for Research into Familial Breast Cancer (kConFab). 


S. Harvey, R. L. Milne, K. E. Birch, P. Weideman, S. McLachlan, M. Friedlander, 

D. Goldgar, J. L. Hopper, K. Phillips 

Brd. 9 Correlation of germ-line BRCA2 mutations with aggressive prostate cancer 

and outcome. (Abstract #1517) 

E. Castro, C. L. Goh, D. Olmos, D. Leongamornlert, E. Saunders, 

M. Tymrakiewicz, N. Mahmud, T. Dadaev, K. Govindasami, M. Guy, L. OBrien, 

E. Sawyer, A. Hall, R. Wilkinson, Z. Kote-Jarai, R. A. Eeles, The UKGPCS 

collaborators 

Brd. 10 Risk of breast cancer (BC) after BRCA-mutation associated ovarian cancer 

(BRCA-OC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. 


K. L. Jhaveri, S. Patil, M. Khasraw, J. Bhatia, Z. K. Stadler, N. D. Kauff, C. Hudis, 

K. Offit, M. E. Robson 

Brd. 11 Breast cancer phenotype in women with TP53 germ-line mutations: An LFS 

consortium effort. (Abstract #1519) 

S. Masciari, D. Dillon, M. G. Dick, M. E. Robson, J. N. Weitzel, J. M. Ford, 

J. Balmaña, S. B. Gruber, D. Euhus, J. E. Garber 

Brd. 12 Li-Fraumeni syndrome: Retesting archival DNA samples identifies previously 

unrecognized germline p53 mutations. (Abstract #1520) 

A. Novokmet, B. Baskin, D. Malkin 

Brd. 13 Factors associated with type I and type II endometrial cancers in women with 

a germline mutation in a mismatch repair gene. (Abstract #1521) 

Y. C. Antill, A. Win, P. Webb, J. L. Hopper, S. Gallinger, N. M. Lindor, 

P. A. Newcomb, R. W. Haile, J. Church, L. Le Marchand, I. Winship, A. B. Spurdle, 

M. A. Jenkins, Colon Cancer Family Registry 

Brd. 14 Incremental impact of breast cancer SNP panel on risk classification and 

screening. (Abstract #1522) 

K. Armstrong, E. Conant, J. Chen, E. Handorf, M. Jones, L. Boghossian, 

S. M. Domchek 

Brd. 15 Single nucleotide polymorphisms and expression/amplification of HER2 in 

patients with breast cancer. (Abstract #1523) 

A. V. Boddy, N. Cresti, D. Jamieson, M. Pinkilgton, M. W. Verrill 

Brd. 16 Prognostic value of single nucleotide polymorphisms (SNPs) of candidate 

genes associated with inflammation in early-stage breast cancer. (Abstract 

#1524) 

J. L. Murray, P. Thompson, R. Zhou, S. Y. Yoo, Y. Liu, K. Do, A. A. Sahin, 

M. Bondy, A. M. Brewster 

Brd. 17 Performance of the Gail model in individual women with benign breast 


Y. Tarabishy, L. C. Hartmann, M. H. Frost, S. D. Maloney, R. A. Vierkant, 

V. S. Pankratz 

Brd. 18 Presentation of breast cancer (BC) diagnosed at or before age 30: 

Implications for screening women at hereditary risk. (Abstract #1526) 

P. de Alcantara Filho, T. A. King, E. A. Morris, C. Hudis, M. E. Robson 

Brd. 19 Safety and efficacy of HRT and low dose tamoxifen in a phase II trial (HOT): 

Analysis of mammographic density and endometrial thickness. (Abstract 

#1527) 

B. Bonanni, P. Maisonneuve, D. Serrano, C. Varricchio, M. Cazzaniga, 

M. Lazzeroni, B. Santillo, R. Di Pace, L. Meneghetti, A. Tagliafico, U. Veronesi, 

A. De Censi 

331 

MONDAY

MONDAY 


Brd. 20 25-hydroxy vitamin D (VitD) and associated variables as predictors of breast 

cancer (BC) risk and tamoxifen benefit in NSABP-P1. (Abstract #1528) 

E. Amir, R. S. Cecchini, P. A. Ganz, J. P. Costantino, S. Beddows, N. Hood, 

P. J. Goodwin 

Brd. 21 Relationship of body mass index to the intrinsic subtypes of breast cancer. 


C. A. Santa-Maria, Y. Zhao, N. Ketring, I. Rodriguez, A. Condren, D. Euhus 

332

8:00 AM - 12:30 PM 







CME credit: 1 



Blase N. Polite, MD, MPH—Co-Chair 


Sharlene Gill, MD—Co-Chair 


Discussion 

11:30 AM John S. Kauh, MD (Abstracts #3512–3517) 


Discussion 

11:45 AM Chris R. Garrett, MD (Abstracts #3518–3522) 


Discussion 

12:00 PM Josep Tabernero, MD (Abstracts #3523–3528) 

Vall d’Hebron University Hospital 

Discussion 

12:15 PM Sabine Tejpar, MD, PhD (Abstracts #3529–3536) 

University Hospital Gasthuisberg 

Brd. 1 The dose-effect relationship in preoperative chemoradiation of locally 

advanced rectal cancer: Preliminary results of a phase III trial. (Abstract 

#3512) 

A. K. Jakobsen, A. L. Appelt, J. Lindebjerg, J. Ploeen, S. R. Rafaelsen, T. Vuong 

Brd. 2 EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant 

capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation 

(CRT) with or without cetuximab followed by total mesorectal excision (TME) 

in patients with MRI-defined, high-risk rectal cancer. (Abstract #3513) 

A. Dewdney, J. Capdevila, B. Glimelius, A. Cervantes, D. M. Tait, G. Brown, 

A. Wotherspoon, D. Gonzalez de Castro, Y. Chua, R. Wong, Y. Barbachano, 

J. R. Oates, I. Chau, D. Cunningham 

Brd. 3 Impact of neoadjuvant chemotherapy following chemoradiation on tumor 

response, adverse events, and surgical complications in patients with 

advanced rectal cancer treated with TME. (Abstract #3514) 

J. Garcia-Aguilar, J. Marcet, T. Coutsoftides, P. Cataldo, A. Fichera, L. E. Smith, 

S. Oommen, S. R. Hunt, D. Herzig, D. Dietz, M. G. Varma, C. A. Ternent, 

M. J. Stamos, K. Avila, D. D. Smith 

Brd. 4 Postoperative adjuvant chemotherapy (CTX) use in patients (Pts) with stage 

II/III rectal treated with neoadjuvant therapy: A National Comprehensive 

Cancer Network (NCCN) analysis. (Abstract #3515) 

P. Khrizman, J. C. Niland, A. ter Veer, D. Milne, K. Bullard Dunn, W. E. Carson III, 

P. F. Engstrom, S. Shibata, J. M. Skibber, M. R. Weiser, D. Schrag, A. B. Benson 

Brd. 5 Preoperative versus postoperative chemoradiotherapy for locally advanced 

rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III 

trial after a median follow-up of 11 years. (Abstract #3516) 

R. Sauer, T. Liersch, S. Merkel, H. Becker, W. Hohenberger, H. Witzigmann, 

C. F. Hess, R. Fietkau, C. Wittekind, C. Roedel, German Rectal Cancer Study 

Group 

333 

MONDAY

MONDAY 


Brd. 6 Efficacy endpoints of RTOG 0247: A randomized phase II study of 

neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with 

concurrent radiation therapy (RT) for locally advanced rectal cancer. 


S. J. Wong, J. Moughan, N. J. Meropol, P. R. Anne, L. A. Kachnic, A. Rashid, 

J. C. Watson, E. P. Mitchell, J. Pollock, M. G. Haddock, B. Erickson, C. G. Willett 

Brd. 7 Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) 

with stage II colon cancer (CC) from CALGB 9581. (Abstract #3518) 

A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. Frankel, 

K. Clark-Langone, C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg, 

N. N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli, Cancer and Leukemia Group B 

Brd. 8 Impact of the type and modalities of preoperative chemotherapy on the 

outcome of liver resection for colorectal metastases. (Abstract #3519) 

R. Adam, E. Barroso, C. Laurent, G. Nuzzo, C. Hubert, G. Mentha, J. Ijzermans, 

L. Capussotti, S. Lopezben, D. Mirza, G. Kaiser, E. Oussoultzoglou, 

T. Gruenberger, G. J. Poston, O. Skipenko, The LiverMetSurvey Centers 

Brd. 9 An Ontario Clinical Oncology Group (OCOG) randomized controlled trial 

(RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma 

metastases (CAM). (Abstract #3520) 

C. Moulton, M. N. Levine, C. Law, R. Hart, L. Ruo, C. Gu, A. Hendler, 

K. Y. Gulenchyn, M. A. Haider, M. Marcaccio, V. Tandan, D. Quan, D. Jalink, 

R. Fairfull Smith, S. Hanna, P. D. Greig, M. Husien, T. Finch, J. A. Julian, 

S. Gallinger 

Brd. 10 Follow-up after colorectal cancer surgery: Preliminary observational findings 

from the UK FACS trial. (Abstract #3521) 

J. N. Primrose, A. Fuller, P. Rose, R. Perera-Salazar, J. Mellor, A. Corkhill, 

S. George, D. Mant 

Brd. 11 Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients 

with resected stage III colon cancer: NCCTG Intergroup N0147. (Abstract 

#3522) 

J. Huang, D. J. Sargent, M. R. Mahoney, A. F. Shields, E. Chan, R. M. Goldberg, 

S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, F. Sinicrope, 

S. G. Nair, S. R. Alberts 

Brd. 12 Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized 

controlled trial in advanced colorectal cancer (aCRC). (Abstract #3523) 

M. T. Seymour, S. R. Brown, S. Richman, G. W. Middleton, T. S. Maughan, 

C. Olivier, S. J. Gwyther, J. Wadsley, I. Chau, T. Hickish, L. K. Dawson, S. Falk, 

A. O’Callaghan, K. Benstead, N. Wadd, A. Oliver, P. Chambers, H. Marshall, 

V. Napp, P. Quirke, UK NCRI Colorectal Clinical Studies Group 

Brd. 13 A randomized phase III study of SOX (S-1/oxaliplatin) versus COX 

(capecitabine/oxaliplatin) in patients with advanced colorectal cancer. 


Y. Park, H. Lim, J. Lee, T. Kim, Y. Hong, S. Kim, J. Baek, J. Kim, K. Lee, I. Chung, 

S. Cho, S. J. Shin, H. Kang, D. Shin, S. Jo 

Brd. 14 Phase II trial of figitumumab in patients with refractory, metastatic colorectal 

cancer (mCRC). (Abstract #3525) 

C. Becerra, R. Salazar, R. Garcia-Carbonero, A. L. Thomas, F. Vázquez- 

Mazón, J. Cassidy, T. Maughan, M. Gallén, T. Iveson, M. Hixon, A. Gualberto, 

D. Yin, D. Li, E. K. Bergsland 

Brd. 15 A randomized phase III trial on maintenance treatment with bevacizumab 

(bev) alone or in combination with erlotinib (erlo) after chemotherapy and 

bev in metastatic colorectal cancer (mCRC). (Abstract #3526) 

A. Johnsson, J. Frodin, A. Berglund, H. Hagman, J. Sundberg, D. Bergstrom, 

R. D. Christensen, N. Keldsen, K. G. Spindler, A. K. Jakobsen 

334


Brd. 16 A double-blind, randomized, placebo-controlled, phase II study of 

maintenance enzastaurin with 5-FU/leucovorin plus bevacizumab following 

first-line therapy for metastatic colorectal cancer (mCRC). (Abstract #3527) 

R. A. Wolff, W. Schepp, M. Di Bartolomeo, A. Hossain, C. Stoffregen, S. Nicol, 

V. Heinemann 

Brd. 17 An international consortium study in chemorefractory metastatic colorectal 

cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms 

on cetuximab efficacy. (Abstract #3528) 

R. Geva, B. V. Jensen, G. Fountzilas, T. Yoshino, D. Paez, C. Montagut, 

I. Sougklakos, F. Cappuzzo, A. Cervantes-Ruiperez, D. Papamichael, M. Frattini, 

B. Vincenzi, T. Macarulla, F. Loupakis, K. G. Spindler, C. Qvortrup, F. Ciardiello, 

S. Tejpar 

Brd. 18 Identification of polymorphisms in ultraconserved elements (UCEs) 

associated with clinical outcomes in patients (pts) with stage II/III colorectal 

cancer (CRC). (Abstract #3529) 

M. Lin, E. Hawk, M. Huang, J. Lin, J. Gu, L. M. Ellis, X. Wu, C. Eng 

Brd. 19 Evaluation of gene mutations beyond KRAS as predictive biomarkers of 

response to panitumumab in a randomized, phase III monotherapy study of 

metastatic colorectal cancer (mCRC). (Abstract #3530) 

K. Oliner, M. Peeters, S. Siena, E. Van Cutsem, J. Huang, Y. Humblet, 

J. Van Laethem, T. Andre, J. S. Wiezorek, S. D. Patterson 

Brd. 20 Vascular endothelial growth factors (VEGF) and VEGF receptor expression 

as predictive biomarkers for benefit with bevacizumab in metastatic 

colorectal cancer (mCRC): Analysis of the phase III MAX study. (Abstract 

#3531) 

A. J. Weickhardt, D. Williams, C. Lee, J. Simes, C. Murone, K. Wilson, 

M. Cummins, K. Asadi, T. J. Price, J. Mariadason, N. C. Tebbutt, 

Australasian GI Trials Group 

Brd. 21 Prediction of survival in patients with metastatic colorectal cancer treated 

with third-line cetuximab and irinotecan through changes in microRNA 

expression in whole blood during treatment (Abstract #3532) 

J. V. Schou, K. K. Andersen, B. V. Jensen, D. L. Nielsen, P. Pfeiffer, E. V. Høgdall, 

M. Yilmaz, M. Kruhoffer, J. S. Johansen 

Brd. 22 The association of alternate VEGF ligands with resistance to anti-VEGF 

therapy in metastatic colorectal cancer. (Abstract #3533) 

C. H. Lieu, H. T. Tran, Z. Jiang, M. Mao, M. J. Overman, C. Eng, J. Morris, 

L. M. Ellis, J. Heymach, S. Kopetz 

Brd. 23 The role of activating mutations of KRAS, BRAF, and PIK3CA pathway 

convergence at the transcriptional level and prediction of treatment 

response to cetuximab in colorectal cancer. (Abstract #3534) 

I. Simon, S. Tian, V. Moreno, P. Roepman, J. Tabernero, M. Snel, T. Macarulla, 

L. van’t Veer, R. Bernards, G. Capella 

Brd. 24 Primary colorectal tumors and their metastasis are genetically not the same: 

Implications for choice of targeted treatment? (Abstract #3535) 

J. S. Vermaat, I. J. Nijman, M. J. Koudijs, W. M. Roessingh, F. L. Gerritse, 

M. Mokry, R. H. Giles, P. J. van Diest, E. Cuppen, E. E. Voest 

Brd. 25 Mutational analysis and clinical correlation of 185 consecutive metastatic 

colorectal patients: Similarities and differences between colon and rectal 


A. L. Russo, D. R. Borger, D. P. Ryan, K. C. Fan, H. Lopez, V. Scialabba, 

L. S. Blaszkowsky, E. L. Kwak, J. W. Clark, J. N. Allen, R. C. Wadlow, A. X. Zhu, 

R. Wang, D. Dias-Santagata, T. S. Hong, A. J. Iafrate 

335 

MONDAY

MONDAY 


8:00 AM - 12:30 PM 







CME credit: 1 


Katherine Pisters, MD—Co-Chair 


William J. Petty, MD—Co-Chair 

Wake Forest University 

Discussion 

11:30 AM Tetsuya Mitsudomi, MD, PhD (Abstracts #7007–7010) 

Aichi Cancer Center Hospital 

Discussion 

11:40 AM Enriqueta Felip, MD (Abstracts #7011–7015) 

Vall d’Hebron University Hospital 

Discussion 

11:55 AM Joseph Kamel Salama, MD (Abstracts #7016–7020) 


Discussion 

12:05 PM Kaoru Kubota, MD (Abstracts #7021–7023) 

National Cancer Center 

Discussion 

12:20 PM Nasser H. Hanna, MD (Abstracts #7024–7028) 


Brd. 1 Use of a three-microRNA signature to discriminate prognostic groups in 

early-stage NSCLC patients in the IFCT-0002 trial. (Abstract #7007) 

C. Mascaux, G. Levallet, E. Bergot, L. Baudrin, M. Antoine, G. Anthoine, 

V. Westeel, A. Lavole, E. A. Quoix, D. Debieuvre, J. Mazieres, J. Pujol, 

D. Moro-Sibilot, F. Morin, B. Milleron, G. Zalcman, on behalf of the Intergroupe 

Francophone de Cancerologie Thoracique (IFCT) 

Brd. 2 Association between DNA-repair gene and glutathione S-transferase gene 

polymorphisms and clinical outcome in patients (pt) with localized nonsmall-cell 

lung cancer (NSCLC) treated with sequential radiochemotherapy. 


J. Stoehlmacher-Williams, B. Krassler, M. Kramer, G. Ehninger, G. Hoeffken, 

E. Goekkurt 

Brd. 3 Genetic variations in multiple drug action pathways and survival in 

advanced-stage non-small cell lung cancer treated with chemotherapy. 


P. Yang, Y. Li, Z. Sun, J. M. Cunningham, M. Aubry, J. A. Wampfler, G. Croghan, 

C. Johnson, D. Wu, J. Aakre, J. R. Molina, L. Wang, V. S. Pankratz 

Brd. 4 Use of a gene expression signature related to epithelial-to-mesenchymal 

transition (EMT) to predict for overall survival (OS) in cohorts of lung and 

head and neck cancer (HNSCC) patients. (Abstract #7010) 

J. S. Yordy, L. Shen, L. Diao, J. Wang, K. Coombes, U. Giri, Y. Xie, J. D. Minna, 

L. Girard, J. Weinstein, J. Heymach, K. Ang, M. D. Story, R. Meyn 

Brd. 5 Oncologists’, physicians’, and surgeons’ opinions on the perceived value 

and appropriateness of the speciality to inform patients on adjuvant 

chemotherapy after radical surgery for non-small cell lung cancer. (Abstract 

#7011) 

K. Khor, D. Tai, S. Popat, M. Beckles, M. Leung, M. Al Sahaf, E. K. Lim 

336


Brd. 6 Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer 

(NSCLC) in the elderly: A population-based outcomes study. (Abstract 

#7012) 

S. Cuffe, C. M. Booth, Y. Peng, G. E. Darling, G. Li, W. Kong, W. J. Mackillop, 

F. A. Shepherd 

Brd. 7 Interim report of on-study demographics and toxicity from E1505, a phase III 

randomized trial of adjuvant (adj) chemotherapy (chemo) with or without 

bevacizumab (B) for completely resected early stage non-small cell lung 

cancer (NSCLC). (Abstract #7013) 

H. A. Wakelee, S. E. Dahlberg, S. M. Keller, D. R. Gandara, S. L. Graziano, 

N. B. Leighl, A. A. Adjei, J. H. Schiller, Eastern Cooperative Oncology Group 

Brd. 8 Platinum-based adjuvant chemotherapy (ACT) in elderly patients with 

non-small cell lung cancer (NSCLC) in the SEER-Medicare database: 

Comparison between carboplatin- and cisplatin-based regimens. (Abstract 

#7014) 

F. Gu, G. M. Strauss, J. P. Wisnivesky 

Brd. 9 Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): 

Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633. 


G. M. Strauss, X. F. Wang, M. Maddaus, D. Johnstone, E. Johnson, D. Harpole, 

H. H. Gillenwater, L. Gu, D. Sugarbaker, M. R. Green, S. L. Graziano, 

R. A. Kratzke, R. L. Schilsky, J. Crawford, E. E. Vokes 

Brd. 10 Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and 

concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic 

conformal radiotherapy (TCRT) in stage III non-small cell lung cancer 


T. Stinchcombe, M. A. Socinski, D. T. Moore, S. N. Gettinger, R. H. Decker, 

W. J. Petty, A. W. Blackstock, G. Schwartz, S. Lankford, D. E. Morris 

Brd. 11 Phase II study of high-dose proton therapy with concurrent chemotherapy 

for unresectable stage III non-small cell lung cancer. (Abstract #7017) 

J. Y. Chang, R. Komaki, C. Lu, H. Y. When, P. Allen, A. S. Tsao, M. Gillin, 

R. Mohan, J. D. Cox 

Brd. 12 An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) 

of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): 

Predictors of overall survival. (Abstract #7018) 

Y. Ung, C. Gu, K. Cline, A. Sun, R. M. MacRae, J. R. Wright, E. Yu, L. Ehrlich, 

K. Y. Gulenchyn, H. Shulman, I. S. Dayes, S. K. Dhesy-Thind, G. E. Darling, 

N. B. Leighl, W. K. Evans, J. A. Julian, M. N. Levine 

Brd. 13 Multicenter phase II study of cetuximab (C) with concomitant radiotherapy 

(RT) followed by consolidation chemotherapy (CT) in locally advanced 


A. P. Kotsakis, S. S. Ramalingam, A. A. Tarhini, D. E. Heron, R. Smith, 

D. Friedland, D. P. Petro, L. E. Raez, J. R. Brahmer, J. S. Greenberger, S. Dacic, 

P. Hershberger, R. J. Landreneau, C. P. Belani, J. D. Luketich, A. Argiris 

Brd. 14 Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for 

patients with stage III non-small cell lung cancer. (Abstract #7020) 

R. Komaki, G. R. Blumenschein Jr., I. I. Wistuba, J. Lee, P. Allen, X. Wei, J. Welsh, 

M. O’Reilly, R. S. Herbst, X. Tang, R. Meyn, D. Liu, W. K. Hong 

Brd. 15 Surgical resection in early limited stage small cell lung cancer: Time to 

rethink? A retrospective analysis of the VA Central Cancer Registry. 


T. Tashi, I. T. Aldoss, W. Gonsalves, A. Ganti, P. T. Silberstein, P. Townley, 

S. Subbiah 

337 

MONDAY

MONDAY 


Brd. 16 COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatinbased 

chemotherapy (CT) as first-line treatment of small cell lung cancer 

(SCLC). (Abstract #7022) 

A. Rossi, M. Di Maio, P. Chiodini, R. Rudd, H. Okamoto, D. Skarlos, M. Frueh, 

W. Qian, T. Tamura, E. Samantas, T. Shibata, F. Perrone, C. Gallo, C. Gridelli, 

O. Martelli, S. M. Lee 

Brd. 17 Thymoma: A population-based study of the management and outcomes for 

the province of British Columbia. (Abstract #7023) 

C. J. Mariano, D. Ionescu, W. Y. Cheung, R. Ali, J. J. Laskin, H. Carolan, K. Evans, 

N. Murray 

Brd. 18 Predictive value of thymidylate synthase and folylpoly-glutamate synthetase 

for clinical benefit from pemetrexed in malignant pleural mesothelioma. 


D. C. Christoph, C. Mascaux, M. W. Wynes, B. Reyna Asuncion, J. Wohlschlaeger, 

D. Theegarten, T. C. Gauler, M. H. Schuler, W. E. Eberhardt, F. R. Hirsch 

Brd. 19 Does disease control rate (DCR) at 9 and 18 weeks predict overall survival 

(OS) in patients with malignant pleural mesothelioma (MPM)? An individual 

patient data combined analysis of 10 European Organisation for Research 

and Treatment of Cancer (EORTC) Lung Cancer Group (LCG) studies. 


L. Greillier, B. Hasan, P. Baas, J. J. Welch, J. P. Van Meerbeeck, R. M. Gaafar, 

R. Sylvester, D. A. Lacombe, M. O’Brien 

Brd. 20 Antitumor activity of SS1P with pemetrexed and cisplatin for front-line 

treatment of pleural mesothelioma and utility of serum mesothelin as a 

marker of tumor response. (Abstract #7026) 

R. Hassan, E. Sharon, B. Schuler, Y. Mallory, J. Zhang, A. Ling, I. Pastan 

Brd. 21 Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II 

trial of The University of Chicago phase II consortium. (Abstract #7027) 

N. P. Campbell, R. Kunnavakkam, N. B. Leighl, M. D. Vincent, D. R. Gandara, 

M. Koczywas, B. J. Gitlitz, E. S. Agamah, S. P. Thomas, W. M. Stadler, 

E. E. Vokes, H. L. Kindler 

Brd. 22 Forced vital capacity (FVC) as a reproducible measure of pulmonary function 

(PF) in chemotherapy-pretreated patients with malignant pleural 


L. M. Krug, J. Arduino, X. Sun, H. L. Kindler, C. Manegold, D. Fennell, 

G. M. Lubiniecki, P. Baas 

338

8:00 AM - 12:30 PM 







CME credit: 1 



Bartosz Chmielowski, MD, PhD—Co-Chair 


Georgina V. Long, MBBS, PhD—Co-Chair 

Royal Prince Alfred Hospital 

Discussion 

11:30 AM David Fisher, MD, PhD (Abstracts #8513–8520) 


Discussion 

11:45 AM Michael S. Sabel, MD (Abstracts #8521–LBA8526 ∧ ) 


Discussion 

12:00 PM Christopher D. Lao, MD (Abstracts #8527–8532) 


Discussion 

12:15 PM F. Stephen Hodi, MD (Abstracts #8533–8537) 


Brd. 1 An analysis of sera-based microRNAs as biomarkers of recurrence in 


E. B. Friedman, S. Shang, E. Vega-Saenz de Miera, M. W. Ma, R. S. Berman, 

R. L. Shapiro, A. C. Pavlick, E. Hernando, Y. Shao, I. Osman 

Brd. 2 Functional characterization of an oncogenic role for the miRNA-506–514 

cluster in initiating melanocyte transformation and promoting melanoma 

growth. (Abstract #8514) 

K. Streicher, W. Zhu, K. Lehmann, R. W. Georgantas III, C. Morehouse, 

P. Brohawn, R. Carrasco, Z. Xiao, D. Tice, B. W. Higgs, L. Richman, B. Jallal, 

Y. Yao 

Brd. 3 Whole-genome expression profiling of brain metastases from melanoma 

(BrMM) provides preliminary insights into its biology and mechanisms of 

development. (Abstract #8515) 

M. T. Krauze, R. H. Hamilton, S. Bortoluzzi, S. C. Buch, M. Romkes, A. H. Mintz, 

D. Kondziolka, J. M. Kirkwood, S. J. Moschos 

Brd. 4 Targeting histone deacetylase to overcome resistance of B-RAF V600E 

melanoma cells to apoptosis. (Abstract #8516) 

P. Hersey, Chen Chen Jiang, Fritz Lai, Xu Dong Zhang 

Brd. 5 Molecular mechanisms underlying disease relapse on treatment with 

selective BRAF inhibitor vemurafenib (RG7204, PLX4032). (Abstract #8517) 

F. Su, H. Yang, B. Higgins, K. D. Kolinsky, K. Packman, M. Kim, B. J. Lestini, 

G. Bollag, D. C. Heimbrook 

Brd. 6 Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in 

BRAFV600E melanoma cells through regulation of endoplasmic reticulum 

stress-related genes. (Abstract #8518) 

F. E. Meier, D. Beck, H. Niessner, K. T. Flaherty, J. Iovanna, D. Kulms, 

D. Schadendorf, C. Garbe 

339 

MONDAY

MONDAY 


Brd. 7 Pattern and outcome of disease progression in phase I study of vemurafenib 

(RG7204) in patients with metastatic melanoma (MM). (Abstract #8519) 

K. B. Kim, K. T. Flaherty, P. B. Chapman, J. A. Sosman, A. Ribas, G. A. McArthur, 

R. K. Amaravadi, R. J. Lee, K. B. Nolop, I. Puzanov 

Brd. 8 Presence of frequent underlying RAS mutations in cutaneous squamous cell 

carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients 

during vemurafenib therapy. (Abstract #8520) 

M. E. Lacouture, P. B. Chapman, A. Ribas, J. A. Sosman, G. A. McArthur, 

K. T. Flaherty, K. B. Kim, I. Puzanov, K. B. Nolop, A. K. Joe, O. Spleiss, A. Koehler, 

W. Wu, C. Robert, A. Hauschild, D. Schadendorf, J. L. Troy, M. Duvic, K. Trunzer 

Brd. 9 Impact of population genetic substructure on association studies and risk 

assessment for melanoma. (Abstract #8521) 

I. Lobach, I. Belitskaya-Levy, J. D. Goldberg, H. Ostrer, R. S. Berman, 

A. C. Pavlick, R. L. Shapiro, I. Osman, P. Manga 

Brd. 10 Disparities in the management of melanoma in elderly patients: An analysis 

of patients from the National Cancer Database. (Abstract #8522) 

S. Tsai, S. Soong, C. M. Balch, J. R. Lange 

Brd. 11 The impact of gender on the outcome of malignant melanoma: Overview of 

seven EORTC phase III trials. (Abstract #8523) 

A. Joosse, S. Collette, S. Suciu, E. de Vries, T. Nijsten, P. Patel, U. R. Kleeberg, 

U. Keilholz, A. M. Eggermont, J. W. Coebergh, EORTC Melanoma Group 

Brd. 12 The effect of beta-blocker treatment in patients with cutaneous melanoma. 


V. De Giorgi, M. Grazzini, S. Gandini, S. Benemei, T. Lotti, N. Marchionni, 

S. Rossari, A. Gori, P. Geppetti 

Brd. 14 A phase III study of receptor-targeted 99m Tc-tilmanocept versus blue dye in 

evaluation of SLNs in breast cancer and melanoma. (Abstract #LBA8526^) 

F. O. Cope, V. K. Sondak, A. M. Wallace 

Brd. 15 Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in 

patients with advanced melanoma treated in two phase I trials. (Abstract 

#8527) 

D. S. Hong, D. S. Boss, H. Glen, J. Mink, M. Ren, C. Andresen, J. P. O’Brien, 

R. Kurzrock, J. H. Schellens, J. J. Nemunaitis, T. Evans 

Brd. 16 A phase II clinical/translational trial of sequential axitinib/carboplatin/ 

paclitaxel in melanoma. (Abstract #8528) 

A. P. Algazi, E. Cha, C. Soon, S. Ortiz-Urda, B. Cortez, L. Ziani, F. V. Coakley, 

A. Daud 

Brd. 17 MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in 

patients (pts) with metastatic melanoma: Results of a phase I study. 


S. Bhatia, O. Hamid, A. C. Pavlick, G. Mulligan, P. G. Smith, M. D. Pickard, 

M. Shultz, R. M. Walker, B. Dezube, S. O’Day 

Brd. 18 Final results of phase I/II study of decitabine (DAC) combined with 

temozolomide (TMZ) in metastatic melanoma (MM). (Abstract #8530) 

J. H. Beumer, H. A. Tawbi, A. A. Tarhini, S. J. Moschos, M. J. Egorin, S. C. Buch, 

Y. Lin, J. M. Kirkwood 

Brd. 19 Survival in a phase III, randomized, double-blind study of dacarbazine with or 

without oblimersen (Bcl-2 antisense) in patients with advanced melanoma 

and low-normal serum lactate dehydrogenase (LDH; AGENDA). (Abstract 

#8531) 

A. Y. Bedikian, C. Lebbé, C. Robert, S. S. Agarwala, T. Cousin, J. Wu, C. Garbe, 

J. J. Grob 

340


Brd. 20 A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) 

or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in 

patients with unresectable stage IV metastatic melanoma: A North Central 

Cancer Treatment Group Study (N0775). (Abstract #8532) 

L. A. Kottschade, V. Suman, D. G. Perez, R. R. McWilliams, J. S. Kaur, 

T. Amatruda, F. J. Geoffroy, H. M. Gross, P. A. Cohen, A. J. Jaslowski, M. L. Kosel, 

S. Markovic 

Brd. 21 Phase II study of recombinant adeno-viral human p53 (rAd-p53) gene therapy 

combined with surgery in treatment of melanomas of oral mucosa. (Abstract 

#8533) 

L. Li 

Brd. 22 Combination immunotherapy for high-risk and advanced melanoma patients. 


A. I. Riker, N. N. Vahanian, C. J. Link, L. Tennant, W. J. Ramsey, G. R. Rossi, 

L. C. Alsfeld, E. Davila, M. Harrison 

Brd. 23 Active immunization toward the MAGE-A3 antigen in patients with metastatic 

melanoma: Four-year follow-up results from a randomized phase II study 

(EORTC16032-18031). (Abstract #8535) 

W. Kruit, S. Suciu, B. Dreno, V. Chiarion-Sileni, L. Mortier, C. Robert, M. Maio, 

F. Lehmann, V. G. Brichard, A. Spatz, A. M. Eggermont, U. Keilholz 

Brd. 24 Neoadjuvant ipilimumab in patients with stage IIIB/C melanoma: 

Immunogenicity and biomarker analysis. (Abstract #8536) 

A. A. Tarhini, H. Edington, L. H. Butterfield, M. Sinha, S. J. Moschos, H. Tawbi, 

Y. Shuai, J. Shipe-Spotloe, M. Simonettta, C. Milburn, M. Horak, C. Sander, 

J. M. Kirkwood 

Brd. 25 Clinical benefit of ipilimumab in patients with metastatic melanoma who 

progress on high-dose IL-2. (Abstract #8537) 

R. W. Joseph, P. Hwu, M. A. Davies, M. B. Atkins, R. J. Sullivan 

341 

MONDAY

MONDAY 


9:30 AM - 12:30 PM 

ORAL ABSRACT SESSION 



CME credit: 3 


Lisa Yee, MD—Chair 

The Ohio State University 

9:30 AM NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early 

breast cancer (Abstract #LBA1003) 

T. J. Whelan, I. Olivotto, I. Ackerman, J. A. W. Chapman, B. Chua, A. Nabid, 

K. A. Vallis, J. R. White, P. Rousseau, A. Fortin, L. J. Pierce, L. Manchul, 

P. Craighead, M. C. Nolan, J. Bowen, D. R. McCready, K. I. Pritchard, 

M. N. Levine, and W. Parulekar 

Discussion 

9:45 AM Thomas A. Buchholz, MD (Abstract #LBA1003) 


10:00 AM First analysis of SWOG S0221: A phase III trial comparing chemotherapy 

schedules in high-risk early breast cancer. (Abstract #1004) 

G. T. Budd, W. E. Barlow, H. C. Moore, T. J. Hobday, J. A. Stewart, C. Isaacs, 

M. Salim, J. K. Cho, K. Rinn, K. S. Albain, H. K. Chew, G. V. Burton, T. D. Moore, 

G. Srkalovic, B. A. McGregor, L. E. Flaherty, R. B. Livingston, D. Lew, J. Gralow, 

G. N. Hortobagyi, SWOG 

10:15 AM The effect on pCR of bevacizumab and/or antimetabolites added to standard 

neoadjuvant chemotherapy: NSABP protocol B-40. (Abstract #LBA1005) 

H. D. Bear, G. Tang, P. Rastogi, C. E. Geyer, A. Robidoux, J. N. Atkins, L. Baez, 

A. Brufsky, R. S. Mehta, L. Fehrenbacher, E. R. Pajon, F. M. Senecal, R. Gaur, 

R. G. Margolese, P. T. Adams, H. M. Gross, S. M. Swain, E. P. Mamounas, 

J. P. Costantino, N. Wolmark 

10:30 AM Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 

686 triple-negative primary breast cancers: Seconday endpoint analysis of 

the GEPARQUINTO study (GBG 44). (Abstract #1006) 

B. Gerber, H. Eidtmann, M. Rezai, P. A. Fasching, H. Tesch, H. Eggemann, 

I. Schrader, K. Kittel, C. A. Hanusch, R. Kreienberg, C. Solbach, C. Jackisch, 

G. Kunz, J. U. Blohmer, J. B. Huober, M. Hauschild, S. Loibl, V. Nekljudova, 

M. Untch, G. Von Minckwitz, GBG/AGO Study Groups 

Discussion 

10:45 AM Hope S. Rugo, MD (Abstracts #1004–1006) 


11:00 AM A randomized phase III study of iniparib (BSI-201) in combination with 

gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer 

(TNBC). (Abstract #1007) 

J. O’Shaughnessy, L. S. Schwartzberg, M. A. Danso, H. S. Rugo, K. Miller, 

D. A. Yardley, R. W. Carlson, R. S. Finn, E. Charpentier, M. Freese, S. Gupta, 

A. Blackwood-Chirchir, E. P. Winer 

Discussion 

11:15 AM Lisa A. Carey, MD (Abstract #1007) 


11:30 AM Randomized, phase II trial comparing continuous versus intermittent 

capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results 

from the GEICAM 2009–05 study. (Abstract #1008) 

M. Martin, N. Martinez, M. Ramos, L. Calvo, A. Lluch, P. Zamora, 

M. Munoz-Mateu, D. Caronia, E. M. Carrasco, J. Garcia Saenz, A. Casado, 

I. Chacón, B. Hernando, M. Ruiz-Borrego, A. Gonzalez-Neira 

342


11:45 AM Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced 

(adv) breast cancer (BC) previously treated with bevacizumab (BEV). 


C. Hudis, K. W. Tauer, R. C. Hermann, G. Makari-Judson, C. Isaacs, J. T. Beck, 

V. G. Kaklamani, E. J. Stepanski, H. S. Rugo, W. Wang, K. M. Bell-McGuinn, 

H. Chera, B. Zaugg, S. Ro, S. Li, L. S. Schwartzberg 

12:00 PM Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) 

for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. (Abstract 

#1010) 

A. Brufsky, V. Valero, B. Tiangco, S. R. Dakhil, A. Brize, N. Bousfoul, H. S. Rugo, 

D. A. Yardley 

Discussion 

12:15 PM Stephen R. D. Johnston, MA, MD, PhD (Abstracts #1008–1010) 


343 

MONDAY

MONDAY 


9:30 AM - 12:30 PM 




CME credit: 3 


Monika K. Krzyzanowska, MD—Co-Chair 


Christopher Ryan Friese, RN, PhD—Co-Chair 


9:30 AM Identification of barriers to clinical trials: The impact of education level. 

(Abstract #CRA6003) 

J. R. Eads, T. L. Albrecht, B. Egleston, J. S. Buzaglo, R. B. Cohen, L. Fleisher, 

T. Foster, M. Katz, T. Kinzy, S. Manne, D. M. Miller, S. M. Miller, S. Raivitch, 

N. Roach, A. Silver, N. J. Meropol 

9:45 AM The impact of socioeconomic status on cancer care and survival. (Abstract 

#6004) 

S. L. Wong, N. Gu, M. Banerjee, J. D. Birkmeyer, N. J. Birkmeyer 

10:00 AM The impact of economic recession on the incidence and treatment of cancer. 


K. Y. Ennis, M. Chen, G. C. Smith, A. V. D’Amico, Y. Zhang, L. B. Harrison, 

R. D. Ennis 

10:15 AM Impact of out-of-pocket expenses on cancer care. (Abstract #6006) 

Y. Zafar, A. M. Goetzinger, R. Fowler, A. Gblokpor, D. Warhadpande, D. H. Taylor, 

D. Schrag, J. M. Peppercorn, A. P. Abernethy 

10:30 AM Cancer diagnosis as a risk factor for personal bankruptcy. (Abstract #6007) 

S. D. Ramsey, C. R. Fedorenko, K. S. Snell, A. C. Kirchhoff, W. Hollingworth, 

D. K. Blough 

Discussion 

10:45 AM Neal J. Meropol, MD (Abstracts #CRA6003–6007) 


11:00 AM Prospective and observational study of pain and analgesic prescribing in 

medical oncology outpatients with breast, colorectal, lung, or prostate 

cancer. (Abstract #CRA6008) 

M. Fisch, J. Lee, M. Weiss, L. I. Wagner, V. T. Chang, D. Cella, J. Manola, 

L. M. Minasian, W. J. McCaskill-Stevens, T. R. Mendoza, C. S. Cleeland 

11:15 AM Effect of early palliative care on chemotherapy utilization and end-of-life care 

in patients with metastatic non-small cell lung cancer (NSCLC). (Abstract 

#6009) 

J. A. Greer, W. F. Pirl, V. A. Jackson, I. T. Lennes, R. S. Heist, 

E. R. Gallagher, J. S. Temel 

Discussion 

11:30 AM Susan Yount, PhD (Abstracts #CRA6008–6009) 

Northwestern University, Feinberg School of Medicine 

11:45 AM Correlates of contralateral prophylactic mastectomy in a population-based 

sample. (Abstract #6010) 

S. T. Hawley, R. Jagsi, M. Morrow, S. J. Katz 

12:00 PM Quality of non-small cell lung cancer (NSCLC) care in the Veterans Health 

Administration (VHA): Impact of patient preference and clinical judgment. 


J. J. Ryoo, B. Kim, D. L. Ordin, S. M. Oishi, S. M. Asch, A. M. Antonio, R. He, 

M. K. Gould, J. Malin 

344

Discussion 

12:15 PM David J. Bentrem, MD (Abstracts #6010–6011) 

Northwestern University, Feinberg School of Medicine 


345 

MONDAY

MONDAY 


9:30 AM - 12:30 PM 




CME credit: 3 


Attaya Suvannasankha, MD—Co-Chair 


Guido Marcucci, MD—Co-Chair 

The Ohio State University Comprehensive Cancer Center 

9:30 AM Results of COMFORT- I, a randomized double-blind phase III trial of JAK 1/2 

inhibitor INCB18424 (424) versus placebo (PB) for patients with 

myelofibrosis (MF). (Abstract #6500) 

S. Verstovsek, R. A. Mesa, J. R. Gotlib, R. S. Levy, V. Gupta, J. F. DiPersio, 

J. Catalano, M. Deininger, C. B. Miller, R. T. Silver, M. Talpaz, E. F. Winton, 

J. H. Harvey, K. Vaddi, S. K. Erickson-Viitanen, I. Koumenis, W. Sun, V. Sandor, 

H. Kantarjian, on behalf of all COMFORT-I investigators 

9:45 AM Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) 

versus best available therapy (BAT) in primary myelofibrosis (PMF), postpolycythemia 

vera-myelofibrosis (PPV-MF), or post-essential 

thrombocythemia-myelofibrosis (PET-MF) (Abstract #LBA6501) 

C. N. Harrison, J. J. Kiladjian, H. K. Al-Ali, H. Gisslinger, R. J. Waltzman, 

V. Stalbovskaya, M. McQuitty, D. S. Hunter, R. S. Levy, F. Cervantes, 

A. M. Vannucchi, T. Barbui, G. Barosi 

10:00 AM The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed 

chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib 

or imatinib in ENESTnd: Twenty-four-month follow-up. (Abstract #6502) 

G. Saglio, H. Kantarjian, J. Reiffers, S. Jootar, M. E. Kalaycio, H. Shibayama, 

X. Fan, N. J. Gallagher, Y. Shou, R. A. Larson, T. P. Hughes, A. Hochhaus 

Discussion 

10:15 AM Ross L. Levine, MD (Abstracts #6500–6502) 


10:30 AM Clofarabine plus cytarabine compared to cytarabine alone in older patients 

with relapsed or refractory (R/R) acute myelogenous leukemia (AML): 

Results from the phase III CLASSIC 1 trial. (Abstract #6503^) 

S. Faderl, M. Wetzler, D. Rizzieri, G. J. Schiller, M. H. Jagasia, R. K. Stuart, 

S. Ganguly, D. Avigan, M. Craig, R. Collins, M. B. Maris, T. Kovacsovics, 

S. Goldberg, K. Seiter, P. Hari, F. Ravandi, E. S. Wang, S. Eckert, D. Huebner, 

H. Kantarjian 

10:45 AM Results from a randomized phase III trial of decitabine versus supportive 

care or low-dose cytarabine for the treatment of older patients with newly 

diagnosed AML. (Abstract #6504) 

X. G. Thomas, A. Dmoszynska, A. Wierzbowska, K. Kuliczkowski, J. Mayer, 

T. Shelekhova, J. Gau, W. Chou, R. Buckstein, J. Cermak, C. Kuo, 

A. O. Rocafiguera, V. Koza, F. Ravandi, H. Kantarjian 

11:00 AM Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: 

completed results of the phase I study. (Abstract #6505) 

D. A. Pollyea, H. E. Kohrt, L. Gallegos, B. Zhang, M. Figueroa, A. Melnick, 

C. Berube, S. E. Coutre, J. R. Gotlib, J. L. Zehnder, M. Liedtke, B. S. Mitchell, 

B. C. Medeiros 

346


11:15 AM Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) 

with relapsed/refractory myeloid malignancies: Evidence of activity in pts 

with RAS mutation. (Abstract #6506) 

G. Borthakur, L. Popplewell, M. H. Kirschbaum, J. M. Foran, T. M. Kadia, 

E. Jabbour, M. Boyiadzis, A. Verma, R. B. Walter, P. S. Wissel, 

L. Xu, J. W. Bauman, J. Z. Zhu, J. Mazumdar, M. Baccus, J. M. Connor, 

J. E. Cortes, H. Kantarjian 

Discussion 

11:30 AM Gail J. Roboz, MD (Abstracts #6503 ∧ –6506) 

Weill Medical College of Cornell University 

11:45 AM Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached 

to calicheamycin, produces complete response (CR) plus complete marrow 

response (mCR) of greater than 50% in refractory relapse (R-R) acute 

lymphocytic leukemia (ALL). (Abstract #6507) 

E. Jabbour, S. M. O’Brien, D. A. Thomas, F. Ravandi, S. York, M. Kwari, S. Faderl, 

T. M. Kadia, C. Wilson, R. Tarnai, A. S. Advani, G. Garcia-Manero, J. E. Cortes, 

H. Kantarjian 

12:00 PM The Bruton’s tyrosine kinase (Btk) inhibitor PCI-32765 is highly active and 

tolerable in patients with chronic lymphocytic leukemia/small lymphocytic 

lymphoma (CLL/SLL): Interim results of a phase Ib/II study. (Abstract #6508) 

J. C. Byrd, K. A. Blum, J. A. Burger, S. E. Coutre, J. P. Sharman, 

R. R. Furman, I. W. Flinn, B. W. Grant, D. A. Richards, W. Zhao, N. A. Heerema, 

A. J. Johnson, R. Izumi, A. Hamdy, S. M. O’Brien 

Discussion 

12:15 PM Ross L. Levine, MD (Abstracts #6507–6508) 


347 

MONDAY

MONDAY 


9:45 AM - 11:00 AM 


AIDS-associated Malignancies in Low- and Middle-income Countries 



Track(s): Special Session, Cancer Prevention/Epidemiology, International 

Clement Adebayo Adebamowo, MD, ScD—Chair 

Institute of Human Virology, University of Maryland School of Medicine 

AIDS-associated Malignancies: An Epidemic Foretold 

Ronald T. Mitsuyasu, MD 

University of California, Los Angeles Care Center 

Conducting Clinical Trials in Resource Low-income Countries: Challenges and Opportunities 

William A. Blattner, MD 

University of Maryland Baltimore 

Patterns and Trends in HIV-associated Malignancy 

E. Akin Abayomi, MBBS, MRCP, MPhil 

Stellenbosch University 

Effect of Antiretroviral Therapy on the Evolving Pattern and Incidence of HIV-related Lymphoma 

in South Africa 

348

9:45 AM - 11:00 AM 


Assessing Patients’ Psychosocial Needs: How to Do This in (Your Busy) 

Practice 



Track(s): Patient and Survivor Care, Breast Cancer 

Michelle Joy Naughton, PhD—Chair 


Overview of Psychosocial Problems and Risk Factors among Cancer Survivors 

Paul B. Jacobsen, PhD 


Psychosocial Screening for Patients with Cancer: Opportunities and Challenges 

David Goldstein, MD 

Prince of Wales Hospital 

Translating Research into Everyday Patient Care: Applying the Outcomes of Psychosocial 

Screening and Intervention Trials into Clinical Practice 

Immunotherapy for Advanced and High-risk Melanoma: Lessons Learned and 

Future Directions 




John M. Kirkwood, MD—Chair 


Historical Perspective of Immunotherapy for Advanced or Metastatic Melanoma 

Thomas Gajewski, MD, PhD 


Limitations of Immunotherapy, Mechanisms of Resistance, Immune Escape, Effect of Tumor 

Microenvironment, and Why Immunotherapy Strategies May Have Been Ineffective 

Suzanne Louise Topalian, MD 


Overview of the Future of Immunotherapy Strategies for Advanced Melanoma 

New Targeted Therapies in Neuroendocrine Cancers: What Should Be the 

Sequence of Therapy? 



Track(s): Gastrointestinal (Noncolorectal) Cancer, Developmental Therapeutics 

Matthew Kulke, MD, MMSc—Chair 


What Is the Best Sequence of Therapy for Pancreatic Neuroendocrine Tumors? 

Emily K. Bergsland, MD 

University of California, San Francisco Cancer Center 

What Is the Best Sequence of Treatment for Carcinoid Tumors? 


Martyn Caplin, MD 

Royal Free Hampstead NHS Trust 

The Role of Somatostatin Analogs in the Treatment of Neuroendocrine Tumors: When Should 

They Be Started and When Do We Add Other Agents? 

349 

MONDAY

MONDAY 


What Is Going on with Mesothelioma? 



Track(s): Lung Cancer, Sarcoma 

Harvey I. Pass, MD—Chair 


Surgery for Pleural Mesothelioma: Are We Closer to Personalized Selection? 

Michele Carbone, MD, PhD 

University of Hawaii Cancer Center 

New Concepts in Mesothelial Carcinogenesis: Fibers, Inflammation, and Hotspots 

Anna K. Nowak, MBBS, PhD 

Sir Charles Gairdner Hospital 

Mesothelioma Chemotherapy, Biologic Therapy, and Immunotherapy: Pathways, Personalized 

Prediction, and Results to Date 

350

9:45 AM - 11:00 AM 


Follicular Lymphoma Case Studies: Blending the Art and Science of Medicine 

Together (M14)—Ticketed Session 




Myron Stefan Czuczman, MD 



Preparing for New Cultural Competence Requirements for Oncology 

Professionals (M21)—Ticketed Session 



Track(s): Ethics, Patient and Survivor Care, Professional Development 

Marjorie Kagawa-Singer, PhD, MA, MN, RN 

University of California, Los Angeles School of Public Health 

Understanding the Notion of Culture and Its Influence on Health-related Matters and Oncology 

Practice 

Antonella Surbone, MD, PhD 

New York University 

Meeting Oncologists’ Educational Needs in Preparation for the Joint Commission 2012 

Standards in Cultural Competence 

351 

MONDAY

MONDAY 


9:45 AM - 11:15 AM 


ASCO/American Association for Cancer Research (AACR) Joint Session: 

Telomeres and Telomerase in Cancer 



Track(s): Tumor Biology, Special Session 




Elizabeth H. Blackburn, PhD—Co-Chair 


Telomeres and Telomerase in Human Cancer and in the Aging Population 

Steven Artandi, MD, PhD 

Stanford School of Medicine 

Functional Involvement of Telomerase in New Cellular Functions 

Kathy Miller, MD 


The Clinical Perspective: Where We Are Going with Telomeres and Telomerase 

352

11:30 AM - 12:45 PM 


Advances in Risk Stratification, Biology, and Treatment of Neuroblastoma 




Susan Lerner Cohn, MD—Chair 

University of Chicago Pritzker School of Medicine 

Refining Risk Classification for Children with Neuroblastoma 

Meredith Irwin, MD 


What Role Do “Stem Cells” Play in Neuroblastoma? 

Rochelle Bagatell, MD 


Advances in the Treatment of Patients with High-risk Neuroblastoma 

Considerations When Standard of Care Fails (eQuestions Session) 



Track(s): Ethics, Clinical Trials, Practice Management and Information Technology 

Jeffrey M. Peppercorn, MD, MPH—Chair 


Options to Consider in Developing an Individualized Approach to Advanced Cancer Care 

Robert L. Erwin, MS 

Marti Nelson Cancer Foundation 

A Patient’s Perspective on Options to Consider When Standard Interventions Are Exhausted 

Thomas J. Smith, MD 


How and Why to Discuss Palliative Care with Patients with Advanced Cancer after Standard 

Care Has Failed 

Management of Complications and Palliative Care for Patients with Brain 

Tumors 



Track(s): Central Nervous System Tumors, Patient and Survivor Care 

Denise Correa, PhD—Chair 


An Overview of Cognitive Functions in Patients with Brain Tumors 

Nigel Key, MD 


Approach to Thromboembolic Disease in Patients with Brain Tumors 

Alan D. Valentine, MD 


Pharmacologic Stimulant Therapies, Such As Methylphenidate and Modafinil 


353 

MONDAY

MONDAY 


The Art and Business of a Successful Early Clinical Trials Program: Academic, 

Private, and Industry Perspectives 



Track(s): Developmental Therapeutics, Clinical Trials 

Chris H. M. Takimoto, MD, PhD—Chair 


Industry Considerations for Phase I Partnerships 

Patricia LoRusso, DO 


Academic Phase I Program: If You Build It, Will They Come? 

Lee S. Rosen, MD 

Premiere Oncology 

A Private Model for a Successful Phase I Clinical Trials Program 

354

11:30 AM - 12:45 PM 


Melanoma FISH ’n’ Chips (M15)—Ticketed Session 




Hensin Tsao, MD 


Multidisciplinary Treatment of Skull Base Tumors (M22)—Ticketed Session 




Francis P. Worden, MD 

University of Michigan Cancer Center 

Chemotherapy for Skull Base Maligancies 

Ehab Y. Hanna, MD 


Surgical Management of Base of Skull Tumors 


355 

MONDAY

MONDAY 


1:00 PM - 4:00 PM 




CME credit: 3 


Tyler J. Curiel, MD—Chair 


1:00 PM Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in 

combination with poly-ICLC in patients with recurrent malignant glioma. 


H. Okada, P. Kalinski, A. H. Mintz, J. A. Engh, L. H. Butterfield, R. H. Hamilton, 

D. M. Potter, A. M. Salazar, F. S. Lieberman 

1:15 PM Effect of denileukin diftitox on serum GM-CSF and clinical responses in 

stage IV melanoma. (Abstract #2507) 

J. Chesney, M. Rasku, A. C. Klarer, D. M. Miller, S. Telang 

1:30 PM Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by 

Newcastle disease virus. (Abstract #2508) 

J. Nesselhut, D. Marx, D. Lorenzen, N. Cillien, W. Goebel, R. Y. Chang, 

W. Brockmann, J. Peters, K. Nesselhut, F. Fändrich, T. Nesselhut 

Discussion 

1:45 PM Tyler J. Curiel, MD (Abstract #2506–2508) 


2:00 PM Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary 


J. Brody, R. Advani, W. Weng, D. Czerwinski, A. A. Alizadeh, H. E. Kohrt, 

R. Negrin, R. Levy 

2:15 PM Phase I clinical trial of cancer vaccine with five novel epitope peptides for 

patients with metastatic colorectal cancer (mCRC). (Abstract #2510) 

S. Hazama, M. Oka, K. Yoshida, T. Tsunoda, S. Yoshino, Y. Hinoda, Y. Nakamura 

2:30 PM The role of relative lymphocyte count as a new biomarker for the effect of 

catumaxomab on overall survival in patients with malignant ascites: Followup 

results from a phase ll/lll study. (Abstract #2512) 

M. M. Heiss, M. A. Ströhlein, C. Bokemeyer, D. Arnold, S. L. Parsons, M. G. Ott, 

E. Schulze, H. Lindhofer, D. Seimetz, M. Hennig 

Discussion 

2:45 PM Eduardo M. Sotomayor, MD (Abstracts #2509–2510, 2512) 


3:00 PM A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated 

peptide inhibitor of p53 ubiquitination in patients with metastatic refractory 


J. M. Richards, M. A. Warso, D. Mehta, K. Christov, C. M. Schaeffer, T. Yamada, 

C. W. Beattie, L. R. Bressler, T. K. Das Gupta 

3:15 PM Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment 

of patients with advanced pancreatic cancer, malignant melanoma, and 

colorectal carcinoma. (Abstract #2513) 

H. Oettle, A. Hilbig, T. Seufferlein, A. Tsianakas, T. Luger, R. M. Schmid, 

G. von Wichert, E. Endlicher, C. Garbe, K. K. Kaehler, A. Hauschild, A. Enk, 

P. Kiessling, S. Schmaus, H. Heinrichs, K. Schlingensiepen 

356


3:30 PM A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), 

pharmacodynamics (PD), and antitumor activity of the humanized 

monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with 

bevacizumab with or without paclitaxel in patients with advanced solid 


L. Naumovski, M. S. Gordon, P. N. Munster, P. Hegde, J. Fredrickson, S. Bai, 

R. P. Funke, I. Chang, G. S. Chandler, D. S. Chen, L. S. Rosen 

Discussion 

3:45 PM Padmanee Sharma, MD, PhD (Abstracts #2511–2514) 


357 

MONDAY

MONDAY 


1:00 PM - 4:00 PM 


Genitourinary (Prostate) Cancer 


CME credit: 3 


Joshi J. Alumkal, MD—Co-Chair 

Oregon Health & Science University 

Ajjai Shivaram Alva, MBBS, MS—Co-Chair 


1:00 PM Randomized, placebo-controlled, phase III trial of sunitinib in combination 

with prednisone (SU�P) versus prednisone (P) alone in men with 

progressive metastatic castration-resistant prostate cancer (mCRPC). 


M. D. Michaelson, Y. Ou, L. Sengeløv, F. Saad, N. Houede, P. J. Ostler, A. Stenzl, 

G. Daugaard, R. J. Jones, F. Laestadius, A. Bahl, D. E. Castellano, J. Gschwend, 

T. Maurina, D. Ye, I. Chen, S. Wang, E. C. Maneval, S. Oudard 

1:15 PM Cabozantinib (XL184) in metastatic castration-resistant prostate cancer 

(mCRPC): Results from a phase II randomized discontinuation trial. (Abstract 

#4516) 

M. Hussain, M. R. Smith, C. Sweeney, P. G. Corn, A. Elfiky, M. S. Gordon, 

N. B. Haas, A. L. Harzstark, R. Kurzrock, P. Lara Jr., C. Lin, A. Sella, E. J. Small, 

A. I. Spira, U. N. Vaishampayan, N. J. Vogelzang, C. Scheffold, M. D. Ballinger, 

F. Schimmoller, D. C. Smith 

1:30 PM Evaluation of circulating tumor cell (CTCs) enumeration as an efficacy 

response biomarker of overall survival (OS) in metastatic castration-resistant 

prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a 

randomized, double-blind, placebo-controlled, phase III study of abiraterone 

acetate (AA) plus low-dose prednisone (P) post docetaxel. (Abstract 

#LBA4517) 

H. I. Scher, G. Heller, A. Molina, T. S. Kheoh, G. Attard, J. Moreira, S. K. Sandhu, 

C. Parker, C. Logothetis, R. T. McCormack, K. Fizazi, A. Anand, D. C. Danila, 

M. Fleisher, D. Olmos, C. M. Haqq, J. S. De Bono 

Discussion 

1:45 PM Daniel J. George, MD (Abstracts #4515–LBA4517) 

Duke Cancer Institute 

2:00 PM Toward a rational strategy for prostate cancer screening based on long-term 

risk of prostate cancer metastases and death: Data from a large, unscreened, 

population-based cohort followed for up to 30 years. (Abstract #4512) 

H. Lilja, C. Savage, A. Gerdtsson, T. Bjork, J. Manjer, P. Nilsson, A. Dahlin, 

A. Bjartell, P. T. Scardino, D. Ulmert, A. J. Vickers 

2:15 PM Docetaxel-estramustine in high-risk localized prostate cancer: First results of 

the French Genitourinary Tumor Group phase III trial (GETUG 12). (Abstract 

#4513) 

K. Fizazi, F. Lesaunier, R. Delva, G. Gravis, F. Rolland, F. Priou, J. Ferrero, 

N. Houede, L. Mourey, C. Theodore, I. Krakowski, J. Berdah, M. Baciuchka, 

P. Kerbrat, J. Davin, J. Berille, M. Habibian, J. Ichante, A. Laplanche, S. Culine 

2:30 PM A phase III randomized trial of intermittent versus continuous androgen 

suppression for PSA progression after radical therapy (NCIC CTG 

PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013). 


J. M. Crook, C. J. O’Callaghan, K. Ding, G. Duncan, D. P. Dearnaley, C. S. Higano, 

E. M. Horwitz, E. Frymire, S. Malone, J. Chin, A. Nabid, P. R. Warde, T. B. Corbett, 

S. Angyalfi, S. L. Goldenberg, M. K. Gospodarowicz, F. Saad, J. P. Logue, 

P. F. Schellhammer, L. Klotz 

358


Discussion 

2:45 PM Joel B. Nelson, MD (Abstracts #4512–4514) 


3:00 PM Randomized phase III study of docetaxel with or without risedronate in 

patients with bone metastases from castration-resistant prostate cancer 

(CRPC): The Netherlands Prostate Study (NePro). (Abstract #4518) 

H. J. Meulenbeld, E. D. van Werkhoven, J. L. Coenen, G. Creemers, 

O. J. Loosveld, P. C. De Jong, A. J. Ten Tije, S. D. Fossa, M. Polee, 

W. R. Gerritsen, O. Dalesio, R. De Wit 

3:15 PM Effect of abiraterone acetate (AA) on pain control and skeletal-related events 

(SRE) in patients (pts) with metastatic castration-resistant prostate cancer 

(mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. 


C. Logothetis, J. S. De Bono, A. Molina, E. M. Basch, K. Fizazi, S. A. North, 

K. N. Chi, R. J. Jones, O. B. Goodman, P. N. Mainwaring, C. N. Sternberg, 

D. D. Gagnon, R. Dhawan, M. Rothman, Y. Hao, C. S. Liu, T. S. Kheoh, 

H. I. Scher, C. M. Haqq 

Discussion 

3:30 PM Michael J. Morris, MD (Abstracts #4518 and 4520) 


359 

MONDAY

MONDAY 


1:00 PM - 4:00 PM 




CME credit: 3 


Teresa Gilewski, MD—Chair 


1:00 PM Does circulating tumor necrosis factor (TNF) play a role in 

post-chemotherapy cerebral dysfunction in breast cancer survivors (BCS)? 


P. A. Ganz, S. A. Castellon, D. H. Silverman, L. Kwan, J. E. Bower, M. R. Irwin, 

S. W. Cole 

1:15 PM Effect of yoga on QOL, cortisol rhythym, and HRV for women with breast 

cancer undergoing radiotherapy. (Abstract #9009) 

L. Cohen, K. Chandwani, N. Raghuram, R. Haddad, G. H. Perkins, A. Spelman, 

R. Nagarathna, K. Johnson, A. Fortier, B. Arun, Q. Wei, C. Kirschbaum, 

H. Nagendra 

Discussion 

1:30 PM Karen Michelle Mustian, PhD, MPH (Abstracts #9008–9009) 


1:45 PM A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic 

acid to prevent platinum-induced polyneuropathy. (Abstract #9010) 

Y. Guo, J. L. Palmer, A. Forman, S. R. Dakhil, M. R. Velasco, M. Weiss, P. Gilman, 

G. M. Mills, S. J. Noga, C. Eng, M. J. Overman, M. Fisch 

2:00 PM A phase III study for prevention of delayed nausea: A University of Rochester 

CCOP study of 1,021 patients receiving chemotherapy. (Abstract #9012) 

G. R. Morrow, J. A. Roscoe, C. Heckler, S. R. Dakhil, J. L. Wade, 

J. P. Kuebler, S. G. Mohile, L. J. Peppone, M. C. Janelsins 

2:15 PM Phase III, double-blind, placebo-controlled, crossover study evaluating a 

5HT3 antagonist with dexamethasone with or without aprepitant in patients 

with germ cell tumor receiving 5-day cisplatin combination chemotherapy: A 

Hoosier Oncology Group (HOG) study. (Abstract #9013) 

M. J. Brames, J. Picus, M. Yu, E. L. Johnston, B. Bottema, C. E. Williams, 

L. H. Einhorn 

Discussion 

2:30 PM Debra L. Barton, PhD, AOCN, RN (Abstracts #9010–9013) 

Mayo Clinic 

2:45 PM The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention 

of venous thromboembolism (VTE) in cancer patients receiving 

chemotherapy: SAVE ONCO study. (Abstract #LBA9014) 

G. Agnelli, D. J. George, W. Fisher, A. K. Kakkar, M. R. Lassen, P. Mismetti, 

P. Mouret, U. Chaudhari, A. G. G. Turpie 

3:00 PM The evaluation of flaxseed for hot flashes: Results of a randomized, 

controlled trial, NCCTG study N08C7. (Abstract #CRA9015) 

S. Pruthi, R. Qin, S. A. Terstriep, H. Liu, C. L. Loprinzi, T. Shah, K. F. Tucker, 

S. R. Dakhil, M. J. Bury, R. L. Carolla, P. D. Steen, J. Vuky, D. L. Barton 

360


3:15 PM Does L-arginine/Korean ginseng/gingko biloba/damiana-based supplement 

improve the sexual function and quality of life of female cancer survivors? A 

randomized trial. (Abstract #9016) 

K. Greven, L. D. Case, L. R. Nycum, P. J. Zekan, D. D. Hurd, E. P. Balcueva, 

G. M. Mills, R. Zon, P. J. Flynn, D. Biggs, E. G. Shaw, Comprehensive Cancer 

Center of Wake Forest University CCOP Research Base 

Discussion 

3:30 PM Vered Stearns, MD (Abstracts #LBA9014–9016) 


361 

MONDAY

MONDAY 


1:00 PM - 5:00 PM 





Brd. 1A Use of a gene profile to identify molecular subtypes of breast cancer. 


W. Zwart, F. De Snoo, O. Krijgsman, P. Roepman, S. Tian, A. Glas, R. A. Bender, 

J. Carroll, R. Bernards 

Brd. 1B Use of insulin-like growth factor (IGF) pathway polymorphism IGF1R 

rs2016347 to predict tumor recurrence in estrogen receptor–positive breast 

cancer patients. (Abstract #538) 

T. Winder, G. Giamas, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, A. Gerger, 

M. J. Labonte, J. Stebbing, H. Lenz 

Brd. 1C Role of Ki67 labeling index (LI) in subdividing homogeneous ER-positive 

grading groups of early breast cancer (EBC) in distinct biologic entities. 


A. Ferro, M. Barbareschi, C. Eccher, A. Caldara, D. Aldovini, R. Triolo, L. Cuorvo, 

F. Berloffa, S. Brugnara, O. Caffo, M. di Pasquale, M. Frisinghelli, V. Murgia, 

B. Soini, F. Valduga, A. Veccia, E. Galligioni 

Brd. 1D Estrogen and vascular endothelial growth factor (VEGF): Their role in breast 

cancer (BC) carcinogenesis and disease progression in premenopause. 


F. Recchia, G. Candeloro, G. Desideri, S. Necozione, S. Rea 

Brd. 1E An evaluation of PI3K pathway activation on the efficacy of both trastuzumab 

and lapatinib. (Abstract #541) 

X. Hu, L. Wang, Q. Zhang, J. Zhang, H. Guo, S. Sun, B. Y. Wang, Z. Jia, Z. Shao, 

Z. Wang 

Brd. 1F Long-term results of the Toronto magnetic resonance imaging (MRI) breast 

surveillance study of women with BRCA1 or BRCA2 mutations. (Abstract 

#542) 

K. Passaperuma, D. B. Plewes, P. Causer, K. A. Hill, S. J. Messner, J. Wong, 

R. A. Jong, F. Wright, M. Yaffe, E. Ramsay, S. Balasingham, L. Verity, A. Eisen, 

B. Curpen, R. Shumak, S. Narod, E. Warner 

Brd. 1G Survival after brain metastases in Asian patients with HER2� breast cancer. 


Y. Yap, B. C. Devi, C. Khorprasert, G. H. Cornelio, N. Sutandyo, E. Yeoh, 

S. Landis, M. Kobayashi, H. Moon, J. Ro 

Brd. 2A A randomized, placebo-controlled phase II study of AMG 386 plus 

bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy 

in patients (pts) with HER2-negative, locally recurrent or metastatic breast 

cancer (LR/MBC). (Abstract #544) 

V. Dieras, J. Jassem, L. Y. Dirix, J. P. Guastalla, P. Bono, S. A. Hurvitz, 

A. Gonçalves, G. Romieu, S. A. Limentani, G. H. Jerusalem, 

K. Lakshmaiah, H. H. Roche, P. Sánchez-Rovira, T. Pienkowski, M. Seguí-Palmer, 

A. Li, Y. Sun, C. A. Pickett-Gies, H. Wildiers 

Brd. 2B Clinical significance of metastatic-tumor HER2 status in patients with 

HER2-positive primary breast cancer. (Abstract #545) 

N. Niikura, J. Liu, N. Hayashi, E. A. Mittendorf, Y. Gong, S. L. Palla, Y. Tokuda, 

A. M. Gonzalez-Angulo, G. N. Hortobagyi, N. T. Ueno 

Brd. 2C Prognosis in women with small (T1mic,T1a,T1b) node-negative operable 

breast cancer by immunohistochemically selected subtypes. (Abstract #546) 

G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, 

G. Pruneri, E. Montagna, S. Dellapasqua, M. Iorfida, A. Cardillo, P. Veronesi, 

A. Luini, M. Intra, O. D. Gentilini, E. Scarano, D. Pastrello, A. Goldhirsch, 

M. Colleoni 

362


Brd. 2D HLA-DRB1*07:01-DQA1*02:01 and UGT1A1*28 allele carriage in hepatic 

serious adverse event cases identified during lapatinib clinical trials. 


C. F. Spraggs, L. R. Budde, L. P. Briley, C. Cox, E. Rappold, G. Aktan, 

L. S. Williams, V. E. Mooser, L. R. Cardon 

Brd. 2E Correlation between miRNA and gene expression profiles and response to 

neoadjuvant chemotherapy in patients with locally advanced and 

inflammatory breast cancer. (Abstract #548) 

G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel, L. Kruper, H. Gao, G. Sun, 

J. H. Yim, A. Hurria, J. E. Mortimer, F. De Snoo, I. B. Paz, J. Rossi, E. Wang, 

P. Roepman, Y. Yen, L. van’t Veer, R. A. Bender 

Brd. 2F Results of a Belgian multicenter retrospective study to determine the 

incidence of HER2 gene amplification in patients scored as 

immunohistochemistry 0 or 1�. (Abstract #549) 

D. Larsimont, C. Colpaert, R. Salgado, N. Vermeesen, V. D’hondt, T. De Celle 

Brd. 2G Double-blind, placebo-controlled, multicentric randomized phase IIb 

neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, 

hormone receptor-positive operable breast cancer. (Abstract #550) 

P. F. Conte, V. Guarneri, D. G. Generali, A. Bottini, L. Bazzola, F. Piacentini, 

F. Artioli, K. Cagossi, G. Bisagni, M. Bagnalasta, E. Tagliafico, E. Barbieri, 

L. Cavanna, A. Ravaioli, R. D’Amico, R. Vicini, A. Frassoldati 

Brd. 3A T1abN0M0 HER2� invasive breast cancer recurrence: Population-based 

cohort of 17,000� consecutive breast cancers 2000–2006 at Kaiser 

Permanente, Northern California (KPNC). (Abstract #551) 

L. Fehrenbacher, P. Shiraz, M. Sattavat, A. Capra, C. Quesenberry, R. Fulton, 

L. A. Habel 

Brd. 3B Pharmacogenetic investigation of lapatinib-associated diarrhea in metastatic 

breast cancer clinical trials. (Abstract #552) 

L. P. Briley, M. Chiano, K. King, M. Casey, A. J. Preston, F. Sapunar, V. E. Mooser, 

L. R. Cardon, C. F. Spraggs 

Brd. 3C Efficacy results of node-negative HER2-amplified breast cancer subset from 

BCIRG 006 study: A phase III randomized trial comparing doxorubicin and 

cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and 

cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with 

docetaxel, carboplatin, and trastuzumab (TCH). (Abstract #553) 

V. Valero, D. J. Slamon, W. Eiermann, N. J. Robert, T. Pienkowski, M. Martin, 

J. R. Mackey, M. Lindsay, V. Bee-Munteanu, M. F. Press, G. Sauter, J. Crown 

Brd. 3D PAM50 intrinsic subtyping and pathological responses to neoadjuvant 

trastuzumab-based chemotherapy in HER2-positive breast cancer. (Abstract 

#554) 

P. Gomez Pardo, A. Prat, G. Bianchini, M. Pickl, A. Belousov, A. Koehler, 

V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, 

F. Vázquez-Mazón, L. Gianni, J. Baselga 

Brd. 3E A molecular portrait of circulating free DNA of patients with breast cancer: 

High resolution analysis using SNP 6.0 arrays. (Abstract #555) 

J. A. Shaw, K. Page, K. Blighe, N. Hava, D. Guttery, B. Ward, J. Brown, 

C. Ruangpratheep, R. Payne, C. Palmieri, S. Cleator, R. Walker, C. Coombes 

Brd. 3F Evaluation of the prognostic and predictive value of tumor-infiltrating 

lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) 

trial (BIG 2–98) of node-positive (N�) BC comparing the addition of docetaxel 

to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). (Abstract 

#556) 

S. Loi, R. Salgado, F. Piette, N. Sirtaine, F. Van Eenoo, R. Kammler, G. Rouas, 

P. A. Francis, J. Crown, B. Nordenskjold, J. Gutierrez, M. Andersson, M. M. Vila, 

R. Jakesz, G. Viale, E. M. Quinaux, A. Di Leo, S. Michiels, 

C. Sotiriou, M. J. Piccart-Gebhart 

363 

MONDAY

MONDAY 


Brd. 3G Treatment of small node-negative HER2� invasive breast carcinomas: 

Forty-month update of the joint Aerio/Remagus study. (Abstract #557) 

J. Wassermann, L. Albiges, M. J. Rodrigues, E. Brain, S. Delaloge, 

J. Guinebretiere, M. Mathieu, E. Guillot, A. Vincent-Salomon, P. H. Cottu, 

AERIO/REMAGUS 

Brd. 3H A study of the recurrence score by the 21-gene signature assay as a 

predictor of clinical response to neoadjuvant exemestane for 24 weeks in 

estrogen receptor–positive breast cancer. (Abstract #558) 

N. Masuda, M. Toi, T. Ueno, T. Yamanaka, S. Saji, K. Kuroi, N. Sato, H. Takei, 

Y. Yamamoto, S. Ohno, H. Yamashita, K. Hisamatsu, K. Aogi, H. Iwata, H. Sasano 

Brd. 4A A phase II clinical trial of drug withdrawal in women with progressive breast 

cancer while on aromatase inhibitor therapy. (Abstract #559) 

T. Cigler, M. J. Higgins, J. Szymonifka, A. H. Partridge, J. A. Ligibel, D. Finkelstein, 

S. E. Come, P. D. Ryan, P. E. Goss 

Brd. 4B Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for 

outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant 

chemotherapy in premenopausal women with early breast cancer. (Abstract 

#560) 

M. Basik, D. Keilty, O. Aleynikova, D. Tu, X. Li, L. E. Shepherd, V. Bramwell 

Brd. 4C A functional assay for the identification of DNA double strand break repair 

deficiency in heterozygous carriers of BRCA1/2 and RAD51C mutations. 


A. Becker, M. Graeser, C. Landwehr, T. Hilger, W. Baus, R. Weber, 

B. Wappenschmidt, R. Schmutzler 

Brd. 4D Association between endoxifen serum concentration and predicted CYP2D6 

phenotype in a prospective cohort of patients with early-stage breast cancer. 


V. O. Dezentje, J. den Hartigh, H. Guchelaar, T. Hessing, T. van der Straaten, 

J. M. Vletter - Bogaartz, R. Vree, E. Maartense, C. H. Smorenburg, H. Putter, 

A. Dieudonné, P. Neven, J. W. Nortier, H. Gelderblom 

Brd. 4E Elevated pretreatment serum CA9 (carbonic anhydrase 9) and correlation 

with progression-free and overall survival in trastuzumab-treated metastatic 


K. Leitzel, H. Hou, U. Anyanwu, V. Shrivastava, M. S. Evans, S. M. Ali, 

W. Koestler, E. Fuchs, F. J. Esteva, W. P. Carney, A. Lipton 

Brd. 4F Sequential administration of trastuzumab and a CD8 T cell-eliciting 

HER2/neu peptide vaccine in patients with breast cancer compared to 

trastuzumab alone. (Abstract #564) 

A. K. Sears, G. T. Clifton, R. Patil, N. M. Shumway, M. G. Carmichael, 

D. C. Van Echo, J. P. Holmes, S. Ponniah, E. A. Mittendorf, G. E. Peoples 

Brd. 4G Fc�-receptor IIa polymorphism and cardiotoxicity in patients with breast 

cancer treated with adjuvant trastuzumab. (Abstract #565) 

N. Cresti, D. Jamieson, M. W. Verrill, M. Pinkilgton, A. V. Boddy 

Brd. 4H Body mass index (BMI) and prognosis in women with metastatic breast 

cancer (MBC). (Abstract #566) 

A. Gennari, M. Puntoni, O. Nanni, P. F. Conte, D. Amadori, V. Lorusso, 

A. De Censi, M. Sormani, V. Guarneri, M. D’Amico, A. Gozza, P. Bruzzi 

Brd. 5A Standardized uptake value (SUV) by positron emission tomography/ 

computed tomography (PET/CT) as a prognostic variable in metastatic breast 


P. G. Morris, M. Fazio, K. L. Jhaveri, C. Serna-Tamayo, A. Eaton, S. Patil, 

G. Ulaner, J. Howard, S. M. Larson, C. Hudis, M. S. Jochelson, H. L. McArthur 

364


Brd. 5B Retreatment with trastuzumab (T)-based therapy in patients (pts) with 

HER2-positive (HER2�) metastatic breast cancer (MBC) resistant to lapatinib 

(L)-based therapy. (Abstract #568) 

S. Gori, F. Montemurro, S. Spazzapan, G. Metro, J. Foglietta, G. Bisagni, A. Ferzi, 

R. R. Silva, T. Gamucci, M. Clavarezza, L. Stocchi, A. Fabi, F. Cognetti, E. Torrisi, 

D. Crivellari 

Brd. 5C Post-operative complications in neoadjuvant treatment including 

bevacizumab for HER2 positive inflammatory breast cancer (IBC): Results 

from a phase II prospective trial. (Abstract #569^) 

R. Rouzier, E. Lambaudie, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, 

J. Gligorov, F. Lerebours, H. Roche, D. Pau, P. Viens, R. J. Salmon 

Brd. 5D Phase I study of lapatinib (L) and temozolomide (T) combination for the 

treatment of progressive brain metastases (BM) in HER2-positive metastatic 

breast cancer patients (Pts) (LAPTEM, LAP 111172). (Abstract #570) 

E. De Azambuja, M. Lemort, J. R. Rossari, C. Moulin, A. Buttice, V. D’hondt, 

F. Lebrun, Y. Lalami, F. Cardoso, C. Sotiriou, T. Gil, D. Devriendt, W. Marinus, 

M. Paesmans, M. Piccart, A. Awada 

Brd. 5E First results of a phase II study of bevacizumab in combination with 

trastuzumab and capecitabine as first-line treatment of HER2� LA/MBC. 


S. Tjulandin, A. Makhson, J. Gligorov, M. Lichinitser, A. Lluch, V. Semiglazov, 

N. Scotto, L. Mitchell, M. Martin 

Brd. 5F Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) 

with HER2-positive (HER2�) metastatic breast cancer (MBC). (Abstract #572) 

A. Berghoff, R. Bartsch, Z. Bago-Horvath, P. C. Dubsky, M. Rudas, U. Pluschnig, 

C. Wiltschke, M. Gnant, G. G. Steger, C. Zielinski 

Brd. 5G The role of the genomic breast cancer index in predicting pathological 

complete response in breast cancer patients treated with neoadjuvant 

anthracycline plus taxane. (Abstract #573) 

M. Mathieu, N. C. Kesty, H. Li, V. Scott, V. Marty, P. Viehl, J. Delacruz, 

S. Delaloge, C. Schnabel, M. G. Erlander, F. Andre 

Brd. 5H Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: 

A phase I study in patients with metastatic HER2-amplified breast cancer. 


D. Gajria, T. A. King, H. Pannu, R. Sakr, A. D. Seidman, A. Syldor, S. Patil, 

M. Maybody, L. Norton, N. Rosen, C. Hudis, S. Chandarlapaty 

Brd. 6A Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2positive 


I. Lang, R. Bell, F. Feng, R. I. Lopez, J. Jassem, V. Semiglazov, N. Al-Sakaff, 

E. Carreras, J. Chang 

Brd. 6B Are St. Gallen endocrine response classes predictive for recurrence rates 

over time? (Abstract #576) 

R. H. Koornstra, K. J. Beelen, A. Vincent, P. J. van Diest, S. C. Linn 

Brd. 6C Measurement of baseline serum SDF-1 levels as a predictive biomarker for 

outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue 

in postmenopausal breast cancer. (Abstract #577) 

A. Aguilar-Mahecha, M. Basik, J. W. Chapman, K. Jahan, S. Hassan, L. Zhu, 

C. F. Wilson, K. I. Pritchard, L. E. Shepherd, M. N. Pollak 

Brd. 6D Discordance in estrogen receptor status between primary, metastatic, and 

second primary breast cancers: Impact of misclassification. (Abstract #578) 

D. Huo, J. Liu, O. I. Olopade 

Brd. 6E Long-term cardiac safety and outcomes of dose dense (dd) doxorubicin and 

cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with 

and without lapatinib (L) in patients (pts) with early breast cancer (BC). 


C. T. Dang, P. G. Morris, S. Patil, C. Chen, A. Abbruzzi, R. Lehman, R. Steingart, 

L. Norton, C. Hudis 

365 

MONDAY

MONDAY 


Brd. 6F Predicting invasive disease at excision of ductal carcinoma in situ in core 

biopsies: A predictive model. (Abstract #580) 

C. McGathey, A. Fought, D. Scholtens, S. A. Khan 

Brd. 6G Salvage stereotactic radiosurgery (SRS) after previous whole brain radiation 

therapy (WBRT) for breast cancer brain metastases: Outcomes and 

prognostic factors including tumor phenotype. (Abstract #581) 

P. J. Kelly, N. U. Lin, E. B. Claus, S. E. Weiss, B. M. Alexander 

Brd. 6H Mutations of the catalytic domain of PI3 kinase and correlation with clinical 

outcome in trastuzumab-treated metastatic breast cancer (MBC). (Abstract 

#582) 

J. W. Cook, E. Paxinos, L. J. Goodman, S. M. Ali, K. Leitzel, W. Koestler, A. Rivera, 

J. M. Weidler, W. Huang, J. Sperinde, S. J. Williams, M. Bates, A. Lipton 

Brd. 7A Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer 

cells. (Abstract #583) 

M. McDermott, B. Browne, J. Crown, N. O’Brien, D. J. Slamon, N. O’Donovan 

Brd. 7B The effect of a tamoxifen dose increase from 20 mg to 40 mg in patients with 

at least one inactive CYP2D6 variant allele and/or concomitant use of a 

CYP2D6 inhibitor. (Abstract #584) 

M. E. Welzen, V. O. Dezentje, R. H. van Schaik, E. P. Colbers, H. Guchelaar, 

J. den Hartigh, D. M. Burger, H. Van Laarhoven 

Brd. 7C Discordance in pathology report after central pathology review in early 

breast cancer and its impact on treatment choice. (Abstract #585) 

L. Orlando, G. Viale, P. Schiavone, P. Fedele, A. Nacci, P. Rizzo, N. Calvani, 

F. Sponziello, C. Chetri, E. Mazzoni, M. D’ Amico, A. Marino, M. Cinefra, S. Cinieri 

Brd. 7D Quantitative measurements of p95HER2 (p95) and total HER2 (H2T) protein 

expression in patients with trastuzumab-treated, metastatic breast cancer 

(MBC): Independent confirmation of clinical cutoffs. (Abstract #586) 

W. Biernat, R. Duchnowska, B. Szostakiewicz, J. Sperinde, M. Haddad, A. Paquet, 

Y. Lie, J. Weidler, W. Huang, J. Winslow, T. Jankowski, B. Arlukowicz-Czartoryska, 

P. J. Wysocki, M. Foszczynska-Kloda, B. Radecka, M. M. Litwiniuk, S. Debska, 

M. Bates, J. Jassem 

Brd. 7E IGF1R and phosphorylated IGF1R in HER2-positive breast cancer. (Abstract 

#587) 

B. Browne, J. Crown, A. J. Eustace, S. Kennedy, N. O’Brien, A. Larkin, J. Ballot, 

T. Mahgoub, Z. Qadir, F. Sclafani, S. F. Madden, M. J. Kennedy, M. J. Duffy, 

N. O’Donovan 

Brd. 7F Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP 

B-43. (Abstract #588) 

K. P. Siziopikou, M. A. Cobleigh, S. J. Anderson, T. B. Julian, D. W. Arthur, 

P. Zheng, E. P. Mamounas, E. R. Pajon, R. J. Behrens, L. Chu, N. C. Leasure, 

J. N. Atkins, J. Polikoff, T. E. Seay, W. J. McCaskill-Stevens, R. Rabinovitch, 

N. Wolmark 

Brd. 7G Bcl2 expression and prediction of outcomes to anthracycline-based 

neoadjuvant chemotherapy in ER-positive breast cancer and to 

nonanthracycline adjuvant therapy. (Abstract #589) 

P. D. Dickinson, T. M. Abdel-Fatah, A. R. Green, P. Moseley, J. S. Reis-Filho, 

I. O. Ellis, S. Chan 

Brd. 7H Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination 

with trastuzumab in patients (pts) with pretreated, locally advanced or 

metastatic HER2-positive breast cancer. (Abstract #590) 

S. Modi, C. Saura, C. A. Henderson, N. U. Lin, R. L. Mahtani, J. Goddard, 

E. Rodenas, J. O’Shaughnessy, J. Baselga 

Brd. 8A Strategies for protecting patients from anthracyline-induced cardiac 

dysfunction. (Abstract #591) 

A. K. Dickey, C. Geisberg, Y. R. Su, I. A. Mayer, J. A. Means-Powell, C. Silverstein, 

X. Peng, D. Freehardt, B. White, D. J. Lenihan, D. Sawyer 

366


Brd. 8B Using the 21-gene recurrence score and the recently developed recurrence 

score clinical pathologic to assess recurrence risk in patients with nodenegative, 

ER-positive early-stage breast cancer receiving aromatase inhibitor 

treatment alone. (Abstract #592) 

M. Crager, G. Tang, S. Shak 

Brd. 8C Population-based comparison of breast cancer screening and treatment 

utilization by remoteness of residence in British Columbia. (Abstract #593) 

R. A. Olson, N. R. Caron, I. Olivotto, C. Speers, A. Davidson, S. K. Chia, 

A. Coldman, A. Nichol, C. Bajdik, S. Tyldesley 

Brd. 8D Association between bone turnover markers and skeletal-related events in 

patients with breast cancer and bone metastases on treatment with 

bisphosphonates (ZOMAR study results at 9 months of follow-up). (Abstract 

#594) 

A. Barnadas, C. De la Piedra, C. Crespo, P. Gomez Pardo, L. Calvo, E. G. Calvo, 

M. Ruiz-Borrego, J. Rifa, L. Manso, A. Anton, M. Codes, M. Margeli, A. Murias, 

J. Salvador, M. Seguí-Palmer, A. De Juan, J. Gavila, D. Perez, M. Luque, 

I. Tusquets 

Brd. 8E Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor 

of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. 


A. Wenners, K. Mehta, S. Loibl, H. Park, N. Arnold, S. Hamann, J. Weimer, 

B. Ataseven, C. Schem, F. Khandan, C. Thomssen, W. Jonat, H. Holzhausen, 

G. Von Minckwitz, C. Denkert, M. Bauer 

Brd. 8F An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal 

(PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs). 


D. W. Cescon, M. Ennis, P. A. Ganz, S. Beddows, F. Z. Stanczyk, S. S. Sridhar, 

P. J. Goodwin 

Brd. 8G Systemic therapy and overall survival (OS) in patients (pts) with brain 

metastases from HER2-positive (HER2�) metastatic breast cancer (MBC). 


R. Bartsch, A. Berghoff, U. Pluschnig, Z. Bago-Horvath, P. C. Dubsky, 

A. Rottenfusser, C. Wenzel, M. Rudas, F. Fitzal, K. Dieckmann, M. Gnant, 

C. Zielinski, G. G. Steger 

Brd. 8H A phase II study of lonafarnib (LF) in patients with locally advanced and 

metastatic breast cancer (MBC): Hoosier Oncology Group BRE07–126. 


B. Leyland-Jones, K. Miller, P. Silverman, C. Shen, C. E. Williams, T. Breen, 

G. W. Sledge Jr. 

Brd. 9A The expression of GATA-3 and FOXA1 in breast cancer: The biomarkers of 

hormonal sensitivity in luminal type tumors. (Abstract #599) 

Y. Hisamatsu, E. Tokunaga, S. Akiyoshi, S. Okada, N. Yamashita, E. Oki, 

M. Morita, Y. Kakeji, Y. Maehara 

Brd. 9B Does metformin use influence outcome in diabetic women with invasive 

breast cancer? (Abstract #600) 

B. Oppong, S. Oskar, M. Stempel, A. Eaton, S. Patil, T. A. King 

Brd. 9C The prognostic value of the cocaine and amphetamine-regulated transcript 

(CART) in breast cancer (BC). (Abstract #601) 

D. P. O’Connor, D. J. Brennan, H. Laursen, S. F. McGee, S. McCarthy, 

R. Zagozdzon, E. Rexhepaj, A. Culhane, F. M. Martin, M. J. Duffy, G. Landberg, 

L. Ryden, S. M. Hewitt, M. J. Kuhar, R. Bernards, R. C. Millikan, J. Crown, 

K. Jirstrom, W. M. Gallagher 

Brd. 9D Costs associated with chemotherapy-related complications in the treatment 

of metastatic breast cancer in a real-world setting. (Abstract #602) 

A. Guerin, D. Lalla, D. Latremouille-Viau, A. P. Yu, E. Q. Wu, M. Brammer, 

S. A. Hurvitz 

367 

MONDAY

MONDAY 


Brd. 9E High false-negative rate of HER2 qRT-PCR of the Oncotype DX test: An 

independent quality assurance study. (Abstract #603) 

D. J. Dabbs, M. Klein, S. Mohsin, R. R. Tubbs, R. Bhargava 

Brd. 9F Association of GP88 (progranulin) tumor expression with decreased diseasefree 

and overall survivals in patients with breast cancer with estrogen 

receptor-positive invasive ductal carcinoma. (Abstract #604) 

G. Serrero, D. M. Hawkins, B. Yue, O. B. Ioffe, P. Bejarano, J. T. Phillips, 

J. F. Head, R. L. Elliott, A. K. Godwin, J. Weaver, W. Kim, S. Kamimura 

Brd. 9G A semiphysiologic population pharmacokinetic/pharmacodynamic (PK/PD) 

model of thrombocytopenia (TCP) characterizing the effect of trastuzumab- 

DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC. 


B. C. Bender, F. Schaedeli Stark, A. Joshi, Y. Chu, H. S. Rugo, I. E. Krop, 

S. Girish, M. Gupta 

Brd. 9H Genomic grade: Feasibility in routine practice and influence on treatment 

decision in early breast cancer. (Abstract #606) 

O. Metzger, A. Catteau, S. Michiels, M. E. Buyse, K. V. Saini, V. Fasolo, J. Canon, 

P. Delrée, M. Coibion, V. Jossa, J. Kains, D. Larsimont, V. Richard, D. Faverly, 

N. Cornez, P. Vuylsteke, B. Vanderschueren, 

H. P. Peyro Saint Paul, M. J. Piccart-Gebhart, C. Sotiriou 

Brd. 10A Adjuvant treatment strategy and results in small breast cancer tumors (pT1) 

with HER2 overexpression. (Abstract #607) 

A. Hinke, P. Dall, G. Lenzen, C. Schumacher, D. Rezek, N. Gazawi, A. Ammon, 

F. G. Foerster, F. Beldermann, U. Cirrincione, J. Wilke 

Brd. 10B Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase 

inhibitors (AIs) in metastatic breast cancer (mBC) patients. (Abstract #608) 

M. Arnedos, R. Ferraldeschi, R. A’Hern, K. Hadfield, S. Roberts, S. Drury, 

A. Howell, D. G. Evans, A. M. Wardley, I. E. Smith, W. G. Newman, M. Dowsett 

Brd. 10C High recurrence risk in pT1bc HER2-positive, triple-negative, node-negative 

early breast cancer patients. (Abstract #609) 

A. Vaccaro, F. Ciancola, L. Pizzuti, I. Sperduti, L. Moscetti, P. Vici, F. Longo, 

E. Ruggeri, M. Di Seri, M. Giampaolo, T. Gamucci 

Brd. 10D Circulating tumor cells as a prognostic factor independent of obesity in 

metastatic breast cancer patients. (Abstract #610) 

M. Giuliano, A. Giordano, A. Patt, L. Hsu, R. H. Alvarez, N. T. Ueno, V. Valero, 

G. N. Hortobagyi, M. Cristofanilli, J. M. Reuben 

Brd. 10E Determining agreement between immunohistochemistry and RT-qPCR for 

standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical 


P. S. Bernard, C. Davis, B. Munarriz, I. J. Stijleman, M. Ruiz-Borrego, M. T. Ebbert, 

A. Rodriguez-Lescure, R. R. Bastien, C. Crespo, C. M. Perou, C. Rodriguez, 

F. I. Aranda, V. Furió, I. Alvarez, M. Seguí, E. Alba, A. Anton, E. M. Carrasco, 

R. Caballero, M. Martin 

Brd. 10F Evaluation of HER2 gene status by qPCR in breast cancer samples with 

nonconclusive FISH. (Abstract #612) 

V. Koudelakova, J. Berkovcova, R. Trojanec, L. Radova, J. Ehrmann, Z. Kolar, 

B. Melichar, M. Hajduch 

Brd. 10G Detection of HER2 status of circulating tumor cells and disseminated tumor 

cells using a microfluidic platform (cell enrichment and extraction 

technology, CEE). (Abstract #613) 

S. Krishnamurthy, F. Z. Bischoff, J. A. Mayer, K. Wong, S. Mikolajczyk, T. Pham, 

H. M. Kuerer, A. Lodhi, A. Bhattacharyya, C. Hall, A. Lucci Jr. 

Brd. 10H Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment 

in postmenopausal women with advanced breast cancer (ABC). (Abstract 

#614) 

L. Chow, B. Xu, L. Y. Dirix, B. Moy, E. Leip, N. Bardy-Bouxin, L. Duvillie, 

T. Sarosiek 

368


Brd. 11A Predictive value of sphingosine kinase-1 expression in neoadjuvant 

treatment of breast cancer. (Abstract #615) 

E. Ruckhäberle, T. Karn, C. Denkert, S. Loibl, B. Ataseven, T. Reimer, 

L. C. Hanker, N. Sänger, U. Holtrich, M. Kaufmann, S. Darb-Esfahani, 

V. Nekljudova, G. Von Minckwitz 

Brd. 11B Prognostic impact of phosphorylated HER2 in HER2-positive primary breast 

cancer using reverse-phase protein array. (Abstract #616) 

N. Hayashi, T. Iwamoto, A. M. Gonzalez-Angulo, J. Ferrer-Lozano, A. Lluch, 

N. Niikura, C. Bartholomeusz, S. Nakamura, G. N. Hortobagyi, N. T. Ueno 

Brd. 11C Long-term survival in patients with HER2-positive metastatic breast cancer 

treated with trastuzumab as first-line therapy: Seven-year follow-up of the 

French observational hermine study. (Abstract #617) 

E. Antoine, F. Dalenc, C. Hebert, P. Rivera, G. Romieu, N. Varoqueaux, 

J. P. Guastalla, M. Namer 

Brd. 11D A multicenter phase II trial of neoadjuvant letrozole plus low dose 

cyclophosphamide in postmenopausal patients with estrogen receptorpositive 

breast cancer (JBCRG07): The efficacy and its correlation with 

circulating endothelial cells. (Abstract #618) 

T. Ueno, N. Masuda, S. Kamigaki, T. Morimoto, S. Nakamura, K. Kuroi, H. Iwata, 

S. Ohno, S. Tanaka, M. Toi 

Brd. 11E Protection of adjuvant trastuzumab in sites of early relapses. (Abstract #619) 

M. Campiglio, E. Tagliabue, A. Balsari, R. Bufalino, E. Ferri, L. Gianni, S. Ménard, 

on the behalf of GHEA group 

Brd. 11F Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African 

American (AA) and Caucasian (C) patients with hormone receptor-positive 

(HR�), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer 

(BC). (Abstract #620) 

K. B. Kabaker, J. Canar, R. D. Rao, M. A. Cobleigh 

Brd. 11G Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally 

advanced breast cancer: A Sarah Cannon Research Institute phase II trial. 


J. D. Zubkus, D. B. Daniel, J. F. Eakle, R. G. Bechhold, M. Shastry, P. S. Tucker, 

H. A. Burris III, J. D. Hainsworth, D. A. Yardley 

Brd. 11H Hormonal therapy versus chemotherapy as first-line line treatment for 

estrogen receptor–positive metastatic breast cancer (MBC) patients. 


T. Y. Chang, C. Lin, Y. Lu, S. H. Kuo, S. Huang, C. Huang, A. Cheng 

Brd. 12A Epithelial-mesenchymal transition in patients with HER2� metastatic breast 


A. Giordano, M. Mego, B. Lee, S. Anfossi, C. A. Parker, R. H. Alvarez, N. T. Ueno, 

V. Valero, M. Cristofanilli, J. M. Reuben 

Brd. 12B Treatment patterns in patients with HER2-positive early-stage breast cancer 

(ESBC) receiving adjuvant treatment with a trastuzumab containing regimen. 


K. Sail, D. Lalla, M. Brammer, M. Halm, D. A. Patt 

Brd. 12C Evaluating utilization characteristics for the Oncotype DX recurrence score 

in early-stage breast cancer. (Abstract #625) 

C. Chen, D. A. Patt, D. R. Kazzaz, J. Shankleton, M. T. Forsyth, R. Ganesh 

Brd. 12D BRCA� test result impact and timing on surgical treatment decisions for 

patients with breast cancer. (Abstract #626) 

K. M. Doll, C. B. Weldon, J. R. Trosman, H. H. Wetzel, T. J. Fallen, 

W. J. Gradishar, J. C. Schink 

Brd. 12E Weekly paclitaxel versus standard 3-week schedule in patients with 


I. I. Abdel Halim, M.El Ashri, W. El Sadda, Clinical Oncology and Nuclear Medicine 

Department 

369 

MONDAY

MONDAY 


Brd. 12F Proteomics-based characterization of potential biomarkers in tamoxifen 

resistance in breast cancer. (Abstract #628) 

B. C. Sanchez, H. Johansson, J. Forshed, O. Stål, J. Lehtio, B. K. Linderholm 

Brd. 12G Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An 

observational study of Turkish Oncology Group. (Abstract #629) 

F. Icli, K. Altundag, U. Coskun, S. Paydas, G. Basaran, P. Saip, G. G. Dogu, 

Y. Eralp, R. Uslu, A. Sevinc, H. Onur, N. M. Mandel, C. Sezgin, M. Altinbas, 

N. Guler, A. Isikdogan, E. Gokmen, K. Uygun, Z. Ustuner, A. Yaren, 

Turkish Oncology Group 

Brd. 12H Final analysis of dose density with zoledronic acid treatment in metastatic 

breast cancer patients: ZARAS study. (Abstract #630) 

J. De la Haba, A. Rodriguez-Lescure, J. Baena, J. Martin Liberal, S. Morales, 

J. Chacon, J. Lopez, I. Fernandez, D. Aguiar, A. Garcia-Palomo, R. Llorente, 

J. Barea, E. Alvarez, I. Blancas, Y. Fernandez, P. Sanchez Rovira, G. Vinyes 

Brd. 13A Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal 

(postm) women with hormone receptor–positive (HR�) HER2-negative 

(HER2–) advanced breast cancer (ABC). (Abstract #631) 

B. Moy, F. Lebrun, M. Bellet, L. Chow, I. Lang, B. Xu, R. A. Badwe, 

D. L. Hershman, E. Leip, N. Bardy-Bouxin, L. Duvillie, P. Neven 

Brd. 13B Evaluation of recurrence score and traditional clinicopathologic 

assessments in a large ER-positive, lymph node-negative patient cohort. 


N. Liebermann, F. L. Baehner, L. Soussan-Gutman, S. Klang, C. Yoshizawa, 

S. Shak, N. Siegelmann-Danieli 

Brd. 13C Pharmacokinetic and pathophysiological covariates influencing treatment 

outcomes with t-DM1 in patients with HER2-positive metastatic breast cancer 

(MBC). (Abstract #633) 

M. Gupta, P. LoRusso, H. A. Burris III, B. Wang, A. Joshi, Y. B. Tong, Y. Chu, 

S. Girish 

Brd. 13D RAD51 and brain metastases (BM) in patients (pts) with HER2� breast 


R. Duchnowska, J. Jassem, E. Szutowicz, W. Biernat, T. Jankowski, W. Och, 

R. Staszkiewicz, M. Chudzik, W. Rogowski, N. Flores, S. Woditschka, L. Li, 

C. Goswami, M. A. Thorat, Y. Gokmen-Polar, G. W. Sledge Jr., P. S. Steeg, 

D. Palmieri, S. S. Badve 

Brd. 13E Effect of a soy isoflavone intervention on estrogen-related gene expression 

in the healthy high risk breast. (Abstract #635) 

S. A. Khan, O. Lee, I. B. Helenowski, D. Ivancic, B. Jovanovic, R. C. Bergan 

Brd. 13F A randomized trial of exercise versus control for musculoskeletal symptoms 

from adjuvant anastrozole (A) for postmenopausal early breast cancer 

(PEBC). (Abstract #636) 

C. A. Lohrisch, D. McKenzie, P. Truong, D. Jesperson, K. A. Gelmon, S. Premji, 

H. F. Kennecke 

370

1:00 PM - 5:00 PM 






Brd. 14A Predictors of recurrence among patients with breast cancer who achieved a 

pathological complete response (pCR) after neoadjuvant systemic 


M. Chavez-MacGregor, X. Lei, J. K. Litton, A. Melhem, E. A. Mittendorf, 

F. Meric-Bernstam, A. A. Sahin, V. Valero, G. N. Hortobagyi, A. M. Gonzalez- 

Angulo 

Brd. 14B Radiation and survival in women over 70 with T1 N0 M0 ER-negative breast 

cancer from 1990–2007: A population-based analysis. (Abstract #1037) 

A. P. Wojcieszynski, X. Shen, M. V. Mishra, P. R. Anne, T. N. Showalter 

Brd. 14C Systematic comparison of tumor phenotype in primary breast cancer versus 

corresponding lymph nodes and disease recurrences: Results of the 

retrospective multicenter WSG/DETECT PriMet study. (Abstract #1038) 

C. Liedtke, O. Gluz, F. Heitz, R. Wuerstlein, R. E. Kates, J. Tio, U. Nitz, A. Du Bois, 

T. N. Fehm, N. Harbeck 

Brd. 14D Incidence of brain metastases as a first site of recurrence among women 

with triple receptor-negative breast cancer. (Abstract #1039) 

X. Lei, S. S. Dawood, J. K. Litton, T. A. Buchholz, G. N. Hortobagyi, 


Brd. 14E Multi-institutional evaluation of sentinel lymph node (SLN) examination by 

one-step nucleic acid amplification (OSNA) assay in breast cancer: 

Performance of metastases detection and prediction of additional nonsentinel 

lymph node (non-SLN) involvement. (Abstract #1040) 

N. Sato, K. Honma, S. Noguchi, Y. Tamaki, H. Tsuda, T. Kinoshita, S. Nakamura, 

K. Tsugawa, K. Suzuki, M. Tsujimoto, K. Yoshidome, F. Akiyama, T. Iwase, 

D. Takabatake, R. Nishimura, K. Taniyama, H. Kato, S. Umemura, Y. Tokuda, 

T. Kamio, OSNA Researchers’ Group 

Brd. 14F A multicenter randomized phase III trial of nonpegylated liposomeencapsulated 

doxorubicin citrate plus cyclophosphamide (MC) versus 

liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line 

in locally advanced (LABC) or metastatic breast cancer (MBC). (Abstract 

#1041) 

V. Lorusso, F. Giotta, R. Bordonaro, E. Maiello, S. Del Prete, V. Gebbia, 

G. Filippelli, S. Pisconti, S. Cinieri, S. Romito, F. Riccardi, G. Cairo, V. E. Chiuri, 

M. Ciccarese, R. Forcignano, L. Petrucelli, V. Saracino, G. Colucci 

Brd. 14G Pathologic characteristics of second breast cancers (SBC) among women 

previously treated for ductal carcinoma in situ (DCIS) with breast 

conservation. (Abstract #1042) 

N. D. Arvold, R. S. Punglia, M. E. Hughes, W. Jiang, S. B. Edge, S. H. Javid, 

C. Laronga, J. C. Niland, R. L. Theriault, J. C. Weeks, Y. Wong, S. J. Lee, 

M. J. Hassett 

Brd. 14H Identification of pathogenic macrophages in breast cancer as markers of 

tumor aggressiveness. (Abstract #1043) 

R. Mukhtar, A. P. Moore, V. Tandon, O. Nseyo, A. Au, F. L. Baehner, C. A. Adisa, 

N. Eleweke, O. I. Olopade, D. H. Moore, M. Campbell, L. Esserman 

Brd. 15A Capecitabine (Cap) combined with bevacizumab (Bev) with or without 

vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety 

results from the randomized CARIN trial. (Abstract #1044) 

S. Hegewisch-Becker, C. A. Lerchenmuller, A. Welt, T. Decker, M. Just, 

C. Steffens, A. Hipper, N. Marschner 

371 

MONDAY

MONDAY 


Brd. 15B Close or positive margins after mastectomy in early-stage, node-negative 

breast cancer: The association of tumor grade with local recurrence. 


J. R. Hastings, S. Iganej, D. M. Bugoci, C. Huang 

Brd. 15C Prevalence and impact of correlative science in breast cancer phase II trials. 


T. Zhang, E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, J. M. Peppercorn 

Brd. 15D Overall survival effect of lower chemotherapy dosing in extremely obese 

(BMI > 35) patients with breast cancer based on adjusted BSA. (Abstract 

#1047) 

P. Sharma, T. A. Samuel, J. C. Wells, E. Mebel, J. T. French, J. A. Crozier, 

S. W. Looney 

Brd. 15E Long-term survival after high-dose chemotherapy followed by peripheral 

stem cell rescue for high-risk locally advanced/inflammatory and metastatic 


A. M. Vanderwalde, W. Ye, P. H. Frankel, D. G. Asuncion, R. D. Pezner, T. H. Luu, 

S. Shibata, L. A. Leong, K. A. Margolin, R. Morgan, M. Koczywas, W. A. Chow, 

P. Twardowski, J. Y. Wong, J. H. Doroshow, S. J. Forman, G. Somlo 

Brd. 15F Can preoperative dynamic contrast enhanced breast MRI predict extensive 

occult axillary lymph node metastases in patients with positive sentinel node 

biopsy? (Abstract #1049) 

C. R. Loiselle, P. R. Eby, J. N. Kim, K. E. Calhoun, K. H. Allison, V. K. Gadi, 

S. Peacock, B. Storer, D. A. Mankoff, S. C. Partridge, C. D. Lehman 

Brd. 15G Risk and health care costs of chemotherapy-induced neutropenic 

complications in women with metastatic breast cancer. (Abstract #1050) 

D. Weycker, J. Edelsberg, A. Kartashov, R. Barron, G. H. Lyman 

Brd. 15H A randomized phase II study of pemetrexed-carboplatin and gemcitabinevinorelbine 

in patients with anthracycline- and taxane-pretreated advanced 


D. Amadori, I. La Torre, E. M. Carrasco, S. Roesel, R. Labianca, V. Moreau- 

Donnet, D. Desaiah, M. Martin 

Brd. 16A Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment 

in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast 


R. Borson, W. G. Harker, J. E. Reeves, D. Drosick, J. T. Beck, S. J. Hager, 

W. L. Horvath, J. Bromund, H. Zeigler, D. Tai, D. A. Yardley 

Brd. 16B Locoregional recurrence after breast cancer surgery: A meta-analysis by 

molecular subtype. (Abstract #1053) 

A. J. Lowery, M. R. Kell, R. W. Glynn, M. J. Kerin, K. J. Sweeney 

Brd. 16C The effect of tetrathiomolybdate on endothelial progenitor cells in patients at 

high risk for breast cancer recurrence. (Abstract #1054) 

S. Jain, J. A. Cohen, M. M. Ward, J. O’Loughlin, M. Boeck, N. Wiener, E. Chuang, 

T. Cigler, A. Moore, D. Donovan, C. Lam, M. E. Cobham, S. E. Schneider, 

P. J. Christos, M. E. Lane, R. Baergen, V. Mittal, S. Rafii, L. T. Vahdat 

Brd. 16D Rechallenging taxanes in recurrent breast cancer in patients treated with 

(neo)adjuvant taxane-based therapy. (Abstract #1055) 

X. Guo, S. Loibl, M. Untch, V. Möbus, K. Schwedler, P. A. Fasching, J. Barinoff, 

F. Holms, C. Thomssen, D. Zahm, R. Kreienberg, M. Hauschild, H. Eidtmann, 

S. Tauchert, K. Mehta, G. Von Minckwitz, German Breast Group and AGO-B 

Study Group 

Brd. 16E Prognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN) 

breast cancer (BC). (Abstract #1056) 

E. Munzone, E. Botteri, A. Sciandivasci, G. Curigliano, F. Nole, N. Rotmensz, 

M. Colleoni, G. Viale, A. Esposito, A. Luini, M. G. Mastropasqua, A. Goldhirsch 

Brd. 16F Clinical outcome of triple-negative primary breast cancer in older women: 

Comparison with their younger counterparts. (Abstract #1057) 

K. Cheung, B. M. Syed, A. R. Green, D. A. Morgan, I. O. Ellis 

372


Brd. 16G 0 6 -methylguanine-DNA methyltransferase (MGMT) promoter gene 

methylation in triple-negative breast cancer (TNBC). (Abstract #1058) 

C. Fumagalli, P. Possanzini, M. O. Biasi, M. Manzotti, M. Barberis, B. Bonanni, 

M. Barile, I. Feroce, G. Viale 

Brd. 16H SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) 

plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women 

with primary breast cancer (BC; GBG 45). (Abstract #1059) 

B. Conrad, N. Harbeck, G. Von Minckwitz, M. Wuellner, M. Warm, K. Schwedler, 

B. Gerber, I. Schrader, H. Eidtmann, K. Mehta, S. Loibl, GBG/AGO-B Study 

Groups 

Brd. 17A The relationship between age and survival outcomes for eribulin in 


C. Twelves, L. T. Vahdat, J. Cortes, J. Wanders, C. E. Dutcus, S. Seegobin, 

H. B. Muss 

Brd. 17B PARP1 in triple-negative breast cancer: Expression and therapeutic 

potential. (Abstract #1061) 

M. B. Cotter, A. Pierce, P. M. McGowan, S. F. Madden, L. Flanagan, C. Quinn, 

D. Evoy, J. Crown, E. McDermott, M. J. Duffy 

Brd. 17C ADAMs as new therapeutic targets for triple-negative breast cancer. 


M. Mullooly, P. M. McGowan, S. Sukor, S. F. Madden, E. McDermott, J. Crown, 

N. O’Donovan, M. J. Duffy 

Brd. 17D Triple-negative breast cancer: The effect of guideline adherent adjuvant 

treatment on the cumulative survival. A retrospective multicenter cohort 

study of 3,658 patients. (Abstract #1063) 

L. Schwentner, R. Wolters, M. Wischnewsky, R. Kreienberg, A. Wöckel 

Brd. 17E Effect of neoadjuvant ixabepilone (Ixa) on cell cycle genes and on tumorinitiating 

cell (TIC) signature in breast cancer (BC). (Abstract #1064) 

H. Chang, C. E. Horak, P. Mukhopadhyay, C. Lowery, J. Baselga, J. A. Sparano 

Brd. 17F Breast conservation therapy: The influence of molecules and margins. 


S. Demirci, G. Broadwater, L. B. Marks, R. Clough, L. R. Prosnitz 

Brd. 17G Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2negative 

breast cancer with exploratory oncotype DX assessments: A Sarah 

Cannon Research Institute phase II trial. (Abstract #1066) 

N. W. Peacock, D. A. Yardley, C. B. Hendricks, S. Y. Huh, S. L. Ketchum, C. Chao, 

C. Yoshizawa, M. Shastry, B. Strike, H. A. Burris III, J. D. Hainsworth 

Brd. 17H A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixeddose 

capecitabine in metastatic breast cancer (MBC). (Abstract #1067) 

R. M. Connolly, M. A. Rudek, H. L. Mc Leod, E. Garrett-Mayer, S. C. Jeter, 

L. A. Wright, V. Stearns, D. K. Armstrong, J. H. Fetting, S. P. Watkins, 

N. E. Davidson, A. C. Wolff 

Brd. 18A The effects of acellular dermal matrix in expander-implant breast 

reconstruction after total skin-sparing mastectomy: Results of a prospective 

practice improvement study. (Abstract #1068) 

A. W. Peled, R. D. Foster, E. Garwood, C. A. Ewing, M. Alvarado, E. S. Hwang, 

L. Esserman 

Brd. 18B Effect of estrogen receptor beta expression (ERße) in triple-negative breast 

cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. (Abstract 

#1069) 

F. Heitz, B. Sinn, S. Loibl, A. Du Bois, C. Jackisch, S. Kuemmel, C. Denkert, 

J. Barinoff, K. Mehta, G. Von Minckwitz, on behalf the GeparTrio trialists 

Brd. 18C The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an 

anthracycline-free chemotherapy regimen in the adjuvant treatment of 

HER2/neu-negative breast cancer. (Abstract #1070) 

U. Ortmann, J. Salmen, P. G. Hepp, M. W. Beckmann, T. N. Fehm, H. Hindenburg, 

W. Lichtenegger, B. K. Rack, A. Schneeweiss, W. Janni 

373 

MONDAY

MONDAY 


Brd. 18D Clinical significance of time to relapse and the distinction between breast 

cancer recurrences and new primary tumors. (Abstract #1071) 

A. Patt, T. Li, M. Cristofanilli, G. M. Freedman, E. R. Sigurdson, R. J. Bleicher 

Brd. 18E Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy or 

external beam radiotherapy for early breast cancer: An objective assessment 

of patients from a randomized controlled trial. (Abstract #1072) 

M. R. Keshtgar, N. R. Williams, T. Corica, C. Saunders, D. J. Joseph, M. Bulsara, 

on behalf of the TARGIT Trialists’ Group 

Brd. 18F Breast cancer carcinomatous meningitis: Differences in survival depending 

on biological subtype, performance status, and treatment methods. (Abstract 

#1073) 

A. M. Niwinska, H. Rudnicka, M. Murawska 

Brd. 18G Clinical risk factors as predictors of potential cardiotoxicity related to 

nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer 

(MBC) patients (pts) previously treated with conventional anthracyclines (A). 


E. Muñoz-Couselo, J. M. Perez-Garcia, C. Saura, M. Vidal, M. Bellet Ezquerra, 

J. Balmaña, B. Graña, P. Gomez Pardo, L. De Mattos-Arruda, S. Di Cosimo, 

S. Muñoz, O. Vidal, B. Garcia Castro, R. Espallargas, V. Esteban, J. Tabernero, 

J. Baselga, J. Cortes 

Brd. 18H Phase II trial report of the new preoperative chemotherapy with S-1 and 

docetaxel for advanced breast cancer. (Abstract #1075) 

M. Nakagawa, M. Aoyama, M. Ikeda, M. Morimoto, H. Takechi, Y. Kawakami, 

K. Kennzaki, A. Tangoku 

Brd. 19A Breast cancer subtypes and outcome after local and regional relapse. 


E. Montagna, V. Bagnardi, N. Rotmensz, G. Viale, G. Renne, G. Cancello, 

A. Balduzzi, E. Scarano, D. Pastrello, P. Veronesi, A. Luini, S. Zurrida, S. Monti, 

M. G. Mastropasqua, L. Bottiglieri, A. Goldhirsch, M. Colleoni 

Brd. 19B Is E-cadherin a useful surrogate marker to predict chemosensitivity of 

chemotherapy for triple-negative breast cancer? (Abstract #1077) 

S. Kashiwagi, M. Yashiro, T. Takashima, N. Aomatsu, H. Kawajiri, N. Onoda, 

B. Nakata, T. Ishikawa, K. Hirakawa 

Brd. 19C Survival of triple-negative and HER2-positive breast cancer by AJCC stage. 


V. Caggiano, K. Bauer, C. Parise 

Brd. 19D Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel 

(Pac): An observational study in 786 patients (pts) with HER2-negative 

metastatic breast cancer (mBC). (Abstract #1079) 

P. Klare, F. G. Foerster, M. Geberth, A. Schneeweiss, H. Tesch, S. Kuemmel, 

C. Schumacher, W. Hollburg, U. Soeling, M. Schmidt 

Brd. 19E Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC). 


N. Harbeck, M. Kaufmann, F. Siedentopf, P. Dalivoust, M. Debled, N. J. Robert, 

J. O’Shaughnessy 

Brd. 19F Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway 

alterations in metastatic triple-negative breast cancer (mTNBC). (Abstract 

#1081) 

M. Oliveira, L. De Mattos-Arruda, G. Sánchez-Ollé, B. Graña, J. Cortes, 

J. M. Perez-Garcia, E. Muñoz-Consuelo, M. Vidal, M. Bellet, S. Di Cosimo, 

P. Gomez Pardo, J. Rodon Ahnert, J. Hernandez-Losa, A. Vivancos, L. Prudkin, 

C. Aura, V. Serra, J. Baselga, J. Tabernero, C. Saura 

Brd. 19G Roles of miRNAs in breast cancer stem cells, drug sensitivity, and 

spontaneous metastases in orthotopic human-in-mouse models. (Abstract 

#1082) 

H. Liu, J. Bockhorn, R. Dalton, M. Dolan, C. M. Perou, O. I. Olopade, M. F. Clarke, 

G. Greene 

374


Brd. 19H Efficacy and safety of ixabepilone plus capecitabine in elderly patients with 

anthracycline- and taxane-pretreated metastatic breast cancer. (Abstract 

#1083) 

L. T. Vahdat, E. Vrdoljak, H. Gomez, R. K. Li, E. Thomas, L. D. Bosserman, 

J. A. Sparano, J. Baselga, P. Mukhopadhyay, V. Valero 

Brd. 20A Adjuvant chemotherapy in American and Italian patients with BRCA1/2associated 


A. Cappetta, R. Nanda, C. Liao, D. Huo, L. F. Chen, G. Artioli, V. Zagonel, 

O. I. Olopade 

Brd. 20B Modeling the risk of secondary lung malignancy in patients treated with 

breast radiation therapy. (Abstract #1085) 

J. Ng, I. Shuryak, A. Xu, I. Deutsch, R. J. Burri, D. J. Brenner 

Brd. 20C Utility of breast MRI for patients with breast cancer scheduled for breast 

conserving surgery. (Abstract #1086) 

H. Shin, W. Han, H. Moon, C. Yom, S. Ahn, H. Kim, D. Noh 

Brd. 20D Comparison of lesion size between preoperative imaging and postoperative 

histopathology in unifocal breast cancer. (Abstract #1087) 

C. R. Abraham, B. Whiteside, M. Schuster, D. Jones, J. Pollard, L. MacFarlan, 

K. Hena, M. A. Hena 

Brd. 20E Repeat use of chemotherapy in metastatic breast cancer. (Abstract #1088) 

A. Im, A. Brufsky, J. G. Reeder, M. Q. Rosenzweig, S. Y. Jung 

Brd. 20F Prognostic impact on FOXP3 expression in triple-negative breast cancer 

(TNBC). (Abstract #1089) 

S. Lee, Y. Park, E. Cho, Y. Ham, J. Seo, J. Ahn, Y. Im 

Brd. 20G Platinum-based chemotherapy in triple-negative breast cancer. (Abstract 

#1090) 

C. Villarreal-Garza, M. Clemons, F. Kassam, K. Enright, S. Verma, J. A. Myers, 

R. A. Dent 

Brd. 20H Is there any utility to frozen section or immunohistochemistry examination of 

the sentinel lymph node (SLN) in patients with ductal carcinoma in situ 

(DCIS)? (Abstract #1091) 

U. K. Ballehaninna, A. R. Reeves, R. S. Chamberlain 

Brd. 21A Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic 

breast cancer: Results of a phase I study. (Abstract #1092) 

E. L. Mayer, M. E. Scheulen, J. Beckman, H. Richly, A. Poli, P. Bhargava, 

A. Duarte, M. M. Cotreau, A. L. Strahs, M. N. Dickler 

Brd. 21B Incidence of anthracycline-induced cardiotoxicity in patients with breast 

cancer: A single center’s experience. (Abstract #1093) 

O. Nadeem, C. Rauwerdink, V. L. Beggs, D. D. Parr, A. T. Kono, G. N. Schwartz 

Brd. 21C Sunitinib as adjuvant therapy for women with early-stage breast cancer and 

disseminated tumor cells in bone marrow. (Abstract #1094) 

J. Li, M. E. Melisko, P. N. Munster, M. Pelayo, M. M. Moasser, A. J. Chien, J. Scott, 

L. Esserman, J. W. Park, H. S. Rugo 

Brd. 21E Prevalence of synchronous metastases of breast cancer depends both on 

tumor subtypes and tumor burden. (Abstract #1096) 

C. Boutros, C. Mazouni, M. Saghatchian, J. Domont, C. Balleyguier, C. Bourgier, 

M. Mathieu, M. Spielmann, S. Delaloge 

Brd. 21F Prognostic index for patients with brain metastases from breast cancer: A 

validation and refinement of the breast-specific graded prognostic 

assessment (GPA) index. (Abstract #1097) 

H. Ahn, S. Lee, J. Sohn, S. Park, Y. Ham, J. Seo, E. Cho, D. Nam, J. Lee, D. Choi, 

W. Park, S. Huh, Y. Park, J. Ahn, Y. Im 

Brd. 21G Basoluminal and luminal phenotypes in triple-negative breast cancer: 

Immunohistochemical profiling and survival. (Abstract #1098) 

H. Sinn, Z. Elsawaf, J. L. Bermejo, S. Aulmann, J. Rom, A. Schneeweiss 

375 

MONDAY

MONDAY 


Brd. 21H Outcomes of children exposed to chemotherapy in utero for breast cancer. 


J. K. Litton, S. Hodge, D. Mattair, M. M. Ramirez, P. H. Morrow, 

A. M. Gonzalez-Angulo, C. M. Barnett, G. N. Hortobagyi, R. L. Theriault 

Brd. 22A Reduction of serum VEGF and IL-6 levels in patients with metastatic breast 

cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF 

synthesis, and aromatase inhibitors. (Abstract #1100) 

M. N. Dickler, B. P. Schneider, M. Volm, J. L. Speyer, Y. Novik, L. A. Callahan, 

C. H. Darby, J. Barth, G. L. Elfring, A. Ogden, A. Tiersten 

Brd. 22B Febrile neutropenia rates during docetaxel and cyclophosphamide (TC) 

adjuvant therapy in early breast cancer (EBC). (Abstract #1101) 

D. Kotasek 

Brd. 22C Magnetic resonance imaging (MRI) as compared to mammogram (MMG) in 

the evaluation of size, number of lesions, and nodal positivity in breast 

cancer (BrCa). (Abstract #1102) 

A. Korant, M. Kanaan, S. Sirop, H. Nuthakki, L. Lawrence, R. Hicks, D. Strahle, 

S. Nagpal, D. Wiese, S. Saha 

Brd. 22D TITAN: Ixabepilone versus weekly paclitaxel following 

doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triplenegative 

breast cancer (TNBC): Preliminary toxicity of a Sarah Cannon 

Research Institute phase III trial. (Abstract #1103) 

D. A. Yardley, J. D. Hainsworth, W. N. Harwin, S. A. Goble, B. R. Daniel, 

M. A. Ackerman, D. Shipley, D. R. Drosick, S. E. Hanson, P. L. Griner, 

H. A. Burris III 

Brd. 22E Increasing use of mastectomy with immediate reconstruction and 

contralateral prophylactic mastectomy in breast conservation candidates: A 

14-year report from a comprehensive cancer center. (Abstract #1104) 

A. E. Dragun, J. Pan, E. C. Riley, B. B. Kruse, M. R. Wilson, S. Rai, D. Jain 

Brd. 22F Are we improving the outcomes of metastatic breast cancer (MBC)? A single 

academic institution experience. (Abstract #1105) 

A. Florescu, S. Giilck, C. Victor, U. Zurawska, D. A. Baribeau, S. Verma 

Brd. 22G Alterations in breast cancer resistance protein in human placentas exposed 

to chemotherapy. (Abstract #1106) 

M. G. Holland, A. McCampbell, J. K. Litton, R. L. Theriault, M. M. Ramirez 

Brd. 22H Oral etoposide monotherapy for Chinese patients with metastatic breast 

cancer: Efficacy and tolerance regardless of heavy prior therapy. (Abstract 

#1107) 

P. Yuan, B. Xu, F. Ma, J. Wang, Y. Fan 

Brd. 23A Comparison of indocyanine green (ICG) fluorescence imaging plus blue dye 

and blue dye alone in sentinel node navigation surgery (SNNS) for breast 


A. Hirano, T. Shimizu, M. Kamimura, K. Ogura, N. Kim, Y. Setoguchi, F. Okubo, 

H. Inoue, R. Miyamoto, J. Kinoshita, K. Ogawa 

Brd. 23B Clinical outcome of triple-negative breast cancer with BRCA mutation in the 

context of dose-dense and or metronomic chemotherapy. (Abstract #1109) 

R. S. Mehta, C. Liu 

Brd. 23C Primary systemic therapy with metronomic doxorubicin, cyclophosphamide, 

and capecitabine in locally advanced and metastatic triple-negative breast 


M. Skrypnikova, M. Frolova, E. Ignatova, I. Pokataev, M. Stenina, S. Tjulandin 

Brd. 23D Prediction of the nonsentinel node metastasis in patients who received 

neoadjuvant chemotherapy for clinically axillary lymph node metastasis. 


S. Lee, S. Y. Jung, S. W. Kim, H. S. Kang, I. Park, K. S. Lee, J. Ro, K. Ko, Y. Kwon, 

K. Shin, S. Kim 

376


Brd. 23E First line with bevacizumab in combination with paclitaxel (P) and 

gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS 


J. Salvador, A. Jaen, E. Ciruelos, M. Codes, M. Gil, A. Murias, A. Galan, 

J. De la Haba, C. Jara, J. L. Bayo, J. Baena, J. Casal, J. Mel, I. Blancas, 

E. Gonzalez, D. Perez, L. Manso 

Brd. 23F Paclitaxel-carboplatin (P-C) regimen for metastatic breast cancer (MBC): 

Single-institution retrospective evaluation. (Abstract #1113) 

M. Zambetti, G. Goisis, A. Moliterni, A. Marchianò, D. Scaramuzza, M. Carcangiu, 

G. Saibene, G. Mariani, G. V. Bianchi, P. Valagussa, L. Gianni 

Brd. 23G Poly (ADP-ribose) polymerase-1 (PARP) expression in triple-negative breast 


P. Possanzini, M. O. Biasi, C. Fumagalli, M. Barberis, M. Barile, B. Bonanni, 

G. Viale 

Brd. 23H Lymphocyte infiltration (LI) and immunohistochemistry (IHC) classification 

of metastatic breast cancer (MBC) correlation with medical survival. 


C. S. Yau, A. R. Trumbly, C. O. Ruud, V. O. Speight, C. Chisholm, J. Song 

Brd. 24A Amrubicin as second- or third-line treatment for patients with HER2-negative 

metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I 


J. H. Barton, K. C. Shih, E. Raefsky, D. W. Haines III, B. Strike, J. D. Hainsworth, 

H. A. Burris III, D. A. Yardley 

Brd. 24B Body mass index in breast cancer subtypes. (Abstract #1117) 

I. Petekkaya, C. Arslan, E. Dogan, M. Solak, Ö. Keskin, N. Kertmen, Y. Y. Ozisik, 

K. Altundag 

Brd. 24C Final results from randomized phase II trial of preoperative docetaxel (D) and 

capecitabine (C) given sequentially or concurrently for HER2-negative breast 


A. B. Zelnak, S. Harichand-Herdt, T. M. Styblo, M. Rizzo, S. G. Gabram, 

H. L. Bumpers, R. C. Hermann, J. Srinivasiah, F. M. Schnell, R. O’Regan 

Brd. 24D Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel 

(wPac) for HER2-negative metastatic breast cancer (MBC): Results of a 

Japanese phase II study (n�120). (Abstract #1119) 

Y. Ito, K. Aogi, N. Masuda, S. Ohno, T. Oda, H. Iwata, M. Kashiwaba, Y. Fujiwara, 

S. Kamigaki, T. Ueno, S. Takashima 

Brd. 24E Oral paricalcitol (19-nor-1,25-Dihydroxyvitamn D2) in women with metastatic 

breast cancer receiving taxanes or ixabepilone: A feasibility trial. (Abstract 

#1120) 

J. Lawrence, J. Lovelace, S. A. Akman, S. A. Melin, L. D. Case, G. Schwartz 

Brd. 24F What is the survival length from the late lines of treatment in metastatic 

breast cancer? (Abstract #1121) 

M. Mouret-Reynier, E. Planchat, E. Thivat, C. Abrial, C. Pomel, P. Dubray- 

Longeras, H. Devaud, B. Nayl, A. Dillies, Q. Wang-Lopez, P. J. Chollet, H. Cure, 

J. Nabholtz, X. Durando 

Brd. 24G Validation study on the clinical usefulness of the ICG fluorescence method 

for detecting sentinel lymph node in early-stage breast cancer in comparison 

with the dye method. (Abstract #1122) 

T. Sugie, T. Sawada, N. Tagaya, T. Kinoshita, K. Yamagami, H. Suwa, 

K. Yoshimura, M. Sumi, M. Toi 

Brd. 24H Association of BRCA1 promoter methylation in triple-negative breast cancer 

(TNBC) with resistance to standard anthracyline-based adjuvant 


P. Sharma, B. F. Kimler, Y. A. Park, S. R. Stecklein, Q. J. Khan, B. K. Petroff, 

O. W. Tawfik, R. A. Jensen 

377 

MONDAY

MONDAY 


Brd. 25A A multidisciplinary protocol for planned skin-preserving delayed breast 

reconstruction for patients with locally advanced breast cancer requiring 

postmastectomy radiation therapy: Three-year follow-up. (Abstract #1124) 

S. J. Kronowitz, W. Tereffe, K. Hunt, H. M. Kuerer, V. Valero, G. L. Robb, L. Feng, 

T. A. Buchholz 

Brd. 25B Final results of a phase II trial of trabectedin (T) in triple-negative, HER2positive 

and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) 

patients (pts). (Abstract #1125) 

K. L. Tedesco, J. L. Blum, A. Goncalves, J. Lubinski, C. R. Osborne, P. Lardelli, 

J. C. Tercero, A. Florez, F. A. Holmes, S. Delaloge 

Brd. 25C Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and 

bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): 

NCCTG N0735. (Abstract #1126) 

D. W. Northfelt, A. C. Dueck, T. P. Flynn, P. J. Zander, P. J. Stella, M. Melnik, 

E. S. Pavey, E. A. Perez 

Brd. 26A Retrospective analysis of the effect on overall-survival of radiotherapy and 

chemotherapy sequence as treatment for primary breast cancer. (Abstract 

#1127) 

E. H. Gort, S. G. Elias, O. Visser, P. H. Elkhuizen, S. C. Linn 

Brd. 26B The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in 

breast cancer (BC): A systematic review and meta-analysis. (Abstract #1128) 

J. J. Biagi, M. Raphael, W. D. King, W. Kong, C. M. Booth, W. J. Mackillop 

Brd. 26C The other triple-negative breast cancer: Immunohistochemical and 

clinicopathological characterization of the claudin-low subtype. (Abstract 

#1129) 

D. Voduc, M. Cheang, A. Prat, X. He, S. Tyldesley, J. Snider, K. DeSchryver, 

S. Davies, M. J. Ellis, C. M. Perou, T. O. Nielsen 

Brd. 27A Effect of body mass index on survival outcome among women with earlystage, 

triple-negative breast cancer. (Abstract #1130) 

S. S. Dawood, X. Lei, J. K. Litton, T. A. Buchholz, G. N. Hortobagyi, 


Brd. 27B Significantly different costs of adjuvant chemotherapy regimens in the 

United States. (Abstract #1131) 

R. G. Chellappah, P. Ravdin 

Brd. 27C Neoadjuvant rh-endostatin, docetaxel, and epirubicin for breast cancer: 

Efficacy and safety in a prospective, randomized, phase II study. (Abstract 

#1132) 

L. Wang, J. Chen, Q. Yao Sr., J. Zhang, T. Wang, H. Wang, X. Zhou, Y. Huan, 

J. Wang 

Brd. 28A Neoadjuvant chemotherapy (NACT) in hormonal receptor-positive (HR�)or 

triple-negative (TN), operable breast cancer (BC): A randomized study 

comparing standard to response–adapted sequence. (Abstract #1133) 

H. Cure, Q. Wang-Lopez, M. Mouret-Reynier, X. Durando, C. Jouannaud, 

J. Charpentier, J. Eymard, P. J. Chollet, C. Garbar, E. Brabencova, I. Raoelfils, 

F. Penault-Llorca, J. Nabholtz 

Brd. 28B Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with 

prophylactic pegfilgrastim in patients with breast cancer: A retrospective 


N. Ngamphaiboon, P. P. Advani, T. L. O’Connor, F. O. Ademuyiwa, E. G. Levine, 

G. Riebandt, E. B. Kossoff 

Brd. 28C Phase II trial, open, single arm: Cisplatin combined with paclitaxel and 

doxorubicin in operable or locally advanced, triple-negative breast cancer. 


A. Alvarado Miranda, F. Lara Medina, C. Arce, N. Castañeda-Soto, 

C. Cano Blanco, J. Aguilar Ponce, E. Bargallo Rocha, V. Perez-Sanchez 

378

1:00 PM - 5:00 PM 






Brd. 29A Correlation of RASGRP1:APTX expression assay with response to tipifarnib 

plus etoposide in elderly patients with newly diagnosed AML. (Abstract 

#6534) 

T. I. Vener, C. Derecho, S. Galkin, J. Greer, M. J. Levis, C. D. Gocke, S. Malek, 

J. F. Palma, M. Raponi, Y. Wang, J. J. Wright, J. E. Karp 

Brd. 29B Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid 

leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or 

nilotinib (NIL). (Abstract #6535) 

T. H. Brummendorf, J. E. Cortes, H. Kantarjian, C. Gambacorti-Passerini, 

M. Baccarani, D. Kim, A. Zaritskey, J. Navarro, A. Rapoport, P. E. Dorlhiac-Llacer, 

J. Milone, M. Zanichelli, N. Besson, E. Leip, V. Kelly, H. J. Khoury 

Brd. 29C Tyrosine kinase inhibitors in BCR/ABL positive ALL . (Abstract #6536) 

A. T. Lopez-Enriquez 

Brd. 30A A phase II study with decitabine, low dose cytarabine, and G-CSF priming in 

high-risk myelodysplastic syndromes, refractory/relapsed acute 

myelogenous leukemia, or acute myeloid leukemia in patients with 

significant comorbidities. (Abstract #6537) 

J. Butera, E. Winer, C. Wang, J. J. Castillo, A. G. Thomas, H. Safran, A. E. Mega, 

G. A. Colvin, B. Rathore, P. J. Quesenberry, Brown Oncology Group 

Brd. 30B Serum galactomannan (GM) assay for invasive aspergillosis (IA) in acute 

leukemia (AL) and hematopoietic stem cell transplantation (HSCT). (Abstract 

#6538) 

I. Ghosh, V. Raina, L. Kumar, A. Sharma, S. Bakhshi, S. Iqbal 

Brd. 30C Etoposide and cytarabine as an effective and safe cytoreductive regimen for 

relapsed or refractory acute myeloid leukemia. (Abstract #6539) 

G. Nair, R. Karmali, S. A. Gregory, J. M. Shammo, H. C. Fung, A. Jimenez, 

P. Venugopal, M. L. Larson 

Brd. 31A Successful autologous hematopoietic stem cell (AHSC) mobilization with 

salvage etoposide (VP16)-ifosfamide-platinum (VIP) followed by high-dose 

chemotherapy (HDC) and AHSC transplantation (AHSCT) in relapsed 

malignancies: preliminary single center experience. (Abstract #6540) 

C. Kosmas, A. Athanasopoulos, P. Politis, T. Papachrysanthou, T. Daladimos, 

A. Papadaki, E. Panagiotidi, D. Moschovis, N. Ziras, A. Karabelis, N. Mylonakis 

Brd. 31B Results of employing a plerixafor dosing algorithm to mobilize hematopoietic 

stem cells in patients with multiple myeloma and lymphoma. (Abstract #6541) 

T. Bechtel, Y. A. Efebera, S. M. Devine, P. Elder 

Brd. 31C A meta-analysis of the complete remission ratio with replaced or refractory 

acute promyelocytic leukemia. (Abstract #6542) 

B. Jiang, Q. Gong, H. Watanabe, S. Zhu, J. Xie, Y. Ohashi 

Brd. 31D Prevention of mucositis with KGF in patients undergoing allogeneic stem cell 

transplantation. (Abstract #6543) 

J. D. Goldberg, J. Zheng, H. Castro-Malaspina, A. A. Jakubowski, G. Heller, 

M. R. Van Den Brink, M. Perales 

Brd. 31E FLT3 positive acute myeloid leukemia: Does timed sequential induction 

therapy influence outcome? (Abstract #6544) 

D. Rifai, M. L. Larson, M. C. Keller, P. Venugopal 

Brd. 31F High-dose melphalan on day 2 versus 1 before autologous stem cell 

transplantation for multiple myeloma. (Abstract #6545) 

K. Rakszawski, J. J. Drabick, N. G. Dolloff, J. M. Sivik, J. Malysz, D. Claxton, 

W. C. Ehmann, W. B. Rybka, G. Talamo 

379 

MONDAY

MONDAY 


Brd. 31G Targeting multiple signal pathways simultaneously might provide effective 

therapeutic strategies in acute myeloid leukemia . (Abstract #6546) 

H. Liu, E. Diaz-Flores, X. Poire, G. Koval, G. Malnassy, M. M. Le Beau, 

K. Shannon, O. Odenike, W. Stock 

Brd. 31H Immunosupressive properties of human placenta-derived mesenchymal 

stem cells on control of acute graft-versus-host disease in mice. (Abstract 

#6547) 

M. Jang, S. Oh, H. Kim, H. Shin, G. Kim, S. Chong, D. Oh, H. Chung 

Brd. 32A Second cancers after hematopoietic stem cell transplantation with total body 

irradiation conditioning regimen in hematologic disorders. (Abstract #6548) 

J. Kim, M. Chung, J. Lee, B. Choi, S. Chung 

Brd. 32B Study of oral clofarabine plus low-dose cytarabine in previously treated AML 

and high-risk MDS patients at least 60 years of age. (Abstract #6549) 

K. M. Smith, E. Estey, J. M. Pagel 

Brd. 32C Long-term follow-up results of imatinib mesylate therapy in chronic phase 

chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure. 


J. Shan, S. M. O’Brien, G. Garcia-Manero, S. Faderl, F. Ravandi, E. Jabbour, 

J. E. Cortes, H. Kantarjian 

Brd. 32D Population pharmacokinetic modelling of decitabine in patients with 

myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). 


B. Mistry, L. Gibiansky, Z. Hussein 

Brd. 32E Healthcare utilization and costs in patients with early onset myelodysplastic 

syndrome in a commercially insured population. (Abstract #6552) 

A. Powers, K. Stein, R. L. Knoth, M. Broder, E. Chang 

Brd. 32F Impact of cytogenetics at diagnosis on outcome of CML: Results from the 

randomized German CML Study IV. (Abstract #6553) 

A. Leitner, S. Saussele, C. Haferlach, G. Goehring, B. Schlegelberger, 

S. Jung-Munkwitz, U. Proetel, M. Lauseker, M. Pfirrmann, J. Hasford, 

A. Hochhaus, R. Hehlmann, German CML Study group 

Brd. 32G Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients 

with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T- 

ALL/LL). (Abstract #6554) 

A. Al-Ameri, D. A. Thomas, F. Ravandi, S. M. O’Brien, H. Kantarjian, G. Borthakur, 

T. M. Kadia, M. Kelly, R. Garris, S. Faderl 

Brd. 32H Survival differences in chronic myeloid leukemia by race in pre- and postimatinib 

era. (Abstract #6555) 

R. Mandal, D. M. Bolt, B. K. Shah 

Brd. 33A LeukemiaNet: A transnational model for cooperative leukemia research. 


R. Hehlmann, B. Simonsson, M. Baccarani, D. Grimwade, J. Apperley, T. Barbui, 

M. C. Bene, T. Buchner, T. J. de Witte, R. Foà, C. Haferlach, M. Hallek, 

J. Hasford, A. Hochhaus, D. Hoelzer, P. Ljungman, D. Niederwieser, M. . Sanz, 

S. Saussele 

Brd. 33B Improved survival in chronic myeloid leukemia (CML) since introduction of 

imatinib therapy: A single-institution experience in 1,570 patients referred 

within 1 month from diagnosis. (Abstract #6557) 

A. Quintas-Cardama, J. E. Cortes, E. Jabbour, S. M. O’Brien, G. Garcia-Manero, 

J. Shan, F. Ravandi, S. Faderl, T. M. Kadia, G. Borthakur, H. Kantarjian 

Brd. 33C Lenalidomide following rituximab and fludarabine in untreated CLL. 


C. S. Ujjani, S. Jamshed, K. Fitzpatrick, E. A. Gehan, J. Crawford, C. M. Broome, 

P. Cohen, C. Kessler, B. D. Cheson 

380


Brd. 33D Intermediate-dose cyclophosphamide (1.5 Gm/M2) with G-CSF as the primary 

peripheral blood progenitor mobilization strategy: A single institution 


A. Padmanabhan, J. W. Hayslip, G. P. Monohan, S. D. Sutphin, H. Weiss, 

D. S. Howard 

Brd. 33E Relationship between age and healthcare utilization in patients with 

myelodysplastic syndrome receiving supportive care. (Abstract #6560) 

K. Stein, A. Powers, R. L. Knoth, M. Broder, E. Chang 

Brd. 33F Impact of combined lymphocyte and monocyte recovery on survival post 

myeloablative allogeneic hematopoietic stem cell transplant for acute 


M. Thoma, T. Huneke, L. DeCook, N. Johnson, R. Wiegand, M. R. Litzow, 

W. J. Hogan, L. F. Porrata, S. G. Holtan 

Brd. 33G An analysis of high ferritin levels before allogeneic hematopoietic cell 

transplantation (AlloHCT): A retrospective study to evaluate prognostic 

factors in patients (pts) undergoing AlloHCT for myelodysplasia. (Abstract 

#6562) 

S. Hashmi, E. S. Rich, S. Basu, J. J. Maciejewski, S. Nathan, P. Venugopal, 

S. A. Gregory, H. C. Fung, J. M. Shammo 

Brd. 33H Survival after nonmyeloablative versus myeloablative allotransplantation for 

AML/MDS. (Abstract #6563) 

M. R. Khawaja, J. E. Schwartz, M. Yu, M. J. Robertson, G. H. Vance, 

S. Srivastava, L. L. Wood, R. Abonour, K. Cornetta, S. Farag, L. D. Cripe, 

R. P. Nelson Jr. 

Brd. 34A Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML): 

Relationships to immunophenotype and treatment outcomes. (Abstract 

#6564) 

A. P. Michelson, K. J. Kopecky, E. R. Koegle, J. E. Anderson, J. E. Godwin, 

S. H. Petersdorf, A. F. List, C. L. Willman, F. R. Appelbaum, J. P. Radich, 

M. K. Ganapathi, R. N. Ganapathi, A. Advani 

Brd. 34B Autologous stem cell transplantation (ASCT) as upfront or salvage therapy 

for non-cutaneous T-cell lymphoma (TCL): The University of Texas M. D. 

Anderson Cancer Center (MDACC) experience. (Abstract #6565) 

A. Beitinjaneh, R. Saliba, G. Okoroji, A. M. Alousi, U. R. Popat, M. Korbling, 

P. Anderlini, M. Qazilbash, P. Kebriaei, C. Hosing, R. E. Champlin, I. F. Khouri 

Brd. 34C An evaluation of the risk/benefit ratio of low molecular weight heparin to 

reduce the high risk of venous thromboembolism in acute leukemia. 


G. L. Simmons, B. E. Hillner, T. J. Smith 

Brd. 34D Therapy-related acute promyelocytic leukemia (t-APL): Observations on APL 

pathogenesis. (Abstract #6567) 

M. A. Elliott, L. Letendre, A. Tefferi, W. J. Hogan, C. C. Hook, R. Pruthi, 

S. H. Kaufmann, A. D. Pardanani, K. Begna, A. Ashrani, A. P. Wolanskyj, 

A. Al-Kali, M. R. Litzow 

Brd. 34E A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and 

gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia 

(AML) and high-risk myelodysplastic syndrome (MDS). (Abstract #6568) 

H. Ghanem, H. Kantarjian, G. Garcia-Manero, F. Ravandi, S. Faderl, J. E. Cortes, 

A. Reyes, S. M. O’Brien, G. Borthakur, T. M. Kadia, J. A. Burger, M. Konopleva, 

E. Jabbour 

Brd. 34F Imatinib mesylate as first-line therapy in patients with chronic myeloid 

leukemia in accelerated phase and blastic crisis: A retrospective analysis. 


N. Thota, S. Gundeti, P. Coca, J. Srirambhatla, R. Parimkayala, V. Linga, 

S. Bheemnathi Hanuman, L. S. Maddali, R. Digumarti 

381 

MONDAY

MONDAY 


Brd. 34G Long-term estimate of quality-adjusted life expectancy for nilotinib and 

imatinib as first-line treatment for newly diagnosed patients with 

Philadelphia chromosome-positive (Ph�) chronic myeloid leukemia in the 

chronic phase (CML-CP). (Abstract #6570) 

M. Botteman, J. Stephens, S. J. Snedecor, X. Ji, M. Hussein, J. Coombs 

Brd. 34H Interim PK analysis results of a phase IIa, open-label, randomized, 

pharmacokinetic comparative, cross-over studyof melphalan HCl for 

injection (Propylene Glycol-Free) and alkeran for injection formyeloablative 

conditioning in multiple myeloma patients undergoing autologous 


O. S. Aljitawi, S. Ganguly, S. H. Abhyankar, D. Robinson, R. Marks, J. Pipkin, 

J. McGuirk 

Brd. 35A Cost-effectiveness of nilotinib versus imatinib as first-line treatment for 

newly diagnosed patients with Philadelphia chromosome-positive (Ph�) 

chronic myeloid leukemia in the chronic phase (CML-CP): Swedish 

perspective. (Abstract #6572) 

A. Ovanfors, J. Stephens, S. J. Snedecor, D. Patel, X. Ji, K. T. Carpiuc, J. Coombs, 

M. Botteman 

Brd. 35B Distinctions between adult T-cell leukemia-lymphoma (ATLL) secondary to 

human T-cell lymphotropic virus 1 (HTLV1) and peripheral T-cell lymphoma 

(TCL). (Abstract #6573) 

G. D. Ayalew, J. Yao, K. A. Killoran, K. Laveaux, C. A. Axiotis, A. S. Braverman 

Brd. 35C Phase II study of AZD2171 for the treatment of patients with acute 

myelogenous leukemia. (Abstract #6574) 

M. Juckett, B. LaPlant, P. J. Flynn, A. Jumonville, A. Moreno-Aspitia, C. Erlichman 

Brd. 35D Mediation of LA-4 lung epithelial cell injury by alloreactive donor T cells. 


S. V. Radhakrishnan, T. Obermeier, G. Mueller, G. C. Hildebrandt 

Brd. 35E The diagnostic and prognostic implications of nucleated red blood cells in 

myelophthisis. (Abstract #6576) 

J. L. Schering, J. Munoz, E. Raybon, S. Hegab, A. S. Hanbali, P. Kuriakose 

Brd. 35F Vaginal bleeding in women with leukemia. (Abstract #6577) 

S. Ghazal, S. Barton, R. Boyajian, J. H. Antin, R. M. Stone, E. S. Ginsburg 

Brd. 35G TLI-ATG for nonmyeloablative stem cell transplant: A single center 


D. A. Wong, A. S. Steinberg, C. Bresee, A. M. Lopez, S. Lim, M. Lill 

Brd. 35H Subdural hematomas in patients with Philadelphia chromosome-positive 

acute lymphoblastic leukemia receiving imatinib mesylate in conjunction 

with multiagent chemotherapy. (Abstract #6579) 

S. B. Patel, I. Gojo, M. Tidwell, Y. Ning, X. F. Zhao, E. A. Sausville, M. R. Baer 

Brd. 36A Effect of lenalidomide on antileukemia activity in vitro against adult T-cell 

leukemia (ATL) . (Abstract #6580) 

Y. Kitagawa, M. Matsuoka, S. Mitani 

Brd. 36B Relation of methylenetetrahydrofolate reductase C677T polymorphism to 

chronic myeloid leukemia in serbia. (Abstract #6581) 

R. N. Jankovic, K. Jakovljevic, M. Cavic, E. Malisic 

Brd. 36C Enhanced risk stratification in young and elderly patients treated with 

induction chemotherapy as well as in frail patients with AML. (Abstract 

#6582) 

S. Wilop, T. H. Brummendorf, M. Crysandt 

Brd. 36D UCBT with ATG in adult patients. (Abstract #6583) 

W. M. Linkesch, D. Strunk, W. Zinke-Cerwenka, H. Sill, P. Neumeister 

Brd. 36E Clinico-hematological characteristics and outcome assessment of chronic 

lymphocytic leukemia patients: A single institution study of 285 cases. 


A. Gogia, A. Sharma, V. Raina, L. Kumar, R. Kumar, R. Gupta, S. Vishnubhatla 

382


Brd. 36F Evaluation of the JAK2 V617F mutational status in coronary patients. 


K. Gasser, A. Muendlein, N. Stark, T. Winder, P. Rein, C. H. Saely, K. Geiger, 

S. Geller-Rhomberg, B. L. Hartmann, B. Kohler, H. Drexel, A. Lang 

Brd. 36G Time from relapse after allogeneic stem cell transplantation (SCT) to donor 

leukocyte infusion (DLI) is longer, incidence of GVHD is higher, but survival 

is similar for recipients of unrelated DLI compared to matched sibling DLI. 


A. Kumar, N. V. Frey, P. Vassilev, S. Goldstein, E. O. Hexner, A. W. Loren, 

R. Reshef, S. M. Luger, D. L. Porter, E. A. Stadtmauer 

Brd. 36H Phase I/II study of sapacitabine and decitabine administered sequentially in 

elderly patients with newly diagnosed acute myeloid leukemia. (Abstract 

#6587) 

F. Ravandi, S. Faderl, J. E. Cortes, G. Garcia-Manero, E. Jabbour, P. A. Boone, 

T. M. Kadia, G. Borthakur, W. G. Wierda, J. H. Chiao, H. Kantarjian 

Brd. 37A Comparison of cytarabine, mitoxantrone and CNDAC in vitro treatment of 

AML bone marrow and peripheral blood cells. (Abstract #6588) 

S. Jagan, L. A. Paganessi, S. Gezer, A. Rizman, D. Rifai, M. C. Keller, 

M. L. Larson, P. Venugopal, S. Frame, K. W. Christopherson II 

Brd. 37B Adherence to treatment with second-line therapies, dasatinib and nilotinib, in 

patients (pts) with chronic myeloid leukemia (CML). (Abstract #6589) 

M. Ulcickas Yood, S. A. Oliveria, I. Hirji, S. Phillips, M. J. Cziraky, C. C. Davis 

Brd. 37C Altered mitochondrial metabolism as a target in acute myeloid leukemia. 


T. S. Pardee, D. A. Levitan, D. D. Hurd 

Brd. 37D LACE: A conditioning regimen for lymphoma patients undergoing 

autologous transplant. (Abstract #6591) 

R. Thippeswamy, L. Mathew, B. Bhosale, N. Kumar, S. Kannan, A. Joshi, 

V. Rangarajan, N. Khattry 

Brd. 37E The role of minimal residual disease (MRD) by flow cytometry (FC) in 

predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) 


H. J. Lee, K. M. Wright, E. Kandeel, W. Tan, G. E. Wilding, L. Ford, S. N. Sait, 

A. W. Block, M. P. Barcos, P. L. McCarthy, C. E. Vigil, E. A. Griffiths, 

J. E. Thompson, E. S. Wang, P. K. Wallace, M. Wetzler 

Brd. 37F Decitabine for the treatment of acute myeloid leukemia (AML): Memorial 

Sloan-Kettering Cancer Center experience. (Abstract #6593) 

A. Ganetsky, N. G. Adel, M. G. Frattini, P. G. Maslak, M. L. Heaney, 

J. G. Jurcic, M. S. Tallman 

Brd. 37G Prognostic factors of long-term survival in patients with acute myeloid 

leukemia after allogeneic or autologous stem cell transplantation. (Abstract 

#6594) 

L. Wang, C. Corona, X. Nie, L. Mejias, S. j. Hou, R. Mullaney, K. M. Ward, 

D. L. Topolsky, M. Styler, P. A. Crilley 

Brd. 37H Prevalence of venous thromboembolism (VTE) among patients (pts) with 

acute leukemia (AL) prior to treatment. (Abstract #6595) 

N. V. Luong, S. Faderl, H. Kantarjian, K. Vu 

Brd. 38A Relevance of PIG-A mutation in aplastic anemia and myelodysplastic 

syndromes. (Abstract #6596) 

J. J. Pu, R. Hu, G. Mukhina, R. A. Brodsky 

Brd. 38B Risk of progression to myelofibrosis and acute myeloid leukemia in patients 

with essential thrombocythemia and polycythemia vera with prior 

malignancy. (Abstract #6597) 

M. A. Cherry, H. Pham, H. Kantarjian, J. E. Cortes, S. Pierce, L. Zhou, 

S. Verstovsek 

383 

MONDAY

MONDAY 


Brd. 38C Retrospective analysis of prognostic factors associated with response and 

overall survival in patients with RAEB-t MDS treated with decitabine. 


A. Malik, G. Garcia-Manero, M. Welch, H. Kantarjian, K. Stein, A. Teng, E. Jabbour 

Brd. 38D Genetic variation in vitamin D pathway and graft-versus-host disease risk 

after blood and marrow transplantation. (Abstract #6599) 

K. Robien, L. G. Strayer, T. E. DeFor, B. Thyagarajan, D. Lazovich, S. A. Cooley, 

J. A. Ross, K. S. Baker 

Brd. 38E Retrospective analysis of effects of dose modification and 

myelosuppression on response to decitabine and overall survival in patients 

with myelodysplastic syndromes. (Abstract #6600) 

M. Cornelison, G. Garcia-Manero, J. E. Cortes, F. Ravandi, H. Kantarjian, K. Stein, 

A. Teng, E. Jabbour 

Brd. 38F Pharmacogenetic variants and outcomes after hematopoietic cell 


B. Thyagarajan, P. Jacobson, S. Jackson, S. Basu, D. J. Weisdorf, M. Gross, 

M. Arora 

Brd. 38G Chronic lymphocytic leukemia (CLL) patients at a VA medical center: 

Comorbidity and survival. (Abstract #6602) 

L. Soriano, S. Srinivas, M. Tufail, K. Kim, R. Paulin, V. T. Chang, B. Kasimis, 

M. L. Gonzalez 

Brd. 38H Role of topotecan, vinorelbine, thiotepa, and gemcitabine (TVTG) 

chemotheapy in relapsed/refractory adult acute leukemia: A 

single-institution retrospective analysis. (Abstract #6603) 

S. A. Srour, M. A. Cherry, E. Borders, H. Parekh, J. L. Holter, T. S. Herman, 

G. B. Selby 

Brd. 39A Model-based prediction of patient-specific residual disease levels for 

imatinib-treated chronic myeloid leukemia. (Abstract #6604) 

M. Loeffler, M. Horn, I. Glauche, M. C. Müller, A. Hochhaus, I. Roeder 

Brd. 39B Analysis of patients (pts) with chronic-phase chronic myeloid leukemia 

(CML-CP) who develop pleural effusion on first-line dasatinib: Management 

and outcomes. (Abstract #6605) 

P. Laneuville, M. Baccarani, J. E. Cortes, A. Hochhaus, H. Kantarjian, N. P. Shah, 

M. Bradley-Garelik, C. Zhu, K. Porkka 

Brd. 39C Disease management and treatment of chronic myeloid leukemia (CML): 

Experience from the patient (pt) perspective. (Abstract #6606) 

T. W. Victor, M. Talpaz, A. Buzyn, C. B. Lemoine, A. Moadel, E. Olavarria, 

S. Leighton, S. Gupta, I. Hirji, C. C. Davis 

Brd. 39D Validation of a transplant-related mortality (TRM) risk score for pediatric 

patients undergoing allogeneic haematopoietic stem cells transplantation. 


P. Angelini, A. Gassas, I. Zaidman, J. Doyle, T. Schechter 

Brd. 39E Analysis of outcomes in relapsed/refractory acute promyelocytic leukemia 

(APL) patients (pts) treated with and without high-dose chemotherapy and 

hematopoietic stem cell transplantation (HCT). (Abstract #6608) 

N. Pemmaraju, F. Ravandi, G. Rondon, S. Giralt, J. Chen, S. Pierce, 

R. E. Champlin, M. De Lima, M. Qazilbash 

Brd. 39F Romiplostim for the treatment of amegakaryocytic thrombocytopenia 

secondary to remission-inducing immunomodulation in a patient with 

relapsing acute lymphoblastic leukemia after allogeneic hematopoietic stem 

cell transplantation. (Abstract #6609) 

L. Volodin, V. K. Bhanderi, J. Shahan, C. Leary, G. Jean, J. Comeau, 

J. Cotelingam, G. C. Hildebrandt 

384


Brd. 39G Symptomatic burden in myelofibrosis (MF): Prospective international 

assessment in 128 MF patients. (Abstract #6610) 

R. M. Scherber, A. C. Dueck, P. Johansson, T. Barbui, G. Barosi, A. M. Vannucchi, 

F. Passamonti, B. I. Andreasson, M. L. Ferarri, A. Rambaldi, J. Samuelsson, 

G. Birgegard, A. Tefferi, N. Maldonado, F. Sackmann, P. Muxi, 

D. Hernandez-Maraver, J. Kiladjian, R. A. Mesa 

Brd. 39H Leukemia regression by targeting c-Kit activity with pazopanib. (Abstract 

#6611) 

A. Trujillo, C. S. McGee, E. Gars, R. Bosse, A. Meacham, E. Wise, S. Bais, 

C. R. Cogle 

Brd. 40A Health-related quality of life (HRQoL) in newly diagnosed chronic phase 

chronic myelogenous leukemia (CP CML) patients (pts) treated with 

bosutinib (BOS) or imatinib (IM). (Abstract #6612) 

J. H. Lipton, P. C. Trask, D. Cella, L. Duvillie, C. Powell, M. V. Ramanan, 

Z. Maslyak, D. Kim 

Brd. 40B Investigation of thrombopoietin (TPO) function in primary chronic 

lymphocytic leukemia cells. (Abstract #6613) 

R. D. Loberg, S. Wang, S. D. Patterson, I. McCaffery 

Brd. 40C Association between chronic myeloid leukemia (CML) treatment responses 

and patient satisfaction, functioning, and quality of life (QOL): Patient survey 


S. Goldberg, V. K. Bollu, R. Morlock, A. Niyazov, A. Guo, E. Jabbour 

Brd. 40D Open-label study evaluating change in chronic low-grade (LG) nonhematologic 

(heme) adverse events (AEs) in Philadelphia positive (Ph�) 

CML-CP patients (pts) switched from imatinib (IM) to nilotinib (NL). (Abstract 

#6615) 

J. E. Cortes, C. B. Miller, J. H. Lipton, L. Busque, L. P. Akard, J. Pinilla-Ibarz, 

S. Ericson, M. J. Mauro 

Brd. 40E Impact of pleural effusion (PE) on treatment adherence, discontinuation, 

switching, and dose modification in patients with chronic myelogenous 

leukemia (CML). (Abstract #6616) 

E. Q. Wu, A. Guerin, V. K. Bollu, A. Guo, M. Cloutier, D. Ponce de Leon Barido, 

S. Ericson, A. Quintas-Cardama 

Brd. 40F Retrospective analysis of effects of transfusion status on response to 

decitabine and survival in patients with myelodysplastic syndromes. 


T. M. Kadia, G. Garcia-Manero, H. Kantarjian, N. Pemmaraju, K. Stein, A. Teng, 

J. E. Cortes 

Brd. 40G Intergroup study in elderly patients with AML to compare complete remission 

rate and overall survival after intermediate dose or low dose AraC. (Abstract 

#6618) 

T. Lange, D. Niederwieser, V. Hoffmann, M. Pfirrmann, G. Maschmeyer, 

T. Fischer, M. Herold, H. G. Sayer, C. Junghanss, R. Krahl, H. Al-Ali, W. Pönisch, 

V. Vucinic, G. Doelken, M. C. Sauerland, A. Heinecke, D. Hoelzer, 

R. Hehlmann, W. E. Berdel, T. Buchner 

Brd. 40H Arsenic trioxide followed by autologous stem cell transplant for patients with 

relapsed APL. (Abstract #6619) 

D. D. Shepard, H. E. Kohrt, T. L. Rosenblat, J. G. Jurcic, J. H. Park, A. Goldman, 

J. S. Dalal, P. G. Maslak, A. A. Jakubowski, V. Klimek, E. Berman, S. Nand, 

S. E. Coutre, M. S. Tallman, H. P. Erba 

Brd. 41A Health-related quality of life (HRQoL) of bosutinib (SKI-606) in imatinibresistant 

(IM-R) or imatinib-intolerant (IM-I) chronic phase chronic myeloid 

leukemia (CP CML). (Abstract #6620) 

P. C. Trask, D. Cella, N. Besson, V. Kelly, T. Masszi, D. Kim 

385 

MONDAY

MONDAY 


Brd. 41B Secondary malignancies in essential thrombocythemia and polycythemia 

vera: A retrospective analysis of 437 patients from a single institution. 


S. Pierce, M. A. Cherry, H. Pham, H. Kantarjian, A. Al-Ameri, J. E. Cortes, L. Zhou, 

S. Verstovsek 

Brd. 41C Incidence of cytogenetic (CG) abnormalities in acute myeloid leukemia (AML) 

in African American (AA) population. (Abstract #6622) 

R. Khillan, A. S. Braverman, C. A. Axiotis, R. Latif, G. S. Sidhu 

Brd. 41D Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) 

with relapsed/refractory CLL. (Abstract #6623) 

J. M. Flynn, J. A. Jones, L. Andritsos, K. A. Blum, A. J. Johnson, J. Hessler, 

E. Wiley, N. A. Heerema, J. Poon, K. A. Small, Y. Jou, D. Zhang, P. Statkevich, 

M. R. Grever, R. Bannerji, J. C. Byrd 

Brd. 41E Modulation of nuclear factor-kb (NF-kb), IkB kinase (IKK), and inducible nitric 

oxide synthase (iNOS) via proinflammatory cytokines with adjuvant 

selenomethionine (Se-Met) in chronic myelogenous leukemia (CML) patients 

with imatinib mesylate (IM) overexpression of bcr-abl fusion protein. 


E. McPherson, K. Patel, P. Tassy, J. Kleinfeld 

Brd. 41F Chronic myelomonocytic leukemia (CMML) associated with symptomatic 

pericardial effusion. (Abstract #6625) 

M. I. Ibrahim, P. G. Maslak, M. L. Heaney, M. S. George, R. J. Downey, 

M. S. Tallman 

Brd. 41G Cytomorphologic and clinical features of AML with translocation (8;16) 

mimicking APL. (Abstract #6626) 

S. Jhanwar, A. Diab, L. Zickl, G. A. Manji, J. Patel, O. I. Abdel-Wahab, J. G. Jurcic, 

P. G. Maslak, P. G. Steinherz, E. Paietta, J. Feldstein, R. L. Levine, M. S. Tallman 

Brd. 41H Chemotherapeutic drugs-induced apoptosis-related mRNAs in whole blood 

ex vivo as a new diagnostic markers for the prediction of clinical outcome of 

AML. (Abstract #6627) 

N. Usui, K. Mitani, T. Maeda, T. Sakura, N. Dobashi, F. Yagasaki, K. Obata, 

M. Mitsubashi, S. Miyawaki 

Brd. 42A Influence of type of antecedent disorder on outcome of therapy-related AML. 


S. R. Mohan, P. Elson, M. E. Kalaycio, R. V. Tiu, A. S. Advani, E. A. Copelan, 

J. P. Maciejewski, M. A. Sekeres 

Brd. 42B A phase II study of chlorambucil plus rituximab followed by maintenance 

versus observation in elderly patients with previously untreated chronic 

lymphocytic leukemia: Results of the induction phase. (Abstract #6629) 

F. R. Mauro, S. Ciolli, F. Di Raimondo, G. Del Poeta, F. Forconi, A. Cuneo, 

A. Cortellezzi, F. Nobile, M. Brugiatelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi, 

L. Orsucci, M. Mura, A. Alietti, E. J. Runggaldier, E. Gamba, A. Guarini, R. Foa 

Brd. 42C Comparison of outcome in erythroleukemia patients treated with standard 

chemotherapy regimens or hypomethylating agents. (Abstract #6630) 

C. E. Vigil, W. Tan, G. E. Wilding, G. Garcia-Manero, E. S. Wang, M. Wetzler, 

A. F. List 

Brd. 42D Phase I study of CAL-101, an isoform-selective inhibitor of 

phosphatidylinositol 3-kinase P110d, in patients with previously treated 

chronic lymphocytic leukemia. (Abstract #6631) 

S. E. Coutre, J. C. Byrd, R. R. Furman, J. R. Brown, D. M. Benson Jr., 

N. D. Wagner-Johnston, I. W. Flinn, B. S. Kahl, S. E. Spurgeon, B. J. Lannutti, 

H. K. Hsu, R. Ulrich, S. Peterman, L. Holes, L. L. Miller, A. S. Yu 

Brd. 42E Effects of eltrombopag on human cord blood hematopoietic stem 

cell/primitive progenitor cell expansion. (Abstract #6632) 

H. Sun, Y. Tsai, J. Liesveld, K. L. Dawson, C. L. Erickson-Miller, Y. Chen 

386

1:00 PM - 5:00 PM 



Lymphoma and Plasma Cell Disorders 



Brd. 43A Six versus eight cycles of biweekly CHOP-14 with or without R in elderly 

patients with aggressive CD20 � B-cell lymphomas: Seven-year FU of the 

RICOVER-60 trial of the DSHNHL. (Abstract #8029) 

M. Pfreundschuh, M. Ziepert, S. Zeynalova, E. Lengfelder, H. Steinhauer, 

M. R. Clemens, C. Nickenig, A. D. Ho, L. H. Truemper, M. Hoffmann, 

R. H. Mertelsmann, B. Metzner, H. Mergenthaler, V. Poeschel, N. Schmitz, 

M. Loeffler, German Non-Hodgkin Lymphoma Study Group (DSHNHL) 

Brd. 43B High response rates with lenalidomide plus rituximab for untreated indolent 

B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. 


F. Samaniego, F. Hagemeister, P. Mclaughlin, L. W. Kwak, J. Romaguera, 

M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, L. Lacerte, 

N. H. Fowler 

Brd. 43C Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in 

patients with relapsed or refractory Hodgkin lymphoma (HL). (Abstract 

#8031) 

R. W. Chen, A. K. Gopal, S. E. Smith, S. M. Ansell, J. D. Rosenblatt, 

K. J. Savage, J. M. Connors, A. Engert, E. K. Larsen, D. A. Kennedy, E. L. Sievers, 

A. Younes 

Brd. 43D Durable remissions with brentuximab vedotin (SGN-35): Updated results of a 

phase II study in patients with relapsed or refractory systemic anaplastic 

large cell lymphoma (sALCL). (Abstract #8032) 

B. Pro, R. Advani, P. Brice, N. Bartlett, J. D. Rosenblatt, T. Illidge, J. Matous, 

R. Ramchandren, M. A. Fanale, J. M. Connors, Y. Yang, E. L. Sievers, 

D. A. Kennedy, A. R. Shustov 

Brd. 43E Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed 

or refractory peripheral T-cell lymphoma (R/R PTCL). (Abstract #8033) 

S. M. Horwitz, B. Coiffier, F. M. Foss, H. M. Prince, L. Sokol, M. Greenwood, 

D. Caballero, P. Borchmann, F. Morschhauser, M. Wilhelm, L. C. Pinter-Brown, 

S. Padmanabhan, A. R. Shustov, J. Nichols, J. Balser, S. Carroll, B. Pro 

Brd. 43F The use of FDG-PET to guide consolidative radiotherapy in patients with 

advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan 

following ABVD chemotherapy. (Abstract #8034) 

K. J. Savage, J. M. Connors, R. J. Klasa, P. Hoskins, T. N. Shenkier, 

R. D. Gascoyne, S. Bhimji, T. Pickles, F. Benard, D. Wilson, L. H. Sehn 

Brd. 43G Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage 

Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. 

Intergroup Trial E2496. (Abstract #8035) 

A. M. Evens, F. Hong, L. I. Gordon, R. I. Fisher, N. Bartlett, J. M. Connors, 

H. Wagner, M. K. Gospodarowicz, B. D. Cheson, R. Advani, B. S. Kahl, 

R. T. Hoppe, S. J. Horning 

Brd. 43H Examination of the Follicular Lymphoma International Prognostic Index 

(FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort 

treated predominantly in community practices. (Abstract #8036) 

A. K. Nooka, N. J. DeJoubner, C. Nabhan, X. Zhou, M. Taylor, M. Byrtek, 

T. P. Miller, J. W. Friedberg, A. D. Zelenetz, B. K. Link, J. R. Cerhan, H. Dillon, 

D. Levy, J. Hirata, C. Flowers 

Brd. 44A Long-term survival among Hodgkin lymphoma (HL) patients with 

gastrointestinal (GI) cancers: A population-based study. (Abstract #8037) 

P. Youn, H. Li, M. T. Milano, M. Stovall, L. S. Constine, L. B. Travis 

387 

MONDAY

MONDAY 


Brd. 44B Aggressive craniofacial lymphoma in the prerituximab and rituximab era. 


V. Poeschel, N. Murawski, B. Glass, S. Zeynalova, J. Fleckenstein, M. Ziepert, 

B. Kempf, M. Loeffler, N. Schmitz, M. Pfreundschuh, German Non-Hodgkin 

Lymphoma Study Group (DSHNHL) 

Brd. 44C Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma 

(cHL). (Abstract #8039) 

Y. L. Kasamon, H. A. Jacene, L. J. Swinnen, L. Popplewell, B. K. Link, 

T. M. Habermann, J. M. Herman, R. J. Jones, R. F. Ambinder 

Brd. 44D The impact of high-intensity conditioning prior to allogeneic stem cell 

transplantation in patients with chemorefractory or relapsed T-cell 


B. Glass, J. Hasenkamp, W. Jung, C. Wilhelm, G. Held, M. Nickelsen, 

M. Pfreundschuh, N. Schmitz, L. H. Truemper, G. Wulf 

Brd. 44E Patients’ versus physicians’ roles in detecting recurrent Hodgkin lymphoma. 


A. Bestawros, L. Foltz, N. Srour, J. M. Connors 

Brd. 44F Multicenter analysis of more than 300 very elderly non-Hodgkin lymphoma 

(NHL) patients (pts): Impact of comorbidities and functional status on 


C. Nabhan, S. M. Smith, I. B. Helenowski, E. E. Ramsdale, R. Karmali, 

B. M. Parsons, J. Feliciano, B. Hanson, S. E. Smith, J. M. Mckoy, A. Larsen, 

A. Hantel, S. A. Gregory, A. M. Evens 

Brd. 44G Impact of conditioning regimen on outcome of 2-year disease-free survivors 

of autologous stem cell transplantation (ASCT) for Hodgkin lymphoma (HL). 


B. M. William, F. R. Loberiza Jr., V. Whalen, P. J. Bierman, G. Bociek, J. Vose, 

J. O. Armitage 

Brd. 44H PET scans in HIV-related Hodgkin lymphoma (HIV-HL): Results of a 

retrospective study. (Abstract #8044) 

M. Hentrich, M. Berger, C. Hoffmann, J. Siehl, T. Wolf, M. Nickelsen, J. Rockstroh, 

D. Schuermann, A. Rieke, R. Schmidmaier, H. Knechten, M. Mueller, 

G. Fätkenheuer, R. Meyer, K. Arastéh, F. A. Mosthaf Sr., C. Wyen 

Brd. 45B Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in 

relapsed/refractory Hodgkin lymphoma (HL) patients following autologous 

stem cell transplant (ASCT). (Abstract #8046) 

S. J. Harrison, A. K. Hsu, P. J. Neeson, A. Younes, A. Sureda, A. Engert, M. Li, 

P. Savage, R. Bugarini, C. Le Corre, D. E. Williams, J. D. Gallagher, A. Shen, 

D. Ritchie 

Brd. 45C Activity of anti-CD20-interferon-� fusion protein against human B-cell 

lymphomas. (Abstract #8047) 

G. Ngarmchamnanrith, R. E. Yamada, K. K. Steward, S. Khare, R. Sachdev, 

S. L. Morrison, J. Timmerman 

Brd. 45D Discriminatory power of the 111-indium scan (111-In) in the prediction of 

altered biodistribution of radio-immunoconjugate in the 90-yttrium 

ibritumomab tiuxetan therapeutic regimen: Meta-analysis of five clinical trials 

and 9 years of post-approval safety data. (Abstract #8048) 

J. W. Kylstra, T. E. Witzig, M. Huang, C. E. Emmanouilides, A. Hagenbeek, 

G. F. Tidmarsh 

Brd. 45E Second-line therapy in follicular lymphoma in the United States: Report of 

NLCS observational study. (Abstract #8049) 

B. K. Link, T. P. Miller, M. Byrtek, J. R. Cerhan, A. D. Zelenetz, H. Dillon, 

C. Flowers, J. W. Friedberg 

388


Brd. 45F The association between the GOELAMS MCL-PET prognostic index and 

survival in patients treated with rituximab-hypercvad (R-HyCVAD) or highdose 

therapy with autologous stem cell rescue (HDT/ASCT). (Abstract #8050) 

T. Feldman, A. R. Mato, T. Zielonka, S. D. Rowley, S. Goldberg, M. Donato, 

D. S. Siegel, K. Facchin, A. Campaiola, D. H. Vesole, C. Bejot, S. Stives, M. Curtin, 

M. Miller, H. Agress, D. Panush, P. Lizotte, P. Bhattacharyya, A. Pecora, A. Goy 

Brd. 45G A new predictive model based on age, pretreatment LDH, and post-therapy 

PET-CT in patients with MCL treated with dose-intensive strategies. (Abstract 

#8051) 

A. R. Mato, T. Feldman, T. Zielonka, S. Goldberg, S. D. Rowley, M. Donato, 

D. S. Siegel, D. H. Vesole, A. Campaiola, K. Facchin, S. Stives, C. Bejot, M. Curtin, 

M. Miller, H. Agress, D. Panush, P. Lizotte, A. Pecora, P. Bhattacharyya, A. Goy 

Brd. 45H Variation of hepatitis C virus genotype distribution between geographically 

related patients: A retrospective multicenter study. (Abstract #8052) 

H. A. Torres, M. Nevah-Rubin, B. J. Barnett, P. Mahale, D. P. Kontoyiannis, 

L. Mishra, M. Hassan, I. Raad 

Brd. 46A Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for 

patients older than age 60 with untreated diffuse large B-cell lymphoma 

(DLBCL). (Abstract #8053) 

M. A. Rodriguez, J. Durand, A. B. Astrow, M. J. Bury, M. A. Fanale, 

F. B. Hagemeister Jr., X. Huang, P. McLaughlin, S. S. Neelapu, B. Pro, 

L. W. Kwak, L. Fayad, J. E. Romaguera, A. Younes, M. Fisch 

Brd. 46B Allograft versus non-allograft post-transplant lymphoproliferative disorder, 

characterization of two distinct subtypes as defined by presentation, 

histology, and outcome: A case series of 165 patients. (Abstract #8054) 

D. E. Tsai, I. S. Hagemann, J. J. Morrissette, R. Daber, D. Xu, S. J. Schuster, 

R. D. Bloom, V. N. Ahya, M. Jessup, G. A. Makar, S. Chen, R. Reshef 

Brd. 46C Identification of prognostic tumor markers in HIV� diffuse large B-cell 

lymphoma (DLBCL). (Abstract #8055) 

C. Chao, M. Silverberg, D. I. Abrams, R. Haque, H. D. Zha, O. Martinez-Maza, 

M. McGuire, M. D. Chi, B. Castor, L. Xu, J. Said 

Brd. 46D Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/ 

relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease. (Abstract 

#8056) 

M. Cotto, F. Cabanillas, G. Garcia-Manero, H. Yang, M. Bruno, O. A. Pavia, 

E. Rivera, I. Liboy, M. Tirado-Gomez 

Brd. 46E Prognostic significance of absolute lymphocyte count in patients with 

early-stage diffuse large B-cell lymphoma treated with RCHOP. (Abstract 

#8057) 

Y. Chae, Y. Lee, B. Kang, J. Moon, J. Kim, S. Sohn, D. Yang, J. Lee, T. Park 

Brd. 46F A phase II study of R-COMP14 in elderly patients with high-risk diffuse large 

B-cell lymphoma (DLBCL) and moderate to high “life threat” impact 

cardiopathy. (Abstract #8058) 

G. Corazzelli, F. Frigeri, M. Arcamone, A. Lucania, G. Capobianco, M. Villa, 

F. Russo, S. Crisci, G. Marcacci, C. Becchimanzi, E. Morelli, F. Volzone, 

R. De Filippi, A. Pinto 

Brd. 46G Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin 

lymphoma (NHL). (Abstract #8059) 

C. A. Thompson, M. J. Maurer, C. Allmer, S. L. Slager, K. J. Yost, W. R. Macon, 

S. M. Ansell, D. J. Inwards, T. M. Habermann, B. K. Link, J. R. Cerhan 

Brd. 46H Differences in regulatory T cells (Tregs) in responding and non-responding 

patients with indolent B-cell or mantle cell lymphoma during treatment with 

lenalidomide and rituximab � dexamethasone. (Abstract #8060) 

N. Aqui, A. Gordon, Y. Xu, E. A. Chong, L. Leinbach, T. Ahmadi, S. Nasta, 

J. Svoboda, S. J. Schuster 

389 

MONDAY

MONDAY 


Brd. 47A Cell cycle effects of CDK 4/6 inhibitor PD 0332991 in diffuse large B-cell 

lymphoma cell lines in vitro. (Abstract #8061) 

H. A. Eradat, M. A. Eckardt, E. Dorfman, H. Hamidi, C. Ginther, R. S. Finn, G. Los, 

J. G. Christensen, S. De Vos, D. J. Slamon 

Brd. 47B Piracy of COX-2/PGE2/EP receptor pathway by Kaposi’s sarcoma associated 

herpes virus (KSHV): A potential Achilles’ heel of KSHV–related diseases. 


A. G. Paul, N. Sharma-Walia, B. Chandran 

Brd. 47C Preliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeled 

antibody fragment targeting the extra-domain A1 of tenascin-C, in patients 

with refractory Hodgkin lymphoma. (Abstract #8063) 

L. Aloj, L. D’Ambrosio, M. Aurilio, R. Marreno, D. Neri, H. D. Menssen, 

L. Giovannoni, F. Di Gennaro, C. Caraco, M. Arcamone, F. Frigeri, A. Pinto, 

S. Lastoria 

Brd. 47D Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy 

(INRT) for nonbulky stage I-II Hodgkin lymphoma: Preliminary results of the 

Stanford G5 Study. (Abstract #8064) 

R. Advani, S. J. Horning, E. Jonathan, S. Daadi, J. Allen, S. A. Rosenberg, 

R. T. Hoppe 

Brd. 47E Outcomes following involved field radiotherapy (IFRT) with or without 

rituximab in patients (Pts) with limited-stage low-grade non-Hodgkin 

lymphoma (NHL) staged with CT versus PET. (Abstract #8065) 

J. N. Lukens, S. Nasta, E. Glatstein, J. P. Plastaras 

Brd. 47F Bendamustine and lenalidomide in relapsed/refractory lymphoid 


B. D. Cheson, C. S. Ujjani, E. A. Gehan, S. M. Karim, T. Goswami, J. Crawford 

Brd. 47G Efficacy of pomalidomide plus low-dose dexamethasone in multiple 

myeloma patients despite previous use of lenalidomide. (Abstract #8067) 

J. Mikhael, V. Rajkumar, V. Roy, S. R. Hayman, R. Fonseca, K. Detweiler Short, 

B. LaPlant, K. M. Laumann, A. Dispenzieri, M. Lacy 

Brd. 47H Extramedullary disease (EMD): A common terminal pathway in multiple 

myeloma (MM) progression. (Abstract #8068) 

S. Z. Usmani, A. Mitchell, J. Szymonifka, J. D. Shaughnessy Jr., A. Hoering, 

Y. Alsayed, S. Waheed, B. Nair, J. Crowley, B. Barlogie 

Brd. 48A Survival outcomes of patients with multiple myeloma (MM) achieving 

stringent complete response (sCR) following upfront autologous stem cell 

transplantation (SCT). (Abstract #8069) 

P. Kapoor, S. Kumar, A. Dispenzieri, M. Lacy, D. Dingli, S. R. Hayman, F. Buadi, 

P. R. Greipp, R. A. Kyle, S. V. Rajkumar, M. A. Gertz 

Brd. 48B Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory 

multiple myeloma: A phase I/II trial. (Abstract #8070) 

J. R. Berenson, O. Yellin, A. Bessudo, R. Boccia, S. Noga, D. Gravenor, 

D. Patel-Donnelly, R. S. Siegel, T. Kewalramani, E. J. Gorak, R. Swift, 

D. Bensen-Kennedy 

Brd. 48C Outcomes of a late second autologous hematopoietic stem cell transplant 

compared to nontransplantation salvage therapy in relapsed multiple 

myeloma after upfront transplant. (Abstract #8071) 

J. M. Azar, S. Abdelqader, R. Abonour, A. Suvannasankha, R. Tabbey, S. Farag 

Brd. 48D Impact of baseline characteristics on efficacy and safety after bortezomibbased 

induction and maintenance in newly diagnosed multiple myeloma 

(MM) patients ineligible for transplant in the phase IIIb UPFRONT study. 


R. Niesvizky, I. W. Flinn, R. M. Rifkin, N. Gabrail, V. Charu, Y. Gaffar, R. Neuwirth, 

D. Corzo, J. Reeves 

390


Brd. 48E Association of familial disease status with inferior treatment outcome in 

patients with Waldenstrom’s macroglobulinemia. (Abstract #8073) 

Z. R. Hunter, C. Hanzis, L. Ioakimidis, C. Tripsas, R. J. Manning, C. J. Patterson, 

P. Sheehy, B. Turnbull, S. P. Treon 

Brd. 48F Efficacy and improved toxicity profile of once a week bortezomib (BZ) with 

dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients 

(pts) with older age and comorbidities: Preliminary results of an ongoing 

clinical study. (Abstract #8074^) 

N. C. Munshi, S. Lee, S. Kambhampati, A. Mohiuddin, M. G. Rose, C. Behler, 

A. Han, Y. A. Efebera, A. Houranieh, M. T. Brophy, A. Zimelman, R. H. Prabhala, 

T. Grady, C. E. Klein, P. Mehta, T. G. Hayes, G. D. Roodman, A. Lichtenstein 

Brd. 48G A phase lb study of oral panobinostat and IV bortezomib in relapsed or 

relapsed and refractory multiple myeloma. (Abstract #8075) 

J. F. San-Miguel, P. G. Richardson, O. Sezer, A. Guenther, D. S. Siegel, J. Blade, 

R. LeBlanc, H. J. Sutherland, M. Mateos, M. Gramatzki, K. M. Hazell, 

B. Bengoudifa, P. M. Bourquelot, K. C. Anderson 

Brd. 48H Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in 

patients with relapsed or refractory multiple myeloma. (Abstract #8076) 

S. Lonial, R. Vij, T. Facon, P. Moreau, X. Leleu, A. Mazumder, J. L. Kaufman, 

C. Westland, C. Tsao, A. K. Singhal, S. Jagannath 

Brd. 49A Prevalence of interleukin-6 receptor polymorphism in Castleman disease and 

association with increased soluble interleukin-6 receptor levels. (Abstract 

#8077) 

K. Stone, E. Woods, S. M. Szmania, O. Stephens, T. K. Garg, A. Moreno-Bost, 

B. Barlogie, J. D. Shaughnessy Jr., B. Hall, M. P. Reddy, F. Van Rhee 

Brd. 49B Effect of MOR202, a human CD38 antibody, in combination with lenalidomide 

and bortezomib, on bone lysis and tumor load in a physiologic model of 

myeloma. (Abstract #8078) 

J. Endell, C. Samuelsson, R. Boxhammer, S. Strauss, S. Steidl 

Brd. 49C Evaluation of pretransplant variables predicting cardiomyopathy following 

high-dose melphalan conditioning and autologous peripheral blood stem cell 


J. S. Bleeker, M. A. Gertz, P. A. Pellikka, F. Buadi, D. Dingli, A. Dispenzieri, 

S. R. Hayman, W. J. Hogan, S. Kumar, M. Lacy 

Brd. 49D Single-agent lenalidomide for newly diagnosed myeloma with on-demand 

dexamethasone: A phase II trial. (Abstract #8080) 

F. Buadi, M. Lacy, A. Dispenzieri, B. LaPlant, K. M. Laumann, G. S. Nowakowski, 

S. R. Hayman, K. Detweiler Short, D. Dingli, M. A. Gertz, P. R. Greipp, J. A. Lust, 

T. E. Witzig, S. R. Zeldenrust, S. J. Russell, V. Rajkumar, S. Kumar 

Brd. 49E The impact of frontline risk-adapted strategy on the overall survival (OS) of 

patients with newly diagnosed multiple myeloma (MM): A population study in 

Singapore (SG). (Abstract #8081) 

D. C. Tan, K. H. Ong, L. P. Koh, S. S. Wong, M. T. Khin, L. H. Lee, 

Y. T. Goh, W. J. Chng 

Brd. 49F A phase II study of pegylated liposomal doxorubicin, bortezomib, 

dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/ 

refractory (R/R) multiple myeloma (MM). (Abstract #8082) 

O. Yellin, J. R. Berenson, T. Kazamel, C. Chen, A. Cartmel, T. B. Woliver, 

M. S. Flam, E. N. Bravin, Y. Nassir, R. A. Vescio, R. Swift 

Brd. 49G Defining the biological subgroup of multiple myeloma patients which 

benefits maximally from the overall survival (OS) benefit associated with 

treatment with zoledronic acid (ZOL). (Abstract #8083) 

G. J. Morgan, F. Davies, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, 

M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie, 

C. Rudin, G. Cook, G. H. Jackson, K. Boyd, J. A. Child, P. Wu 

391 

MONDAY

MONDAY 


Brd. 49H An evaluation of MIST 1 as an indicator of plasmacytic differentiation. 


C. C. Yeung, J. Mills, J. Frater 

Brd. 50A Effect of NF-kB2 mutation on pathway activitation in the pathogenesis of 

B-cell lymphomas. (Abstract #8085) 

B. A. McCarthy, L. Yang, D. Liu, J. Ding, H. Ding 

Brd. 50B Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple 

myeloma (RRMM) patients (Pts): Analysis of pooled data. (Abstract #8086) 

B. G. Durie, G. Morgan, J. F. San-Miguel, R. Z. Orlowski, S. Lonial, R. Niesvizky, 

Z. Yu, K. C. Anderson 

392

1:15 PM - 2:30 PM 


ASCO/Union for International Cancer Control (UICC) Joint Session: Breast 

Cancer Health Disparities—Challenges and Opportunities from an 

International Perspective 



Track(s): Breast Cancer, International, Special Session 

Eduardo L. Cazap, MD—Co-Chair 

Latin American-Caribbean Society of Medical Oncology 



Larry Norton, MD 


Developing a Strategy for Independent Breast Cancer Research 

Benjamin O. Anderson, MD 


Controversies in Screening for Breast Cancer 

Mary K. Gospodarowicz, MD 

Princess Margaret Hospital and University of Toronto 

Role of Radiotherapy in Low-resource Scenarios 

Gabriel N. Hortobagyi, MD 


How to Treat Advanced Breast Cancer with Limited Resources 


393 

MONDAY

MONDAY 


1:15 PM - 2:30 PM 


Challenges in Treating Children, Adolescents, and Adults with Benign and 

Malignant Vascular Tumors 




Denise Adams, MD—Chair 

Cincinnati Children’s Hospital 

Multidisciplinary Strategies for the Treatment of Vascular Malformations and Tumors in Children 

Anthony Montag, MD 


The Pathology and Biology of Vascular Tumors in Children and Young Adults 

Steven J. Fishman, MD 

Children’s Hospital Boston 

The Role of the Surgeon in the Diagnosis and Management of Vascular Tumors 

Evolving Therapy of Hodgkin Lymphoma 



Track(s): Lymphoma and Plasma Cell Disorders, General Oncology 

Joseph M. Connors, MD—Chair 

British Columbia Cancer Agency Center for Lymphoid Cancer 

Advanced-stage Hodgkin Lymphoma 

Andreas Engert, MD 

University Hospital of Cologne 

Limited-stage Hodgkin Lymphoma 

Francisco J. Hernandez-Ilizaliturri, MD 


New Therapies in Hodgkin Lymphoma 

How to Advise the Patient with Early-stage Esophageal Carcinoma and Highgrade 

Dysplasia Arising in Barrett’s Esophagus: Endoluminal Therapies to 

Resection 




Martin S. Karpeh Jr., MD—Chair 

Beth Israel Medical Center 

What Are the Surgical Options for High-grade Dysplasia and Carcinoma in Situ? 

Blair A. Jobe, MD 


What Are the Endoluminal Therapies for High-grade Dysplasia or Carcinoma in Situ? 

394

Myelodysplastic Disorders and Myeloproliferative Disorders: New Therapeutic 

Developments 




Alan F. List, MD—Chair 


Update of Therapy for Myelodysplastic Syndromes 

Pierre Fenaux, MD, PhD 

Hopital Avicenne 

The Biology and Prognostic Factors of Myelodysplastic Syndromes 

Srdan Verstovsek, MD, PhD 


Myeloproliferative Disorders: JAK2 and Beyond 

Optimizing Data Collection for Clinical Trials to Support Clinically Relevant 

Decisions (eQuestions Session) 



Track(s): Clinical Trials 

Richard L. Schilsky, MD—Chair 


Data Collection and Optimization in the Cooperative Group Setting 

Jeffrey S. Abrams, MD 


Challenges in the Coordination of Clinical Trials 


Ann T. Farrell, MD 


FDA Recommendations for Sponsors on Data Collection for Cancer Clinical Trials 

Peter C. Adamson, MD 

Children’s Hospital of Philadelphia 

Data Collection Standards to Establish Safety and Efficacy in Pediatric Clinical Trials 

395 

MONDAY

MONDAY 


1:15 PM - 2:30 PM 


Non-oncogene Addiction to Stress: A Cancer Cell Fix Exploited for Cancer 

Therapy (M23)—Ticketed Session 




Kapil N. Bhalla, MD 


Oncogene and Non-oncogene Addiction in Cancer 

Sex and the Survivor (M16)—Ticketed Session 




Leslie R. Schover, PhD 


396

1:15 PM - 2:45 PM 


BRAF: From Biology to Patients 





Keith T. Flaherty, MD—Co-Chair 


Richard Kefford, MD, PhD—Co-Chair 

Westmead Institute for Cancer Research 

Discussion 

1:15 PM Levi A. Garraway, MD, PhD 


1:30 PM Clinical characteristics and outcomes associated with BRAF and NRAS 

mutations in metastatic melanoma. (Abstract #8500) 

J. A. Jakob, R. L. Bassett Jr., C. S. Ng, A. J. Lazar, G. C. Alvarado, M. L. Rohlfs, 

J. Richard, J. E. Gershenwald, P. Hwu, K. B. Kim, M. A. Davies 

1:45 PM Tumor genetic analyses of patients with metastatic melanoma treated with 

the BRAF inhibitor GSK2118436 (GSK436). (Abstract #8501) 

K. L. Nathanson, A. Martin, R. Letrero, K. P. D’Andrea, S. O’Day, J. R. Infante, 

G. S. Falchook, M. Millward, C. M. Curtis Jr., B. Ma, R. C. Gagnon, P. F. Lebowitz, 

G. V. Long, R. F. Kefford 

2:00 PM Molecular analyses from a phase I trial of vemurafenib to study mechanism 

of action (MOA) and resistance in repeated biopsies from BRAF 

mutation–positive metastatic melanoma patients (pts). (Abstract #8502) 

G. A. McArthur, A. Ribas, P. B. Chapman, K. T. Flaherty, K. B. Kim, I. Puzanov, 

K. L. Nathanson, R. J. Lee, A. Koehler, O. Spleiss, G. Bollag, W. Wu, K. Trunzer, 

J. A. Sosman 

2:15 PM Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral 

MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral 

BRAF inhibitor GSK2118436 (GSK436). (Abstract #CRA8503) 

J. R. Infante, G. S. Falchook, D. P. Lawrence, J. S. Weber, R. F. Kefford, 

J. C. Bendell, R. Kurzrock, G. Shapiro, R. R. Kudchadkar, G. V. Long, 

H. A. Burris III, K. B. Kim, A. Clements, S. Peng, B. Yi, A. J. Allred, D. Ouellet, 

K. Patel, P. F. Lebowitz, K. T. Flaherty 

Discussion 

2:30 PM Reinhard Dummer, MD (Abstracts #8500–CRA8503) 

University Hospital of Zurich 

397 

MONDAY

MONDAY 


1:15 PM - 2:45 PM 


Molecular Biomarkers in Neuro-oncology: Ready for Clinical Practice? 




Markus Bredel, MD, PhD—Co-Chair 

University of Freiburg 

Rimas Vincas Lukas, MD—Co-Chair 


Discussion 

1:15 PM Martin J. Van Den Bent, MD 

Daniel den Hoed Cancer Center 

1:30 PM RTOG 0525: Molecular correlates from randomized phase III trial of newly 

diagnosed glioblastoma. (Abstract #LBA2000) 

K. D. Aldape, M. Wang, E. P. Sulman, D. P. Cahill, M. Hegi, H. Colman, G. Jones, 

A. Chakravarti, M. P. Mehta, D. W. Andrews, L. Long, K. Diefes, L. Heathcock, 

R. Jenkins, C. J. Schultz, M. R. Gilbert 

1:45 PM Impact of MGMT promoter methylation in glioblastoma of the elderly. 


M. Weller, B. Hentschel, J. Felsberg, G. Schackert, M. Simon, O. Schnell, 

M. Westphal, W. Wick, T. Pietsch, M. Loeffler, G. Reifenberger, German Glioma 

Network 

2:00 PM Predictive value of IDH1 mutation assessed by immunohistochemistry and 

DNA sequencing in WHO grade 3 oligodendrogliomas. (Abstract #2002) 

J. Frenel, C. Leux, D. Loussouarn, A. Le Loupp, F. Leclair, A. Von Deimling, 

M. Aumont, S. Martin, M. G. Denis, M. Campone 

2:15 PM Prediction of glioblastoma outcome using combined analysis of MGMT 

protein expression and promoter methylation (Abstract #2003) 

A. Lai, S. Lalezari, A. P. Chou, A. Tran, O. E. Solis, J. A. Carrillo, W. Chen, 

P. S. Mischel, R. M. Green, P. L. Nghiemphu, L. M. Liau, H. Wang, R. M. Elashoff, 

T. F. Cloughesy, W. H. Yong 

Discussion 

2:30 PM Michael Prados, MD (Abstract #LBA2000–2003) 


398

2:00 PM - 6:00 PM 







CME credit: 1 



Abby B. Siegel, MD, MS—Co-Chair 


Gauri R. Varadhachary, MD—Co-Chair 


Discussion 

5:00 PM Alexandria T. Phan, MD (Abstracts #4008–4011) 


Discussion 

5:15 PM Ian Chau, MD (Abstracts #4012–4019) 


Discussion 

5:30 PM Eunice Lee Kwak, MD, PhD (Abstracts #4020–4027) 

Massachusetts General Hospital and Harvard Medical School 

Discussion 

5:45 PM Colin D. Weekes, MD, PhD (Abstracts #4028–LBA4032) 


Brd. 1 Updated overall survival (OS) and progression-free survival (PFS) by blinded 

independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for 

patients (Pts) with advanced unresectable pancreatic neuroendocrine 

tumors (NET). (Abstract #4008) 

E. Raymond, P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, 

J. W. Valle, P. Metrakos, D. Smith, A. Vinik, J. Chen, D. Hoersch, D. E. Castellano, 

H. F. Kennecke, J. Picus, G. Van Hazel, D. Lu, S. Patyna, R. C. Chao, 

E. Van Cutsem 

Brd. 2 Everolimus in patients with advanced pancreatic neuroendocrine tumors 

(pNET): Updated results of a randomized, double-blind, placebo-controlled, 

multicenter, phase III trial (RADIANT-3). (Abstract #4009) 

J. R. Strosberg, J. Lincy, R. E. Winkler, E. M. Wolin 

Brd. 3 Everolimus in patients with advanced pancreatic neuroendocrine tumors 

(pNET): Impact of somatostatin analog use on progression-free survival in 

the RADIANT-3 trial. (Abstract #4010) 

M. H. Shah, C. Lombard-Bohas, T. Ito, E. M. Wolin, E. Van Cutsem, C. Sachs, 

R. E. Winkler, J. Lincy, T. J. Hobday, J. C. Yao 

Brd. 4 Everolimus plus octreotide LAR versus placebo plus octreotide LAR in 

patients with advanced neuroendocrine tumors (NET): Updated safety and 

efficacy results from RADIANT-2. (Abstract #4011) 

J. C. Yao, S. Ricci, R. E. Winkler, V. Jehl, M. E. Pavel 

Brd. 5 HER2 expression/amplification: Frequency, clinicopathologic features, and 

prognosis in 713 patients with esophageal adenocarcinoma (EAC). (Abstract 

#4012) 

H. H. Yoon, Q. Shi, W. R. Sukov, A. E. Wiktor, M. Khan, C. A. Sattler, A. Grothey, 

T. Wu, R. B. Diasio, R. B. Jenkins, F. Sinicrope 

399 

MONDAY

MONDAY 


Brd. 6 Impact of human epidermal growth factor receptor (EGFR) and ERBB2 

(HER2) expressions on survival in patients with stage II/III gastric cancer, 

enrolled in the ACTS-GC study. (Abstract #4013) 

M. Terashima, A. Ochiai, K. Kitada, W. Ichikawa, I. Kurahashi, S. Sakuramoto, 

T. Fukagawa, T. Sano, H. Imamura, M. Sasako 

Brd. 7 Prognostic significance of human epidermal growth factor-2 (HER2) in 

advanced gastric cancer: A U.S. and European international collaborative 


M. A. Shah, Y. Y. Janjigian, C. Pauligk, D. Werner, D. P. Kelsen, E. Jaeger, 

H. Altmannsberger, E. Robinson, L. H. Tang, V. V. Barbashina, S. Al-Batran 

Brd. 8 Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in 

patients with metastatic gastric and/or gastroesophagel junction 

adenocarcinoma: Results of a randomized phase II study. (Abstract #4015) 

D. A. Richards, D. M. Kocs, A. I. Spira, A. D. McCollum, K. A. Boehm, F. Zhan, 

L. Asmar 

Brd. 9 Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in 

the treatment for advanced gastric cancer (AGC): The START trial update. 


M. Fujii, Y. H. Kim, T. Satoh, H. Hosaka, T. Kim, A. Tsuji, M. Inokuchi, 

A. Takagane, S. Oh, K. Tanabe, T. Okuno, K. Chin, T. Ura, J. I. Lee, Y. Kakudo, 

K. Yamaguchi, S. Iijima, M. Takeuchi, H. Kim, T. Nakajima, Japan Clinical Cancer 

Research Organization and Korean Cancer Study Group Inter-Group Study 

Brd. 10 SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial 

to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines 

(FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with 

gastric cancer. (Abstract #4017) 

A. Tsuburaya, K. Yoshida, M. Kobayashi, S. Yoshino, Y. Miyashita, S. Morita, 

K. Oba, M. E. Buyse, J. S. Macdonald, J. Sakamoto 

Brd. 11 Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or 

without fluorouracil or capecitabine in metastatic or locally recurrent gastric 


E. Van Cutsem, C. Boni, J. Tabernero, B. Massuti, D. A. Richards, H. Prenen, 

I. Steinberg, P. Rougier 

Brd. 12 A randomized, double-blind, multicenter, phase II, three-arm, placebo-control 

study of apatinib as third-line treatment in patients with metastatic gastric 


J. Li, S. Qin, J. Xu, W. j. Guo, J. p. Xiong, Y. Bai, G. Sun, Y. Yang, L. Wang, N. Xu, 

Y. Cheng, W. Zhe-Hai, L. Zheng, M. Tao 

Brd. 13 Evaluation of putative prognostic tissue biomarkers in pancreatic ductal 


J. M. Winter, L. H. Tang, D. S. Klimstra, M. F. Brennan, E. M. O’Reilly, 

W. R. Jarnagin, P. J. Allen 

Brd. 14 Molecular prognostic markers in advanced gastric cancer: Correlative study 

in the Japan Clinical Oncology Group trial JCOG9912. (Abstract #4021) 

Y. Yamada, J. Mizusawa, A. Takashima, K. Nakamura, Y. Tsuji, Y. Suzuki, 

K. Amagai, K. Yamaguchi, K. Konishi, T. Yoshino, T. Denda, W. Koizumi, 

S. Ohkawa, H. Kawai, H. Kojima, H. Nishizaki, T. Nishina, A. Tsuji, H. Fukuda, 

N. Boku 

Brd. 15 Genome-wide interaction study of gemcitabine treatment and genotype on 

survival in pancreatic cancer. (Abstract #4022) 

R. R. McWilliams, W. R. Bamlet, M. Matsumoto, G. P. Kim, P. A. Burch, 

D. Grendahl, G. M. Petersen 

400


Brd. 16 Association of excision repair cross-complementation group 1 (ERCC1) gene 

expression (GE) with outcome in stage II-III esophageal adenocarcinoma 

(EA) patients treated with preoperative platinum-based chemoradiation 

(CRT) in a phase II cooperative group study (SWOG S0356). (Abstract #4023) 

P. O. Bohanes, B. H. Goldman, L. P. Leichman, C. D. Blanke, S. Iqbal, 

C. R. Thomas Jr., C. L. Corless, K. G. Billingsley, K. D. Danenberg, W. Zhang, 

J. K. Benedetti, P. J. Gold, H. Lenz 

Brd. 17 Prediction of gemcitabine benefit after curative-intent resection of pancreatic 

adenocarcinoma using HENT1 and dCK protein expression. (Abstract #4024) 

R. Maréchal, j. Bachet, J. R. Mackey, P. Demetter, K. Graham, A. Couvelard, 

M. Svrcek, A. Bardier, P. Hammel, A. Sauvanet, C. Louvet, F. Paye, P. Rougier, 

L. Hannoun, T. Andre, C. M. Dumontet, C. Cass, I. Salmon, J. Emile, 

J. Van Laethem 

Brd. 18 Comparing the classification precision and prognostic performance of an 

intrinsic gastric cancer signature with existing genomic signatures in six 

independent datasets. (Abstract #4025) 

I. B. Tan, H. Grabsch, H. Toh, J. Lee, A. Boussioutas, S. Y. Rha, J. A. Ajani, P. Tan 

Brd. 19 Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody 

MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced 


M. M. Javle, G. R. Varadhachary, D. R. Fogelman, R. T. Shroff, M. J. Overman, 

L. Ukegbu, B. N. Bekele, S. P. Kar, R. A. Wolff, J. L. Abbruzzese 

Brd. 20 Validated biomarker signatures that predict pathologic response to 

preoperative chemoradiation therapy (CTRT) with high specificity and 

desirable sensitivity levels in patients with esophageal cancer (EC). (Abstract 

#4027) 

J. A. Ajani, X. Wang, Y. Hayashi, D. Maru, J. Welsh, W. L. Hofstetter, J. H. Lee, 

M. S. Bhutani, A. Suzuki, D. A. Berry, J. Izzo 

Brd. 21 BAYPAN study: A double-blind, phase III randomized trial of gemcitabine 

plus sorafenib versus gemcitabine plus placebo in patients with advanced 


A. Goncalves, F. Viret, E. François, L. Dahan, H. Perrier, R. Lamy, D. Re, 

R. Largillier, M. Gasmi, X. Tchiknavorian, O. Turrini, L. Moureau-Zabotto, 

J. Delpero, P. Viens 

Brd. 22 A randomized phase II study of gemcitabine plus S-1 versus gemcitabine 

alone in patients with unresectable pancreatic cancer. (Abstract #4029) 

Y. Omuro, T. Ikari, H. Ishii, M. Ozaka, M. Suyama, Y. Matsumura, T. Itoi, 

N. Egawa, S. Yano, K. Hanada, Y. Kimura, T. Ukita, Y. Ishida, M. Tani, S. Ohoka, 

Y. Hirose, S. Hijioka, R. Watanabe, T. Ikeda, T. Nakajima, 

Japan Clinical Cancer Research Organization 

Brd. 23 Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) 

versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic 

pancreatic adenocarcinoma. (Abstract #4030) 

G. P. Kim, N. R. Foster, M. Salim, P. J. Flynn, D. F. Moore, R. Zon, R. B. Mowat, 

M. Wiesenfeld, A. E. McCullough, S. R. Alberts 

Brd. 24 Global, multicenter, open-label, randomized phase II trial comparing 

gemcitabine (G) with G plus AGS-1C4D4 (A) in patients (pts) with metastatic 

pancreatic cancer (mPC). (Abstract #4031) 

B. M. Wolpin, E. M. O’Reilly, Y. Ko, L. S. Blaszkowsky, M. U. Rarick, 

C. S. Rocha Lima, P. S. Ritch, E. Chan, J. L. Spratlin, T. Macarulla, E. McWhirter, 

D. Pezet, M. Lichinitser, L. D. Roman, A. Hartford, L. Jackson, M. Vincent, 

L. M. Reyno, M. Hidalgo 

Brd. 25 Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib 

in unresectable, metastatic biliary tract carcinoma. (Abstract #LBA4032) 

H. Y. Lim, J. Lee, H. M. Chang, J. S. Kim, H. J. Choi, M. A. Lee, J. S. Jang, 

H. C. Jeung, J. H. Kang, H. W. Lee, D. Shin, H. J. Jang, J. M. Sun, S. H. Park, 

J. O. Park, Y. Park, W. K. Kang 

401 

MONDAY

MONDAY 


2:00 PM - 6:00 PM 







CME credit: 1 


Michael J. Hassett, MD, MPH—Co-Chair 


Scott Michael Gilbert, MD, MS—Co-Chair 

University of Florida 

Discussion 

5:00 PM Scott David Ramsey, MD, PhD (Abstracts #6012–6016) 


Discussion 

5:15 PM Jennifer J. Griggs, MD, MPH (Abstracts #6017–6023) 


Discussion 

5:30 PM Lynne I. Wagner, PhD (Abstracts #6024–6028) 


Discussion 

5:45 PM Michael J. Hall, MD (Abstracts #6029–6036) 


Brd. 1 Validation of specific chemotherapy drugs in Medicare data. (Abstract #6012) 

J. L. Lund, T. Sturmer, R. S. Sandler, H. K. Sanoff, L. C. Harlan, J. L. Warren 

Brd. 2 Changes in cancer survival by ethnicity between 1992–1996 and 2002–2006: 

Are survival disparities increasing or decreasing? (Abstract #6013) 

D. Pulte, T. Redaniel, H. Brenner, M. Jeffreys 

Brd. 3 High-cost imaging for managed care Medicare beneficiaries with cancer, 

2001–2006. (Abstract #6014) 

E. T. Loggers, P. A. Fishman, M. C. Hornbrook, C. C. Greenberg, 

M. C. O’Keeffe-Rosetti, A. Ramaprasan, N. Q. Vanneman, E. H. Wagner, 

J. C. Weeks, D. P. Ritzwoller 

Brd. 4 Costs and trends in pancreatic cancer treatment: A population-based 


C. B. O’Neill, C. L. Atoria, E. M. O’Reilly, J. LaFemina, E. B. Elkin 

Brd. 5 Costs of medical care after open or minimally-invasive prostate cancer 

surgery: A population-based analysis. (Abstract #6016) 

E. B. Elkin, W. T. Lowrance, B. Denton, J. N. Mirkin, J. A. Eastham 

Brd. 6 Different risk factors for mortality in younger and older women after breastconserving 

surgery. (Abstract #6017) 

G. G. Kimmick, F. Camacho, W. Hwang, H. B. Mackley, J. H. Stewart IV, 

R. T. Anderson 

Brd. 7 Associations between county-level surgeon density and colorectal cancer 

(CRC) mortality. (Abstract #6018) 

J. S. Albarrak, M. Y. Ho, W. Y. Cheung 

Brd. 8 Concordance with NCCN practice guidelines for local therapies as a measure 

of quality of care: Review of practice and identification of quality gaps. 


V. Francescutti, N. L. Watroba, S. B. Edge 

402


Brd. 9 Physicians characteristics and variability of erythropoiesis-stimulating agent 

use among Medicare patients with cancer. (Abstract #6020) 

J. D. Wright, A. I. Neugut, E. T. Wilde, D. Buono, J. Malin, W. Tsai, D. L. Hershman 

Brd. 10 Patient access to breast reconstruction after mastectomy and long-term 

outcomes. (Abstract #6021) 

M. Morrow, A. K. Alderman, S. T. Hawley, S. J. Katz 

Brd. 11 Timing in adjuvant chemotherapy (CTX) initiation among women with breast 

cancer (BC) at National Comprehensive Cancer Network (NCCN) centers: An 

analysis from the NCCN Outcomes Database. (Abstract #6022) 

J. L. Vandergrift, J. C. Niland, R. L. Theriault, S. B. Edge, Y. Wong, 

L. S. Loftus, T. M. Breslin, C. Hudis, S. H. Javid, H. S. Rugo, S. M. Silver, 

E. M. Lepisto, J. C. Weeks 

Brd. 12 The association of obesity, smoking, and access to oncology services with 

cancer mortality in the United States. (Abstract #6023) 

A. J. Hayanga, S. B. Zeliadt, D. E. Wood, L. M. Backhus 

Brd. 13 Early palliative care, depression, and survival in metastatic NSCLC. (Abstract 

#6024) 

W. F. Pirl, J. A. Greer, E. R. Gallagher, V. A. Jackson, I. T. Lennes, J. S. Temel 

Brd. 14 Fertility concerns in young women with breast cancer: Results from a 

prospective cohort study. (Abstract #6025) 

K. J. Ruddy, S. Gelber, R. M. Tamimi, E. S. Ginsburg, L. Schapira, S. E. Come, 

M. E. Meyer, E. P. Winer, A. H. Partridge 

Brd. 15 Discussions about end-of-life care planning between physicians and patients 

with stage IV lung or colorectal cancer. (Abstract #6026) 

J. W. Mack, A. Cronin, N. Taback, H. Huskamp, N. L. Keating, J. L. Malin, C. Earle, 

J. C. Weeks 

Brd. 16 Patient perspectives on a treatment plan and summary program in 

community oncology care. (Abstract #6027) 

V. S. Blinder, V. W. Norris, N. W. Peacock, J. J. Griggs, D. P. Harrington, A. Moore, 

R. L. Theriault, A. H. Partridge 

Brd. 17 Evaluation of an intervention to improve communication about phase I/II 


L. Fallowfield, I. Solis-Trapala, C. I. Langridge, V. A. Jenkins 

Brd. 18 Patients’ understanding of how genotype variation affects benefits of 

tamoxifen therapy for breast cancer. (Abstract #6029) 

N. T. Brewer, C. M. Walko, W. K. Chiu, L. G. Dressler, A. Yuen, P. Rubin, 

O. A. Olajide, S. G. Moore, R. E. Raab, D. R. Carrizosa, S. W. Corso, G. Schwartz, 

J. M. Peppercorn, H. L. McLeod, L. A. Carey, W. J. Irvin Jr. 

Brd. 19 The balance between benefits and harms of molecular targeted agents. 


S. Niraula, E. Amir, A. Ocana, B. Seruga, I. Tannock 

Brd. 20 Adjuvant hormone therapy use in early-stage breast cancer patients insured 

by the New York State Medicaid program. (Abstract #6031) 

R. L. Yung, M. J. Hassett, K. Chen, F. C. Gesten, P. R. Roohan, F. P. Boscoe, 

A. H. Sinclair, M. J. Schymura, D. Schrag 

Brd. 21 Persistence with adjuvant hormonal therapy in older breast cancer survivors. 


T. Hedin, C. Guo, A. Nattinger 

Brd. 22 Anthracycline adherence in older patients with breast cancer. (Abstract 

#6033) 

C. H. Barcenas, N. Zhang, H. Zhao, Z. Duan, G. N. Hortobagyi, S. H. Giordano 

Brd. 23 Racial disparities in chemotherapy for breast cancer: Are delays explained 

by hospital quality and volume? (Abstract #6034) 

R. A. Freedman, Y. He, N. L. Keating 

403 

MONDAY

MONDAY 


Brd. 24 Preoperative breast MRI in early-stage breast cancer: A decision analysis. 


P. Young, B. Kim, J. Malin 

Brd. 25 Abandoning oral oncolytic prescriptions at the pharmacy: Patient and health 

plan factors influencing adherence. (Abstract #6036) 

L. S. Schwartzberg, S. B. Streeter, N. Husain, M. Johnsrud 

404

2:00 PM - 6:00 PM 







CME credit: 1 



Shadia Ibrahim Jalal, MD—Co-Chair 


Robert Charles Doebele, MD, PhD—Co-Chair 


Discussion 

5:00 PM Kenneth John O’Byrne, MD (Abstracts #LBA7512–7518) 

St. James Hospital 

Discussion 

5:15 PM Rebecca Suk Heist, MD (Abstracts #7519–7523) 


Discussion 

5:30 PM Shirish M. Gadgeel, MD (Abstracts #7524–7529) 


Discussion 

5:45 PM Fred R. Hirsch, MD (Abstracts #7530–7536) 


Brd. 1 An international, randomized, placebo-controlled, double-blind phase III 

study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients 

with advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract 

#LBA7512) 

G. Scagliotti, I. Vynnychenko, Y. Ichinose, K. Park, K. Kubota, F. H. Blackhall, 

R. Pirker, R. Galiulin, T. E. Ciuleanu, O. Sydorenko, M. Dediu, Z. Papai-Szekely, 

N. Martinez Banaclocha, S. McCoy, B. Yao, Y. J. Hei, D. R. Spigel 

Brd. 2 A randomized phase II study of pemetrexed (PEM) with or without sorafenib 

(S) as second line therapy in advanced non-small cell lung cancer (NSCLC) 

of non-squamous histology: NCCTG N0626 study. (Abstract #7513) 

J. R. Molina, G. K. Dy, N. R. Foster, K. L. Allen Ziegler, A. Adjei, K. M. Rowland, 

M. Aubry, P. J. Flynn, S. J. Mandrekar, S. E. Schild, A. A. Adjei, North Central 

Cancer Treatment Group (NCCTG) 

Brd. 3 Initial phase II results with crizotinib in advanced ALK-positive non-small cell 

lung cancer (NSCLC): PROFILE 1005. (Abstract #7514) 

L. Crinò, D. Kim, G. J. Riely, P. A. Janne, F. H. Blackhall, D. R. Camidge, 

V. Hirsh, T. Mok, B. J. Solomon, K. Park, S. M. Gadgeel, R. Martins, J. Han, 

T. M. De Pas, A. Bottomley, A. Polli, J. Petersen, V. R. Tassell, A. T. Shaw 

Brd. 4 Comparative analyses of overall survival of anaplastic lymphoma kinase 

(ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who 

did not receive ALK inhibitors. (Abstract #7515) 

D. Kim, J. Lee, H. S. Park, K. Kulig, T. M. Kim, S. Lee, Y. Jeon, D. H. Chung, 

D. S. Heo, W. Kim, Y. Bang 

Brd. 5 Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in 

pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC). 


G. J. Riely, S. N. Gettinger, R. G. Stoller, N. Y. Gabrail, G. K. Dy, G. J. Weiss, 

C. Tunkey, G. Skliris, S. Strychor, J. Dunbar, D. DeLucia, R. W. Ross, J. E. Gray 

405 

MONDAY

MONDAY 


Brd. 6 The introduction of systematic genomic testing for patients with non-small 

cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). (Abstract 

#7517) 

T. M. Ortiz, V. A. Joshi, S. Heon, M. Butaney, L. Chen, D. M. Jackman, 

D. J. Kwiatkowski, N. I. Lindeman, P. A. Janne, B. E. Johnson 

Brd. 7 SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical 

practice. (Abstract #7518) 

L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, J. S. Temel, I. T. Lennes, 

E. Bast, B. A. Waltman, M. Lanuti, A. Muzikansky, M. Mino-Kenudson, A. J. Iafrate, 

D. R. Borger, D. Dias-Santagata, J. A. Engelman 

Brd. 8 Final overall survival results of NEJ002, a phase III trial comparing gefitinib to 

carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for 

advanced non-small cell lung cancer (NSCLC) with EGFR mutations. 


A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, H. Isobe, 

A. Gemma, Y. Saijo, H. Yoshizawa, S. Morita, K. Hagiwara, T. Nukiwa, 

North-East Japan Study Group 

Brd. 9 Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, 

randomized, open-label study of first-line erlotinib versus gemcitabine/ 

carboplatin in patients with EGFR activating-mutation positive (EGFR Act 

Mut�) advanced non-small cell lung cancer (NSCLC). (Abstract #7520) 

C. Zhou, Y. Wu, G. Chen, J. Feng, X. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou, 

S. Ren, S. Lu, L. Zhang, On behalf of the OPTIMAL investigators 

Brd. 10 IFCT-0504 trial: Mucinous (M) and non-mucinous (NM) cytological subtypes 

interaction effect in first-line treatment of advanced bronchioloalveolar 

carcinoma (BAC), by erlotinib (E) or carboplatin/paclitaxel (C/P). (Abstract 

#7521) 

J. Cadranel, R. Gervais, M. Wislez, P. Merle, D. Moro-Sibilot, V. Westeel, 

L. Bigay-Game, E. A. Quoix, S. Friard, F. Barlesi, M. Zaegel, L. Moreau, I. Monnet, 

J. Duhamel, G. Oliviero, P. J. Souquet, L. Thiberville, L. Baudrin, F. Morin, 

G. Zalcman, on behalf of the Intergroupe Francophone de Cancérologie 

Thoracique (IFCT) 

Brd. 11 A randomized, double-blind phase III study of icotinib versus gefitinib in 

patients with advanced non-small cell lung cancer (NSCLC) previously 

treated with chemotherapy (ICOGEN). (Abstract #7522) 

Y. Sun, Y. Shi, L. Zhang, X. Liu, C. Zhou, D. Wang, Q. Li, S. Zhang, S. Qin, C. Hu, 

Y. Zhang, J. Chen, Y. Song, J. Feng, Y. Cheng, H. Zhang, Y. Wu, N. Xu, J. Zhou 

Brd. 12 An evaluation of the possible interaction of gastric acid suppressive 

medication and the EGFR tyrosine kinase inhibitor erlotinib. (Abstract #7523) 

J. F. Hilton, L. Seymour, A. Le Maitre, D. Tu, F. A. Shepherd, P. A. Bradbury 

Brd. 13 A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced 

non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G) 


N. Yamamoto, N. Katakami, S. Atagi, T. Hida, K. Goto, T. Horai, A. Inoue, 

Y. Ichinose, K. Kobayashi, K. Takeda, K. Kiura, H. Saka, T. Tamura, I. Okamoto, 

N. Nogami, R. Morinaga, K. Nishio, Y. Seki, R. M. Lorence, M. Shahidi 

Brd. 14 Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC 

patients with acquired resistance to erlotinib or gefitinib. (Abstract #7525^) 

Y. Y. Janjigian, H. J. Groen, L. Horn, E. F. Smit, Y. Fu, F. Wang, M. Shahidi, 

L. J. Denis, W. Pao, V. A. Miller 

Brd. 15 A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib 

in second-line treatment for locally advanced or metastatic, non-squamous 

NSCLC. (Abstract #7526) 

J. Von Pawel, Z. Papai-Szekely, N. Vinolas, C. Sederholm, M. Klima, D. Desaiah, 

M. I. Leschinger, C. Dittrich 

406


Brd. 16 Randomized, double-blind, phase II study of erlotinib in combination with 

placebo or R1507, a monoclonal antibody to insulin-like growth factor 

receptor-1 (IGF-1R), for advanced stage non-small cell lung cancer (NSCLC). 


S. S. Ramalingam, D. R. Spigel, M. Steins, J. A. Engelman, C. Schneider, 

S. Novello, W. E. Eberhardt, L. Crino, P. A. Janne, L. Liu, C. M. Brownstein, 

M. Reck 

Brd. 17 Apricot-l: Results of a biomarker-based phase II randomized placebocontrolled 

study of apricoxib in combination with erlotinib in non-small cell 

lung cancer (NSCLC) patients. (Abstract #7528) 

B. J. Gitlitz, E. D. Bernstein, G. P. Keogh, E. S. Santos, G. A. Otterson, G. Milne, 

M. Syto, S. L. Zaknoen 

Brd. 18 Exploratory biomarker analyses from OAM4558g: A placebo-controlled 

phase II study of erlotinib with or without MetMAb in patients with advanced 

non-small-cell lung cancer (NSCLC). (Abstract #7529) 

W. Yu, A. Pandita, E. Penuel, R. Raja, J. Zha, S. Mohan, R. D. Patel, R. Desai, 

L. Fu, A. Do, J. Mango, V. Parab, M. Lipkind, J. Huang, M. Lazarov, 

V. Ramakrishnan, L. C. Amler, A. C. Peterson, P. H. Patel, R. L. Yauch 

Brd. 19 Use of negative thyroid transcription factor (TTF-1) status to predict for 

negative epidermal growth factor receptor (EGFR) mutations (Mts) status 

with a high negative predictive value (NPV) in patients (pts) with 

adenocarcinomas (AC) of the lung. (Abstract #7530) 

N. Somaiah, E. Garrett-Mayer, X. Huang, A. E. Wahlquist, K. Danenberg, 

G. R. Simon 

Brd. 20 Hepatocyte growth factor expression in EGFR mutant lung cancer with 

intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese 

cohort. (Abstract #7531) 

S. Yano, T. Yamada, S. Takeuchi, K. Tachibana, Y. Minami, M. Noguchi, 

F. R. Hirsch 

Brd. 21 An evaluation of phosphorylated EGFR expression in predicting outcome of 

EGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type. 


F. Wang, J. Wang, H. Bai, J. Zhao, Z. Wang, M. Zhuo, T. An, J. Duan, L. Yang, 

M. Wu, Y. Wang, S. Wang, X. Liu 

Brd. 22 Meta-analysis of the predictive and prognostic value of erlotinib-related 

biomarkers in phase III, placebo-controlled trials in non-small cell lung 

cancer (NSCLC): Recommendations of the BioLOGUE advisors. (Abstract 

#7533) 

D. Soulieres, J. Wolf, F. A. Shepherd, F. Cappuzzo, P. A. Bunn, R. S. Herbst, 

F. R. Hirsch, K. M. Kerr, T. Mitsudomi, M. S. Tsao, C. Yang, F. C. Richardson, 

B. Klughammer, B. Wacker, D. Sternberg, A. M. Davies 

Brd. 23 Comparison of high sensitive IHC, FISH, and RT-PCR direct sequencing for 

detection of ALK translocation in lung cancer. (Abstract #7534) 

T. Mitsudomi, K. Tomizawa, Y. Horio, T. Hida, Y. Yatabe 

Brd. 24 Associations between biomarkers and outcomes of first-line chemotherapy 

in advanced non-small cell lung cancer (NSCLC). (Abstract #7535) 

B. H. Grønberg, M. Lund-Iversen, E. H. Strøm, O. Brustugun, H. Scott, 

Norwegian Lung Cancer Study Group 

Brd. 25 Drug pathway-associated gene polymorphisms in patients with advanced 

non-small cell lung cancer receiving first-line platinum-gemcitabine 

combination chemotherapy: A prospective multicenter observational study. 


M. Joerger, S. A. Burgers, P. Baas, E. F. Smit, T. J. Haitjema, M. P. Bard, 

V. D. Doodeman, P. H. Smits, A. Vincent, A. Huitema, J. H. Beijnen, 

J. H. Schellens 

407 

MONDAY

MONDAY 


3:00 PM - 4:15 PM 


Why Isn’t Cancer Research More Successful? 




Laurence H. Baker, DO—Chair 


You Reap What You Sow: Research Goals (Incremental versus Large Gains) and Practical 

Barriers 

Lee M. Ellis, MD 


Challenges in Translating Success from the Lab to the Clinic: A Perspective on Our Current 

Infrastructure and Suggestions on Ways to Improve It 

Andrea Denicoff, RN, MSN, ANP 


Science of Patient Participation: Ethics, Decision-making Process, and Informed Consent 

408

3:00 PM - 4:15 PM 


From Minimalist Therapy to Bilateral Mastectomy: Controversies in Locoregional 

Management of Breast Cancer 




Armando E. Giuliano, MD—Chair 

John Wayne Cancer Institute 

Overview and Evolution of Axillary Management: What to Do With Isolated Tumor Cells and 

When Do You Need to Dissect the Axilla? 

Julia R. White, MD 

Radiation Therapy Oncology Group and Medical College of Wisconsin 

What Are the Clinical Data Regarding Partial Breast and Other Novel Radiation Techniques and 

Schedules? 

Monica Morrow, MD 


The Bilateral Mastectomy Epidemic 

Managing Electronic Education (eQuestions Session) 



Track(s): Professional Development, Practice Management and Information Technology 

Michael Fisch, MD, MPH—Chair 


Mobile Applications for Professional and Patient Education 

Peter Ravdin, MD, PhD 


Using ASCO and Non-ASCO Web-based Resources 

David L. Graham, MD 

Carle Clinic Associates 

Professional and Social Networking Resources for Oncologists: Using Electronic Media to 

Improve Cancer Care 

Recent Advances in Non-small Cell Lung Cancer: Best of 2010 Basic and 

Clinical Research in Lung Cancer 



Track(s): Lung Cancer, General Oncology 

Lawrence H. Einhorn, MD—Chair 


Best of 2010: In the Context of My Own Four Decades of Experience 

Pasi A. Janne, MD, PhD 


Best of 2010: Basic Research in Lung Cancer 

Gregory Peter Kalemkerian, MD 


Best of 2010: Lung Cancer Clinical Research 


409 

MONDAY

MONDAY 


Update on Quality Improvement Initiatives in Oncology 



Track(s): Health Services Research, Practice Management and Information Technology 

Michael N. Neuss, MD—Chair 

Oncology/Hematology Care, Inc. 

Quality Oncology Practice Initiative (QOPI) and QOPI Certification 

Andrew Stewart, MA 

Commission on Cancer, American College of Surgeons 

American College of Surgeons Electronic Quality Improvement Packets (e-QuIP) 

Steven M. Asch, MD, MPH 

VA Greater Los Angeles Healthcare System 

The VA’s Cancer Quality Improvement Toolkits 

410

3:00 PM - 4:15 PM 


Update on the Treatment of Adolescents and Young Adults with Acute 

Lymphocytic Leukemia (M17)—Ticketed Session 



Track(s): Pediatric Oncology, Leukemia, Myelodysplasia, and Transplantation 

Stephen Hunger, MD 

University of Colorado Denver Health Science Center 


411 

MONDAY

MONDAY 


3:00 PM - 6:00 PM 




CME credit: 3 


Michaela Jane Higgins, MD—Co-Chair 


Dean E. Brenner, MD—Co-Chair 


3:00 PM Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 

mutation carriers: A combined analysis from the Kathleen Cuningham 

Foundation Consortium for Research into Familial Breast Cancer (kConFab), 

the International BRCA1 and BRCA2 Carrier Cohort Study (IBCCS), and the 

Breast Cancer Family Registry (BCFR). (Abstract #1500) 

K. Phillips, R. L. Milne, M. A. Rookus, D. Goldgar, M. Friedlander, S. McLachlan, 

S. S. Buys, A. C. Antoniou, K. E. Birch, M. Terry, D. Easton, P. Weideman, 

M. B. Daly, N. Andrieu, E. M. John, M. Hooning, I. L. Andrulis, T. Caldes, 

H. Olsson, J. L. Hopper 

3:15 PM Is hormone replacement therapy (HRT) following risk-reducing salpingooophorectomy 

(RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers 

associated with an increased risk of breast cancer? (Abstract #1501) 

S. M. Domchek, T. Friebel, S. L. Neuhausen, H. T. Lynch, C. F. Singer, 

R. A. Eeles, C. Isaacs, N. M. Tung, P. A. Ganz, F. J. Couch, J. N. Weitzel, 

O. I. Olopade, W. S. Rubinstein, G. E. Tomlinson, G. C. Pichert, M. B. Daly, 

E. T. Matloff, D. G. Evans, J. E. Garber, T. R. Rebbeck, PROSE Consortium 

3:30 PM Past use of hormone therapy and breast cancer risk. (Abstract #1502) 

W. Y. Chen, B. A. Rosner, S. E. Hankinson, Nurses’ Health Study Research Group 

Discussion 

3:45 PM Lynn C. Hartmann, MD (Abstracts #1500–1502) 

Mayo Clinic 

4:00 PM Metformin and breast cancer incidence in postmenopausal diabetic women 

in the Women’s Health Initiative (WHI). (Abstract #1503) 

R. T. Chlebowski, A. McTiernan, A. K. Aragaki, T. Rohan, J. Wactawski-Wende, 

E. Ipp, D. Euhus, V. G. Kaklamani, M. Vitolins, R. B. Wallace, S. Liu, 

M. J. Gunter, L. Phillips, H. Strickler, B. Howard 

4:15 PM Incident cancers in people with dysglycemia and other cardiovascular risk 

factors: Cohort study of the ORIGIN trial. (Abstract #1504) 

L. Bordeleau, G. Dagenais, N. Yakubovich, S. Yusuf, J. Probstfield, M. Riddle, 

L. Ryden, L. Xu, J. Bosch, H. Gerstein 

4:30 PM Cigarette smoking, fitness, and alcohol use as predictors of cancer 

outcomes among women in the National Surgical Adjuvant Breast and Bowel 

Project (NSABP) Breast Cancer Prevention Trial (BCPT). (Abstract #1505) 

S. R. Land, N. Christian, D. L. Wickerham, J. P. Costantino, P. A. Ganz 

Discussion 

4:45 PM Pamela Jean Goodwin, MD (Abstracts #1503–1505) 


5:00 PM DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development. 


P. Saintigny, J. Jelinek, C. R. Pickering, W. Lang, M. J. Frederick, L. Zhang, 

H. Ren, V. Papadimitrakopoulou, J. Lee, E. S. Kim, Y. H. Fan, A. K. El-Naggar, 

W. K. Hong, J. Myers, J. J. Issa, S. M. Lippman, L. Mao 

5:15 PM Final results of a chemoprevention trial with enzastaurin in former smokers. 


J. E. Gray, S. Altiok, M. Alexandrow, F. Walsh, J. Chen, D. Tai, G. Bepler 

412


5:30 PM Cervical cancer risk for 330,000 women undergoing concurrent HPV testing 

and cervical cytology in routine clinical practice. (Abstract #1508) 

H. A. Katki, W. K. Kinney, B. Fetterman, T. Lorey, N. E. Poitras, L. Cheung, 

F. Demuth, M. Schiffman, S. Wacholder, P. E. Castle 

Discussion 

5:45 PM Eva Szabo, MD (Abstracts #1506–1507) 


413 

MONDAY

MONDAY 


3:00 PM - 6:00 PM 




CME credit: 3 


Ezra E. W. Cohen, MD—Co-Chair 


David N. Hayes, MD, MPH—Co-Chair 


3:00 PM A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation 

plus cisplatin with or without cetuximab for stage III-IV head and neck 

squamous cell carcinomas (HNC). (Abstract #5500) 

K. Ang, Q. Zhang, D. I. Rosenthal, P. Nguyen-Tan, E. J. Sherman, R. S. Weber, 

J. M. Galvin, D. L. Schwartz, A. K. El-Naggar, M. L. Gillison, R. Jordan, M. A. List, 

A. A. Konski, W. L. Thorstad, A. Trotti, J. J. Beitler, A. S. Garden, W. J. Spanos, 

S. Yom, R. S. Axelrod 

3:15 PM Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results 

of the randomized phase II TREMPLIN study. (Abstract #5501) 

J. Lefebvre, Y. Pointreau, F. Rolland, M. Alfonsi, A. Baudoux, C. Sire, 

D. De Raucourt, E. Bardet, C. Tuchais, P. Garaud, G. Calais 

Discussion 

3:30 PM Ezra E. W. Cohen, MD (Abstracts #5500–5501) 


3:45 PM A randomized phase II/III trial of a tumor vascular disrupting agent 

fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in 

anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. 


J. A. Sosa, R. Elisei, B. Jarzab, C. S. Bal, H. Koussis, A. W. Gramza, 

R. Ben-Yosef, B. J. Gitlitz, B. Haugen, S. M. Karandikar, F. R. Khuri, L. F. Licitra, 

S. C. Remick, S. Marur, C. Lu, F. G. Ondrey, S. Lu, J. Balkissoon 

4:00 PM A phase II trial of the multitargeted kinase inhibitor E7080 in advanced 

radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). (Abstract 

#5503) 

S. I. Sherman, B. Jarzab, M. E. Cabanillas, L. F. Licitra, F. Pacini, R. Martins, 

B. Robinson, D. Ball, J. McCaffrey, M. H. Shah, D. Bodenner, R. Allison, 

K. Newbold, R. Elisei, J. P. O’Brien, M. Schlumberger 

Discussion 

4:15 PM Marcia S. Brose, MD, PhD (Abstracts #5502–5503) 

University of Pennsylvania 

4:30 PM Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort 

study on the use of FDG PET/CT to predict the need for neck dissection 

following radiation therapy of head and neck cancer (HNC). (Abstract #5504) 

J. N. Waldron, R. W. Gilbert, L. Eapen, A. Hammond, D. I. Hodson, A. Hendler, 

B. Perez-Ordonez, C. Gu, J. A. Julian, D. H. Julian, M. N. Levine 

Discussion 

4:45 PM Randal S. Weber, MD (Abstract #5504) 


5:00 PM Prediction of clinical outcome in patients with primary laryngeal carcinoma 

using gene expression profiling. (Abstract #5505) 

E. Fountzilas, N. Angouridakis, I. Karasmanis, R. M. Wirtz, A. G. Eleftheraki, 

E. Veltrup, K. Markou, A. Nikolaou, P. Konstantinopoulos, V. Kotoula, D. Spentzos, 

G. Fountzilas 

414


5:15 PM Prognostic significance of plasma osteopontin in patients with locally 

advanced head and neck squamous cell carcinoma (HNSCC) treated with 

chemoradiation on TROG 02.02 phase III trial. (Abstract #5506) 

A. M. Lim, D. Rischin, H. Cao, R. Fisher, G. A. McArthur, L. J. Peters, R. J. Young, 

Q. Le 

Discussion 

5:30 PM David N. Hayes, MD, MPH (Abstracts #5505–5506) 


415 

MONDAY

MONDAY 


3:00 PM - 6:00 PM 


Sarcoma 


CME credit: 3 


Andrew J. Wagner, MD, PhD—Co-Chair 


Bruce Brockstein, MD—Co-Chair 

NorthShore University Health System 

3:00 PM Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker 

and subset results of a phase II randomized discontinuation trial. (Abstract 

#10000) 

G. K. Schwartz, R. G. Maki, M. J. Ratain, S. D. Undevia, R. L. Jones, 

C. M. Rudin, L. L. Siu, B. Brockstein, D. Khayat, T. Gil, M. J. De Jonge, 

M. B. Sawyer, T. Evans, J. Medioni, P. J. O’Dwyer, C. Hartman, V. Poulart, 

I. B. Walters 

3:15 PM An evaluation of cediranib as a new agent for alveolar soft part sarcoma 

(ASPS). (Abstract #10001) 

S. Kummar, A. Strassberger, A. Monks, S. P. Ivy, I. B. Turkbey, P. L. Choyke, 

S. M. Steinberg, R. Simon, J. H. Doroshow, L. J. Helman, Developmental 

Therapeutics Clinical Group, National Cancer Institute 

3:30 PM PALETTE: A randomized, double-blind, phase III trial of pazopanib versus 

(vs) placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease 

has progressed during or following prior chemotherapy—An EORTC STBSG 

global network study (EORTC 62072). (Abstract #LBA10002) 

W. T. A. Van Der Graaf, J. Y. Blay, S. P. Chawla, D. W. Kim, B. Bui Nguyen, 

P. G. Casali, P. Schöffski, M. Aglietta, A. P. Staddon, Y. Beppu, A. Le Cesne, 

H. Gelderblom, I. R. Judson, N. Araki, M. Ouali, S. Marreaud, R. Hodge, M. Dewji, 

A. P. Dei Tos, and P. Hohenberger 

Discussion 

3:45 PM Shreyaskumar Patel, MD (Abstracts #10000–LBA10002) 


4:00 PM Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in 

advanced sarcoma. (Abstract #10003) 

S. Schuetze, L. Zhao, R. Chugh, M. Zalupski, D. Thomas, D. R. Lucas, L. H. Baker 

4:15 PM Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced 

or metastatic soft-tissue sarcoma and Ewing family of tumors. (Abstract 

#10004) 

P. Schoffski, D. Adkins, J. Blay, T. Gil, A. D. Elias, P. Rutkowski, G. K. Pennock, 

H. Youssoufian, N. J. Zojwalla, R. Willey, D. O. Grebennik 

4:30 PM Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the 

mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced 

sarcoma patients (pts) following clinical benefit from prior standard 

cytotoxic chemotherapy (CT). (Abstract #10005) 

S. P. Chawla, J. Blay, I. Ray-Coquard, A. Le Cesne, A. P. Staddon, M. M. Milhem, 

N. Penel, R. F. Riedel, B. Bui Nguyen, L. D. Cranmer, P. Reichardt, E. Bompas, 

Y. Song, R. Lee, J. E. Eid, J. Loewy, F. G. Haluska, P. F. Dodion, G. D. Demetri 

Discussion 

4:45 PM Scott H. Okuno, MD (Abstracts #10003–10005) 

Mayo Clinic 

5:00 PM A phase II study of dasatinib for patients with imatinib-resistant 

gastrointestinal stromal tumor (GIST). (Abstract #10006) 

J. C. Trent, K. Wathen, M. von Mehren, B. L. Samuels, A. P. Staddon, E. Choy, 

J. E. Butrynski, R. Chugh, W. A. Chow, D. A. Rushing, C. A. Forscher, L. H. Baker, 

S. Schuetze, Sarcoma Alliance for Research through Collaboration 

416


5:15 PM A multicenter phase II study of regorafenib in patients (pts) with advanced 

gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and 

sunitinib (SU). (Abstract #10007) 

S. George, M. von Mehren, M. C. Heinrich, Q. Wang, C. L. Corless, J. E. Butrynski, 

J. A. Morgan, A. J. Wagner, E. Choy, W. D. Tap, J. Manola, J. T. Yap, 

A. D. Van Den Abbeele, S. Solomon, J. A. Fletcher, G. D. Demetri 

5:30 PM Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and 

dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) 

biomarker study. (Abstract #10007b) 

I. Ray-Coquard, J. Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, A. 

Beryozkina, F. Heil, R. Rueger, G. L. Nichols, and B. Bui Nguyen 

Discussion 

5:45 PM Jaap Verweij, MD, PhD (Abstracts #10006–1007b) 


417 

MONDAY

MONDAY 


3:00 PM - 6:00 PM 


Tumor Biology 


CME credit: 3 


Robert Arthur Kratzke, MD—Co-Chair 


Kapil N. Bhalla, MD—Co-Chair 


3:00 PM Comparative genomic analysis of primary versus metastasis in colorectal 


E. Vakiani, M. Janakiraman, R. Shen, Z. Zeng, A. Cercek, N. E. Kemeny, 

A. Heguy, P. Paty, T. A. Chan, L. Saltz, M. R. Weiser, D. B. Solit 

3:15 PM Exomic sequencing of pancreatic neuroendocrine tumors: Detection of 

alterations in chromatin remodeling and mTOR pathway genes. (Abstract 

#10501) 

L. A. Diaz, Y. Jiao, C. Shi, B. H. Edil, R. de Wilde, D. S. Klimstra, A. Maitra, 

L. H. Tang, A. L. Blackford, V. Velculescu, B. Vogelstein, K. W. Kinzler, 

R. H. Hruban, N. Papadopoulos 

3:30 PM Tumor genomic profiling of FFPE samples by massively parallel sequencing. 


N. Wagle, M. F. Berger, M. J. Davis, B. Blumenstiel, M. DeFelice, W. C. Hahn, 

M. Meyerson, S. B. Gabriel, L. E. MacConaill, L. A. Garraway 

Discussion 

3:45 PM A. John Iafrate, MD, PhD (Abstracts #10500–10502) 


4:00 PM Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in 

early-stage HER2� breast cancer in NCCTG N9831 trial. (Abstract #10503) 

M. M. Reinholz, A. C. Dueck, B. Chen, X. Geiger, A. E. McCullough, R. B. Jenkins, 

W. L. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh, 

G. W. Sledge Jr., L. Harris, J. Gralow, E. A. Perez 

4:15 PM Effect of PTEN protein expression on benefit to adjuvant trastuzumab in 

early-stage HER2� breast cancer in NCCTG adjuvant trial N9831. (Abstract 

#10504) 

E. A. Perez, A. C. Dueck, M. M. Reinholz, B. Chen, X. Geiger, R. B. Jenkins, 

W. L. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh, 

G. W. Sledge Jr., L. Harris, J. Gralow, A. E. McCullough 

4:30 PM Genomic patterns resembling BRCA-mutated breast cancers and benefit of 

intensified carboplatin-based chemotherapy in HER2-negative breast cancer. 


S. C. Linn, E. H. Lips, P. M. Nederlof, L. F. Wessels, J. Wesseling, 

M. van de Vijver, E. De Vries, H. van Tinteren, J. Jonkers, M. Hauptmann, 

S. Rodenhuis, M. A. Vollebergh 

Discussion 

4:45 PM Ana M. Gonzalez-Angulo, MD, MSc (Abstracts #10503–10505) 


5:00 PM Detection of circulating miRNAs in serum from patients with breast cancer 

and their association with the presence of metastatic disease. (Abstract 

#10506) 

E. van Schooneveld, M. Wouters, I. Van der Auwera, D. Peeters, P. Huget, 

P. A. van Dam, P. B. Vermeulen, S. J. Van Laere, L. Y. Dirix, Translational Cancer 

Research Group Antwerp, GZA Hospitals Sint-Augustinus 

418


5:15 PM Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in 

early-phase protocols with PI3K/mTOR pathway inhibitors. (Abstract #10507) 

F. Janku, I. Garrido-Laguna, J. J. Wheler, D. S. Hong, A. Naing, G. S. Falchook, 

S. Fu, S. L. Moulder, R. Luthra, J. Lee, A. M. Tsimberidou, R. Kurzrock 

5:30 PM Prognostic and predictive blood-based biomarkers in patients with advanced 

pancreatic cancer: Results from CALGB 80303. (Abstract #10508) 

A. B. Nixon, H. Pang, M. Starr, D. Hollis, P. N. Friedman, M. M. Bertagnolli, 

H. L. Kindler, R. M. Goldberg, A. P. Venook, H. Hurwitz 

Discussion 

5:45 PM David Paul Carbone, MD, PhD (Abstracts #10506–10508) 

Vanderbilt-Ingram Cancer Center 

419 

MONDAY

MONDAY 


4:45 PM - 6:00 PM 


Developing and Implementing More Informative Phase II Oncology Clinical 

Trials 



Track(s): Clinical Trials, Genitourinary Cancer, Lung Cancer 

David B. Solit, MD—Chair 


How Do We Improve Phase II Trial Designs to Better Ensure Success in Phase III? 

Catherine M. Tangen, PhD 


The Randomized Phase II Trial: Is it Useful in Predicting Results of Phase III Studies? 

Primo Lara, MD 


Pitfalls in the Use of Progression-free Survival in Patients with Lung and Prostate Cancer 

Implementing an Electronic Health Record (EHR) in Different Practice Settings: 

Strategies for Success (eQuestions Session) 



Track(s): Practice Management and Information Technology, Professional Development 

William M. Jordan, DO—Chair 

The Center for Cancer and Blood Disorders 

EHR Implementation: Community Practice Perspective 

Nancy T. Sklarin, MD 


EHR Implementation: Academic Practice Perspective 

Carolyn P. Hartley, MD 

Physician’s EHR 

The Practice EHR Implementation Team 

To Transplant or Not to Transplant? Current Controversies in Transplantation 

for Pediatric Acute Leukemias 



Track(s): Pediatric Oncology, Leukemia, Myelodysplasia, and Transplantation 

Michael Pulsipher, MD—Chair 

University of Utah 

Chemotherapy versus Transplant for Pediatric Acute Lymphoblastic Leukemia 

Richard Aplenc, MD 


Chemotherapy versus Transplant for Pediatric Acute Myeloblastic Leukemia 

Saro Armenian, DO, MPH 


Long-term Outcome of Children with Leukemia after Treatment with Stem Cell Transplant 

420

Treating Genitourinary Malignancies (Prostate, Kidney, and Urothelial 

Cancers): The Latest and Greatest 



Track(s): Genitourinary Cancer, Clinical Trials, General Oncology 

Gary R. MacVicar, MD—Chair 

Northwestern University Feinberg School of Medicine 

Advances in Prostate Cancer Therapeutics 

Christopher Sweeney, MBBS 


What’s New in Urothelial Cancer 

Elisabeth I. Heath, MD 


Renal Cell Cancer Update 


421 

MONDAY

MONDAY 


4:45 PM - 6:00 PM 


Finding the Best Job for You/Contract Negotiation (M18)—Ticketed Session 



Track(s): Professional Development, Practice Management and Information Technology 

Douglas W. Blayney, MD 


422

7:30 AM - 9:00 AM 


Highlights of the Day III 




Ronald Levy, MD—Chair 


7:30 AM 

Stephen K. L. Chia, MD 


Breast Cancer—Triple-negative/Cytotoxics/Local Therapy and Cancer 

Prevention/Epidemiology 

7:50 AM 

A. Oliver Sartor, MD 

Tulane University School of Medicine 

Genitourinary (Prostate and Nonprostate) Cancer 

8:10 AM 

Vassiliki Papadimitrakopoulou, MD 



8:25 AM 

Thomas J. Smith, MD 



8:40 AM 

Jean-Yves Blay, MD, PhD 

Centre Léon Bérard 

Sarcoma 

Tuesday, June 7, 2011 

423 

TUESDAY

TUESDAY 


8:00 AM - 9:15 AM 


How the Human Genome Project Will Help Us in the Clinic 



Track(s): Tumor Biology, Cancer Genetics, Developmental Therapeutics 

Todd Golub, MD—Chair 


Genomic Mutations Mediating Sensitivity and Resistance to Targeted Therapies 

Jordi Barretina, PhD 

Broad Institute of MIT and Harvard 

Exploiting Genomic Mutations and Pathway Analysis for the Rationale Development of Effective 

Therapeutics 

Joe W. Gray, PhD 

Oregon Health and Science University 

The Future of Genomics in Directing Personalized Cancer Therapy 

Targeting Angiogenesis in Breast Cancer: Where Do We Stand in 2011? 



Track(s): Breast Cancer, Tumor Biology 

Maura N. Dickler, MD—Chair 


Antiangiogenic Therapy in Breast Cancer: The Current Status and Controversy 

Robert S. Kerbel, PhD 

Sunnybrook Research Institute 

Angiogenesis as a Target 

Daniel J. Sargent, PhD 

Mayo Clinic 

Appropriate Endpoints for Clinical Trials and Source of U.S. Food and Drug 

Administration/Oncologic Drugs Advisory Committee Controversy 

424

8:00 AM - 9:15 AM 


Orthopedic Oncology for the Rest of Us (M19)—Ticketed Session 




R. Lor Randall, MD 

Huntsman Cancer Institute, University of Utah 

Kristy Weber, MD 



425 

TUESDAY

TUESDAY 


8:00 AM - 9:30 AM 


Immune Correlates of Clinical Outcomes 




Thomas Gajewski, MD, PhD—Chair 


8:00 AM Pharmacodynamic and predictive markers of ipilimumab on melanoma 

patients’ T cells. (Abstract #2503) 

J. S. Weber, B. Yu, M. Hall, D. Morelli, D. Yu, Y. Zhang, X. Zhao, A. Sarnaik, 

W. Wang 

Discussion 

8:15 AM Thomas Gajewski, MD, PhD (Abstract #2503) 


8:30 AM Phase II cancer vaccination trial with multiple peptides derived from novel 

oncoantigens against advanced esophageal cancer. (Abstract #2504) 

K. Kono, H. Iinuma, Y. Akutsu, H. Tanaka, N. Hayashi, Y. Uchikado, T. Noguchi, 

H. Fujii, R. Fukushima, H. Matsubara, K. Hirakawa, H. Baba, S. Natsugoe, 

S. Kitano, K. Yoshida, T. Tsunoda, Y. Nakamura 

Discussion 

8:45 AM Mary L. Disis, MD (Abstract #2504) 


9:00 AM Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with 

colitis. (Abstract #2505) 

M. K. Callahan, A. Yang, S. Tandon, Y. Xu, S. K. Subudhi, R. Roman, A. I. Heine, 

E. Pogoriler, D. Kuk, K. Panageas, J. D. Yuan, J. P. Allison, J. D. Wolchok 

Discussion 

9:15 AM To be determined 

426

8:00 AM - 11:00 AM 




CME credit: 3 



Tom Stinchcombe, MD—Co-Chair 


Wilfried Ernst Erich Eberhardt, MD—Co-Chair 

University Hospital–University Duisburg-Essen 

8:00 AM Randomized phase III trial of amrubicin versus topotecan (Topo) as secondline 

treatment for small cell lung cancer (SCLC). (Abstract #7000) 

R. Jotte, J. Von Pawel, D. R. Spigel, M. A. Socinski, M. O’Brien, E. H. Paschold, 

J. Mezger, M. Steins, L. Bosquée, J. A. Bubis, K. Nackaerts, J. Trigo Perez, 

P. R. Clingan, W. Schuette, P. Lorigan, M. Reck, M. Domine, F. A. Shepherd, 

R. McNally, M. F. Renschler 

8:15 AM A randomized phase II study of carboplatin (C) and etoposide (E) with or 

without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell 

lung cancer (ES-SCLC). (Abstract #7001) 

C. J. Langer, I. Albert, P. Kovacs, L. Blakely, G. Pajkos, P. Petrov, A. Somfay, 

A. Szczesna, P. Zatloukal, A. Kazarnowicz, M. M. Moezi, M. T. Schreeder, 

J. Schnyder, M. S. Berger 

Discussion 

8:30 AM Bonnie S. Glisson, MD (Abstracts #7000–7001) 


8:45 AM Randomized phase II trial on refinement of early-stage NSCLC adjuvant 

chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and 

vinorelbine (CVb): TREAT. (Abstract #7002) 

M. Kreuter, J. F. Vansteenkiste, J. R. Fischer, W. E. Eberhardt, H. Zabeck, 

J. Kollmeier, M. H. Serke, N. Frickhofen, M. Reck, W. Engel-Riedel, S. Neumann, 

M. Thomeer, C. Schumann, P. Deleyn, T. Graeter, G. Stamatis, I. Zuna, 

F. Griesinger, M. Thomas 

Discussion 

9:00 AM Heather A. Wakelee, MD (Abstracts #7002) 


9:15 AM Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031. 


D. Harpole, K. V. Ballman, A. L. Oberg, G. Whiteley, R. Cerfolio, R. Keenan, 

D. R. Jones, T. A. D’Amico, J. Shrager, J. B. Putnam, American College of 

Surgeons Oncology Group 

Discussion 

9:30 AM To be determined 

9:45 AM Evaluation of disease-free survival as surrogate endpoint for overall survival 

using two individual patient data meta-analyses of adjuvant chemotherapy in 

operable non-small cell lung cancer. (Abstract #7004) 

S. Michiels, A. Mauguen, D. Fisher, S. Burdett, R. Paulus, S. J. Mandrekar, 

C. P. Belani, F. A. Shepherd, T. Eisen, H. Pang, L. Collette, C. Le Pechoux, 

J. Pignon, Surrogate Lung Project Collaborative Group 

10:00 AM Systematic evaluation of the impact of disease progression (DP) date 

determination on progression-free survival (PFS) in advanced lung cancer: A 

joint North Central Cancer Treatment Group (NCCTG) and Southwest 

Oncology Group (SWOG) investigation. (Abstract #7005) 

S. J. Mandrekar, Y. Qi, K. Allen-Ziegler, S. L. Hillman, M. W. Redman, S. E. Schild, 

D. R. Gandara, A. A. Adjei 

427 

TUESDAY

TUESDAY 


Discussion 

10:15 AM Suzanne Eleanor Dahlberg, PhD (Abstracts #7004–7005) 


10:30 AM A multicenter, randomized phase III maintenance study of thalidomide (arm 

A) versus observation (arm B) in patients with malignant pleural 

mesothelioma (MPM) after induction chemotherapy. (Abstract #7006) 

P. Baas, W. Buikhuisen, O. Dalesio, A. Vincent, N. Pavlakis, R. Van Klaveren, 

F. Schramel, F. Custers, H. Schouwink, S. A. Burgers 

Discussion 

10:45 AM Rolf A. Stahel, MD (Abstract #7006) 

University Hospital Zurich 

428

8:00 AM - 12:30 PM 






Discussion Location: Arie Crown Theater 

CME credit: 1 



Herve R. Bonnefoi, MD—Co-Chair 

Institut Bergonie Cancer Center 

Anne F. Schott, MD—Co-Chair 


Discussion 

11:30 AM Jennifer J. Griggs, MD, MPH (Abstracts #512–520) 


Discussion 

11:45 AM Charles L. Loprinzi, MD (Abstracts #521–526) 

Mayo Clinic 

Discussion 

12:00 PM Herve R. Bonnefoi, MD (Abstracts #527–532) 

Institut Bergonie Cancer Center 

Discussion 

12:15 PM Anne F. Schott, MD (Abstracts #533–536) 


Brd. 1 Randomized trial of a lifestyle intervention for women with early-stage breast 

cancer (BC) receiving adjuvant hormone therapy: Initial results. (Abstract 

#512) 

R. Segal, G. R. Pond, M. Vallis, M. Dion, K. I. Pritchard, J. A. Ligibel, M. N. Levine, 

P. J. Goodwin 

Brd. 2 Impact of a change of body mass index (BMI) on outcome following adjuvant 

endocrine therapy, chemotherapy, or trastuzumab for breast cancer. 


R. Yerushalmi, B. Dong, J. W. Chapman, P. E. Goss, M. N. Pollak, M. J. Burnell, 

V. H. Bramwell, M. N. Levine, K. I. Pritchard, T. J. Whelan, J. N. Ingle, 

W. Parulekar, L. E. Shepherd, K. A. Gelmon 

Brd. 3 Effect of change of body mass index (BMI) during therapy on the efficacy of 

endocrine therapy in premenopausal patients with breast cancer: An 

analysis of the ABCSG-12 trial. (Abstract #514) 

G. Pfeiler, R. Königsberg, B. Mlineritsch, H. Stoger, C. F. Singer, S. Poestlberger, 

G. G. Steger, M. Seifert, P. C. Dubsky, R. Jakesz, H. Samonigg, V. Bjelic-Radisic, 

R. Greil, C. Marth, C. Fesl, M. Gnant 

Brd. 4 Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in 

postmenopausal women with breast cancer (BC) during letrozole (L) 

treatment. (Abstract #515) 

G. Lunardi, L. Del Mastro, C. Bighin, G. Bisagni, P. Driol, O. Garrone, S. Giraudi, 

P. Marroni, P. Piccioli, R. Ponzone, M. Porpiglia, M. Venturini, Gruppo Italiano 

Mammella (GIM) 

Brd. 5 Bone mineral density (BMD) in participants (pts) of trial BIG 1–98 comparing 

adjuvant letrozole (L) versus tamoxifen (T) or their sequence. (Abstract #516) 

A. De Censi, Z. Sun, B. J. Thurlimann, C. McIntosh, A. Guerrieri-Gonzaga, 

A. Monnier, C. Tondini, M. Campone, L. Mauriac, K. Zaman, A. Schoenberger, 

K. N. Price, R. D. Gelber, A. Goldhirsch, A. S. Coates, S. P. Aebi, BIG 1–98 

Collaborative and International Breast Cancer Study Groups 

429 

TUESDAY

TUESDAY 


Brd. 6 Bone effects of adjuvant tamoxifen (T), letrozole (L), or L � zoledronic acid 

(Z) in early breast cancer (EBC): The phase III HOBOE study. (Abstract #517) 

F. Perrone, C. Gallo, S. Lastoria, F. Nuzzo, A. Gravina, G. Landi, E. Rossi, 

C. Pacilio, V. Labonia, F. Di Rella, M. De Laurentiis, M. Piccirillo, M. Di Maio, 

P. Giordano, G. Daniele, G. De Feo, R. Fiore, S. Signoriello, G. Esposito, 

A. de Matteis 

Brd. 7 Effects of adjuvant exemestane versus anastrozole on bone mineral density: 

Two-year results of the NCIC CTG MA.27 bone companion study. (Abstract 

#518) 

D. L. Hershman, A. M. Cheung, J. W. Chapman, J. N. Ingle, F. Ahmed, H. Hu, 

J. Scher, S. Leeson, C. Elliott, A. Le Maitre, L. E. Shepherd, P. E. Goss 

Brd. 8 A population-based assessment of the risk of fragility fracture associated 

with the use of adjuvant hormone therapy for early breast cancer in older 

women. (Abstract #519) 

K. Enright, M. E. Trudeau, N. Taback, M. K. Krzyzanowska 

Brd. 9 Overall survival with adjuvant zoledronic acid in patients with 

premenopausal breast cancer with complete endocrine blockade: Long-term 

results from ABCSG-12. (Abstract #520) 

M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger, 

P. C. Dubsky, R. Jakesz, C. F. Singer, H. Eidtmann, R. Greil 

Brd. 10 Incidence and predictors of ovarian function recovery (OFR) in exemestane 

patients with breast cancer (BC) with chemotherapy-induced amenorrhea 

(CIA) using two estradiol assays. (Abstract #521) 

A. Guerrero-Zotano, J. Gavila, E. Folkerd, B. Ortiz, T. Labrador, F. Martinez, 

A. Garcia, M. Climent, V. Guillem, M. Dowsett, A. Ruiz 

Brd. 11 Symptoms of endocrine treatment and outcome: A retrospective analysis of 

the monotherapy arms of the BIG 1–98 trial. (Abstract #522) 

J. B. Huober, B. F. Cole, J. Wu, A. Giobbie-Hurder, M. Rabaglio, H. T. Mouridsen, 

L. Mauriac, J. F. Forbes, R. Paridaens, I. Lang, I. E. Smith, A. M. Wardley, 

K. N. Price, A. Goldhirsch, A. S. Coates, B. J. Thurlimann, BIG 1–98 

Collaborative and International Breast Cancer Study Groups 

Brd. 12 Increased progression-free and overall survival in patients with breast 

cancer with menopausal symptoms or arthralgia/myalgia during adjuvant 

treatment with exemestane or tamoxifen: Results of the German TEAM trial. 


D. G. Kieback, P. Hadji, T. Menschik, A. Hasenburg, J. Tams, M. Ziller 

Brd. 13 Symptom experiences and nonadherent medication-taking behaviors of 

breast cancer patients taking adjuvant hormone therapy. (Abstract #524) 

R. A. Shelby, F. J. Keefe, S. N. Red, K. L. Blackwell, J. M. Peppercorn, 

P. K. Marcom, G. G. Kimmick 

Brd. 14 Relationship of treatment-emergent symptoms and recurrence-free survival 

in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. (Abstract #525) 

V. Stearns, J. W. Chapman, C. X. Ma, M. J. Ellis, J. N. Ingle, K. I. Pritchard, 

G. T. Budd, M. Rabaglio, G. W. Sledge Jr., A. Le Maitre, J. Kundapur, 

L. E. Shepherd, P. E. Goss 

Brd. 15 24-month follow-up from the Patient’s Anastrozole Compliance to Therapy 

(PACT) program evaluating the influence of a standardized information 

service on compliance in postmenopausal women with early breast cancer. 


H. Lück, P. Hadji, N. Harbeck, C. Jackisch, M. Blettner, M. Glados, J. Terhaag, 

R. Hackenberg, T. Goehler, S. Zaun, A. Rexrodt von Fircks, R. Kreienberg 

Brd. 16 TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) 

with HER2� metastatic breast cancer (MBC). (Abstract #527) 

N. U. Lin, I. A. Mayer, J. S. Najita, T. J. Hobday, C. I. Falkson, E. C. Dees, 

M. F. Rimawi, R. Nanda, R. S. Gelman, K. Josephs, A. Richardson, L. Flores, 

A. D. Van Den Abbeele, J. T. Yap, C. L. Arteaga, A. C. Wolff, I. E. Krop, 

E. P. Winer, Translational Breast Cancer Research Consortium 

430


Brd. 17 The role of EGFR amplification in trastuzumab resistance: A correlative 

analysis of TBCRC003. (Abstract #528) 

I. E. Krop, L. Flores, J. S. Najita, I. A. Mayer, T. J. Hobday, C. I. Falkson, 

C. L. Arteaga, A. C. Wolff, E. C. Dees, M. F. Rimawi, R. Nanda, K. Josephs, 

N. U. Lin, E. P. Winer, Translational Breast Cancer Research Consortium 

Brd. 18 Response to neoadjuvant trastuzumab and chemotherapy in ER� and ER- 

HER2-positive breast cancers: Gene expression analysis. (Abstract #529) 

G. Bianchini, A. Prat, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, 

W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, 

F. J. Vazquez Mazon, J. Baselga, L. Gianni 

Brd. 19 Validation of p95 as predictive marker for trastuzumab-based therapy in 

primary HER2-positive breast cancer: A translational investigation from the 

neoadjuvant GeparQuattro study. (Abstract #530) 

S. Loibl, J. Bruey, G. Von Minckwitz, J. B. Huober, M. F. Press, S. Darb-Esfahani, 

C. Solbach, C. Denkert, H. Tesch, F. Holms, T. N. Fehm, K. Mehta, M. Untch 

Brd. 20 Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab 

(BEV), chemotherapy (CT), and trastuzumab (H) in HER2-positive 

inflammatory breast cancer (IBC): BEVERLY2 study. (Abstract #531) 

P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, 

F. Lerebours, H. H. Roche, M. Pavlyuk, T. D. Bachelot, E. Charafe-Jauffret 

Brd. 21 Efficacy of neoadjuvant therapy with trastuzumab concurrent with 

anthracycline- and nonanthracycline-based regimens for HER2-positive 


S. Bayraktar, A. M. Gonzalez-Angulo, X. Lei, A. Buzdar, V. Valero, A. Melhem, 

H. M. Kuerer, G. N. Hortobagyi, A. A. Sahin, F. Meric-Bernstam 

Brd. 22 Etoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phase 

III). (Abstract #533) 

M. S. Rosati, M. Di Seri, G. Baciarello, V. LO Russo, P. Grassi, L. Marchetti, 

S. Giovannoni, M. Basile, L. Frati 

Brd. 23 Final analysis of the NEOMET trial of neoadjuvant metformin: Examining 

effects on Ki67, gene expression, and pathway analysis in primary operable 


A. M. Thompson, T. Iwamoto, L. Jordan, C. Purdie, S. E. Bray, L. Baker, G. Hardie, 

L. Pusztai, S. L. Moulder, J. A. Dewar, S. M. Hadad 

Brd. 24 Use of genomic grade index to improve tumor grading of invasive lobular 

breast carcinoma. (Abstract #535) 

D. Fumagalli, O. Metzger, I. Veys, A. Catteau, S. Michiels, H. Sandy, R. Salgado, 

S. K. Singhal, K. V. Saini, C. Galant, N. Galland, F. Bertucci, H. P. Peyro Saint Paul, 

M. J. Piccart-Gebhart, C. Sotiriou, D. Larsimont 

Brd. 25 A randomized controlled trial of primary tamoxifen versus mastectomy plus 

adjuvant tamoxifen in fit elderly women with breast carcinoma of high 

estrogen receptor content: Long-term results at 20 years of follow-up. 


S. J. Johnston, F. S. Kenny, B. M. Syed, J. F. Robertson, S. Pinder, 

L. Winterbottom, I. O. Ellis, R. W. Blamey, K. Cheung 

431 

TUESDAY

TUESDAY 


8:00 AM - 12:30 PM 


Genitourinary (Nonprostate) Cancer 




Discussion Location: E354a 

CME credit: 1 


Emmanuel S. Antonarakis, MD—Co-Chair 


Scott E. Eggener, MD—Co-Chair 


Discussion 

11:30 AM Walter Michael Stadler, MD (Abstracts #4546–4552) 


Discussion 

11:45 AM Thomas Powles, MD (Abstracts #4553–4560) 

St. Bartholomew’s Hospital 

Discussion 

12:00 PM Christian K. Kollmannsberger, MD (Abstracts #4561–4565) 


Discussion 

12:15 PM Matt D. Galsky, MD (Abstracts #4566–4570) 

Tisch Cancer Institute, Mount Sinai Medical Center 

Brd. 1 BEVLiN: Prospective study of the safety and efficacy of first-line 

bevacizumab (BEV) plus low-dose interferon-�2a (IFN) in patients (pts) with 

metastatic renal cell carcinoma (mRCC). (Abstract #4546) 

B. Melichar, S. Bracarda, V. Matveev, I. Rusakov, A. Kaprin, A. Zyryanov, 

R. Janciauskiene, E. Fernebro, G. H. Mickisch, M. E. Gore, A. Schulze, S. Jethwa, 

V. Sneller, P. Mulders, J. Bellmunt, on behalf of the BEVLiN Investigators 

Brd. 2 Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): 

Five-year (yr) overall survival (OS) data from a phase II trial. (Abstract #4547) 

R. J. Motzer, T. de La Motte Rouge, A. L. Harzstark, D. Michaelson, G. Liu, 

V. Gruenwald, A. Ingrosso, M. A. Tortorici, P. W. Bycott, S. Kim, B. I. Rini 

Brd. 3 Final phase II safety and efficacy results of study MC0452: Phase I/II trial of 

CCI 779 and bevacizumab in advanced renal cell carcinoma. (Abstract #4548) 

J. R. Merchan, H. C. Pitot, R. Qin, G. Liu, T. R. Fitch, W. J. Maples, J. Picus, 

C. Erlichman 

Brd. 4 Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus 

therapy in patients (pts) with renal cell carcinoma (RCC). (Abstract #4549) 

F. F. Kabbinavar, S. Srinivas, R. J. Hauke, R. J. Amato, W. B. Esteves, 

M. M. Cotreau, A. L. Strahs, P. Bhargava, M. N. Fishman 

Brd. 5 Final analysis of the phase II randomized discontinuation trial (RDT) of 

tivozanib (AV-951) versus placebo in patients with renal cell carcinoma 

(RCC). (Abstract #4550) 

D. Nosov, P. Bhargava, W. B. Esteves, A. L. Strahs, O. N. Lipatov, O. O. Lyulko, 

A. O. Anischenko, R. T. Chacko, D. Doval, W. J. Slichenmyer 

Brd. 6 A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in 

patients with advanced or metastatic renal cell cancer (mRCC). (Abstract 

#4551) 

E. Angevin, V. Grünwald, A. Ravaud, D. E. Castellano, C. Lin, J. E. Gschwend, 

A. L. Harzstark, J. Chang, Y. Wang, M. M. Shi, B. J. Escudier 

432


Brd. 7 A noninterventional study of everolimus in metastatic renal cell cancer after 

use of one VEGFR-TKI: Results of a preplanned interim analysis of a 

prospective study. (Abstract #4552) 

L. Bergmann, U. Kube, M. Kindler, T. Koepke, G. Steiner, J. Janssen, S. Fries, 

P. Goebell, A. Jakob, T. Steiner, M. D. Staehler, F. Overkamp, M. Albrecht, 

C. Doehn 

Brd. 8 Circulating baseline plasma cytokines and angiogenic factors (CAF) as 

markers of tumor burden and therapeutic response in a phase III study of 

pazopanib for metastatic renal cell carcinoma (mRCC). (Abstract #4553) 

Y. Liu, H. T. Tran, Y. Lin, A. Martin, A. J. Zurita, C. N. Sternberg, R. G. Amado, 

L. N. Pandite, J. Heymach, VEG105192 Team 

Brd. 9 Risk factor migration and survival: Analysis from international dataset of 

3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical 


S. Patil, J. Manola, P. Elson, W. Bro, S. Negrier, B. Escudier, R. M. Bukowski, 

R. J. Motzer 

Brd. 10 The association of clinical outcome to front-line VEGF-targeted therapy with 

clinical outcome to second-line VEGF-targeted therapy in metastatic renal 

cell carcinoma (mRCC) patients (Pts). (Abstract #4555) 

M. Y. Al-Marrawi, B. I. Rini, L. C. Harshman, G. A. Bjarnason, L. Wood, 

U. N. Vaishampayan, M. J. MacKenzie, J. J. Knox, N. Agarwal, 

C. K. Kollmannsberger, M. Tan, S. Y. Rha, F. Donskov, S. A. North, T. K. Choueiri, 

D. Y. Heng, International mRCC Database Consortium 

Brd. 11 Molecular classification of sunitinib response in metastatic renal cell 

carcinoma (mRCC) patients by gene expression profiling. (Abstract #4556) 

V. J. Thodima, A. M. Molina, X. Jia, J. Zhang, M. E. Georges, S. Patil, V. E. Reuter, 

R. J. Motzer, R. S. Chaganti 

Brd. 12 Host-mediated changes in patients receiving antiangiogenic therapy for 

resected RCC. (Abstract #4557) 

R. S. Bhatt, J. Manola, A. J. Bullock, L. Zhang, N. B. Haas, M. Pins, M. B. Atkins, 

R. S. DiPaola 

Brd. 13 Association of germ-line SNPs with overall survival (OS) in pazopanibtreated 

patients (Pts) with advanced renal cell carcinoma (RCC). (Abstract 

#4558) 

C. Xu, N. Bing, H. A. Ball, C. N. Sternberg, I. D. Davis, Z. Xue, L. McCann, K. King, 

J. C. Whittaker, C. F. Spraggs, V. E. Mooser, L. N. Pandite 

Brd. 14 Polymorphisms as markers of sunitinib efficacy and toxicity in first-line 

treatment of renal clear cell carcinoma: Final results of a multicentric 

prospective study by the Spanish Oncology Genitourinary Group. (Abstract 

#4559) 

J. Garcia-Donas, E. Esteban, L. J. Leandro-García, D. E. Castellano, 

A. Gonzalez del Alba, M. Climent, J. A. Arranz, E. Gallardo, J. Puente, J. Bellmunt, 

B. Mellado, E. Martínez, F. Moreno, A. Font, M. Robledo, C. Rodriguez de Antona, 

Spanish Oncology GenitoUrinary Group (SOGUG) 

Brd. 15 External validation of the International Metastatic Renal Cell Carcinoma 

(mRCC) Database Consortium prognostic model and comparison to four 

other models in the era of targeted therapy. (Abstract #4560) 

D. Y. Heng, W. Xie, L. C. Harshman, G. A. Bjarnason, U. N. Vaishampayan, 

J. Lebert, L. Wood, F. Donskov, M. Tan, S. Y. Rha, C. Wells, Y. Wang, 

C. K. Kollmannsberger, B. I. Rini, T. K. Choueiri, International mRCC Database 

Consortium 

Brd. 16 Accelerated BEP for advanced germ cell tumors: An Australian multicenter 

phase I/II trial. (Abstract #4561) 

P. S. Grimison, D. B. Thomson, M. R. Stockler, M. D. Chatfield, M. Friedlander, 

V. Gebski, A. L. Boland, B. B. Houghton, H. Gurney, M. Rosenthal, N. Singhal, 

G. Kichenadasse, S. S. Wong, C. R. Lewis, P. A. Vasey, G. C. Toner, 

Australian and New Zealand Urogenital and Prostate Cancer Trials Group 

433 

TUESDAY

TUESDAY 


Brd. 17 Long-term survival with paclitaxel and gemcitabine for germ cell tumors after 

progression following high-dose chemotherapy with tandem transplants. 


B. P. Mulherin, M. J. Brames, L. H. Einhorn 

Brd. 18 Reproduction rates prior to diagnosis of testicular cancer: Does the 

testicular dysgenesis syndrome exist? (Abstract #4563) 

M. Cvancarova, J. Oldenburg, M. Sprauten, H. Stensheim, S. D. Fossa 

Brd. 19 Association of single-nucleotide polymorphism (SNP) in the 

5-alpha-reductase gene (SRD5A2) with increased prevalence of metabolic 

syndrome in chemotherapy-treated testicular cancer (TC) survivors. 


H. Boer, C. Meijer, J. D. Dijck-Brouwer, I. P. Kema, J. D. Lefrandt, N. Zwart, 

H. M. Boezen, A. J. Smit, J. A. Gietema 

Brd. 20 Evaluation of low-dose CT scans for surveillance in stage I testicular cancer. 


P. W. Chung, M. O’Malley, M. A. Jewett, T. Panzarella, D. Hogg, M. J. Moore, 

P. Bedard, L. Anson-Cartwright, B. Tew-George, M. A. Haider, 

M. K. Gospodarowicz, P. R. Warde 

Brd. 21 Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients 

(pts) with advanced/metastatic urothelial carcinoma (UC). (Abstract #4566) 

A. V. Balar, M. I. Milowsky, A. B. Apolo, I. Ostrovnaya, A. Iasonos, A. Trout, 

A. M. Regazzi, I. R. Garcia-Grossman, D. J. Gallagher, D. F. Bajorin 

Brd. 22 Clinical outcome of single agent volasertib (BI 6727) as second-line 

treatment of patients (pts) with advanced or metastatic urothelial cancer 

(UC). (Abstract #4567) 

W. M. Stadler, D. J. Vaughn, G. Sonpavde, N. J. Vogelzang, S. T. Tagawa, 

D. P. Petrylak, P. J. Rosen, C. Lin, J. F. Mahoney, S. S. Modi, P. Lee, 

M. S. Ernstoff, W. Su, A. I. Spira, M. Ould Kaci, J. M. Watrous, T. Taube, 

R. Vinisko, C. Schloss, C. Zhao, M. A. Carducci 

Brd. 23 Identification of ALK gene alterations in urothelial carcinoma (UC). (Abstract 

#4568) 

J. Bellmunt, S. Selvarajah, S. Rodig, M. Salido, I. Costa, B. Bellosillo, L. Werner, 

C. Namgyal, F. A. Schutz, F. Pons, R. O’Brien, J. Barretina, S. Signoretti, M. Loda, 

J. Albanell, T. K. Choueiri, D. M. Berman, P. W. Kantoff, J. E. Rosenberg 

Brd. 24 Identification of a novel urothelial carcinoma (UC) biomarker of lethality. 


J. E. Rosenberg, L. Werner, S. Selvarajah, B. Weir, M. M. Regan, S. J. Jacobus, 

D. M. Berman, F. A. Schutz, R. O’Brien, T. K. Choueiri, J. Barretina, S. Signoretti, 

M. Loda, E. A. Guancial, E. Gallardo, F. G. Rojo, J. Lloreta, W. C. Hahn, 

P. W. Kantoff, J. Bellmunt 

Brd. 25 Optimization of the size variation threshold for imaging evaluation of 

response in patients with platinum-refractory advanced transitional cell 

carcinoma of the urothelium treated with vinflunine. (Abstract #4570) 

K. M. Krajewski, R. Fougeray, T. K. Choueiri, F. Pons, F. A. Schutz, 

J. E. Rosenberg, Y. Salhi, J. Bellmunt 

434

9:30 AM - 12:30 PM 




CME credit: 3 



Jennifer J. Knox, MD—Co-Chair 


Andrea Wang-Gillam, MD, PhD—Co-Chair 


9:30 AM Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced 

hepatocellular carcinoma (HCC). (Abstract #4000) 

A. Cheng, Y. Kang, D. Lin, J. Park, M. Kudo, S. Qin, M. Omata, 

S. W. Pitman Lowenthal, S. Lanzalone, L. Yang, M. Lechuga, E. Raymond, 

SUN1170 HCC Study Group 

9:45 AM Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma 

and of its Treatment with Sorafenib (GIDEON) second interim analysis in 

more than 1,500 patients: Clinical findings in patients with liver dysfunction. 


J. A. Marrero, R. Lencioni, M. Kudo, S. Ye, K. Nakajima, F. Cihon, A. P. Venook 

Discussion 

10:00 AM Bert H. O’Neil, MD (Abstracts #4000–4001) 


10:15 AM Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the 

phase III CLASSIC trial. (Abstract #LBA4002) 

Y. J. Bang, Y. W. Kim, H. K. Yang, H. C. Chung, Y. K. Park, K. W. Lee, K. H. Lee, 

Y. H. Kim, S. I. Noh, J. Ji, M. Johnston, F. Sirzen, and S. H. Noh 

10:30 AM Postoperative adjuvant chemoradiation for gastric or gastroesophageal 

junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional 

(CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared 

with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. 


C. S. Fuchs, J. E. Tepper, D. Niedzwiecki, D. Hollis, H. J. Mamon, R. Swanson, 

D. G. Haller, T. Dragovich, S. R. Alberts, G. A. Bjarnason, C. G. Willett, 

P. C. Enzinger, R. M. Goldberg, A. P. Venook, R. J. Mayer 

10:45 AM A multicenter, randomized phase III trial comparing second-line 

chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for 

pretreated advanced gastric cancer (AGC). (Abstract #4004) 

S. Park, D. Lim, K. Park, S. Lee, S. Oh, H. Kwon, J. Kang, I. Hwang, J. Lee, 

J. Park, Y. Park, H. Lim, W. Kang 

Discussion 

11:00 AM Florian Lordick, MD (Abstracts #LBA4002–4004) 

Klinikum Rechts der Isar, Technische Universitaet Muenchen 

11:15 AM Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal 

carcinoma: Disease-free and overall survival with RT�5FU-mitomycin versus 

RT�5FU-cisplatin. (Abstract #4005) 

L. L. Gunderson, K. A. Winter, J. A. Ajani, J. E. Pedersen, A. B. Benson, 

C. R. Thomas Jr., R. J. Mayer, M. G. Haddock, T. A. Rich, C. G. Willett 

Discussion 

11:30 AM Theodore S. Hong, MD (Abstract #4005) 


435 

TUESDAY

TUESDAY 


11:45 AM Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, 

randomized controlled phase III trial of adjuvant chemotherapy versus 

observation in patients with adenocarcinoma of the ampulla of vater. 


J. P. Neoptolemos, M. J. Moore, T. F. Cox, J. W. Valle, D. H. Palmer, A. Mcdonald, 

R. Carter, N. C. Tebbutt, C. Dervenis, D. Smith, B. Glimelius, F. Y. Coxon, 

F. Lacaine, M. R. Middleton, P. Ghaneh, C. Bassi, C. Halloran, A. Olah, 

C. L. Rawcliffe, and M. W. Büchler 

12:00 PM Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus 

gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in 

Japan and Taiwan: GEST study. (Abstract #4007) 

T. Ioka, M. Ikeda, S. Ohkawa, H. Yanagimoto, A. Fukutomi, K. Sugimori, H. Baba, 

K. Yamao, T. Shimamura, J. Chen, K. Mizumoto, J. Furuse, A. Funakoshi, 

T. Hatori, T. Yamaguchi, S. Egawa, A. Sato, Y. Ohashi, A. Cheng, T. Okusaka 

Discussion 

12:15 PM Dan Laheru, MD (Abstracts #LBA4006–4007) 


436

9:45 AM - 11:00 AM 


Biomarkers for Vascular Endothelial Growth Factor (VEGF)-targeted Agents 




Michael L. Maitland, MD, PhD—Chair 


Hypertension Is a Biomarker for Vascular Endothelial Growth Factor (VEGF)-targeted 

Therapies 

Herbert Hurwitz, MD 


Hypertension Is Not a Biomarker for VEGF-targeted Therapies 

Bryan P. Schneider, MD 

Indiana University School of Medicine 

Single-nucleotide Polymorphisms (SNPs) as Potential Predictive Biomarkers for VEGF-targeted 

Agents 

Emile E. Voest, MD, PhD 

University Medical Center Utrecht 

Novel Approaches to Identify Predictive Biomarkers for VEGF-targeted Therapies 

Effective Time Management for the Busy Oncologist 



Track(s): Professional Development, General Oncology, Practice Management and Information 

Technology 

Timothy Jerome Moynihan, MD—Chair 

Mayo Clinic 

What Is Effective Time Management? 

Martha P. Mims, MD, PhD 

Baylor College of Medicine 

Developing a Healthy Balance of Work and Home-life Duties 

David H. Johnson, MD 


How to Protect “Protected Time”: Prioritizing Competing Responsibilities 

The Changing Face of Castration-resistant Prostate Cancer: Standard Therapy 

and New Targets 




Kim N. Chi, MD—Chair 


Emerging Investigational Therapies in Castration-resistant Prostate Cancer 

Charles G. Drake, MD, PhD 

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University 

Immunotherapy in Castration-resistant Prostate Cancer 


Thomas W. Flaig, MD 


New Standards in the Medical Management of Castration-resistant Prostate Cancer 

437 

TUESDAY

TUESDAY 


9:45 AM - 11:00 AM 


Non-melanoma Skin Cancer: Surgical Management of Aggressive Cases and 

Molecular Targeted Therapies (M24)—Ticketed Session 



Track(s): Head and Neck Cancer, Melanoma/Skin Cancers 

Randal S. Weber, MD 


Surgical Management of Aggressive Squamous Cell Carcinoma of the Skin 

David G. Pfister, MD 


Role of Molecularly Targeted Therapy in the Management of Non-melanoma Skin Cancer 

438

9:45 AM - 11:15 AM 


Emerging Issues in Comparative Effectiveness Research 





Sharon Hermes Giordano, MD, MPH—Chair 


9:45 AM Development of a guideline for including patient-reported outcomes in 

post-approval clinical trials of oncology drugs for comparative effectiveness 

research. (Abstract #6000) 

E. M. Basch, A. P. Abernethy, C. D. Mullins, M. R. Tiglao, S. R. Tunis 

10:15 AM The relationship between cost, quality, and outcomes among women with 

breast cancer in SEER–Medicare. (Abstract #6001) 

M. J. Hassett, B. A. Neville, J. C. Weeks 

Discussion 

10:30 AM Steven J. Katz, MD, MPH (Abstract #6001) 

University of Michigan Medical School 

10:45 AM Utilization and costs of nonevidence-based antineoplastic agents in patients 

with metastatic colon cancer. (Abstract #6002) 

J. A. de Souza, B. N. Polite, S. Zhu, J. J. Dignam, N. J. Meropol, M. J. Ratain, 

L. N. Newcomer, G. C. Alexander 

Discussion 

11:00 AM Marcelo Blaya, MD (Abstract #6002) 

Tulane University Health Sciences Center 

439 

TUESDAY

TUESDAY 


11:30 AM - 12:45 PM 


Cancer Stem Cells as a Therapeutic Target: Fact or Fiction? 




Max Wicha, MD—Chair 

University of Michigan Cancer Center 

Targeted Cancer Stem Cells: Is This Really the Answer? 

Michael Kahn, PhD 

University of Southern California 

Targeting Wnt-B-catenin Signaling in Cancer Stem Cells 

Joan Seoane, PhD 

Vall d’Hebron University Hospital, Institut d’Oncologia 

Targeting Signaling Pathways That Mediate Cancer Stem Cell Survival 

The Importance of Histology and Molecular Testing (EGFR and EML4-ALK) in 

the Initial Evaluation of Advanced Non-small Cell Lung Cancer 




Renato Martins, MD, MPH—Chair 

Seattle Cancer Care Alliance 

Epidermal Growth Factor Receptor Testing: Who, What, When, and How? 

David N. Hayes, MD, MPH 


The Role of Histology in Managing Non-small Cell Lung Cancer 

Alice Tsang Shaw, MD, PhD 


EML4-ALK Testing: Who, What, When, and How? 

440

11:30 AM - 12:45 PM 


How to Develop a Successful Career in Health Services Research 




Track(s): Health Services Research, Professional Development 

Jane C. Weeks, MD, MSc 



441 

TUESDAY

American Society of Clinical Oncology 47th Annual Meeting Meeting ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?